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Summary
Each year, the American Heart Association (AHA), in con-
junction with the Centers for Disease Control and Prevention, 
the National Institutes of Health, and other government agen-
cies, brings together the most up-to-date statistics related to 
heart disease, stroke, and other cardiovascular and metabolic 
diseases and presents them in its Heart Disease and Stroke 
Statistical Update. The Statistical Update represents a criti-
cal resource for the lay public, policy makers, media profes-
sionals, clinicians, healthcare administrators, researchers, and 
others seeking the best available data on these conditions. 
Together, cardiovascular disease (CVD) and stroke produce 
immense health and economic burdens in the United States 
and globally. The Statistical Update brings together in a single 
document up-to-date information on the core health behaviors 
and health factors that define cardiovascular health; a range of 
major clinical disease conditions (including stroke, congeni-
tal heart disease, rhythm disorders, subclinical atherosclero-
sis, coronary heart disease, heart failure, valvular disease, 
and peripheral arterial disease); and the associated outcomes 
(including quality of care, procedures, and economic costs). 
Since 2009, the annual versions of the Statistical Update have 
been cited >20 000 times in the literature. In 2014 alone, the 
various Statistical Updates were cited >5700 times.
Each annual version of the Statistical Update undergoes major 
revisions to include the newest nationally representative data, 
add additional relevant published scientific findings, remove 
older information, add new sections or chapters, and increase 
the number of ways to access and use the assembled informa-
tion. This year-long process, which begins as soon as the previ-
ous Statistical Update is published, is performed by the AHA 
Statistics Committee faculty volunteers and staff. For example, 
this year’s edition includes a new chapter on cardiac arrest, new 
data on the monitoring and benefits of cardiovascular health in 
the population, additional information in many chapters on the 
global CVD and stroke burden, and further new focus on evi-
dence-based approaches to changing behaviors, implementation 
strategies, and implications of the AHA’s 2020 Impact Goals. 
Below are a few highlights from this year’s Update.
Current Status of Cardiovascular Health in the 
United States (Chapter 2)
 ● The concept of cardiovascular health represents a height-
ened focus for the AHA, with 3 central and novel emphases:
—An expanded focus on not only CVD prevention but also 
promotion of positive cardiovascular health, in addition 
to the treatment of established CVD.
—The prioritization of both health behaviors (healthy 
diet pattern, appropriate energy intake, physical activ-
ity [PA], and nonsmoking) and health factors (optimal 
blood lipids, blood pressure, glucose levels) throughout 
the lifespan as primary goals unto themselves.
—Population-level health promotion strategies to shift 
the majority of the public toward greater cardiovascu-
lar health, in addition to targeting those individuals at 
greatest CVD risk, because CVD occurs at all risk levels 
across the population and because healthy lifestyles are 
uncommon throughout the US population.
 ● The prevalence of ideal cardiovascular health is higher in US 
children and young adults than in US middle-aged and older 
adults, largely because of the higher prevalence of ideal levels 
of health factors in US children and young adults. However, 
with regard to health behaviors, children and young adults 
were similar to (PA) or worse than (diet) middle-aged and 
older adults. Poor diet and physical inactivity in childhood and 
younger age are strong predictors of suboptimal health factors 
later in life.
 ● Approximately 50% of US children 12 to 19 years of age 
have ≥5 metrics at ideal levels, with lower prevalence in 
girls (47%) than in boys (52%).
 ● Only 18% of US adults have ≥5 metrics with ideal levels, 
with lower prevalence in men (11%) than in women (25%).
 ● Among children, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
<1% for the healthy diet pattern (ie, <1 in 100 US children 
meets at least 4 of the 5 dietary components) to >80% for 
the smoking, blood pressure, and fasting glucose metrics.
 ● Among US adults, the prevalence of ideal levels of cardio-
vascular health behaviors and factors currently varies from 
0.5% for the healthy diet pattern to up to 78% for the smok-
ing metric (never having smoked or being a former smoker 
who has quit for >12 months).
Effective Approaches to Improve Cardiovascular 
Health (Chapter 2)
 ● The current evidence supports a range of complementary 
strategies to improve cardiovascular health, including:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level
—Healthcare systems approaches, which encourage, facili-
tate, and reward efforts by providers to improve health 
behaviors and health factors
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation
 ● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particu-
lar, children, adolescents, and young adults) as they age.
 ● The metrics with the greatest potential for improvement 
are health behaviors, including diet quality, PA, and body 
Click here to go to the Table of Contents
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weight. However, each of the cardiovascular health metrics 
can be improved and deserves major focus.
 ● The AHA has a broad range of policy initiatives to improve 
cardiovascular health among all Americans and meet the 
2020 Strategic Impact Goals.
Health Behaviors (Chapters 3 to 6)
Based on comparable risk assessment methods, poor lifestyle 
behaviors and lifestyle-related risk factors are the foremost causes 
of death and disability in the United States and in the world.
Smoking/Tobacco Use (Chapter 3)
 ● Although tobacco use has declined substantially in the 
United States, it remains the second-leading cause of 
total deaths and disability. The percentage of adults who 
reported current cigarette use declined from 24.1% in 1998 
to 17.9% in 2013; among high school students, the decline 
was from 36.4% in 1997 to 15.7% in 2013. Still, almost 
one third of coronary heart disease deaths are attributable 
to smoking and exposure to secondhand smoke.
 ● Declines in tobacco usage in the United States may be 
threatened by the >250 e-cigarette products that were avail-
able in 2014. To date, the risks and benefits of e-tobacco 
products remain controversial but are an area of intense 
investigation by scientists, as well as scrutiny by the US 
Food and Drug Administration. Public health experts are 
concerned that e-cigarettes may be a gateway to smoking 
traditional cigarettes and may be eroding gains in the pub-
lic’s awareness of the harms of tobacco products.
 ● Annual smoking-attributable economic costs in the United 
States, including direct medical costs and lost productivity, 
are estimated to exceed $289 billion.
Physical Inactivity (Chapter 4)
 ● In 2013, 15.2% of adolescents reported being inactive dur-
ing the prior week, and inactivity was more likely to be 
reported by girls (19.2%) than boys (11.2%). Inactivity was 
more commonly reported by black (27.3%) and Hispanic 
(20.3%) girls than their white counterparts (16.1%); simi-
larly, black (15.2%) and Hispanic (12.1%) boys reported 
more inactivity than white boys (9.2%).
 ● According to 2013 National Health Interview Survey data, 
only half of American adults met the current aerobic PA 
guidelines (≥150 minutes of moderate PA or 75 minutes 
of vigorous PA or an equivalent combination each week). 
Women (46.1%) were less likely to meet the guidelines 
than men (54.2%), and non-Hispanic blacks (41.4%) and 
Hispanics (42.9%), were less likely to meet them than non-
Hispanic whites (53.4%).
 ● Unfortunately, the proportion of individuals meeting PA 
recommendations is likely to be lower than indicated by 
self-report data. Studies examining actual (with accelerom-
eters, pedometers, etc) versus self-reported PA indicate that 
both men and women overestimate their PA substantially 
(by 44% and 138% for men and women, respectively).
Nutrition (Chapter 5)
 ● The leading risk factor for death and disability in the 
United States is suboptimal diet quality, which in 2010 
led to 678 000 annual deaths of all causes. Major contribu-
tors were insufficient intakes of fruits, nuts/seeds, whole 
grains, vegetables, and seafood, as well as excess intakes 
of sodium. In the United States, an estimated 58 000 annual 
CVD deaths (95% confidence interval, 37 000–80 000) in 
2010 were attributable to sodium intake >2.0 g/d, repre-
senting 1 in 16 (6.3%) of all CVD deaths and 1 in 8 (13.1%) 
CVD deaths before age 70 years. Globally, an estimated 
1.65 million annual CVD deaths (95% confidence interval, 
1.10–2.22) were attributable to sodium intake >2.0 g/d, rep-
resenting nearly 1 in 10 (9.5%) of all CVD deaths.
 ● Although healthier diets cost modestly more than unhealth-
ful diets, comparing extremes of unhealthful versus health-
ful food-based diet patterns, the more healthful patterns 
cost on average ≈$1.50 per day more. Similarly priced 
options are also common; in a comparison of 20 fruits and 
vegetables versus 20 common snack foods such as cookies, 
chips, pastries, and crackers, the average price per portion 
of fruits and vegetables was 31 cents, with an average of 57 
calories per portion, versus 33 cents and 183 calories per 
portion for snack foods.
Obesity (Chapter 6)
 ● Although the overall prevalence of obesity in US youth did 
not change between 2003 to 2004 and 2011 to 2012, the 
prevalence decreased among those aged 2 to 5 years. Obe-
sity decreased among those of higher socioeconomic status 
but increased among those of lower socioeconomic status. In 
addition, the overall prevalence of severe obesity in US youth 
continued to increase, especially among adolescent boys.
 ● Overweight and obesity predispose individuals to most 
major risk factors, including physical inactivity, hyperten-
sion, hyperlipidemia, and diabetes mellitus.
 ● Excess body weight is among the leading causes of death 
and disability in the United States and globally, with bur-
dens expected to increase in coming years.
 ● Among overweight and obese individuals, existing car-
diometabolic risk factors should be monitored and treated 
intensively with diet quality, PA, and pharmacological 
or other treatments as necessary. Each of these interven-
tions provides benefits independent of weight loss and 
maintenance.
Health Factors and Other Risk Factors  
(Chapters 7 to 12)
The prevalence and control of cardiovascular health factors 
and risks remains a major issue for many Americans.
Family History and Genetics (Chapter 7)
 ● Familial aggregation of CVD is related to the clustering 
of specific lifestyle factors and risk factors, both of which 
have environmental and genetic contributors. Patients with 
a family history of coronary artery disease have a higher 
prevalence of traditional CVD risk factors, underscoring 
opportunities for prevention.
 ● The risk of most CVD conditions is higher in the presence 
of a family history, including CVD (45% higher odds with 
sibling history), stroke (50% higher odds with history in 
a first-degree relative), atrial fibrillation (AF, 80% higher 
odds with parental history), heart failure (70% higher odds 
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with parental history), and peripheral arterial disease (80% 
higher odds with family history).
High Blood Cholesterol and Other Lipids (Chapter 8)
 ● 75.7% of children and 46.6% of adults have ideal choles-
terol levels (untreated total cholesterol <170 mg/dL for 
children and <200 mg/dL for adults). Prevalence of ideal 
levels has improved over the past decade in children but 
remained the same in adults.
 ● According to 2009 to 2012 data, >100 million US adults 
≥20 years of age have total cholesterol levels ≥200 mg/dL; 
almost 31 million have levels ≥240 mg/dL.
High Blood Pressure (Chapter 9)
 ● Based on 2009 to 2012 data, 32.6% of US adults ≥20 
years of age have hypertension, which represents ≈80.0 
million US adults. African American adults have among 
the highest prevalence of hypertension in the world. 
Among non-Hispanic black men and women, the age-
adjusted prevalence of hypertension was 44.9% and 
46.1%, respectively.
 ● National Health and Nutrition Examination Survey 
(NHANES) data from 2009 to 2012 revealed that among 
US adults with hypertension, 54.1% were controlled, 
76.5% were currently treated, 82.7% were aware they had 
hypertension, and 17.3% were undiagnosed.
Diabetes Mellitus (Chapter 10)
 ● Diabetes mellitus affects 1 in 10 US adults, with 90% to 
95% of cases being type 2 diabetes mellitus. Diabetes melli-
tus disproportionately affects racial/ethnic minorities. Type 
2 diabetes mellitus is increasingly common in children and 
adolescents; the disease historically was diagnosed primar-
ily in adults ≥40 years of age. The prevalence of type 2 
diabetes mellitus in children/adolescents has increased 
by 30.5% between 2001 and 2009, and it now constitutes 
≈50% of all childhood diabetes mellitus.
 ● Diabetes mellitus is associated with reduced longevity, 
with men with diabetes mellitus living an average of 7.5 
years and women with diabetes mellitus living an average 
of 8.2 years less than their counterparts without diabetes 
mellitus.
Metabolic Syndrome (Chapter 11)
 ● From 1999 to 2010, the age-adjusted national prevalence 
of metabolic syndrome in the United States peaked (in 
the 2001–2002 cycle) and began to fall. This is attribut-
able to decreases in the age-adjusted prevalence among 
women and no change in men. In addition, there has 
been variation in the trends over time for each individual 
component of the metabolic syndrome. Generally, the 
national prevalences of hypertriglyceridemia and ele-
vated blood pressure have decreased, whereas hypergly-
cemia and elevated waist circumference have increased. 
However, these trends also vary significantly by sex and 
race/ethnicity.
Cardiovascular Conditions/Diseases  
(Chapters 13 to 22)
Rates of death attributable to CVD have declined in the United 
States, but the burden remains high.
Total Cardiovascular Diseases (Chapter 13)
 ● The 2011 overall rate of death attributable to CVD was 
229.6 per 100 000 Americans. The death rates were 275.7 
for males and 192.3 for females. The rates were 271.9 
for white males, 352.4 for black males, 188.1 for white 
females, and 248.6 for black females.
 ● From 2001 to 2011, death rates attributable to CVD declined 
30.8%. In the same 10-year period, the actual number of 
CVD deaths per year declined by 15.5%. Yet in 2011, CVD 
still accounted for 31.3% (786 641) of all 2 515 458 deaths, 
or ≈1 of every 3 deaths in the United States.
 ● On the basis of 2011 death rate data, >2150 Americans die 
of CVD each day, an average of 1 death every 40 seconds. 
Approximately 155 000 Americans who died of CVD 
in 2011 were <65 years of age. In 2011, 34% of deaths 
attributable to CVD occurred before the age of 75 years, 
which is younger than the current average life expectancy 
of 78.7 years.
Stroke (Chapter 14)
 ● From 2001 to 2011, the relative rate of stroke death fell 
by 35.1% and the actual number of stroke deaths declined 
by 21.2%. Yet each year, ≈795 000 people continue to 
experience a new or recurrent stroke (ischemic or hem-
orrhagic). Approximately 610 000 of these are first events 
and 185 000 are recurrent stroke events. In 2011, stroke 
caused ≈1 of every 20 deaths in the United States. On aver-
age, every 40 seconds, someone in the United States has 
a stroke, and someone dies of one approximately every 4 
minutes.
 ● The decline in stroke mortality over the past decades, a 
major improvement in population health observed for both 
sexes and all race and age groups, has resulted from reduced 
stroke incidence and lower case fatality rates. The signifi-
cant improvements in stroke outcomes are concurrent with 
cardiovascular risk factor control interventions. The hyper-
tension control efforts initiated in the 1970s appear to have 
had the most substantial influence on the accelerated decline 
in stroke mortality, with lower blood pressure distributions 
in the population. Control of diabetes mellitus and high 
cholesterol and smoking cessation programs, particularly 
in combination with hypertension treatment, also appear to 
have contributed to the decline in stroke mortality.
Atrial Fibrillation (Chapter 16)
 ● Multiple lines of evidence have increased awareness of the 
burden of unrecognized AF. In individuals without a history 
of AF with recent pacemaker or defibrillator implantation, 
subclinical atrial tachyarrhythmias were detected in 10.1% 
of patients. Subclinical atrial tachyarrhythmias were associ-
ated with a 5.6-fold higher risk of clinical AF and ≈13% of 
ischemic strokes or embolism. A recent systematic review 
suggested that one needs to screen 170 community-based 
individuals at least 65 years of age to detect 1 case of AF.
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Sudden Cardiac Arrest (Chapter 17)
 ● In 2011, ≈326 200 people experienced emergency medi-
cal services–assessed out-of-hospital cardiac arrests in the 
United States. Survival to hospital discharge after nontrau-
matic EMS-treated cardiac arrest with any first recorded 
rhythm was 10.6% for patients of any age. Of the 19 300 
bystander-witnessed out-of-hospital cardiac arrests in 
2011, 31.4% of victims survived.
 ● Each year, ≈209 000 people are treated for in-hospital cardiac 
arrest.
Coronary Heart Disease (Chapter 19)
 ● Coronary heart disease alone caused ≈1 of every 7 deaths 
in the United States in 2011. In 2011, 375 295 Americans 
died of coronary heart disease. Each year, an estimated 
≈635 000 Americans have a new coronary attack (defined 
as first hospitalized myocardial infarction or coronary heart 
disease death) and ≈300 000 have a recurrent attack. It is 
estimated that an additional 155 000 silent first myocardial 
infarctions occur each year. Approximately every 34 sec-
onds, 1 American has a coronary event, and approximately 
every 1 minute 24 seconds, an American will die of one.
Heart Failure (Chapter 20)
 ● In 2011, 1 in 9 death certificates (284 388 deaths) in 
the United States mentioned heart failure. Heart failure 
was the underlying cause in 58 309 of those deaths. The 
number of any-mention deaths attributable to heart fail-
ure was approximately as high in 1995 (287 000) as it 
was in 2011 (284 000). Additionally, hospital discharges 
for heart failure remained stable from 2000 to 2010, 
with first-listed discharges of 1 008 000 and 1 023 000, 
respectively.
Cardiovascular Quality of Care, Procedure 
Utilization, and Costs (Chapters 23 to 25)
The Statistical Update provides critical data in several sec-
tions on the magnitude of healthcare delivery and costs, as 
well as the quality of healthcare delivery, related to CVD risk 
factors and conditions.
Quality-of-Care Metrics for CVD (Chapter 23)
 ● The Institute of Medicine has identified 6 domains of qual-
ity of care, including safety, effectiveness, patient-centered 
care, timely care, efficiency, and equitable care.
 ● According to the Medicare Patient Safety Monitoring Sys-
tem, between 2005 and 2011, adverse event rates in hos-
pitalized patients declined for both myocardial infarction 
(from 5.0% to 3.7%) and congestive heart failure (from 
3.7% to 2.7%)
 ● However, in the American College of Cardiology’s Practice 
Innovation and Clinical Excellence (PINNACLE) outpa-
tient registry, only 66.5% of eligible patients with coronary 
artery disease received the optimal evidenced-based com-
bination of medications.
 ● A randomized trial of post–acute coronary care syn-
drome that used multiple modalities to enhance adher-
ence to 4 indicated medications (clopidogrel, statins, 
angiotensin-converting enzyme inhibitors/angiotensin 
receptor blockers, and β-blockers) demonstrated bet-
ter adherence in the intervention group (89.3% versus 
73.9%) at 1 year.
 ● Similarly, challenges persist in the outpatient setting, in 
discussion and counseling for PA and dietary habits.
Cardiovascular Procedure Use and Costs  
(Chapters 24 and 25)
 ● The total number of inpatient cardiovascular operations and 
procedures increased 28% between 2000 and 2010, from 
5 939 000 to 7 588 000.
 ● According to the 2012 National Healthcare Cost and Utili-
zation Project statistics, the mean hospital charge for a vas-
cular or cardiac surgery or procedure in 2012 was $78 897: 
cardiac revascularization cost $149 480, and percutaneous 
interventions cost ≈$70 027.
 ● For 2011, the estimated annual costs for CVD and stroke 
were $320.1 billion, including $195.6 billion in direct 
costs (hospital services, physicians and other profession-
als, prescribed medications, home health care, and other 
medical durables) and $124.5 billion in indirect costs 
from lost future productivity (cardiovascular and stroke 
premature deaths). CVD costs more than any other diag-
nostic group.
 ● By comparison, in 2009, the estimated cost of all cancer 
and benign neoplasms was $216.6 billion ($86.6 billion in 
direct costs and $130 billion in mortality indirect costs).
Conclusions
The AHA, through its Statistics Committee, continuously 
monitors and evaluates sources of data on heart disease and 
stroke in the United States to provide the most current infor-
mation available in the Statistical Update. This annual Statis-
tical Update is the product of a full year’s worth of effort by 
dedicated volunteer physicians and scientists, committed gov-
ernment professionals, and outstanding AHA staff members, 
without whom publication of this valuable resource would be 
impossible. Their contributions are gratefully acknowledged.
Dariush Mozaffarian, MD, DrPH, FAHA
Emelia J. Benjamin, MD, ScM, FAHA
Melanie B. Turner, MPH
On behalf of the American Heart Association Statistics  
  Committee and Stroke Statistics Subcommittee
Note: Population data used in the compilation of NHANES 
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1 . About These Statistics
The AHA works with the CDC’s NCHS, the NHLBI, the 
NINDS, and other government agencies to derive the annual 
statistics in this Heart Disease and Stroke Statistical Update. 
This chapter describes the most important sources and the 
types of data we use from them. For more details, see Chapter 
27 of this document, the Glossary.
The surveys used are the following:
 ● BRFSS—ongoing telephone health survey system
 ● GCNKSS—stroke incidence rates and outcomes within a 
biracial population
 ● MEPS—data on specific health services that Americans 
use, how frequently they use them, the cost of these ser-
vices, and how the costs are paid
 ● NHANES—disease and risk factor prevalence and nutri-
tion statistics
 ● NHIS—disease and risk factor prevalence
 ● NHDS—hospital inpatient discharges and procedures (dis-
charged alive, dead, or status unknown)
 ● NAMCS—physician office visits
 ● NHHCS—staff, services, and patients of home health and 
hospice agencies
 ● NHAMCS—hospital outpatient and ED visits
 ● Nationwide Inpatient Sample of the AHRQ—hospital inpa-
tient discharges, procedures, and charges
 ● NNHS—nursing home residents
 ● National Vital Statistics System—national and state mor-
tality data
 ● WHO—mortality rates by country
 ● YRBSS—health-risk behaviors in youth and young adults
Disease Prevalence
Prevalence is an estimate of how many people have a disease 
at a given point or period in time. The NCHS conducts health 
examination and health interview surveys that provide esti-
mates of the prevalence of diseases and risk factors. In this 
Update, the health interview part of the NHANES is used for 
the prevalence of CVDs. NHANES is used more than the NHIS 
because in NHANES, AP is based on the Rose Questionnaire; 
estimates are made regularly for HF; hypertension is based on 
BP measurements and interviews; and an estimate can be made 
for total CVD, including MI, AP, HF, stroke, and hypertension.
A major emphasis of this Statistical Update is to present the 
latest estimates of the number of people in the United States 
who have specific conditions to provide a realistic estimate of 
burden. Most estimates based on NHANES prevalence rates 
are based on data collected from 2009 to 2012 (in most cases, 
these are the latest published figures). These are applied to 
census population estimates for 2012. Differences in popula-
tion estimates cannot be used to evaluate possible trends in 
prevalence because these estimates are based on extrapola-
tions of rates beyond the data collection period by use of more 
recent census population estimates. Trends can only be evalu-
ated by comparing prevalence rates estimated from surveys 
conducted in different years.
Risk Factor Prevalence
The NHANES 2009 to 2012 data are used in this Update to 
present estimates of the percentage of people with high lipid 
values, DM, overweight, and obesity. The NHIS is used for the 
prevalence of cigarette smoking and physical inactivity. Data for 
students in grades 9 through 12 are obtained from the YRBSS.
Incidence and Recurrent Attacks
An incidence rate refers to the number of new cases of a dis-
ease that develop in a population per unit of time. The unit 
of time for incidence is not necessarily 1 year, although we 
often discuss incidence in terms of 1 year. For some statis-
tics, new and recurrent attacks or cases are combined. Our 
national incidence estimates for the various types of CVD are 
extrapolations to the US population from the FHS, the ARIC 
study, and the CHS, all conducted by the NHLBI, as well 
as the GCNKSS, which is funded by the NINDS. The rates 
Abbreviations Used in Chapter 1
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AP angina pectoris
ARIC Atherosclerosis Risk in Communities Study
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHS Cardiovascular Health Study
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
HD heart disease
HF heart failure
ICD International Classification of Diseases
ICD-9-CM International Classification of Diseases, Clinical 
Modification, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHHCS National Home and Hospice Care Survey 
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institute of Neurological Disorders and Stroke
NNHS National Nursing Home Survey
PAD peripheral artery disease
WHO World Health Organization
YRBSS Youth Risk Behavior Surveillance System
See Glossary (Chapter 27) for explanation of terms.
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change only when new data are available; they are not com-
puted annually. Do not compare the incidence or the rates with 
those in past editions of the Heart Disease and Stroke Statis-
tics Update (also known as the Heart and Stroke Statistical 
Update for editions before 2005). Doing so can lead to serious 
misinterpretation of time trends.
Mortality
Mortality data are generally presented according to the 
underlying cause of death. “Any-mention” mortality means 
that the condition was nominally selected as the underlying 
cause or was otherwise mentioned on the death certificate. 
For many deaths classified as attributable to CVD, selection 
of the single most likely underlying cause can be difficult 
when several major comorbidities are present, as is often the 
case in the elderly population. It is useful, therefore, to know 
the extent of mortality attributable to a given cause regardless 
of whether it is the underlying cause or a contributing cause 
(ie, its “any-mention” status). The number of deaths in 2011 
with any mention of specific causes of death was tabulated 
by the NHLBI from the NCHS public-use electronic files on 
mortality.
The first set of statistics for each disease in this Update 
includes the number of deaths for which the disease is the 
underlying cause. Two exceptions are Chapter 9 (High 
Blood Pressure) and Chapter 20 (Cardiomyopathy and 
Heart Failure). High BP, or hypertension, increases the 
mortality risks of CVD and other diseases, and HF should 
be selected as an underlying cause only when the true 
underlying cause is not known. In this Update, hyperten-
sion and HF death rates are presented in 2 ways: (1) As 
nominally classified as the underlying cause and (2) as any-
mention mortality.
National and state mortality data presented according to the 
underlying cause of death were computed from the mortality 
tables of the NCHS World Wide Web site or the CDC com-
pressed mortality file. Any-mention numbers of deaths were 
tabulated from the electronic mortality files of the NCHS 
World Wide Web site.
Population Estimates
In this publication, we have used national population esti-
mates from the US Census Bureau for 2012 in the computa-
tion of morbidity data. NCHS population estimates for 2011 
were used in the computation of death rate data. The Census 
Bureau World Wide Web site1 contains these data, as well as 
information on the file layout.
Hospital Discharges and Ambulatory Care Visits
Estimates of the numbers of hospital discharges and numbers 
of procedures performed are for inpatients discharged from 
short-stay hospitals. Discharges include those discharged 
alive, dead, or with unknown status. Unless otherwise speci-
fied, discharges are listed according to the first-listed (primary) 
diagnosis, and procedures are listed according to all listed pro-
cedures (primary plus secondary). These estimates are from 
the NHDS of the NCHS unless otherwise noted. Ambulatory 
care visit data include patient visits to physician offices and 
hospital outpatient departments and EDs. Ambulatory care 
visit data reflect the first-listed (primary) diagnosis. These 
estimates are from the NAMCS and NHAMCS of the NCHS.
International Classification of Diseases
Morbidity (illness) and mortality (death) data in the United 
States have a standard classification system: the ICD. 
Approximately every 10 to 20 years, the ICD codes are 
revised to reflect changes over time in medical technol-
ogy, diagnosis, or terminology. Where necessary for com-
parability of mortality trends across the 9th and 10th ICD 
revisions, comparability ratios computed by the NCHS are 
applied as noted.2 Effective with mortality data for 1999, we 
are using the 10th revision (ICD-10). It will be a few more 
years before the 10th revision is systematically used for hos-
pital discharge data and ambulatory care visit data, which are 
based on ICD-9-CM.3
Age Adjustment
Prevalence and mortality estimates for the United States or 
individual states comparing demographic groups or estimates 
over time either are age specific or are age adjusted to the 
2000 standard population by the direct method.4 International 
mortality data are age adjusted to the European standard.5 
Unless otherwise stated, all death rates in this publication are 
age adjusted and are deaths per 100 000 population.
Data Years for National Estimates
In this Update, we estimate the annual number of new (inci-
dence) and recurrent cases of a disease in the United States 
by extrapolating to the US population in 2011 from rates 
reported in a community- or hospital-based study or multi-
ple studies. Age-adjusted incidence rates by sex and race are 
also given in this report as observed in the study or studies. 
For US mortality, most numbers and rates are for 2011. For 
disease and risk factor prevalence, most rates in this report 
are calculated from the 2009 to 2012 NHANES. Because 
NHANES is conducted only in the noninstitutionalized popu-
lation, we extrapolated the rates to the total US population in 
2012, recognizing that this probably underestimates the total 
prevalence, given the relatively high prevalence in the insti-
tutionalized population. The numbers and rates of hospital 
inpatient discharges for the United States are for 2010. Num-
bers of visits to physician offices, hospital EDs, and hospital 
outpatient departments are for 2010. Except as noted, eco-
nomic cost estimates are for 2011.
Cardiovascular Disease
For data on hospitalizations, physician office visits, and 
mortality, CVD is defined according to ICD codes given in 
Chapter 27 of the present document. This definition includes 
all diseases of the circulatory system, as well as congenital 
CVD. Unless so specified, an estimate for total CVD does not 
include congenital CVD. Prevalence of CVD includes people 
with hypertension, HD, stroke, PAD, and diseases of the veins.
Race
Data published by governmental agencies for some racial 
groups are considered unreliable because of the small sample 
size in the studies. Because we try to provide data for as many 
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racial groups as possible, we show these data for informa-
tional and comparative purposes.
Contacts
If you have questions about statistics or any points made in 
this Update, please contact the AHA National Center, Office 
of Science & Medicine at statistics@heart.org. Direct all 
media inquiries to News Media Relations at inquiries@heart.
org or 214-706-1173.
We do our utmost to ensure that this Update is error free. 
If we discover errors after publication, we will provide cor-
rections at our World Wide Web site, http://www.heart.org/ 
statistics, and in the journal Circulation.
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2 . Cardiovascular Health
See Tables 2-1 through 2-7 and Charts 2-1 through 2-13.
After achieving its major Impact Goals for 2010, the AHA 
created a new set of central organizational Impact Goals for 
the current decade1:
By 2020, to improve the cardiovascular health of all 
Americans by 20%, while reducing deaths from CVDs 
and stroke by 20%.1
These goals introduce a new concept, cardiovascular health, 
which is characterized by 7 health metrics. Ideal cardiovascu-
lar health is defined by the absence of clinically manifest CVD 
together with the simultaneous presence of optimal levels of all 
7 metrics, including 4 health behaviors (not smoking and having 
sufficient PA, a healthy diet pattern, and appropriate energy bal-
ance as represented by normal body weight) and 3 health factors 
(optimal total cholesterol, BP, and fasting blood glucose, in the 
absence of drug treatment; Table 2-1). Because a spectrum of car-
diovascular health can also be envisioned and the ideal cardiovas-
cular health profile is known to be rare in the US population, a 
broader spectrum of cardiovascular health can also be represented 
as being “ideal,” “intermediate,” or “poor” for each of the health 
behaviors and health factors.1 Table 2-1 provides the specific defi-
nitions for ideal, intermediate, and poor cardiovascular health for 
each of the 7 metrics, both for adults (≥20 years of age) and chil-
dren (age ranges for each metric depending on data availability).
This concept of cardiovascular health represents a new 
focus for the AHA, with 3 central and novel emphases:
 ● An expanded focus on CVD prevention and promotion of 
positive “cardiovascular health,” in addition to the treat-
ment of established CVD.
 ● Efforts to promote both healthy behaviors (healthy diet pat-
tern, appropriate energy intake, PA, and nonsmoking) and 
healthy biomarker levels (optimal blood lipids, BP, glucose 
levels) throughout the lifespan.
 ● Population-level health promotion strategies to shift the 
majority of the public toward greater cardiovascular health, 
in addition to targeting those individuals at greatest CVD 
risk, since healthy lifestyles in all domains are uncommon 
throughout the US population.
Beginning in 2011, and recognizing the time lag in the nation-
ally representative US data sets, this chapter in the annual 
Statistical Update evaluates and publishes metrics and infor-
mation to provide insights into both progress toward meeting 
the 2020 AHA goals and areas that require greater attention to 
meet these goals. The AHA has advocated for raising the vis-
ibility of patient-reported cardiovascular health status, which 
includes symptom burden, functional status, and health-related 
quality of life, as an indicator of cardiovascular health in future 
organizational goal setting.2
Cardiovascular Health: Current Prevalence
 ● The most up-to-date data on national prevalence of ideal, inter-
mediate, and poor levels of each of the 7 cardiovascular health 
metrics are shown for adolescents and teens 12 to 19 years of 
age (Chart 2-1) and for adults ≥20 years of age (Chart 2-2).
 ● For most metrics, the prevalence of ideal levels of health 
behaviors and health factors is higher in US children than 
in US adults. Major exceptions are diet and PA, for which 
prevalence of ideal levels in children is similar to (for PA) 
or worse (for diet) than in adults.
 ● Among children (Chart 2-1), the prevalence (unadjusted) of 
ideal levels of cardiovascular health behaviors and factors cur-
rently varies from <1% for the healthy diet pattern (ie, <1 in 
100 US children meets at least 4 of the 5 dietary components) 
to >80% for the smoking, BP, and fasting glucose metrics.
 ● Among US adults (Chart 2-2), the age-standardized preva-
lence of ideal levels of cardiovascular health behaviors and 
factors currently varies from 0.5% for having at least 4 of 
5 components of the healthy diet pattern to up to 78% for 
never having smoked or being a former smoker who has 
quit for >12 months.
LWW
Abbreviations Used in Chapter 2
ACA Affordable Care Act
AED automated external defibrillator
AHA American Heart Association
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CACFP Child and Adult Care Food Program
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CI confidence interval
CPR cardiopulmonary resuscitation
CVD cardiovascular disease
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DM diabetes mellitus
EMS emergency medical services
FDA US Food and Drug Administration
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HBP high blood pressure
HD heart disease
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
IMT intima-media thickness
NEMSIS National Emergency Medical Services Information System
NHANES National Health and Nutrition Examination Survey
OR odds ratio
PA physical activity
PE physical education
REGARDS Reasons for Geographic and Racial Differences in Stroke
SBP systolic blood pressure
SE standard error
SNAP Supplemental Nutrition Assistance Program
STEMI ST-segment–elevation myocardial infarction
WIC Women, Infants, and Children program
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 ● Age-standardized and age-specific prevalence estimates for 
ideal cardiovascular health and for ideal levels of each of 
its components are shown for 2011 to 2012 (excluding diet 
metrics, which are 2009 to 2010) in Table 2-2.
—In 2011 to 2012, the prevalence of ideal levels across 7 
health factors and health behaviors decreased dramati-
cally from younger to older age groups. The same trend 
was seen in 2007 to 2010.
—The prevalence of both children and adults meeting 
the dietary goals appeared to improve between 2007 
to 2008 and 2009 to 2010, although this improvement 
should be viewed with caution given the challenges 
of accurately determining time trends across only 2 
cycles of NHANES data collection. The improvement 
was attributable to the greater numbers of children and 
adults who met the whole grains goal, greater numbers 
of middle-aged and older adults who met the fruits and 
vegetables goal, and greater numbers of adults who met 
the fish goal.
 ● Chart 2-3 displays the prevalence estimates for the popula-
tion of US children (12–19 years of age) meeting different 
numbers of criteria for ideal cardiovascular health (out of 7 
possible) in 2009 to 2010.
—Few US children (≈5%) meet only 0, 1, or 2 criteria for 
ideal cardiovascular health.
—Nearly half of US children (45%) meet 3 or 4 criteria for 
ideal cardiovascular health, and about half meet 5 or 6 
criteria (mostly 5 criteria).
—Virtually no children meet all 7 criteria for ideal cardio-
vascular health.
—Overall distributions are similar in boys and girls.
 ● Charts 2-4 and 2-5 display the age-standardized prevalence 
estimates of US adults meeting different numbers of cri-
teria for ideal cardiovascular health (out of 7 possible) in 
2009 to 2010, overall and stratified by age, sex, and race.
—Approximately 2% of US adults have 0 of the 7 criteria 
at ideal levels, and another 12% meet only 1 of 7 crite-
ria. This is much worse than among children.
—Most US adults (≈68%) have 2, 3, or 4 criteria at ideal 
cardiovascular health, with ≈1 in 4 adults within each of 
these categories.
—Approximately 13% of US adults meet 5 criteria, 5% 
meet 6 criteria, and 0.1% meet 7 criteria at ideal levels.
—Presence of ideal cardiovascular health is both age and 
sex related (Chart 2-4). Younger adults are more likely 
to meet greater numbers of ideal metrics than are older 
adults. More than 60% of Americans >60 years of age 
have ≤2 metrics at ideal levels. At any age, women tend 
to have more metrics at ideal levels than do men.
—Race is also related to presence of ideal cardiovascular 
health (Chart 2-5). Blacks and Mexican Americans tend 
to have fewer metrics at ideal levels than whites or other 
races. Approximately 6 in 10 white adults and 7 in 10 
black or Mexican American adults have no more than 3 
of 7 metrics at ideal levels.
 ● Chart 2-6 displays the age-standardized percentages of US 
adults and percentages of children who have ≥5 of the met-
rics (out of 7 possible) at ideal levels.
—Approximately 50% of US children 12 to 19 years of age 
have ≥5 metrics at ideal levels, with lower prevalence in 
girls (47%) than in boys (52%).
—In comparison, only 18% of US adults have ≥5 metrics 
with ideal levels, with lower prevalence in men (11%) 
than in women (25%).
—All populations have improved since baseline year 2007 
to 2008 except for men.
 ● Chart 2-7 displays the age-standardized percentages of US 
adults meeting different numbers of criteria for both poor 
and ideal cardiovascular health. Meeting the AHA 2020 
Strategic Impact Goals is predicated on reducing the rela-
tive percentage of those with poor levels while increasing 
the relative percentage of those with ideal levels for each of 
the 7 metrics.
—Approximately 92% of US adults have ≥1 metric at poor 
levels.
—Approximately 34% of US adults have ≥3 metrics at 
poor levels.
—Few US adults (<3%) have ≥5 metrics at poor levels.
—More US adults have 4 to 6 ideal metrics than 4 to 6 poor 
metrics.
 ● Using data from the BRFSS, Fang and colleagues3 esti-
mated the prevalence of ideal cardiovascular health by 
state, which ranged from 1.2% (Oklahoma) to 6.9% (Dis-
trict of Columbia). Southern states tended to have higher 
rates of poor cardiovascular health, lower rates of ideal car-
diovascular health, and lower mean cardiovascular health 
scores than New England and Western states (Chart 2-8).
Cardiovascular Health: Trends Over Time
 ● The trends over the past decade in each of the 7 cardio-
vascular health metrics (for diet, trends from 2005–2006 
to 2009–2010) are shown in Chart 2-9 (for children 12–19 
years of age) and Chart 2-10 (for adults ≥20 years of age).
—Fewer children over time are meeting the ideal BMI met-
ric, whereas more are meeting the ideal smoking and 
total cholesterol metrics. Other metrics do not show 
consistent trends over time in children.
—More adults over time are meeting the smoking metric, 
whereas fewer are meeting the BMI and glucose metrics. 
Trends for other metrics are not evident over time in adults.
 ● On the basis of NHANES data from 1988 to 2008, if cur-
rent trends continue, estimated cardiovascular health is 
projected to improve by 6% between 2010 and 2020, short 
of the AHA’s goal of 20% improvement (Chart 2-11).4 
On the basis of current trends among individual metrics, 
anticipated declines in prevalence of smoking, high choles-
terol, and high BP (in men) would be offset by substantial 
increases in the prevalence of obesity and DM and small 
changes in ideal dietary patterns or PA.4
 ● On the basis of these projections in cardiovascular health 
factors and behaviors, CHD deaths are projected to 
decrease by 30% between 2010 and 2020 because of pro-
jected improvements in total cholesterol, SBP, smoking, 
and PA (≈167 000 fewer deaths), offset by increases in DM 
and BMI (≈24 000 more deaths).5
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CVD Mortality
 ● In 2011, the age-standardized death rate attributable to all 
CVD was 229.6 per 100 000 (includes congenital CVD 
[ICD-10 I00–I99, Q20–Q28]; Chart 2-12), down 11.5% 
from 259.4 per 100 000 in 2007 (baseline data for the 2020 
Impact Goals on CVD and stroke mortality).6
—Death rates in 2011 attributable to stroke, CHD, and 
other CVDs were 37.9, 109.2, and 81.5 per 100 000, 
respectively.6
Relevance of Ideal Cardiovascular Health
Since the AHA announced its 2020 Impact Goals, multiple 
investigations have confirmed the importance of these met-
rics of cardiovascular health. Overall, these data demonstrate 
the relevance of the concept of cardiovascular health to the 
risk of future risk factors, disease, and mortality, including 
a strong inverse, stepwise association with all-cause, CVD, 
and ischemic HD mortality, as well as preclinical measures of 
atherosclerosis, including carotid IMT, arterial stiffness, and 
coronary artery calcium prevalence and progression.
 ● A stepwise association was present between the number 
of ideal cardiovascular health metrics and risk of all-cause 
mortality, CVD mortality, and ischemic HD mortality after 
14.5 years of follow-up based on NHANES 1988 to 2006 
data.7 The HRs for individuals with 6 or 7 ideal health met-
rics compared with individuals with 0 ideal health metrics 
were 0.49 (95% CI, 0.33–0.74) for all-cause mortality, 0.24 
(95% CI, 0.13–0.47) for CVD mortality, and 0.30 (95% CI, 
0.13–0.68) for ischemic HD mortality.7 Ford et al8 demon-
strated similar relationships.
 ● The adjusted population attributable fractions for CVD 
mortality were as follows7:
—40.6% (95% CI, 24.5%–54.6%) for HBP
—13.7% (95% CI, 4.8%–22.3%) for smoking
—13.2% (95% CI, 3.5%–29.2%) for poor diet
—11.9% (95% CI, 1.3%–22.3%) for insufficient PA
—8.8% (95% CI, 2.1%–15.4%) for abnormal glucose 
levels
 ● The adjusted population attributable fractions for ischemic 
HD mortality were as follows7:
—34.7% (95% CI, 6.6%–57.7%) for HBP
—16.7% (95% CI, 6.4%–26.6%) for smoking
—20.6% (95% CI, 1.2%–38.6%) for poor diet
—7.8% (95% CI, 0%–22.2%) for insufficient PA
—7.5% (95% CI, 3.0%–14.7%) for abnormal glucose 
levels
 ● Data from the REGARDS cohort also demonstrate a step-
wise association between cardiovascular health metrics and 
incident stroke among 22 914 participants free from base-
line CVD with a mean follow-up of 4.9 years. Using a car-
diovascular health score scale ranging from 0 to 14, every 
unit increase in cardiovascular health was associated with 
8% lower risk of incident stroke (HR, 0.92; 95% CI, 0.88–
0.95), with a similar effect size for white (HR, 0.91; 95% 
CI, 0.86–0.96) and black (HR, 0.93; 95% CI, 0.87–0.98) 
participants.9
 ● Data from the Cardiovascular Lifetime Risk Pooling Proj-
ect indicate that adults with all-optimal risk factor levels 
(similar to having ideal cardiovascular health factor levels 
of cholesterol, blood sugar, and BP, as well as nonsmok-
ing status) have substantially longer overall and CVD-free 
survival than those who have poor levels of ≥1 of these car-
diovascular health factor metrics. For example, at an index 
age of 45 years, men with optimal risk factor profiles lived 
on average 14 years longer free of all CVD events, and ≈12 
years longer overall, than individuals with ≥2 risk factors.10
 ● Importantly, in many of these analyses, ideal health behav-
iors and ideal health factors were each independently asso-
ciated with lower CVD risk in a stepwise fashion (Chart 
2-13). Thus, across any levels of health behaviors, health 
factors were still associated with incident CVD, and across 
any levels of health factors, health behaviors were still 
associated with incident CVD.11
 ● Interestingly, based on NHANES 1999 to 2002, only mod-
est intercorrelations are present between different cardio-
vascular health metrics. For example, these ranged from a 
correlation of −0.12 between PA and HbA1c to a correlation 
of 0.29 between BMI and HbA1c. Thus, although the 7 AHA 
cardiovascular health metrics appear modestly interrelated, 
substantial independent variation in each exists, and each is 
independently related to cardiovascular outcomes.8
 ● Cardiovascular health has been associated with prevalent 
cognitive function across the domains of visual-spatial 
memory, working memory, scanning and tracking, execu-
tive function, and the global composite score (P<0.05 for 
all) in the Maine-Syracuse Longitudinal Study.12 Ideal car-
diovascular health is also directly associated with global 
cognitive performance.
 ● In REGARDS, black and white adults aged ≥45 years, 
free of stroke and baseline cognitive impairment, with mid 
(OR, 0.65; 95% CI, 0.52–0.81) to high (OR, 0.63; 95% CI, 
0.51–0.79) cardiovascular health scores at baseline were 
found to have a lower associated incidence of clinically 
relevant cognitive impairment (verbal learning, memory, 
and fluency) than those with low cardiovascular health. No 
significant difference was seen between the mid and high 
ranges, which indicates that even when high levels of car-
diovascular health are not achieved, intermediate levels are 
preferable to low levels.13
 ● The AHA cardiovascular health metrics have also been 
associated with a lower prevalence of incident depressive 
symptoms in the REGARDS14 and Aerobics Center Longi-
tudinal Study15 cohorts, respectively.
 ● Recent analyses from the US Burden of Disease Collabo-
rators demonstrated that each of the 7 health factors and 
behaviors causes substantial mortality and morbidity in the 
United States. The top risk factor related to overall disease 
burden was suboptimal diet, followed by tobacco smok-
ing, high BMI, raised BP, high fasting plasma glucose, and 
physical inactivity.16
Achieving the 2020 Impact Goals
 ● Taken together, these data continue to demonstrate both the 
tremendous relevance of the AHA 2020 Impact Goals for 
cardiovascular health and the substantial progress that will 
be needed to achieve these goals over the next decade.
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 ● A range of complementary strategies and approaches can 
lead to improvements in cardiovascular health. These 
include each of the following:
—Individual-focused approaches, which target lifestyle 
and treatments at the individual level (Table 2-3)
—Healthcare systems approaches, which encourage, facili-
tate, and reward efforts by providers to improve health 
behaviors and health factors (Table 2-4)
—Population approaches, which target lifestyle and treat-
ments in schools or workplaces, local communities, and 
states, as well as throughout the nation (Table 2-5)
● Such approaches can focus on both (1) improving cardio-
vascular health among those who currently have less than 
optimal levels and (2) preserving cardiovascular health 
among those who currently have ideal levels (in particular, 
children, adolescents, and young adults) as they age.
 ● The metrics with the greatest potential for improvement 
are health behaviors, including diet quality, PA, and body 
weight. However, each of the cardiovascular health metrics 
can be improved and deserves major focus.
 ● Continued emphasis is also needed on the treatment of 
acute CVD events and secondary prevention through treat-
ment and control of health behaviors and risk factors.
 ● For each cardiovascular health metric, modest shifts in 
the population distribution toward improved health would 
produce relatively large increases in the proportion of 
Americans in both ideal and intermediate categories. For 
example, on the basis of NHANES 2009 to 2010, the cur-
rent prevalence of ideal levels of BP among US adults is 
44.3%. To achieve the 2020 goals, a 20% relative improve-
ment would require an increase in this proportion to 53.1% 
by 2020 (44.3% × 1.20). On the basis of NHANES data, a 
reduction in population mean BP of just 2 mm Hg would 
result in 56.1% of US adults having ideal levels of BP, 
which represents a 26.8% relative improvement in this 
metric (Table 2-6). Larger population reductions in BP 
would lead to even larger numbers of people with ideal 
levels. Such small reductions in population BP could result 
from small health behavior changes at a population level, 
such as increased PA, increased fruit and vegetable con-
sumption, decreased sodium intake, decreased adiposity, 
or some combination of these and other lifestyle changes, 
with resulting substantial projected decreases in CVD 
rates in US adults.17
 ● The AHA has a broad range of policy initiatives to improve 
cardiovascular health and meet the 2020 Strategic Impact 
Goals (Table 2-7). Future Statistical Updates will update these 
initiatives and track progress toward the 2020 Impact Goals.
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Table 2-1. Definitions of Poor, Intermediate, and Ideal Cardiovascular Health for Each Metric in the AHA 2020 Goals
Level of Cardiovascular Health for Each Metric
Poor Intermediate Ideal
Current smoking
  Adults ≥20 y of age Yes Former ≥12 mo Never or quit >12 mo
  Children 12–19 y of age Tried during the prior 30 d … Never tried; never smoked whole 
cigarette
BMI*
  Adults ≥20 y of age ≥30 kg/m2 25–29.9 kg/m2 <25 kg/m2
  Children 2–19 y of age >95th percentile 85th–95th percentile <85th percentile
PA
  Adults ≥20 y of age None 1–149 min/wk moderate or
1–74 min/wk vigorous or
1–149 min/wk moderate + 2×vigorous
≥150 min/wk moderate or ≥75 min/wk 
vigorous or ≥150 min/wk moderate + 
2×vigorous
  Children 12–19 y of age None >0 and <60 min of moderate or vigorous 
every day
≥60 min of moderate or vigorous 
every day
Healthy diet pattern, No. of components†
  Adults ≥20 y of age 0–1 2–3 4–5
  Children 5–19 y of age 0–1 2–3 4–5
Total cholesterol, mg/dL
  Adults ≥20 y of age ≥240 200–239 or treated to goal <200
  Children 6–19 y of age ≥200 170–199 <170
Blood pressure
  Adults ≥20 y of age SBP ≥140 mm Hg or DBP ≥90 mm Hg SBP 120–139 mm Hg or DBP 80–89 
mm Hg or treated to goal
<120 mm Hg/<80 mm Hg
  Children 8–19 y of age >95th percentile 90th–95th percentile or SBP ≥120 mm Hg 
or DBP ≥80 mm Hg
<90th percentile
Fasting plasma glucose, mg/dL
  Adults ≥20 y of age ≥126 100–125 or treated to goal <100
  Children 12–19 y of age ≥126 100–125 <100
AHA indicates American Heart Association; BMI, body mass index; DBP, diastolic blood pressure; ellipses (. . .), data not available; PA, physical activity; and SBP, 
systolic blood pressure.
*Represents appropriate energy balance, that is, appropriate dietary quantity and PA to maintain normal body weight.
†In the context of a healthy dietary pattern that is consistent with a Dietary Approaches to Stop Hypertension [DASH]–type eating pattern, to consume ≥4.5 cups/d of 
fruits and vegetables, ≥2 servings/wk of fish, and ≥3 servings/d of whole grains and no more than 36 oz/wk of sugar-sweetened beverages and 1500 mg/d of sodium.
Reprinted from Lloyd-Jones et al1 with permission. Copyright © 2010, American Heart Association, Inc.
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Table 2-2. Prevalence of Ideal Cardiovascular Health and Its Components in the US Population in Selected Age Strata, From 
NHANES 2011 to 2012
NHANES 
Cycle Age 12–19 y Age ≥20 y* Age 20–39 y Age 40–59 y Age ≥60 y
Ideal cardiovascular health profile (7/7) 2009–2010 0.0 (0.0) 0.1 (0.1) 0.3 (0.3) 0.0 (0.0) 0.0 (0.0)
  ≥6 Ideal 2009–2010 19.3 (2.6) 4.6 (0.6) 8.2 (1.5) 2.9 (0.9) 0.8 (0.5)
  ≥5 Ideal 2009–2010 49.5 (2.5) 17.6 (1.3) 30.3 (2.6) 11.1 (1.6) 5.8 (1.4)
Ideal health factors (4/4) 2011–2012 47.8 (2.1) 16.7 (1.1) 32.1 (2.3) 8.8 (1.1) 2.5 (1.2)
  Total cholesterol <200 mg/dL 2011–2012 75.7 (1.9) 46.6 (0.7) 70.4 (1.7) 34.2 (1.7) 23.9 (1.1)
  SBP <120 and DBP <80 mm Hg 2011–2012 82.3 (1.6) 42.2 (1.3) 64.4 (2.1) 34.4 (1.5) 15.7 (1.6)
  Not current smoker 2011–2012 87.1 (1.1) 77.8 (1.3) 75.2 (2.1) 74.3 (1.7) 87.1 (1.3)
  Fasting blood glucose <100 mg/dL 2011–2012 85.3 (2.8) 56.5 (1.4) 74.7 (1.7) 52.4 (2.7) 31.3 (2.3)
Ideal health behaviors (4/4) 2009–2010 0.0 (0.0) 0.1 (0.1) 0.4 (0.2) 0.0 (0.0) 0.0 (0.0)
  PA at goal 2011–2012 36.5 (2.6) 44.0 (1.8) 53.0 (2.2) 41.0 (2.4) 35.2 (2.3)
  Not current smoker 2011–2012 87.1 (1.1) 77.8 (1.3) 75.2 (2.1) 74.3 (1.7) 87.1 (1.3)
  BMI <25 kg/m2 2011–2012 64.7 (2.1) 31.3 (1.4) 39.7 (2.8) 24.7 (1.4) 28.4 (2.1)
  4–5 Diet goals met† 2009–2010 0.1 (0.1) 0.5 (0.2) 0.7 (0.4) 0.5 (0.3) 0.3 (0.1)
   Fruits and vegetables ≥4.5 cups/d 2009–2010 7.5 (1.7) 13.7 (0.8) 11.5 (1.4) 13.8 (1.4) 17.0 (1.0)
   Fish ≥2 servings/wk 2009–2010 8.5 (1.2) 23.6 (1.6) 21.8 (2.1) 24.3 (2.4) 26.0 (1.8)
   Sodium <1500 mg/d 2009–2010 0.2 (0.1) 0.2 (0.1) 0.2 (0.1) 0.3 (0.2) 0.3 (0.2)
   Sugar-sweetened beverages  
<36 oz/wk
2009–2010 29.5 (2.4) 55.1 (1.0) 41.9 (2.5) 58.1 (1.0) 73.5 (1.2)
   Whole grains ≥3 1-oz equivalents/d 2009–2010 5.7 (1.0) 11.0 (0.7) 10.8 (1.2) 10.2 (1.1) 11.9 (1.3)
Secondary diet metrics 2009–2010
  Nuts/legumes/seeds ≥4 servings/wk 2009–2010 12.2 (1.5) 23.6 (1.1) 21.3 (1.2) 25.3 (1.9) 24.8 (1.4)
  Processed meats <2 servings/wk 2009–2010 53.3 (2.5) 57.7 (1.5) 53.9 (2.0) 58.6 (2.2) 62.3 (1.9)
  Saturated fat <7% total kcal 2009–2010 8.2 (1.8) 11.8 (0.7) 13.8 (1.3) 10.2 (0.9) 11.3 (0.9)
Values are mean percentage (SE).
BMI indicates body mass index; DBP, diastolic blood pressure; NHANES, National Health and Nutrition Examination Survey; PA, physical activity; and SBP, systolic 
blood pressure.
*Standardized to the age distribution of the 2000 US Standard population.
†Scaled to 2000 kcal/d and in the context of appropriate energy balance and a DASH (Dietary Approaches to Stop Hypertension)–type eating pattern.
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Table 2-3. Evidence-Based Individual Approaches for Improving Health Behaviors and Health Factors in the Clinic Setting
●   Set specific goals (Class I; Level of Evidence A). Set specific, proximal goals with the patient, including a personalized plan to achieve the goals (eg, over the next 3 
mo, increase fish by 1 serving/wk, reduce smoking by half a pack per day, or walk 30 min 3 times/wk).
●   Establish self-monitoring (Class I; Level of Evidence A). Develop a strategy for self-monitoring, such as a dietary or physical activity diary or Web-based or mobile 
applications.
●   Schedule follow-up (Class I; Level of Evidence A). Schedule regular follow-up (in-person, telephone, written, and/or electronic), with clear frequency and duration of 
contacts, to assess success, reinforce progress, and set new goals as necessary.
●   Provide feedback (Class I; Level of Evidence A). Provide feedback on progress toward goals, including using in-person, telephone, and/or electronic feedback.
●   Increase self-efficacy (Class I; Level of Evidence A). Increase the patient’s perception that they can successfully change their behavior.*
●   Use motivational interviewing† (Class I; Level of Evidence A). Use motivational interviewing when patients are resistant or ambivalent about behavior change.
●   Provide long-term support (Class I; Level of Evidence B). Arrange long-term support from family, friends, or peers for behavior change, such as in other workplace, 
school, or community-based programs.
●   Use a multicomponent approach (Class I; Level of Evidence A). Combine 2 or more of the above strategies into the behavior change efforts.
*Examples of approaches include mastery experiences (set a reasonable, proximal goal that the person can successfully achieve); vicarious experiences (have the 
person see someone with similar capabilities performing the behavior, such as walking on a treadmill or preparing a healthy meal); physiological feedback (explain to 
the patient when a change in their symptoms is related to worse or improved behaviors); and verbal persuasion (persuade the person that you believe in their capability 
to perform the behavior).
†Motivational interviewing represents use of individual counseling to explore and resolve ambivalence toward changing behavior. Major principles include fostering 
the person’s own awareness and resolution of their ambivalence, as well as their own self-motivation to change, in a partnership with the counselor or provider.
Modified from Artinian et al18 with permission. Copyright © 2010, American Heart Association, Inc.
Table 2-4. Evidence-Based Healthcare Systems Approaches to Support and Facilitate Improvements in Health Behaviors and 
Health Factors19–23
●  Electronic systems for scheduling and tracking initial visits and regular follow-up contacts for behavior change and treatments.
●  Electronic medical records systems to help assess, track, and report on specific health behaviors (diet, PA, tobacco, body weight) and health factors (BP, 
cholesterol, glucose), as well as to provide feedback and the latest guidelines to providers.
●  Practical paper or electronic toolkits for assessment of key health behaviors and health factors, including during, before, and after provider visits.
●  Electronic systems to facilitate provision of feedback to patients on their progress during behavior change and other treatment efforts.
●  Education and ongoing training for providers on evidence-based behavior change strategies, as well as the most relevant behavioral targets, including training on 
relevant ethnic and cultural issues.
●  Integrated systems to provide coordinated care by multidisciplinary teams of providers, including physicians, nurse practitioners, dietitians, PA specialists, and 
social workers.
●  Reimbursement guidelines and incentives that reward efforts to change health behaviors and health factors. Restructuring of practice goals and quality benchmarks 
to incorporate health behavior (diet, PA, tobacco, body weight) and health factor (BP, cholesterol, glucose) interventions and targets for both primary and secondary 
prevention.
BP indicates blood pressure; and PA, physical activity.
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Table 2-5. Summary of Evidence-Based Population Approaches for Improving Diet, Increasing Physical Activity, and Reducing 
Tobacco Use*
Diet
Media and education Sustained, focused media and educational campaigns, using multiple modes, for increasing consumption of specific healthful foods 
or reducing consumption of specific less healthful foods or beverages, either alone (Class IIa; Level of Evidence B) or as part of 
multicomponent strategies (Class I; Level of Evidence B)†‡§
On-site supermarket and grocery store educational programs to support the purchase of healthier foods (Class IIa; Level of Evidence B)†
Labeling and information Mandated nutrition facts panels or front-of-pack labels/icons as a means to influence industry behavior and product formulations  
(Class IIa; Level of Evidence B)†
Economic incentives Subsidy strategies to lower prices of more healthful foods and beverages (Class I; Level of Evidence A)†
Tax strategies to increase prices of less healthful foods and beverages (Class IIa; Level of Evidence B)†
Changes in both agricultural subsidies and other related policies to create an infrastructure that facilitates production, transportation, 
and marketing of healthier foods, sustained over several decades (Class IIa; Level of Evidence B)†
Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized educational curricula, trained 
teachers, supportive school policies, a formal PE program, healthy food and beverage options, and a parental/family component (Class 
I; Level of Evidence A)†
School garden programs, including nutrition and gardening education and hands-on gardening experiences (Class IIa; Level of Evidence A)†
Fresh fruit and vegetable programs that provide free fruits and vegetables to students during the school day (Class IIa; Level of Evidence A)†
Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
Increased availability of healthier food/beverage options and/or strong nutrition standards for foods and beverages served, in 
combination with vending machine prompts, labels, or icons to make healthier choices (Class IIa; Level of Evidence B)†
Local environment Increased availability of supermarkets near homes (Class IIa; Level of Evidence B)†‡║
Restrictions and mandates Restrictions on television advertisements for less healthful foods or beverages advertised to children (Class I; Level of Evidence B)†
Restrictions on advertising and marketing of less healthful foods or beverages near schools and public places frequented by youths  
(Class IIa; Level of Evidence B)†
General nutrition standards for foods and beverages marketed and advertised to children in any fashion, including on-package 
promotion (Class IIa; Level of Evidence B)†
Regulatory policies to reduce specific nutrients in foods (eg, trans fats, salt, certain fats) (Class I; Level of Evidence B)†§
Physical activity
Labeling and information Point-of-decision prompts to encourage use of stairs (Class IIa; Level of Evidence A)†
Economic incentives Increased gasoline taxes to increase active transport/commuting (Class IIa; Level of Evidence B)†
Schools Multicomponent interventions focused on improving both diet and physical activity, including specialized educational curricula, 
trained teachers, supportive school policies, a formal PE program, serving of healthy food and beverage options, and a parental/family 
component (Class IIa; Level of Evidence A)†
Increased availability and types of school playground spaces and equipment (Class I; Level of Evidence B)†
Increased number of PE classes, revised PE curricula to increase time in at least moderate activity, and trained PE teachers at schools 
(Class IIa; Level of Evidence A/Class IIb; Level of Evidence A¶)†
Regular classroom physical activity breaks during academic lessons (Class IIa; Level of Evidence A)†§
Workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
Structured worksite programs that encourage activity and also provide a set time for physical activity during work hours (Class IIa; 
Level of Evidence B)†
Improving stairway access and appeal, potentially in combination with “skip-stop” elevators that skip some floors (Class IIa; Level of 
Evidence B)†
Adding new or updating worksite fitness centers (Class IIa; Level of Evidence B)†
Local environment Improved accessibility of recreation and exercise spaces and facilities (eg, building of parks and playgrounds, increasing operating 
hours, use of school facilities during nonschool hours) (Class IIa; Level of Evidence B)†
Improved land-use design (eg, integration and interrelationships of residential, school, work, retail, and public spaces) (Class IIa; Level 
of Evidence B)†
Improved sidewalk and street design to increase active commuting (walking or bicycling) to school by children (Class IIa; Level of 
Evidence B)†
Improved traffic safety (Class IIa; Level of Evidence B)†
Improved neighborhood aesthetics (to increase activity in adults) (Class IIa; Level of Evidence B)†
Improved walkability, a composite indicator that incorporates aspects of land-use mix, street connectivity, pedestrian infrastructure, 
aesthetics, traffic safety, and/or crime safety (Class IIa; Level of Evidence B)†
(Continued)
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Smoking, continued
Media and education Sustained, focused media and educational campaigns to reduce smoking, either alone (IIa B) or as part of larger multicomponent 
population-level strategies (Class I; Level of Evidence A)†
Labeling and information Cigarette package warnings, especially those that are graphic and health related (Class I; Level of Evidence B)†‡§
Economic incentives Higher taxes on tobacco products to reduce use and fund tobacco control programs (Class I; Level of Evidence A)†‡§
Schools and workplaces Comprehensive worksite wellness programs with nutrition, physical activity, and tobacco cessation/prevention components (Class IIa; 
Level of Evidence A)†
Local environment Reduced density of retail tobacco outlets around homes and schools (Class I; Level of Evidence B)†
Development of community telephone lines for cessation counseling and support services (Class I; Level of Evidence A)†
Restrictions and mandates Community (city, state, or federal) restrictions on smoking in public places (Class I; Level of Evidence A)†
Local workplace-specific restrictions on smoking (Class I; Level of Evidence A)†‡§
Stronger enforcement of local school-specific restrictions on smoking (Class IIa; Level of Evidence B)†
Local residence-specific restrictions on smoking (Class IIa; Level of Evidence B)†§
Partial or complete restrictions on advertising and promotion of tobacco products (Class I; Level of Evidence B)†
PE indicates physical education.
*The specific population interventions listed here are either a Class I or IIa recommendation with a Level of Evidence grade of either A or B.
†At least some evidence from studies conducted in high-income Western regions and countries (eg, North America, Europe, Australia, New Zealand).
‡At least some evidence from studies conducted in high-income non-Western regions and countries (eg, Japan, Hong Kong, South Korea, Singapore).
§At least some evidence from studies conducted in low- or middle-income regions and countries (eg, Africa, China, Pakistan, India).
║Based on cross-sectional studies only; only 2 longitudinal studies have been performed, with no significant relations seen.
¶Class IIa; Level of Evidence A for improving physical activity; Class IIb; Level of Evidence B for reducing adiposity.
Reprinted from Mozaffarian et al19 with permission. Copyright © 2012, American Heart Association, Inc.
Table 2-5. Continued
Table 2-6. Reduction in BP Required to Increase Prevalence 
of Ideal BP Among Adults ≥20 Years, NHANES 2011 to 2012
Percent BP ideal among adults, 2011–2012 42.17
20% Relative increase 50.60
Percent whose BP would be ideal if population mean BP were  
lowered by*
2 mm Hg 53.62
3 mm Hg 57.42
4 mm Hg 59.39
5 mm Hg 63.40
Values are percentages. Data are standardized to the age distribution of the 
2000 US standard population.
BP indicates blood pressure; and NHANES, National Health and Nutrition 
Examination Survey.
*Reduction in BP=(observed average systolic−X mm Hg) AND (observed 
average diastolic−X mm Hg).
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Table 2-7. AHA Advocacy and Policy Strategies Related to the 2020 Impact Goals for Ideal Cardiovascular Health
Measure of Cardiovascular Health Advocacy/Policy Solutions
Smoking status
Children
Ideal: Never tried or never smoked a  
whole cigarette
Intermediate: Quit <12 mo
Poor: Current smoker
Adults
Ideal: Never smoked or quit >1 y ago
Intermediate: Quit <12 mo
Poor: Current smoker
Increase excise taxes, including federal tobacco tax parity 
(state and federal)
Support comprehensive clean indoor air laws/regulations 
(state/community level/multiunit housing/hospitals/college campuses, and federal office buildings)
Ensure comprehensive tobacco cessation benefits in private and public insurance plans with minimal copay 
(federal level with Center for Medicare and Medicaid Services and implementation of the ACA and state level 
with Medicaid and state healthcare plans)
Increase funding for tobacco cessation and prevention programs that meet or exceed the CDC recommended 
levels 
(state)
Ensure FDA regulation of tobacco including cigars and e-cigarettes 
(federal)
Monitor the role of mobile technologies to improve cessation therapy
(federal/state)
Improve surveillance for the increasing use of e-cigarettes and smokeless tobacco products 
(federal/state/local)
Eliminate the sale of tobacco in pharmacies and other health-related institutions 
(state/local)
Physical activity
 Children
Ideal: ≥60 min of moderate to  
vigorous physical activity per day
Intermediate: 1–59 min of moderate  
to vigorous physical activity per day
Poor: No physical activity
Adults
Ideal: At least 150 min of moderate or  
75 min of vigorous physical activity  
each week
Intermediate: 1–149 min/wk moderate or  
1–74 min/wk vigorous activity
Poor: No physical activity
Increase quality and quantity of physical education in schools 
(federal/state/local)
Increase the quantity of other physical activity opportunities during the school day, such as
● Recess
● Classroom breaks/activity between classes
●  Physical activity integrated into the curriculum 
(state/local)
Support the creation and implementation, through legislation and regulation (including licensing), of physical 
activity standards for preschool, day care, and other out-of-school care programs 
(state/local)
Increase funding for and implementation of Safe Routes to School 
(federal/state/local)
Improve implementation of local wellness policies in schools 
(federal/state/local)
Promote robust physical activity policies in early childcare 
(state/local)
Promote physical activity standards in before-school and after-school programs 
(federal/state/local)
Support and promote healthy meeting/conference guidelines 
(state/local)
Support physical activity opportunities and screening within comprehensive worksite wellness programs, 
workplace design, and ensure consumer protections with financial incentives tied to healthcare plans 
(federal/state/local)
Change zoning laws to favor/require mixed-use development that places destinations within walking distance of homes 
(state/local)
Promote street-level design and connectivity that facilitate active transport within communities (including 
Complete Streets policies) 
(federal/state/local)
Change transportation goals away from moving cars to a balanced approach to moving people 
(federal/state/local)
Promote shared use of school facilities 
(state/local)
Provide tax incentives and reimbursement policies that cover health/fitness counseling 
(federal/state)
(Continued)
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Physical activity, continued Ensure regular revision and update of the Physical Activity Guidelines for Americans 
(federal)
Target funding for physical activity environments, policy implementation, and program to communities with 
high need; high need could be defined as low-income, high rates of CVD, shorter lifespans 
(federal/state/local)
Target technical assistance and support for grant preparation for physical activity–related grants to low-
resource communities 
(federal/state/local)
Screen for physical activity in the clinical environment as a vital sign and incorporate quality measure into 
electronic health records 
(federal/state)
BMI
Adults
Ideal: BMI between 18.5 and 25 kg/m2
Intermediate: 25–29.9 kg/m2
Poor: >30 kg/m2
Children
Ideal: BMI between the 15th and 85th  
percentile
Intermediate: BMI between 85th and  
95th percentile
Poor: >95th percentile
Provide comprehensive coverage for guidelines-based prevention, diagnosis, and treatment of overweight and 
obesity in the healthcare environment 
(federal/state)
Provide robust surveillance and monitoring of obesity
(federal/state)
Healthy diet
Adults and Children
Ideal for cardiovascular health: In the  
context of a DASH-type dietary pattern,  
adults and children should achieve at  
least 4 of the 5 following key  
components of a healthy diet:
Fruits and vegetables: >4.5 cups/d
Fish: More than two, 3.5-oz servings/wk  
(preferably oily fish)
Fiber-rich whole grains (>1.1 g of fiber per  
10 g of carbohydrates): three 1-oz-equivalent 
servings/d
Sodium: <1500 mg/d
Sugar-sweetened beverages: <450 kcal  
(36 oz)/wk
Children/adults
Ideal: Diet Score 4–5
Intermediate: Diet Score 2–3
Poor: Diet Score 0–1
Reduce sodium in the food supply:
Finalize voluntary FDA standards for reduction of sodium across all food and beverage categories 
(federal)
Improve food labeling
●  Update of the Nutrition Facts Panel
●  On-package symbols
●  Health claims
● Structure/function claims
(federal)
Help shape the Dietary Guidelines for Americans through regulatory means 
(federal)
Robust implementation of school nutrition standards for meals and competitive foods 
(federal/state)
Implement procurement standards for food service and purchasing across federal and state agencies 
(federal/state)
Increase fruit and vegetable consumption:
Promote and protect the implementation of robust nutrition standards for school meals and competitive foods 
(federal/state/local)
Promote robust nutrition policies in early childcare 
(state/local)
Promote nutrition standards, nutrition education, and physical activity standards in before-school and after-
school programs 
(federal/state/local)
Eliminate unhealthy food marketing and advertising to children Increase healthy food marketing and advertising
(state/local)
Promote procurement, meeting, and vending standards for foods purchased by governments and employers
(federal/state/local)
Improve access to healthy affordable foods in the community:
● Healthy food financing
● Farmers’ markets
● School/community gardens
● SNAP education
● Fresh fruit and vegetable program
(federal/state/local)
Table 2-7. Continued
Measure of Cardiovascular Health Advocacy/Policy Solutions
(Continued)
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
 Heart Disease and Stroke Statistics—2015 Update: Chapter 2  e51
Healthy diet, continued Continue to improve nutrition standards and nutrition education in government feeding programs such as:
● WIC
● SNAP
● CACFP
(federal)
Reduce sugar-sweetened beverage consumption:
Support sugar-sweetened beverage taxes
(state/local)
Increase water subsidies
(state/local)
Provide funding for placement and maintenance of water fountains or dispensers in public places
 (federal/state/local)
Other disincentives/incentives for healthy beverages within government feeding programs, healthy vending, 
restaurants, hospital systems, schools, healthy food financing initiatives, and procurement standards
(federal/state/local)
Blood pressure
Adults
Ideal: BP <120/<80 mm Hg
Intermediate: SBP 120–139 mm Hg or DBP  
80–89 mm Hg, or treated <140/<90 mm Hg
Poor: Treated BP >140/>90 mm Hg or  
untreated >140/>90 mm Hg
Children
Ideal: <90th percentile
Intermediate: 90th-95th percentile or SBP  
≥120 or DBP ≥80 mm Hg
Poor: >95th percentile
Blood glucose
Children and adults
Ideal: <100 mg/dL
Intermediate: 100–125 mg/dL or  
treated to goal
Poor: ≥126 mg/dL 
Cholesterol
Adults
Ideal: <200 mg/dL
Intermediate: 200–239 mg/dL or  
treated to goal
Poor: ≥240 mg/dL
Children
Ideal: <170 mg/dL
Intermediate: 170–199 mg/dL
Poor: ≥200 mg/dL
Expand and protect access to affordable, adequate, transparent insurance coverage for all; support 
implementation of the ACA
(federal/state)
Expand coverage for groups not adequately covered by the ACA (eg, those in states that do not expand Medicaid; 
mixed-status families, tobacco users); work to eliminate health insurance disparities that minorities face
(federal/state)
Support reimbursement and minimal copays for preventive services
(federal/state)
Help inform/guide Medicare national coverage determinations to ensure that Medicare beneficiaries have 
access to appropriate treatments and services.
(federal)
Partner with the Department of Health and Human Services to promote the Million Hearts campaign
(federal/state)
Ensure continued funding and implementation of the Million Hearts campaign
(federal)
Promote public funding for heart disease and stroke prevention programs
(state)
Monitor issues around drugs and devices; address drug formularies
(federal/state)
Ensure adherence to clinical guidelines and treatment protocols
(federal/state/local)
Monitor mobile technologies to improve health
(federal)
Reduce CVD mortality by 20% by 2020
 Acute event: Improve systems of care (acute 
 response and acute care)
Support comprehensive, coordinated systems of care
● EMS
 —Support strengthening 9-1-1 systems
 —Emergency medical dispatch
 —Support the establishment of quality community CPR/AED programs
 —Support the establishment of quality school-based programs to promote CPR, AED, and first aid
 —Promote credentialing for professionals to support strong EMS systems
 —Support and protect funding for NEMSIS
● STEMI
● Stroke
● Out-of-hospital cardiac arrest
●  Telehealth (reimbursement/ease licensing/credentialing)
(federal/state/local)
(Continued)
Table 2-7. Continued
Measure of Cardiovascular Health Advocacy/Policy Solutions
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e52  Circulation  January 27, 2015
Reduce CVD mortality by 20%  
by 2020, continued
Improve care coordination models:
● Medical homes
● Other delivery systems reforms
(federal/state/local)
Ensure optimal use of health information technology
(federal)
Explore evidence-based opportunities for integration with mobile health technologies in delivery systems of 
care (federal)
Improve the quality and comprehensiveness of healthcare data reporting
(federal/state/local)
Increase the use of clinical registries
(federal/state)
Ensure implementation of pulse oximetry screening for newborns
(state/local)
Integrate the AHA’s principles for palliative care within delivery of care
(federal)
Postevent rehabilitation: Increase  
referral for, use of, adequate reimbursement  
for, and completion of cardiac rehabilitation  
and stroke rehabilitation
Ensure adequate insurance coverage for cardiac rehabilitation and establish a national coverage determination 
for cardiac rehabilitation for heart failure patients (federal)
Support funding for demonstration projects that expand access to and increase use of cardiac rehabilitation in 
different settings
(federal/state)
Ensure adequate coverage/reimbursement for comprehensive stroke rehabilitation
(federal/state)
Broadly implement automatic and coordinated referral strategies
(federal/state/local)
For AHA advocacy resources, including fact sheets, policy briefs, published papers, and position statements, go to http://www.heart.org/HEARTORG/Advocate/
PolicyResources/Policy-Resources_UCM_001135_SubHomePage.jsp. 
ACA indicates Affordable Care Act; AED, automated external defibrillator; AHA, American Heart Association; BMI, body mass index; BP, blood pressure; CACFP, 
Child and Adult Care Food Program; CDC, Centers for Disease Control and Prevention; CPR, cardiopulmonary resuscitation; CVD, cardiovascular disease; DASH, 
Dietary Approaches to Stop Hypertension; DBP, diastolic blood pressure; EMS, emergency medical services; FDA, US Food and Drug Administration; NEMSIS, National 
Emergency Medical Services Information System; PA, physical activity; SBP, systolic blood pressure; SNAP, Supplemental Nutrition Assistance Program; STEMI, ST-
segment–elevation myocardial infarction; and WIC, Women, Infants, and Children program.
Table 2-7. Continued
Measure of Cardiovascular Health Advocacy/Policy Solutions
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Chart 2-1. Prevalence (unadjusted) estimates for poor, intermediate, and ideal cardiovascular health for each of the 7 metrics of cardio-
vascular health in the American Heart Association 2020 goals, US children aged 12 to 19 years, National Health and Nutrition Examination 
Survey (NHANES) 2011 to 2012. *Healthy diet score data reflects 2009 to 2010 NHANES data.
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Chart 2-2. Prevalence (unadjusted) estimates of poor, intermediate, and ideal cardiovascular health for each of the 7 metrics of cardio-
vascular health in the American Heart Association 2020 goals among US adults aged 20 to 49 years and ≥50 years, National Health and 
Nutrition Examination Survey (NHANES) 2011 to 2012. *Healthy diet score data reflects 2009 to 2010 NHANES data. 
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Chart 2-4. Age-standardized prevalence estimates of US adults aged ≥20 years meeting different numbers of criteria for ideal cardiovas-
cular health, overall and by age and sex subgroups, National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-3. Proportion (unadjusted) of US children aged 12 to 19 years meeting different numbers of criteria for ideal cardiovascular 
health, overall and by sex, National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-5. Age-standardized prevalence estimates of US adults aged ≥20 years meeting different numbers of criteria for ideal cardiovas-
cular health, overall and in selected race subgroups, National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-6. Prevalence for meeting ≥5 criteria for ideal cardiovascular health among US adults aged ≥20 years (age standardized) and US 
children aged 12 to 19 years, overall and by sex, National Health and Nutrition Examination Survey 2005 to 2006 and 2009 to 2010.
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Chart 2-7. Age-standardized prevalence estimates of US adults meeting different numbers of criteria for ideal and poor cardiovascular 
health, for each of the 7 metrics of cardiovascular health in the American Heart Association 2020 goals among US adults aged ≥20 years, 
National Health and Nutrition Examination Survey 2009 to 2010.
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Chart 2-8. Age-standardized cardiovascular health status by US states, Behavioral Risk Factor Surveillance System, 2009.  
A, Age-standardized prevalence of population with ideal cardiovascular health by states. B, Age-standardized percentage of popula-
tion with 0 to 2 cardiovascular health metrics by states. C, Age-standardized mean score of cardiovascular health metrics by states. 
Reprinted from Fang et al.3
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Chart 2-9. Trends in prevalence (unadjusted) of meeting criteria for ideal cardiovascular health for each of the 7 metrics of cardiovascular 
health in the American Heart Association 2020 goals among US children aged 12 to 19 years, National Health and Nutrition Examina-
tion Survey (NHANES) 1999 to 2000 through 2011 to 2012. *Because of changes in the physical activity questionnaire between different 
cycles of the NHANES, trends over time for this indicator should be interpreted with caution, and statistical comparisons should not be 
attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only available for the 2005 to 2006, 2007 to 2008, 
and 2009 to 2010 NHANES cycles at the time of this analysis.
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Chart 2-10. Age-standardized trends in prevalence of meeting criteria for ideal cardiovascular health for each of the 7 metrics of cardio-
vascular health in the American Heart Association 2020 goals among US adults aged ≥20 years, National Health and Nutrition Examina-
tion Survey (NHANES) 1999 to 2000 through 2011 to 2012. *Because of changes in the physical activity questionnaire between different 
cycles of the NHANES, trends over time for this indicator should be interpreted with caution, and statistical comparisons should not be 
attempted. †Data for the Healthy Diet Score, based on a 2-day average intake, were only available for the 2005 to 2006, 2007 to 2008, 
and 2009 to 2010 NHANES cycles at the time of this analysis.
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Chart 2-11. Prevalence of ideal, intermediate, and poor cardiovascular health metrics in 2006 (American Heart Association 2020 Impact 
Goals baseline year) and 2020 projections assuming current trends continue. The 2020 targets for each cardiovascular health metric 
assume a 20% relative increase in ideal cardiovascular health prevalence metrics and a 20% relative decrease in poor cardiovascu-
lar health prevalence metrics for men and women. Reprinted from Huffman et al4 with permission. Copyright © 2012, American Heart 
Association.
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Chart 2-12. US age-standardized death rates* from cardiovascular diseases, 2000 to 2012. CHD indicates coronary heart disease;  
and CVD, cardiovascular disease. *Directly standardized to the age distribution of the 2000 US standard population. †Total CVD: Interna-
tional Classification of Diseases, 10th Revision (ICD-10) I00 to I99, Q20 to Q28. §Stroke (all cerebrovascular disease): ICD-10 I60 to I69. 
¶CHD: ICD-10 I20 to I25. **Other CVD: ICD-10 I00 to I15, I26 to I51, I70 to I78, I80 to I89, I95 to I99. Source: Centers for Disease Control 
and Prevention, National Center for Health Statistics.24
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Chart 2-13. Incidence of cardiovascular disease according to the number of ideal health behaviors and health factors. Reprinted from 
Folsom et al.11 Copyright © 2011, with permission from the American College of Cardiology Foundation.
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3 . Smoking/Tobacco Use
See Table 3-1 and Charts 3-1 through 3-3.
Smoking is a major risk factor for CVD and stroke.1 The AHA 
has identified never tried or never smoked a whole cigarette 
(for children) and never smoking or quitting >12 months ago 
(for adults) as 1 of the 7 components of ideal cardiovascular 
health.2 According to NHANES 2011 to 2012 data, 87.1% of 
adolescents and 77.8% of adults met these criteria.
Prevalence
Youth
(See Charts 3-1 and 3-2.)
 ● In 2013, in grades 9 through 123:
— 15.7% of students reported current cigarette use (on ≥1 
day during the 30 days before the survey), 12.6% of stu-
dents reported current cigar use, and 8.8% of students 
reported current smokeless tobacco use. Overall, 22.4% 
of students reported any current tobacco use (YRBS).
— Male students were more likely than female students 
to report current cigarette use (16.4% compared with 
15.0%). Male students were also more likely than female 
students to report current cigar use (16.5% compared 
with 8.7%) and current smokeless tobacco use (14.7% 
compared with 2.9%; YRBS).4
— Non-Hispanic white students were more likely than 
Hispanic or non-Hispanic black students to report any 
current tobacco use, which includes cigarettes, cigars, 
or smokeless tobacco (26.9% compared with 18.0% for 
Hispanic students and 14.3% for non-Hispanic black 
students; YRBS).
 ● Among youths 12 to 17 years of age in 2012, 2.2 mil-
lion (8.6%) used a tobacco product (cigarettes, cigars, or 
smokeless tobacco) in the past month, down from 10.0% 
in 2011. Cigarette use in the past month in this age group 
declined significantly from 12.2% in 2003 to 6.6% (1.6 
million smokers) in 2012 (NSDUH).5
 ● Smoking among adolescent males declined from 12.5% in 
2003 to 6.8% in 2012 and for females from 11.9% to 6.3% 
over the same time period (NSDUH).5
 ● Data from the YRBS in 2013 for students in grades 9 to 12 
indicated the following3:
— The percentage of students who reported ever smoking 
cigarettes remained stable from 1991 to 1999 and then 
declined from 70.4% in 1999 to 41.1% in 2013.
— The percentage who reported current cigarette use (on at 
least 1 day in the 30 days before the survey) increased 
between 1991 and 1997 and then declined from 36.4% 
in 1997 to 15.7% in 2013.
— The percentage who reported current frequent cigarette 
use (smoked on ≥20 of the 30 days before the survey) 
increased from 1991 to 1997 and then declined from 
16.7% in 1997 to 5.6% in 2013.
— 48.0% of students in grades 9 to 12 who currently 
smoked cigarettes had tried to quit smoking cigarettes 
during the previous 12 months. The prevalence of trying 
to quit smoking was higher among female student smok-
ers (51.0%) than among male student smokers (45.4%). 
Six of 10 black student smokers (61.0%) tried to quit 
compared with 48.0% of white students and 42.4% of 
Hispanic students (YRBS).
Adults
(See Table 3-1 and Charts 3-2 and 3-3.)
 ● In 2013, among adults ≥18 years of age:
— 20.4% of men and 15.5% of women were current ciga-
rette smokers (NHIS).6
— The percentage of current cigarette smokers (17.9%) 
declined 26% since 1998 (24.1%).6,7
 ● In 2012, the states with the highest percentage of current 
cigarette smokers were Kentucky (28.3%), West Virginia 
(28.2%), and Arkansas (25.0%). Utah had the lowest per-
centage of smokers (10.6%) (BRFSS).8
 ● In 2012, an estimated 69.5 million Americans ≥12 years of 
age were current (past month) users of a tobacco product (cig-
arettes, cigars, smokeless tobacco, or tobacco in pipes). The 
rate of current use of any tobacco product in this age range 
declined from 2007 to 2012 (from 28.6% to 26.7%; NSDUH).5
 ● From 1998 to 2007, cigarette smoking prevalence among 
adults ≥18 years of age decreased in 44 states and the Dis-
trict of Columbia. Six states had no substantial changes in 
prevalence after controlling for age, sex, and race/ethnicity 
(BRFSS).9
 ● On the basis of age-adjusted estimates in 2010 to 2012, 
among people ≥65 years of age, 9.2% of men and 8.0% 
of women were current smokers. In this age group, men 
were more likely than women to be former smokers (52.4% 
compared with 31.5%) (NHIS).10
 ● In 2013, among adults ≥18 years of age, Asian men (14.7%) 
and Hispanic men (16.6%) were less likely to be current 
cigarette smokers than non-Hispanic white men (21.7%), 
non-Hispanic black men (21.1%), and American Indian or 
Alaska Native men (25.7%) on the basis of age-adjusted 
Abbreviations Used in Chapter 3
AHA American Heart Association
AIAN American Indian or Alaska Native
AMI acute myocardial infarction
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
DM diabetes mellitus
FDA US Food and Drug Administration
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
NSDUH National Survey on Drug Use and Health
RR relative risk
WHO World Health Organization
YRBS Youth Risk Behavior Survey
Click here to go to the Table of Contents
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e62  Circulation  January 27, 2015
estimates (NHIS). Similarly, in 2013, Asian women (4.8%) 
and Hispanic women (6.7%) were less likely to be cur-
rent cigarette smokers than non-Hispanic black women 
(15.0%), non-Hispanic white women (18.7%), and Ameri-
can Indian or Alaska Native women (16.7%; NHIS).6
 ● Smoking among 18- to 44-year-old males declined from 
27.9% in 2003 to 22.9% in 2013, and for 18- to 44-year-old 
females, smoking declined from 22.5% to 16.6% over the 
same time period (NHIS).6
 ● In 2011 to 2012, among women 15 to 44 years of age, 
past-month cigarette use was lower among those who were 
pregnant (15.9%) than among those who were not pregnant 
(24.6%). Rates were higher among women 18 to 25 years 
of age (20.9% versus 28.2% for pregnant and nonpregnant 
women, respectively) than among women 26 to 44 years of 
age (12.5% versus 25.2%, respectively; NSDUH).5
Incidence
 ● In 20125:
— Approximately 2.3 million people ≥12 years of age 
smoked cigarettes for the first time within the past 12 
months, which was similar to the estimate in 2011. 
The 2012 estimate averages out to ≈6300 new ciga-
rette smokers every day. Half of new smokers (51.4%) 
in 2012 were <18 years of age when they first smoked 
cigarettes (NSDUH).
— The number of new smokers <18 years of age (1.2 mil-
lion) was similar to that in 2002 (1.3 million); however, 
new smokers ≥18 years of age increased from ≈600 000 
in 2002 to 1.1 million in 2012 (NSDUH).
— Among people 12 to 49 years of age who had started 
smoking within the past 12 months, the average age of 
first cigarette use was 17.8 years, similar to the average 
in 2011 (17.2 years).
Morbidity
 ● A 2010 report of the US Surgeon General on how tobacco 
causes disease summarized an extensive body of litera-
ture on smoking and CVD and the mechanisms through 
which smoking is thought to cause CVD.11 There is a sharp 
increase in CVD risk with low levels of exposure to ciga-
rette smoke, including secondhand smoke, and a less rapid 
further increase in risk as the number of cigarettes per day 
increases.
 ● Smoking is an independent risk factor for CHD and appears 
to have a multiplicative effect with the other major risk fac-
tors for CHD: high serum levels of lipids, untreated hyper-
tension, and DM.11
 ● A meta-analysis comparing pooled data of ≈2.4 million 
smokers and nonsmokers found the RR ratio of smokers 
to nonsmokers for developing CHD was 25% higher in 
women than in men (95% CI, 1.12–1.39).12
 ● Current smokers have a 2 to 4 times increased risk of stroke 
compared with nonsmokers or those who have quit for >10 
years.13,14
 ● Tobacco exposure is a top risk factor for disability in the 
United States, second only to dietary risks.15
Mortality
 ● Annually from 2005 to 2009, smoking was responsible 
for >480 000 premature deaths in the United States among 
those ≥35 years of age. Furthermore, almost one third of 
deaths of CHD are attributable to smoking and secondhand 
smoke exposure.16
 ● Each year from 2005 to 2009, an estimated 41 000 US 
deaths were attributable to exposure to secondhand smoke 
among those ≥35 years of age.16
 ● In 2009, smoking was estimated to cause 3.3 million years 
of potential life lost for males and 2.2 million years for 
females, excluding deaths attributable to smoking-attribut-
able residential fires and adult deaths attributable to sec-
ondhand smoke.16
 ● From 2005 to 2009, smoking during pregnancy resulted in 
an estimated 970 infant deaths annually.16
 ● On average, male smokers die 13.2 years earlier than male 
nonsmokers, and female smokers die 14.5 years earlier than 
female nonsmokers.1
 ● In 2010, tobacco smoking was the second-leading risk fac-
tor for death in the United States, after dietary risks.15
 ● Overall mortality among US smokers is 3 times higher than 
that for never-smokers.17
 ● If current smoking trends continue, 5.6 million U.S. chil-
dren will die prematurely during adulthood of smoking.16
Smoking Cessation
 ● Smoking cessation reduces the risk of cardiovascular mor-
bidity and mortality for smokers with and without CHD.
— There is no convincing evidence to date that reducing 
the amount smoked by smoking fewer cigarettes per day 
reduces the risk of CVD, although in several studies a 
dose-response relationship has been seen among current 
smokers between the number of cigarettes smoked per 
day and CVD incidence.11
 ● Quitting smoking at any age significantly lowers mortal-
ity from smoking-related diseases, and the risk declines 
more the longer the time since quitting smoking.18 Cessa-
tion appears to have both short-term (weeks to months) and 
long-term (years) benefits for lowering CVD risk. Overall, 
risk appears to approach that of nonsmokers after ≈10 years 
of cessation.
 ● Smokers who quit smoking at 25 to 34 years of age gained 
10 years of life compared with those who continued to 
smoke. Those aged 35 to 44 years gained 9 years and those 
aged 45 to 54 years gained 6 years of life, on average, com-
pared with those who continued to smoke.17
 ● In 2010, 48.3% of adult current smokers ≥18 years of 
age who had a health checkup during the preceding year 
reported that they had been advised to quit. Smokers 
between 18 and 24 (31%) and 24 to 44 (44%) years of age 
were less likely to be advised to quit than those at older 
ages (57%; NHIS).19
 ● Cessation medications (including sustained-release bupro-
pion, varenicline, and nicotine gum, lozenge, nasal spray, 
and patch) are effective for helping smokers quit.20
 ● In addition to medications, smoke-free policies, increases 
in tobacco prices, cessation advice from healthcare 
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professionals, and quitlines and other counseling have con-
tributed to smoking cessation.19
 ● In 2010, 52.4% of adult smokers reported trying to quit 
smoking in the past year; 6.2% reported they recently quit 
smoking. Of those who tried to quit smoking, 30.0% used 
cessation medications.19
Electronic Cigarettes
 ● Electronic nicotine delivery systems, more commonly 
called electronic cigarettes or e-cigarettes, are battery-
operated devices that deliver nicotine, flavors, and other 
chemicals to the user in an aerosol. Although e-cigarettes 
were introduced less than a decade ago, there are currently 
>250 e-cigarette brands on the market, and sales in the 
United States were projected to be $1.7 billion in 2013.21,22
 ● Because these products have not been well studied, their 
risks and benefits are not fully understood. Specifically, the 
health risks from the inhaled nicotine and other chemicals 
in e-cigarettes are not entirely known. E-cigarettes may 
play a beneficial role in helping smokers reduce or elimi-
nate their conventional cigarette habit. However, there are 
concerns that e-cigarettes may be a gateway to tobacco use 
by nonsmokers, especially teenagers. Furthermore, many 
public health advocates are worried that e-cigarettes will 
reverse decades of efforts to denormalize smoking, which 
contributed to the decline in smoking.16,21,22
 ● The answers to some of these questions may become 
clearer as the regulatory oversight of e-cigarettes becomes 
more defined.16 Currently, only e-cigarettes that are mar-
keted for therapeutic purposes are regulated by the FDA, 
but in April 2014, the FDA proposed extending its tobacco 
product authorities to include e-cigarettes.23
Secondhand Smoke
 ● Data from the US Surgeon General on the consequences of 
secondhand smoke indicate the following:
— Nonsmokers who are exposed to secondhand smoke at 
home or at work increase their risk of developing CHD 
by 25% to 30%.11
— Short exposures to secondhand smoke can cause blood 
platelets to become stickier, damage the lining of blood 
vessels, and decrease coronary flow velocity reserves, 
potentially increasing the risk of an AMI.11
— Exposure to secondhand smoke increases the risk of 
stroke by 20% to 30%.16
— Nearly 34 000 premature deaths of heart disease occur 
each year in the United States among nonsmokers.16
 ● In 2008, data from 11 states showed that the majority of 
people surveyed in each state reported having smoke-free 
home rules, ranging from 68.8% in West Virginia to 85.6% 
in Arizona (BRFSS).24
 ● As of January 2, 2014, 25 states and the District of Colum-
bia had laws that prohibited smoking in indoor areas of 
worksites, restaurants, and bars; no states had such laws 
in 2000. As of January 2, 2014, an additional 12 states had 
laws that prohibited smoking in 1 or 2 but not all 3 venues.25
 ● In 2012, 30 of the 50 largest US cities prohibited indoor 
smoking in private workplaces, either through state or local 
ordinances.26
 ● Pooled data from 17 studies in North America, Europe, and 
Australasia suggest that smoke-free legislation can reduce 
the incidence of acute coronary events by 10%.27
 ● The percentage of the US nonsmoking population with 
serum cotinine ≥0.05 ng/mL declined from 52.5% in 1999 
to 2000 to 40.1% in 2007 to 2008, with declines occurring 
for both children and adults. During 2007 to 2008, the per-
centage of nonsmokers with detectable serum cotinine was 
53.6% for those 3 to 11 years of age, 46.5% for those 12 
to 19 years of age, and 36.7% for those ≥20 years of age. 
The percentage was also higher for non-Hispanic blacks 
(55.9%) than for non-Hispanic whites (40.1%) and Mexi-
can Americans (28.5%; NHANES).28
Cost
 ● Each year from 2005 to 2009, US smoking-attributable 
economic costs were between $289 billion and $333 bil-
lion, including $133 billion to $176 billion for direct medi-
cal care of adults and $151 billion for lost productivity 
related to premature death.16
 ● In 2008, $9.94 billion was spent on marketing cigarettes in 
the United States.29
 ● Cigarette prices in the United States have increased 283% 
between the early 1980s and 2011, in large part because 
of excise taxes on tobacco products. Higher taxes have 
decreased cigarette consumption, which fell from ≈30 mil-
lion packs sold in 1982 to ≈14 million packs sold in 2011.29
Global Burden of Smoking
 ● Worldwide, tobacco smoking (including secondhand 
smoke) was 1 of the top 3 leading risk factors for disease 
and contributed to an estimated 6.2 million deaths in 2010.30
 ● To help combat the global problem of tobacco exposure, in 
2003 the WHO adopted the Framework Convention on Tobacco 
Control treaty. The WHO Framework Convention on Tobacco 
Control contains a set of universal standards to limit tobacco 
supply and demand worldwide. These standards include the 
use of tax policies to reduce tobacco consumption, a ban on the 
indoor use of tobacco products, implementation of educational 
programs about the dangers of tobacco use, and restrictions of 
the sale of tobacco products to international travelers. Since it 
came into force in 2005, >175 countries have ratified the WHO 
Framework Convention on Tobacco Control.31
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Table 3-1. Cigarette Smoking
Population Group
Prevalence, 2013 Age 
≥18 y*6 Cost16
Both sexes 43 415 000 (17.9%) $289 Billion per year
Males 24 080 000 (20.4%) …
Females 19 298 000 (15.5%) …
NH white males 21.7% …
NH white females 18.7% …
NH black males 21.1% …
NH black females 15.0% …
Hispanic or Latino males 16.6% …
Hispanic or Latino 
females
6.7% …
Asian males 14.7% …
Asian females 4.8% …
American Indian/Alaska 
Native males
25.7% …
American Indian/Alaska 
Native females
16.7% …
Percentages are age adjusted. Estimates for Asian only and American Indian/
Alaska Native only include non-Hispanic and Hispanic people.
Ellipses (. . .) indicate data not available; and NH, non-Hispanic.
*Rounded to the nearest thousand; based on total resident population.
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Chart 3-1. Prevalence (%) of students in grades 9 to 12 reporting current cigarette use by sex and race/ethnicity (Youth Risk Behavior 
Surveillance System, 2013). NH indicates non-Hispanic. Data derived from MMWR: Morbidity and Mortality Weekly Report.3
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Chart 3-2. Prevalence (%) of current smoking for adolescents and adults, by sex and age (National Health Interview Survey, 2003–2012; 
National Survey on Drug Use and Health, 2003–2012). Data derived from the Centers for Disease Control and Prevention/National Center 
for Health Statistics and Substance Abuse and Mental Health Services Administration.5
Chart 3-3. Prevalence (%) of current smoking for adults ≥18 years of age by race/ethnicity and sex (National Health Interview Survey: 
2010–2012). All percentages are age adjusted. AIAN indicates American Indian or Alaska Native; NH, non-Hispanic. *Includes both His-
panics and non-Hispanics. Data derived from the Centers for Disease Control and Prevention/National Center for Health Statistics, Health 
Data Interactive.10
22.6
19.8
22.8
15.415.9
8.3
15 15
23.7 23.3
0
5
10
15
20
25
Male Female
Pe
rc
en
t o
f P
op
ul
at
io
n
NH White NH Black Hispanic Asian AIAN
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2015 Update: Chapter 4  e67
4 . Physical Inactivity
See Table 4-1 and Charts 4-1 through 4-5.
Physical inactivity is a major risk factor for CVD and stroke.1 
PA is 1 of the AHA’s 7 components of ideal cardiovascular 
health for both children and adults.2 The AHA and 2008 fed-
eral guidelines on PA recommend that children get at least 60 
minutes of PA daily (including aerobic and muscle- and bone-
strengthening activity). The guidelines recommend that adults 
get at least 150 minutes of moderate-intensity or 75 minutes of 
vigorous-intensity aerobic activity (or an equivalent combina-
tion) per week and perform muscle-strengthening activities at 
least 2 days per week (US Department of Health and Human 
Services). In 2011 to 2012, on the basis of survey interviews, 
36.5% of children and 44.0% of adults met these criteria.
Not only does being physically active improve health, but being 
inactive is unhealthy.3 PA reduces premature mortality. In addition, 
PA improves risk factors for CVD (such as HBP and high cho-
lesterol) and reduces the likelihood of diseases related to CVD, 
including CHD, stroke, type 2 DM, and sudden heart attacks 
(US Department of Health and Human Services). Benefits from 
PA are seen for all ages and groups, including older adults, preg-
nant women, and people with disabilities and chronic conditions. 
Therefore, the federal guidelines recommend being as physically 
active as abilities and conditions allow and increasing PA gradually.
There are 4 dimensions of PA (mode or type, frequency, 
duration, and intensity) and 4 common domains (occupational, 
domestic, transportation, and leisure time). Historically, recom-
mendations on PA for health purposes have focused on leisure-
time activity. However, because all domains of PA could have an 
impact on health, and because an increase in 1 domain may some-
times be compensated for by a decrease in another domain, it is 
important to generate data on all dimensions and domains of PA.
There are 2 broad categories of methods to assess PA: (1) 
subjective methods that use questionnaires and diaries/logs 
and (2) objective methods that use wearable monitors (pedom-
eters, accelerometers, etc). It is very important to keep in 
mind that the bulk of the data available linking inactivity/PA 
to cardiovascular outcomes has been obtained with the use of 
questionnaires. Thus, prevalence data on inactivity/PA must be 
interpreted with an understanding of the limitations of the tools 
that have been used to generate such data. Although any activ-
ity is better than none, the federal guidelines specify the sug-
gested frequency, duration, and intensity of activity.
Studies that used both subjective and objective methods 
(such as wearable monitors, like pedometers or accelerom-
eters) have found that there is marked discordance between 
reported and measured PA.4,5
 Therefore, PA estimates based on 
participant report may overstate the level of PA. Furthermore, 
surveys often ask only about leisure-time PA; however, PA 
also may come from occupational, domestic, and transporta-
tion responsibilities. People who get a lot of PA from these 
other responsibilities may be less like to engage in leisure-
time PA, and yet they may meet the federal PA guidelines.
Chronic physical inactivity contributes to a poor level of car-
diorespiratory (or aerobic) fitness, which is a stronger predictor 
of adverse cardiometabolic and cardiovascular outcomes than 
traditional risk factors. Although both PA and cardiorespiratory 
fitness are inversely related to the risk of CVD and other clinical 
outcomes, they are in part distinct measures in the assessment 
of CVD risk.6 PA is a behavior that can potentially improve car-
diorespiratory fitness. Although many studies have shown that 
increasing the amount and quality of PA can improve cardiore-
spiratory fitness, other factors can contribute, such as a genetic 
predisposition to perform aerobic exercise. Because cardiore-
spiratory fitness is directly measured and reflects both partici-
pation in PA and the state of physiological systems affecting 
performance, the relationship between cardiorespiratory fitness 
and clinical outcomes is stronger than the relationship of PA to a 
series of clinical outcomes.6 Unlike health behaviors such as PA 
and risk factors that are tracked by federally funded programs, 
there are no national data on cardiorespiratory fitness, and the 
development of a national cardiorespiratory fitness registry has 
been proposed.6 Such additional data on the cardiorespiratory 
fitness levels of Americans may give a fuller and more accurate 
picture of physical fitness levels.6
Abbreviations Used in Chapter 4
AHA American Heart Association
BMI body mass index
BNP B-type natriuretic peptide
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
EF ejection fraction
EPIC-Norfolk European Prospective Investigation Into Cancer and 
Nutrition—Norfolk Cohort
FMD flow-mediated dilation
HbA
1c hemoglobin A1c
HBP high blood pressure
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
LV left ventricular
MI myocardial infarction
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHIS National Health Interview Survey
PA physical activity
PAD peripheral artery disease
PAR population attributable risk
RR relative risk
SBP systolic blood pressure
SD standard deviation
WHI Women’s Health Initiative
WHO World Health Organization
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Prevalence
Youth
Inactivity
(See Chart 4-1.)
In 20137:
 ● Nationwide, 15.2% of adolescents reported that they were 
inactive during the previous 7 days, as indicated by their 
response that they did not participate in ≥60 minutes of any 
kind of PA that increased their heart rate and made them 
breathe hard on any 1 of the previous 7 days.
 ● Girls were more likely than boys to report inactivity (19.2% 
versus 11.2%).
 ● The prevalence of inactivity was highest among black 
(27.3%) and Hispanic (20.3%) girls, followed by white 
girls (16.1%), black boys (15.2%), Hispanic boys (12.1%), 
and white boys (9.2%).
Television/Video/Computers
(See Chart 4-2.)
In 20137:
 ● Nationwide, 41.3% of adolescents used a computer for activ-
ities other than school work (eg, videogames or other com-
puter games) for ≥3 hours per day on an average school day.
 ● The prevalence of using computers ≥3 hours per day was 
highest among black boys (51.9%) and black girls (46.6%), 
followed by Hispanic girls (44.8%), Hispanic boys (42.0%), 
white boys (39.1%), and white girls (35.6%).
 ● 32.5% of adolescents watched television for ≥3 hours 
per day.
 ● The prevalence of watching television ≥3 hours per day 
was highest among black boys (55.3%) and girls (52.2%), 
followed by Hispanic girls (39.0%) and boys (36.5%) and 
white boys (25.7%) and girls (24.3%).
 ● Increased television time has significant nutritional asso-
ciations with weight gain (refer to Chapter 5, Nutrition).
Activity Recommendations
(See Chart 4-3.)
 ● In 20137:
— The proportion of students who met activity recommen-
dations of ≥60 minutes of PA on 7 days of the week 
was 27.1% nationwide and declined from 9th (30.4%) to 
12th (24.3%) grades. At each grade level, the proportion 
was higher in boys than in girls.
— More high school boys (36.6%) than girls (17.7%) self-
reported having been physically active ≥60 minutes per 
day on all 7 days; self-reported rates of activity were 
higher in white (28.2%) than in black (26.3%) or His-
panic (25.5%) adolescents.
— The proportion of students who participated in muscle-
strengthening activities on ≥3 days of the week was 
51.7% nationwide and declined from 9th (54.8%) to 
12th (47.7%) grades. At each grade level, the proportion 
was higher in boys than in girls.
— More high school boys (61.8%) than girls (41.6%) self-
reported having participated in muscle-strengthening 
activities on ≥3 days of the week; self-reported rates 
were higher in Hispanic (53.3%) than in white (52.4%) 
or black (48.8%) adolescents.
 ● There was a marked discrepancy between the propor-
tion of youth (ages 6–11 years) who reported engaging 
in ≥60 minutes of moderate to vigorous PA on most days 
of the week and those who actually engaged in moder-
ate to vigorous PA for ≥60 minutes when activity was 
measured objectively with accelerometers (ie, portable 
motion sensors that record and quantify the duration and 
intensity of movements) in the NHANES 2003 to 2004 
survey.4
 ● On the basis of accelerometer counts per minute >2020, 
42% of 6- to 11-year-olds accumulated ≥260 minutes of 
moderate to vigorous PA on ≥5 days per week, whereas 
only 8% of 12- to 15-year-olds and 7.6% of 16- to 19-year-
olds achieved similar counts.4
 ● More boys than girls met PA recommendations (≥60 min-
utes of moderate to vigorous activity on most days of the 
week) as measured by accelerometry.4
Structured Activity Participation
 ● Despite recommendations from the National Associa-
tion for Sport and Physical Education that schools should 
require daily physical education for students in kindergar-
ten through 12th grade,8 only 29.4% of students attended 
physical education classes in school daily (34.9% of boys 
and 24.0% of girls).7
 ● Physical education class participation declined from the 9th 
grade (47.8% for boys, 36.5% for girls) through the 12th 
grade (24.4% for boys, 16.1% for girls).7
 ● Little more than half (54.0%) of high school students 
played on at least 1 school or community sports team in the 
previous year: 48.5% of girls and 59.6% of boys.7
Adults
Inactivity
According to 2013 data from the NHIS, in adults ≥18 years 
of age9:
 ● 30.5% do not engage in leisure-time PA (“no leisure-time 
PA/inactivity” refers to no sessions of light/moderate or 
vigorous PA of ≥10 minutes’ duration).
 ● Inactivity was higher among women than men (32.3% 
versus 28.6%, age adjusted) and increased with age 
from 25.1% to 32.8%, 35.7%, and 51.9% among adults 
18 to 44, 45 to 64, 65 to 74, and ≥75 years of age, 
respectively.
 ● Non-Hispanic black and Hispanic adults were more likely 
to be inactive (38.8% and 39.7%, respectively) than were 
non-Hispanic white adults (27.0%) on the basis of age-
adjusted estimates.
Activity Recommendations
(See Table 4-1 and Chart 4-4.)
 ● According to 2013 data from the NHIS, in adults ≥18 years 
of age9:
— 20.9% met the 2008 federal PA guidelines for both aero-
bic and strengthening activity, an important component 
of overall physical fitness.
— The age-adjusted proportion who reported engaging 
in moderate or vigorous PA that met the 2008 aero-
bic PA guidelines for Americans (≥150 minutes of 
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moderate PA or 75 minutes of vigorous PA or an equiv-
alent combination each week) was 50.0%; 54.2% of 
men and 46.1% of women met the recommendations. 
Age-adjusted prevalence was 53.4% for non-Hispanic 
whites, 41.4% for non-Hispanic blacks, and 42.9% for 
Hispanics.7
— The proportion of respondents who did not meet the 
federal aerobic PA guidelines increased with age from 
43.1% of 18- to 44-year-olds to 72.4% of adults ≥75 
years of age.
— Non-Hispanic black adults (58.6%) and Hispanic/Latino 
adults (57.1%) were more likely not to meet the federal 
aerobic PA guidelines than non-Hispanic white (46.6%) 
adults, according to age-adjusted estimates.
— The percentage of adults ≥25 years of age not meeting 
the full (aerobic and muscle-strengthening) federal PA 
guidelines was inversely associated with education; 
66.6% of participants with no high school diploma, 
57.2% of those with a high school diploma or a high 
school equivalency credential, 46.8% of those with some 
college, and 35.1% of those with a bachelor’s degree or 
higher did not meet the full federal PA guidelines.
— The proportion of adults ≥25 years of age who met the 
2008 federal PA guidelines for aerobic activity was posi-
tively associated with education level: 61.2% of those 
with a college degree or higher met the PA guidelines 
compared with 30.7% of adults with less than a high 
school diploma.
 ● The proportion of adults reporting levels of PA consistent 
with the 2008 Physical Activity Guidelines for Americans 
remains low and decreases with age.10,11 Thirty-three per-
cent of respondents in a study examining awareness of 
current US PA guidelines had direct knowledge of the rec-
ommended dosage of PA (ie, frequency/duration).12
 ● The percentage of adults reporting ≥150 minutes of moder-
ate PA or 75 minutes of vigorous PA or an equivalent com-
bination weekly decreased with age from 55.8% for adults 
18 to 44 years of age to 27.4% for those ≥75 years of age, 
on the basis of the 2011 NHIS.11
 ● The percentage of men who engaged in both leisure-
time aerobic and strengthening activities decreased with 
age, from 39.8% at age 18 to 24 years to 11.1% at ≥75 
years of age. The percentage of women who engaged in 
both leisure-time aerobic and strengthening activities also 
decreased with age, from 20.7% at age 18 to 24 years to 
5.3% at ≥75 years of age, on the basis of the 2011 NHIS.11
 ● Using PA recommendations that existed at the time of the 
survey, adherence to PA recommendations was much lower 
when based on PA measured by accelerometer in NHANES 
2003 to 20044:
— Among adults 20 to 59 years of age, 3.8% of men and 
3.2% of women met recommendations to engage in 
moderate to vigorous PA (accelerometer counts >2020/
min) for 30 minutes (in sessions of ≥10 minutes) on ≥5 
of 7 days.
— Among those ≥60 years of age, adherence was 2.5% in 
men and 2.3% in women.
 ● Accelerometry data from NHANES 2003 to 2006 showed 
that men engaged in 35 minutes of moderate activity per 
day, whereas for women, it was 21 minutes. More than 75% 
of moderate activity was accumulated in 1-minute bouts. 
Levels of activity declined sharply after the age of 50 years 
in all groups.13
 ● In a review examining self-reported versus actual measured 
PA (eg, accelerometers, pedometers, indirect calorimetry, 
doubly labeled water, heart rate monitor), 60% of respon-
dents self-reported higher values of activity than what was 
measured by use of direct methods.14
 ● Among men, self-reported PA was 44% greater than actual 
measured values; among women, self-reported activity was 
138% greater than actual measured PA.14
 ● The discrepancy between reported versus measured PA 
activity clearly indicates that the proportion of sufficiently 
active individuals is overestimated and that there is a need 
to monitor nationwide levels of measured PA.
Trends
Youth
(See Chart 4-5.)
 ● In 20137:
— Among adolescents, a significant decrease occurred 
overall in the prevalence of having watched television 
for ≥3 hours per day compared with 1999 (42.8% versus 
32.5%); however, the prevalence did not change from 
2011 (32.4%) to 2013 (32.5%).
— Among students nationwide, there was a significant 
increase in the prevalence of having participated in 
muscle-strengthening activities on ≥3 days per week, 
from 47.8% in 1991 to 51.7%; however, the prevalence 
decreased from 2011 (55.6%) to 2013 (51.7%).
— A significant increase occurred in the prevalence of hav-
ing used computers for ≥3 hours per day compared with 
2003 (22.1% versus 41.3%). The prevalence increased 
from 2003 to 2009 (22.1% versus 24.9%) and then 
increased more rapidly from 2009 to 2013 (24.9% versus 
41.3%). Even more recently, the prevalence increased to 
31.1% in 2011.
— Among adolescents nationwide, the prevalence of attend-
ing physical education classes at least once per week did 
not increase significantly, from 25.4% in 1995 to 29.4%.
— The prevalence of adolescents playing ≥1 team sport in 
the past year decreased from 58.4% in 2011 to 54.0%.
 ● In 2012, the prevalence of adolescents aged 12 to 15 years 
with adequate levels of cardiorespiratory fitness (based on 
age- and sex-specific standards) was 42.2% in 2012, down 
from 52.4% in 1999 to 2000.15
Adults
 ● Between NHANES III (1988–1994) and NHANES 2001 
to 2006, the non–age-adjusted proportion of adults who 
reported engaging in >12 bouts of PA per month declined 
from 57.0% to 43.3% in men and from 49.0% to 43.3% in 
women.16
 ● The proportion of US adults who meet criteria for muscle 
strength has improved between 1998 and 2011. Annual 
estimates of the percentage of US adults who met the 
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muscle-strengthening criteria increased from 17.7% in 
1998 to 24.5% in 2011, and estimates of the percentage 
who met both the muscle-strengthening and aerobic criteria 
increased from 14.4% in 1998 to 21.0% in 2011.10,17
 ● A 2.3% decline in physical inactivity between 1980 and 
2000 was estimated to have prevented or postponed ≈17 445 
deaths (≈5%) attributable to CHD in the United States.18
CVD and Metabolic Risk Factors
Youth
 ● In 2011, more girls (67.9%) than boys (55.7%) reported 
having exercised to lose weight or to keep from gaining 
weight. White girls (72.2%) were more likely than black 
(54.2%) and Hispanic (66.3%) girls to report exercising to 
lose weight or to keep from gaining weight.19
 ● Total and vigorous PA are inversely correlated with body 
fat and the prevalence of obesity.20
 ● Among children 4 to 18 years of age, increased time in mod-
erate to vigorous PA was associated with improvements in 
waist circumference, SBP, fasting triglycerides, HDL cho-
lesterol, and insulin. These findings were significant regard-
less of the amount of the children’s sedentary time.21
 ● Among children aged 4 to 18 years, both higher activity 
levels and lower sedentary time measured by accelerometry 
were associated with more favorable metabolic risk factor 
profiles.21
Adults
 ● Participants in the Diabetes Prevention Program random-
ized trial who met the PA goal of 150 minutes of PA per 
week were 44% less likely to develop DM after 3.2 years of 
follow-up, even if they did not meet the weight-loss target.22
 ● Exercise for weight loss, without dietary interventions, was 
associated with significant reductions in DBP (–2 mm Hg; 
95% CI, –4 to –1 mm Hg), triglycerides (–0.2 mmol/L; 
95% CI, –0.3 to –0.1 mmol/L), and fasting glucose (–0.2 
mmol/L; 95% CI, –0.3 to –0.1 mmol/L).23
 ● A total of 120 to 150 minutes per week of moderate-inten-
sity activity, compared with none, can reduce the risk of 
developing metabolic syndrome.24
 ● In CARDIA, women who maintained high activity through 
young adulthood gained 6.1 fewer kilograms of weight and 
3.8 fewer centimeters in waist circumference in middle age 
than those with lower activity. Highly active men gained 
2.6 fewer kilograms and 3.1 fewer centimeters than their 
lower-activity counterparts.25
 ● Self-reported low lifetime recreational activity has been 
associated with increased PAD.26
 ● In 3 US cohort studies, men and women who increased 
their PA over time gained less weight in the long term, 
whereas those who decreased their PA over time gained 
more weight and those who maintained their current PA 
had intermediate weight gain.27
 ● Among US men and women, every hour per day of 
increased television watching was associated with 0.3 lb of 
greater weight gain every 4 years, whereas every hour per 
day of decreased television watching was associated with a 
similar amount of relative weight loss.27
 ● In a sample of 466 605 participants in the China Kadoorie 
Biobank study, a 1-SD (1.5 h/d) increase in sedentary time 
was associated with a 0.19-unit higher BMI, a 0.57-cm 
larger waist circumference, and 0.44% more body fat. Both 
sedentary leisure time and lower PA were independently 
associated with an increased BMI.28
Morbidity and Mortality
 ● Physical inactivity is responsible for 12.2% of the global 
burden of MI after accounting for other CVD risk factors 
such as cigarette smoking, DM, hypertension, abdominal 
obesity, lipid profile, no alcohol intake, and psychosocial 
factors.29
 ● In a meta-analysis of longitudinal studies among women, 
RRs of incident CHD were 0.83 (95% CI, 0.69–0.99), 0.77 
(95% CI, 0.64–0.92), 0.72 (95% CI, 0.59–0.87), and 0.57 
(95% CI, 0.41–0.79) across increasing quintiles of PA com-
pared with the lowest quintile.30
 ● A 2003 meta-analysis of 23 studies on the association of 
PA with stroke indicated that compared with low levels of 
activity, high (RR, 0.79; 95% CI, 0.69–0.91) and moder-
ate (RR, 0.91; 95% CI, 0.80–1.05) levels of activity were 
inversely associated with the likelihood of developing total 
stroke (ischemic and hemorrhagic).31
 ● With television watching as a sedentary activity, 2 hours of 
television per day is associated with an RR for type 2 DM 
of 1.20 (95% CI, 1.14–1.27), an RR for fatal or nonfatal 
CVD of 1.15 (95% CI, 1.06–1.23), and an RR for all-cause 
mortality of 1.13 (95% CI, 1.07–1.18). The risk for all-
cause mortality further increases with >3 hours of televi-
sion daily.32
 ● Longitudinal studies commonly report a graded, inverse 
association of PA amount and duration (ie, dose) with inci-
dent CHD and stroke.33
 ● The PA guidelines for adults cite evidence that ≈150 min-
utes per week of moderate-intensity aerobic activity, com-
pared with none, can reduce the risk of CVD.34
 ● Adherence to PA guidelines for both aerobic and muscle-
strengthening activities is associated with 27% lower all-
cause mortality among adults without existing chronic 
conditions such as DM, cancer, MI, angina, CVD, stroke, or 
respiratory diseases and with 46% lower mortality among 
people with chronic comorbidities.34
 ● In the Health Professionals Follow-Up Study, for every 
3-hour-per-week increase in vigorous-intensity activity, the 
multivariate RR of MI was 0.78 (95% CI, 0.61–0.98) for 
men. This 22% reduction of risk can be explained in part 
by beneficial effects of PA on HDL cholesterol, vitamin D, 
apolipoprotein B, and HbA1c.35
 ● In a 20-year study of older male veterans, an inverse, 
graded, and independent association between impaired 
exercise capacity and all-cause mortality risk was found. 
For each increase of 1 metabolic equivalent tasks in exer-
cise capacity, mortality risk was 12% lower (HR, 0.88; 95% 
CI, 0.86–0.90). Unfit individuals who improved their fit-
ness status had a 35% lower mortality risk (HR, 0.65; 95% 
CI, 0.46–0.93) than those who remained unfit.36
 ● In the EPIC-Norfolk study, men and women with abdomi-
nal obesity with features of the metabolic syndrome who 
reported themselves to be physically very active were 
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characterized by a lower (≈50%) risk of CHD than sed-
entary abdominally obese subjects with the metabolic 
syndrome.37
 ● In the WHI observational study (n=71 018), sitting for ≥10 
h/d compared with ≤5 h/d was associated with increased 
CVD risk (HR, 1.18) in multivariable models that included 
PA. Low PA was also associated with higher CVD risk. It 
was concluded that both low PA and prolonged sitting aug-
ment CVD risk.38
 ● In a study that prospectively assessed the association of con-
tinuous inactivity and of changes in sitting time for 2 years 
with subsequent long-term all-cause mortality, it was found 
that compared with people who remained consistently sed-
entary, the HRs for mortality were 0.91 in those who were 
newly sedentary, 0.86 in formerly sedentary individuals, 
and 0.75 in those who remained consistently nonsedentary. 
Thus, subjects who reduced their sitting time over 2 years 
experienced an immediate reduction in mortality.39
 ● A meta-analysis of 17 eligible studies on PA in patients 
with DM revealed that the highest PA category in each 
study was associated with a lower RR (0.61) for all-cause 
mortality and CVD (0.71) than the lowest PA category. 
Although more PA was associated with larger reductions in 
future all-cause mortality and CVD, in patients with DM, 
any amount of habitual PA was better than inactivity.40
 ● In a special issue of The Lancet on PA, it was reported that 
the prevalence of physical inactivity (35%) worldwide is 
now greater than the prevalence of smoking (26%). On the 
basis of the HRs associated with these 2 behaviors (1.57 
for smoking and 1.28 for inactivity), it was concluded that 
the PAR was greater for inactivity (9%) than for smoking 
(8.7%). Thus, inactivity was estimated to be responsible 
for 5.3 million deaths compared with 5.1 million deaths for 
smoking.41
Secondary Prevention
 ● PA improves inflammatory markers in people with existing 
stable CHD. After a 6-week training session, CRP levels 
declined by 23.7% (P<0.001), and plasma vascular cell 
adhesion molecule-1 levels declined by 10.23% (P<0.05); 
there was no difference in leukocyte count or levels of 
intercellular adhesion molecule-1.42
 ● In a randomized trial of patients with PAD, supervised 
treadmill exercise training and lower-extremity resistance 
training were each associated with significant improve-
ments in functional performance and quality of life com-
pared with a usual-care control group. Exercise training 
was additionally associated with improved brachial artery 
FMD, whereas resistance training was associated with bet-
ter stair-climbing ability versus control.43
 ● On the basis of a meta-analysis of 34 randomized con-
trolled trials, exercise-based cardiac rehabilitation after 
MI was associated with lower rates of reinfarction, cardiac 
mortality, and overall mortality.44
 ● The benefit of intense exercise training for cardiac rehabili-
tation in people with HF was tested in a trial of 27 patients 
with stable, medically treated HF. Intense activity (an 
aerobic interval-training program 3 times per week for 12 
weeks) was associated with a significant 35% improvement 
in LV EF and decreases in pro-BNP (40%), LV end-diastolic 
volume (18%), and LV end-systolic volume (25%) com-
pared with control and endurance-training groups.45
 ● Exercise training in patients with HF with preserved EF 
was associated with improved exercise capacity and favor-
able changes in diastolic function.46
Costs
 ● The economic consequences of physical inactivity are sub-
stantial. In a summary of WHO data sources, the economic 
costs of physical inactivity were estimated to account for 
1.5% to 3.0% of total direct healthcare expenditures in 
developed countries such as the United States.47
 ● Interventions and community strategies to increase PA have 
been shown to be cost-effective in terms of reducing medi-
cal costs48:
— Nearly $3 in medical cost savings is realized for every $1 
invested in building bike and walking trails.
— Incremental cost and incremental effectiveness ratios 
range from $14 000 to $69 000 per quality-adjusted life-
year gained from interventions such as pedometer or 
walking programs compared with no intervention, espe-
cially in high-risk groups.
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Chart 4-1. Prevalence of students in grades 9 to 12 who did not participate in ≥60 minutes of physical activity on any day in the past 
7 days by race/ethnicity and sex (Youth Risk Behavior Surveillance: 2013). NH indicates non-Hispanic. Data derived from MMWR 
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Table 4-1. Met 2008 Federal Aerobic and Strengthening PA 
Guidelines for Adults
Population Group Prevalence, 2013 (Age ≥18 y), %
Both sexes 20.9
Males 24.9
Females 17.0
NH white only 22.7
NH black only 17.7
Hispanic or Latino 16.6
Asian only 18.2
American Indian/Alaska Native only 16.6
“Met 2008 federal PA guidelines for adults” is defined as engaging in ≥150 
minutes of moderate or 75 minutes of vigorous aerobic leisure-time physical 
activity per week (or an equivalent combination) and engaging in leisure-time 
strengthening physical activity at least twice a week.
Data are age adjusted for adults ≥18 years of age.
NH indicates non-Hispanic; and PA, physical activity.
Source: National Health Interview Survey 2013 (National Center for Health 
Statistics).9
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Chart 4-2. Percentage of students in grades 9 to 12 who used a computer for ≥3 hours on an average school day by race/ethnicity and 
sex (Youth Risk Behavior Surveillance: 2013). NH indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.7
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Chart 4-3. Prevalence of students in grades 9 to 12 who met currently recommended levels of physical activity during the past 7 days by 
race/ethnicity and sex (Youth Risk Behavior Surveillance: 2013). “Currently recommended levels” was defined as activity that increased 
their heart rate and made them breathe hard some of the time for a total of ≥60 minutes per day on 5 of the 7 days preceding the survey. 
NH indicates non-Hispanic. Data derived from MMWR Surveillance Summaries.7
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Chart 4-5. Prevalence of children 12 to 15 years of age who had adequate levels of cardiorespiratory fitness, by sex and age (National 
Health and Nutrition Examination Survey, National Youth Fitness Survey: 2012). Source: Gahche et al.15
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Chart 4-4. Prevalence of meeting the aerobic guidelines of the 2008 Federal Physical Activity Guidelines among adults ≥18 years of 
age by race/ethnicity and sex (National Health Interview Survey: 2013). NH indicates non-Hispanic. Percentages are age adjusted. The 
 aerobic guidelines of the 2008 Federal Physical Activity Guidelines recommend engaging in moderate leisure-time physical activity for 
≥150 minutes per week or vigorous activity ≥75 minutes per week or an equivalent combination. Source: National Health Interview Survey 
2013 (National Center for Health Statistics).9
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5 . Nutrition
See Tables 5-1 and 5-2 and Charts 5-1 through 5-3.
This chapter of the Update highlights national dietary con-
sumption data, focusing on key foods, nutrients, dietary pat-
terns, and other dietary factors related to cardiometabolic 
health. It is intended to examine current intakes, trends and 
changes in intakes, and estimated effects on disease to support 
and further stimulate efforts to monitor and improve dietary 
habits in relation to cardiovascular health.
Prevalence of Specific Dietary Habits
Foods and Nutrients: Adults
(See Table 5-1 and Chart 5-1; NHANES 2009–2010.)
The dietary consumption by US adults of selected foods and 
nutrients related to cardiometabolic health is detailed in Table 
5-1 according to sex and race or ethnic subgroups. Compared 
to prior AHA Statistical Updates, the calculations for foods 
now utilize the USDA Food Patterns Equivalent Database on 
composition of various mixed dishes, which incorporates par-
tial amounts of various foods (eg, vegetables, nuts, processed 
meats, etc) in mixed dishes. In addition, the characterization 
of whole grains is now derived from the USDA database 
instead of the ratio of carbohydrate to fiber.
 ● Average consumption of whole grains was 0.9 to 1.0 servings 
per day by white men and women and 0.8 servings per day by 
black men and women, and 0.5 to 0.6 servings by Mexican 
American men and women. For each of these groups, less 
than 6% of adults meet guidelines of ≥3 servings per day.
 ● Average fruit consumption ranged from 1.1 to 1.8 servings 
per day in these sex and race or ethnic subgroups: 10% to 
12% of whites, 5% to 6% of blacks, and 10% to 11% of 
Mexican Americans met guidelines of ≥2 cups per day. 
When 100% fruit juices were included, the number of serv-
ings increased, and the proportions of adults consuming ≥2 
cups per day approximately doubled in whites and Mexican 
Americans and tripled in blacks.
 ● Average vegetable consumption ranged from 1.7 to 2.7 
servings per day; 9% to 11% of whites, 2% to 6% of 
blacks, and 4 to 9% of Mexican Americans consumed ≥2.5 
cups per day; with intakes higher in women than in men in 
each race/ethnicity subgroup. The inclusion of vegetable 
juices and sauces produced only modest increases in these 
consumption patterns.
 ● Average consumption of fish and shellfish was lowest among 
Mexican American and white women (1.0 and 1.2 servings 
per week, respectively) and highest among black women 
and Mexican American men (1.6 and 1.7 servings per week, 
respectively); less than 1 in 4 of all adults in each sex and race 
or ethnic subgroup consumed at least 2 servings per week. 
Approximately 9% to 10% of whites, 10% to 12% of blacks, 
and 7% to 13% of Mexican Americans consumed ≥250 mg 
of eicosapentaenoic acid and docosahexaenoic acid per day.
 ● Average consumption of nuts, seeds, and beans was ≈4.0 serv-
ings per week among whites, 3.0 servings per week among 
blacks, and 4 to 6 servings per week among Mexican Ameri-
cans. Approximately 1 in 3 whites, 1 in 4 blacks, and 2 in 5 
Mexican Americans met guidelines of ≥4 servings per week.
 ● Average consumption of processed meats was lowest 
among Mexican American women (0.9 servings per week) 
and highest among white men (2.6 servings per week). 
Between 54% (white men) and 82% (Mexican American 
women) of adults consumed 2 or fewer servings per week.
 ● Average consumption of sugar-sweetened beverages 
ranged from ≈6.5 servings per week among white women 
to nearly 14 servings per week among Mexican American 
men. Women generally consumed less than men. From 
28% (Mexican American men) to 65% (white women) of 
adults consumed no more than 36 oz per week.
 ● Average consumption of sweets and bakery desserts ranged 
from ≈4.5 servings per day (Mexican Americans) to 7 serv-
ings per day (white women). Approximately one third of 
white women and up to half of all other sex and race groups 
consumed no more than 2.5 servings per week.
Abbreviations Used in Chapter 5
ALA α-linoleic acid
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DALY disability-adjusted life-year
DASH Dietary Approaches to Stop Hypertension
DBP diastolic blood pressure
DHA docosahexaenoic acid
DM diabetes mellitus
EPA eicosapentaenoic acid
GFR glomerular filtration rate
GISSI Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto 
miocardico
HD heart disease
HDL high-density lipoprotein
HEI Healthy Eating Index
HF heart failure
LDL low-density lipoprotein
MI myocardial infarction
n-6-PUFA ω-6-polyunsaturated fatty acid
NA not available
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
OR odds ratio
PA physical activity
PREDIMED Prevención con Dieta Mediterránea
RR relative risk
SBP systolic blood pressure
SD standard deviation
WHI Women’s Health Initiative
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 ● Between 35% and 58% of adults in each sex and race 
or ethnic subgroup consumed <10% of total calories 
from saturated fat, and between 56% and 72% consumed 
<300 mg of dietary cholesterol per day.
 ● Only 6% to 12% of whites, 2% to 5% of blacks, and 13% of 
Mexican Americans consumed ≥28 g of dietary fiber per day.
 ● Only 5% to 7% of whites, 6% to 12% of blacks, and 10% 
of Mexican Americans consumed <2.3 g of sodium per day.
 ● Average daily caloric intake in the United States was ≈2500 
calories in adult men and 1800 calories in adult women.
 ● Sodium is widespread in the US food supply, with diverse 
sources (Chart 5-1).
Foods and Nutrients: Children and Teenagers
(See Table 5-2; NHANES 2009–2010.)
The dietary consumption by US children and teenagers of 
selected foods and nutrients related to cardiometabolic health 
is detailed in Table 5-2:
 ● Average whole grain consumption was low, between 0.6 to 
0.8 servings per day in all age and sex groups, with <4% 
of all children in different age and sex subgroups meeting 
guidelines of ≥3 servings per day.
 ● Average fruit consumption was low and decreased with 
age: 1.5 to 1.7 servings per day in younger boys and girls 
(5–9 years of age), 1.2 servings per day in adolescent boys 
and girls (10–14 years of age), and 0.9 to 1.2 servings per 
day in teenage boys and girls (15–19 years of age). The 
proportion meeting guidelines of ≥2 cups per day was also 
low and decreased with age: about 8% to 9% in those 5 to 9 
years of age, 5% to 7% in those 10 to 14 years of age, and 
5% in those 15 to 19 years of age. When 100% fruit juices 
were included, the number of servings consumed approxi-
mately doubled, and proportions consuming ≥2 cups per 
day increased to nearly 1 in 5 of those 5 to 9 years of age 
and 1 in 7 of those 10 to 14 years and 15 to 19 years of age.
 ● Average vegetable consumption was low, ranging from 1.1 to 
1.7 servings per day, with <5% (and often <1%) of children 
in different age and sex subgroups meeting guidelines of 
≥2.5 cups per day.
 ● Average consumption of fish and shellfish was low, rang-
ing between 0.3 and 0.8 servings per week in all age and 
sex groups. Among all ages, only 4% to 11% of youth con-
sumed ≥2 servings per week.
 ● Average consumption of nuts, seeds, and beans ranged 
from 2.3 to 3.0 servings per week among different age and 
sex groups. The distribution of consumption tended to be 
skewed to the right, and only between 1 in 4 and 1 in 5 of 
children in different age and sex subgroups consumed 
≥4 servings per week.
 ● Average consumption of processed meats ranged from 1.4 to 
2.4 servings per week and was up to 10 fold higher than the 
average consumption of fish and shellfish. The distribution of 
consumption tended to be skewed to the right, and the majority 
of children consumed no more than 2 servings per week.
 ● Average consumption of sugar-sweetened beverages was 
higher in boys than in girls and increased with age, from ≈7 
to 8 servings (8 fl oz) per week in 5- to 9-year-olds, 9 to 11 
servings per week in 10- to 14-year-olds, and 14 to 17 serv-
ings per week in 15- to 19-year-olds (each energy adjusted 
to 2000 kcal/d). This was generally considerably higher than 
the average consumption of whole grains, fruits, vegetables, 
fish and shellfish, or nuts, seeds, and beans. Less than half 
of children 5 to 9 years of age and only 1 in 5 boys 15 to 19 
years of age consumed <4.5 servings per week.
 ● Average consumption of sweets and bakery desserts was 
highest (≈9 servings per week) in 5- to 9-year-olds, about 
8 servings per week in 10- to 14-year-olds, and 5 to 8 
servings per week in 15- to 19-year-olds. Only about 1 in 4 
children 5 to 14 years of age, and 1 in 3 youths 15 to 19 
years of age, consumed no more than 2.5 servings per week.
 ● Average consumption of eicosapentaenoic acid and doco-
sahexaenoic acid was low, ranging from 39 to 63 mg/d in 
boys and girls at all ages. Fewer than 6% of children and 
teenagers at any age consumed ≥250 mg/d.
 ● Average consumption of saturated fat was ≈11% of calo-
ries, and average consumption of dietary cholesterol ranged 
from 225 to 250 mg/d. Approximately 30% to 40% of youth 
consumed <10% energy from saturated fat, and >75% con-
sumed <300 mg of dietary cholesterol per day.
 ● Average consumption of dietary fiber ranged from 14 to 15 
g/d. Less than 2% of children in all age and sex subgroups 
consumed ≥28 g/d.
 ● Average consumption of sodium ranged from 3.3 to 3.5 g/d. 
Only between 2% and 9% of children in different age and 
sex subgroups consumed <2.3 g/d.
 ● In children and teenagers, average daily caloric intake is 
higher in boys than in girls and increases with age in boys.
Dietary Patterns
In addition to individual foods and nutrients, overall dietary 
patterns can be used to assess more global dietary quality. 
Different dietary patterns have been defined, including the 
HEI, Alternative HEI, Western versus prudent dietary pat-
terns, Mediterranean dietary pattern, and DASH-type diet. 
The higher-monounsaturated-fat DASH-type diet is generally 
similar to a traditional Mediterranean dietary pattern.1
 ● In 1999 to 2004, only 19.4% of hypertensive US adults 
were following a DASH-type diet (based on intake of fiber, 
magnesium, calcium, sodium, potassium, protein, total fat, 
saturated fat, and cholesterol). This represented a decrease 
from 26.7% of hypertensive US adults in 1988 to 1994.2
 ● Among older US adults (≥60 years of age) in 1999 to 2002, 
72% met guidelines for dietary cholesterol intake, but only 
between 18% and 32% met guidelines for the HEI food 
groups (meats, dairy, fruits, vegetables, and grains). On the 
basis of the HEI score, only 17% of older US adults con-
sumed a good-quality diet. Higher HEI scores were seen in 
white adults and individuals with greater education; lower 
HEI scores were seen in black adults and smokers.3
Dietary Supplements
Use of dietary supplements is common in the United States 
among both adults and children:
 ● Approximately half of US adults in 2007 to 2010 used ≥1 
dietary supplement, with the most common supplement 
being multivitamin-multimineral products (32% of men 
and women reporting use).4 It has been shown that most 
supplements are taken daily and for ≥2 years.5 Supplement 
use is associated with older age, higher education, greater 
PA, moderate alcohol consumption, lower BMI, abstinence 
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from smoking, having health insurance, and white race.4,5 
Previous research also suggests that supplement users have 
higher intakes of most vitamins and minerals from their 
food choices alone than nonusers.6,7 The primary reasons 
US adults in 2007 to 2010 reported for using dietary sup-
plements were to “improve overall health” (45%) and to 
“maintain health” (33%).4
 ● One third (32%) of US children (birth to 18 years of age) 
used dietary supplements in 1999 to 2002, with the highest 
use (48.5%) occurring among 4- to 8-year-olds. The most 
common supplements were multivitamins and multimin-
erals (58% of supplement users). The primary nutrients 
supplemented (either by multivitamins or individual vita-
mins) included vitamin C (29% of US children), vitamin A 
(26%), vitamin D (26%), calcium (21%), and iron (19%). 
Supplement use was associated with higher family income, 
a smoke-free home environment, lower child BMI, and less 
screen time (television, video games, or computers).8
 ● In a 2005 to 2006 telephone survey of US adults, 41.3% 
were making or had made in the past a serious weight-loss 
attempt. Of these, one third (33.9%) had used a dietary 
supplement for weight loss, with such use being more com-
mon in women (44.9%) than in men (19.8%) and in blacks 
(48.7%) or Hispanics (41.6%) than in whites (31.2%); in 
those with high school education or less (38.4%) than in 
those with some college or more (31.1%); and in those with 
household income <$40 000 per year (41.8%) than in those 
with higher incomes (30.3%).9
 ● Multiple trials of most dietary supplements, including 
folate, vitamin C, and vitamin E, have generally shown 
no significant benefits for CVD risk, and even potential 
for harm.10 For example, a multicenter randomized trial in 
patients with diabetic nephropathy found that B vitamin 
supplementation (folic acid 2.5 mg/d, vitamin B6 25 mg/d, 
and vitamin B12 1 mg/d) decreased GFR and increased risk 
of MI and stroke compared with placebo.11
 ● Fish oil supplements at doses of 1 to 2 g/d have shown CVD 
benefits in 2 large randomized, open-label trials and 1 large 
randomized, placebo-controlled trial (GISSI-Prevenzione, 
Japan Eicosapentaenoic Acid Lipid Intervention Study, and 
GISSI-HF),12–14 but several other trials of fish oil have not 
shown significant effects on CVD risk.15 A meta-analysis of 
all randomized controlled clinical trials demonstrated a sig-
nificant reduction for cardiac mortality but no statistically 
significant effects on other CVD end points.16
Trends in Energy Balance and Adiposity
(See Chapter 6 on Overweight and Obesity.)
 ● The average US adult gains ≈1 lb per year. Energy balance, 
or consumption of total calories appropriate for needs, is 
determined by the balance of average calories consumed 
versus expended. This balance depends on multiple factors, 
including calories consumed, PA, body size, age, sex, and 
underlying basal metabolic rate. Thus, one individual may 
consume relatively high calories but have negative energy 
balance (as a result of even greater calories expended), 
whereas another individual may consume relatively few cal-
ories but have positive energy balance (because of low calo-
ries expended). Given such variation, the most practical and 
reasonable method to assess energy balance in populations 
is to assess changes in weight over time. Growing evidence 
indicates that, calorie for calorie, certain foods may be more 
highly obesogenic; others, modestly obesogenic; others, rel-
atively neutral; and still others, actually protective against 
weight gain when their consumption is increased. These 
varying effects appear to relate to complex physiological 
responses to different foods and drinks, including responses 
related to hunger, satiety, brain reward, hepatic de novo lipo-
genesis, visceral adiposity, interactions with the intestinal 
inflammasome and microbiome, and metabolic expenditure 
(calories expended). This evidence is detailed below.
 ● The US obesity epidemic began in approximately 1980, 
with dramatic increases in ensuing years in obesity 
compared to prior decades among both children and 
adults across broad cross sections of sex, race/ethnicity, 
geographic residence, and socioeconomic status. In more 
recent years, rates of obesity and overweight among both 
US adults and children have begun to level off.17 Examina-
tion of trends in diet, activity, and other factors from 1980 
to the present is important to elucidate the drivers of this 
remarkably recent epidemic.
 ● Until 1980, total energy intake remained relatively con-
stant.18,19 Data from NHANES indicate that between 1971 
and 2004, average total energy consumption among US 
adults increased by 22% in women (from 1542 to 1886 
kcal/d) and by 10% in men (from 2450 to 2693 kcal/d).20 
These increases are supported by data from 2 older surveys, 
the Nationwide Food Consumption Survey (1977–1978) 
and the Continuing Surveys of Food Intake (1989–1998).21 
However, recent data show that energy intake appeared 
relatively stable among US adults during 1999 to 2008.22
 ● Another analysis of national data estimated that increases in 
energy intake between 1980 and 1997 were primarily attrib-
utable to increases in dietary carbohydrate.23 Specifically, 
nearly 80% of the increase in total energy came from car-
bohydrates, 12% from protein, and only 8% from fat. These 
increases in calories were primarily attributable to greater 
refined carbohydrate intake, particularly of starches, refined 
grains, and sugars (see Trends in Specific Dietary Habits).
 ● Other specific changes related to increased caloric intake 
in the United States since 1980 include larger portion sizes, 
greater food quantity and calories per meal, and increased 
consumption of sugar-sweetened beverages, snacks, and 
commercially prepared (especially fast-food) meals.21,24–29 
In more recent years, intakes of sugar-sweetened beverages 
are decreasing nationally.
 ● Between 1977 and 1996, the average portion sizes for many 
foods increased at fast-food outlets, other restaurants, and 
home. Based on one study, these included a 33% increase 
in the average portion of Mexican food (from 408 to 541 
calories), a 34% increase in the average portion of cheese-
burgers (from 397 to 533 calories), a 36% increase in the 
average portion of french fries (from 188 to 256 calories), 
and a 70% increase in the average portion of salty snacks 
such as crackers, potato chips, pretzels, puffed rice cakes, 
and popcorn (from 132 to 225 calories).21
 ● In one analysis, among US children 2 to 7 years of age, an 
estimated energy imbalance of only 110 to 165 kcal/d (the 
equivalent of one 12- to 16-oz bottle of soda/cola) was suf-
ficient to account for the excess weight gain between 1988 
and 1994 and 1999 and 2002.30
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 ● In a quantitative analysis using various US surveys between 
1977 and 2010, the relations of national changes in energy 
density, portion sizes, and number of daily eating/drink-
ing occasions to changes in total energy intake were 
assessed.18,19 Changes in energy density were not consis-
tently linked to energy intake over time, whereas increases 
in both portion size and number of eating occasions were 
linked to greater energy intake.
 ● Among US children 2 to 18 years of age, increases in 
energy intake between 1977 and 2006 (179 kcal/d) were 
entirely attributable to substantial increases in energy eaten 
away from home (255 kcal/d).31 The percentage of energy 
eaten away from home increased from 23.4% to 33.9% dur-
ing this time, with a shift toward energy from fast food as 
the largest contributor to foods away from home for all age 
groups.
 ● A county-level investigation based on BRFSS and 
NHANES data found that prevalence of sufficient PA in 
the United States actually increased from 2001 to 2009 but 
that this was matched by increases in obesity in almost all 
counties during the same time period, with low correlation 
between level of PA and obesity in US counties.32
Determinants: Nutrients
 ● For weight loss among overweight and obese individuals, 
low-carbohydrate, higher-fat diets achieve greater weight 
loss than low-fat, higher-carbohydrate diets.33
 ● In ad libitum (not energy restricted) diets, intake of dietary 
sugars is positively linked to weight gain.34 However, isoen-
ergetic exchange of dietary sugars with other carbohydrates 
had no relationship with body weight,34 which suggests that 
all refined carbohydrates may be similarly obesogenic.
 ● In pooled analyses across 3 prospective cohort studies of 
US men and women, increased glycemic index and gly-
cemic load were independently associated with greater 
weight gain over time.35
 ● At the individual food level, energy density (total calories 
per gram of food) is not consistently linked with weight gain 
or obesity. For example, nuts have relatively high energy 
density and are inversely linked to weight gain, whereas 
sugar-sweetened beverages have low energy density and 
increase obesity. National changes in energy density over 
time are not consistently linked to changes in energy intake.
Determinants: Foods
 ● In an analysis of >120 000 US men and women in 3 sepa-
rate US cohorts followed up for up to 20 years, changes 
in intakes of different foods and beverages were linked 
to long-term weight gain in different ways.36 Foods and 
beverages most positively linked to weight gain included 
refined grains, starches, and sugars, including potatoes, 
white bread, white rice, low-fiber breakfast cereals, sweets/
desserts, and sugar-sweetened beverages, as well as red 
and processed meats. In contrast, increased consumption 
of several other foods, including nuts, whole grains, fruits, 
vegetables, and yogurt, was linked to relative weight loss 
over time. These findings indicate that attention to dietary 
quality, not simply counting total calories, is crucial for 
energy balance.36
 ● In both adults and children, intake of sugar-sweetened 
beverages has been linked to weight gain and obesity.37 
Randomized trials in children demonstrate reductions in 
obesity when sugar-sweetened beverages are replaced with 
noncaloric beverages.37
Determinants: Mechanisms
 ● Diet quality influences activation of brain reward centers, 
such as the nucleus accumbens. Isocaloric meals richer in 
rapidly digestible carbohydrate increased hunger and stim-
ulated brain regions associated with reward and craving 
compared with isocaloric meals that had identical macro-
nutrient content, palatability, and sweetness but were lower 
in rapidly digestible carbohydrate.38
 ● Dietary factors that stimulate hepatic de novo lipogenesis, 
such as rapidly digestible grains, starches, and sugars, as 
well as trans fat, appear more strongly related to weight 
gain.36,39
 ● In animal experiments, probiotics in yogurt alter gut 
immune responses and protect against obesity and nonal-
coholic fatty acid liver disease.40–42
 ● Diet quality may also influence energy expenditure. After 
intentional weight loss, isocaloric diets higher in fat and 
lower in rapidly digestible carbohydrates produced sig-
nificantly smaller declines in total energy expenditure than 
low-fat, high-carbohydrate diets, with a mean difference of 
>300 kcal/d.43
 ● Other possible nutritional determinants of positive energy 
balance (more calories consumed than expended), as deter-
mined by adiposity or weight gain, include larger portion 
sizes, skipping breakfast, consumption of fast food, and 
eating foods prepared outside the home, but evidence for 
relevance of these factors has been inconsistent.44–47
Determinants: Other
 ● Although sedentary activity has been hypothesized to be 
linked to weight gain because of changes in metabolism, 
the strongest and most consistent associations are seen for 
television watching as opposed to other sedentary activi-
ties. In 2 randomized controlled trials, the effects of tele-
vision watching on obesity were mediated by changes in 
diet rather than by changes in PA, which may be related to 
greater snacking/eating in front of the television, as well as 
the influence of television advertising on poor food choices 
overall.36,48–52
 ● PA influences adiposity, as covered in Chapter 4 of this 
update.
 ● Lower average sleep duration is consistently linked to 
greater adiposity in both children and adults, and short-
term trials demonstrate effects of insufficient sleep on hun-
ger, food choices, and leptin/ghrelin concentrations.53
 ● Societal and environmental factors independently associ-
ated with diet quality, adiposity, and/or weight gain include 
education, income, race/ethnicity, and (at least cross-sec-
tionally) availability of supermarkets.10,54,55
 ● Other local food-environment characteristics, such as avail-
ability of grocery stores (ie, smaller stores than supermar-
kets), convenience stores, and fast food restaurants, are not 
consistently associated with diet quality or adiposity.56
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Trends in Specific Dietary Habits
Several changes in foods and nutrients have occurred over 
time. Selected changes are highlighted below.
Trends in Nutrients
 ● Starting in 1977 and continuing until the most recent 
dietary guidelines revision in 2010, a major focus of US 
dietary guidelines was reduction of dietary fats.57 Dur-
ing this time, average total fat consumption declined as a 
percent of calories from 36.9% to 33.4% in men and from 
36.1% to 33.8% in women.20 However, more recent analy-
ses show that there were no significant trends in total fat 
intake among US adults from 1999 to 2008.22
 ● Dietary guidelines during this time also emphasized carbo-
hydrate consumption as the base of one’s dietary pattern58 
and more recently specified the importance of complex 
rather than refined carbohydrates (eg, as the base of the 
Food Guide Pyramid).57 From 1971 to 2004, total carbo-
hydrate intake increased from 42.4% to 48.2% of calories 
in men and from 45.4% to 50.6% of calories in women.20 
Evaluated as absolute intakes, the increase in total calo-
ries consumed during this period was attributable primar-
ily to the greater consumption of carbohydrates, both as 
foods (starches and grains) and as beverages.59,60 However, 
more recent analyses show that there has been a decrease 
in carbohydrate intake (expressed as percentage of energy) 
among US adults from 1999 to 2008.22
Trends in Sugar-Sweetened Beverages
(See Chart 5-2.)
 ● Between 1965 and 2002, the average percentage of total calo-
ries consumed from beverages in the United States increased 
from 11.8% to 21.0% of energy, which represents an overall 
absolute increase of 222 kcal/d per person.28 This increase was 
largely caused by increased consumption of sugar-sweetened 
beverages and alcohol: Average consumption of fruit juices 
went from 20 to 39 kcal/d; of milk, from 125 to 94 kcal/d; of 
alcohol, from 26 to 99 kcal/d; of sweetened fruit drinks, from 
13 to 38 kcal/d; and of soda/cola, from 35 to 143 kcal/d.18
 ● In addition to increased overall consumption, the average 
portion size of a single sugar-sweetened beverage increased 
by >50% between 1977 and 1996, from 13.1 to 19.9 fl oz.21
 ● Among children and teenagers (2–19 years of age), the larg-
est increases in consumption of sugar-sweetened beverages 
between 1988 to 1994 and 1999 to 2004 were seen among 
black and Mexican American youths compared with white 
youths.29
 ● In contrast, between 1999 and 2010, sugar-sweetened beverage 
intake decreased among both youth and adults in the United 
States, consistent with increased attention to their importance 
as a cause of obesity. In 2009 to 2010, youth and adults con-
sumed a daily average of 155 and 151 kcal from sugar-sweet-
ened beverages, respectively, a decrease from 1999 to 2000 of 
68 and 45 kcal/d, respectively.61 This reduction parallels the 
plateau of the obesity epidemic in US youth.17
Trends in Fruits and Vegetables
 ● Between 1994 and 2005, the average consumption of fruits 
and vegetables declined slightly, from a total of 3.4 to 3.2 
servings per day. The proportions of men and women con-
suming combined fruits and vegetables ≥5 times per day 
were low (≈20% and 29%, respectively) and did not change 
during this period.62
Morbidity and Mortality
Effects on Cardiovascular Risk Factors and Type 2 DM
Dietary habits affect multiple cardiovascular risk factors, 
including both established risk factors (SBP, DBP, LDL cho-
lesterol levels, HDL cholesterol levels, glucose levels, and 
obesity/weight gain) and novel risk factors (eg, inflammation, 
cardiac arrhythmias, endothelial cell function, triglyceride 
levels, lipoprotein[a] levels, and heart rate):
 ● A DASH dietary pattern with low sodium reduced SBP 
by 7.1 mm Hg in adults without hypertension and by 11.5 
mm Hg in adults with hypertension.63
 ● Compared with the low-fat DASH diet, DASH-type diets 
that increased consumption of either protein or unsatu-
rated fat had similar or greater beneficial effects on CVD 
risk factors. Compared with a baseline usual diet, each of 
the DASH-type diets, which included various percentages 
(27%–37%) of total fat and focused on whole foods such as 
fruits, vegetables, whole grains, and fish, as well as potas-
sium and other minerals and low sodium, reduced SBP by 
8 to 10 mm Hg, DBP by 4 to 5 mm Hg, and LDL choles-
terol by 12 to 14 mg/dL. The diets that had higher levels 
of protein and unsaturated fat also lowered triglyceride 
levels by 16 and 9 mg/dL, respectively.64 The DASH-type 
diet higher in unsaturated fat also improved glucose-insulin 
homeostasis compared with the low-fat/high-carbohydrate 
DASH diet.65
 ● In a meta-analysis of 60 randomized controlled feeding 
trials, consumption of 1% of calories from saturated fat 
in place of carbohydrate raised LDL cholesterol concen-
trations but also raised HDL cholesterol and lowered tri-
glycerides, with no significant effects on apolipoprotein B 
concentrations.66
 ● In a meta-analysis of randomized controlled trials, con-
sumption of 1% of calories from trans fat in place of 
saturated fat, monounsaturated fat, or polyunsaturated fat, 
respectively, increased the ratio of total to HDL cholesterol 
by 0.031, 0.054, and 0.67; increased apolipoprotein B lev-
els by 3, 10, and 11 mg/L; decreased apolipoprotein A-1 
levels by 7, 5, and 3 mg/L; and increased lipoprotein(a) lev-
els by 3.8, 1.4, and 1.1 mg/L.67
 ● In meta-analyses of randomized controlled trials, consump-
tion of eicosapentaenoic acid and docosahexaenoic acid for 
212 weeks lowered SBP by 2.1 mm Hg68 and lowered rest-
ing heart rate by 2.5 beats per minute.69
 ● In a pooled analysis of 25 randomized trials totaling 583 
men and women both with and without hypercholesterol-
emia, nut consumption significantly improved blood lipid 
levels.70 For a mean consumption of 67 g of nuts per day, 
total cholesterol was reduced by 10.9 mg/dL (5.1%), LDL 
cholesterol by 10.2 mg/dL (7.4%), and the ratio of total 
cholesterol to HDL cholesterol by 0.24 (5.6% change; 
P<0.001 for each). Triglyceride levels were also reduced 
by 20.6 mg/dL (10.2%) in subjects with high triglycerides 
(2150 mg/dL). Different types of nuts had similar effects.70
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 ● A review of cross-sectional and prospective cohort studies 
suggests that higher intake of sugar-sweetened beverages is 
associated with greater visceral fat and higher risk of type 
2 DM.71
 ● In a randomized controlled trial, compared with a low-fat 
diet, 2 Mediterranean dietary patterns that included either 
virgin olive oil or mixed nuts lowered SBP by 5.9 and 7.1 
mm Hg, plasma glucose by 7.0 and 5.4 mg/dL, fasting insulin 
by 16.7 and 20.4 pmol/L, the homeostasis model assessment 
index by 0.9 and 1.1, and the ratio of total to HDL choles-
terol by 0.38 and 0.26 and raised HDL cholesterol by 2.9 and 
1.6 mg/dL, respectively. The Mediterranean dietary patterns 
also lowered levels of CRP, interleukin-6, intercellular adhe-
sion molecule-1, and vascular cell adhesion molecule-1.72
 ● Among 24 prospective cohort studies, greater consumption 
of refined carbohydrates and sugars, as measured by higher 
glycemic load, was positively associated with risk of type 
2 DM: for each 100-g increment, 45% higher risk was seen 
(95% CI, 1.31–1.61) for a 100-g increment in glycemic 
load (P<0.001; n=24 studies, 7.5 million person-years of 
follow-up).73
 ● In one meta-analysis of observational studies and trials, 
greater consumption of nuts was linked to lower incidence 
of type 2 DM (RR per 4 weekly 1-oz servings, 0.87; 95% 
CI, 0.81–0.94).74
Effects on Cardiovascular Outcomes
Because dietary habits affect a broad range of established and 
novel risk factors, estimation of the impact of nutritional factors 
on cardiovascular health by considering only a limited number 
of pathways (eg, only effects on lipids, BP, and obesity) will 
systematically underestimate or even misconstrue the actual 
total impact on cardiovascular health. Randomized controlled 
trials and prospective observational studies have been used to 
quantify the total effects of dietary habits on clinical outcomes.
Fats and Carbohydrates
 ● In the WHI randomized clinical trial (n=48 835), reduction of 
total fat consumption from 37.8% energy (baseline) to 24.3% 
energy (at 1 year) and 28.8% energy (at 6 years) had no effect 
on incidence of CHD (RR, 0.98; 95% CI, 0.88–1.09), stroke 
(RR, 1.02; 95% CI, 0.90–1.15), or total CVD (RR, 0.98; 95% 
CI, 0.92–1.05) over a mean of 8.1 years.75 This was consis-
tent with null results of 4 prior randomized clinical trials and 
multiple large prospective cohort studies that indicated little 
effect of total fat consumption on CVD risk.76
 ● In 3 separate meta-analyses of prospective cohort stud-
ies, the largest of which included 21 studies with up to 2 
decades of follow-up, saturated fat consumption overall had 
no significant association with incidence of CHD, stroke, 
or total CVD.77–79 In comparison, in a pooled individual-
level analysis of 11 prospective cohort studies, the specific 
exchange of polyunsaturated fat consumption in place of 
saturated fat was associated with lower CHD risk, with 
13% lower risk for each 5% energy exchange (RR, 0.87; 
95% CI, 0.70–0.97).80 These findings are consistent with 
a meta-analysis of randomized controlled trials in which 
increased polyunsaturated fat consumption in place of satu-
rated fat reduced CHD events, with 10% lower risk for each 
5% energy exchange (RR, 0.90; 95% CI, 0.83–0.97).81
 ● In a pooled analysis of individual-level data from 11 pro-
spective cohort studies in the United States, Europe, and 
Israel that included 344 696 participants, each 5% higher 
energy consumption of carbohydrate in place of saturated 
fat was associated with a 7% higher risk of CHD (RR, 1.07; 
95% CI, 1.01–1.14).80 Each 5% higher energy consumption 
of monounsaturated fat in place of saturated fat was not sig-
nificantly associated with CHD risk.80 A more recent meta-
analysis of prospective cohort studies found that increased 
intake of polyunsaturated fats was associated with lower risk 
of CHD, whether replacing saturated fat or carbohydrate.80a
 ● Together these findings suggest that reducing saturated 
fat without specifying the replacement may have minimal 
effects on CHD risk, whereas increasing polyunsaturated 
fats from vegetable oils will reduce CHD, whether replacing 
saturated fat or carbohydrate.1
 ● In a meta-analysis of prospective cohort studies, each 2% 
of calories from trans fat was associated with a 23% higher 
risk of CHD (RR, 1.23; 95% CI, 1.11–1.37).82
 ● In meta-analyses of prospective cohort studies, greater con-
sumption of refined complex carbohydrates, starches, and 
sugars, as assessed by glycemic index or load, was associ-
ated with significantly higher risk of CHD and DM. When 
the highest category was compared with the lowest cate-
gory, risk of CHD was 36% greater (glycemic load: RR, 
1.36; 95% CI, 1.13–1.63), and risk of DM was 40% greater 
(glycemic index: RR, 1.40; 95% CI, 1.23–1.59).83,84
Foods and Beverages
 ● In meta-analyses of prospective cohort studies, each daily 
serving of fruits or vegetables was associated with a 4% 
lower risk of CHD (RR, 0.96; 95% CI, 0.93–0.99) and a 
5% lower risk of stroke (RR, 0.95; 95% CI, 0.92–0.97).85,86
 ● In a meta-analysis of prospective cohort studies, greater 
whole grain intake (2.5 compared with 0.2 servings per day) 
was associated with a 21% lower risk of CVD events (RR, 
0.79; 95% CI, 0.73–0.85), with similar estimates in men and 
women and for various outcomes (CHD, stroke, and fatal 
CVD). In contrast, refined grain intake was not associated 
with lower risk of CVD (RR, 1.07; 95% CI, 0.94–1.22).87
 ● In a meta-analysis of 16 prospective cohort studies that 
included 326 572 generally healthy individuals in Europe, 
the United States, China, and Japan, fish consumption was 
associated with significantly lower risk of CHD mortality.88 
Compared with no consumption, an estimated 250 mg of 
long-chain omega-3 fatty acids per day was associated with 
35% lower risk of CHD death (P<0.001).
 ● In a meta-analysis of prospective cohort and case-control 
studies from multiple countries, consumption of unpro-
cessed red meat was not significantly associated with inci-
dence of CHD. In contrast, each 50-g serving per day of 
processed meats (eg, sausage, bacon, hot dogs, deli meats) 
was associated with a higher incidence of CHD (RR, 1.42; 
95% CI, 1.07–1.89).89
 ● In a meta-analysis of prospective cohort studies that 
included 442 101 participants and 28 228 DM cases, unpro-
cessed red meat consumption was associated with a higher 
risk of DM (RR, 1.19; 95% CI, 1.04–1.37, per 100 g/d). On 
a per g/d basis, risk of DM was nearly 7-fold higher for pro-
cessed meat consumption (RR, 1.51; 95% CI, 1.25–1.83, 
per 50 g/d).90
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 ● In a meta-analysis of 6 prospective observational studies, 
nut consumption was associated with lower incidence of 
fatal CHD (RR per 4 weekly 1-oz servings, 0.76; 95% CI, 
0.69–0.84) and nonfatal CHD (RR, 0.78; 95% CI, 0.67–
0.92).74 Nut consumption was not significantly associated 
with stroke risk based on 4 studies.74
 ● In a meta-analysis of 6 prospective observational studies, 
consumption of legumes (beans) was associated with lower 
incidence of CHD (RR per 4 weekly 100-g servings, 0.86; 
95% CI, 0.78–0.94).74
 ● Higher consumption of dairy or milk products is associated 
with lower incidence of DM and trends toward lower risk 
of stroke.70,83,84 The inverse associations with DM appear 
strongest for both yogurt and cheese.91
 ● Dairy consumption is not significantly associated with 
higher or lower risk of CHD.78,92
 ● Among 88 520 generally healthy women in the Nurses’ 
Health Study who were 34 to 59 years of age in 1980 and 
were followed up from 1980 to 2004, regular consumption 
of sugar-sweetened beverages was independently associ-
ated with higher incidence of CHD, with 23% and 35% 
higher risk with 1 and ≥2 servings per day, respectively, 
compared with <1 per month.93 Among the 15 745 partici-
pants in the ARIC study, the OR for developing CHD was 
2.59 for participants who had a serum uric acid level >9.0 
mg/dL and who drank >1 sugar-sweetened soda per day.94
Sodium and Potassium
 ● Lower estimated consumption of dietary sodium was not 
associated with lower CVD mortality among adults 30 
years of age and older with no history of CVD events in 
NHANES,95 although such findings may be limited by 
changes in behaviors that could result from underlying risk 
(reverse causation). In a post hoc analysis of the Trials of 
Hypertension Prevention, participants randomized to low-
sodium interventions had a 25% lower risk of CVD (RR, 
0.75; 95% CI, 0.57–0.99) after 10 to 15 years of follow-up 
after the original trials.96
 ● In a meta-analysis of small randomized trials of sodium 
reduction of ≥6 months’ duration, nonsignificant trends 
were seen toward fewer CVD events in subjects with nor-
mal BP (RR, 0.71; 95% CI, 0.42–1.20; n=200 events) or 
hypertension (RR, 0.84; 95% CI, 0.57–1.23; n=93 events), 
but findings were not statistically significant, with rela-
tively low statistical power because of the small numbers of 
events. Sodium restriction increased total mortality in trials 
of patients with CHF (RR, 2.59; 95% CI, 1.04–6.44), but 
these data were based on very few events (n=21 deaths).97
 ● In a meta-analysis of 13 prospective cohorts that included 
177 025 participants and >11 000 vascular events, higher 
sodium consumption was associated with greater risk of 
stroke (pooled RR, 1.23; 95% CI, 1.06–1.43; P=0.007) and 
a trend toward higher risk of CVD (1.14; 95% CI, 0.99–
1.32; P=0.07). These associations were greater with larger 
differences in sodium intake and longer follow-up.98
 ● In a meta-analysis of 15 prospective cohort samples that 
included 247 510 participants and 7066 strokes, 3058 CHD 
events, and 2497 total CVD events, each 1.64-g/d (42 mmol/d) 
higher potassium intake was associated with a 21% lower risk 
of stroke (RR, 0.79; 95% CI, 0.68–0.90) and trends toward 
lower risk of CHD and total CVD.99
Dietary Patterns
 ● In a cohort of 380 296 US men and women, greater versus 
lower adherence to a Mediterranean dietary pattern, char-
acterized by higher intakes of vegetables, legumes, nuts, 
fruits, whole grains, fish, and unsaturated fat and lower 
intakes of red and processed meat, was associated with a 
22% lower cardiovascular mortality (RR, 0.78; 95% CI, 
0.69–0.87).100 Similar findings have been seen for the Med-
iterranean dietary pattern and risk of incident CHD and 
stroke101 and for the DASH-type dietary pattern.102
 ● In a cohort of 72 113 US female nurses, a dietary pat-
tern characterized by higher intakes of vegetables, fruits, 
legumes, fish, poultry, and whole grains was associated 
with a 28% lower cardiovascular mortality (RR, 0.72; 95% 
CI, 0.60–0.87), whereas a dietary pattern characterized by 
higher intakes of processed meat, red meat, refined grains, 
french fries, and sweets/desserts was associated with a 22% 
higher cardiovascular mortality (RR, 1.22; 95% CI, 1.01–
1.48).103 Similar findings have been seen in other cohorts 
and for other outcomes, including development of DM and 
metabolic syndrome.104–110
 ● The observational findings for benefits of a healthy food–
based dietary pattern have been confirmed in 2 randomized 
clinical trials, including a small secondary prevention trial 
in France among patients with recent MI111 and a large pri-
mary prevention trial in Spain among patients with CVD 
risk factors.112 The latter trial, PREDIMED, demonstrated a 
30% reduction in the risk of stroke, MI, and death attribut-
able to cardiovascular causes in those patients randomized 
to Mediterranean-style diets.
Impact on US Mortality
 ● One report used consistent and comparable risk assessment 
methods and nationally representative data to estimate the 
impact of all major modifiable risk factors on mortality 
and morbidity in the United States in 1990 and in 2010.113 
Suboptimal dietary habits were the leading cause of both 
mortality and DALY lost, exceeding even tobacco. In 2010, 
a total of 678 000 deaths of all causes were attributable to 
suboptimal diet.
 ● A previous investigation reported the estimated mortal-
ity effects of several specific dietary risk factors in 2005 
in the United States. High dietary salt consumption was 
estimated to be responsible for 102 000 annual deaths, 
low dietary omega-3 fatty acids for 84 000 annual deaths, 
high dietary trans fatty acids for 82 000 annual deaths, 
and low consumption of fruits and vegetables for 55 000 
annual deaths.114
Cost
(See Chart 5-3.)
The US Department of Agriculture forecast that the 
Consumer Price Index for all food would increase 3.0% to 
4.0% in 2013 as retailers continued to pass on higher com-
modity and energy costs to consumers in the form of higher 
retail prices. The Consumer Price Index for food increased 
3.7% in 2011. Prices for foods eaten at home increased 4.8% 
in 2011, whereas prices for foods eaten away from home 
increased by 1.9%.115
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 ● The proportion of total US food expenditures for meals out-
side the home, as a share of total food dollars, increased 
from 27% in 1961 to 40% in 1981 to 49% in 2011.58
 ● The proportion of sales of meals and snacks from fast-food 
restaurants compared with total meals and snacks away 
from home increased from 5% in 1958 to 29% in 1982 to 
36% in 2011.115
 ● As a proportion of income, food has become less expensive 
over time in the United States. As a share of personal dis-
posable income, average (mean) total food expenditures by 
families and individuals have decreased from 22.3% (1949) 
to 18.1% (1961) to 14.9% (1981) to 11.3% (2011). For any 
given year, the share of disposable income spent on food 
is inversely proportional to absolute income. The share 
increases as absolute income levels decline.115
 ● Among 153 forms of fruits and vegetables priced with 2008 
Nielsen Homescan data, price and calorie per portion of 20 
fruits and vegetables were compared with 20 common snack 
foods such as cookies, chips, pastries, and crackers. Aver-
age price per portion of fruits and vegetables was 31 cents 
with an average of 57 calories per portion, compared with 
33 cents and 183 calories per portion for snack foods.115
 ● An overview of the costs of various strategies for primary 
prevention of CVD determined that the estimated costs per 
year of life gained were between $9800 and $18 000 for 
statin therapy, ≈$1500 for nurse screening and lifestyle 
advice, $500 to $1250 for smoking cessation, and $20 to 
$900 for population-based healthy eating.116
 ● Each year, >$33 billion in medical costs and $9 billion in 
lost productivity resulting from HD, cancer, stroke, and 
DM are attributed to poor nutrition.117–120
 ● Two separate cost-effectiveness analyses estimated that 
population reductions in dietary salt would not only be 
cost-effective but actually cost-saving.121,122 In 1 analysis, a 
1.2-g/d reduction in dietary sodium was projected to reduce 
US annual cases of incident CHD by 60 000 to 120 000, 
stroke by 32 000 to 66 000, and total mortality by 44 000 to 
92 000.122 If accomplished through a regulatory interven-
tion, estimated savings in healthcare costs would be $10 
to $24 billion annually.122 Such an intervention would be 
more cost-effective than using medications to lower BP in 
all people with hypertension.
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Table 5-1. Dietary Consumption in 2009 to 2010 Among US Adults ≥20 Years of Age of Selected Foods and Nutrients Related to 
Cardiometabolic Health97–100
NH White Men NH White Women NH Black Men NH Black Women Mexican American Men
Mexican American 
Women
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Foods
  Whole grains, 
servings/d
0.9±0.7 5.8 1.0±0.7 5.0 0.8±1.0 3.7 0.8±0.8 4.2 0.6±0.2 2.9 0.5±0.5 1.4
  Total fruit, servings/d 1.5±1.6 9.7 1.7±1.4 11.5 1.1±1.4 6.2 1.2±1.1 5.1 1.6±1.3 11.3 1.8±2.0 10.4
  Total fruits 
including 100% 
juices, servings/d
2.0±1.9 16.1 2.2±1.6 18.3 2.1±1.7 17.4 2.1±1.5 18.7 2.4±1.7 22.6 2.6±2.2 23.0
  Total vegetables 
(starchy up to 
3 cups/wk), 
servings/d
2.4±1.6 8.5 2.7±1.6 11.4 1.7±0.9 2.1 1.9±1.0 5.8 2.0±1.0 4.1 2.4±1.4 8.5
  Total vegetables 
(starchy up to 3 
cups/wk), including 
vegetable juices/
sauces, servings/d
2.6±1.6 9.9 2.9±1.7 12.4 1.7±1.0 2.4 2.0±1.1 6.7 2.3±1.0 4.7 2.6±1.4 9.8
  Fish and shellfish, 
servings/wk
1.3±0.5 19.6 1.2±1.3 19.9 1.4±1.5 23.5 1.6±1.3 24.4 1.7±1.3 23.8 1.0±1.3 18.9
  Nuts, seeds, and 
beans, servings/wk
4.1±4.3 33.7 4.0±3.8 36.1 2.8±4.0 23.5 3.2±3.3 26.8 5.9±4.1 44.5 4.4±2.3 41.2
  Processed meats, 
servings/wk
2.6±1.1 53.8 1.7±1.3 68.4 2.4±0.6 59.6 1.7±1.1 69.6 1.5±1.2 71.0 0.9±1.2 82.5
  Sugar-sweetened 
beverages, 
servings/wk
9.3±11.7 52.8 6.5±10.4 65.0 13.5±9.7 33.7 13.0±9.4 33.7 13.7±8.8 27.7 11.3±10.6 39.6
  Sweets and 
bakery desserts, 
servings/wk
5.9±3.9 40.3 6.7±4.3 34.9 6.1±3.6 43.0 5.9±3.9 42.0 4.1±1.1 50.7 4.5±3.2 49.1
Nutrients
  Total calories, 
kcal/d
2532±705 NA 1766±414 NA 2365±699 NA 1785±476 NA 2367±664 NA 1690±502 NA
  EPA/DHA, g/d 0.101±0.052 10.1 0.095±0.052 8.8 0.116±0.069 9.7 0.110±0.064 12.3 0.136±0.064 13.4 0.083±0.064 7.2
  ALA, g/d 1.44±0.31 29.3 1.60±0.37 75.2 1.43±0.25 30.6 1.49±0.17 73.6 1.19±0.33 17.8 1.41±0.33 66.9
  n-6 PUFA,  
% energy
7.4±1.5 NA 7.6±1.4 NA 7.4±1.2 NA 7.6±1.0 NA 6.3±1.4 NA 7,1±1.5 NA
  Saturated fat,  
% energy
11.1±2.3 35.4 10.9±2.1 41.9 10.2±2.2 44.9 10.5±1.8 45.5 9.7±1.8 54.4 9.7±1.6 57.9
  Dietary 
cholesterol, mg/d
263±106 71.5 260±104 71.1 311±83 56.2 306±83 57.8 293±75 65.6 300±60 63.0
  Total fat, % energy 33.9±5.3 52.2 33.3±4.4 57.3 32.5±4.5 59.3 33.1±3.4 56.8 29.8±5.4 66.6 30.6±4.0 74.4
  Carbohydrate,  
% energy
47.2±7.3 NA 50.1±6.6 NA 48.8±6.2 NA 51.1±5.4 NA 51.9±3.9 NA 54.3±5.6 NA
  Dietary fiber, g/d 16.3±6.1 6.4 18.3±6.3 11.7 13.6±4.3 2.2 15.0±5.2 4.8 19.2±5.9 13.2 19.6±5.3 13.0
  Sodium, g/d 3.4±0.6 6.5 3.6±0.5 4.6 3.3±0.6 11.5 3.5±0.4 6.0 3.2±0.5 10.3 3.4±0.5 9.5
Data from the National Health and Nutrition Examination Survey 2009 to 2010, derived from two 24-hour dietary recalls per person, with population SDs adjusted for within-person vs 
between-person variation. All values are energy adjusted by individual regressions or percent energy, and for comparability, means and proportions are reported for a 2000-kcal/d diet. To 
obtain actual mean consumption levels, the group means for each food or nutrient can be multiplied by the group-specific total calories (kcal/d) divided by 2000 kcal/d. Compared to prior AHA 
Statistical Updates, the calculations for foods now utilize the USDA Food Patterns Equivalent Database on composition of various mixed dishes, which incorporates partial amounts of various 
foods (eg, vegetables, nuts, processed meats, etc) in mixed dishes; in addition, the characterization of whole grains is now derived from the USDA database instead of the ratio of carbohydrate 
to fiber (analyses courtesy of Dr. Colin Rehm, Tufts University). 
ALA indicates α-linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NA, not available; NH, non-Hispanic; and n-6-PUFA, ω-6-polyunsaturated fatty acid.
*All intakes and guidelines adjusted to 2000 kcal/d diet.  Servings defined as follows: whole grains (1-oz equivalents), fruits and vegetables (1/2 cup equivalents), fish/shellfish (3.5 oz or 100 g), 
nuts/seeds/beans (50 g), processed meat (3.5 oz or 100 g), sugar-sweetened beverages (8 fl oz), sweets and bakery desserts (50 g). Foods and guidelines defined as follows: whole grains, 3 
or more 1-oz equivalent (eg, 21 g whole wheat bread, 82 g cooked brown rice, 31 g Cheerios) servings per day (Dietary Guidelines for Americans123; fish or shellfish, 2 or more 100-g (3.5-oz) 
servings/wk123; fruits, 2 or more cups/d119; vegetables, 2 1/2 or more cups/d, including up to 3 cups/wk of starchy vegetables119; nuts, seeds, and beans, 4 or more 50-g servings/wk123 processed 
meats (bacon, hot dogs, sausage, processed deli meats), 2 or fewer 100-g (3.5-oz) servings/wk (1/4 of discretionary calories)119; sugar-sweetened beverages (defined as ≥50 cal/8 oz, excluding 
whole 100% fruit juices), ≤36 oz/wk (≈1/4 of discretionary calories),119,123; sweets and bakery desserts, 2.5 or fewer 50-g servings/wk (≈1/4 of discretionary calories),119,123; EPA/DHA, ≥0.250 g/
d124; ALA, ≥1.6/1.1 g/d (men/women)120; saturated fat, <10% energy; dietary cholesterol, <300 mg/d119; total fat, 20% to 35% energy119; dietary fiber, ≥28/d119; and sodium, <2.3 g/d.119
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Table 5-2. Dietary Consumption in 2009 to 2010 Among US Children and Teenagers of Selected Foods and Nutrients Related to 
Cardiometabolic Health
Boys (5–9 y) Girls (5–9 y) Boys (10–14 y) Girls (10–14 y) Boys (15–19 y) Girls (15–19 y)
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Average 
Consumption 
(Mean±SD)
% Meeting 
Guidelines*
Foods
  Whole grains, 
servings/d
0.8±0.5 1.7 0.6±0.3 0.5 0.7±0.3 2.4 0.6±0.3 0.9 0.7±0.6 3.0 0.6±0.2 3.6
  Total Fruits, 
servings/d
1.5±1.2 8.6 1.7±0.9 8.5 1.2±1.7 6.6 1.2±0.7 5.1 1.2±1.0 5.9 0.9±1.0 4.6
  Total fruit including 
100% fruit juice, 
servings/d
2.4±1.5 18.0 2.5±1.1 18.6 2.0±1.9 13.8 2.0±1.8 12.4 2.1±0.9 15.7 1.6±1.0 8.9
  Total vegetables 
(starchy up to 
3 cups/wk), 
servings/d
1.1±0.7 0.4 1.2±0.5 0.9 1.0±0.3 0.3 1.7±0.3 3.4 1.6±0.3 4.1 1.5±0.3 1.2
  Total vegetables 
(starchy up to  
3 cups/wk),  
including vegetable 
juices/sauces 
servings/d
1.2±0.7 0.8 1.3±0.4 1.0 1.2±0.4 0.3 1.8±0.4 3.6 1.7±0.2 4.1 1.7±0.2 2.0
  Fish and shellfish, 
servings/wk
0.3±0.8 8.5 0.5±0.8 8.5 0.4±0.8 7.7 0.2±0.8 4.4 0.8±0.8 11.2 0.4±0.7 7.4
  Nuts, seeds, and 
beans, servings/wk
2.4±2.1 23.2 2.5±1.1 21.3 2.3±1.7 22.0 2.4±1.7 21.2 2.6±0.4 25.2 3.0±2.0 25.8
  Processed meats, 
servings/wk
1.9±1.1 63.7 1.4±0.2 71.1 2.4±1.4 57.7 2.0±1.4 58.4 2.2±0.6 61.8 1.4±0.6 75.1
  Sugar-sweetened 
beverages, 
servings/wk
8.0±4.3 45.0 7.5±5.2 40.4 11.0±6.1 27.8 9.2±3.4 30.6 17.3±12.4 20.1 13.6±10.9 27.0
  Sweets and 
bakery desserts, 
servings/wk
8.5±4.4 24.5 9.4±4.4 22.5 7.2±2.5 25.4 7.7±2.6 26.8 5.2±3.0 38.9 7.5±3.9 38.8
Nutrients
  Total calories, kcal/d 1828±276 NA 1757±312 NA 2163±560 NA 1865±377 NA 2532±500 NA 1836±308 NA
  EPA/DHA, g/d 0.045±0.049 3.2 0.051±0.048 4.6 0.048±0.049 2.5 0.039±0.048 0.9 0.063±0.052 6.2 0.058±0.067 3.7
  ALA, g/d 1.18±0.16 10.7 1.24±0.17 57.1 1.17±0.24 12.9 1.33±0.21 63.0 1.28±0.16 22.3 1.37±0.32 63.0
  n-6 PUFA, % 
energy
6.6±1.2 NA 6.8±1.2 NA 6.7±0.9 NA 7.1±0.8 NA 6.9±0.5 NA 7.6±1.8 NA
  Saturated fat,  
% energy
11.3±1.7 31.0 11.2±1.1 33.2 11.3±0.9 37.8 11.4±1.6 33.5 11.0±1.4 34.7 10.7±1.5 40.2
  Dietary cholesterol, 
mg/d
225±46 80.6 234±64 75.3 234±90 82.9 250±48 75.2 230±68 82.2 240±67 75.8
  Total fat, % energy 32.1±2.4 69.6 32.0±1.8 72.6 32.4±1.8 62.3 32.9±1.7 64.5 32.2±3.4 62.6 32.4±3.0 65.4
  Carbohydrate,  
% energy
54.4±2.4 NA 54.8±2.2 NA 53.1±3.3 NA 53.1±3.3 NA 52.5±4.8 NA 53.2±3.8 NA
  Dietary fiber, g/d 14.7±3.5 1.9 15.4±3.5 1.5 13.9±2.6 0.5 14.7±3.2 0.7 13.9±2.8 0.7 14.1±4.7 2.2
  Sodium, g/d 3.3±0.4 5.5 3.3±0.4 4.8 3.4±0.3 2.7 3.5±0.2 2.3 3.4±0.4 8.7 3.5±0.4 5.0
Data from the National Health and Nutrition Examination Survey 2009 to 2010, derived from two 24-hour dietary recalls per person, with population SDs adjusted for within-person vs 
between-person variation. All values are energy adjusted by individual regressions or percent energy, and for comparability, means and proportions are reported for a 2000-kcal/d diet. To 
obtain actual mean consumption levels, the group means for each food or nutrient can be multiplied by the group-specific total calories (kcal/d) divided by 2000 kcal/d. Compared to prior AHA 
Statistical Updates, the calculations for foods now utilize the USDA Food Patterns Equivalent Database on composition of various mixed dishes, which incorporates partial amounts of various 
foods (eg, vegetables, nuts, processed meats, etc) in mixed dishes; in addition, the characterization of whole grains is now derived from the USDA database instead of the ratio of carbohydrate 
to fiber (analyses courtesy of Dr. Colin Rehm, Tufts University).
ALA indicates α-linoleic acid; DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; NA, not available; and n-6-PUFA, ω-6-polyunsaturatedfatty acid.
*All intakes and guidelines adjusted to 2000 kcal/d diet.  Servings defined as follows: whole grains (1-oz equivalents), fruits and vegetables (1/2 cup equivalents), fish/shellfish (3.5 oz or 100 g), 
nuts/seeds/beans (50 g), processed meat (3.5 oz or 100 g), sugar-sweetened beverages (8 fl oz), sweets and bakery desserts (50 g). Foods and guidelines defined as follows: whole grains, 
3 or more 1-oz equivalent (eg, 21 g whole wheat bread, 82 g cooked brown rice, 31 g Cheerios) servings per day (Dietary Guidelines for Americans123; fruits, 2 or more cups/d119; vegetables, 
2 1/2 or more cups/d, including up to 3 cups/wk of starchy vegetables119; nuts, seeds, and beans, 4 or more 50-g servings/wk123; processed meats (bacon, hot dogs, sausage, processed deli 
meats), 2 or fewer 100-g (3.5-oz) servings/wk (1/4 of discretionary calories)119; sugar-sweetened beverages (defined as ≥50 cal/8 oz, excluding whole 100% fruit juices), ≤36 oz/wk (≈1/4 
of discretionary calories)119,123; sweets and bakery desserts, 2.5 or fewer 50-g servings/wk (≈1/4 of discretionary calories)119,123; EPA/DHA, ≥0.250 g/d124; ALA, ≥1.6/1.1 g/d (men/women)120; 
saturated fat, <10% energy; dietary cholesterol, <300 mg/d119; total fat, 20% to 35% energy119; dietary fiber, ≥28/d119; and sodium, <2.3 g/d.119
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Chart 5-1. Percentage of sodium from dietary sources in the United States, 2005 to 2006. Source: Applied Research Program, National 
Cancer Institute.125
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Chart 5-2. Per capita calories consumed from different beverages by US adults (≥19 years of age), 1965 to 2010. Source: Nationwide 
Food Consumption Surveys (1965, 1977–1978) and National Health and Nutrition Examination Survey (1988–2010), based on data from 
Duffey and Popkin18 and Kit et al.61 Data from 2010 were only analyzed for soda/cola and sweetened fruit drinks.
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23%
3%
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62%
2%
1% 5%
Sales
Eating and drinking places Retail stores, direct selling Schools and colleges
Foods at home Hotels and motels Recreational places
All other foods away from home
1977 2007
36%
2%
3%
51%
2%
2% 4%
Chart 5-3. Total US food expenditures away from home and at home, 1977 and 2007. Data derived from Davis et al.58
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6 . Overweight and Obesity
See Table 6-1 and Charts 6-1 through 6-3.
Overweight and obesity are typically classified by use of BMI 
cutoffs, but variations in body fat distribution (eg, larger waist 
circumference) are also associated with increased cardiovas-
cular risk.1 Overweight and obesity are major risk factors for 
CVD, including CHD, stroke,2,3 AF,4 VTE,5 and CHF. The 
AHA has identified BMI <85th percentile (for children) and 
<25 kg/m2 (for adults aged ≥20 years) as 1 of the 7 compo-
nents of ideal cardiovascular health.6 In 2011 to 2012, 64.7% 
of children and 31.3% of adults met these criteria (Chapter 2, 
Cardiovascular Health).
Prevalence
Youth
(See Table 6-1 and Chart 6-1.)
 ● According to 2011 to 2012 data from NHANES (NCHS), 
the overall prevalence of overweight and obesity in chil-
dren aged 2 to 19 years is 31.8% based on a BMI-for-age 
value ≥85th percentile of the 2000 CDC growth charts. 
The overall prevalence of overweight and obesity in chil-
dren aged 2 to 5 years of age was 21.8% for non-Hispanic 
white boys and 19.9% for non-Hispanic white girls, 22.2% 
for non-Hispanic black boys and 21.6% for non-Hispanic 
black girls, 8.3% for Asian boys and 9.7% for Asian girls, 
and 31.4% for Hispanic boys and 28.1% for Hispanic girls.7 
In children 6 to 11 years of age, the prevalence was 26.5% 
for non-Hispanic white boys and 32.7% for non-Hispanic 
white girls, 39.3% for non-Hispanic black boys and 36.9% 
for non-Hispanic black girls, 24.5% for Asian boys and 
14.9% for Asian girls, and 48.7% for Hispanic boys and 
43.6% for Hispanic girls. For those 12 to 19 years of age, 
the prevalence was 31.5% for non-Hispanic white boys and 
31.0% for non-Hispanic white girls, 37.3% for non-His-
panic black boys and 42.5% for non-Hispanic black girls, 
33.9% for Asian boys and 15% for Asian girls, and 39.6% 
for Hispanic boys and 36.5% for Hispanic girls.7
 ● According to 2011 to 2012 data from NHANES (NCHS), 
the overall prevalence of obesity in children aged 2 to 19 
years was 16.9% based on a BMI-for-age value ≥95th per-
centile of the 2000 CDC growth charts. Among children 
aged 2 to 5 years of age, the prevalence of obesity was 6.3% 
for non-Hispanic white boys and 0.6% for non-Hispanic 
white girls, 9.0% for non-Hispanic black boys and 13.9% 
for non-Hispanic black girls, 1.9% for Asian boys and 4.7% 
for Asian girls, and 18.0% for Hispanic boys and 15.2% for 
Hispanic girls.7 In children 6 to 11 years of age, the preva-
lence of obesity was 8.8% for non-Hispanic white boys and 
17.9% for non-Hispanic white girls, 25.9% for non-Hispanic 
black boys and 21.7% for non-Hispanic black girls, 13.2% 
for Asian boys and 3.7% for Asian girls, and 28.6% for His-
panic boys and 23.4% for Hispanic girls. For those 12 to 19 
years of age, the prevalence was 18.3% for non-Hispanic 
white boys and 20.9% for non-Hispanic white girls, 21.4% 
for non-Hispanic black boys and 22.7% for non-Hispanic 
black girls, 14.8% for Asian boys and 7.3 for Asian girls, 
and 23.9% for Hispanic boys and 21.3% for Hispanic girls.7
 ● Childhood sociodemographic factors may contribute to sex 
disparities in obesity prevalence. A study of data from the 
National Longitudinal Study of Adolescent Health (Add 
Health) found that parental education consistently modified 
sex disparity in blacks. The sex gap was largest in those 
with low parental education (16.7% of men compared with 
45.4% of women were obese) and smallest in those with 
high parental education (28.5% of men compared with 
31.4% of women were obese). In whites, there was little 
overall sex difference in obesity prevalence.8
Abbreviations Used in Chapter 6
AF atrial fibrillation
AFFIRM Atrial Fibrillation Follow-up Investigation of Rhythm Management
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CAC coronary artery calcification
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
FHS Framingham Heart Study
HbA1c hemoglobin A1c
HDL high-density lipoprotein
HR hazard ratio
HUNT 2 Nord-Trøndelag Health Study
IMT intima-media thickness
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
RR relative risk
SBP systolic blood pressure
SD standard deviation
STEMI ST-segment–elevation myocardial infarction
Teen-LABS Teen Longitudianl Assessment of Bariatric Surgery
VTE venous thromboembolism
WHI Women’s Health Initiative
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 ● The obesity epidemic is disproportionally more rampant 
among children living in low-income, low-education, 
and higher-unemployment households, according to data 
from the National Survey of Children’s Health.9 Data 
from 2011 show that among low-income preschool chil-
dren, American Indians/Alaskan Natives have an obesity 
rate of 17.7%, whereas rates are 14.7% for Hispanics, 
10.6% for non-Hispanic blacks, 10.3% for non-Hispanic 
whites, and 9.3% for Asian/Pacific Islanders.10 According 
to 1999 to 2008 NHANES survey data, lowest-income 
girls had an obesity prevalence of 17.9% compared with 
13.1% among those with higher income; similar obser-
vations were observed for boys (20.6% versus 15.6%, 
respectively).11
 ● NHANES 2003 to 2004 and 2005 to 2006 data were 
used to determine overweight and obesity prevalence in 
rural versus urban youth; the results showed that 39% 
of rural versus 32% of urban children had BMI >85th 
percentile.12
 ● A recent AHA Scientific Statement regarding severe obe-
sity in children and adolescents recommended that for 
children and adolescents, the definition of severe obesity 
should include class II obesity, defined as BMI ≥120% of 
the 95th percentile for age and sex, or BMI ≥35 kg/m2.13 By 
this definition, in NHANES 1999 to 2006, the prevalence 
of severe obesity for those aged 2 to 19 years was 5.1% in 
boys and 4.7% in girls.14 According to NHANES data from 
2011 to 2012, 5.9% of children aged 2 to 19 had class II 
obesity, defined as BMI ≥120% of the 95th percentile for 
age and sex, or BMI ≥35 kg/m2, and 2.1% had class III 
obesity, defined as BMI ≥140% of the 95th percentile for 
age and sex, or BMI ≥40 kg/m2.15
 ● According to the National Longitudinal Study of Adoles-
cent Health, compared with those with normal weight or 
those who were overweight, obese adolescents had a 16-fold 
increased risk of having severe obesity (BMI ≥40 kg/m2) 
as adults. Furthermore, the majority (70.5%) of adoles-
cents with severe obesity maintained this weight status into 
adulthood.16
Adults
(See Table 6-1 and Chart 6-2.)
 ● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulations of measured height and weight):
— Overall, 69% of US adults were overweight or obese 
(73% of men and 65% of women).
— Among men, Hispanics (80%) and non-Hispanic whites 
(73%) were more likely to be overweight or obese than 
non-Hispanic blacks (69%).
— Among women, non-Hispanic blacks (82%) and Hispan-
ics (76%) were more likely to be overweight or obese 
than non-Hispanic whites (61%).
— Among US adults, 35% were obese (34% of men and 
36% of women).
— Among men, Hispanics and non-Hispanic blacks 
(38%) were more likely to be obese than non-Hispanic 
whites (34%).
— Among women, non-Hispanic blacks (58%) and His-
panics (43%) were more likely to be obese than non-
Hispanic whites (33%).
 ● On the basis of self-reported weights and heights from the 
2013 NHIS17:
— Blacks ≥18 years of age (27.6%), American Indians or 
Alaska Natives (23.2%), and whites (35.8%) were less 
likely than Asians (57.4%) to be at a healthy weight. 
Blacks ≥18 years of age (36.3%) and American Indians 
or Alaska Natives (46.5%) were more likely to be obese 
than were whites (27.9%) and Asians (10.8%).
 ● In 2004 to 2006, most adults in Asian subgroups were in the 
healthy weight range, with rates ranging from 51% for Fili-
pino adults to 68% for Chinese adults. Although the preva-
lence of obesity is low within the Asian adult population, 
Filipino adults (14%) were more than twice as likely to be 
obese (BMI ≥30 kg/m2) as Asian Indian (6%), Vietnamese 
(5%), or Chinese (4%) adults.18
 ● As estimated from self-reported height and weight in the 
BRFSS/CDC survey in 2013, the prevalence of obesity 
ranged from 21.3% in Colorado to 35.3% in West Virginia 
and Mississippi.19 Additionally, no state met the Healthy 
People 2010 goal of reducing obesity to 15% of adults.20
 ● According to NHANES 2007 to 2010 data, 35% of US 
adults >65 years of age were obese, which represents 13 
million individuals.21
 ● According to the 2008 National Healthcare Disparities 
Report (based on NHANES 2003–2006)22:
— Approximately 64.8% of obese adults were told by a 
doctor or health professional that they were overweight.
— The proportion of obese adults told that they were over-
weight was significantly lower for non-Hispanic blacks 
(60.5%) and Mexican Americans (57.1%) than for non-
Hispanic whites (66.4%), for middle-income people 
than for high-income people (62.4% versus 70.6%), and 
for adults with less than a high school education than for 
those with any college education (59.2% versus 70.3%).
Trends
Youth
(See Chart 6-3.)
 ● Among infants and children between 6 and 23 months of 
age, the prevalence of high weight for recumbent length 
was 7% in 1976 to 1980, 12% in 2003 to 2006 (NHANES, 
NCHS),23 and 8.1% in 2011 to 2012 (NHANES).7
 ● According to NHANES data, overall obesity prevalence 
in youth between 2003 to 2004 and 2011 to 2012 was 
unchanged, although for children aged 2 to 5 years, the 
prevalence of obesity was decreased.7 Among adolescents, 
a socioeconomic gradient has been reported, in which the 
prevalence of obesity is decreasing among adolescents with 
high socioeconomic status but continues to increase among 
adolescents with low socioeconomic status.24 Furthermore, 
according to NHANES data, among children aged 2 to 19 
years, the prevalence of severe obesity has increased during 
the past decade, particularly among adolescent boys.15
Adults
 ● Forecasts through 2030 using the BRFSS 1990 to 2008 data 
set suggest that by 2030, 51% of the population will be 
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obese, with 11% with severe obesity, an increase of 33% 
for obesity and 130% for severe obesity.25
 ● According to NHANES data, there have been no overall 
changes in obesity prevalence in adults between 2003 to 
200426 and 2011 to 2012.7 However, among women aged 
≥60 years, the prevalence of obesity increased 6.6% from 
2003–2004 to 2011–2012.7
Morbidity
Youth
 ● Overweight children and adolescents are at increased risk 
for future adverse health effects, including the following27:
— Increased prevalence of traditional cardiovascular risk 
factors such as hypertension, hyperlipidemia, and DM.
— Poor school performance, tobacco use, alcohol use, pre-
mature sexual behavior, and poor diet.
— Other associated health conditions, such as asthma, 
hepatic steatosis, sleep apnea, stroke, some cancers 
(breast, colon, and kidney), renal insufficiency, muscu-
loskeletal disorders, and gallbladder disease.
 ● Data from 4 Finnish cohort studies examining childhood 
and adult BMI with a mean follow-up of 23 years found 
that overweight or obese children who remained obese in 
adulthood had increased risks of type 2 DM, hypertension, 
dyslipidemia, and carotid atherosclerosis; however, those 
who achieved normal weight by adulthood had risks com-
parable to individuals who were never obese.28
 ● The CARDIA study showed that young adults who were 
overweight or obese had lower health-related quality of life 
than normal-weight participants 20 years later.29
Adults
 ● Data from the FHS indicate that obesity is driving the dou-
bling in the incidence of DM over the past 30 years, most 
dramatically during the 1990s and primarily among indi-
viduals with a BMI >30 kg/m2.30
 ● Among 68 070 participants across multiple NHANES sur-
veys, the decline in BP in recent birth cohorts is slowing, 
mediated by BMI.31
 ● Cardiovascular risks may be even higher with severe obe-
sity (class III, BMI ≥40 kg/m2) than with class I or class 
II obesity.32 Among 156 775 postmenopausal women 
in the WHI, for severe obesity versus normal BMI, HRs 
(95% CIs) for mortality were 1.97 (1.77–2.20) in white 
women, 1.55 (1.20–2.00) in African American women, and 
2.59 (1.55–4.31) in Hispanic women; for CHD, HRs were 
2.05 (1.80–2.35), 2.24 (1.57–3.19), and 2.95 (1.60–5.41) 
respectively; and for CHF, HRs were 5.01 (4.33–5.80), 
3.60 (2.30–5.62), and 6.05 (2.49–14.69). However, CHD 
risk was strongly related to CVD risk factors across BMI 
categories, even in severe obesity, and CHD incidence was 
similar by race/ethnicity when adjusted for differences in 
BMI and CVD risk factors.32
 ● In a meta-analysis from 58 cohorts, representing 221 934 
people in 17 developed countries with 14 297 incident CVD 
outcomes, BMI, waist circumference, and waist-to-hip ratio 
were strongly associated with intermediate risk factors of 
SBP, DM, and total and HDL cholesterol. These risk fac-
tors, along with age, sex and smoking status, accounted 
for almost all of the association of BMI, waist circumfer-
ence, and waist-to-hip ratio with CVD outcomes, so that 
they were only minimally associated with CVD outcomes 
after adjustment for those intermediate risk factors. Mea-
sures of adiposity also did not improve risk discrimination 
or reclassification when data on intermediate risk factors 
were included.33
 ● Obesity is associated with subclinical atherosclerosis 
including CAC and carotid IMT, and this association per-
sists after adjustment for CVD risk factors, as shown in 
MESA.34
 ● The population attributable fraction for CHD associated 
with reducing current population mean BMI to 21 kg/m2 
in the Asia-Pacific region ranged from 2% in India to 58% 
in American Samoa; the population attributable fraction 
for ischemic stroke ranged from 3% in India to 64% in 
American Samoa. These data from 15 countries show the 
proportion of CVD that would be prevented if the popula-
tion mean BMI were reduced below the current overweight 
cut point.35
 ● Obesity is also a strong predictor of sleep-disordered 
breathing, itself strongly associated with the development 
of CVD, as well as with myriad other health conditions, 
including numerous cancers, nonalcoholic fatty liver dis-
ease, gallbladder disease, musculoskeletal disorders, and 
reproductive abnormalities.36
 ● A systematic review of prospective studies examining over-
weight and obesity as predictors of major stroke subtypes in 
>2 million participants over ≥4 years found an adjusted RR 
for ischemic stroke of 1.22 (95% CI, 1.05–1.41) in over-
weight individuals and an RR of 1.64 (95% CI, 1.36–1.99) 
for obese individuals relative to normal-weight individuals. 
RRs for hemorrhagic stroke were 1.01 (95% CI, 0.88–1.17) 
and 1.24 (95% CI, 0.99–1.54) for overweight and obese 
individuals, respectively. These risks were graded with 
increasing BMI and were independent of age, lifestyle, and 
other cardiovascular risk factors.37
 ● A recent report from ARIC showed that VTE risk over 15.5 
years (237 375 person-years) was associated with higher 
BMI (and current smoking) but not with other CVD risk 
factors.5
 ● A recent meta-analysis of 15 prospective studies demon-
strated the increased risk for Alzheimer disease or vas-
cular dementia and any dementia was 1.35 and 1.26 for 
overweight, respectively, and 2.04 and 1.64 for obesity, 
respectively.38 The inclusion of obesity in dementia fore-
cast models increases the estimated prevalence of demen-
tia through 2050 by 9% in the United States and 19% in 
China.39
 ● Ten-year follow-up data from the Swedish Obese Subjects 
intervention study indicated that to maintain a favorable 
effect on cardiovascular risk factors, more than the short-
term goal of 5% weight loss is needed to overcome secular 
trends and aging effects.40
 ● A randomized clinical trial of 130 severely obese adult 
individuals randomized to either 12 months of diet and PA 
or only 6 months of PA resulted in 12.1 and 9.9 kg, respec-
tively, of weight loss at 1 year, with improvements in waist 
circumference, visceral fat, BP, and insulin resistance.41
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Mortality
 ● Elevated childhood BMIs in the highest quartile were asso-
ciated with premature death as an adult in a cohort of 4857 
American Indian children during a median follow-up of 
23.9 years.42
 ● According to NHIS data, among young adults aged 18 to 
39 years, the HR for all-cause mortality was 1.07 (95% 
CI, 0.91–1.26) for overweight individuals, 1.41 (95% CI, 
1.16–1.73) for obese individuals, and 2.46 for extremely 
obese individuals (95% CI, 1.91–3.16).43
 ● Among adults, obesity was associated with nearly 112 000 
excess deaths (95% CI, 53 754–170 064) relative to normal 
weight in 2000. Grade 1 obesity (BMI 30 to <35 kg/m2) 
was associated with almost 30 000 of these excess deaths 
(95% CI, 8534–68 220) and grade 2 to 3 obesity (BMI ≥35 
kg/m2) with >82 000 (95% CI, 44 843–119 289). Under-
weight was associated with nearly 34 000 excess deaths 
(95% CI, 15 726–51 766). As other studies have found,44 
overweight (BMI 25 to <30 kg/m2) was not associated with 
excess deaths.45
 ● A recent systematic review (2.88 million individuals and 
>270 000 deaths) showed that relative to normal BMI (18.5 
to <25 kg/m2), all-cause mortality was lower for overweight 
(HR, 0.94; 95% CI, 0.91–0.96) but was not elevated for 
grade 1 obesity (HR, 0.95; 95% CI, 0.88–1.01). All-cause 
mortality was higher for obesity (all grades; HR, 1.18; 95% 
CI, 1.12–1.25) and grades 2 and 3 obesity (HR, 1.29; 95% 
CI, 1.18–1.41).46
 ● In a collaborative analysis of data from almost 900 000 
adults in 57 prospective studies, mostly in western Europe 
and North America, overall mortality was lowest at a BMI 
of ≈22.5 to 25 kg/m2 in both sexes and at all ages, after 
exclusion of early follow-up and adjustment for smok-
ing status. Above this range, each 5- kg/m2-higher BMI 
was associated with ≈30% higher all-cause mortality, and 
no specific cause of death was inversely associated with 
BMI. Below 22.5 to 25 kg/m2, the overall inverse associa-
tion with BMI was predominantly related to strong inverse 
associations for smoking-related respiratory disease, and 
the only clearly positive association was for ischemic heart 
disease.47
 ● In a meta-analysis of 1.46 million white adults, over a mean 
follow-up period of 10 years, all-cause mortality was low-
est at BMI levels of 20.0 to 24.9 kg/m2. Among women, 
compared with a BMI of 22.5 to 24.9 kg/m2, the HRs for 
death were as follows: BMI 15.0 to 18.4 kg/m2, 1.47; 18.5 
to 19.9 kg/m2, 1.14; 20.0 to 22.4 kg/m2, 1.0; 25.0 to 29.9 
kg/m2, 1.13; 30.0 to 34.9 kg/m2, 1.44; 35.0 to 39.9 kg/m2, 
1.88; and 40.0 to 49.9 kg/m2, 2.51. Similar estimates were 
observed in men.48
 ● Overweight was associated with significantly increased 
mortality resulting from DM or kidney disease and was 
not associated with increased mortality resulting from can-
cer or CVD in an analysis of 2004 data from NHANES. 
Obesity was associated with significantly increased mor-
tality caused by CVD, some cancers, and DM or kidney 
disease. Obesity was associated with 13% of CVD deaths 
in 2004.49
 ● A BMI paradox has been reported, with higher-BMI 
patients demonstrating favorable outcomes in CHF, hyper-
tension, peripheral vascular disease, and CAD; similar 
findings have been seen for percent body fat. In AFFIRM, 
a multicenter trial of AF, obese patients had lower all-cause 
mortality (HR, 0.77; P=0.01) than normal-weight patients 
after multivariable adjustment over a 3-year follow-up 
period.50
 ● Interestingly, among 2625 participants with new-onset 
DM, rates of total, CVD, and non-CVD mortality were 
higher among normal-weight people compared with over-
weight/obese participants, with adjusted HRs of 2.08 (95% 
CI, 1.52–2.85), 1.52 (95% CI, 0.89–2.58), and 2.32 (95% 
CI, 1.55–3.48), respectively.51
 ● Calculations based on NHANES data from 1978 to 2006 
suggest that the gains in life expectancy from smoking ces-
sation are beginning to be outweighed by the loss of life 
expectancy related to obesity.52
 ● Because of the increasing prevalence of obesity, the num-
ber of quality-adjusted life-years lost as a result of obesity 
is similar to or greater than that lost as a result of smoking, 
according to data from the BRFSS.53
 ● According to data from the NCDR, among patients present-
ing with STEMI and a BMI ≥40 kg/m2, in-hospital mortal-
ity rates were higher for patients with class III obesity (OR, 
1.64; 95% CI, 1.32–2.03) when class I obesity was used as 
the referent.54
 ● In a study of 22 203 women and men from England and 
Scotland, metabolically unhealthy obese individuals were 
at an increased risk of all-cause mortality compared with 
metabolically healthy obese individuals (HR, 1.72; 95% 
CI, 1.23–2.41).55
 ● Recent estimates suggest that reductions in smoking, cho-
lesterol, BP, and physical inactivity levels resulted in a gain 
of 2 770 500 life-years; however, these gains were reduced 
by a loss of 715 000 life-years caused by the increased prev-
alence of obesity and DM.56
 ● In a comparison of 5 different anthropometric variables 
(BMI, waist circumference, hip circumference, waist-
to-hip ratio, and waist-to-height ratio) in 62 223 indi-
viduals from Norway with 12 years of follow-up from 
the HUNT 2 study, the risk of death per SD increase in 
each measure was 1.02 (95% CI, 0.99–1.06) for BMI, 
1.10 (95% CI, 1.06–1.14) for waist circumference, 1.01 
(95% CI, 0.97–1.05) for hip circumference, 1.15 (95% 
CI, 1.11–1.19) for waist-to-hip ratio, and 1.12 (95% CI, 
1.08–1.16) for waist-to-height ratio. For CVD mortal-
ity, the risk of death per SD increase was 1.12 (95% CI, 
1.06–1.20) for BMI, 1.19 (95% CI, 1.12–1.26) for waist 
circumference, 1.06 (95% CI, 1.00–1.13) for hip circum-
ference, 1.23 (95% CI, 1.16–1.30) for waist-to-hip ratio, 
and 1.24 (95% CI, 1.16–1.31) for waist-to-height ratio.57
 ● However, because BMI and waist circumference are 
strongly correlated, large samples are needed to evaluate 
their independent contributions to risk.1,58 A recent pooled 
analysis of waist circumference and mortality in 650 386 
adults followed up for a median of 9 years revealed that 
a 5-cm increment in waist circumference was associated 
with an increase in all-cause mortality at all BMI categories 
examined from 20 to 50 kg/m2.59 Similarly, in an analysis 
of postmenopausal women in the WHI limited to those 
with BMI ≥40 kg/m2, mortality, CHD, and CHF incidence 
all increased with waist circumference >115 and >122 cm 
compared with ≤108.4 cm.32
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Cost
 ● In 2008 US dollars, the estimated annual medical cost of 
obesity was $147 billion; the medical costs for those who 
were obese were $1429 higher than for those at normal 
weight.60
 ● The total excess cost related to the current prevalence of 
adolescent overweight and obesity is estimated to be $254 
billion ($208 billion in lost productivity secondary to pre-
mature morbidity and mortality and $46 billion in direct 
medical costs).61
 ● If current trends in the growth of obesity continue, total 
healthcare costs attributable to obesity could reach $861 to 
$957 billion by 2030, which would account for 16% to 18% 
of US health expenditures.62
 ● According to NHANES I data linked to Medicare and 
mortality records, obese 45-year-olds had lifetime Medi-
care costs of $163 000 compared with $117 000 among 
those with normal weight by the time they reached 65 
years of age.63
 ● According to 2006 MEPS and 2006 BRFSS data, annual 
medical expenditures would be 6.7% to 10.7% lower in the 
absence of obesity.64
 ● According to data from the Medicare Current Beneficiary 
Survey from 1997 to 2006, in 1997, expenditures for a Part 
A and Part B services beneficiary were $6832 for a normal-
weight individual, which was more than for overweight 
($5473) or obese ($5790) individuals. However, over time, 
expenses increased more rapidly for overweight and obese 
individuals.65
 ● The costs of obesity are high: Obese people pay on average 
$1429 (42%) more for healthcare costs than normal-weight 
individuals. For obese beneficiaries, Medicare pays $1723 
more, Medicaid pays $1021 more, and private insurers 
pay $1140 more than for beneficiaries who are at normal 
weight. Similarly, obese people have 46% higher inpatient 
costs and 27% more outpatient visits and spend 80% more 
on prescription drugs.60
Bariatric Surgery
 ● Patients with BMI >40 kg/m2 or >35 kg/m2 with an obesity-
related comorbidity are eligible for gastric bypass surgery, 
which is typically performed as either a Roux-en-Y gastric 
bypass or a biliopancreatic diversion.
 ● According to the 2006 NHDS, the incidence of bariatric 
surgery was estimated at 113 000 cases per year, with costs 
of nearly $1.5 billion annually.66
 ● In a large bariatric surgery cohort, the prevalence of high 
10-year predicted CVD risk was 36.5%,67 but 76% of those 
with low 10-year risk had high lifetime predicted CVD risk. 
The corresponding prevalence in US adults is 18% and 
56%, respectively.68
 ● Among obese Swedish patients undergoing bariatric sur-
gery and followed up for up to 15 years, maximum weight 
loss was 32%. The risk of death was 0.76 among those who 
underwent bariatric surgery compared with matched con-
trol subjects.60 More recent data examining MI and stroke 
showed that bariatric surgery was associated with fewer 
CVD deaths (HR, 0.47; 95% CI, 0.29–0.76) and fewer 
strokes (HR, 0.67; 95% CI, 0.54–0.83) than in the control 
group. However, CVD risk was related to baseline CVD 
risk factors rather than to baseline BMI or 2-year weight 
change.69
 ● Among 641 patients followed up for 10 years compared 
with 627 matched control subjects, after 2 years of follow-
up, 72% of the surgically treated patients versus 21% of the 
control patients had remission of their DM; at 10 years of 
follow-up, results were 36% and 13%, respectively. Similar 
results have been observed for hypertension, elevated tri-
glycerides, and low HDL cholesterol.70
 ● According to retrospective data from the United States, 
among 9949 patients who underwent gastric bypass sur-
gery, after a mean of 7 years, long-term mortality was 40% 
lower among the surgically treated patients than among 
obese control subjects. Specifically, cancer mortality was 
reduced by 60%, DM mortality by 92%, and CAD mortal-
ity by 56%. Nondisease death rates (eg, accidents, suicide) 
were 58% higher in the surgery group.71
 ● A recent retrospective cohort from the Veterans Affairs 
medical system showed that in a propensity-matched analy-
sis, bariatric surgery was not associated with reduced mor-
tality compared with obese control subjects (time-adjusted 
HR, 0.94; 95% CI, 0.64–1.39).72
 ● Two recent randomized controlled trials were performed 
that randomized bariatric surgery compared with inten-
sive medical treatment among patients with type 2 DM. 
The first study randomized 150 patients and conducted 
12-month follow-up; this study showed that glycemic 
control improved (6.4%) and weight loss was greater 
(29.4 versus 5.4 kg) in the surgical arm.73 The second trial 
randomized 60 patients to bariatric surgery versus medi-
cal therapy and conducted follow-up for 24 months. The 
results showed that DM remission occurred in 75% of the 
group that underwent gastric bypass surgery compared 
with 0% of those in the medical treatment arm, with HbA1c 
values of 6.35% in the surgical arm compared with 7.69% 
in the medical treatment arm.74
 ● Of 120 patients with type 2 DM and a BMI between 30 
and 39.9 kg/m2, 60 who were randomized to Roux-en-Y 
gastric bypass were almost 5-fold (OR, 4.8; 95% CI, 1.9–
11.7) more likely to achieve an HbA1c <7.0% at 12-month 
follow-up. However, there were 22 serious adverse events 
in the intervention arm, including early and late periopera-
tive complications and nutritional deficiencies.75
 ● Adolescents (aged 10–19 years old) underwent bariatric 
surgery at a rate of 0.8/100 000 procedures, which increased 
to 2.3/100 000 in 2003 and remained constant by 2009 at 
2.4/100 000.76 The Teen-LABS study recently reported a 
favorable short-term (30 day) complications profile of bar-
iatric surgery among 242 patients aged 13 to 19 years.77
 ● A recent cost-effectiveness study of laparoscopic adjustable 
gastric banding showed that after 5 years, $4970 was saved 
in medical expenses; if indirect costs were included (absen-
teeism and presenteeism), savings increased to $6180 and 
$10 960, respectively.78 However, when expressed per qual-
ity-adjusted life expectancy, only $6600 was gained for 
laparoscopic gastric bypass, $6200 for laparoscopic adjust-
able gastric band, and $17 300 for open Roux-en-Y gas-
tric bypass, none of which exceeded the standard $50 000 
per quality-adjusted life expectancy gained.79 Two other 
recent large studies failed to demonstrate a cost benefit for 
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bariatric surgery versus matched patients over 6 years of 
follow-up.80,81 However, another study showed cost savings 
for bariatric surgery among patients with DM at baseline.82
Global Burden of High BMI and Obesity
 ● Between 1980 and 2008, mean BMI has increased world-
wide by 0.4 kg/m2 per decade for men and 0.5 kg/m2 per 
decade for women, with trends varying between nations. In 
2008, an estimated 1.46 billion adults were overweight or 
obese. The prevalence of obesity was estimated at 205 mil-
lion men and 297 million women. The highest prevalence 
of male obesity is in the United States, Southern and Cen-
tral Latin America, Australasia, and Central and Western 
Europe, and the lowest prevalence is in South and South-
east Asia and East, Central, and West Africa. For women, 
the highest prevalence of obesity is in Southern and North 
Africa; the Middle East; Central and Southern Latin Amer-
ica; and the United States; and the lowest is in South, East, 
and Southeast Asia; the Asia-Pacific (high income); and 
East, Central, and West Africa.83
 ● Between 1990 and 2010, estimated deaths attributable to 
high BMI increased 1.7-fold, from 1 963 549 to 3 371 232, 
and DALYs lost because of high BMI rose 1.8-fold, from 
51 565 to 93 609. Therefore, between 1990 and 2010, high 
BMI went from tenth to sixth in ranking of contribution to 
the global burden of disease and was among the top 5 risk 
factors for global burden of disease in all regions except 
high-income Asia-Pacific; East, Southeast, and South Asia; 
and East, Central, and West sub-Saharan Africa.84
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Table 6-1. Overweight and Obesity
Prevalence of Overweight 
and Obesity, 2009–2012, 
Age >20 y
Prevalence of Obesity, 
2009–2012,  
Age >20 y
Prevalence of Overweight 
and Obesity 2011–2012, 
Ages 2–19 y
Prevalence of Obesity, 
2011–2012, Ages 
2–19 y Cost, 2008*
Both sexes, n (%) 159 200 000 (68.5) 81 800 000 (35.2) 23 700 000 (31.8) 12 600 000 (16.9) $147 Billion
  Males 81 500 000 (72.5) 38 600 000 (34.4) 12 200 000 (32.0) 6 300 000 (16.7) …
  Females 77 700 000 (64.7) 43 200 000 (36.0) 11 500 000 (31.6) 6 300 000 (17.2) …
NH white males, % 72.7 34.2 27.8 12.6 …
NH white females, % 61.2 32.5 29.2 15.6 …
NH black males, % 69.4 37.9 34.4 19.9 …
NH black females, % 81.9 57.5 36.1 20.5 …
Hispanic males, % 80.1 38.4 40.7 24.1 …
Hispanic females, % 76.3 42.9 37.0 20.6 …
Overweight and obesity in adults is defined as body mass index (BMI) ≥25 kg/m2. Obesity in adults is defined as BMI ≥30 kg/m2. In children, overweight and obesity 
are based on BMI-for-age values at or above the 85th percentile of the 2000 Centers for Disease Control and Prevention (CDC) growth charts. In children, obesity is based 
on BMI-for-age values at or above the 95th percentile of the CDC growth charts. In January 2007, the American Medical Association’s Expert Task Force on Childhood 
Obesity recommended new definitions for overweight and obesity in children and adolescents85; however, statistics based on this new definition are not yet available.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Data from Finkelstein et al.60
Sources: National Health and Nutrition Examination Survey (NHANES) 2009 to 2012 (adults), unpublished National Heart, Lung, and Blood Institute (NHLBI) tabulation; 
NHANES 2011 to 2012 (ages 2–19 years) from Ogden et al.86 Extrapolation for ages 2 to 19 years from NHLBI tabulation of US Census resident population on July 1, 
2012.
16.9
14.3
15.2
22.8
17.4
19.2
16.5
9.7
14.8
16.7
19.0
8.6
0
5
10
15
20
25
NH White Males NH White
Females
NH Black Males NH Black
Females
Hispanic Males Hispanic Females
Pe
rc
en
t o
f P
op
ul
at
io
n
Overweight Obese
Chart 6-1. Prevalence of overweight and obesity among students in grades 9 through 12 by sex and race/ethnicity. NH indicates non-
Hispanic. Data derived from Kann et al (Table 101).87
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Chart 6-2. Age-adjusted prevalence of obesity in adults 20 to 74 years of age by sex and survey year (National Health Examination 
 Survey: 1960–1962; National Health and Nutrition Examination Survey: 1971–1974, 1976–1980, 1988–1994, 1999–2002, 2003-2006, and 
2009–2012). Obesity is defined as body mass index of 30.0 kg/m2. Data derived from Health, United States, 2013 (National Center for 
Health Statistics).88
10.7
15.7
12.2
16.8
12.8
17.1
20.6
26.0
28.1
34.033.1
35.235.1
36.4
0
5
10
15
20
25
30
35
40
Men Women
Pe
rc
en
t o
f P
op
ul
at
io
n
1960-62 1971-74 1976-80 1988-94 1999-2002 2003-2006 2009-2012
Chart 6-3. Trends in the prevalence of obesity among US children and adolescents by age and survey year (National Health and Nutrition 
Examination Survey:1988–1994, 1999–2000, 2001–2002, 2003–2004, 2005–2006, 2007–2008, 2009–2010, and 2011–2012). Red line indi-
cates ages 2 to 5 years; blue line, ages 6 to 11 years; and green line, ages 12 to 19 years. Data derived from Health, United States, 2013 
(National Center for Health Statistics).88
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7 . Family History and Genetics
See Tables 7-1 through 7-3.
Biologically related first-degree relatives (siblings, offspring, 
and parents) share roughly 50% of their genetic variation with 
one another. This constitutes much greater sharing of genetic 
variation than with a randomly selected person from the popu-
lation, and thus, familial aggregation of traits lends support 
for a genetic basis for the trait. Similarly, racial/ethnic minori-
ties are more likely to share their genetic variation within 
their demographic than with other demographics. Familial 
aggregation of CVD may be related to aggregation of spe-
cific behaviors (eg, smoking, alcohol use) or risk factors (eg, 
hypertension, DM, obesity) that may themselves have envi-
ronmental and genetic contributors. Unlike classic mende-
lian genetic risk factors, whereby usually 1 mutation directly 
causes 1 disease, a complex trait’s genetic contributors may 
increase risk without necessarily always causing the condi-
tion. The effect size of any specific contributor to risk may be 
small but widespread throughout a population, or may be large 
but affect only a small population, or may have an enhanced 
risk when an environmental contributor is present. We present 
a summary of evidence that a genetic risk for CVD is likely, as 
well as a summary of evidence on the most consistently repli-
cated genetic markers for CHD and stroke identified to date. A 
comprehensive scientific statement on the role of genetics and 
genomics for the prevention and treatment of CVD is avail-
able elsewhere.1
Family History
Prevalence
 ● Among adults ≥20 years of age, 12.0% (SE 0.4%) reported 
having a parent or sibling with a heart attack or angina 
before the age of 50 years. The racial/ethnic breakdown 
is as follows (NHANES 2009–2012, unpublished NHLBI 
tabulation):
—For non-Hispanic whites, 11.5% (SE 0.6%) for men, 
14.6% (SE 0.8%) for women
—For non-Hispanic blacks, 9.1% (SE 0.8%) for men, 
12.3% (SE 0.7%) for women
—For Hispanics, 7.6% (SE 0.7%) for men, 10.1% (SE 
1.0%) for women
 ● HD occurs as people age, so the prevalence of family his-
tory will vary depending on the age at which it is assessed. 
The breakdown of reported family history of heart attack 
by age of survey respondent in the US population as mea-
sured by NHANES is as follows (NHANES 2009–2012, 
unpublished NHLBI tabulation):
—Age 20 to 39 years, 8.0% (SE 0.6%) for men, 9.7% (SE 
0.8%) for women
—Age 40 to 59 years, 12.1% (SE 0.8%) for men, 15.2% 
(SE 1.4%) for women
—Age 60 to 79 years, 13.3% (SE 1.5%) for men, 16.6% 
(SE 1.3%) for women
—Age ≥80 years, 8.7% (SE 1.9%) for men, 15.5% (SE 
2.4%) for women
 ● In the multigenerational FHS, only 75% of participants 
with a documented parental history of a heart attack before 
age 55 years reported that history when asked.2
Impact of Family History
Coronary Heart Disease
 ● Paternal history of premature heart attack has been shown 
to approximately double the risk of a heart attack in men 
and increase the risk in women by ≈70%.3,4
 ● History of a heart attack in both parents increases the risk 
of heart attack, especially when 1 parent had a premature 
heart attack5 (Table 7-1).
 ● Sibling history of CVD has been shown to increase the 
odds of CVD in men and women by 45% (OR, 1.45; 
95% CI, 1.19–1.91) in models accounting for CVD risk 
factors.6
Abbreviations Used in Chapter 7
AAA abdominal aortic aneurysm
ABI ankle-brachial index
ACS acute coronary syndrome
AF atrial fibrillation
BMI body mass index
CAC coronary artery calcification
CAD coronary artery disease
CARDIoGRAMplusC4D Coronary Artery Disease Genome-wide Replication 
and Meta-Analysis (CARDIOGRAM) plus the 
Coronary Artery Disease (C4D) Genetics Consortium
CHD coronary heart disease
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
GFR glomerular filtration rate
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
LDL low-density lipoprotein
MI myocardial infarction
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PAD peripheral artery disease
SBP systolic blood pressure
SE standard error
SNP single-nucleotide polymorphism
VTE venous thromboembolism
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 ● Family history of premature angina, MI, angioplasty, or 
bypass surgery increased the lifetime risk by ≈50% for both 
HD (from 8.9% to 13.7%) and CVD (from 14.1% to 21%) 
mortality.7
 ● In a recent international study of individuals with prema-
ture ACS (age ≤55 years), more women (28%) than men 
(20%) had a family history of CAD (P=0.008). However, 
compared with patients without, patients with a family his-
tory of CAD had a higher prevalence of traditional CVD 
risk factors, including dyslipidemia and obesity. Women 
with a family history had a higher prevalence of each tradi-
tional risk factor (obesity, DM, dyslipidemia, and hyperten-
sion) except smoking.8
Other CVDs
 ● A parental history of AF was associated with ≈80% 
increased odds of AF in men and women.9 The risk of AF 
was increased the younger the age of onset and the more 
family members affected.10 In a Swedish study, the odds of 
AF associated with familial AF (OR, 5.04; 95% CI, 4.26–
5.82) were higher in people with a history of premature AF 
(diagnosed AF at age <50 years). Interestingly, there was 
modest spousal aggregation of AF, consistent with a con-
tribution of shared environment to AF risk; the spousal OR 
for AF was 1.16 (95% CI, 1.13–1.19).11
 ● A history of stroke in a first-degree relative increases the 
odds of stroke in men and women by ≈50%.12
 ● A parental history of HF also is associated with an increased 
odds of offspring HF (multivariable-adjusted HR, 1.7; 95% 
CI, 1.11–2.60).13
 ● In a Swedish population-based case control study, the risk of 
thoracic aortic disease increased the greater the number of 
affected relatives and the younger the individual affected. The 
OR was 5.8 (95% CI, 4.3–7.7) with 1 affected relative versus 
20 (95% CI, 2.2–179) with at least 2 affected relatives.14
 ● Similarly, the odds of having PAD were elevated (OR, 
1.83; 95% CI, 1.03–3.26) in individuals with a family his-
tory of PAD.15
 ● A family history of VTE is associated with a 2- to 3-fold 
odds of VTE, irrespective of identified known predisposing 
genetic factors.16,17
Genetics
Heart Disease
 ● Genome-wide association is a robust technique to identify 
associations between genotypes and phenotypes. Table 7-2 
presents results from the CARDIoGRAMplusC4D Consor-
tium, which represents the largest genetic study of CAD 
to date. Although the ORs are modest, ranging from 1.06 
to 1.51 per copy of the risk allele (individuals may harbor 
up to 2 copies of a risk allele), these are common alleles, 
which suggests that the attributable risk may be substan-
tial. Additional analysis suggested that loci associated with 
CAD were involved in lipid metabolism and inflammation 
pathways.18
 ● The relationship between genetic variants associated with 
CHD and measured CHD risk factors is complex, with 
some genetic markers associated with multiple risk fac-
tors and other markers showing no association with risk 
factors.19
 ● Genetic markers discovered thus far have not been shown 
to add to cardiovascular risk prediction tools beyond cur-
rent models that incorporate family history.20 Genetic 
markers also have not been shown to improve prediction of 
subclinical atherosclerosis beyond traditional risk factors.21 
However, an association between genetic markers and CAC 
has been seen.22
 ● The most consistently replicated genetic marker for HD in 
European-derived populations is located at 9p21.3. At this 
single-nucleotide polymorphism, ≈27% of the white popu-
lation is estimated to have 0 risk alleles, 50% is estimated 
to have 1 risk allele, and the remaining 23% is estimated to 
have 2 risk alleles.23 In meta-analyses of individuals of East 
Asian ancestry, variants at 9p21.3 have also been reported 
to be associated with CHD (OR per risk allele, 1.3; 95% 
CI, 1.25–1.35).24
 ● The 10-year HD risk for a 65-year-old man with 2 risk 
alleles at 9p21.3 and no other traditional risk factors is 
≈13.2%, whereas a similar man with 0 alleles would have a 
10-year risk of ≈9.2%. The 10-year HD risk for a 40-year-
old woman with 2 alleles and no other traditional risk 
factors is ≈2.4%, whereas a similar woman with 0 alleles 
would have a 10-year risk of ≈1.7%.23
 ● Variation at the 9p21.3 region also is associated with an 
increased risk of HF25 and sudden death.26 Associations 
have also been observed between the 9p21.3 region and 
CAC.27,28 Additionally, stronger associations have been 
found between variation at 9p21.3 and earlier27,28 and more 
severe29 heart attacks. Paradoxically, a recent meta-analysis 
reported that variants at 9p21.3 were associated with inci-
dent (HR, 1.19; 95% CI, 1.17–1.22) but not recurrent (HR, 
1.01; 95% CI, 0.97–1.06) CHD events,30 which supports 
the genetic complexity of CHD. The biological mecha-
nisms underpinning the association of genetic variation 
in the 9p21 region with disease outcomes are still under 
investigation.
Stroke
 ● The same 9p21.3 region has also been associated with 
intracranial aneurysm,31 AAA,32 and ischemic stroke.33
 ● For large-vessel ischemic stroke, an association for large-
vessel stroke with histone deacetylase 9 on chromosome 
7p21.1 has been identified (>9000 subjects) and replicated 
(>12 000 subjects).33,34
CVD Risk Factors
 ● Heritability is the ratio of genetically caused variation to 
the total variation of a trait or measure. Table 7-3 presents 
heritability estimates for standard CVD risk factors using 
data generated from the FHS. These data suggest that most 
CVD risk factors have at least moderate heritability.
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Table 7-1. OR for Combinations of Parental Heart Attack History
OR (95% CI)
No family history 1.00
One parent with heart attack ≥50 y of age 1.67 (1.55–1.81)
One parent with heart attack <50 y of age 2.36 (1.89–2.95)
Both parents with heart attack ≥50 y of age 2.90 (2.30–3.66)
Both parents with heart attack, one <50 y of age 3.26 (1.72–6.18)
Both parents with heart attack, both <50 y of age 6.56 (1.39–30.95)
CI indicates confidence interval; and OR, odds ratio.
Data derived from Chow et al.5
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Table 7-3. Heritability of CVD Risk Factors From the FHS
Trait Heritability
ABI 0.2135
SBP 0.4236
DBP 0.3936
Left ventricular mass 0.24–0.3237
BMI 0.37 (mean age 40 y)–0.52  
(mean age 60 y)38
Waist circumference 0.4139
Visceral abdominal fat 0.3640
Subcutaneous abdominal fat 0.5740
Fasting glucose 0.3441
CRP 0.3042
HbA1c 0.27
41
Triglycerides 0.4843
HDL cholesterol 0.5243
Total cholesterol 0.5743
LDL cholesterol 0.5943
Estimated GFR 0.3344
ABI indicates ankle-brachial index; BMI, body mass index; CRP, C-reactive 
protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; FHS, 
Framingham Heart Study; GFR, glomerular filtration rate; HbA1c, glycosylated 
hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and 
SBP, systolic blood pressure.
Table 7-2. Validated SNPs for CAD, the Nearest Gene, and the 
OR From the CARDIoGRAMplusC4D Consortium
SNP Chromosome Gene Effect Size (OR)
Effect Allele 
Frequency
rs602633 1 SORT1 1.12 0.77
rs17464857 1 MIA3 1.05 0.87
rs17114036 1 PPAP2B 1.11 0.91
rs11206510 1 PCSK9 1.06 0.84
rs4845625 1 IL6R 1.04 0.47
rs6725887 2 WDR12 1.12 0.11
rs515135 2 APOB 1.08 0.82
rs2252641 2 ZEB2-AC074093.1 1.04 0.46
rs1561198 2 VAMP5- 
VAMP8-GGCX
1.05 0.45
rs6544713 2 ABCG5-ABCG8 1.06 0.30
rs9818870 3 MRAS 1.07 0.14
rs7692387 4 GUCY1A3 1.06 0.81
rs1878406 4 EDNRA 1.06 0.15
rs273909 5 SLC22A4-
SLC22A5
1.09 0.14
rs12205331 6 ANKS1A 1.04 0.81
rs9369640 6 PHACTR1 1.09 0.65
rs12190287 6 TCF21 1.07 0.59
rs3798220 6 LPA 1.28 0.01
rs10947789 6 KCNK5 1.06 0.76
rs4252120 6 PLG 1.06 0.73
rs11556924 7 ZC3HC1 1.08 0.65
rs12539895 7 - 1.08 0.19
rs2023938 7 HDAC9 1.07 0.10
rs264 8 LPL 1.05 0.86
rs2954029 8 TRIB1 1.04 0.55
rs1333049 9 CDKN2A, CDKN2B 1.23 0.47
rs579459 9 ABO 1.07 0.21
rs2505083 10 KIAA1462 1.06 0.42
rs501120 10 CXCL12 1.07 0.83
rs12413409 10 CYP17A1- 
CNNM2-NT5C2
1.10 0.89
rs2246833 10 LIPA 1.06 0.38
rs9326246 11 ZNF259- 
APOA5-A4-C3-A1
1.09 0.10
rs974819 11 PDGFD 1.07 0.29
rs3184504 12 SH2B3 1.07 0.40
rs4773144 13 COL4A1-COL4A2 1.07 0.42
rs9319428 13 FLT1 1.05 0.32
rs2895811 14 HHIPL1 1.06 0.43
rs7173743 15 ADAMTS7 1.07 0.58
rs17514846 15 FURIN-FES 1.05 0.44
rs2281727 17 SMG6-SRR 1.05 0.36
rs12936587 17 RASD1- 
SMCR3-PEMT
1.06 0.59
rs15563 17 UBE2Z-GIP-
ATP5G1-SNF8
1.04 0.52
rs1122608 19 LDLR 1.10 0.76
rs2075650 19 ApoE-ApoC1 1.11 0.14
rs9982601 21 KCNE2 1.13 0.13
CAD indicates coronary artery disease; CARDIoGRAMplusC4D, Coronary 
Artery Disease Genome-wide Replication and Meta-analysis (CARDIOGRAM) 
plus the Coronary Artery Disease (C4D) Genetics Consortium; OR, odds ratio; 
and SNP, single-nucleotide polymorphism.
Data derived from Deloukas et al.18
Table 7-2. Continued
SNP Chromosome Gene Effect Size (OR)
Effect Allele 
Frequency
(Continued)
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8 . High Blood Cholesterol and Other Lipids
See Table 8-1 and Charts 8-1 through 8-4.
High cholesterol is a major risk factor for CVD and stroke.1 
The AHA has identified untreated total cholesterol <170 mg/
dL (for children) and <200 mg/dL (for adults) as 1 of the 7 
components of ideal cardiovascular health.2 In 2011 to 2012, 
75.7% of children and 46.6% of adults met these criteria.
Prevalence of High Total Cholesterol
For information on dietary cholesterol, total fat, saturated 
fat, and other factors that affect blood cholesterol levels, see 
Chapter 5 (Nutrition).
Youth
(See Chart 8-1.)
 ● Among children 6 to 11 years of age, the mean total choles-
terol level is 160.2 mg/dL. For boys, it is 160.5 mg/dL; for 
girls, it is 159.8 mg/dL. The racial/ethnic breakdown is as fol-
lows (NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 158.6 mg/dL for boys and 
158.2 mg/dL for girls
—For non-Hispanic blacks, 163.7 mg/dL for boys and 
159.8 mg/dL for girls
—For Hispanics, 160.5 mg/dL for boys and 161.2 mg/dL 
for girls
 ● Among adolescents 12 to 19 years of age, the mean total cho-
lesterol level is 158.3 mg/dL. For boys, it is 155.2 mg/dL; for 
girls, it is 161.6 mg/dL. The racial/ethnic breakdown is as fol-
lows (NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 155.2 mg/dL for boys and 
163.2 mg/dL for girls
—For non-Hispanic blacks, 153.9 mg/dL for boys and 
158.6 mg/dL for girls
—For Hispanics, 157.0 mg/dL for boys and 160.4 mg/dL 
for girls
 ● The prevalence of abnormal lipid levels among youths 
12 to 19 years of age is 20.3%; 14.2% of normal-weight 
youths, 22.3% of overweight youths, and 42.9% of obese 
youths have ≥1 abnormal lipid level (NHANES 1999–
2006, NCHS).3
 ● Approximately 8.5% of adolescents 12 to 19 years of age 
have total cholesterol levels ≥200 mg/dL (NHANES 2009–
2012, unpublished NHLBI tabulation).
 ● Twenty percent of male adolescents and 27% of female ado-
lescents have total cholesterol levels of 170 to 199 mg/dL.4
 ● Among youths aged 6 to 19 years, there was a decrease 
in mean total cholesterol from 165 to 160 mg/dL and a 
decrease in the prevalence of elevated total cholesterol 
from 11.3% to 8.1% from 1988–1994 to 2007–2010.5
 ● Mean non-HDL cholesterol (111.7 mg/dL) and preva-
lence of elevated non-HDL cholesterol both significantly 
decreased from the periods 1988–1994 to 2007–2010. In 
2007 to 2010, 22% of youths had either a low HDL choles-
terol level or a high non-HDL cholesterol level, which was 
lower than the 27.2% in 1988 to 1994.5
 ● Among adolescents (aged 12–19 years) between 1988 to 
1994 and 2007 to 2010, there was a decrease in mean LDL 
cholesterol from 95 to 90 mg/dL and a decrease in geo-
metric mean triglycerides from 82 to 73 mg/dL. The preva-
lence of elevated LDL cholesterol and triglycerides also 
decreased significantly between 1988 to 1994 and 2007 to 
2010.5
 ● Fewer than 1% of adolescents are potentially eligible for 
pharmacological treatment on the basis of guidelines from 
the American Academy of Pediatrics.3,6
Adults
(See Table 8-1 and Charts 8-2 through 8-4.)
 ● An estimated 30.9 million adults ≥20 years of age have 
serum total cholesterol levels ≥240 mg/dL (extrapolated for 
2012 by use of NCHS/NHANES 2009–2012 data), with a 
prevalence of 13.1%.
 ● Approximately 6.2% of adults ≥20 years of age have 
undiagnosed hypercholesterolemia, defined as a total 
cholesterol level ≥240 mg/dL and the participant having 
responded “no” to ever having been told by a doctor or 
other healthcare professional that the participant’s blood 
cholesterol level was high (NHANES 2009–2012, unpub-
lished NHLBI tabulation).
 ● In 2011 to 2012, an estimated 12.9% of US adults aged 
≥20 years (11.1% of men and 14.4% of women) had high 
total cholesterol, which was unchanged since 2009 to 2010, 
according to NCHS/NHANES 2011 to 2012 data.7
—Non-Hispanic black adults had consistently lower percent-
ages with high total cholesterol (9.8% overall, 7.4% for 
men, and 11.5% for women) than non-Hispanic white adults 
(13.5% overall, 11.6% for men, and 15.2% for women).7
—Overall, 14.2% of Hispanic adults had high total 
cholesterol.7
 ● The age-adjusted mean total cholesterol level for adults 
≥20 years of age declined linearly from 206 mg/dL (95% 
Abbreviations Used in Chapter 8
ACC American College of Cardiology
AHA American Heart Association
ASCVD atherosclerotic cardiovascular disease
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CI confidence interval
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
HDL high-density lipoprotein
LDL low-density lipoprotein
Mex. Am. Mexican American
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHLBI National Heart, Lung, and Blood Institute
WHO World Health Organization
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CI, 205–207 mg/dL) in 1988 to 1994 to 203 mg/dL (95% 
CI, 201–205 mg/dL) in 1999 to 2002 and to 196 mg/dL 
(95% CI, 195–198 mg/dL) in 2007 to 2010 (P<0.001 for 
linear trend).8
 ● Data from NHANES 2007 to 2010 (NCHS) showed the 
serum total crude mean cholesterol level in adults to be 132 
mg/dL for men and 197 mg/dL for women.8 Statistically 
significant declining trends in age-adjusted mean total 
cholesterol levels from 1988–1994 to 2007–2010 were 
observed in all sex and race/ethnicity subgroups except 
for Mexican American men (P=0.03). The Healthy People 
2010 guideline9 of an age-adjusted mean total cholesterol 
level of ≤200 mg/dL has been achieved in adults, in men, 
in women, and in all race/ethnicity and sex subgroups.
 ● Overall, the decline in cholesterol levels in recent years 
appears to reflect greater uptake of cholesterol-lowering 
medications rather than changes in dietary patterns.10
 ● The declining total cholesterol level appears to reflect a 
worldwide trend; a report on trends in total cholesterol 
in 199 countries and territories indicated that total cho-
lesterol declined in high-income regions of the world 
(Australasia, North America, and Western Europe).11 Dur-
ing the period from 1999 to 2006, 26.0% of adults had 
hypercholesterolemia, 9% of adults had both hypercho-
lesterolemia and hypertension, 1.5% of adults had DM 
and hypercholesterolemia, and 3% of adults had all 3 
conditions.12
Screening
 ● Data from the 2013 BRFSS study of the CDC shows that 
the percentage of adults who had been screened for high 
cholesterol in the preceding 5 years ranged from 68.2% in 
Utah to 84.0% in Massachusetts. The median percentage 
among all 50 states was 76.4%.13
 ● The percentage of adults who reported having had their 
cholesterol level checked increased from 68.6% during 
1999 to 2000 to 74.8% during 2005 to 200614 and then 
declined to 69.4% in 2011 to 2012.7
 ● Nearly 70% of adults (67% of men and nearly 72% of 
women) had been screened for cholesterol (defined as 
being told by a doctor their cholesterol was high and indi-
cating they had their blood cholesterol checked <5 years 
ago) according to data from NHANES 2011 to 2012, which 
was unchanged since 2009 to 2010.7
—Among non-Hispanic whites, 71.8% were screened 
(70.6% of men and 72.9% of women).
—Among non-Hispanic blacks, 71.9% were screened 
(66.8% of men and 75.9% of women).
—Among non-Hispanic Asians, 70.8% were screened 
(70.6% of men and 70.9% of women).
—Among Hispanic adults, 59.3% were screened (54.6% 
of men and 64.2% of women). The percentage of adults 
screened for cholesterol in the past 5 years was lower 
for Hispanic adults than for non-Hispanic white, non-
Hispanic black, and non-Hispanic Asian adults.7
Awareness
 ● Data from the 2005 to 2008 BRFSS (CDC) survey in 2011 
showed that among adults screened for high cholesterol, 
the percentage who had been told that they had high cho-
lesterol ranged from 33.5% in Colorado to 42.3% in Mis-
sissippi. The median percentage among states was 38.4%.13 
The percentage of adults reporting having been screened 
for high blood cholesterol within the preceding 5 years 
increased overall from 72.7% in 2005 to 76.0% in 2011.13
 ● Among adults with hypercholesterolemia, 42% were told 
they had high total cholesterol in 1999 to 2000 compared 
with 50.4% during 2005 to 2006.14
Treatment
 ● The ACC/AHA recently released a revised recommenda-
tion for statin treatment.15 Unlike previous recommenda-
tions, which had fixed LDL and non-HDL cholesterol 
goals, the ACC/AHA recommended lipid measurement at 
baseline, at 1 to 3 months after statin initiation, and then 
annually to check for the expected percentage decrease 
of LDL cholesterol levels (30% to 45% with a moderate-
intensity statin and ≥50% with a high-intensity statin). They 
also recommended statin therapy in 4 identified groups in 
whom it has been clearly shown to reduce ASCVD risk. 
The 4 statin benefit groups are (1) people with clinical 
ASCVD, (2) those with primary elevations of LDL choles-
terol >190 mg/dL, (3) people aged 40 to 75 years who have 
DM with LDL cholesterol 70 to 189 mg/dL and without 
clinical ASCVD, and (4) those without clinical ASCVD or 
DM with LDL cholesterol 70 to 189 mg/dL and estimated 
10-year ASCVD risk >7.5%. Approximately 31.9% of the 
ASCVD-free, nonpregnant US population between 40 and 
79 years of age has a 10-year risk of a first hard CHD event 
of ≥10% or has DM.16
 ● According to a recent analysis of NHANES data from 2005 
to 2010, the number of people eligible for statin therapy 
would rise from 43.2 million US adults (37.5%) to 50.6 
million (48.6%) based on the new ACC/AHA guidelines 
for the management of blood cholesterol. Most of the 
increase comes from adults 60 to 75 years old without CVD 
who have a 10-year ASCVD risk >7.5%; the net number of 
new statin prescriptions could potentially increase by 12.8 
million, including 10.4 million for primary prevention.17
 ● NHANES data on the treatment of high LDL cholesterol 
showed an increase from 28.4% of people during 1999 to 
2002 to 48.1% during 2005 to 2008.18
 ● Self-reported use of cholesterol-lowering medications 
increased from 8.2% during 1999 to 2000 to 14% in 2005 
to 200614 and reached 23% in 2007 to 2010.19
Adherence
Youth
 ● The American Academy of Pediatrics recommends screen-
ing for dyslipidemia in children and adolescents who have 
a family history of dyslipidemia or premature CVD, those 
whose family history is unknown, and those youths with 
risk factors for CVD, such as being overweight or obese, 
having hypertension or DM, or being a smoker.3
 ● Analysis of data from NHANES 1999 to 2006 showed 
that the overall prevalence of abnormal lipid levels among 
youths 12 to 19 years of age was 20.3%.3
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Adults
 ● New criteria from the “2013 ACC/AHA Guideline on the 
Treatment of Blood Cholesterol to Reduce Atherosclerotic 
Cardiovascular Risk in Adults”15 could result in >45 million 
middle-aged Americans who do not have CVD being rec-
ommended for consideration of statin therapy: 33.0 million 
are at ≥7.5% 10-year risk and 12.8 million are at >5.0% 
to 7.4% 10-year risk. This is approximately 1 in every 3 
American adults, many of whom are already undergoing 
statin treatment under the previous US guidelines.20
 ● On the basis of data from the 2005 to 2008 NHANES, an 
estimated 71 million US adults (33.5%) aged ≥20 years had 
high LDL cholesterol, but only 34 million (48.1%) were 
treated and only 23 million (33.2%) had their LDL choles-
terol controlled.18
—The proportion of adults with high LDL cholesterol who 
were treated increased from 28.4% to 48.1% between 
the 1999 to 2002 and 2005 to 2008 study periods.
—Among adults with high LDL cholesterol, the prevalence 
of LDL cholesterol control increased from 14.6% to 
33.2% between the periods. The prevalence of LDL cho-
lesterol control was lowest among people who reported 
receiving medical care less than twice in the previous 
year (11.7%), being uninsured (13.5%), being Mexican 
American (20.3%), or having income below the poverty 
level (21.9%).
Global Burden of Hypercholesterolemia
 ● Between 1980 and 2008, the mean age-adjusted total cho-
lesterol level decreased from 4.72 to 4.64 mmol/L (95% CI, 
4.51–4.76 mmol/L) for men and from 4.83 to 4.76 mmol/L 
(95% CI, 4.62–4.91 mmol/L) for women. Globally, mean 
total cholesterol changed little between 1980 and 2008, 
falling by <0.1 mmol/L per decade in men and women.21
 ● Total cholesterol went from being the 14th leading risk fac-
tor in 1990 for the global burden of disease, as quantified 
by DALYs, to the number 15 risk factor in 2010.22
 ● Raised cholesterol, defined as ≥190 mg/dL or ≥5.0 mmol/L, 
is estimated to cause 2.6 million deaths (4.5% of total 
deaths) and 29.7 million DALYs (2.0% of total DALYs).23
 ● The prevalence of elevated total cholesterol was highest in 
the WHO European Region (54% for both sexes), followed 
by the WHO Region of the Americas (48% for both sexes). 
The WHO African Region and the WHO South-East Asia 
Region showed the lowest percentages (23% and 30%, 
respectively).23
 ● Twenty-nine percent of ischemic heart disease DALYs can 
be attributed to high total cholesterol, the second-leading 
physiological risk factor.22
Lipid Levels
LDL (Bad) Cholesterol
Youth
There are limited data available on LDL cholesterol for chil-
dren 6 to 11 years of age.
 ● Among adolescents 12 to 19 years of age, the mean LDL 
cholesterol level is 89.3 mg/dL (boys, 88.3 mg/dL; girls, 
90.3 mg/dL). The racial/ethnic breakdown is as follows 
(NHANES 2009–2012, unpublished NHLBI tabulation):
—For non-Hispanic whites, 89.5 mg/dL for boys and 91.1 
mg/dL for girls
—For non-Hispanic blacks, 86.7 mg/dL for boys and 90.9 
mg/dL for girls
—For Hispanic Americans, 87.4 mg/dL for boys and 88.9 
mg/dL for girls
 ● High levels of LDL cholesterol occurred in 7.1% of male 
adolescents and 7.4% of female adolescents during 2009 to 
2012 (unpublished NHLBI tabulation).
Adults
 ● The mean level of LDL cholesterol for American adults 
≥20 years of age was 115.8 mg/dL in 2009 to 2012 (unpub-
lished NHLBI tabulation).
 ● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulation):
—Among non-Hispanic whites, mean LDL cholesterol 
levels were 113.8 mg/dL for men and 116.8 mg/dL for 
women.
—Among non-Hispanic blacks, mean LDL cholesterol 
levels were 113.4 mg/dL for men and 115.5 mg/dL for 
women.
—Among Hispanics, mean LDL cholesterol levels were 
120.1 mg/dL for men and 114.8 mg/dL for women.
 ● The prevalence of high LDL cholesterol decreased from 
59% in 1976 to 1980 to 42% in 1988 to 1994 and to 33% 
in 2001 to 2004, reaching 27% in 2007 to 2010. Between 
1976 to 1980 and 2007 to 2010, the prevalence of high 
LDL cholesterol significantly decreased for men (from 
65% to 31%), women (54% to 24%), and adults aged 
40 to 64 years (56% to 27%) and 65 to 74 years (72% 
to 30%).19
 ● The age-adjusted prevalence of high LDL cholesterol 
in US adults was 26.6% in 1988 to 1994 and 25.3% in 
1999 to 2004 (NHANES/NCHS). Between 1988 to 1994 
and 1999 to 2004, awareness increased from 39.2% to 
63.0%, and use of pharmacological lipid-lowering treat-
ment increased from 11.7% to 40.8%. LDL cholesterol 
control increased from 4.0% to 25.1% among those with 
high LDL cholesterol. In 1999 to 2004, rates of LDL cho-
lesterol control were lower among adults 20 to 49 years 
of age than among those ≥65 years of age (13.9% versus 
30.3%, respectively), among non-Hispanic blacks and 
Mexican Americans than among non-Hispanic whites 
(17.2% and 16.5% versus 26.9%, respectively), and 
among men than among women (22.6% versus 26.9%, 
respectively).24
 ● Mean levels of LDL cholesterol decreased from 126.2 mg/
dL during 1999 to 2000 to 115.5 mg/dL during 2011 to 
2012. The age-adjusted prevalence of high LDL cholesterol 
decreased from 42.9% during 1999 to 2000 to 32.2% dur-
ing 2011 to 2012 (unpublished NHLBI tabulation).
 ● Data from NHANES 2005 to 2006 indicate that among 
those with elevated LDL cholesterol levels, 35.5% had not 
been screened previously, 24.9% were screened but not 
told they had elevated cholesterol, and 39.6% were treated 
inadequately.19
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HDL (Good) Cholesterol
Youth
 ● Among children 6 to 11 years of age, the mean HDL cho-
lesterol level is 53.9 mg/dL. For boys, it is 55.4 mg/dL, 
and for girls, it is 52.4 mg/dL. The racial/ethnic breakdown 
is as follows (NHANES 2009–2012, unpublished NHLBI 
tabulation):
—For non-Hispanic whites, 55.1 mg/dL for boys and 52.5 
mg/dL for girls
—For non-Hispanic blacks, 58.5 mg/dL for boys and 54.5 
mg/dL for girls
—For Hispanics, 53.5 mg/dL for boys and 51.4 mg/dL for 
girls
 ● Among adolescents 12 to 19 years of age, the mean HDL 
cholesterol level is 51.4 mg/dL. For boys, it is 49.4 mg/dL, 
and for girls, it is 53.4 mg/dL. The racial/ethnic breakdown 
is as follows (NHANES 2009–2012, unpublished NHLBI 
tabulation):
—For non-Hispanic whites, 48.9 mg/dL for boys and 52.4 
mg/dL for girls
—For non-Hispanic blacks, 52.6 mg/dL for boys and 55.1 
mg/dL for girls
—For Hispanics, 48.1 mg/dL for boys and 53.6 mg/dL for 
girls
 ● Low levels of HDL cholesterol occurred in 19.5% of male 
adolescents and 11.1% of female adolescents during 2009 
to 2012 (NHANES 2009–2012, unpublished NHLBI 
tabulation).
Adults
 ● The mean level of HDL cholesterol for American adults 
≥20 years of age is 52.9 mg/dL (NHANES 2009–2012, 
unpublished NHLBI tabulation).
 ● According to NHANES 2009 to 2012 (unpublished NHLBI 
tabulation):
—Among non-Hispanic whites, mean HDL cholesterol 
levels were 47.7 mg/dL for men and 58.5 mg/dL for 
women
—Among non-Hispanic blacks, mean HDL cholesterol 
levels were 51.9 mg/dL for men and 57.4 mg/dL for 
women
—Among Hispanics, mean HDL cholesterol levels were 
45.4 mg/dL for men and 54.3 mg/dL for women.
 ● Approximately 17% of adults (just over one quarter of men 
and <10% of women) had low HDL cholesterol during 
2011 to 2012. The percentage of adults with low HDL cho-
lesterol has decreased 20% since 2009 to 2010.7
—Among non-Hispanic whites, 17.1% (25.4% of men and 
9.3% of women) had low HDL.
—Among non-Hispanic blacks, 12.7% (19.1% of men and 
7.8% of women) had low HDL. The percentage of adults 
with low HDL cholesterol was lower in non-Hispanic 
black adults than in non-Hispanic white adults. These 
racial and ethnic differences were also observed in men 
but not in women.
—Among non-Hispanic Asians, 14.3% (24.5% of men 
and 5.1% of women) had low HDL. The prevalence of 
low HDL cholesterol was 5 times greater among non-
Hispanic Asian men than women. Non-Hispanic Asian 
adults had consistently lower percentages of low HDL 
cholesterol than Hispanic adults.
 ● The prevalence of low HDL cholesterol was 5 times higher 
in non-Hispanic Asian men (24.5%) than in non-Hispanic 
Asian women (5.1%).25
—Among Hispanic adults, 21.8% (32.6% of men and 
11.3% of women) had low HDL. The percentage of 
adults with low HDL cholesterol was higher in Hispanic 
adults than in non-Hispanic black or non-Hispanic white 
adults. These racial and ethnic differences were also 
observed in men but not in women.
Triglycerides
Youth
There are limited data available on triglycerides for children 6 
to 11 years of age.
 ● Among adolescents 12 to 19 years of age, the geometric 
mean triglyceride level is 82.1 mg/dL. For boys, it is 84.6 
mg/dL, and for girls, it is 79.5 mg/dL. The racial/ethnic 
breakdown is as follows (NHANES 2009–2012):
—Among non-Hispanic whites, 83.1 mg/dL for boys and 
82.4 mg/dL for girls
—Among non-Hispanic blacks, 70.4 mg/dL for boys and 
62.2 mg/dL for girls
—Among Hispanics, 90.3 mg/dL for boys and 84.9 mg/
dL for girls
 ● High levels of triglycerides occurred in 10.0% of male 
adolescents and 6.5% of female adolescents during 2009 
to 2012.
Adults
 ● The geometric mean level of triglycerides for American 
adults ≥20 years of age is 108.8 mg/dL (NHANES 2009–
2012, unpublished NHLBI tabulation).
 ● Approximately 25.1% of adults had high triglyceride levels 
during 2009 to 2012 (NHANES 2009–2012, unpublished 
NHLBI tabulation).
 ● Among men, the age-adjusted geometric mean triglycer-
ide level is 117.2 mg/dL (NHANES 2009–2012, unpub-
lished NHLBI tabulation), with the following racial/ethnic 
breakdown:
—117.7 mg/dL for non-Hispanic white men
—92.7 mg/dL for non-Hispanic black men
—134.7 mg/dL for Hispanic men
 ● Among women, the age-adjusted geometric mean triglyc-
eride level is 101.4 mg/dL (NHANES 2009–2012, unpub-
lished NHLBI tabulation), with the following racial/ethnic 
breakdown:
—104.0 mg/dL for non-Hispanic white women
—83.5 mg/dL for non-Hispanic black women
—109.7 mg/dL for Hispanic women
 ● Fewer than 3% of adults with a triglyceride level ≥150 
mg/dL received pharmacological treatment during 1999 to 
2004.26
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e110  Circulation  January 27, 2015
References
 1. Expert Panel on Detection, Evaluation, and Treatment of High Blood 
Cholesterol in Adults. Executive summary of the Third Report of the Na-
tional Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult 
Treatment Panel III). JAMA. 2001;285:2486–2497.
 2. Lloyd-Jones DM, Hong Y, Labarthe D, Mozaffarian D, Appel LJ, Van Horn 
L, Greenlund K, Daniels S, Nichol G, Tomaselli GF, Arnett DK, Fonarow 
GC, Ho PM, Lauer MS, Masoudi FA, Robertson RM, Roger V, Schwamm 
LH, Sorlie P, Yancy CW, Rosamond WD; on behalf of the American Heart 
Association Strategic Planning Task Force and Statistics Committee. De-
fining and setting national goals for cardiovascular health promotion and 
disease reduction: the American Heart Association’s strategic Impact Goal 
through 2020 and beyond. Circulation. 2010;121:586–613.
 3. Centers for Disease Control and Prevention. Prevalence of abnormal lipid 
levels among youths: United States, 1999–2006 [published correction ap-
pears in MMWR Morb Mortal Wkly Rep. 2010;59:78]. MMWR Morb Mor-
tal Wkly Rep. 2010;59:29.
 4. Shay CM, Ning H, Daniels SR, Rooks CR, Gidding SS, Lloyd-Jones DM. 
Status of cardiovascular health in US adolescents: prevalence estimates 
from the National Health and Nutrition Examination Surveys (NHANES) 
2005–2010. Circulation. 2013;127:1369–1376.
 5. Kit BK, Carroll MD, Lacher DA, Sorlie PD, DeJesus JM, Ogden C. 
Trends in serum lipids among US youths aged 6 to 19 years, 1988–2010. 
JAMA. 2012;308:591–600.
 6. Ford ES, Li C, Zhao G, Mokdad AH. Concentrations of low-density lipo-
protein cholesterol and total cholesterol among children and adolescents 
in the United States. Circulation. 2009;119:1108–1115.
 7. Carroll MD, Kit BK, Lacher DA, Yoon SSS. Total and high-density lipo-
protein cholesterol in adults: National Health and Nutrition Examination 
Survey, 2011–2012. NCHS Data Brief. 2013;(132):1–8.
 8. Carroll MD, Kit BK, Lacher DA, Shero ST, Mussolino ME. Trends in lipids 
and lipoproteins in US adults, 1988–2010. JAMA. 2012;308:1545–1554.
 9. US Department of Health and Human Services. Healthy People 2010: Un-
derstanding and Improving Health. 2nd ed. Washington, DC: US Govern-
ment Printing Office; 2000.
 10. Ford ES, Capewell S. Trends in total and low-density lipoprotein choles-
terol among U.S. adults: contributions of changes in dietary fat intake and 
use of cholesterol-lowering medications. PLoS One. 2013;8:e65228.
 11. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek 
CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN; Farzadfar F, Riley 
LM, Ezzati M; on behalf of the Global Burden of Metabolic Risk Fac-
tors of Chronic Diseases Collaborating Group (Body Mass Index). 
National, regional, and global trends in body-mass index since 1980: 
systematic analysis of health examination surveys and epidemiologi-
cal studies with 960 country-years and 9.1 million participants. Lancet. 
2011;377:557–567.
 12. Fryar CD, Hirsch R, Eberhardt MS, Yoon SS, Wright JD. Hypertension, 
high serum total cholesterol, and diabetes: racial and ethnic prevalence 
differences in US adults, 1999–2006. NCHS Data Brief. 2010;(36):1–8.
 13. Behavioral Risk Factor Surveillance System: prevalence and trends data. 
Centers for Disease Control and Prevention Web site. http://apps.nccd.cdc.
gov/brfss/index.asp. Accessed November 12, 2014.
 14. Ford ES, Li C, Pearson WS, Zhao G, Mokdad AH. Trends in hypercholes-
terolemia, treatment and control among United States adults. Int J Cardiol. 
2010;140:226–235.
 15. Stone NJ, Robinson JG, Lichtenstein AH, Merz CNB, Blum CB, Eck-
el RH, Goldberg AC,Gordon D, Levy D, Lloyd-Jones DM, McBride 
P,Schwartz JS,Shero ST,Smith SC Jr,Watson K, Wilson PWF. 2013 ACC/
AHA guideline on the treatment of blood cholesterol to reduce athero-
sclerotic cardiovascular risk in adults: a report of the American College 
of Cardiology/American Heart Association Task Force on Practice Guide-
lines [published correction appears in J Am Coll Cardiol. 2014;63(pt 
B):3024–3025]. J Am Coll Cardiol. 2014;63(pt B):2889–2934.
 16. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB Sr, 
Gibbons R, Greenland P, Lackland DT, Levy D, O’Donnell CJ, Robin-
son JG, Schwartz JS, Shero ST,Smith SC Jr,Sorlie P,Stone NJ,Wilson PW. 
2013 ACC/AHA guideline on the assessment of cardiovascular risk: a 
report of the American College of Cardiology/American Heart Associa-
tion Task Force on Practice Guidelines [published correction appears in J 
Am Coll Cardiol. 2014;63(pt B):3026]. J Am Coll Cardiol. 2013.
 17. Pencina MJ, Navar-Boggan AM, D’Agostino RB Sr, Williams K, Neely B, 
Sniderman AD, Peterson ED. Application of new cholesterol guidelines to 
a population-based sample. N Engl J Med. 2014;370:1422–1431.
 18. Centers for Disease Control and Prevention (CDC). Vital signs: preva-
lence, treatment, and control of high levels of low-density lipoprotein cho-
lesterol: United States, 1999–2002 and 2005–2008. MMWR Morb Mortal 
Wkly Rep. 2011;60:109–114.
 19. Kuklina EV, Yoon PW, Keenan NL. Trends in high levels of low-den-
sity lipoprotein cholesterol in the United States, 1999–2006. JAMA. 
2009;302:2104–2110.
 20. Ridker PM, Cook NR. Statins: new American guidelines for prevention of 
cardiovascular disease. Lancet. 2013;382:1762–1765.
 21. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. 
Global burden of hypertension: analysis of worldwide data. Lancet. 
2005;365:217–223.
 22. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, 
Amann M, Anderson HR, Andrews KG, Aryee M, Atkinson C, Bacchus 
LJ, Bahalim AN, Balakrishnan K, Balmes J, Barker-Collo S, Baxter A, 
Bell ML, Blore JD, Blyth F, Bonner C, Borges G, Bourne R, Boussin-
esq M, Brauer M, Brooks P, Bruce NG, Brunekreef B, Bryan-Hancock 
C, Bucello C, Buchbinder R, Bull F, Burnett RT, Byers TE, Calabria B, 
Carapetis J, Carnahan E, Chafe Z, Charlson F, Chen H, Chen JS, Cheng 
AT, Child JC, Cohen A, Colson KE, Cowie BC, Darby S, Darling S, Davis 
A, Degenhardt L, Dentener F, Des Jarlais DC, Devries K, Dherani M, 
Ding EL, Dorsey ER, Driscoll T, Edmond K, Ali SE, Engell RE, Erwin 
PJ, Fahimi S, Falder G, Farzadfar F, Ferrari A, Finucane MM, Flaxman 
S, Fowkes FG, Freedman G, Freeman MK, Gakidou E, Ghosh S, Giovan-
nucci E, Gmel G, Graham K, Grainger R, Grant B, Gunnell D, Gutierrez 
HR, Hall W, Hoek HW, Hogan A, Hosgood HD 3rd, Hoy D, Hu H, Hub-
bell BJ, Hutchings SJ, Ibeanusi SE, Jacklyn GL, Jasrasaria R, Jonas JB, 
Kan H, Kanis JA, Kassebaum N, Kawakami N, Khang YH, Khatibzadeh 
S, Khoo JP, Kok C, Laden F, Lalloo R, Lan Q, Lathlean T, Leasher JL, 
Leigh J, Li Y, Lin JK, Lipshultz SE, London S, Lozano R, Lu Y, Mak 
J, Malekzadeh R, Mallinger L, Marcenes W, March L, Marks R, Martin 
R, McGale P, McGrath J, Mehta S, Mensah GA, Merriman TR, Micha 
R, Michaud C, Mishra V, Mohd Hanafiah K, Mokdad AA, Morawska L, 
Mozaffarian D, Murphy T, Naghavi M, Neal B, Nelson PK, Nolla JM, 
Norman R, Olives C, Omer SB, Orchard J, Osborne R, Ostro B, Page A, 
Pandey KD, Parry CD, Passmore E, Patra J, Pearce N, Pelizzari PM, Pet-
zold M, Phillips MR, Pope D, Pope CA 3rd, Powles J, Rao M, Razavi H, 
Rehfuess EA, Rehm JT, Ritz B, Rivara FP, Roberts T, Robinson C, Rodri-
guez-Portales JA, Romieu I, Room R, Rosenfeld LC, Roy A, Rushton L, 
Salomon JA, Sampson U, Sanchez-Riera L, Sanman E, Sapkota A, Seedat 
S, Shi P, Shield K, Shivakoti R, Singh GM, Sleet DA, Smith E, Smith KR, 
Stapelberg NJ, Steenland K, Stockl H, Stovner LJ, Straif K, Straney L, 
Thurston GD, Tran JH, Van Dingenen R, van Donkelaar A, Veerman JL, 
Vijayakumar L, Weintraub R, Weissman MM, White RA, Whiteford H, 
Wiersma ST, Wilkinson JD, Williams HC, Williams W, Wilson N, Woolf 
AD, Yip P, Zielinski JM, Lopez AD, Murray CJ, Ezzati M, AlMazroa MA, 
Memish ZA. A comparative risk assessment of burden of disease and in-
jury attributable to 67 risk factors and risk factor clusters in 21 regions, 
1990–2010: a systematic analysis for the Global Burden of Disease Study 
2010 [published corrections appear in Lancet. 2013;381:1276 and Lancet. 
2013;381:628]. Lancet. 2012;380:2224–2260.
 23. Alwan A. Global Status Report on Noncommunicable Diseases 2010. Ge-
neva, Switzerland: World Health Organization; 2011.
 24. Hyre AD, Muntner P, Menke A, Raggi P, He J. Trends in ATP-III-defined 
high blood cholesterol prevalence, awareness, treatment and control 
among U.S. adults. Ann Epidemiol. 2007;17:548–555.
 25. Aoki Y, Yoon SS, Chong Y, Carroll MD. Hypertension, abnormal choles-
terol, and high body mass index among non-Hispanic Asian adults: United 
States, 2011–2012. NCHS Data Brief, no 140. 2014;(140):1–8.
 26. Ford ES, Li C, Zhao G, Pearson WS, Mokdad AH. Hypertriglyceride-
mia and its pharmacologic treatment among US adults. Arch Intern Med. 
2009;169:572–578.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2015 Update: Chapter 8  e111
Table 8-1. High Total and LDL Cholesterol and Low HDL Cholesterol
Population Group
Prevalence of Total Cholesterol 
≥200 mg/dL, 2012 Age ≥20 y
Prevalence of Total Cholesterol 
≥240 mg/dL, 2012 Age ≥20 y
Prevalence of LDL Cholesterol 
≥130 mg/dL, 2012 Age ≥20 y
Prevalence of HDL Cholesterol 
<40 mg/dL, 2012 Age ≥20 y
Both sexes, n (%)* 100 100 000 (42.8) 30 900 000 (13.1) 73 500 000 (31.7) 44 600 000 (19.9)
Males, n (%)* 45 300 000 (40.4) 13 000 000 (11.6) 34 900 000 (31.0) 32 400 000  (28.9)
Females, n (%)* 54 830 000 (44.9) 17 900 000 (14.4) 38 600 000 (32.0) 12 200 000 (10.4)
NH white males, % 39.9 11.5 29.4 28.7
NH white females, % 45.9 15.3 32.0 10.2
NH black males, % 37.4 8.8 30.7 20.0
NH black females, % 40.7 10.9 33.6 10.3
Hispanic males, % 46.2 14.8 38.8 33.8
Hispanic females, % 43.4 13.7 31.8 12.8
Prevalence of total cholesterol ≥200 mg/dL includes people with total cholesterol ≥240 mg/dL. In adults, levels of 200 to 239 mg/dL are considered borderline high. 
Levels of ≥240 mg/dL are considered high.
HDL indicates high-density lipoprotein; LDL, low-density lipoprotein; and NH, non-Hispanic.
*Total data for total cholesterol are for Americans ≥20 years of age. Data for LDL cholesterol, HDL cholesterol, and all racial/ethnic groups are age adjusted for age 
≥20 years.
Source for total cholesterol ≥200 mg/dL, ≥240 mg/dL, LDL, and HDL: National Health and Nutrition Examination Survey (2009–2012), National Center for Health 
Statistics, and National Heart, Lung, and Blood Institute. Estimates from National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health 
Statistics) were applied to 2012 population estimates.
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Chart 8-1. Trends in mean serum total cholesterol among adolescents 12 to 19 years of age by race, sex, and survey year (National 
Health and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Values are in mg/dL. Mex. Am. indicates Mexican 
American; and NH, non-Hispanic. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-2. Age-adjusted trends in mean serum total cholesterol among adults ≥20 years old by race and survey year (National Health 
and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Values are in mg/dL. NH indicates non-Hispanic. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 8-3. Age-adjusted trends in the prevalence of serum total cholesterol ≥200 mg/dL in adults ≥20 years of age by sex, race/ethnicity, 
and survey year (National Health and Nutrition Examination Survey 2007–2008, 2009–2010, and 2011–2012). NH indicates non-Hispanic.
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Chart 8-4. Age-adjusted trends in the prevalence of serum total cholesterol ≥240 mg/dL in adults ≥20 years of age by sex, race/ethnic-
ity, and survey year (National Health and Nutrition Examination Survey 2009–2010 and 2011-2012). NH indicates non-Hispanic. *Data not 
available for non-Hispanic Asians in 2009 to 2010. † 2009 to 2010 data are for Mexican Americans only.
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9 . High Blood Pressure
ICD-9 401 to 404, ICD-10 I10 to I15. See Tables 9-1 and 9-2 
and Charts 9-1 through 9-5.
HBP is a major risk factor for CVD and stroke.1 The AHA 
has identified untreated BP <90th percentile (for children) and 
<120/<80 mm Hg (for adults aged ≥20 years) as 1 of the 7 
components of ideal cardiovascular health.2 In 2011 to 2012, 
82.3% of children and 42.2% of adults met these criteria 
(Chapter 2, Cardiovascular Health).
Prevalence
(See Table 9-1 and Chart 9-1.)
 ● Surveillance definitions vary widely in the published 
literature.3
 ● For surveillance purposes, the following definition of HBP 
has been proposed3:
—SBP ≥140 mm Hg or DBP ≥90 mm Hg or taking antihy-
pertensive medicine, or
—Having been told at least twice by a physician or other 
health professional that one has HBP.
 ● With this definition, the prevalence of hypertension (age 
adjusted) among US adults ≥20 years of age was estimated 
to be 32.6% in NHANES 2009 to 2012. This equates to an 
estimated 80.0 million adults ≥20 years of age who have 
HBP (38.3 million men and 41.7 million women), extrapo-
lated to 2012 data (Table 9-1).
 ● In 2009 to 2012, the age-adjusted prevalence of hyperten-
sion was 44.9% and 46.1% among non-Hispanic black men 
and women, respectively; 32.9% and 30.1% among non-
Hispanic white men and women, respectively; and 29.6% 
and 29.9% among Hispanic men and women, respectively.
 ● NHANES data show that a higher percentage of men than 
women have hypertension until 45 years of age. From 45 
to 54 years of age and from 55 to 64 years of age, the per-
centages of men and women with hypertension are similar. 
After that, a higher percentage of women have hyperten-
sion than men (Chart 9-1).
 ● The prevalence of hypertension increased between 1988 to 
1994, 1999 to 2006, and 2007 to 2012 among non-Hispanic 
black men (37.5%, 39.5%, and 40.1%, respectively) and 
women (38.2%, 41.7%, and 42.9%, respectively), non-
Hispanic men (25.6%, 28.7%, and 30.1%, respectively) 
and women (22.9%, 27.8%, and 27.7%, respectively), and 
Mexican American women (25.0%, 26.1%, and 27.0%, 
respectively) but not Mexican American men (26.9%, 
24.3%, and 26.6%, respectively).
 ● Data from NHANES 2011 to 2012 found that 17.2% of US 
adults are not aware they have hypertension.4
 ● Data from the 2007 to 2008 BRFSS, NHIS, and NHANES 
surveys found 27.8%, 28.5%, and 30.7% of US adults, 
respectively, had been told they had hypertension.5
 ● Among those 18 to 39 years of age, prevalence was 7.3%; 
among those 40 to 59 years of age, prevalence was 32.4%; 
and among those ≥60 years of age, prevalence was 65.0%.4
 ● Oral contraceptive use was less common among women 
with than among those without hypertension.6
 ● Data from NHANES 2011 to 2012 estimated the preva-
lence of hypertension in men and women ≥18 years of age 
to be 29.7% and 28.5%, respectively.4
 ● Data from the 2013 BRFSS/CDC indicate that the percent-
age of adults ≥18 years of age who had been told that they 
had HBP ranged from 25.5% in Minnesota and Colorado 
to 38.3% in Louisiana. The mean percentage for the United 
States was 30.4%.7
Abbreviations Used in Chapter 9
AHA American Heart Association
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
CKD chronic kidney disease
CRP C-reactive protein
CVD cardiovascular disease
DALY disability-adjusted life-year
DBP diastolic blood pressure
DM diabetes mellitus
ED emergency department
ESRD end-stage renal disease
FHS Framingham Heart Study
HBP high blood pressure
HD heart disease
ICD-9 International Classification of Diseases, 9th Revision
ICD-9-CM International Classification of Diseases, Clinical Modification,  
9th Revision
ICD-10 International Classification of Diseases, 10th Revision
JNC Joint National Committee on Prevention, Detection, Evaluation, 
and Treatment of High Blood Pressure
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHES National Health Examination Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NNHS National Nursing Home Survey
PA physical activity
REGARDS Reasons for Geographic and Racial Differences in Stroke
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
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 ● According to 2003 to 2008 NHANES data, among US 
adults with hypertension, 11.8% met the criteria for resis-
tant hypertension (SBP/DBP ≥140/90 mm Hg and reported 
use of antihypertensive medications from 3 different drug 
classes or drugs from ≥4 antihypertensive drug classes 
regardless of BP). This represents an increase from 5.5% in 
1998 to 1994 and 8.5% in 1999 to 2004.8
 ● The “2014 Evidence-Based Guideline for the Management 
of High Blood Pressure in Adults” report recommends a 
higher SBP threshold (150 mm Hg) for treatment initiation 
and goal attainment in adults ≥60 years of age without DM 
or CKD. Additionally, the SBP treatment/goal threshold 
increased from 130 to 140 mm Hg among individuals with 
DM or CKD. The DBP goal remained at 90 mm Hg.9 This 
change should have minimal impact on the percentage of 
US adults <60 years of age with hypertension.
—The prevalence of hypertension using the 2014 defini-
tion versus the JNC 7 definition declined from 20.3% 
to 19.2%.10 Among US adults ≥60 years of age, the 
percentage with hypertension decreased from 68.9% 
to 61.2% between JNC 7 and the 2014 definition, with 
above-goal BP declining from 41.3% to 20.9%.10
—In 2005 to 2010, more US adults ≥60 years of age had 
SBP ≥150 mm Hg than between 140 and 149 mm Hg.11
 ● Projections show that by 2030, ≈41.4% of US adults will 
have hypertension, an increase of 8.4% from 2012 esti-
mates (unpublished AHA computation, based on method-
ology described by Heidenreich et al12).
Older Adults
 ● In 2009 to 2010, hypertension was among the diagnosed 
chronic conditions that were more prevalent among older 
(≥65 years of age) women than older men (57% prevalence 
for women, 54% for men). Ever-diagnosed conditions that 
were more prevalent among older men than older women 
included HD (37% for men, 26% for women) and DM 
(24% for men, 18% for women), on the basis of data from 
NHIS/NCHS.13
 ● The age-adjusted prevalence of hypertension (both diag-
nosed and undiagnosed) in 2003 to 2006 was 75% for older 
women and 65% for older men on the basis of data from 
NHANES/NCHS.14
 ● Data from the 2004 NNHS revealed the most frequent chronic 
medical condition among this nationally representative sam-
ple of long-term stay nursing home residents aged ≥65 years 
was hypertension (53% of men and 56% of women). In men, 
prevalence of hypertension decreased with increasing age.15
 ● Among US adults ≥60 years of age in NHANES 2011 to 
2012, prevalence of hypertension was 65.0%, awareness of 
hypertension was 86.1%, treatment for hypertension was 
82.2%, and control of hypertension was 50.5%.4
 ● Data from NHANES 2005 to 2010 found that 76.5% of US 
adults ≥80 years of age had hypertension. Of this popu-
lation, 43.9% had isolated systolic hypertension and 2.0% 
had systolic and diastolic hypertension.16
 ● In 2005 to 2010, 30.9% of US adults ≥80 years of age were 
taking ≥3 classes of antihypertensive medication. This rep-
resents an increase from 7.0% and 19.2% in 1988 to 1994 
and 1999 to 2004, respectively.16
Children and Adolescents
 ● Data from participants aged 12 to 19 years in the 2005 to 
2010 NHANES found ideal BP (<95th percentile) to be 
present in 78% of males and 90% of females; poor BP 
(>95th percentile) was found in 2.9% of male and 3.7% of 
female participants.17
 ● Analysis of data from NHANES III (1988–1994) and 
NHANES 1999 to 2008 found the prevalence of elevated 
BP (SBP or DBP ≥90th percentile or SBP/DBP ≥120/80 
mm Hg) increased from 15.8% to 19.2% among boys and 
from 8.2% to 12.6% among girls.18
 ● Among older children, male sex, black race/ethnicity, 
higher BMI, and higher sodium intake were independently 
associated with elevated BP for participants 8 to 17 years of 
age in NHANES 1999 to 2008.18
 ● In a study of 199 513 children (aged 3 to 17 years) across 3 
large, integrated healthcare delivery systems, 81.9% were 
normotensive (<90th percentile of BP), 12.7% had prehy-
pertension (90th to 94th percentiles), and 5.4% had hyper-
tension (≥95th percentile) based on a single visit. After 2 
additional visits, the prevalence of hypertension (≥95th 
percentile at all 3 visits) was confirmed to be present in 
only 0.14% of the children. The prevalence of confirmed 
hypertension was higher in non-Hispanic blacks and Asian/
Pacific Islanders than in whites and was higher at higher 
BMI percentiles.19
 ● Analysis of the NHES, the Hispanic Health and Nutrition 
Examination Survey, and the NHANES/NCHS surveys of 
the NCHS (1963–2002) found that the BP, pre-HBP, and 
HBP trends in children and adolescents 8 to 17 years of age 
moved downward from 1963 to 1988 and upward thereaf-
ter. Pre-HBP and HBP increased 2.3% and 1%, respectively, 
between 1988 and 1999. Increased obesity (abdominal obe-
sity more so than general obesity) partially explained the 
HBP and pre-HBP rise from 1988 to 1999. BP and HBP 
reversed their downward trends 10 years after the increase in 
the prevalence of obesity. In addition, an ethnic and sex gap 
appeared in 1988 for pre-HBP and in 1999 for HBP: Non-
Hispanic blacks and Mexican Americans had a greater prev-
alence of HBP and pre-HBP than non-Hispanic whites, and 
the prevalence was greater in boys than in girls. In that study, 
HBP in children and adolescents was defined as SBP or DBP 
that was, on repeated measurement, ≥95th percentile.20
 ● A study in Ohio of >14 000 children and adolescents 3 to 
18 years of age who were observed at least 3 times between 
1999 and 2006 found that 507 children (3.6%) had hyper-
tension. Of these, 131 (26%) had been diagnosed and 376 
(74%) were undiagnosed. In addition, 3% of those with 
hypertension had stage 2 hypertension, and 41% of those 
with stage 2 hypertension were undiagnosed. Criteria for 
prehypertension were met by 485 children. Of these, 11% 
were diagnosed. In this study, HBP in children and ado-
lescents was defined as SBP or DBP that was, on repeated 
measurement, ≥95th percentile.21
 ● Analysis of data from the SEARCH study, which 
included children 3 to 17 years of age with type 1 and 
type 2 DM, found the prevalence of elevated BP to be 
5.9% among those with type 1 DM and 23.7% among 
those with type 2 DM.22
 ● Longitudinal BP outcomes from the National Childhood 
Blood Pressure database (ages 13–15 years) were examined 
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after a single BP measurement. Among those determined to 
have prehypertension, 14% of boys and 12% of girls had 
hypertension 2 years later; the overall rate of progression 
from prehypertension to hypertension was ≈7%.23
Race/Ethnicity and HBP
(See Table 9-1 and Chart 9-2.)
 ● The prevalence of hypertension in blacks in the United 
States is among the highest in the world. From 1988 to 
1994 through 1999 to 2002, the prevalence of HBP in 
adults increased from 35.8% to 41.4% among blacks, and it 
was particularly high among black women at 44.0%. Preva-
lence among whites also increased, from 24.3% to 28.1%.24
 ● From 1999 to 2000 through 2009 to 2010, the prevalence 
of hypertension did not increase among non-Hispanic black 
men (38.0% and 39.6% in 1999–2000 and 2009–2010, 
respectively) or women (40.8% and 43.1% in 1999–2000 
and 2009–2010, respectively).25
 ● In 2011 to 2012, non-Hispanic blacks had a higher preva-
lence of hypertension (42.1%) than non-Hispanic whites 
(28.0%), Hispanics (24.7%), and non-Hispanic Asians 
(24.7%).4
 ● Compared with whites, blacks develop HBP earlier in life, 
and their average BP is much higher.26,27
 ● The incidence of hypertension is higher for blacks than 
whites through 75 years of age; for a 45-year-old without 
hypertension, the 40-year risk for hypertension is 92.7% 
among blacks, 92.4% among Hispanics, 86.0% among 
whites, and 84.1% among Asians.28
 ● Compared with whites, blacks have a 1.3 times greater rate 
of nonfatal stroke, a 1.8 times greater rate of fatal stroke, 
a 1.5 times greater rate of death attributable to HD, and a 
4.2 times greater rate of ESRD (fifth and sixth reports of 
the JNC).
 ● The same increment in SBP is associated with a higher 
stroke risk for blacks than for whites.29
 ● Higher SBP explains ≈50% of the excess risk among blacks 
compared with whites.30
 ● Data from the 2013 NHIS showed that black adults 18 
years of age were more likely (32.6%) to have been told 
on ≥2 occasions that they had hypertension than Ameri-
can Indian/Alaska Native adults (26.2%), white adults 
(22.8%), Hispanic or Latino adults (21.6%), or Asian 
adults (21.0%).31
 ● In NHANES 2011 to 2012, age-adjusted awareness of 
hypertension was similar among non-Hispanic blacks 
(85.7%), non-Hispanic whites (82.7%), and Hispanics 
(82.2%) and lower among non-Hispanic Asians (72.8%).4
 ● In the Hispanic Community Health Study/Study of Latinos, 
the age-standardized prevalence of hypertension ranged 
from a low of 19.9% among US men from South America 
to 32.6% among their counterparts from the Dominican 
Republic. For US women, the age-standardized prevalence 
of hypertension was lowest for those of South American 
descent (15.9%) and highest for their counterparts from 
Puerto Rico (29.1%).32
 ● Among NHIS 1997 to 2005 respondents, in multivariate-
adjusted analyses that controlled for sociodemographic 
and health-related factors, odds of self-reported hyperten-
sion were 67% higher among Dominicans and 20% to 27% 
lower among Mexicans/ Mexican Americans and Central/ 
South Americans than among non-Hispanic whites.33
 ● Data from MESA found that being born outside the United 
States, speaking a language other than English at home, and 
living fewer years in the United States were each associated 
with a decreased prevalence of hypertension.34
 ● Filipino (27%) and Japanese (25%) adults were more likely 
than Chinese (17%) or Korean (17%) adults to have ever 
been told that they had hypertension.35
Mortality
(See Table 9-1.)
 ● In 2011, there were 65 123 deaths attributable to HBP. In 
2011, there were 377 258 any-mention deaths for HBP. The 
2011 death rate was 18.9. Death rates were 17.6 for white 
males, 47.1 for black males, 15.2 for white females, and 
35.1 for black females.36
 ● When any-mention mortality for 2011 was used, the over-
all death rate was 110.0. Death rates were 114.5 for white 
males, 212.8 for black males, 90.1 for Asian or Pacific 
Islander males, and 100.6 for American Indian or Alaska 
Native males (underestimated because of underreporting). 
In females, rates were 92.0 for white females, 157.9 for 
black females, 71.5 for Asian or Pacific Islander females, 
and 83.3 for American Indian or Alaska Native females 
(underestimated because of underreporting).37
 ● From 2001 to 2011, the death rate attributable to HBP 
increased 13.2%, and the actual number of deaths rose 
39.3% (NHLBI tabulation).36
 ● A mathematical model was developed to estimate the num-
ber of deaths that potentially could be prevented annually 
by increasing the use of 9 clinical preventive services. The 
model predicted that a 10% increase in hypertension treat-
ment would result in ≈14 000 deaths prevented.38
 ● Data from the Harvard Alumni Health Study found that 
higher BP in early adulthood was associated several 
decades later with higher risk for all-cause mortality, CVD 
mortality, and CHD mortality but not stroke mortality.39
 ● An analysis of NHANES I and III that compared mortality 
over time in hypertensive and nonhypertensive US adults 
found a reduction in the age-adjusted mortality rate from 
18.8 per 1000 person-years for NHANES I (follow-up: 
1971–1992) to 14.3 for NHANES III (follow-up: 1988–
2006) among people with hypertension. The reduction was 
higher in men than in women but was similar for blacks 
and whites.40
 ● Compared with other dietary, lifestyle, and metabolic risk 
factors, HBP is the leading cause of death in women and the 
second-leading cause of death in men, behind smoking.41
 ● The CDC analyzed death certificate data from 1995 to 2002 
(any-mention mortality; ICD-9 codes 401–404 and ICD-10 
codes I10–I13). The results indicated that Puerto Rican 
Americans had a consistently higher hypertension-related 
death rate than all other Hispanic subpopulations and 
non-Hispanic whites. The age-standardized hypertension-
related mortality rate was 127.2 per 100 000 population 
for all Hispanics, similar to that of non-Hispanic whites 
(135.9). The age-standardized rate for Hispanic females 
(118.3) was substantially lower than that observed for 
Hispanic males (135.9). Hypertension-related mortality 
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rates for males were higher than rates for females for all 
Hispanic subpopulations. Puerto Rican Americans had 
the highest hypertension-related death rate among all His-
panic subpopulations (154.0); Cuban Americans had the 
lowest (82.5).42
 ● Assessment of 30-year follow-up of the Hypertension 
Detection and Follow-up Program identified the long-term 
benefit of stepped care, as well as the increased survival 
for hypertensive African Americans, although disparities in 
death rates did persist.43
 ● Assessment of the Charleston Heart Study and Evans 
County Heart Study identified the excess burden of ele-
vated BP for African Americans and its effect on long-term 
health outcomes.44
Risk Factors
 ● Numerous risk factors and markers for development of 
hypertension have been identified, including age, ethnicity, 
family history of hypertension and genetic factors, lower 
education and socioeconomic status, greater weight, lower 
PA, tobacco use, psychosocial stressors, sleep apnea, and 
dietary factors (including dietary fats, higher sodium intake, 
lower potassium intake, and excessive alcohol intake).
 ● A study of related individuals in the NHLBI’s FHS sug-
gested that different sets of genes regulate BP at different 
ages.45
 ● Recent data from the Nurses’ Health Study suggest that 
a large proportion of incident hypertension in women 
can be prevented by controlling dietary and lifestyle risk 
factors.46
 ● Risk prediction models for developing hypertension have 
been developed and validated. A commonly used risk pre-
diction model was developed in the FHS and includes age, 
sex, SBP, DBP, BMI, smoking, and parental history of 
hypertension.47,48
Aftermath
 ● Approximately 69% of people who have a first heart attack, 
77% of those who have a first stroke, and 74% of those who 
have CHF have BP ≥140/90 mm Hg (NHLBI unpublished 
estimates from ARIC, CHS, and FHS Cohort and Offspring 
studies).
 ● Data from FHS/NHLBI indicate that recent (within the 
past 10 years) and remote antecedent BP levels may be an 
important determinant of risk over and above the current 
BP level.49
 ● Data from the FHS/NHLBI indicate that hypertension is 
associated with shorter overall life expectancy, shorter life 
expectancy free of CVD, and more years lived with CVD.50
—Total life expectancy was 5.1 years longer for normo-
tensive men and 4.9 years longer for normotensive 
women than for hypertensive people of the same sex 
at 50 years of age.
—Compared with hypertensive men at 50 years of age, men 
with untreated BP <140/90 mm Hg survived on aver-
age 7.2 years longer without CVD and spent 2.1 fewer 
years of life with CVD. Similar results were observed 
for women.
Hospital Discharges/Ambulatory Care Visits
(See Table 9-1.)
 ● From 2000 to 2010, the number of inpatient discharges 
from short-stay hospitals with HBP as the first-listed diag-
nosis increased from 457 000 to 488 000 (no significant 
difference; NCHS, NHDS). The number of all-listed dis-
charges increased from 8 034 000 to 11 282 000 (NHLBI, 
unpublished data from the NHDS, 2010; diagnoses in 2010 
were truncated at 7 diagnoses for comparability with earlier 
year).
 ● Data from the Nationwide Inpatient Sample from the 
years 2000 to 2007 found the frequency of hospitaliza-
tions for adults aged ≥18 years of age with a hyperten-
sive emergency increased from 101 to 111 per 100 000 
in 2007 (average increase of 1.11%). In contrast to the 
increased number of hospitalizations, the all-cause in-
hospital mortality rate decreased during the same period 
from 2.8% to 2.6%.51
 ● Data from ambulatory medical care use estimates for 2010 
showed that the number of visits for essential hypertension 
was 43 436 000. Of these, 38 916 000 were physician office 
visits, 940 000 were ED visits, and 3 580 000 were outpa-
tient department visits (NAMCS and NHAMCS, NHLBI 
tabulation).
 ● In 2010, there were 280 000 hospitalizations with a first-
listed diagnosis of essential hypertension (ICD-9-CM code 
401), but essential hypertension was listed as either a pri-
mary or a secondary diagnosis on 11 048 000 hospitalized 
inpatient visits (unpublished data from the NHDS, NHLBI 
tabulation).
Awareness, Treatment, and Control
(See Table 9-2 and Charts 9-3 through 9-5.)
 ● Data from NHANES 2009 to 2012 showed that of those 
with hypertension who were ≥20 years of age, 82.7% were 
aware of their condition, 76.5% were under current treat-
ment, 54.1% had their hypertension under control, and 
45.9% did not have it controlled. Awareness and treat-
ment of hypertension were higher at older ages. Hyper-
tension control was higher in US adults 40 to 59 years of 
age (58.0%) and those ≥60 years of age (54.1%) than in 
their counterparts 20 to 39 years of age (35.4%). Non-His-
panic black adults were more aware of their hypertension 
than Hispanics (87.0% and 77.7%, respectively; NHLBI 
tabulation).
 ● Data from NHANES 1999 to 2008 and BRFSS 1997 to 
2009 showed awareness, treatment, and control of hyper-
tension varied across the country and were highest in the 
southeastern United States.52
 ● Analysis of NHANES 1999 to 2006 and 2009 to 2012 
found the proportion of adults aware of their hypertension 
increased within each race-ethnicity/sex subgroup. Simi-
larly, large increases in hypertension treatment and control 
(≈10%) occurred in each of these groups (Table 9-2).
 ● According to data from NHANES 1999 to 2000 through 
2009 to 2010, HBP control rates improved from 27.5% 
to 46.5%, treatment improved from 56.9% to 71.6%, and 
the control among those treated improved from 46.5% 
to 64.4%.53
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 ● In 2009 to 2010, controlled hypertension increased from 
48.4% to 53.3%, respectively. Medication use to lower 
hypertension was lowest for those aged 18 to 39 years 
(46.0%) compared with those aged 40 to 59 years (77.1%) 
and those aged ≥60 years (80.7%). Non-Hispanic black 
adults were more likely to take antihypertensive medica-
tion than non-Hispanic whites or Hispanic adults (79.7%, 
76.6%, and 69.6%, respectively).54
 ● Data from the NHANES 2005 to 2010 show that among 
those ≥80 years of age, 79.4% of those with hypertension 
were aware of this condition, 57.4% were treated, and 
39.8% had controlled their BP to JNC 7 targets.16
 ● The change in SBP threshold from JNC 7 to the 2014 JAMA 
definition resulted in 5.8 million fewer US adults having 
antihypertensive medication treatment recommended to 
them, and 13.5 million fewer US adults taking treatment 
were recommended to be prescribed dose intensification or 
additional medication classes.10
 ● Among a cohort of postmenopausal women taking hor-
mone replacement, hypertension was the most common 
comorbidity, with a prevalence of 34%.55
 ● A study of >300 women in Wisconsin showed a need for 
significant improvement in BP and LDL levels. Of the 
screened participants, 35% were not at BP goal, 32.4% 
were not at LDL goal, and 53.5% were not at both goals.56
 ● In 2005, a survey of people in 20 states conducted by the 
BRFSS of the CDC found that 19.4% of respondents had 
been told on ≥2 visits to a health professional that they 
had HBP. Of these, 70.9% reported changing their eating 
habits; 79.5% reduced the use of or were not using salt; 
79.2% reduced the use of or eliminated alcohol; 68.8% 
were exercising; and 73.4% were taking antihypertensive 
medication.57
 ● Among 1509 NHANES 2005 to 2006 participants aged ≥30 
years with hypertension, 24% were categorized as low risk, 
21% as intermediate risk, and 23% as high risk according to 
Framingham global risk. Treatment for hypertension varied 
by risk category and ranged from 58% to 75%; hyperten-
sion control was 80% for those in the low-risk category and 
<50% for those in the high-risk category.58
 ● According to data from NHANES 2001 to 2006, non-His-
panic blacks had 90% higher odds of poorly controlled BP 
than non-Hispanic whites. Among those who were hyper-
tensive, non-Hispanic blacks and Mexican Americans had 
40% higher odds of uncontrolled BP than non-Hispanic 
whites.59
 ● According to data from NHANES 1998 to 2008 for adults 
with DM, prevalence of hypertension increased, whereas 
awareness, treatment, and control improved during these 
time periods; however, for adults 20 to 44 years of age, 
there was no evidence of improvement.60
Global Burden of Hypertension
 ● In 2000, it was estimated that 972 million adults worldwide 
had hypertension.61
 ● Between 1980 and 200862:
—The global mean age-adjusted SBP declined from 130.5 
mm Hg in 1980 to 128.1 mm Hg in men and from 127.2 
to 124.4 mm Hg in women.
—The global age-adjusted prevalence of uncontrolled 
hypertension decreased from 33% to 29% among men 
and from 29% to 25% among women.
—Because of population growth and aging, the number of 
people worldwide with uncontrolled hypertension (SBP 
≥140 mm Hg or DBP ≥90 mm Hg) increased from 605 
million to 978 million between 1980 and 2008.62
 ● HBP went from being the fourth-leading risk factor in 
1990, as quantified by DALYs, to being the number 1 risk 
factor in 2010.63
 ● In 2010, HBP was 1 of the 5 leading risk factors in all 
regions with the exception of Oceania, Eastern sub-Saharan 
Africa, and Western sub-Saharan Africa.63
Cost
(See Table 9-1.)
 ● The estimated direct and indirect cost of HBP for 2011 is 
$46.4 billion (MEPS, NHLBI tabulation).
 ● Projections show that by 2030, the total cost of HBP could 
increase to an estimated $274 billion (unpublished AHA 
computation, based on methodology described in Heiden-
reich et al12).
Prehypertension
 ● Prehypertension is untreated SBP of 120 to 139 mm Hg or 
untreated DBP of 80 to 89 mm Hg and not having been told 
on 2 occasions by a physician or other health professional 
that one has hypertension.
 ● Among disease-free participants in NHANES 1999 to 
2006, the prevalence of prehypertension was 36.3%. Preva-
lence was higher in men than in women. Furthermore, 
prehypertension was correlated with an adverse cardiomet-
abolic risk profile.64
 ● Follow-up of 9845 men and women in the FHS/NHLBI 
who attended examinations from 1978 to 1994 revealed 
that at 35 to 64 years of age, the 4-year incidence of hyper-
tension was 5.3% for those with baseline BP <120/80 
mm Hg, 17.6% for those with SBP of 120 to 129 mm Hg 
or DBP of 80 to 84 mm Hg, and 37.3% for those with SBP 
of 130 to 139 mm Hg or DBP of 85 to 89 mm Hg. At 65 
to 94 years of age, the 4-year incidences of hypertension 
were 16.0%, 25.5%, and 49.5% for these BP categories, 
respectively.65
 ● Among participants with and without prehypertension in 
MESA, 23.6% and 5.3%, respectively, developed hyperten-
sion over 4.8 years of follow-up.48
 ● Data from FHS/NHLBI also reveal that prehypertension 
is associated with elevated relative and absolute risks for 
CVD outcomes across the age spectrum. Compared with 
normal BP (<120/80 mm Hg), prehypertension was associ-
ated with a 1.5- to 2-fold increased risk for major CVD 
events in those <60, 60 to 79, and ≥80 years of age. Abso-
lute risks for major CVD associated with prehypertension 
increased markedly with age: 6-year event rates for major 
CVD were 1.5% in prehypertensive people <60 years of 
age, 4.9% in those 60 to 79 years of age, and 19.8% in those 
≥80 years of age.66
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 ● In a study of NHANES 1999 to 2000 (NCHS), people 
with prehypertension were more likely than those with 
normal BP levels to have above-normal cholesterol levels 
(≥200 mg/dL) and to be overweight or obese, whereas the 
probability of current smoking was lower. People with pre-
hypertension were 1.65 times more likely to have ≥1 of 
these adverse risk factors than were those with normal BP.67
 ● In the REGARDS study, prehypertension was more 
common in blacks than whites and was more common 
among people with other risk factors, including DM and 
elevated CRP.68
 ● A meta-analysis of 29 prospective cohort studies (including 
1 010 858 participants) found prehypertension was associ-
ated with CVD incidence or death, stroke, and MI. The 
risk was particularly noted for those with BP values in the 
higher prehypertension range.69
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studies. Curr Hypertens Rep. 2013;15:703–716.
Table 9-1.  High Blood Pressure
Population Group Prevalence, 2012, Age ≥20 y Mortality,* 2011, All Ages Hospital Discharges, 2010, All Ages Estimated Cost, 2011
Both sexes 80 000 000 (32.6%) 65 123 488 000 $46.4 Billion
Males 38 300 000 (33.5%) 29 363 (45.0%)† 216 000 …
Females 41 700 000 (31.7%) 35 760 (55.0%)† 272 000 …
NH white males 32.9% 21 830 … …
NH white females 30.1% 27 907 … …
NH black males 44.9% 6610 … …
NH black females 46.1% 6783 … …
Hispanic males 29.6% * … …
Hispanic females 29.9% * … …
Asian … 1667‡ … …
American Indian or Alaska Native 26.2%§ 326 … …
Hypertension is defined in terms of National Health and Nutrition Examination Survey blood pressure measurements and health interviews. A subject was considered 
hypertensive if systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, if the subject said “yes” to taking antihypertensive medication, or 
if the subject was told on 2 occasions that he or she had hypertension. Prevalence in American Indian or Alaska Natives is based on self-report data from the National 
Health Interview Survey, with hypertension defined as subjects having been told on ≥2 different visits that they had hypertension or high blood pressure.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of Hispanic and 
non-Hispanic origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of 
inconsistencies in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting 
on death certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total high blood pressure mortality that is for males vs females.
‡ Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
§ National Health Interview Survey (2013), National Center for Health Statistics; data are weighted percentages for Americans ≥18 years of age. Persons had to have 
been told on 2 or more different visits that they had hypertension or high blood pressure to be classified as hypertensive.31
Sources: Prevalence: National Health and Nutrition Examination Survey (2009–2012), National Center for Health Statistics, and National Heart, Lung, and Blood 
Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 US population 
estimates. Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2011 Mortality Multiple Cause-of-Death–United States. These data 
represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, National Center for Health Statistics; data include those discharged 
alive, dead, or status unknown. Cost: Medical Expenditure Panel Survey data include estimated direct costs for 2011; indirect costs calculated by National Heart, Lung, 
and Blood Institute for 2011.
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Table 9-2.  Hypertension Awareness, Treatment, and Control: NHANES 1999 to 2006 and 2007 to 2012, by Race/Ethnicity and Sex
Awareness Treatment Control
1999–2006 2007–2012 1999–2006 2007–2012 1999–2006 2007–2012
NH white males 71.8 80.2 61.8 72.6 41.9 53.3
NH white females 76.9 84.4 68.1 80.2 40.0 56.7
NH black male 70.1 80.0 59.6 67.9 34.1 40.7
NH black females 85.3 88.2 76.6 81.1 43.8 54.1
Mexican American males 57.7 67.0 41.8 57.9 25.6 35.0
Mexican American females 69.9 78.6 57.9 70.5 31.9 47.0
Values are percentages. Hypertension is defined in terms of NHANES blood pressure measurements and health interviews. A subject was considered hypertensive if 
systolic blood pressure was ≥140 mm Hg or diastolic blood pressure was ≥90 mm Hg, or if the subject said “yes” to taking antihypertensive medication.
NH indicates non-Hispanic; and NHANES, National Health and Nutrition Examination Survey.
Sources: NHANES (1999–2006, 2007–2012) and National Heart, Lung, and Blood Institute.
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Chart 9-1. Prevalence of high blood pressure in adults ≥20 years of age by age and sex (National Health and Nutrition Examination 
Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the sub-
ject said “yes” to taking antihypertensive medication, or if the subject was told on 2 occasions that he or she had hypertension. Source: 
National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-2. Age-adjusted prevalence trends for high blood pressure in adults ≥20 years of age by race/ethnicity, sex, and survey (National 
Health and Nutrition Examination Survey: 1988–1994, 1999–2006, and 2007–2012). Hypertension is defined as systolic blood pressure 
≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, if the subject said “yes” to taking antihypertensive medication, or if the subject 
was told on 2 occasions that he or she had hypertension. NH indicates non-Hispanic. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 9-3. Extent of awareness, treatment, and control of high blood pressure by race/ethnicity (National Health and Nutrition Examina-
tion Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or if the 
subject said “yes” to taking antihypertensive medication. NH indicates non-Hispanic. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 9-4. Extent of awareness, treatment, and control of high blood pressure by age (National Health and Nutrition Examination Survey: 
2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, or if the subject said 
“yes” to taking antihypertensive medication. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 9-5. Extent of awareness, treatment, and control of high blood pressure by race/ethnicity and sex (National Health and Nutrition 
Examination Survey: 2007–2012). Hypertension is defined as systolic blood pressure ≥140 mm Hg or diastolic blood pressure ≥90 mm Hg, 
or if the subject said “yes” to taking antihypertensive medication. NH indicates non-Hispanic. Source: National Center for Health Statis-
tics and National Heart, Lung, and Blood Institute.
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10 . Diabetes Mellitus
ICD-9 250; ICD-10 E10 to E14. See Table 10-1, Charts 10-1 
through 10-6.
DM is a major risk factor for CVD and stroke.1 The AHA has 
identified untreated fasting blood glucose levels of <100 mg/
dL for children and adults as 1 of the 7 components of ideal 
cardiovascular health.2 In 2011 to 2012, 85.3% of children and 
56.5% of adults met these criteria.
Prevalence
Youth
 ● Approximately 186 000 people <20 years of age have DM. 
Each year, ≈15 000 people <20 years of age are diagnosed 
with type 1 DM. Healthcare providers are finding more and 
more children with type 2 DM, a disease usually diagnosed 
in adults ≥40 years of age. Children who develop type 2 
DM are typically overweight or obese and have a family 
history of the disease. Most are American Indian, black, 
Asian, or Hispanic/Latino.3
 ● During 2008 to 2009, an estimated 18 436 people <20 years 
of age in the United States were newly diagnosed with type 
1 DM annually, and 5089 people <20 years old were newly 
diagnosed with type 2 DM annually.4
 ● Between 2001 and 2009, the prevalence of type 2 DM in 
youth increased by 30.5%.5
 ● Among adolescents 10 to 19 years of age diagnosed with 
DM, 57.8% of blacks were diagnosed with type 2 versus 
type 1 DM compared with 46.1% of Hispanic youth and 
14.9% of white youth.6
 ● According to the Bogalusa Heart Study, a long-term fol-
low-up study of youth aging into adulthood, youth who 
were prediabetic or who had DM were more likely to have 
a constellation of metabolic disorders in young adulthood 
(19–44 years of age), including obesity, hypertension, dys-
lipidemia, and metabolic syndrome, all of which predis-
pose to CHD.7
 ● Among youth with type 2 DM, 10.4% are overweight and 
79.4% are obese.8
 ● According to NHANES data from 1999 to 2007, among US 
adolescents aged 12 to 19 years, the prevalence of predia-
betes and DM increased from 9% to 23%.9
 ● The TODAY cohort comprised youth aged 10 to 17 years 
(41.1% Hispanic and 31.5% non-Hispanic black) par-
ticipating in a randomized controlled study of new-onset 
type 2 DM; 41.5% of participants had household income 
Abbreviations Used in Chapter 10
ACC American College of Cardiology
ACCORD Action to Control Cardiovascular Risk in Diabetes
ACS acute coronary syndrome
ADVANCE Action in Diabetes and Vascular Disease: Preterax and 
Diamicron Modified Release Controlled Evaluation
AF atrial fibrillation
AHA American Heart Association
AHRQ Agency for Healthcare Research and Quality
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities 
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CVD cardiovascular disease
DCCT Diabetes Control and Complications Trial
DM diabetes mellitus
ED emergency department
EDIC Epidemiology of Diabetes Interventions and  
Complications Study
ESRD end-stage renal disease
EURODIAB Europe and Diabetes
EVEREST Efficacy of Vasopressin Antagonism in Heart Failure Outcome 
Study With Tolvaptan
FHS Framingham Heart Study
HbA
1c hemoglobin A1c
HD heart disease
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IDDM insulin-dependent diabetes mellitus
LDL low-density lipoprotein
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NRMI National Registry of Myocardial Infarction
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PA physical activity
PAR population attributable risk
RR relative risk
SBP systolic blood pressure
SEARCH Search for Diabetes in Youth Study
STEMI ST-segment–elevation myocardial infarction
TIMI Thrombolysis in Myocardial Infarction
TODAY Treatment Options for Type 2 Diabetes in Adolescents and 
Youth
UA unstable angina
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<$25 000.10 The results of the clinical trial demonstrated 
that only half of the children maintained durable glycemic 
control with monotherapy,11 a higher rate of treatment fail-
ure than observed in adult cohorts.
 ● In the TODAY cohort, youth who had type 2 DM were sed-
entary >56 minutes longer per day (via accelerometry) than 
obese youth from NHANES.12
 ● Of 1514 SEARCH participants, 95% reported having under-
gone BP checks and 88% reported having had lipid-level 
checks, whereas slightly more than two thirds (68%) reported 
having had HbA1c testing or eye examinations (66%).13
Adults
(See Table 10-1 and Charts 10-1 through 10-4.)
 ● On the basis of data from NHANES 2009 to 2012 (unpub-
lished NHLBI tabulation), an estimated 21.1 million adults 
have diagnosed DM, 8.1 million adults have undiagnosed 
DM, and 80.8 million adults (35.3%) have prediabetes (eg, 
fasting blood glucose of 100 to <126 mg/dL).
 ● Analysis of NHANES/NCHS data from 1988 to 1994 and 
from 2005 to 2010 in adults ≥20 years of age showed that 
the prevalence of DM (diagnosed DM or HbA1c ≥6.5%) 
among adults ≥20 years of age increased from 6.2% in 
1988 to 1994 to 9.9% (21 million adults) in 2005 to 2010.14
 ● Minority groups remain disproportionately affected by DM.14 
The prevalence of total DM (diagnosed DM or HbA1c ≥6.5%) 
in non-Hispanic blacks is almost twice as high as whites 
(15.4% versus 8.6%), and Mexican Americans had a 35% 
higher prevalence of DM than whites (11.6% versus 8.6%).14
 ● The prevalence of diagnosed DM in adults ≥65 years of age 
was 26.9% in 2010, and an additional 50% (>20 million) 
had prediabetes based on fasting glucose, oral glucose tol-
erance testing, or HbA1c. In addition, data from NHANES 
2005 to 2006 show that 46% of DM cases remain undiag-
nosed in this group aged ≥65 years.15
 ● According to the Bogalusa Heart Study, men >20 years of 
age have a slightly higher prevalence of DM (11.8%) than 
women (10.8%).6
 ● After adjustment for population age differences, 2010 to 
2012 national survey data for people >20 years of age 
indicate that 7.6% of non-Hispanic whites, 9.0% of Asian 
Americans, 12.8% of Hispanics, 13.2% of non-Hispanic 
blacks, and 15.9% of American Indians/Alaska Natives had 
diagnosed DM.4
 ● Compared with non-Hispanic white adults, the risk of diag-
nosed DM was 18% higher among Asian Americans, 66% 
higher among Hispanics/Latinos, and 77% higher among 
non-Hispanic blacks.16
 ● In 2004 to 2006, the prevalence of diagnosed DM was more 
than twice as high for Asian Indian adults (14%) as for Chi-
nese (6%) or Japanese (5%) adults.17
 ● Type 2 DM accounts for 90% to 95% of all diagnosed cases 
of DM in adults.4
 ● On the basis of 2013 BRFSS (CDC) data, the prevalence of 
adults in the United States who reported ever having been 
told by a physician that they had DM ranged from 6.2% 
in Colorado to 12.6% in Alabama. The mean percentage 
among all states was 9.4%.18
 ● The CDC analyzed data from 1994 to 2004 collected by the 
Indian Health Service that indicated that the age-adjusted 
prevalence of DM per 1000 population increased 101.2% 
among American Indian/Alaska Native adults <35 years 
of age (from 8.5% to 17.1%). During this time period, the 
prevalence of diagnosed DM was greater among females 
than males in all age groups.19
 ● On the basis of projections from NHANES studies between 
1984 and 2004, the total prevalence of DM in the United 
States is expected to more than double from 2005 to 2050 
(from 5.6% to 12.0%) in all age, sex, and race/ethnicity 
groups. Increases are projected to be largest for the old-
est age groups (for instance, projected to increase by 220% 
among those 65–74 years of age and by 449% among those 
≥75 years of age). DM prevalence is projected to increase 
by 99% among non-Hispanic whites, by 107% among non-
Hispanic blacks, and by 127% among Hispanics. The age/
race/ethnicity group with the largest increase is expected to 
be blacks ≥75 years of age (projected increase of 606%).20
 ● According to NHIS data from 1997 to 2008, the preva-
lence of DM was higher at both time points among Asian 
Americans (4.3%–8.2%) than among whites (3.8%–6.0%), 
with the Asian American group also having a greater pro-
portional increase (1.9- versus 1.5-fold increase). This was 
observed despite lower BMI levels (23.6 versus 26.1 kg/m2 
in the earliest time period) among Asians.21
Global Burden of DM
 ● The prevalence of DM for adults worldwide was estimated 
to be 6.4% in 2010 and is projected to be 7.7% in 2030. The 
total number of people with DM is projected to rise from 
285 million in 2010 to 439 million in 2030.22
 ● According to international survey and epidemiological 
data from 2.7 million participants, the prevalence of DM 
in adults increased from 8.3% in men and 7.5% in women 
in 1980 to 9.8% in men and 9.2% in women in 2008. The 
number of individuals affected with DM increased from 
153 million in 1980 to 347 million in 2008.23
 ● In 2010, DM and other endocrine disorders caused >2.7 
million deaths worldwide, accounting for 5.2% of all 
deaths.24
Incidence
Youth
 ● In the SEARCH study, the incidence of DM in youth 
overall was 24.3 per 100 000 person-years. Among chil-
dren <10 years of age, most had type 1 DM, regardless 
of race/ethnicity. The highest rates of incident type 1 DM 
were observed in non-Hispanic white youth (18.6, 28.1, 
and 32.9 per 100 000 person-years for age groups of 0–4, 
5–9, and 10–14 years, respectively). Overall, type 2 DM 
was relatively infrequent, with the highest rates (17.0–49.4 
per 100 000 person-years) seen among 15- to 19-year-old 
minority groups.6
 ● Of 2291 individuals <20 years of age with newly diagnosed 
DM, slightly more than half (54.5%) had autoimmune, 
insulin-sensitive DM, and 15.9% had nonautoimmune, 
insulin-resistant DM.25
 ● Projecting disease burden for the US population <20 years 
of age by 2050, the number of youth with type 1 DM will 
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conservatively increase from 166 018 to 203 382, and 
the number with type 2 DM will increase from 20 203 to 
30 111. Less conservative modeling projects the number of 
patients with type 1 DM at 587 488 and those with type 2 
DM at 84 131 by 2050.26
Adults
(See Table 10-1.)
 ● A total of 1.7 million new cases of DM (type 1 or type 2) 
were diagnosed in US adults ≥20 years of age in 2010.4
 ● Data from the FHS indicate a doubling in the incidence of 
DM over the past 30 years, most dramatically during the 
1990s. Among adults 40 to 55 years of age in each decade 
of the 1970s, 1980s, and 1990s, the age-adjusted 8-year 
incidence rates of DM were 2.0%, 3.0%, and 3.7% among 
women and 2.7%, 3.6%, and 5.8% among men, respec-
tively. Compared with the 1970s, the age-and sex-adjusted 
OR for DM was 1.40 in the 1980s and 2.05 in the 1990s 
(P for trend=0.0006). Most of the increase in absolute inci-
dence of DM occurred in individuals with a BMI ≥30 kg/m2 
(P for trend=0.03).27
 ● DM incidence in adults also varies markedly by race. Over 
5 years of follow-up in 45- to 84-year-olds in MESA, 8.2% 
of the cohort developed DM. The cumulative incidence was 
highest in Hispanics (11.3%), followed by black (9.5%), 
Chinese (7.7%), and white (6.3%) participants.28
 ● On the basis of meta-analyses of 4 longitudinal cohort 
studies comprising 175 938 individuals and 1.1 million per-
son-years of follow-up, a statistically significant adjusted 
association was observed between net duration of televi-
sion viewing and risk for incident type 2 DM, with a 20% 
increased risk per each 2-hour daily increment of exposure 
(adjusted RR, 1.20; 95% CI, 1.14–1.27).29
 ● According to NHANES data from 1988 to 1994 compared 
with 2005 to 2010, the prevalence of DM increased from 
8.4% to 12.1%. This increase was most pronounced among 
those ≥65 years of age (increase in prevalence from 18.6% to 
28.5%).30
 ● According to data from NHANES and BRFSS, up to 48.7% 
of individuals with self-reported DM did not meet glyce-
mic, BP, and lipid targets, and only 14.3% met all 3 targets 
and did not smoke.31
 ● Gestational DM complicates 2% to 10% of pregnancies 
and increases the risk of developing type 2 DM by 35% 
to 60%.16
Mortality
(See Table 10-1.)
 ● DM mortality in 2011 was 73 831. Any-mention mortality 
in 2011 was 239 189.32
 ● The 2011 overall underlying-cause death rate attributable 
to DM was 21.7. Death rates per 100 000 population were 
24.3 for white males, 44.9 for black males, 16.2 for white 
females, and 35.8 for black females.32
 ● According to data from the CDC, the National Diabetes 
Information Clearinghouse, the National Institute of Dia-
betes and Digestive and Kidney Diseases, and the National 
Institutes of Health:
—At least 68% of people >65 years of age with DM die of 
some form of HD; 16% die of stroke.
—HD death rates among adults with DM are 2 to 4 times 
higher than the rates for adults without DM.16
 ● In a collaborative meta-analysis of 820 900 individuals 
from 97 prospective studies, DM was associated with the 
following risks: all-cause mortality, HR 1.80 (95% CI, 
1.71–1.90); cancer death, HR 1.25 (95% CI, 1.19–1.31); 
and vascular death, HR 2.32 (95% CI, 2.11–2.56). In par-
ticular, DM was associated with death attributable to the 
following cancers: liver, pancreas, ovary, colorectal, lung, 
bladder, and breast. A 50-year-old with DM died on aver-
age 6 years earlier than an individual without DM.33
 ● FHS/NHLBI data show that having DM significantly 
increased the risk of developing CVD (HR 2.5 for women 
and 2.4 for men) and of dying when CVD was present (HR 
2.2 for women and 1.7 for men). Diabetic men and women 
≥50 years of age lived an average of 7.5 and 8.2 years 
less than their nondiabetic counterparts. The differences 
in life expectancy free of CVD were 7.8 and 8.4 years, 
respectively.34
 ● Analysis of data from the FHS from 1950 to 2005 found 
reductions in all-cause and CVD mortality among men and 
women with and without DM; however, all-cause and CVD 
mortality rates among individuals with DM remain ≈2-fold 
higher than for individuals without DM.35
 ● Analysis of data from NHANES 1971 to 2000 found that 
men with DM experienced a 43% relative reduction in the 
age-adjusted mortality rate, which was similar to that of 
nondiabetic men. Among women with DM, however, mor-
tality rates did not decrease, and the incremental mortality 
risk for diabetic compared with nondiabetic women dou-
bled during this period of study.36
 ● During 1979 to 2004, DM death rates for black youth 1 to 
19 years of age were approximately twice those for white 
youth. During 2003 to 2004, the annual average DM death 
rate per 1 million youth was 2.46 for black youth and 0.91 
for white youth.37
 ● Among individuals ≥65 years of age participating in the 
CHS, during follow-up for up to 16 years, adjusted CHD 
mortality risk was similar for those with prevalent CHD 
free of DM at study entry compared with participants with 
DM but free of CHD (HR, 1.04; 95% CI, 0.83–1.30).38
 ● According to NHIS data from 1997 to 2006, the rate of 
CVD death among adults with DM decreased by 40% (95% 
CI, 23%–54%). Similarly, all-cause mortality decreased 
by 23% (95% CI, 10%–35%). In contrast, over this same 
period among adults without DM, the CVD mortality 
rate decreased by 60%, and the all-cause mortality rate 
decreased by 44%.39
Awareness
(See Chart 10-5.)
 ● On the basis of analyses of NHANES/NCHS data from 
2005 to 2010, 11% of adults with DM did not know they 
had it.14 Although the prevalence of diagnosed DM has 
increased significantly over the past decade, the numbers of 
adults with undiagnosed DM and impaired fasting glucose 
has remained relatively stable.
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 ● Analysis of NHANES data collected during 2005 to 2010 
indicated that the prevalence of diagnosed DM, defined as 
people told by a physician or other health professional that 
they had DM, was 8.4% among people ≥20 years of age.14
 ● Of the estimated 21 million adults with DM, 84.8% were 
told they had DM or were undergoing treatment, and 11% 
(2.3 million) of those with confirmed DM (calibrated HbA1c 
level ≥6.5% and fasting plasma glucose level ≥126 mg/dL) 
were unaware of the diagnosis.14
 ● Of 15.4 million people being treated with glucose-lowering 
medication (86.6% of the diagnosed diabetic population), 
8.5 million (55.2%) had their hyperglycemia under control 
(ie, had calibrated HbA1c <7%), and 6.9 million (44.8%) 
were being treated but did not have their hyperglycemia 
under control (HbA1c ≥7%). An estimated 2.4 million indi-
viduals with diagnosed DM are not treated with glucose-
lowering therapy.14
Aftermath
(See Chart 10-6.)
 ● Although the exact date of DM onset can be difficult to 
determine, increasing duration of DM diagnosis is asso-
ciated with increasing CVD risk. Longitudinal data from 
FHS suggest that the risk factor–adjusted RR of CHD is 
1.38 (95% CI, 0.99–1.92) times higher and the risk for 
CHD death is 1.86 (95% CI, 1.17–2.93) times higher for 
each 10-year increase in duration of DM.40
 ● On the basis of data from the NCHS/NHIS, 1997 to 200541
—The estimated number of people ≥35 years of age with 
DM with a self-reported cardiovascular condition 
increased 36%, from 4.2 million in 1997 to 5.7 million 
in 2005; however, the respective age-adjusted preva-
lence decreased 11.2%, from 36.6% in 1997 to 32.5% 
in 2005, which reflects an increase in the number of 
patients diagnosed with DM that exceeded the increase 
in CVD prevalence.
—Age-adjusted CVD prevalence was higher among men 
than among women, among whites than among blacks, 
and among non-Hispanics than among Hispanics. 
Among women, the age-adjusted prevalence decreased 
by 11.2%; among men, it did not decrease significantly. 
Among blacks, the age-adjusted prevalence of self-
reported CVD decreased by 25.3%; among whites, no 
significant decrease occurred; among non-Hispanics, the 
rate decreased by 12%. No clear trends were detected 
among Hispanics.
—Because the total number of people with DM and self-
reported CVD increased over this period but proportions 
with self-reported CVD declined, the data suggest that 
the mean age at which people are diagnosed with DM 
is decreasing, or the higher CVD mortality rate among 
older diabetic individuals is removing them from ability 
to self-report CVD. These and other data show a consis-
tent increase over time in the United States of the num-
ber of people with DM and CVD.
 ● Data from the FHS show that despite improvements in 
CVD morbidity and mortality over >4 decades of obser-
vation, DM continues to be associated with incremental 
CVD risk. Participants 45 to 64 years of age from the FHS 
original and offspring cohorts who attended examinations 
in 1950 to 1966 (“earlier” time period) and in 1977 to 
1995 (“later” time period) were followed up for incident 
MI, CHD death, and stroke. Among participants with DM, 
the age- and sex-adjusted CVD incidence rate was 286.4 
per 10 000 person-years in the earlier period and 146.9 per 
10 000 person-years in the later period, a 35.4% decline. 
HRs for DM as a predictor of incident CVD were not sig-
nificantly different in the earlier (risk factor–adjusted HR, 
2.68; 95% CI, 1.88–3.82) versus later (HR, 1.96; 95% CI, 
1.44–2.66) period. Thus, although there was a 50% reduc-
tion in the rate of incident CVD events among adults with 
DM, the absolute risk of CVD remained 2-fold greater than 
among people without DM.42
—Data from these earlier and later time periods in FHS 
also suggest that the increasing prevalence of DM is 
leading to an increasing rate of CVD, resulting in part 
from CVD risk factors that commonly accompany DM. 
The age- and sex-adjusted HR for DM as a CVD risk 
factor was 3.0 in the earlier time period and 2.5 in the 
later time period. Because the prevalence of DM has 
increased over time, the PAR for DM as a CVD risk 
factor increased from 5.4% in the earlier time period 
to 8.7% in the later time period (attributable risk ratio, 
1.62; P=0.04). Adjustment for CVD risk factors (age, 
sex, hypertension, current smoking, high cholesterol, 
and obesity) weakened this attributable risk ratio to 1.5 
(P=0.12).43
—Other data from FHS show that over a 30-year period, 
CVD among women with DM was 54.8% among normal-
weight women but 78.8% among obese women. Among 
normal-weight men with DM, the lifetime risk of CVD 
was 78.6%, whereas it was 86.9% among obese men.44
 ● Data from the ARIC study of the NHLBI found that the 
magnitude of incremental CHD risk associated with DM 
was smaller in blacks than in whites.45
 ● In analyses from the NRMI comprising data registered on 
1 734 431 patients admitted with AMI to 1964 participat-
ing US hospitals, the incremental adjusted OR for hospital 
mortality associated with DM declined from 1.24 (95% CI, 
1.16–1.32) in 1994 to 1.08 (95% CI, 0.99–1.19) in 2006, 
which demonstrates a closing of the acute hospital mortal-
ity gap associated with DM.46
 ● On the basis of analyses of data from the NHIS, the NHDS, 
the US Renal Data System, and the US National Vital Sta-
tistics System, between 1990 and 2010, the rate of incident 
MI among patients with DM declined 67.8%47 (Chart 10-6).
 ● A subgroup analysis was conducted of patients with DM 
enrolled in randomized clinical trials that evaluated ACS 
therapies. The data included 62 036 patients from TIMI stud-
ies (46 577 with STEMI and 15 459 with UA/NSTEMI). Of 
these, 17.1% had DM. Modeling showed that mortality at 
30 days was significantly higher among patients with DM 
than among those without DM who presented with UA/
NSTEMI (2.1% versus 1.1%; P≤0.001) and STEMI (8.5% 
versus 5.4%; P=0.001), with adjusted risks for 30-day mor-
tality in DM versus no DM of 1.78 for UA/NSTEMI (95% 
CI, 1.24–2.56) and 1.40 (95% CI, 1.24–1.57) for STEMI. 
DM was also associated with significantly higher mortality 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
 Heart Disease and Stroke Statistics—2015 Update: Chapter 10  e129
1 year after UA/NSTEMI or STEMI. By 1 year after ACS, 
patients with DM who presented with UA/NSTEMI had a 
risk of death that approached that of patients without DM 
who presented with STEMI (7.2% versus 8.1%).48
 ● In an analysis of provincial health claims data for adults liv-
ing in Ontario, Canada, between 1992 and 2000, the rate of 
patients admitted for AMI and stroke decreased to a greater 
extent in the diabetic than the nondiabetic population (AMI, 
−15.1% versus −9.1%, P=0.0001; stroke, −24.2% versus 
−19.4%, P=0.0001). Patients with DM experienced reduc-
tions in case fatality rates related to AMI and stroke similar 
to those without DM (−44.1% versus −33.2%, P=0.1, and 
−17.1% versus −16.6%, P=0.9, respectively) and similarly 
comparable decreases in all-cause mortality. Over the same 
period, the number of DM cases increased by 165%, which 
translates to a marked increase in the proportion of CVD 
events occurring among patients with DM: AMI, 44.6%; 
stroke, 26.1%; AMI deaths, 17.2%; and stroke deaths, 
13.2%.48a
 ● In the same data set, the transition to a high-risk category 
(an event rate equivalent to a 10-year risk of 20% or an 
event rate equivalent to that associated with previous MI) 
occurred at a younger age for men and women with DM 
than for those without DM (mean difference, 14.6 years). 
For the outcome of AMI, stroke, or death resulting from 
any cause, men and women with DM entered the high-risk 
category at 47.9 and 54.3 years of age, respectively. The 
data suggest that DM confers a risk equivalent to aging 15 
years. In North America, diverse data show lower rates of 
CVD among people with DM, but as the prevalence of DM 
has increased, so has the absolute burden of CVD, espe-
cially among middle-aged and older individuals.49
 ● DM increases the risk of HF and adversely affects out-
comes among patients with HF.
—DM alone qualifies for the most recent ACC Foundation/
AHA diagnostic criteria for stages A and B HF, a clas-
sification of patients without HF but at notably high risk 
for its development.50
—In MESA, DM was associated with a 2-fold increased 
adjusted risk of incident HF among 6814 individuals 
free of CVD at baseline over a mean follow-up of 4 
years (HR, 1.99; 95% CI, 1.08–3.68).51
—Post hoc analysis of data from the EVEREST random-
ized trial of patients hospitalized with decompensated 
systolic HF stratified by DM status, which evaluated 
cardiovascular outcomes over a follow-up period of 9.9 
months, demonstrated an increased adjusted HR for the 
composite of cardiovascular mortality and HF rehos-
pitalization associated with DM (HR, 1.17; 95% CI, 
1.04–1.31).52
 ● DM increases the risk of AF. On the basis of meta-analysis 
of published observational data comprising 11 studies and 
>1.6 million participants, DM was crudely associated with 
a 40% increased risk for AF (RR, 1.39; 95% CI, 1.10–1.75), 
with the association remaining significant after multivari-
able adjustment (adjusted RR, 1.24; 95% CI, 1.06–1.44), 
yielding an estimate of the population attributable fraction 
of AF attributable to DM of 2.5%.53
 ● DM increases the risk of stroke, with the RR ranging from 
1.8- to 6-fold increased risk.40,54
—DM is associated with increased ischemic stroke inci-
dence at all ages, with the incremental risk associated 
with DM being most prominent before 55 years of age 
in blacks and before 65 years of age in whites.54
—Ischemic stroke patients with DM are younger, more 
likely to be black, and more likely to have hypertension, 
prior MI, and high cholesterol than nondiabetic patients.54
 ● On the basis of analyses of data from the NHIS, the 
NHDS, the US Renal Data System, and the US National 
Vital Statistics System, between 1990 and 2010, the rate of 
incident stroke among patients with DM declined 52.7%47 
(Chart 10-6).
 ● DM accounted for 44% of the new cases of ESRD in 2011.55
 ● In 2012, the incidence rate of ESRD attributed to DM 
in adults ≥20 years in the Veterans Affairs health system 
increased with age, from 4.44 per 100 000 in those aged 
20 to 29 years to 110.35 per 100 000 in those ≥70 years 
old compared with rates of 2.40 and 81.88, respectively, in 
those without DM.56
 ● On the basis of analyses of data from the NHIS, the NHDS, 
the US Renal Data System, and the US National Vital Sta-
tistics System, between 1990 and 2010, the rate of incident 
ESRD among patients with DM declined 28.3%47 (Chart 
10-6).
 ● HbA1c levels ≥6.5% can be used to diagnose DM.57 In the 
population-based ARIC study, over a 14-year follow-up 
period that preceded the endorsement of HbA1c as a diag-
nostic criterion, HbA1c levels ≥6.5% at study entry were 
associated with a multivariable-adjusted HR of 16.5 (95% 
CI, 14.2–19.1) for diagnosed DM based on contemporane-
ous diagnostic criteria and 1.95 (95% CI, 1.53–2.48) for 
CHD relative to those with HbA1c <5.0%.58
Risk Factors for Developing DM
 ● Risk for developing type 2 DM is higher in men than in 
women even after accounting for other risk factors.59–61
 ● DM, especially type 2 DM, is associated with clustered 
risk factors for CHD, with a prevalence of 75% to 85% 
for hypertension among adults with DM, 70% to 80% for 
elevated LDL, and 60% to 70% for obesity.14,62
 ● Aggressive treatment of hypertension is recommended for 
adults with DM to prevent cardiovascular complications.63 
Between NHANES III (1984–1992) and NHANES 1999 
to 2004, the proportion of patients with DM whose BP was 
treated increased from 76.5% to 87.8%, and the proportion 
whose BP was controlled nearly doubled (from 15.9% to 
29.6%).64
 ● Aggressive treatment of hypercholesterolemia is recom-
mended for adults with DM, with the cornerstone of treat-
ment being statin therapy, which is recommended for all 
patients with DM >40 years of age independent of base-
line cholesterol, with at least a moderate dose of statin 
therapy.65
 ● CHD risk factors among patients with DM remain subopti-
mally treated, although improvements have been observed 
over the past decade. Between 1999 and 2008, in up to 
2623 adult participants with DM, data from NHANES 
showed that improvements were observed for the achieved 
targets for control of HbA1c (from 37.0% to 55.2%), BP 
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(from 35.2% to 51.0%), and LDL cholesterol (from 32.5% 
to 52.9%).66
 ● Data from the 2012 National Healthcare Disparities Report 
(AHRQ, US Department of Health and Human Services) 
found that only ≈23% of adults >40 years of age with DM 
received all 4 interventions to reduce risk factors recom-
mended for comprehensive DM care in 2009. The propor-
tion receiving all 4 interventions was lower among blacks 
and Hispanics than whites.67
—In multivariable models, among those aged 40 to 64 years, 
only about 65% had their BP <140/80 mm Hg, with 
blacks less likely than whites to achieve this BP level.67
 ● In 1 large academic medical center, outpatients with type 2 
DM were observed during an 18-month period for propor-
tions of patients who had HbA1c levels, BP, or total choles-
terol levels measured; who had been prescribed any drug 
therapy if HbA1c levels, SBP, or LDL cholesterol levels 
exceeded recommended treatment goals; and who had been 
prescribed greater-than-starting-dose therapy if these values 
were above treatment goals. Patients were less likely to have 
cholesterol levels measured (76%) than HbA1c levels (92%) 
or BP (99%; P<0.0001 for either comparison). The propor-
tion of patients who received any drug therapy was greater 
for above-goal HbA1c (92%) than for above-goal SBP (78%) 
or LDL cholesterol (38%; P<0.0001 for each comparison). 
Similarly, patients whose HbA1c levels were above the treat-
ment goal (80%) were more likely to receive greater-than-
starting-dose therapy than were those who had above-goal 
SBP (62%) and LDL cholesterol levels (13%; P<0.0001).68
—Data from the same academic medical center also 
showed that CVD risk factors among women with DM 
were managed less aggressively than among men with 
DM. Women were less likely than men to have HbA1c 
<7% (without CHD: adjusted OR for women ver-
sus men 0.84, P=0.005; with CHD: 0.63, P<0.0001). 
Women without CHD were less likely than men to be 
treated with lipid-lowering medication (0.82; P=0.01) 
or, when treated, to have LDL cholesterol levels <100 
mg/dL (0.75; P=0.004) and were less likely than men 
to be prescribed aspirin (0.63; P<0.0001). Women with 
DM and CHD were less likely than men to be prescribed 
aspirin (0.70, P<0.0001) and, when treated for hyper-
tension or hyperlipidemia, were less likely to have BP 
levels <130/80 mm Hg (0.75; P<0.0001) or LDL choles-
terol levels <100 mg/dL (0.80; P=0.006).69
 ● Analysis of data from the CHS of the NHLBI found that 
lifestyle risk factors, including PA level, dietary hab-
its, smoking habits, alcohol use, and adiposity measures, 
assessed late in life, were each independently associated 
with risk of new-onset DM. Participants whose PA level 
and dietary, smoking, and alcohol habits were all in the 
low-risk group had an 82% lower incidence of DM than all 
other participants. When absence of adiposity was added to 
the other 4 low-risk lifestyle factors, incidence of DM was 
89% lower.70
 ● According to 2007 data from the BRFSS, only 25% of 
adults with DM achieved recommended levels of total 
PA based on the 2007 American Diabetes Association 
guidelines.71
Hospitalizations
(See Table 10-1.)
Youth
 ● Nationwide Inpatient Sample data from 1993 to 2004 were 
analyzed for individuals 0 to 29 years of age with a diag-
nosis of DM. Rates of hospitalizations increased by 38%. 
Hospitalization rates were higher for females (42%) than 
for males (29%). Inflation-adjusted total charges for DM 
hospitalizations increased 130%, from $1.05 billion in 
1993 to $2.42 billion in 2004.72
Adults
 ● According to NHDS data reported by the CDC in an analy-
sis of data from 2010, DM was a listed diagnosis in 16% of 
US adult hospital discharges. Of the 5.1 million discharges 
with DM listed, circulatory diseases was the most com-
mon first-listed diagnosis (24.1%; 1.3 million discharges) 
and DM the second most common (11.5%; 610 000 
discharges).73
Hypoglycemia
 ● Hypoglycemia is a common side effect of DM treatment, 
typically defined as a blood glucose level <50 mg/dL; 
severe hypoglycemia is additionally defined as patients 
needing assistance to treat themselves.
 ● In the ADVANCE trial, 2.1% of patients had an episode of 
severe hypoglycemia.
 ● Severe hypoglycemia was associated with an increased risk 
of major macrovascular events (HR, 2.88; 95% CI, 2.01–
4.12), cardiovascular death (HR, 2.68; 95% CI, 1.72–4.19), 
and all-cause death (HR, 2.69; 95% CI, 1.97–3.67), includ-
ing nonvascular outcomes. The lack of specificity of hypo-
glycemia with vascular outcomes suggests that it might be 
a marker for susceptibility. Risk factors for hypoglycemia 
included older age, DM duration, worse renal function, 
lower BMI, lower cognitive function, use of multiple glu-
cose-lowering medications, and randomization to the inten-
sive glucose control arm.74
 ● According to data from the 2004 to 2008 MarketScan data-
base of type 2 DM, which consisted of 536 581 individuals, 
the incidence rate of hypoglycemia was 153.8 per 10 000 
person-years and was highest in adults aged 18 to 34 years 
(218.8 per 10 000 person-years).75
 ● According to data from 2956 adults >55 years of age from 
the ACCORD trial, poor cognitive function, defined as a 
5-point poorer baseline score on the Digit Symbol Substi-
tution Test, was associated with a 13% increased risk of 
severe hypoglycemia that required medical assistance.76
 ● In a sample of 813 adults with type 2 DM enrolled in com-
mercial health plans, 71% reported experiencing symptoms 
of hypoglycemia.77
Cost
(See Table 10-1.)
 ● In 2012, the cost of DM was estimated at $245 billion, up 
from $174 billion in 2007, accounting for 1 in 5 healthcare 
dollars. Of these costs, $176 billion were direct medical 
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costs and $69 billion resulted from reduced productivity. 
Inpatient care accounted for 43% of these costs, 18% were 
attributable to prescription costs to treat DM complications, 
and 12% were related to antidiabetes agents and supplies.78
 ● After adjustment for age and sex, medical costs for patients 
with DM were 2.3 times higher than for people without DM.16
 ● According to the insurance claims and MarketScan data 
from 7556 youth <19 years of age with insulin-treated DM, 
costs for youth with hypoglycemia were $12 850 compared 
with $8970 for youth without hypoglycemia. For diabetic 
ketoacidosis, costs were $14 236 for youth with versus 
$8398 for youth without diabetic ketoacidosis.79
 ● The cost of hypoglycemia, according to data from 536 581 
individuals with type 2 DM from the 2004 to 2008 Mar-
ketScan database, was $52 223 675, which accounted for 
1.0% of inpatient costs, 2.7% of ED costs, and 0.3% of out-
patient costs. This resulted in a mean cost of $17 564 for an 
inpatient admission, $1387 for an ED visit, and $394 for an 
outpatient visit.75
Type 1 DM
 ● Type 1 DM constitutes 5% to 10% of DM in the United 
States.80
 ● The Colorado IDDM Study Registry and SEARCH registry 
demonstrated an increasing incidence of type 1 DM among 
Colorado youth ≤17 years of age, with an increase in the 
incidence of 2.3% (95% CI, 1.6%–3.1%) per year over the 
past 26 years.81
 ● Between 1996 and 2010, the number of youth with type 1 
DM increased by 5.7% per year.82
 ● Among youth with type 1 DM, the prevalence of over-
weight is 22.1% and the prevalence of obesity is 12.6%.8
 ● A long-term study of patients with type 1 DM that began 
in 1966 showed that over 30 years of follow-up, overall 
risk of mortality associated with type 1 DM was 7 times 
greater than that of the general population. Females had a 
13.2-fold incremental mortality risk compared with a 5.0-
fold increased risk in males. During the course of study, 
the incremental mortality risk associated with type 1 DM 
declined from 9.3 to 5.6 times that of nondiabetic control 
subjects.83
 ● According to 30-year mortality data from Allegheny 
County, PA, those with type 1 DM have a mortality rate 5.6 
times higher than the general population.84
 ● The leading cause of death among patients with type 1 DM 
is CVD, which accounted for 22% of deaths among those 
in the Allegheny County, PA, type 1 DM registry, followed 
by renal (20%) and infectious (18%) causes.85
 ● Long-term follow-up data from the DCCT/EDIC Research 
Group showed that intensive versus conventional treatment 
in the DCCT was associated with a 42% reduced risk of 
CVD (P=0.02) and a 57% reduced risk of the composite 
end point (P=0.02; included nonfatal MI, stroke, and CVD 
death).86
 ● Observational data from the Swedish National Diabetes 
Register showed that most CVD risk factors were more 
adverse among patients with HbA1c between 8.0% and 
11.9% than among those with HbA1c between 5.0% and 
7.9%. Per 1% unit increase in HbA1c, the HR of fatal and 
nonfatal CHD was 1.30 in multivariable-adjusted models 
and 1.27 for fatal and nonfatal CVD. Among patients with 
HbA1c 8.0% to 11.9% compared with those with HbA1c 
5.0% to 7.9%, the HR of fatal/nonfatal CHD was 1.71 and 
the risk of fatal/nonfatal CVD was 1.59.87
 ● Among 2787 patients from the EURODIAB Prospective 
Complications Study, age, waist-hip ratio, pulse pressure, 
non-HDL cholesterol, microalbuminuria, and peripheral 
and autonomic neuropathy were risk factors for all-cause, 
CVD, and non-CVD mortality.88
 ● Among 3610 older patients (>60 years of age) with type 
1 DM, the risk of severe hypoglycemia was twice as high 
as for those <60 years of age (40.1 versus 24.3 per 100 
patient-years).89
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Table 10-1.  Diabetes Mellitus
Population Group
Prevalence 
of Physician- 
Diagnosed DM, 
2012: Age ≥20 y
Prevalence of 
Undiagnosed DM, 
2012: Age ≥20 y
Prevalence of 
Prediabetes, 2012: 
Age ≥20 y
Incidence of 
Diagnosed DM:  
Age ≥20 y*
Mortality, 2011:  
All Ages†
Hospital Discharges, 
2010: All Ages Cost, 2012‡
Both sexes 21 100 000 (8.5%) 8 100 000 (3.3%) 80 800 000 (35.3%) 1 700 000 73 831 630 000 $245 Billion
Males 10 500 000 (9.0%) 5 100 000 (4.4%) 46 400 000 (42.4%) … 38 324 (51.9%)§ 311 000 …
Females 10 600 000 (8.0%) 3 000 000 (2.4%) 34 400 000 (28.4%) … 35 507 (48.1%)§ 319 000 …
NH white males 7.6% 4.0% 43.0% … 30 783 … …
NH white females 6.1% 1.7% 28.9% … 27 191 … …
NH black males 13.8% 4.8% 36.3% … 6048 … …
NH black females 14.6% 2.3% 27.8% … 6847 … …
Hispanic males 12.5% 6.8% 43.0% … * … …
Hispanic females 11.8% 5.0% 26.0% … * … …
Asian or Pacific Islander … … … … 2035 … …
American Indian or  
Alaska Native
… … … … 927 … …
Undiagnosed DM is defined as those whose fasting glucose is ≥126 mg/dL but who did not report being told by a healthcare provider that they had DM. Prediabetes 
is a fasting blood glucose of 100 to <126 mg/dL (impaired fasting glucose); prediabetes includes impaired glucose tolerance.
DM indicates diabetes mellitus; ellipses (…), data not available; and NH, non-Hispanic.
*Centers for Disease Control and Prevention, National Diabetes Statistics Report, 2014.4
†Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of Hispanic and NH 
origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
‡Yang et al.78
§These percentages represent the portion of total DM mortality that is for males vs females.
Sources: Prevalence: Prevalence of diagnosed and undiagnosed DM: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health 
Statistics (NCHS), and National Heart, Lung, and Blood Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific 
percentages are extrapolations to the 2012 US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2011 Mortality Multiple Cause-of-
Death–United States. These data represent underlying cause of death only. Hospital discharges: National Hospital Discharge Survey, NCHS; data include those inpatients 
discharged alive, dead, or status unknown.
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Chart 10-1. Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age by race/ethnicity and sex 
(National Health and Nutrition Examination Survey: 2009–2012). NH indicates non-Hispanic. Source: National Center for Health Statistics 
and National Heart, Lung, and Blood Institute.
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Chart 10-2. Age-adjusted prevalence of physician-diagnosed diabetes mellitus in adults ≥20 years of age by race/ethnicity and years of 
education (National Health and Nutrition Examination Survey: 2009–2012). NH indicates non-Hispanic. Source: National Center for Health 
Statistics and National Heart, Lung, and Blood Institute.
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Chart 10-3. Trends in diabetes mellitus prevalence in adults ≥20 years of age by sex (National Health and Nutrition Examination Survey: 
1988–1994 and 2009–2012). Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 10-4. Trends in the prevalence of diagnosed and undiagnosed diabetes mellitus (calibrated hemoglobin A1c levels >6.5%), by race/
ethnic group. Data from US adults aged 20 years in NHANES 1988 to 1994, 1999 to 2004, and 2005 to 2010. Source: National Health and 
Nutrition Examination Survey.14
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Chart 10-5. Diabetes mellitus awareness, treatment, and control in adults ≥20 years of age (National Health and Nutrition Examination 
Survey: 2009–2012). Source: National Heart, Lung, and Blood Institute.
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Chart 10-6. Trends in age-standardized rates of diabetes mellitus-related complications among US adults with and without diagnosed 
diabetes mellitus.47
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11 . Metabolic Syndrome
See Charts 11-1 through 11-6.
 ● Metabolic syndrome is a multicomponent risk factor for 
CVD and type 2 DM that reflects the clustering of individ-
ual cardiometabolic risk factors related to abdominal obe-
sity and insulin resistance. Clinically, metabolic syndrome 
is a useful entity for communicating the nature of lifestyle-
related cardiometabolic risk to both patients and other cli-
nicians. Although several different clinical definitions for 
metabolic syndrome have been proposed, the International 
Diabetes Federation, NHLBI, AHA, and others recently 
proposed a harmonized definition for metabolic syndrome.1 
By this definition, metabolic syndrome is diagnosed when 
any 3 of the following 5 risk factors are present:
—Fasting plasma glucose ≥100 mg/dL or undergoing drug 
treatment for elevated glucose
—HDL cholesterol <40 mg/dL in men or <50 mg/dL in women 
or undergoing drug treatment for reduced HDL cholesterol
—Triglycerides ≥150 mg/dL or undergoing drug treatment 
for elevated triglycerides
—Waist circumference >102 cm in men or >88 cm in 
women for people of most ancestries living in the United 
States. Ethnicity and country-specific thresholds can be 
used for diagnosis in other groups, particularly Asians 
and individuals of non-European ancestry who have pre-
dominantly resided outside the United States.
—BP ≥130 mm Hg systolic or ≥85 mm Hg diastolic or 
undergoing drug treatment for hypertension or antihy-
pertensive drug treatment in a patient with a history of 
hypertension.
 ● The new harmonized metabolic syndrome definition identi-
fies a similar risk group and predicts CVD risk similarly to 
the prior metabolic syndrome definitions.2
 ● There are many adverse health conditions that are related 
to metabolic syndrome but are not part of its clinical defini-
tion. These include nonalcoholic fatty liver disease, sexual 
dysfunction (erectile dysfunction in men and polycystic 
ovarian syndrome in women), obstructive sleep apnea, cer-
tain forms of cancer, and possibly osteoarthritis, as well as 
a general proinflammatory and prothrombotic state.3
 ● Those with a fasting glucose level ≥126 mg/dL or a casual 
glucose value ≥200 mg/dL or taking hypoglycemic medi-
cation will normally be classified separately as having DM; 
many of these people will also have metabolic syndrome 
Abbreviations Used in Chapter 11
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AF atrial fibrillation
AHA American Heart Association
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ASCVD atherosclerotic cardiovascular disease
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BP blood pressure
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CRP C-reactive protein
CT computed tomography
CVD cardiovascular disease
DESIR Data From an Epidemiological Study on the Insulin 
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because of the presence of ≥2 of the additional risk factors 
noted above. For treatment purposes, many will prefer to 
separate those with DM into a separate group.
 ● Identification and treatment of metabolic syndrome fits 
closely with the current AHA 2020 Impact Goals, includ-
ing emphasis on PA, healthy diet, and healthy weight for 
attainment of ideal BP, serum cholesterol, and fasting blood 
glucose. Metabolic syndrome should be considered largely 
a disease of unhealthy lifestyle. Prevalence of metabolic 
syndrome is a secondary metric in the 2020 Impact Goals. 
Identification of metabolic syndrome represents a call to 
action for the healthcare provider and patient to address 
the underlying lifestyle-related risk factors. A multidis-
ciplinary team of healthcare professionals is desirable to 
adequately address these multiple issues in patients with 
metabolic syndrome.4
 ● Despite its prevalence (see below), the public’s recognition 
of metabolic syndrome is limited.5 A diagnosis of meta-
bolic syndrome may increase risk perception and motiva-
tion toward a healthier behavior.6
Prevalence
Youth
(See Chart 11-1.)
 ● According to the 2009 AHA scientific statement about 
metabolic syndrome in children and adolescents, meta-
bolic syndrome should be diagnosed with caution in this 
age group, because metabolic syndrome categorization in 
adolescents is not stable.7 Approximately half of the 1098 
adolescent participants in the Princeton School District 
Study diagnosed with pediatric Adult Treatment Panel 
III metabolic syndrome lost the diagnosis over 3 years of 
follow-up.8
 ● Additional evidence of the instability of the diagnosis of 
metabolic syndrome in children exists. In children 6 to 17 
years of age participating in research studies in a single 
clinical research hospital, the diagnosis of metabolic syn-
drome was unstable in 46% of cases after a mean of 5.6 
years of follow-up.9
 ● Uncertainty remains concerning the definition of the obe-
sity component of metabolic syndrome in the pediatric 
population because it is age dependent. Therefore, use of 
BMI percentiles10 and waist-height ratio11 has been rec-
ommended. Using standard CDC and FITNESSGRAM 
standards for pediatric obesity, the prevalence of metabolic 
syndrome in obese youth ranges from 19% to 35%.10 On 
the basis of NHANES 1999 to 2002 data, the prevalence 
of metabolic syndrome in adolescents 12 to 19 years of age 
was 9.4%, which represents ≈2.9 million people. It was 
13.2% in boys, 5.3% in girls, 10.7% in whites, 5.2% in 
blacks, and 11.1% in Mexican Americans.12
 ● In 1999 to 2004, ≈4.5% of US adolescents 12 to 17 years 
of age had metabolic syndrome according to the definition 
developed by the International Diabetes Federation.13 In 
2006, this prevalence would have represented ≈1.1 million 
adolescents 12 to 17 years of age with metabolic syndrome. 
It increased from 1.2% among those 12 to 13 years of age 
to 7.1% among those 14 to 15 years of age and was higher 
among boys (6.7%) than girls (2.1%). Furthermore, 4.5% of 
white adolescents, 3.0% of black adolescents, and 7.1% of 
Mexican American adolescents had metabolic syndrome.
 ● In the most recent report using NHANES data, the age-
adjusted prevalence of metabolic syndrome in those aged 12 
to 19 years appeared to be decreasing. In this report, the age-
adjusted prevalence from 1988 to 1994 was 7.3%, dropping 
to 6.7% from 1999 to 2002 and to 6.5% from 2003 to 2006. 
This is contrast to the Korean NHANES, in which the preva-
lence of metabolic syndrome in those aged 12 to 19 years 
increased from 4.0% to 7.8%. In the United States, improve-
ments in HDL cholesterol and BP led to the decreased prev-
alence, whereas increases in dyslipidemia and abdominal 
obesity contributed to the increasing prevalence in Korea.14
 ● Of 31 participants in the NHLBI Lipid Research Clinics 
Princeton Prevalence Study and the Princeton Follow-Up 
Study who had metabolic syndrome at baseline, 21 (68%) 
had metabolic syndrome 25 years later.15 After adjustment 
for age, sex, and race, the baseline status of metabolic syn-
drome was significantly associated with an increased risk 
of having metabolic syndrome during adulthood (OR, 6.2; 
95% CI, 2.8–13.8).
 ● In the Bogalusa Heart Study, 4 variables (BMI, homeo-
stasis model assessment of insulin resistance, ratio of 
triglycerides to HDL cholesterol, and mean arterial pres-
sure) considered to be part of metabolic syndrome clus-
tered together in blacks and whites and in both children 
and adults16; however, the degree of clustering was stronger 
among adults than among children. As in adults, preclinical 
cardiovascular abnormalities, such as elevated carotid IMT, 
are closely associated with metabolic syndrome in children 
and adolescents.17,18
Adults
(See Charts 11-2 through 11-5.)
The following estimates include many who also have DM, 
in addition to those with metabolic syndrome without DM:
 ● Prevalence of metabolic syndrome varies by the defini-
tion used, with definitions such as that from the Interna-
tional Diabetes Federation and the harmonized definition 
suggesting lower thresholds for defining central obesity 
in European whites, Asians (in particular, South Asians), 
Middle Easterners, Sub-Saharan Africans, and Hispanics, 
which results in higher prevalence estimates.19
 ● The phenotypic expression of metabolic syndrome also 
varies by race/ethnicity20 and is likely influenced by genetic 
factors. For example, in population-based US data, nonal-
coholic fatty liver disease is present in only 18% of African-
Americans with metabolic syndrome but is present in 39% 
of Hispanics with metabolic syndrome.21 The phenotypic 
expression of metabolic syndrome also varies by country 
and culture, particularly in Europe.22
 ● On the basis of data from NHANES 1999 to 2010, the age-
adjusted prevalence of metabolic syndrome in the United 
States has peaked (in the 2001–2002 cycle) and has begun 
to fall.23
—In the 1999 to 2000 cycle, the age-adjusted prevalence of 
metabolic syndrome was 25.54%. In 2001 to 2002, the 
age-adjusted prevalence peaked at 27.37%. In 2009 to 
2010, the age-adjusted prevalence was 22.90%.
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—Although the age-adjusted prevalence of metabolic 
syndrome has remained flat over time in men, the age-
adjusted prevalence in women has decreased. In 1999 to 
2000, the age-adjusted prevalence was 23.35% in men 
and 27.50% in women. In 2009 to 2010, the age adjusted 
prevalence was 23.69% in men and 21.80% in women.
—The reduced prevalence of metabolic syndrome has been 
observed predominantly in non–Mexican American 
whites, in whom the age-adjusted prevalence has fallen 
from 25.59% in 1999 to 2000 to 21.77% in 2009 to 
2010. In contrast, the prevalence of metabolic syndrome 
in non–Mexican American blacks and Mexican Ameri-
cans has remained stable.
—Although the age-adjusted prevalence of metabolic 
syndrome was once higher in non-Mexican American 
whites than in non–Mexican American blacks, the age-
adjusted prevalence in 2009 to 2010 was similar between 
these groups. In 2009 to 2010, the age-adjusted preva-
lence of metabolic syndrome was 40% to 46% higher 
among Mexican Americans than among non–Mexican 
American whites and blacks. Differences in prevalence 
are more pronounced in men than in women.
—In 2009 to 2010, the age-adjusted prevalence of meta-
bolic syndrome was lowest among non-Mexican Ameri-
can black men (18.99%) and highest among Mexican 
American men (34.76%).
—The changing trends in age-adjusted metabolic syndrome 
prevalence are attributable to changes in the prevalence 
of its individual components. In general, hypertriglyc-
eridemia and elevated BP have decreased, whereas 
hyperglycemia and elevated waist circumference have 
increased. However, these trends varied significantly by 
sex and race/ethnicity.
 ● Using different modeling strategies, other reports using 
NHANES 2003 to 2006 data and National Cholesterol 
Education Program/Adult Treatment Panel III definitions 
reported an age-adjusted prevalence of ≈34% for adults 
≥20 years of age.24 Differences in the prevalence statis-
tics are the result of different handling of age adjustment 
as the prevalence of metabolic syndrome increases with 
age and handling of medication therapy for its component 
conditions.
 ● Additionally, on the basis of NHANES 2003 to 2006 data24
—Among men, the age-specific prevalence of metabolic 
syndrome ranged from 20.3% among people 20 to 39 
years of age to 40.8% for people 40 to 59 years of age 
and 51.5% for people ≥60 years of age. Among women, 
the age-specific prevalence ranged from 15.6% among 
people 20 to 39 years of age to 37.2% for people 40 to 
59 years of age and 54.4% for those ≥60 years of age.
 ● The prevalence of metabolic syndrome is also high among 
immigrant Asian Indians, ranging between 26.8% and 
38.2% depending on the definition used.25
 ● Among American Indian and Alaska Native people living 
in the southwestern United States, the prevalence of meta-
bolic syndrome was reported to be 43.2% in men and 47.3% 
in women; among Alaska Native people, prevalences were 
26.5% and 31.2%, respectively.26
 ● The prevalence of metabolic syndrome among pregnant 
women increased to 26.5% during 1999 to 2004 from 
17.8% during 1988 to 1994.27
 ● The prevalence of metabolic syndrome has been noted to 
be high among select special populations, including those 
taking atypical antipsychotic drugs,28 those receiving prior 
organ transplants,29 HIV-infected individuals,30 those pre-
viously treated for blood cancers,31 those with systemic 
inflammatory disorders such as psoriasis,32 and individu-
als in select professions, including law enforcement33 and 
firefighters.34
 ● There is a bidirectional relationship between metabolic 
syndrome and depression. In prospective studies, the pres-
ence of depression increases the risk of metabolic syn-
drome (OR, 1.49; 95% CI, 1.19–1.87), whereas metabolic 
syndrome increases the risk of depression (OR, 1.52; 95% 
CI, 1.20–1.91).35
 ● Perhaps most importantly with respect to meeting the 2020 
goals, the prevalence of metabolic syndrome increases 
with greater cumulative life-course exposure to sedentary 
behavior and physical inactivity36; screen time, including 
television viewing37; and intake of sugar-sweetened bever-
ages.38,39 Each of these risk factors is reversible with life-
style change.
Global Burden of Metabolic Syndrome
(See Chart 11-6.)
 ● Metabolic syndrome is becoming hyperendemic around 
the world. Recent evidence has described the prevalence of 
metabolic syndrome in Canada,40 Latin America,41 India,42 
and Bangladesh,43 as well as many other countries. On 
the basis of data from NIPPON DATA, the age-adjusted 
prevalence of metabolic syndrome in a Japanese population 
was 19.3%.44 In a partially representative Chinese popula-
tion, the age-adjusted prevalence of metabolic syndrome in 
China was 21.3%,45 whereas in northwest China, the preva-
lence was 15.1%.46
 ● In the INTERHEART case-control study of MI in 26 903 
subjects from 52 countries, metabolic syndrome was pres-
ent in 29.1% of case subjects and just 16.8% of control 
subjects. The age- and obesity-adjusted prevalence of meta-
bolic syndrome was highest among women (32.1%), South 
Asians (29.8%), and other Asians (28.7%).47
 ● In a report from BIOSHARE-EU, which harmonizes mod-
ern data from 10 different population-based cohorts in 7 
European countries, the age-adjusted prevalence of meta-
bolic syndrome in obese subjects ranged from 24% to 65% 
in women and from 24% to 65% in men. In the obese popu-
lation, the prevalence of metabolic syndrome far exceeded 
the prevalence of metabolically healthy obesity, which had 
a prevalence of 7% to 28% in women and 2% to 19% in 
men. The prevalence of metabolic syndrome varied con-
siderably by European country in the BIOSHARE-EU 
consortium.48
 ● In a recent systematic review of 10 Brazilian studies, the 
weighted mean prevalence of metabolic syndrome in Brazil 
was 29.6%.49
 ● The metabolic syndrome is highly prevalent in modern 
indigenous populations, notably in Brazil49 and Australia. 
The prevalence of metabolic syndrome was estimated to be 
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33.0% in Australian Aborigines and 50.3% in Torres Strait 
Islanders.50
Risk
Youth
 ● Few prospective pediatric studies have examined the future 
risk for CVD or DM according to baseline metabolic syn-
drome status. Data from 771 participants 6 to 19 years 
of age from the NHLBI’s Lipid Research Clinics Princ-
eton Prevalence Study and the Princeton Follow-up Study 
showed that the risk of developing CVD was substantially 
higher among those with metabolic syndrome than among 
those without this syndrome (OR, 14.6; 95% CI, 4.8–45.3) 
who were followed up for 25 years.15
 ● Another analysis of 814 participants in this cohort showed 
that those 5 to 19 years of age who had metabolic syndrome 
at baseline had an increased risk of having DM 25 to 30 
years later compared with those who did not have the syn-
drome at baseline (OR, 11.5; 95% CI, 2.1–63.7).51
 ● Additional data from the Princeton Follow-Up Study, the 
Fels Longitudinal Study, and the Muscatine Study suggest 
that the absence of components of metabolic syndrome 
in childhood has a high negative predictive value for the 
development of metabolic syndrome or DM in adulthood.52
 ● In a study of 6328 subjects from 4 prospective studies, 
compared with people with normal BMI as children and as 
adults, those with consistently high adiposity from child-
hood to adulthood had an increased risk of the following 
metabolic syndrome components: hypertension (RR, 2.7; 
95% CI, 2.2–3.3), low HDL (RR, 2.1; 95% CI, 1.8–2.5), 
elevated triglycerides (RR, 3.0; 95% CI, 2.4–3.8), type 2 
DM (RR, 5.4; 95% CI, 3.4–8.5), and increased carotid IMT 
(RR, 1.7; 95% CI, 1.4–2.2). Those who were overweight or 
obese during childhood but were not obese as adults had no 
increased risk compared with those with consistently nor-
mal BMI.53
 ● In 1757 youths from the Bogalusa Heart Study and the Car-
diovascular Risk in Young Finns Study, those with meta-
bolic syndrome in youth and adulthood were at 3.4 times 
increased risk of high carotid IMT and 12.2 times increased 
risk of type 2 DM in adulthood as those without metabolic 
syndrome at either time. Adults whose metabolic syndrome 
had resolved after their youth were at no increased risk of 
having high IMT or type 2 DM.54
Adults
 ● Consistent with 2 earlier meta-analyses, a recent meta-
analysis of prospective studies concluded that metabolic 
syndrome increased the risk of developing CVD (summary 
RR, 1.78; 95% CI, 1.58–2.00).55 The risk of CVD tended 
to be higher in women (summary RR, 2.63) than in men 
(summary RR, 1.98; P=0.09). On the basis of results from 
3 studies, metabolic syndrome remained a predictor of 
cardiovascular events after adjustment for the individual 
components of the syndrome (summary RR, 1.54; 95% CI, 
1.32–1.79). A more recent meta-analysis among 87 studies 
comprising 951 083 subjects showed an even higher risk of 
CVD associated with metabolic syndrome (summary RR, 
2.35; 95% CI, 2.02–2.73), with significant increased risks 
(RRs ranging from 1.6 to 2.9) for all-cause mortality, CVD 
mortality, MI, and stroke, as well as for those with meta-
bolic syndrome without DM.56
 ● In one of the earlier studies among US adults, mortality fol-
low-up of the second NHANES showed a stepwise increase 
in risk of CHD, CVD, and total mortality across the spec-
trum of no disease, metabolic syndrome (without DM), 
DM, prior CVD, and those with CVD and DM, with an HR 
for CHD mortality of 2.02 (95% CI, 1.42–2.89) associated 
with metabolic syndrome. Increased risk was seen with 
increased numbers of metabolic syndrome risk factors.57
 ● Estimates of RR for CVD generally increase as the number 
of components of metabolic syndrome increases.58 Com-
pared with men without an abnormal component in the 
Framingham Offspring Study, the HRs for CVD were 1.48 
(95% CI, 0.69–3.16) for men with 1 or 2 components and 
3.99 (95% CI, 1.89–8.41) for men with ≥3 components.59 
Among women, the HRs were 3.39 (95% CI, 1.31–8.81) 
for 1 or 2 components and 5.95 (95% CI, 2.20–16.11) for 
≥3 components. Compared with men without a metabolic 
abnormality in the British Regional Heart Study, the HRs 
were 1.74 (95% CI, 1.22–2.39) for 1 component, 2.34 (95% 
CI, 1.65–3.32) for 2 components, 2.88 (95% CI, 2.02–4.11) 
for 3 components, and 3.44 (95% CI, 2.35–5.03) for 4 or 5 
components.58
 ● The cardiovascular risk associated with metabolic syn-
drome varies on the basis of the combination of metabolic 
syndrome components present. Of all possible ways to have 
3 metabolic syndrome components, the combination of 
central obesity, elevated BP, and hyperglycemia conferred 
the greatest risk for CVD (HR, 2.36; 95% CI, 1.54–3.61) 
and mortality (HR, 3.09; 95% CI, 1.93–4.94) in the Fram-
ingham Offspring Study.60
 ● Data from the Aerobics Center Longitudinal Study indicate 
that risk for CVD mortality is increased in men without 
DM who have metabolic syndrome (HR, 1.8; 95% CI, 
1.5–2.0); however, among those with metabolic syndrome, 
the presence of DM is associated with even greater risk 
for CVD mortality (HR, 2.1; 95% CI, 1.7–2.6).61 Analysis 
of data from NCHS was used to determine the number of 
disease-specific deaths attributable to all nonoptimal levels 
of each risk factor exposure by age and sex. The results 
of the analysis of dietary, lifestyle, and metabolic risk fac-
tors show that targeting a handful of risk factors has large 
potential to reduce mortality in the United States.62
 ● Among stable CAD patients in the COURAGE trial, the 
presence of metabolic syndrome was associated with an 
increased risk of death or MI (unadjusted HR, 1.41; 95% 
CI, 1.15–1.73; P=0.001); however, after adjustment for its 
individual components, metabolic syndrome was no longer 
significantly associated with outcome (HR, 1.15; 95% CI, 
0.79–1.68; P=0.46).63
 ● In the INTERHEART case-control study of 26 903 subjects 
from 52 countries, metabolic syndrome was associated 
with an increased risk of MI, both according to the WHO 
(OR, 2.69; 95% CI, 2.45–2.95) and the International Diabe-
tes Federation (OR, 2.20; 95% CI, 2.03–2.38) definitions, 
with a PAR of 14.5% (95% CI, 12.7%–16.3%) and 16.8% 
(95% CI, 14.8%–18.8%), respectively, and associations 
that were similar across all regions and ethnic groups. In 
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addition, the presence of ≥3 risk factors with subthreshold 
values was associated with increased risk of MI (OR, 1.50; 
95% CI, 1.24–1.81) compared with having “normal” val-
ues. Similar results were observed when the International 
Diabetes Federation definition was used.47
 ● In the Three-City Study, among 7612 participants aged ≥65 
years who were followed up for 5.2 years, metabolic syn-
drome was associated with increased total CHD (HR, 1.78; 
95% CI, 1.39–2.28) and fatal CHD (HR, 2.40; 95% CI, 
1.41–4.09); however, metabolic syndrome was not associ-
ated with CHD beyond its individual risk components.64
 ● The United States has a higher prevalence of metabolic 
syndrome and a higher CVD mortality rate than Japan. It is 
estimated that 13.3% to 44% of the excess CVD mortality 
in the Unites States is explained by metabolic syndrome or 
metabolic syndrome–related existing CVD.44
 ● In MESA, among 6603 people aged 45 to 84 years (1686 
[25%] with metabolic syndrome without DM and 881 
[13%] with DM), subclinical atherosclerosis assessed by 
CAC was more severe in people with metabolic syndrome 
and DM than in those without these conditions, and the 
extent of CAC was a strong predictor of CHD and CVD 
events in these groups.65 Furthermore, the progression of 
CAC was greater in people with metabolic syndrome and 
DM than in those without, and progression of CAC pre-
dicted future CVD event risk both in those with metabolic 
syndrome and in those with DM.66,67
 ● In addition to CVD, metabolic syndrome has been associ-
ated with incident AF,68 HF,69 and cognitive decline.70
 ● Although associated with increased risk, the metabolic 
syndrome is not designed to be risk predictive tool and 
should not be compared to dedicated risk prediction tools 
such as the FRS71 or the new 2013 ACC/AHA ASCVD risk 
estimator.72
 ● Metabolic syndrome is associated with increased health-
care use and healthcare-related costs among individuals 
with and without DM. Overall, healthcare costs increase by 
≈24% for each additional metabolic syndrome component 
present.73
Risk Factors
 ● Risk of metabolic syndrome probably begins before birth. 
The Prediction of Metabolic Syndrome in Adolescence 
Study showed that the coexistence of low birth weight, 
small head circumference, and parental history of over-
weight or obesity places children at the highest risk for 
metabolic syndrome in adolescence. Other risk factors 
identified included parental history of DM, gestational 
hypertension in the mother, and lack of breastfeeding.74
 ● In prospective or retrospective cohort studies, the follow-
ing factors have been reported as being directly associated 
with incident metabolic syndrome, defined by one of the 
major definitions: age,23 low educational attainment,75,76 
low socioeconomic status,77 not being able to understand 
or read food labels,78 urbanization,79 smoking,76,77,80,81 
parental smoking,82 low levels of PA,76,77,80,81 low levels of 
physical fitness,83–85 intake of soft drinks,86 intake of diet 
soda,87 magnesium intake,88,89 energy intake,90 carbohydrate 
intake,75,80,91 total fat intake,51,92 Western dietary pattern,87 
meat intake,87 intake of fried foods,87 skipping breakfast,93 
heavy alcohol consumption,94 abstention from alcohol 
use,75 parental history of DM,51 long-term stress at work,95 
pediatric metabolic syndrome,51 obesity or BMI,54,61,65,92,96 
childhood obesity,97 intra-abdominal fat,98 gain in weight 
or BMI,82,92 weight fluctuation,99 heart rate,100 homeostasis 
model assessment,101,102 fasting insulin,101 2-hour insulin,101 
proinsulin,101 oxidized LDL,102 uric acid,103,104 γ-glutamylt
ransferase,103,105,106 alanine transaminase,103,105,107,108 plas-
minogen activator inhibitor-1,109 aldosterone,109 leptin,110 
CRP,111,112 adipocyte–fatty acid binding protein,113 testos-
terone and sex hormone–binding globulin,114,115 active peri-
odontitis,116 and urinary bisphenol A levels.117
 ● The following factors have been reported as being inversely 
associated with incident metabolic syndrome, defined by 
one of the major definitions, in prospective or retrospective 
cohort studies: muscular strength,118 increased PA or physi-
cal fitness,80,119 aerobic training,120 alcohol intake,59,65 fiber 
intake,121 Mediterranean diet,122 dairy consumption,87 hot 
tea consumption (but not sugar-sweetened iced tea),123 vita-
min D intake,124,125 intake of tree nuts,126 avocado intake,127 
potassium intake,128 ability to interpret nutrition labels,78 
insulin sensitivity,101 ratio of aspartate aminotransferase 
to alanine transaminase,107 total testosterone,98,101,129 serum 
25-hydroxyvitamin D,130 sex hormone–binding globu-
lin,98,101,129 and Δ5-desaturase activity.131
 ● In the DESIR cohort, metabolic syndrome was associ-
ated with an unfavorable hemodynamic profile, including 
increased brachial central pulse pressure and increase pulse 
pressure amplification, compared with similar individu-
als with isolated hypertension but without metabolic syn-
drome.132 In MESA, metabolic syndrome was associated 
with major and minor ECG abnormalities, although this 
varied by sex.133
 ● Individuals with metabolic syndrome have a higher degree 
of endothelial dysfunction than individuals with a similar 
burden of traditional cardiovascular risk factors.134 Meta-
bolic syndrome is associated with increased thrombosis, 
including increased resistance to aspirin.135
 ● In modern imaging studies using echocardiography, mag-
netic resonance imaging, cardiac CT, and positron emis-
sion tomography, metabolic syndrome has been shown 
to be closely related to increased epicardial adipose tis-
sues,136 increased visceral fat in other locations,137 high-
risk coronary plaque features including increased necrotic 
core,138 impaired coronary flow reserve,139 and LV diastolic 
dysfunction.140
 ● In >6 years of follow-up in the ARIC Study, 1970 individu-
als (25%) developed metabolic syndrome, and compared 
with the normal-weight group (BMI <25 kg/m2), the ORs 
of developing metabolic syndrome were 2.81 (95% CI, 
2.50–3.17) and 5.24 (95% CI, 4.50–6.12) for the over-
weight (BMI 25–30 kg/m2) and obese (BMI ≥30 kg/m2) 
groups, respectively. Compared with the lowest quartile 
of leisure-time PA, the ORs of developing metabolic syn-
drome were 0.80 (95% CI, 0.71–0.91) and 0.92 (95% CI, 
0.81–1.04) for people in the highest and middle quartiles, 
respectively.141
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Chart 11-1. Secular trend of metabolic syndrome components in the US National Health and Nutrition Examination Survey (NHANES) 
and the Korean NHANES (KNHANES) cohorts over the past decade. BP indicates blood pressure; HDL, high-density lipoprotein choles-
terol; TG, triglycerides; and WC, waist circumference. aSignificant difference between NHANES 2003 to 2006 and NHANES III. bSignificant 
difference between NHANES 2003 to 2006 and NHANES 1999 to 2002. cSignificant difference between KNHANES 2007 and KNHANES 
1998. dSignificant difference between KNHANES 2007 and KNHANES 2001. Source: Lim et al.14
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Chart 11-2. Age-adjusted prevalence of metabolic syndrome in the United States, National Health and Nutrition Examination Survey 
(NHANES) 1999 to 2010. Data derived from Beltrán-Sánchez et al.23
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Chart 11-3. Age-adjusted prevalence of metabolic syndrome among men by race, National Health and Nutrition Examination Survey 
(NHANES) 1999 to 2010. Data derived from Beltrán-Sánchez et al.23
23.9%
28.1%
26.5%
25.2%
27.2%
22.9%
17.4%
19.9%
17.5%
16.3%
17.3%
19.0%
26.8%
33.7%
26.2%
27.2%
31.1%
34.8%
0%
5%
10%
15%
20%
25%
30%
35%
40%
1999-2000 2001-2002 2003-2004 2005-2006 2007-2008 2009-2010
Pe
rc
en
t o
f P
op
ul
at
io
n
Whites Blacks Mexican-Americans
Chart 11-4. Age-adjusted prevalence of metabolic syndrome among women by race, National Health and Nutrition Examination Survey 
(NHANES) 1999 to 2010. Data derived from Beltrán-Sánchez et al.23
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Chart 11-5. Prevalence and trends of the 5 components of metabolic syndrome in the adult US population (≥20 years old), 1999 to 2010, 
by sex (first column), race/ethnicity (second column), and race/ethnicity and sex (third and fourth columns). HDL-C indicates high-
density lipoprotein cholesterol; Mex-Am, Mexican American; and Waist circumf., waist circumference. Shaded areas represent 95% con-
fidence intervals. Source: Beltrán-Sánchez et al.23
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Chart 11-6. Age-standardized prevalence of metabolic syndrome (MetS) and metabolically healthy obesity (MHO) among obese (body 
mass index ≥30 kg/m2) men (A) and women (B) in different cohorts. CHRIS indicates Collaborative Health Research in South Tyrol Study; 
DILGOM, Dietary, Lifestyle, and Genetics Determinants of Obesity and Metabolic Syndrome; EGCUT, Estonian Genome Center of the 
University of Tartu; HUNT2, Nord-Trøndelag Health Study; KORA, Cooperative Health Research in the Region of Augsburg; MICROS, 
Microisolates in South Tyrol Study; NCDS, National Child Development Study; NL, The Netherlands; and PREVEND, Prevention of Renal 
and Vascular End-Stage Disease. Source: van Vliet-Ostaptchouk et al.48
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12 . Chronic Kidney Disease
ICD-10 N18.0. See Tables 12-1 through 12-3.
End-Stage Renal Disease
Prevalence, Incidence, and Risk
(See Tables 12-1 and 12-2.)
ESRD is a condition that is most commonly associated with 
DM or HBP, occurs when the kidneys are functioning at a very 
low level, and is currently defined as the receipt of chronic renal 
replacement treatment such as hemodialysis, peritoneal dialy-
sis, or kidney transplantation. The ESRD population is increas-
ing in size and cost as those with CKD transition to ESRD and 
as a result of changing practice patterns in the United States.
 ● Data from the 2010 annual report of the US Renal Data 
System showed that in 2008, the prevalence of ESRD was 
547 982, with 70% of these prevalent cases being treated 
with hemodialysis.1
 ● In 2008, 112 476 new cases of ESRD were reported.1
 ● In 2008, 17 413 kidney transplants were performed.1
 ● Data from a large cohort of insured patients showed that in 
addition to established risk factors for ESRD, lower hemo-
globin levels, higher serum uric acid levels, self-reported 
history of nocturia, and family history of kidney disease are 
independent risk factors for ESRD.2
 ● Data from a large insured population revealed that among 
adults with a GFR >60 mL·min−1·1.73 m−2 and no evidence 
of proteinuria or hematuria at baseline, risks for ESRD 
increased dramatically with higher baseline BP level, and 
in this same patient population, BP-associated risks were 
greater in men than in women and in blacks than in whites.3
 ● Compared with white patients with similar levels of kidney 
function, black patients are much more likely to progress 
to ESRD and are on average 10 years younger when they 
reach ESRD.4,5
 ● Results from a large community-based population showed 
that higher BMI also independently increased the risk of 
ESRD. The higher risk of ESRD with overweight and obe-
sity was consistent across age, sex, and race and in the pres-
ence or absence of DM, hypertension, or known baseline 
kidney disease.6
Age, Sex, Race, and Ethnicity
 ● The median age of the population with ESRD in 2008 
varied across different racial/ethnic groups: 57.4 years for 
blacks, 58.0 years for Native Americans, 59.3 years for 
Asians, and 60.6 years for whites.1
 ● Treatment of ESRD is more common in men than in women.1
 ● Blacks, Hispanics, Asian Americans, and Native Americans 
have significantly higher rates of ESRD than do whites/
Europeans. Blacks represent nearly 32% of treated patients 
with ESRD.1
Chronic Kidney Disease
Prevalence
 ● CKD, defined as reduced GFR, excess urinary protein excre-
tion, or both, is a serious health condition and a worldwide 
public health problem. The incidence and prevalence of 
CKD are increasing in the United States and are associated 
with poor outcomes and a high cost to the US healthcare 
system. Controversy exists about whether CKD itself inde-
pendently causes incident CVD, but it is clear that people 
with CKD, as well as those with ESRD, represent a popula-
tion at very high risk for CVD events. In fact, individuals 
with CKD are more likely to die of CVD than to transi-
tion to ESRD. The US Renal Data System estimates that by 
2020, >700 000 Americans will have ESRD, with >500 000 
requiring dialysis and >250 000 receiving a transplant.
 ● The National Kidney Foundation Kidney Disease Out-
come Quality Initiative developed guidelines in 2002 that 
provided a standardized definition for CKD. Prevalence 
estimates may differ depending on assumptions used in 
obtaining estimates, including which equation is used to 
estimate GFR and methods for measuring proteinuria.7
 ● The most recent US prevalence estimates of CKD come 
from NHANES 1988 to 1994 and 1999 to 2004 (NCHS) in 
adults ≥20 years of age.8
—The prevalence of CKD in 1999 to 2004 (stages 1 to 5)9 was 
13.1%. This represents an increase from the 10.0% preva-
lence estimate from NHANES 1988 to 1994 (NCHS).
—The prevalence of stage 1 CKD (eGFR ≥90 mL·min−1· 
1.73 m−2 with kidney damage, ie, presence of albumin-
uria) is 1.8%.
Abbreviations Used in Chapter 12
ACTION Acute Coronary Treatment and Intervention Outcomes 
Network
AF atrial fibrillation
AMI acute myocardial infarction
BMI body mass index
BP blood pressure
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DM diabetes mellitus
eGFR estimated glomerular filtration rate
ESRD end-stage renal disease
GFR glomerular filtration rate
HBP high blood pressure
HF heart failure
HR hazard ratio
ICD-10 International Classification of Diseases, 10th Revision
JNC V fifth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure
MI myocardial infarction
NCHS National Center for Health Statistics
NHANES National Health and Nutrition Examination Survey
PAD peripheral arterial disease
RR relative risk
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—The prevalence of stage 2 CKD (eGFR 60–89 
mL·min−1·1.73 m−2 with kidney damage) is 3.2%.
—The prevalence of stage 3 CKD (eGFR 30–59 
mL·min−1·1.73 m−2) is 7.7%.
—The prevalence of stages 4 and 5 CKD (eGFR <29 
mL·min−1·1.73 m−2) is 0.4%.
 ● More than 26 million people (13%) in the United States 
have CKD, and most are undiagnosed.8 Another 20 million 
are at increased risk for CKD.10
Demographics
 ● According to current definitions, the prevalence of CKD 
was higher with older age,1 as follows:
—6.0% for those 20 to 39 years of age
—11.6% for those 40 to 59 years of age
—38.8% for those ≥60 years of age
 ● CKD prevalence was greater among those with DM 
(43.8%) and hypertension (29.4%) than among those with-
out these chronic conditions.1
 ● The prevalence of CKD was slightly higher among Mexi-
can Americans (18.7%) and non-Hispanic blacks (19.9%) 
than among non-Hispanic whites (16.1%). This disparity 
was most evident for those with stage 1 CKD; non-His-
panic whites had a CKD prevalence of 4.2% compared with 
prevalences among Mexican Americans and non-Hispanic 
blacks of 10.2% and 9.4%, respectively.11
Risk Factors
 ● Many traditional CVD risk factors are also risk factors for 
CKD, including older age, male sex, hypertension, DM, 
smoking, and family history of CVD.
 ● Recent evidence suggests that BMI is associated with wors-
ening CKD.
—In a cohort of 652 African American individuals with 
hypertensive nephrosclerosis, BMI was independently 
associated with urine total protein and albumin excretion.12
 ● In addition, both the degree of CKD (ie, eGFR) and urine 
albumin are strongly associated with the progression from 
CKD to ESRD. Furthermore, urine albumin level is associated 
with progression to CKD across all levels of reduced eGFR.13
 ● Other risk factors include systemic conditions such as auto-
immune diseases, systemic infections, and drug exposure, 
as well as anatomically local conditions such as urinary 
tract infections, urinary stones, lower urinary tract obstruc-
tion, and neoplasia. Even after adjustment for these risk 
factors, excess CVD risk remains.14
ESRD/CKD and CVD
(See Table 12-3.)
 ● CVD is the leading cause of death among those with ESRD, 
although the specific cardiovascular cause of death may be 
more likely to be arrhythmic than an AMI, end-stage HF, 
or stroke. CVD mortality is 5 to 30 times higher in dialysis 
patients than in subjects from the general population of the 
same age, sex, and race.15,16
—Individuals with less severe forms of kidney disease are 
also at significantly increased CVD risk independent of 
typical CVD risk factors.17
—CKD is a risk factor for recurrent CVD events.18
—CKD is also a risk factor for AF.19
 ● Studies from a broad range of cohorts demonstrate an asso-
ciation between reduced eGFR and elevated risk of CVD, 
CVD outcomes, and all-cause death17,20–25 that appears to 
be largely independent of other known major CVD risk 
factors.
 ● Although clinical practice guidelines recommend manage-
ment of mineral and bone disorders secondary to CKD, a 
recent meta-analysis suggests that there is no consistent 
association between calcium and parathyroid hormone and 
the risk of death or cardiovascular events.26
 ● Any degree of albuminuria, starting below the microalbu-
minuria cut point, has been shown to be an independent risk 
factor for cardiovascular events, CHF hospitalization, PAD, 
and all-cause death in a wide variety of cohorts.27–32
 ● A recent meta-analysis of 21 published studies of albumin-
uria involving 105 872 participants (730 577 person-years) 
from 14 studies with urine albumin/creatinine ratio mea-
surements and 1 128 310 participants (4 732 110 person-
years) from 7 studies with urine dipstick measurements 
showed that excess albuminuria or proteinuria is indepen-
dently associated with a higher risk of CVD and all-cause 
mortality.33
—People with both albuminuria/proteinuria and reduced 
eGFR are at particularly high risk for CVD, CVD out-
comes, and death.34
—The exact reasons why CKD and ESRD increase the 
risk of CVD have not been completely delineated but 
are clearly multifactorial and likely involve pathological 
alterations in multiple organ systems and pathways.
 ● One potential explanation for the higher CVD event rate in 
patients with CKD is the low uptake of standard therapies 
for patients presenting with MI. In a recent analysis from 
the ACTION registry, patients presenting with CKD had 
a substantially higher mortality rate. In addition, patients 
with CKD were less likely to receive standard therapies for 
the treatment of MI.35
Cost: ESRD
 ● The total annual cost of treating ESRD in the United States 
was $26.8 billion in 2008, which represents nearly 6% of 
the total Medicare budget.1
 ● The total annual cost associated with CKD has not been 
determined accurately to date.
Cystatin C: Kidney Function and CVD
 ● Serum cystatin C, another marker of kidney function, has 
been proposed to be a more sensitive indicator of kid-
ney function than serum creatinine and creatinine-based 
estimating formulas at higher levels of GFR. It is a low-
molecular-weight protein produced at a constant rate by all 
nucleated cells and appears not to be affected significantly 
across age, sex, and levels of muscle mass. Cystatin C is 
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2015 Update: Chapter 12  e153
excreted by the kidneys, filtered through the glomerulus, 
and nearly completely reabsorbed by proximal tubular 
cells.36 Several equations have been proposed using cys-
tatin C alone and in combination with serum creatinine to 
estimate kidney function.37,38
All-Cause Mortality
 ● Elevated levels of cystatin C have been shown to be associ-
ated with increased risk for all-cause mortality in studies 
from a broad range of cohorts.39–41
 ● In addition to GFR and urine albumin-to-creatinine ratio, 
cystatin C provides incremental information for the predic-
tion of ESRD and mortality.
—In a recent analysis of 26 643 US adults, the addition of 
cystatin C to the combination of creatinine and albumin-
to-creatinine ratio resulted in a significant improvement 
in the prediction of both all-cause mortality and the 
development of ESRD.42
Cardiovascular Disease
 ● Data from a large national cohort found higher values of 
cystatin C to be associated with prevalent stroke, angina, 
and MI,43 as well as higher BMI.44
 ● Elevated cystatin C was an independent risk factor for 
HF,45,46 PAD events,47 clinical atherosclerosis, and subclini-
cal measures of CVD in older adults,48 as well as for cardio-
vascular events among those with CHD.39,49
 ● In several diverse cohorts, elevated cystatin C has been 
found to be associated with CVD-related mortality,41,50,51 
including sudden cardiac death.52
 ● In a recent clinical trial of 9270 patients with CKD, the 
effect of lipid-lowering therapy with simvastatin plus ezeti-
mibe was associated with a lower risk for major atheroscle-
rotic events compared with placebo.53 
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Table 12-1. BP and the Adjusted Risk of ESRD Among 
316 675 Adults Without Evidence of Baseline Kidney Disease
JNC V BP Category Adjusted RR (95% CI)
Optimal 1.00 (Reference)
Normal, not optimal 1.62 (1.27–2.07)
High normal 1.98 (1.55–2.52)
Hypertension
  Stage 1 2.59 (2.07–3.25)
  Stage 2 3.86 (3.00–4.96)
  Stage 3 3.88 (2.82–5.34)
  Stage 4 4.25 (2.63–6.86)
BP indicates blood pressure; CI, confidence interval; ESRD, end-stage renal 
disease; JNC V, fifth report of the Joint National Committee on Prevention, 
Detection, Evaluation, and Treatment of High Blood Pressure; and RR, relative risk.
Table 12-2. Multivariable Association Between BMI and Risk 
of ESRD Among 320 252 Adults
BMI, kg/m2 Adjusted RR (95% CI)
18.5–24.9 (Normal weight) 1.00 (Reference)
25.0–29.9 (Overweight) 1.87 (1.64–2.14)
30.0–34.9 (Class I obesity) 3.57 (3.05–4.18)
35.0–39.9 (Class II obesity) 6.12 (4.97–7.54)
≥40.0 (Extreme obesity) 7.07 (5.37–9.31)
BMI indicates body mass index; CI, confidence interval; ESRD, end-stage 
renal disease; and RR, relative risk.
Table 12-3. Adjusted HR for Death of Any Cause, 
Cardiovascular Events, and Hospitalization Among 1 120 295 
Ambulatory Adults, According to eGFR*
Adjusted HR (95% CI)
eGFR, mL·min−1·1.73 m−2
Death of  
Any Cause
Any Cardiovascular 
Event
Any  
Hospitalization
≥60† 1.00 1.00 1.00
45–59 1.2 (1.1–1.2) 1.4 (1.4–1.5) 1.1 (1.1-1.1)
30–44 1.8 (1.7–1.9) 2.0 (1.9–2.1) 1.5 (1.5-1.5)
15–29 3.2 (3.1–3.4) 2.8 (2.6–2.9) 2.1 (2.0–2.2)
<15 5.9 (5.4–6.5) 3.4 (3.1–3.8) 3.1 (3.0–3.3)
CI indicates confidence interval; eGFR, estimated glomerular filtration rate; 
and HR, hazard ratio.
*The analyses were adjusted for age, sex, income, education, use or nonuse 
of dialysis, and presence or absence of prior coronary heart disease, prior 
chronic heart failure, prior ischemic stroke or transient ischemic attack, prior 
peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, a 
serum albumin level of ≤3.5 g/dL, dementia, cirrhosis or chronic liver disease, 
chronic lung disease, documented proteinuria, and prior hospitalizations.
†This group served as the reference group.
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13 . Total Cardiovascular Diseases
ICD-9 390 to 459, 745 to 747, ICD-10 I00 to I99, Q20 to Q28; 
see Glossary (Chapter 27) for details and definitions.
See Tables 13-1 through 13-3 and Charts 13-1 through 13-21.
Prevalence
(See Table 13-1 and Chart 13-1.)
An estimated 85.6 million American adults (>1 in 3) have 
≥1 types of CVD. Of these, 43.7 million are estimated to be 
≥60 years of age. Total CVD includes diseases listed in the 
bullet points below, with the exception of congenital CVD. 
Because of overlap across conditions, it is not possible to add 
these conditions to arrive at a total.
 ● HBP—80.0 million (defined as systolic pressure ≥140 
mm Hg and/or diastolic pressure ≥90 mm Hg, use of anti-
hypertensive medication, or being told at least twice by a 
physician or other health professional that one has HBP).
 ● CHD—15.5 million
—MI (heart attack)—7.6 million
—AP (chest pain)—8.2 million
—HF—5.7 million
—Stroke (all types)—6.6 million
—Congenital cardiovascular defects— 650 000 to 1.3 million
 ● The following age-adjusted race-ethnicity prevalence esti-
mates from the NHIS, NCHS are for diagnosed conditions 
for people ≥18 years of age in 20131:
—Among whites only, 11.1% have HD (Includes CHD, AP, 
MI, or any other heart condition or disease), 6.1% have 
CHD (Includes CHD, AP, or MI), 22.8% have hyperten-
sion, and 2.5% have had a stroke.
—Among blacks or African Americans, 10.3% have HD, 
6.3% have CHD, 32.6% have hypertension, and 3.6% 
have had a stroke.
—Among Hispanics or Latinos, 8.3% have HD, 5.4% have 
CHD, 21.6% have hypertension, and 2.6% have had a stroke.
—Among Asians, 6.1% have HD, 3.7% have CHD, 21.0% 
have hypertension, and 1.9% have had a stroke.
—Among American Indians or Alaska Natives, 8.2% have HD 
and 26.2% have hypertension. The statistics for CHD and 
stroke for this group are not shown because of unreliability.*
 ● Asian Indian adults (9%) are ≈2-fold more likely than 
Korean adults (4%) to have ever been told they have HD, 
based on data for 2004 to 2006.2
 ● By 2030, 43.9% of the US population is projected to have 
some form of CVD (unpublished AHA tabulation, based on 
methodology described by Heidenreich et al2).
Incidence
(See Chart 13-2.)
 ● On the basis of the NHLBI’s FHS original and offspring 
cohort data from 1980 to 20033
—The average annual rate of first cardiovascular events 
rises from 3 per 1000 men at 35 to 44 years of age to 
74 per 1000 men at 85 to 94 years of age. For women, 
comparable rates occur 10 years later in life. The age 
gap narrows with advancing age.
—Before 75 years of age, a higher proportion of CVD 
events attributable to CHD occur in men than in women, 
and a higher proportion of events attributable to stroke 
occur in women than in men.
Abbreviations Used in Chapter 13
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities 
ASCVD atherosclerotic cardiovascular disease
BMI body mass index
BP blood pressure
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CLRD chronic lower respiratory disease
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
FHS Framingham Heart Study
HBP high blood pressure
HD heart disease
HDL high-density lipoprotein
HF heart failure
HIV human immunodeficiency virus
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LDL low-density lipoprotein
MEPS Medical Expenditure Panel Survey
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHHCS National Home and Hospice Care Survey
NHLBI National Heart, Lung, and Blood Institute
PA physical activity
RR relative risk
SBP systolic blood pressure
SE standard error
SHS Strong Heart Study
WONDER Wide-ranging Online Data for Epidemiologic Research
*Statistics 12.5% and 10.3% are statistically unreliable (relative SE 
>30% and <50%). The statistic not shown has a relative SE >50%.
Click here to go to the Table of Contents
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 ● Among American Indian men 45 to 74 years of age in the 
SHS, the incidence of CVD ranges from 20 to 28 per 1000 
population. Among women, it ranges from 9 to 15 per 1000.4
 ● Data from the FHS indicate that the subsequent lifetime risk for 
all CVD in recipients starting free of known disease is almost 2 
in 3 for men and >1 in 2 for women at 45 years of age.5
 ● Analysis of FHS data among participants free of CVD at 50 
years of age showed the lifetime risk for developing CVD 
was 51.7% for men and 39.2% for women. Median overall 
survival was 30 years for men and 36 years for women.6
Mortality
(See Tables 13-1 through 13-3 and Charts 13-3 through 13-18.)
ICD-10 I00 to I99, Q20 to Q28 for CVD; C00 to C97 for 
cancer; C33 to C34 for lung cancer; C50 for breast cancer; 
J40 to J47 for CLRD; G30 for Alzheimer disease; E10 to E14 
for DM; and V01 to X59 and Y85 to Y86 for accidents.
 ● In every year since 1900 except 1918, CVD accounted for 
more deaths than any other major cause of death in the 
United States.7,8
 ● Based on 2011 mortality data8
—CVD as the listed underlying cause of death accounted 
for 31.3% (786 641) of all 2 515 458 deaths, or ≈1 of 
every 3 deaths in the United States. CVD any-mentions 
(1 361 165 deaths in 2011) constituted 54.1% of all 
deaths that year (NHLBI; NCHS public use data files).
—On average, >2150 Americans die of CVD each day, an 
average of 1 death every 40 seconds.
—CVD currently claims more lives each year than cancer 
and CLRD combined.
—The death rate attributable to CVD was 229.6 per 100 000.
—The death rates were 275.7 for males and 192.3 for 
females. The rates were 271.9 for white males, 352.4 for 
black males, 188.1 for white females, and 248.6 for black 
females.
—From 2001 to 2011, death rates attributable to CVD 
declined 30.8%. In the same 10-year period, the actual 
number of CVD deaths per year declined by 15.5% 
(NHLBI tabulation).
—Among other causes of death, cancer caused 576 691 
deaths; CLRD, 142 943; accidents, 126 438; and 
Alzheimer disease, 84 974.
—The leading causes of death in women ≥65 years of age 
were diseases of the heart (No. 1), cancer (No. 2), stroke 
(No. 3), and CLRD (No. 4). In older men, they were 
diseases of the heart (No. 1), cancer (No. 2), CLRD (No. 
3), and stroke (No. 4).9
—CVD (including congenital cardiovascular defects) 
caused ≈1 death per minute among females, or 398 035 
deaths. That represents approximately the same num-
ber of female lives as were claimed by cancer, CLRD, 
and DM combined (unpublished NHLBI tabulation). 
There were 40 931 deaths attributable to breast cancer 
in females; lung cancer claimed 70 243 females. Death 
rates for females were 21.6 for breast cancer and 37.1 for 
lung cancer. One in 30.8 deaths of females was attribut-
able to breast cancer, whereas 1 in 7.5 was attributable to 
CHD. For comparison, 1 in 4.6 females died of cancer, 
whereas 1 in 3.2 died of CVD.
—Approximately 155 000 Americans who were <65 years 
of age died of CVD, and 34% of deaths attributed to 
CVD occurred before the age of 75 years, which is well 
below the average life expectancy of 78.7 years.
 ● If all forms of major CVD were eliminated, life expectancy 
could rise by almost 7 years. If all forms of cancer were 
eliminated, the estimated gain could be 3 years. Accord-
ing to the same study, the probability at birth of eventu-
ally dying of major CVD (ICD-10 I00–I78) is 47%, and the 
chance of dying of cancer is 22%. Additional probabilities 
are 3% for accidents, 2% for DM (unrelated to CVD), and 
0.7% for HIV.10
 ● A study of the decrease in US deaths attributable to CHD 
from 1980 to 2000 suggests that ≈47% of the decrease was 
attributable to increased use of evidence-based medical 
therapies for secondary prevention and 44% to changes in 
risk factors in the population attributable to lifestyle and 
environmental changes.7
 ● Analysis of data from NCHS was used to determine the 
number of disease-specific deaths attributable to all non-
optimal levels of each risk factor exposure, by age and sex. 
In 2005, tobacco smoking and HBP were estimated to be 
responsible for 467 000 deaths, accounting for ≈1 in 5 or 6 
deaths among US adults. Overweight/obesity and physical 
inactivity were each estimated to be responsible for nearly 
1 in 10 deaths. High dietary salt, low dietary omega-3 fatty 
acids, and high dietary trans fatty acids were the dietary 
risks with the largest estimated excess mortality effects.10
Aftermath
 ● Among the estimated 45 million people with functional 
disabilities in the United States, HD, stroke, and hyperten-
sion are among the 15 leading conditions that caused those 
disabilities. Disabilities were defined as difficulty with 
activities of daily living or instrumental activities of daily 
living, specific functional limitations (except vision, hear-
ing, or speech), and limitation in ability to do housework or 
work at a job or business.11
Awareness of Warning Signs and Risk Factors  
for CVD
 ● Surveys conducted every 3 years since 1997 by the AHA 
to evaluate trends in women’s awareness, knowledge, and 
perceptions related to CVD found most recently (in 2012) 
that awareness of HD as the leading cause of death among 
women was 56%, 30% higher than in 1997 (P<0.001). 
Awareness among black and Hispanic women in 2012 was 
similar to that of white women in 1997; however, awareness 
rates in 2012 among black and Hispanic women remained 
well below that of white women. Awareness of heart attack 
signs remained low for all racial/ethnic and age groups sur-
veyed during the same time.12
Disparities in CVD Risk Factors
(See Chart 13-19.)
 ● Analysis of several data sets by the CDC showed that in 
adults ≥18 years of age, disparities were common in all 
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risk factors examined. In men, the highest prevalence of 
obesity (29.7%) was found in Mexican Americans who had 
completed a high school education. Black women with or 
without a high school education had a high prevalence of 
obesity (48.4%). Hypertension prevalence was high among 
blacks (41.2%) regardless of sex or educational status. 
Hypercholesterolemia was high among white and Mexican 
American men and white women regardless of educational 
status. CHD and stroke were inversely related to educa-
tion, income, and poverty status. Hospitalization for total 
HD and AMI was greater among men, but hospitalization 
for CHF and stroke was greater among women. Among 
Medicare enrollees, CHF hospitalization was higher among 
blacks, Hispanics, and American Indian/Alaska Natives 
than among whites, and stroke hospitalization was highest 
among blacks. Hospitalizations for CHF and stroke were 
highest in the southeastern United States. Life expectancy 
remains higher in women than in men and in whites than in 
blacks by ≈5 years. CVD mortality at all ages tended to be 
highest in blacks.13
 ● Analysis of >14 000 middle-aged subjects in the ARIC 
study sponsored by the NHLBI showed that >90% of CVD 
events in black subjects, compared with ≈70% in white 
subjects, appeared to be explained by elevated or borderline 
risk factors. Furthermore, the prevalence of participants 
with elevated risk factors was higher in black subjects; 
after accounting for education and known CVD risk fac-
tors, the incidence of CVD was identical in black and white 
subjects. Although organizational and social barriers to 
primary prevention do exist, the primary prevention of ele-
vated risk factors might substantially impact the future inci-
dence of CVD, and these beneficial effects would likely be 
applicable not only for white but also for black subjects.14
 ● Data from the MEPS 2004 Full-Year Data File showed that 
nearly 26 million US adults ≥18 years of age were told by 
a doctor that they had HD, stroke, or any other heart-related 
disease15:
—Among those told that they had HD, 33.9% had a healthy 
weight compared with 39.3% who had never been told 
they had HD.
—Among those ever told that they had indicators of HD, 
18.3% continued to smoke.
—More than 93% engaged in at least 1 recommended 
behavior for prevention of HD (not smoking, engaging 
in physical exercise regularly, and maintaining healthy 
weight): 75.5% engaged in 1 or 2; 18% engaged in all 
3; and 6.5% did not engage in any of the recommended 
behaviors.
—Age-based variations:
 ◯ Moderate to vigorous PA ≥3 times per week varied 
according to age. Younger people (18–44 years of 
age) were more likely (59.9%) than those who were 
older (45–64 and ≥65 years of age, 55.3% and 48.5%, 
respectively) to engage in regular PA.
 ◯ A greater percentage of those 18 to 44 years of age 
had a healthy weight (43.7%) than did those 45 to 64 
years of age and ≥65 years of age (31.4% and 37.3%, 
respectively).
 ◯ People ≥65 years of age were more likely to be non-
smokers (89.7%) than were people 18 to 44 years 
of age and 45 to 64 years of age (76.1% and 77.7%, 
respectively).
—Race/ethnicity-based variations:
 ◯ Non-Hispanic whites were more likely than His-
panics or non-Hispanic blacks to engage in moder-
ate to vigorous PA (58.5% versus 51.4% and 52.5%, 
respectively).
 ◯ Non-Hispanic whites were more likely to have main-
tained a healthy weight than were Hispanics or non-
Hispanic blacks (39.8% versus 32.1% and 29.7%, 
respectively).
 ◯ Hispanics were more likely to be nonsmokers (84.2%) 
than were non-Hispanic whites and non-Hispanic 
blacks (77.8% and 76.3%, respectively).
—Sex-based variations:
 ◯ Men were more likely to have engaged in moderate to 
vigorous PA ≥3 times per week than women (60.3% 
versus 53.1%, respectively).
 ◯ Women were more likely than men to have maintained 
a healthy weight (45.1% versus 31.7%, respectively).
 ◯ 81.7% of women did not currently smoke, compared 
with 75.7% of men.
—Variations based on education level:
 ◯ A greater percentage of adults with at least some col-
lege education engaged in moderate to vigorous PA 
≥3 times per week (60.8%) than did those with a high 
school education or less than a high school education 
(55.3% and 48.3%, respectively).
 ◯ A greater percentage of adults with at least some col-
lege education had a healthy weight (41.2%) than did 
those with a high school or less than high school edu-
cation (36.2% and 36.1%, respectively).
 ◯ There was a greater percentage of nonsmokers among 
those with a college education (85.5%) than among 
those with a high school or less than high school edu-
cation (73.8% and 69.9%, respectively).
 ● A study of nearly 1500 participants in MESA found that 
Hispanics with hypertension, hypercholesterolemia, or DM 
who spoke Spanish at home (as a proxy of lower levels 
of acculturation) or had spent less than half a year in the 
United States had higher SBP, LDL cholesterol, and fast-
ing blood glucose, respectively, than Hispanics who were 
preferential English speakers and who had lived a longer 
period of time in the United States.16
 ● Recent findings from >15 000 Hispanics of diverse back-
ground demonstrated that a sizeable proportion of both men 
and women had major CVD risk factors, with higher preva-
lence among Puerto Rican subgroups and those with lower 
socioeconomic status and a higher level of acculturation.17
Family History of CVD
(See Chapter 7 for more detailed information.)
 ● A family history of CVD increases risk of CVD, with the 
largest increase in risk if the family member’s CVD was 
premature.18
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 ● There is consistent evidence from multiple large-scale pro-
spective epidemiology studies for a strong and significant 
association of a reported family history of premature paren-
tal CHD with incident MI or CHD in offspring. In the FHS, 
the occurrence of a validated premature ASCVD event in 
either a parent19 or a sibling20 was associated with an ≈2-
fold elevated risk for CVD, independent of other traditional 
risk factors. Addition of a family history of premature CVD 
to a model that contained traditional risk factors provided 
improved prognostic value in the FHS.19
 ● Parental history of premature CHD is associated with 
increased burden of subclinical atherosclerosis in the coro-
nary arteries and the abdominal aorta.21,22
 ● In the FHS, a parental history of validated HF was associ-
ated with a 1.7-fold higher risk of HF in offspring, after 
multivariable adjustment.23
 ● Despite the importance of family history, several barriers 
impede first-degree relatives of people with CVD from 
engaging in risk-reducing behaviors, such as few being 
aware of the specific health information from relatives 
necessary to develop a family history; in addition, there is 
an inappropriate risk perception or an underestimation of 
one’s own sense of vulnerability.24
Impact of Healthy Lifestyle and Low Risk Factor 
Levels
(See Chapter 2 for more detailed statistics regarding healthy 
lifestyles and low risk factor levels.)
A number of studies suggest that prevention of risk factor 
development at younger ages may be the key to “success-
ful aging,” and they highlight the need for evaluation of the 
potential benefits of intensive prevention efforts at younger 
and middle ages once risk factors develop to increase the like-
lihood of healthy longevity.
 ● Approximately 80% of CVDs can be prevented through not 
smoking, eating a healthy diet, engaging in PA, maintaining 
a healthy weight, and controlling HBP, DM, and elevated 
lipid levels.
 ● Data from the Cardiovascular Lifetime Risk Pooling Proj-
ect, which involved 18 cohort studies and combined data on 
257 384 black men and women and white men and women, 
indicate that at 45 years of age, participants with optimal 
risk factor profiles had a substantially lower lifetime risk 
of CVD events than those with 1 major risk factor (1.4% 
versus 39.6% among men; 4.1% versus 20.2% among 
women). Having ≥2 major risk factors further increased 
lifetime risk to 49.5% in men and 30.7% in women.25
 ● In another study, FHS investigators followed up 2531 men 
and women who were examined between the ages of 40 
and 50 years and observed their overall rates of survival 
and survival free of CVD to 85 years of age and beyond. 
Low levels of the major risk factors in middle age were 
associated with overall survival and morbidity-free survival 
to ≥85 years of age.26
 ● Data from the Chicago Heart Association Detection Proj-
ect (1967–1973, with an average follow-up of 31 years) 
showed the following:
—In younger women (18–39 years of age) with favorable 
levels for all 5 major risk factors (BP, serum cholesterol, 
BMI, DM, and smoking), future incidence of CHD and 
CVD is rare, and long-term and all-cause mortality are 
much lower than for those who have unfavorable or ele-
vated risk factor levels at young ages. Similar findings 
applied to men in this study.27
—Participants (18–64 years of age at baseline) without a 
history of MI were investigated to determine whether 
traditional CVD risk factors were similarly associated 
with CVD mortality in black and white men and women. 
In general, the magnitude and direction of associations 
were similar by race. Most traditional risk factors dem-
onstrated similar associations with mortality in black 
and white adults of the same sex. Small differences 
were primarily in the strength and not the direction of 
the association.28
 ● However, data from NHANES 1999 to 2002 showed that 
only approximately one third of adults complied with ≥6 of 
the recommended heart-healthy behaviors. Dietary recom-
mendations in general and daily fruit intake recommenda-
tions in particular were least likely to be followed.29
 ● Seventeen-year mortality data from the NHANES II Mor-
tality Follow-Up Study indicated that the RR for fatal CHD 
was 51% lower for men and 71% lower for women with 
none of the 3 major risk factors (hypertension, current 
smoking, and elevated total cholesterol [≥240 mg/dL]) than 
for those with ≥1 risk factor. Had all 3 major risk factors 
not occurred, it is hypothesized that 64% of all CHD deaths 
among women and 45% of CHD deaths in men could have 
been avoided.30
Hospital Discharges, Ambulatory Care Visits, Home 
Healthcare Patients, Nursing Home Residents, and 
Hospice Care Discharges
(See Table 13-1 and Charts 13-20 and 13-21.)
 ● From 2000 to 2010, the number of inpatient discharges from 
short-stay hospitals with CVD as the first-listed diagnosis 
decreased from 6 294 000 to 5 802 000 (NHDS, NCHS, 
and NHLBI). In 2010, CVD ranked highest among all dis-
ease categories in hospital discharges (NHDS, NCHS, and 
NHLBI).
 ● In 2010, there were 75 432 000 physician office visits with 
a primary diagnosis of CVD (NCHS, NAMCS, NHLBI 
tabulation). In 2010, there were 4 640 000 ED visits and 
7 829 000 hospital outpatient department visits with a pri-
mary diagnosis of CVD (NHAMCS, NHLBI tabulation).
 ● Among the 1 459 900 home healthcare patients each day in 
2007, CVD was the leading primary diagnosis; almost one 
fifth of home healthcare patients had a primary diagnosis of 
CVD at admission into home health care (18.3% or 267 300 
residents) or at the time of interview (18.9% or 275 700 res-
idents) (NCHS, NHHCS). The majority (62.9% or 918 900 
patients) of home healthcare patients each day in 2007 had 
any diagnosis of CVD at the time of interview.31
 ● Among the 1 045 100 patients discharged from hospice 
in 2007, CVD was the primary diagnosis for 15.8% (or 
165 100 discharges) at admission and 15.9% (or 165 700 
discharges) at discharge. Half (50% or 523 000) of all hos-
pice discharges had any diagnosis of CVD at the time of 
discharge.31
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Operations and Procedures
(See Chapter 24 for detailed information.)
 ● In 2010, an estimated 7 588 000 inpatient cardiovascular 
operations and procedures were performed in the United 
States; 4.4 million were performed on males, and 3.2 mil-
lion were performed on females (NHLBI tabulation of 
NHDS, NCHS).
Cost
(See Chapter 25 for detailed information.)
 ● The estimated direct and indirect cost of CVD for 2011 is 
$320.1 billion (MEPS, NHLBI tabulation).
 ● By 2030, (2012$) total direct medical costs of CVD are 
projected to increase to ≈$918 billion (unpublished AHA 
tabulation based on methodology described by Heidenreich 
et al2).
Global Burden of CVD
(See Table 13-3.)
 ● CVD is the leading global cause of death, accounting for 
17.3 million deaths per year, a number that is expected to 
grow to >23.6 million by 2030.32
 ● In 2008, CVD deaths represented 30% of all global deaths.32
 ● Eighty percent of CVD deaths take place in low- and mid-
dle-income countries and occur almost equally in men and 
women.32
 ● In May 2012, during the World Health Assembly, Ministers 
of Health agreed to adopt a global target to reduce prema-
ture (age 30–70 years) noncommunicable disease mortal-
ity 25% by 2025.33 Targets for 6 risk factors (tobacco and 
alcohol use, salt intake, obesity, and raised BP and glucose) 
were also agreed on to address this goal. It is projected that 
if the targets are met, premature death attributable to CVDs 
in 2025 will be reduced by 34%, with 11.4 million and 15.9 
million deaths delayed or prevented in those aged 30 to 69 
years and ≥70 years, respectively.34
 ● In 2010, the estimated global cost of CVD was $863 bil-
lion, and this cost is estimated to rise to $1044 billion by 
2030.35
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Table 13-1. Cardiovascular Diseases
Population Group Prevalence, 2012: Age ≥20 y Mortality, 2011: All Ages*
Hospital Discharges, 
2010: All Ages Cost, 2011
Both sexes 85 600 000 (35.0%) 786 641 5 802 000 $320.1 Billion
  Males 41 800 000 (36.4%) 388 606 (49.4%)† 3 021 000 …
  Females 43 800 000 (33.7%) 398 035 (50.6%)† 2 781 000 …
NH white males 36.1% 331 751 … …
NH white females 31.9% 340 803 … …
NH black males 46.0% 46 081 … …
NH black females 48.3% 47 130 … …
Hispanic males 32.4% * … …
Hispanic females 32.5% * … …
Asian or Pacific Islander … 17 050‡ … …
American Indian or Alaska Native … 3826 … …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of Hispanic and non-
Hispanic origin. Numbers of deaths for the American Indian or Alaska Native and Asian or Pacific Islander populations are known to be underestimated. Death rates for 
Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies in reporting Hispanic 
origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death certificates of American 
Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total cardiovascular disease mortality that is attributable to males vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health Statistics (NCHS) and National Heart, Lung, and 
Blood Institute (NHLBI). Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 
US population estimates. Mortality: Centers for Disease Control and Prevention/NCHS, 2011 Mortality Multiple Cause-of-Death–United States. These data represent 
underlying cause of death only for International Classification of Diseases, 10th Revision codes I00 to I99 (diseases of the circulatory system) and Q20 to Q28 (congenital 
malformations of the circulatory system). Hospital discharges: National Hospital Discharge Survey, NCHS. Data include those inpatients discharged alive, dead, or of 
unknown status. Cost: NHLBI. Data include estimated direct and indirect costs for 2011.
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Table 13-2. Age-Adjusted Death Rates per 100 000 Population for CVD, CHD, and Stroke by State, 2009–2011
CVD* CHD† Stroke‡
State Rank§ Death Rate
% Change, 
2000–2002 to 
2009–2011 Rank§ Death Rate
% Change, 
2000–2002 to 
2009–2011 Rank§ Death Rate
% Change, 
2000–2002 to 
2009–2011
Alabama 51 306.7 −20.9 26 107.4 −32.1 51 51.5 −26.2
Alaska 16 208.6 −23.4 8 85.8 −30.4 31 40.6 −32.1
Arizona 8 199.6 −28.8 28 108.5 −31.1 5 31.4 −37.9
Arkansas 49 289.8 −24.0 48 143.6 −24.1 52 52.4 −31.5
California 25 218.7 −31.4 30 110.5 −39.5 20 37.6 −39.2
Colorado 3 184.2 −32.3 4 78.0 −36.5 12 35.3 −37.3
Connecticut 11 200.8 −31.3 11 89.5 −41.8 2 30.0 −38.9
Delaware 30 232.5 −28.9 35 117.1 −38.0 34 41.3 −22.1
District of 
Columbia
44 265.2 −29.5 49 147.4 −30.1 10 33.8 −28.2
Florida 15 207.8 −31.3 29 109.3 −39.7 7 32.5 −32.6
Georgia 41 257.4 −30.5 10 89.0 −43.2 44 45.3 −35.1
Hawaii 4 189.0 −29.5 3 72.7 −32.9 18 37.4 −39.1
Idaho 21 213.7 −26.5 14 93.6 −33.9 33 40.8 −34.6
Illinois 32 236.2 −30.0 31 110.8 −39.3 24 38.9 −34.7
Indiana 40 254.6 −27.5 33 116.6 −34.5 41 44.2 −32.6
Iowa 29 228.8 −25.9 43 125.7 −29.9 22 38.0 −35.2
Kansas 27 225.4 −28.6 15 95.0 −36.2 35 41.3 −31.8
Kentucky 45 274.5 −28.6 44 126.2 −34.5 43 45.1 −31.6
Louisiana 48 288.0 −22.0 39 121.9 −32.3 45 46.0 −28.5
Maine 13 202.3 −32.4 13 92.3 −40.9 16 36.1 −35.0
Maryland 31 235.7 −29.5 38 120.1 −35.2 23 38.7 −35.8
Massachusetts 6 195.9 −30.8 12 92.0 −35.0 4 31.3 −37.4
Michigan 42 261.2 −27.9 46 135.6 −33.6 27 39.3 −34.3
Minnesota 1 170.7 −31.4 1 67.5 −40.4 11 35.1 −34.4
Mississippi 52 323.3 −25.2 41 124.3 −38.2 50 50.2 −30.4
Missouri 43 262.2 −27.9 45 133.2 −31.9 40 44.1 −30.4
Montana 17 208.6 −25.6 9 87.7 −27.0 29 39.7 −34.4
Nebraska 18 208.7 −29.2 7 82.8 −35.0 26 39.1 −30.4
Nevada 37 249.7 −25.4 21 100.6 −34.0 13 35.4 −37.3
New 
Hampshire
9 199.9 −35.1 16 95.1 −47.0 9 33.3 −37.8
New Jersey 28 227.0 −29.9 36 117.1 −38.6 8 32.9 −28.5
New Mexico 12 201.2 −24.9 22 102.3 −30.3 14 35.6 −25.2
New York 36 246.8 −28.5 50 149.5 −35.4 1 27.5 −29.8
North Carolina 33 236.5 −31.8 27 107.4 −38.6 42 45.0 −38.4
North Dakota 19 210.7 −27.5 25 106.8 −33.7 28 39.4 −31.2
Ohio 38 252.4 −29.0 40 123.1 −36.7 37 41.9 −30.1
Oklahoma 50 299.1 −26.1 52 150.9 −33.9 49 48.6 −28.3
Oregon 7 198.4 −31.9 6 79.2 −39.3 36 41.7 −41.1
Pennsylvania 35 244.2 −28.2 34 116.9 −36.3 30 39.9 −30.0
Puerto Rico 2 179.6 −27.5 5 80.5 −35.5 15 35.9 −25.8
Rhode Island 20 212.9 −31.9 42 125.4 −39.8 3 30.7 −34.4
South Carolina 39 253.8 −28.7 24 106.0 −36.6 48 48.4 −37.4
South Dakota 24 218.6 −26.4 37 119.4 −24.9 32 40.7 −27.8
Tennessee 46 280.0 −27.9 51 150.2 −31.0 47 48.3 −35.1
(Continued)
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Texas 34 238.7 −31.2 32 111.2 −40.7 39 43.8 −32.6
Utah 5 194.8 −28.0 2 71.4 −33.8 19 37.5 −37.9
Vermont 10 200.1 −32.5 23 103.0 −35.9 6 31.5 −40.1
Virginia 26 225.4 −30.3 18 95.7 −37.3 38 42.1 −35.5
Washington 14 203.6 −30.6 19 99.8 −34.6 17 37.1 −45.3
West Virginia 47 282.4 −27.0 47 136.8 −35.1 46 46.4 −22.9
Wisconsin 22 217.6 −29.7 20 100.2 −35.8 21 37.9 −37.9
Wyoming 23 217.9 −24.8 17 95.6 −31.5 25 39.0 −30.2
Total United 
States
234.5 −29.4 113.4 −36.9 38.9 −33.8
CHD indicates coronary heart disease; and CVD, cardiovascular disease.
*CVD is defined here as International Classification of Diseases, 10th Revision (ICD-10) codes I00 to I99.
†CHD is defined here as ICD-10 codes I20 to I25.
‡Stroke is defined here as ICD-10 codes I60 to I69.
§Rank is lowest to highest.
Source: Centers for Disease Control and Prevention (CDC) Wide-Ranging Online Data for Epidemiologic Research (WONDER), 2009 to 2011. Data provided by personal 
communication with the National Heart, Lung, and Blood Institute. Additional resources: The Agency for Healthcare Research and Quality has released state-level data 
for heart disease for all 50 states and the District of Columbia; the data are taken from the congressionally mandated National Healthcare Quality Report.36 In addition, 
the Women’s Health and Mortality Chartbook of the National Center for Health Statistics has state-related data for women.37 Metropolitan/micropolitan area risk data 
are available for 500 such areas nationwide.38 Behavioral Risk Factor Surveillance System data are also collected within each state.39 The CDC has the Geographic 
Information Systems, which provides mortality rates down to the county level, by sex and ethnicity.40 The 2008 Atlas of Stroke Hospitalizations Among Medicare 
Beneficiaries is a new resource that provides data down to the county level, by sex and race.41
Table 13-2. Continued
CVD* CHD† Stroke‡
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Table 13-3. International Death Rates (Revised March 2014): Death Rates (per 100 000 Population) for Total CVD, CHD, Stroke, and 
Total Deaths in Selected Countries (Most Recent Year Available)
Sorted Alphabetically by 
Country CVD CHD Stroke Total
Sorted by Descending 
CVD Death Rate CVD CHD Stroke Total
Men aged 35–74 y
  Argentina (2010) 305.6 88.8 62.9 1062.8 Russian Federation 
(2010)
1173.3 654.8 299.2 2400.7
  Australia (2011) 126.1 76.9 18.7 530.3 Ukraine (2012) 1067.2 718.1 216.6 2069.3
  Austria (2011) 182.4 108.9 23.7 700.6 Romania (2010) 657.9 268.2 195.9 1548.4
  Belgium (2010) 167.6 73.5 28.2 751.9 Hungary (2012) 524.8 280.1 101.0 1459.5
  Brazil (2010) 347.7 134.5 95.8 1143.9 Czech Republic (2012) 359.2 192.1 54.2 1001.1
  Canada (2009) 154.4 101.9 19.2 607.9 Brazil (2010) 347.7 134.5 95.8 1143.9
  Chile (2009) 220.5 91.7 63.4 864.6 Cuba (2010) 347.5 175.4 80.1 957.5
  Cuba (2010) 347.5 175.4 80.1 957.5 Argentina (2010) 305.6 88.8 62.9 1062.8
  Czech Republic (2012) 359.2 192.1 54.2 1001.1 Finland (2011) 261.0 153.9 39.6 772.7
  Denmark (2011) 146.0 62.0 29.1 722.0 United States (2011) 235.5 132.4 27.5 815.9
  Finland (2011) 261.0 153.9 39.6 772.7 Mexico (2010) 224.1 130.9 46.0 1022.6
  France (2010) 127.1 48.9 23.3 740.1 Chile (2009) 220.5 91.7 63.4 864.6
  Germany (2012) 197.1 97.2 27.3 721.8 Ireland (2009) 210.0 140.6 29.2 701.3
  Hungary (2012) 524.8 280.1 101.0 1459.5 United Kingdom (2010) 197.5 121.1 29.8 673.6
  Ireland (2009) 210.0 140.6 29.2 701.3 Germany (2012) 197.1 97.2 27.3 721.8
  Israel (2011) 118.7 60.1 25.4 574.7 New Zealand (2009) 184.4 121.1 26.5 605.2
  Italy (2010) 145.6 68.4 27.8 585.1 Austria (2011) 182.4 108.9 23.7 700.6
  Japan (2011) 142.7 47.0 49.0 611.5 Belgium (2010) 167.6 73.5 28.2 751.9
  Korea, South (2011) 123.4 36.5 54.7 736.3 Sweden (2010) 165.1 93.1 26.3 556.1
  Mexico (2010) 224.1 130.9 46.0 1022.6 Canada (2009) 154.4 101.9 19.2 607.9
  Netherlands (2011) 136.8 53.1 21.9 586.6 Portugal (2011) 148.1 55.0 53.7 777.7
  New Zealand (2009) 184.4 121.1 26.5 605.2 Denmark (2011) 146.0 62.0 29.1 722.0
  Norway (2012) 136.4 71.1 22.5 555.9 Italy (2010) 145.6 68.4 27.8 585.1
  Portugal (2011) 148.1 55.0 53.7 777.7 Japan (2011) 142.7 47.0 49.0 611.5
  Romania (2010) 657.9 268.2 195.9 1548.4 Spain (2011) 141.5 65.3 26.2 651.6
  Russian Federation (2010) 1173.3 654.8 299.2 2400.7 Netherlands (2011) 136.8 53.1 21.9 586.6
  Spain (2011) 141.5 65.3 26.2 651.6 Norway (2012) 136.4 71.1 22.5 555.9
  Sweden (2010) 165.1 93.1 26.3 556.1 Switzerland (2010) 131.6 67.7 16.3 538.1
  Switzerland (2010) 131.6 67.7 16.3 538.1 France (2010) 127.1 48.9 23.3 740.1
  Ukraine (2012) 1067.2 718.1 216.6 2069.3 Australia (2011) 126.1 76.9 18.7 530.3
  United Kingdom (2010) 197.5 121.1 29.8 673.6 Korea, South (2011) 123.4 36.5 54.7 736.3
  United States (2011) 235.5 132.4 27.5 815.9 Israel (2011) 118.7 60.1 25.4 574.7
Women aged 35–74 y
  Argentina (2010) 139.7 28.4 35.5 574.3 Russian Federation 
(2010)
466.0 226.3 155.0 915.7
  Australia (2011) 52.3 21.6 13.5 318.3 Ukraine (2012) 454.2 294.7 115.8 833.7
  Austria (2011) 69.7 32.0 14.4 361.3 Romania (2010) 312.2 105.8 111.4 692.3
  Belgium (2010) 78.5 24.3 20.4 419.8 Hungary (2012) 218.4 105.7 48.9 672.1
  Brazil (2010) 205.1 63.9 63.0 638.9 Cuba (2010) 209.2 90.1 61.0 613.8
  Canada (2009) 65.9 33.1 14.5 388.1 Brazil (2010) 205.1 63.9 63.0 638.9
  Chile (2009) 103.5 29.5 37.4 455.0 Czech Republic (2012) 142.4 61.0 27.6 475.4
  Cuba (2010) 209.2 90.1 61.0 613.8 Argentina (2010) 139.7 28.4 35.5 574.3
  Czech Republic (2012) 142.4 61.0 27.6 475.4 Mexico (2010) 137.0 59.6 36.0 638.8
  Denmark (2011) 64.6 18.3 20.7 462.9 United States (2011) 117.1 51.6 21.0 518.6
  Finland (2011) 74.8 31.4 20.8 358.6 Chile (2009) 103.5 29.5 37.4 455.0
(Continued)
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  France (2010) 46.6 10.5 13.1 339.4 Ireland (2009) 86.8 40.9 21.9 419.8
  Germany (2012) 80.2 28.1 16.7 387.8 United Kingdom (2010) 84.7 36.8 21.6 431.5
  Hungary (2012) 218.4 105.7 48.9 672.1 Germany (2012) 80.2 28.1 16.7 387.8
  Ireland (2009) 86.8 40.9 21.9 419.8 New Zealand (2009) 79.9 35.4 23.0 410.0
  Israel (2011) 51.3 15.3 14.7 347.4 Belgium (2010) 78.5 24.3 20.4 419.8
  Italy (2010) 58.3 18.4 16.1 308.6 Finland (2011) 74.8 31.4 20.8 358.6
  Japan (2011) 53.5 12.6 21.6 284.3 Austria (2011) 69.7 32.0 14.4 361.3
  Korea, South (2011) 55.5 11.6 28.5 288.6 Sweden (2010) 67.8 31.1 16.2 357.1
  Mexico (2010) 137.0 59.6 36.0 638.8 Portugal (2011) 66.6 16.5 29.0 343.2
  Netherlands (2011) 65.9 18.0 16.7 408.8 Canada (2009) 65.9 33.1 14.5 388.1
  New Zealand (2009) 79.9 35.4 23.0 410.0 Netherlands (2011) 65.9 18.0 16.7 408.8
  Norway (2012) 53.1 21.4 14.9 360.9 Denmark (2011) 64.6 18.3 20.7 462.9
  Portugal (2011) 66.6 16.5 29.0 343.2 Italy (2010) 58.3 18.4 16.1 308.6
  Romania (2010) 312.2 105.8 111.4 692.3 Korea, South (2011) 55.5 11.6 28.5 288.6
  Russian Federation (2010) 466.0 226.3 155.0 915.7 Japan (2011) 53.5 12.6 21.6 284.3
  Spain (2011) 50.8 15.2 13.6 280.0 Norway (2012) 53.1 21.4 14.9 360.9
  Sweden (2010) 67.8 31.1 16.2 357.1 Australia (2011) 52.3 21.6 13.5 318.3
  Switzerland (2010) 49.3 19.4 11.1 308.9 Israel (2011) 51.3 15.3 14.7 347.4
  Ukraine (2012) 454.2 294.7 115.8 833.7 Spain (2011) 50.8 15.2 13.6 280.0
  United Kingdom (2010) 84.7 36.8 21.6 431.5 Switzerland (2010) 49.3 19.4 11.1 308.9
  United States (2011) 117.1 51.6 21.0 518.6 France (2010) 46.6 10.5 13.1 339.4
Rates are per 100 000 population, adjusted to the European Standard population. International Classification of Diseases, 10th Revision codes used were I00 to I99 
for CVD, I20 to I25 for CHD, and I60 to I69 for stroke. 
CHD indicates coronary heart disease; and CVD, cardiovascular disease. 
Sources: The World Health Organization, National Center for Health Statistics, and National Heart, Lung, and Blood Institute.
Table 13-3. Continued
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Chart 13-1. Prevalence of cardiovascular disease in adults ≥20 years of age by age and sex (National Health and Nutrition Examina-
tion Survey: 2009–2012). These data include coronary heart disease, heart failure, stroke, and hypertension. Source: National Center for 
Health Statistics and National Heart, Lung, and Blood Institute. 
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Chart 13-2. Incidence of cardiovascular disease (coronary heart disease, heart failure, stroke, or intermittent claudication; does not 
include hypertension alone) by age and sex (Framingham Heart Study, 1980–2003). Source: National Heart, Lung, and Blood Institute.3
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Chart 13-3. Deaths attributable to diseases of the heart (United States: 1900–2011). See Glossary (Chapter 27) for an explanation of 
“diseases of the heart.” Note: In the years 1900 to 1920, the International Classification of Diseases codes were 77 to 80; for 1925, 87 to 
90; for 1930 to 1945, 90 to 95; for 1950 to 1960, 402 to 404 and 410 to 443; for 1965, 402 to 404 and 410 to 443; for 1970 to 1975, 390 to 
398 and 404 to 429; for 1980 to 1995, 390 to 398, 402, and 404 to 429; for 2000 to 2011, I00 to I09, I11, I13, and I20 to I51. Before 1933, 
data are for a death registration area and not the entire United States. In 1900, only 10 states were included in the death registration area, 
and this increased over the years, so part of the increase in numbers of deaths is attributable to an increase in the number of states. 
Source: National Center for Health Statistics.
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Chart 13-4. Deaths attributable to cardiovascular disease (United States: 1900–2011). Cardiovascular disease (International Classification 
of Diseases, 10th Revision codes I00–I99) does not include congenital heart disease. Before 1933, data are for a death registration area 
and not the entire United States. Source: National Center for Health Statistics.
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Chart 13-5. Percentage breakdown of deaths attributable to cardiovascular disease (United States: 2011). Total may not add to 100 
because of rounding. Coronary heart disease includes International Classification of Diseases, 10th Revision (ICD-10) codes I20 to I25; 
stroke, I60 to I69; heart failure, I50; high blood pressure, I10 to I15; diseases of the arteries, I70 to I78; and other, all remaining ICD-I0 I 
categories and Q20 to Q28. *Not a true underlying cause. With any-mention deaths, heart failure accounts for 36% of cardiovascular dis-
ease deaths. Source: National Heart, Lung, and Blood Institute from National Center for Health Statistics reports and data sets.
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Chart 13-6. Cardiovascular disease (CVD) deaths versus cancer deaths by age (United States: 2011). CVD includes International Classifi-
cation of Diseases, 10th Revision codes I00 to I99 and Q20 to Q28; cancer, C00 to C97. Source: National Center for Health Statistics.
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Chart 13-7. Cardiovascular disease (CVD) and other major causes of death: total, <85 years of age, and ≥85 years of age. Deaths among 
both sexes, United States, 2011. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to I09, I11, I13, 
and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory disease (CLRD), 
J40 to J47; Alzheimer disease, G30; and accidents, V01 to X59 and Y85 and Y86. Source: National Center for Health Statistics and 
National Heart, Lung, and Blood Institute.
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Chart 13-8. Cardiovascular disease (CVD) and other major causes of death in males: total, <85 years of age, and ≥85 years of age. 
Deaths among males, United States, 2011. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to I09, 
I11, I13, and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory dis-
ease (CLRD), J40 to J47; and accidents, V01 to X59 and Y85 and Y86. Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 13-9. Cardiovascular disease (CVD) and other major causes of death in females: total, <85 years of age, and ≥85 years of age. 
Deaths among females, United States, 2011. Heart disease includes International Classification of Diseases, 10th Revision codes I00 to 
I09, I11, I13, and I20 to I51; stroke, I60 to I69; all other CVD, I10, I12, I15, and I70 to I99; cancer, C00 to C97; chronic lower respiratory 
disease (CLRD), J40 to J47; and Alzheimer disease, G30. Source: National Center for Health Statistics and National Heart, Lung, and 
Blood Institute.
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Chart 13-10. Cardiovascular disease and other major causes of death for all males and females (United States: 2011). A indicates cardio-
vascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99 and  
Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, chronic lower respiratory disease (J40–J47); E, diabetes mel-
litus (E10–E14); and F, Alzheimer disease (G30). Source: National Center for Health Statistics and National Heart, Lung, and  
Blood Institute.
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Chart 13-11. Cardiovascular disease and other major causes of death for white males and females (United States: 2011). A indicates 
cardiovascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99 and 
Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 andY85–Y86); D, chronic lower respiratory disease (J40–J47); E, diabetes mellitus 
(E10–E14); and F, Alzheimer disease (G30). Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-12. Cardiovascular disease and other major causes of death for black males and females (United States: 2011). A indicates 
cardiovascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99 and 
Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respiratory dis-
ease (J40–J47); and F, nephritis (N00–N07, N17–N19, and N25–N27). Source: National Center for Health Statistics and National Heart, 
Lung, and Blood Institute.
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Chart 13-13. Cardiovascular disease and other major causes of death for Hispanic or Latino males and females (United States: 2011). 
A indicates cardiovascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th Revision codes 
I00–I99, Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respira-
tory disease (J40–J47); and F, Alzheimer disease (G30). Number of deaths shown may be lower than actual because of underreporting in 
this population. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-14. Cardiovascular disease and other major causes of death for Asian or Pacific Islander males and females (United States: 
2011). “Asian or Pacific Islander” is a heterogeneous category that includes people at high cardiovascular disease risk (eg, South Asian) 
and people at low cardiovascular disease risk (eg, Japanese). More specific data on these groups are not available. A indicates cardio-
vascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th Revision codes I00–I99 and Q20–
Q28); B, cancer (C00–C97); C, accidents (V01–X59 and Y85–Y86); D, diabetes mellitus (E10–E14); E, chronic lower respiratory disease 
(J40–J47); F, influenza and pneumonia (J09–J18). Number of deaths shown may be lower than actual because of underreporting in this 
population. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-15. Cardiovascular disease and other major causes of death for American Indian or Alaska Native males and females (United 
States: 2011). A indicates cardiovascular disease plus congenital cardiovascular disease (International Classification of Diseases, 10th 
Revision codes I00–I99 and Q20–Q28); B, cancer (C00–C97); C, accidents (V01–X59 andY85–Y86); D, diabetes mellitus (E10–E14); E, 
chronic liver disease (K70 and K73–K74); and F, chronic lower respiratory disease (J40–J47). Number of deaths shown may be lower than 
actual because of underreporting in this population. Source: National Center for Health Statistics and National Heart, Lung, and Blood 
Institute.
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Chart 13-16. Age-adjusted death rates for coronary heart disease (CHD), stroke, and lung and breast cancer for white and black females 
(United States: 2011). CHD includes International Classification of Diseases, 10th Revision codes I20 to I25; stroke, I60 to I69; lung can-
cer, C33 to C34; and breast cancer, C50. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-17. Cardiovascular disease (CVD) mortality trends for males and females (United States: 1979–2011). CVD excludes congenital 
cardiovascular defects (International Classification of Diseases, 10th Revision [ICD-10] codes I00–I99). The overall comparability for car-
diovascular disease between the International Classification of Diseases, 9th Revision (1979–1998) and ICD-10 (1999–2011) is 0.9962. No 
comparability ratios were applied. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-18. US maps corresponding to state death rates (including the District of Columbia), 2011.
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Chart 13-19. Estimated average 10-year cardiovascular disease risk in adults 50 to 54 years of age according to levels of various risk 
factors (Framingham Heart Study). BP indicates blood pressure; and HDL, high-density lipoprotein. Data derived from D’Agostino et al43 
with permission of the publisher. Copyright © 2008, American Heart Association.
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Chart 13-20. Hospital discharges for cardiovascular disease (United States: 1970–2010). Hospital discharges include people discharged 
alive, dead, and “status unknown.” Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 13-21. Hospital discharges (ICD-9) for the 10 leading diagnostic groups (United States: 2010). Source: National Hospital Discharge 
Survey/National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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14 . Stroke (Cerebrovascular Disease)
ICD-9 430 to 438; ICD-10 I60 to I69. See Tables 14-1 and 
14-2 and Charts 14-1 through 14-12.
Stroke Prevalence
(See Table 14-1 and Chart 14-1.)
 ● An estimated 6.6 million Americans ≥20 years of age have 
had a stroke (extrapolated to 2012 by use of NHANES 
2009–2012 data). Overall stroke prevalence during this 
period is an estimated 2.6% (NHANES, NHLBI).
 ● According to data from the 2013 BRFSS (CDC), 2.7% of 
men and 2.7% of women ≥18 years of age had a history of 
stroke; 2.5% of non-Hispanic whites, 4.0% of non-Hispanic 
blacks, 1.3% of Asian/Pacific Islanders, 2.3% of Hispanics 
(of any race), 4.6% of American Indian/Alaska Natives, and 
4.6% of other races or multiracial people had a history of 
stroke.1
 ● Over the time period 2006 to 2010, data from BRFSS 
show that the overall self-reported stroke prevalence did 
not change. Older adults, blacks, people with lower levels 
of education, and people living in the southeastern United 
States had higher stroke prevalence.2
 ● The prevalence of silent cerebral infarction is estimated to 
range from 6% to 28%, with higher prevalence with increas-
ing age.3–5 The prevalence estimates also vary depending on 
the population studied (eg, ethnicity, sex, risk factor pro-
file), definition of silent cerebral infarction, and imaging 
technique. It has been estimated that 13 million people had 
prevalent silent stroke in the 1998 US population.6,7
 ● The prevalence of stroke-related symptoms was found to 
be relatively high in a general population free of a prior 
diagnosis of stroke or TIA. On the basis of data from 18 462 
participants enrolled in a national cohort study, 17.8% of 
the population >45 years of age reported at least 1 symp-
tom. Stroke symptoms were more likely among blacks 
than whites, among those with lower income and lower 
educational attainment, and among those with fair to poor 
perceived health status. Symptoms also were more likely 
in participants with higher Framingham stroke risk score 
(REGARDS, NINDS).8
Abbreviations Used in Chapter 14
ACCORD Action to Control Cardiovascular Risk in Diabetes
AF atrial fibrillation
AHA American Heart Association
AHI apnea-hypopnea index
ARIC Atherosclerosis Risk in Communities study
AHRQ Agency for Healthcare Research and Quality
BASIC Brain Attack Surveillance in Corpus Christi
BNP B-type natriuretic peptide
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CDC Centers for Disease Control and Prevention
CHD coronary heart disease
CHF congestive heart failure
CHS Cardiovascular Health Study
CI confidence interval
CLRD chronic lower respiratory disease
CREST Carotid Revascularization Endarterectomy Versus Stenting Trial
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ED emergency department
eGFR estimated glomerular filtration rate
FHS Framingham Heart Study
FRS Framingham Risk Score
FUTURE Follow-up of TIA and Stroke Patients and Unelucidated Risk 
Factor Evaluation
GCNKSS Greater Cincinnati/Northern Kentucky Stroke Study
GFR glomerular filtration rate
GWTG Get With The Guidelines
HBP high blood pressure
HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL high-density lipoprotein
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
ICH intracerebral hemorrhage
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Survey
NHLBI National Heart, Lung, and Blood Institute
NINDS National Institutes of Neurological Disorders and Stroke
NOMAS Northern Manhattan Study
ONTARGET Ongoing Telmisartan Alone and in Combination With Ramipril 
Global Endpoint Trial
OR odds ratio
PA physical activity
PAR population attributable risk
REGARDS Reasons for Geographic and Racial Differences in Stroke 
RR relative risk
SAH subarachnoid hemorrhage
SBP systolic blood pressure
SHS Strong Heart Study
SPS3 Secondary Prevention of Small Subcortical Strokes
STOP Stroke Prevention Trial in Sickle Cell Anemia
TIA transient ischemic attack
tPA tissue-type plasminogen activator
Click here to go to the Table of Contents
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 ● Projections show that by 2030, an additional 3.4 million 
people aged ≥18 years will have had a stroke, a 20.5% 
increase in prevalence from 2012. The highest increase 
(29%) is projected to be in Hispanic men.9
 ● With the increase in the aging population, prevalence of 
stroke survivors is projected to increase, especially among 
elderly women.10
Stroke Incidence
(See Table 14-1 and Charts 14-2 through 14-5.)
 ● Each year, ≈795 000 people experience a new or recurrent 
stroke. Approximately 610 000 of these are first attacks, 
and 185 000 are recurrent attacks (GCNKSS, NINDS, and 
NHLBI; GCNKSS and NINDS data for 1999 provided July 
9, 2008; estimates compiled by NHLBI).
 ● Of all strokes, 87% are ischemic and 10% are ICH strokes, 
whereas 3% are SAH strokes (GCNKSS, NINDS, 1999).
 ● On average, every 40 seconds, someone in the United 
States has a stroke (AHA computation based on the latest 
available data).
 ● Temporal trend data from the BASIC Project for the time 
period 2000 through 2010 demonstrated that ischemic 
stroke rates declined significantly in people aged ≥60 years 
but remained largely unchanged over time in those aged 
45 to 59 years. Rates of decline did not differ significantly 
for non-Hispanic whites and Mexican Americans in any 
age group. Therefore, ethnic disparities in stroke rates in 
the 45- to 59-year-old and 60- to 74-year-old age groups 
persist.11
 ● Analysis of data from the FHS suggests that stroke inci-
dence is declining over time in this largely white cohort. 
Data from 1950 to 1977, 1978 to 1989, and 1990 to 2004 
showed that the age-adjusted incidence of first stroke per 
1000 person-years in each of the 3 periods was 7.6, 6.2, 
and 5.3 in men and 6.2, 5.8, and 5.1 in women, respec-
tively. Lifetime risk for incident stroke at 65 years of age 
decreased significantly in the latest data period compared 
with the first, from 19.5% to 14.5% in men and from 18.0% 
to 16.1% in women.12
 ● In a similar fashion, data from the most recent GCNKSS 
show that compared with the 1990s, when incidence 
rates of stroke were stable, stroke incidence in 2005 was 
decreased for whites. A similar decline was not seen in 
blacks. These changes for whites were driven by a decline 
in ischemic strokes. There were no changes in incidence 
of ischemic stroke for blacks or of hemorrhagic strokes in 
blacks or whites.13
 ● In an analysis of temporal trends in ischemic stroke 
incidence stratified by age, the GCNKSS found an 
increased incidence of ischemic stroke over time for 
both blacks and whites aged 20 to 54 years, especially 
in 2005 compared with earlier time periods. There were 
declining incidence rates in the oldest age groups for 
both race groups.14
 ● Data from the BASIC Project showed that the age-, sex-, 
and ethnicity-adjusted incidence of ICH decreased from 
2000 to 2010 (from an annual incidence rate of 5.21/10 000 
[95% CI, 4.36–6.24] to 4.30/10 000 [95% CI, 3.21–5.76]).15
 ● Each year, ≈55 000 more women than men have a stroke 
(GCNKSS, NINDS).13
 ● Women have a higher lifetime risk of stroke than men. In 
the FHS, lifetime risk of stroke among those 55 to75 years 
of age was 1 in 5 for women (20% to 21%) and ≈1 in 6 for 
men (14% to 17%).16
 ● Age-specific incidence rates are substantially lower in 
women than men in younger and middle-age groups, but 
these differences narrow so that in the oldest age groups, 
incidence rates in women are approximately equal or even 
higher than in men.10,17–21
 ● In the national REGARDS cohort, in 27 744 participants 
followed up for 4.4 years (2003–2010), the overall age- and 
sex-adjusted black/white incidence rate ratio was 1.51, but 
for ages 45 to 54 years, it was 4.02, whereas for those ≥85 
years of age, it was 0.86.22 Similar trends for decreasing 
black/white incidence rate ratio with age were seen in the 
GCNKSS.23
 ● The BASIC Project (NINDS) demonstrated an increased 
incidence of stroke among Mexican Americans compared 
with non-Hispanic whites in a community in southeast 
Texas. The crude 3-year cumulative incidence (2000–2002) 
was 16.8 per 1000 in Mexican Americans and 13.6 per 
1000 in non-Hispanic whites. Specifically, Mexican Ameri-
cans had a higher cumulative incidence of ischemic stroke 
at younger ages (45–59 years of age: RR, 2.04; 95% CI, 
1.55–2.69; 60–74 years of age: RR, 1.58; 95% CI, 1.31–
1.91) but not at older ages (≥75 years of age: RR, 1.12; 
95% CI, 0.94–1.32). Mexican Americans also had a higher 
incidence of ICH and SAH than non-Hispanic whites, after 
adjustment for age.24
 ● The age-adjusted incidence of first ischemic stroke per 
1000 was 0.88 in whites, 1.91 in blacks, and 1.49 in His-
panics according to data from NOMAS (NINDS) for 1993 
to 1997. Among blacks, compared with whites, the relative 
rate of intracranial atherosclerotic stroke was 5.85; of extra-
cranial atherosclerotic stroke, 3.18; of lacunar stroke, 3.09; 
and of cardioembolic stroke, 1.58. Among Hispanics (pri-
marily Cuban and Puerto Rican), compared with whites, 
the relative rate of intracranial atherosclerotic stroke was 
5.00; of extracranial atherosclerotic stroke, 1.71; of lacunar 
stroke, 2.32; and of cardioembolic stroke, 1.42.25
 ● Among 4507 American Indian participants without a prior 
stroke in the SHS in 1989 to 1992, the age- and sex-adjusted 
incidence of stroke through 2004 was 6.79 per 100 person-
years, with 86% of incident strokes being ischemic.26
 ● In the REGARDS study, the increased risk of ICH with age 
differed between blacks and whites: There was a 2.25-fold 
(95% CI, 1.63–3.12) increase per decade in whites but no 
age association with ICH risk in blacks (HR, 1.09; 95% CI, 
0.70–1.68).27
TIA: Prevalence, Incidence, and Prognosis
 ● In a nationwide survey of US adults, the estimated preva-
lence of self-reported physician-diagnosed TIA increased 
with age and was 2.3% overall, which translates to ≈5 mil-
lion people. The true prevalence of TIA is greater, because 
many patients who experience neurological symptoms 
consistent with a TIA fail to report it to their healthcare 
provider.28
 ● In the GCNKSS, according to data from 1993 and 1994, 
the age-, sex-, and race-adjusted incidence rate for TIA was 
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0.83 per 10 000.29 The age- and sex-adjusted incidence rate 
for TIA in Rochester, MN, was estimated at 0.68 per 1000 
for the years 1985 through 1989.30 In a more recent Italian 
community-based registry conducted in 2007 to 2009, the 
crude TIA incidence rate was 0.52 per 1000.31
 ● Incidence of TIA increases with age and varies by sex and 
race/ethnicity. Men, blacks, and Mexican Americans have 
higher rates of TIA than their female and non-Hispanic 
white counterparts.24,29,31
 ● Approximately 15% of all strokes are heralded by a TIA.32
 ● TIAs confer a substantial short-term risk of stroke, hospi-
talization for CVD events, and death. Of 1707 TIA patients 
evaluated in the ED of Kaiser Permanente Northern Califor-
nia, 180 (11%) experienced a stroke within 90 days, and 91 
(5%) had a stroke within 2 days. Predictors of stroke included 
age >60 years, DM, focal symptoms of weakness or speech 
impairment, and symptoms that lasted >10 minutes.33
 ● Meta-analyses of cohorts of patients with TIA have shown 
the short-term risk of stroke after TIA to be ≈3% to 10% at 
2 days and 9% to 17% at 90 days.34,35
 ● Individuals who have a TIA and survive the initial high-
risk period have a 10-year stroke risk of roughly 19% and a 
combined 10-year stroke, MI, or vascular death risk of 43% 
(4% per year).36
 ● In the GCNKSS, the 1-year mortality rate after a TIA 
was 12%.29
 ● In the population-based Oxford Vascular Study, among 
patients with TIA, disability levels increased from 14% 
(modified Rankin scale >2) before the TIA to 23% at 
5 years after the TIA (P=0.002). In this same study, the 
5-year risk of institutionalization after TIA was 11%.37
 ● In a meta-analysis of 47 studies,38 it was estimated that 
approximately one third of TIA patients have an acute 
diffusion-weight imaging lesion present on magnetic reso-
nance imaging and thus would be classified as having had 
a stroke under a tissue-based case definition39,40; however, 
substantial between-study heterogeneity was noted.
Recurrent Stroke
 ● In a cohort of 10 399 patients discharged with a primary 
diagnosis of stroke in the state of South Carolina in 2002, 
recurrent stroke rates were 1.8% at 1 month, 5% at 6 
months, 8% at 1 year, and 18.1% at 4 years.41
 ● Annual recurrent stroke rates in control arms of stroke 
prevention trials fell from 8.71% in trials launched in the 
1960s to 6.10% in the 1970s, 5.41% in the 1980s, 4.04% 
in the 1990s, and 4.98% in the 2000s. If one assumes a 
continued linear decline, the annual recurrent stroke rate 
in trial control arms in the coming decade is projected to 
be 2.25%.42
 ● From 1994 to 2002, 1-year recurrent ischemic stroke rates 
declined by almost 5% among elderly Medicare beneficia-
ries, but declines were heterogeneous across geographic 
regions of the United States.43
 ● Among 600 Scandinavian stroke patients followed up for 
2 years, 55 (9.2%) had had a recurrent stroke, 15 (2.5%) 
had a TIA, 4 (0.7%) had a coronary event, and 24 (4.0%) 
had died. Recurrent stroke occurred in 19.2% of patients 
with index stroke caused by large-artery disease, 4.9% with 
small-vessel disease, 8.2% with cardioembolic cause, 5.6% 
with cryptogenic cause, and 12.8% with other and undeter-
mined cause combined.44
 ● Recurrent stroke is associated with a greater number of risk 
factors and a higher incidence of large-artery atherosclero-
sis than the first stroke.45
 ● Among 1626 first-ever stroke patients in the South Lon-
don Register,46 first stroke recurrence rates during the 
first, second, third, fourth, and fifth years were 8% (95% 
CI, 6.5%–9.8%), 3.3% (2.2%–4.9%), 3.5% (2.1%–5.8%), 
1.2% (0.4%–3.7%), and 1.8% (0.4%–7.4%), respectively. 
Cumulative risks of first stroke recurrence were 2.6% (95% 
CI, 1.9%–3.7%) at 3 months, 8.0% (6.5%–9.8%) at 1 year, 
14.1% (11.8%–16.7%) at 3 years, and 16.6% (13.5%–
20.4%) at 5 years.46
 ● During a median 5.3 years of follow-up among 987 ARIC 
participants with first-ever strokes, there were 183 recur-
rent strokes among 147 participants. Approximately 70% 
of recurrent strokes were of the same subtype; however, 
28% were the same when the index stroke was lacunar. 
One-year stroke recurrence rates by index subtype were 
7.9% for thrombotic, 6.5% for cardioembolic and 6.5% for 
lacunar events.47
 ● In the FUTURE prospective cohort of 724 patients aged 18 
to 50 years with first ever TIA, stroke, or ICH, after a mean 
follow-up of 9.1 years, cumulative 20-year risk of recurrent 
stroke was 19.4% (95% CI, 14.6%–24.3%) after ischemic 
stroke and 9.8% (95% CI, 1.0%–18.7%) after ICH.48
Stroke Mortality
(See Table 14-1 and Charts 14-6 and 14-7.)
See “Factors influencing the decline in stroke mortality: 
a statement from the American Heart Association/American 
Stroke Association”49 for more in-depth coverage of factors 
contributing to the decline in stroke mortality over the past 
several decades.
 ● In 201150
—On average, every 4 minutes, someone died of a stroke 
(NCHS, NHLBI).
—Stroke accounted for ≈1 of every 20 deaths in the United 
States.
—When considered separately from other CVDs, stroke 
ranks No. 4 among all causes of death, behind diseases 
of the heart, cancer, and CLRD (NCHS mortality data).
—The number of deaths with stroke as an underlying cause 
was 128 932; any-mention mortality was 218 352, and 
the age-adjusted death rate for stroke as an underlying 
cause of death was 37.9 per 100 000.
—Approximately 57% of stroke deaths occurred out of the 
hospital (unpublished NHLBI tabulation from NCHS 
2011 mortality data set).
—More women than men die of stroke each year because of 
the larger number of elderly women. Women accounted 
for almost 60% of US stroke deaths (AHA tabulation).
—From 2001 to 2011, the stroke death rate decreased 
35.1% and the actual number of stroke deaths declined 
21.2% (NHLBI computation).
 ● Data from the BASIC Project showed there was no change 
in ICH case fatality or long-term mortality from 2000 to 
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2010. Yearly age-,sex-, and ethnicity-adjusted 30-day case 
fatality ranged from 28.3% (95% CI, 19.9%–40.3%) in 
2006 to 46.5% (95% CI, 35.3%–60.8%) in 2008.15
 ● Conclusions about changes in stroke death rates from 1981 
to 2010 are as follows51:
—There was a slightly greater decline in age-adjusted 
stroke death rates in men (−58.5%) than in women 
(−55.2%).
—Stroke death rates declined more in people aged 45 to 64 
years (−53.1%) than in those ≥65 years of age (−48.9%) 
or those aged 18 to 44 years (−37.8%).
 ● In examining trends in stroke mortality by US census divi-
sions between 1999 and 2007 for people ≥45 years of age, 
the rate of decline varied by geographic region and race/
ethnic group. Among black and white women and white 
men, rates declined by ≥2% annually in every census divi-
sion, but among black men, rates declined little in the East 
and West South Central divisions.52
 ● On the basis of national death statistics for the time period 
1990 to 2009, stroke mortality rates among American 
Indian and Alaska Native people were higher than whites 
for both men and women in contract health services deliv-
ery area counties in the United States and were highest in 
the youngest age groups (35–44 years old). Stroke mortal-
ity rates and the rate ratios for American Indians/Alaska 
Natives to whites varied by region, with the lowest in the 
Southwest and the highest in Alaska. Starting in 2001, rates 
among American Indian/Alaska Native people decreased in 
all regions.53
 ● From 1995 to 1998, age-standardized mortality rates for 
ischemic stroke, SAH, and ICH were higher among blacks 
than whites. Death rates attributable to ICH also were 
higher among Asians/Pacific Islanders than among whites. 
All minority populations had higher death rates attribut-
able to SAH than did whites. Among adults 25 to 44 years 
of age, blacks and American Indian/Alaska Natives had 
higher risk ratios for stroke mortality than did whites for 
all 3 stroke subtypes. Age-standardized mortality rates for 
ischemic stroke and ICH were lower for Hispanics than for 
whites.54
 ● In 2002, death certificate data showed that the mean age 
at stroke death was 79.6 years; however, males had a 
younger mean age at stroke death than females. Blacks, 
American Indian/Alaska Natives, and Asian/Pacific Island-
ers had younger mean ages than whites, and the mean age 
at stroke death was also younger among Hispanics than 
non-Hispanics.55
 ● A report released by the CDC in collaboration with the 
Centers for Medicare & Medicaid Services, the Atlas of 
Stroke Hospitalizations Among Medicare Beneficiaries, 
found that in Medicare beneficiaries over the time period 
1995 to 2002, the 30-day mortality rate varied by age: 9% 
in patients 65 to 74 years of age, 13.1% in those 74 to 84 
years of age, and 23% in those ≥85 years of age.56
 ● Between 1980 and 2010, the FUTURE study in the Neth-
erlands followed 959 stroke and TIA patients aged 18 to 50 
years at enrollment for a mean of 11.1 years (follow-up rate 
of 97%). Among 30-day survivors, the observed 20-year 
mortality for each stroke type exceeded the expected 
mortality in the general population. Among the patients, 
mortality ranged from 1.2% to 2.9% at 1 year to 2.5% to 
6.1% at 5 years, 9.2% to 12.4% at 10 years, and 13.7% 
to 26.8% at 20 years. Among the stroke cases, the relative 
excess of deaths compared with the general population 
was greatest among the youngest subjects, but the absolute 
excess of deaths was highest among the older subjects.57
 ● There are substantial geographic disparities in stroke mortal-
ity, with higher rates in the southeastern United States, known 
as the “stroke belt.” This area is usually defined to include the 
8 southern states of North Carolina, South Carolina, Geor-
gia, Tennessee, Mississippi, Alabama, Louisiana, and Arkan-
sas. These geographic differences have existed since at least 
1940,58 and despite some minor shifts,59 they persist.56,60,61 
Within the stroke belt, a “buckle” region along the coastal 
plain of North Carolina, South Carolina, and Georgia has 
been identified with an even higher stroke mortality rate than 
the remainder of the stroke belt. The overall average stroke 
mortality is ≈20% higher in the stroke belt than in the rest of 
the nation and ≈40% higher in the stroke buckle.62
Stroke Risk Factors
(See Table 14-2 and Chart 14-8.)
For prevalence and other information on any of these spe-
cific risk factors, refer to the specific risk factor chapters.
High BP
(See Chapter 9 for more information.)
 ● Median SBP declined 16 mm Hg between 1959 and 2010 
for different age groups in association with large acceler-
ated reductions in stroke mortality. In clinical trials, antihy-
pertensive therapy has been associated with reductions in 
stroke incidence, with an average 41% reduction in stroke 
risks with SBP reductions of 10 mm Hg.49
 ● BP is a powerful determinant of risk for both ischemic 
stroke and intracranial hemorrhage.
—Approximately 77% of those who have a first stroke 
have BP >140/90 mm Hg (NHLBI unpublished esti-
mates from ARIC, CHS, and FHS Cohort and Offspring 
studies).
—Diabetic subjects with BP <120/80 mm Hg have approx-
imately half the lifetime risk of stroke of subjects with 
hypertension. The treatment and lowering of BP among 
diabetic hypertensive individuals was associated with a 
significant reduction in stroke risk.63
 ● In the REGARDS study (NINDS), between the ages of 45 
and 64 years (an age group in which African Americans are 
at 2 to 3 times the risk of stroke as whites), ≈40% of the 
excess stroke risk in African Americans is attributable to 
traditional stroke risk factors, with levels of SBP account-
ing for approximately one half of this impact.64 For each 
10 mm Hg increase in levels of SBP, the increased stroke 
risk in whites is ≈8%; however, a similar 10 mm Hg 
increase in SBP in African Americans is associated with a 
24% increase in stroke risk, an impact 3 times greater than 
in whites.65
 ● Cross-sectional baseline data from the SPS3 trial showed 
that more than half of all symptomatic lacunar stroke 
patients had uncontrolled hypertension at 2.5 months after 
stroke.66
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
 Heart Disease and Stroke Statistics—2015 Update: Chapter 14  e183
 ● A meta-analysis of 12 prospective cohort studies (including 
518 520 participants) found that prehypertension is associ-
ated with incident stroke. The risk is particularly noted 
in nonelderly people and for those with BP values in the 
higher prehypertension range.67
 ● In cross-sectional analysis from the REGARDS study 
(NINDS), blacks with hypertension were more aware of 
their HBP and more frequently received treatment for it 
than whites but were less likely than whites to have their 
BP controlled.68
 ● The higher stroke risk for the stroke belt compared with 
other regions does not appear to be attributable to hyperten-
sion management, because treatment and control rates were 
similar for the 2 geographic areas.68
 ● Several studies have shown significantly lower rates of 
recurrent stroke with lower BPs. Most recently, the BP-
reduction component of the SPS3 trial showed that target-
ing an SBP <130 mm Hg was likely to reduce recurrent 
stroke by ≈20% (P=0.08) and significantly reduced ICH by 
two thirds.69
Diabetes Mellitus
(See Chapter 10 for more information.)
 ● DM increases ischemic stroke incidence at all ages, but this 
risk is most prominent (risk ratio for ischemic stroke con-
ferred by DM >5) before 65 years of age in both blacks and 
whites. According to data from the GCNKSS in 2005, the 
risk ratio for ischemic stroke in blacks <65 years of age was 
5.2 compared with 12.0 for whites; the trend for greater risk 
conferred by DM at age <65 years in whites was noted in 
all 3 prior study periods. Overall, ischemic stroke patients 
with DM are younger, more likely to be black, and more 
likely to have HBP, MI, and high cholesterol than nondia-
betic patients.70
 ● In people with a history of TIA or minor stroke, impaired 
glucose tolerance nearly doubled the stroke risk compared 
with those with normal glucose levels and tripled the risks 
for those with DM.71
 ● A meta-analysis of prospective randomized controlled tri-
als of interventions that targeted people with prediabetes 
revealed a 24% relative risk reduction in fatal and nonfatal 
strokes (HR, 0.76; 95% CI, 0.58–0.99).72
 ● Data from the US Nationwide Inpatient Sample revealed 
that from 1997 to 2006, the absolute number of acute 
ischemic stroke hospitalizations declined by 17% (from 
489 766 in 1997 to 408 378 in 2006); however, the abso-
lute number of acute ischemic stroke hospitalizations with 
comorbid DM rose by 27% (from 97 577 [20%] in 1997 
to 124 244 [30%] in 2006). The rise in comorbid DM 
was more pronounced in individuals who were relatively 
younger, black or “other” race, on Medicaid, or admitted to 
hospitals located in the South. Factors independently asso-
ciated with higher odds of DM in acute ischemic stroke 
patients were black or “other” (versus white) race, CHF, 
peripheral vascular disease, and history of MI, renal dis-
ease, or hypertension.73
 ● A population-based study of 12 375 first-ever stroke 
patients 25 to 74 years old who were followed up for ≤23 
years found that diabetic patients had a higher risk of death 
than nondiabetic patients (adjusted HR, 1.67; 95% CI, 
1.58–1.76). The reduced survival of diabetic stroke patients 
was more pronounced in women (P=0.02) and younger 
individuals (P<0.001).74
 ● A retrospective analysis of diabetic patients with acute 
ischemic stroke revealed that those who had been taking 
and continued taking sulfonylureas were less likely to 
experience symptomatic hemorrhagic transformation than 
those who did not take sulfonylureas (P=0.016).75
 ● The ACCORD study showed that in patients with type 2 
DM, targeting SBP to <120 mm Hg did not reduce the rate 
of cardiovascular events compared with subjects in whom 
the SBP target was <140 mm Hg, except for the end point 
of stroke, for which intensive therapy reduced the risk of 
any stroke (HR, 0.59; 95% CI, 0.39–0.89) and nonfatal 
stroke (HR, 0.63; 95% CI, 0.41–0.96).63
 ● The ONTARGET trial revealed that in both patients with 
and without DM, the adjusted risk of stroke continued to 
decrease down to achieved SBP values of 115 mm Hg, 
whereas there was no benefit for other fatal or nonfatal car-
diovascular outcomes below an SBP of 130 mm Hg.76
Disorders of Heart Rhythm
(See Chapter 16 for more information.)
 ● AF is a powerful risk factor for stroke, independently 
increasing risk ≈5-fold throughout all ages. The percentage 
of strokes attributable to AF increases steeply from 1.5% at 
50 to 59 years of age to 23.5% at 80 to 89 years of age.77,78
 ● Because AF is often asymptomatic79,80 and likely frequently 
undetected clinically,81 the stroke risk attributed to AF may 
be substantially underestimated.82 Screening for AF in 
patients with cryptogenic stroke or TIA by use of outpatient 
telemetry for 21 to 30 days has resulted in an AF detection 
rate of 12% to 23%.81–83
 ● Among 2580 participants ≥65 years of age with hyper-
tension in whom a cardiac rhythm device that included 
an atrial lead was implanted, 35% developed subclinical 
tachyarrhythmias (defined as an atrial rate ≥190 beats per 
minute that lasted ≥6 minutes). These subclinical events 
were independently associated with a 2.5-fold increased 
risk of ischemic stroke or systemic embolism.84
 ● Important risk factors for stroke in the setting of AF include 
advancing age, hypertension, HF, DM, previous stroke or 
TIA, vascular disease, and female sex.85–87 Additional 
biomarkers, including high levels of troponin and BNP, 
increase the risk of stroke in the setting of AF independent 
of those well-established clinical characteristics.88
High Blood Cholesterol and Other Lipids
(See Chapter 8 for more information.)
For clarity, different types of cholesterol (total cholesterol, 
subfractions) are described here and are bolded in each bul-
let point. Overall the association of each cholesterol subfrac-
tion with total stroke has shown inconsistent results, and the 
data are limited on associations with specific ischemic stroke 
subtypes.
 ● An association between total cholesterol and ischemic 
stroke has been found in some prospective studies,89–91 but 
not others.92–94 Elevated total cholesterol is inversely asso-
ciated in multiple studies with hemorrhagic stroke.95
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 ● Data from the Honolulu Heart Program//NHLBI found 
that in Japanese men 71 to 93 years of age, low concentra-
tions of HDL cholesterol were more likely to be associated 
with a future risk of thromboembolic stroke than were high 
concentrations.96 However, a meta-analysis of 23 studies 
performed in the Asia-Pacific Region showed no signifi-
cant association between low HDL cholesterol and stroke 
risk.97 A Finish study of 27 703 men and 30 532 women fol-
lowed up for >20 years for ischemic stroke found an inde-
pendent inverse association of HDL cholesterol with the 
risks of total and ischemic stroke in women.94
 ● In an analysis by the Emerging Risk Factors Collaboration of 
individual records on 302 430 people without initial vascular 
disease from 68 long-term prospective studies, HR for isch-
emic stroke was 1.12 (95% CI, 1.04–1.20) with non-HDL 
 cholesterol.98 In a pooled analysis of CHS and ARIC, low LDL 
 cholesterol was associated with an increased risk of ICH.99
 ● Among 13 951 patients in the Copenhagen Heart Study 
followed up for 33 years for ischemic stroke, increasing 
stepwise levels of nonfasting triglycerides were associ-
ated with increased risk of ischemic stroke in both men 
and women. In the Rotterdam study (n=9068), increasing 
quartiles of serum triglycerides were associated with a 
reduced risk of ICH.100
Smoking
(See Chapter 3 for more information.)
 ● Current smokers have a 2 to 4 times increased risk of stroke 
compared with nonsmokers or those who have quit for >10 
years.101,102
 ● Cigarette smoking is a risk factor for ischemic stroke and 
SAH, but the data for ICH are less consistent.101,102
 ● In a large Danish cohort study, among people with AF, 
smoking was associated with a higher risk of ischemic 
stroke/arterial thromboembolism or death, even after 
adjustment for other traditional risk factors.103
 ● Smoking is perhaps the most important modifiable risk fac-
tor in preventing SAH, with the highest PAR of any SAH 
risk factor.104
 ● Data also support a dose-response relationship between 
smoking and risk of stroke across old and young age 
groups.101,105
 ● Discontinuation of smoking has been shown to reduce 
stroke risk across sex, race, and age groups.105
 ● Exposure to secondhand smoke (also termed passive smok-
ing or environmental tobacco smoke) is a risk factor for 
stroke. Meta-analyses have estimated a pooled RR of 1.25 
for exposure to spousal smoking (or nearest equivalent) and 
risk of stroke. A dose-response relationship between expo-
sure to secondhand smoke and stroke risk has also been 
reported.106,107
Physical Inactivity
(See Chapter 4 for more information.)
 ● Results from REGARDS found that participants reporting 
PA <4 times per week had a 20% increased risk of inci-
dent stroke over a mean of 5.7 years compared with those 
exercising ≥4 times per week. This relationship, which was 
more pronounced in men than in women, may be explained 
in large part by the effect of PA on reducing traditional risk 
factors, such as obesity and DM.108
 ● Over a mean follow-up of 17 years, the ARIC study found a 
significant trend among African-Americans toward reduced 
incidence of stroke with increasing level of PA; a similar 
trend was observed for Caucasians in the study, although 
it was not statistically significant. Data from this study 
showed that although the highest levels of activity were 
most protective, even modest levels of PA appeared to be 
beneficial.109
 ● In NOMAS, a prospective cohort that included white, 
black, and Hispanic adults in an urban setting followed up 
for a median of 9 years, moderate to vigorous leisure-time 
PA was associated with an overall 35% reduction in risk of 
ischemic stroke.110
 ● In the Aerobics Center Longitudinal Study of participants 
who underwent evaluation at the Cooper Clinic in Dal-
las, TX (46 405 men and 15 282 women), investigators 
found that cardiorespiratory fitness as measured by exer-
cise treadmill testing was associated with a reduced risk of 
fatal and nonfatal stroke. Investigators noted that the effect 
was mainly notable for a higher intensity level of fitness 
achieved (7 to 8 maximum metabolic equivalents).111 A 
prospective cohort study of 22 841 men and 24 880 women 
in Finland found a similar dose-response–independent pro-
tective effect from vigorous leisure-time PA on ischemic 
stroke, ICH, and SAH. The effect was more modest for 
commuting-time PA and was no longer present after adjust-
ment for leisure-time PA.112
 ● Timing of PA in relation to stroke onset has also been exam-
ined in several studies. In a hospital-based case-control 
study from Heidelberg, Germany, recent activity (within 
the prior months) was associated with reduced odds of hav-
ing a stroke or TIA, whereas sports activity during young 
adulthood that was not continued showed no benefit.113 In 
a Danish case-control study, ischemic stroke patients were 
less physically active in the week preceding the stroke than 
age- and sex-matched control subjects, with the highest 
activity scores associated with the greatest reduction in 
odds of stroke.114
Nutrition
(See Chapter 5 for more information.)
 ● Adherence to a Mediterranean-style diet that was higher 
in nuts and olive oil was associated with a reduced risk of 
stroke (HR, 0.54; 95% CI, 0.35–0.84) in a randomized clin-
ical trial conducted in Spain. The protective benefit of the 
Mediterranean diet observed was greater for strokes than 
for MI, but stroke subtype was not available.115
 ● In the Nurses Health and Health Professionals Follow-up 
Studies, each 1-serving increase in sugar-sweetened soda 
beverage was associated with a 13% increased risk of isch-
emic stroke but not hemorrhagic stroke. Conversely, each 
1-serving increase in low-calorie or diet soda was associ-
ated with a 7% increased risk of ischemic stroke and 27% 
increased risk of hemorrhagic stroke.116
 ● A meta-analysis of >94 000 people with 34 817 stroke 
events demonstrated that eating ≥5 servings of fish per 
week versus eating <1 serving per week was associated 
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with a 12% reduction in stroke risk; however, these results 
were not consistent across all cohort studies.117
 ● Using registry data from Sweden, people eating ≥7 serv-
ings of fruits and vegetables per day had a 19% reduced 
risk of stroke compared with those only eating 1 serving 
per day. This effect was only seen in people who did not 
have hypertension.118
Family History and Genetics
(See Chapter 7 for more information.)
 ● In the FHS, a documented parental ischemic stroke by the 
age of 65 years was associated with a 3-fold increase in 
ischemic stroke risk in offspring, even after adjustment for 
other known stroke risk factors. The absolute magnitude of 
the increased risk was greatest in those in the highest quin-
tile of the FRS. By age 65 years, people in the highest FRS 
quintile with an early parental ischemic stroke had a 25% 
risk of stroke compared with a 7.5% risk of ischemic stroke 
for those without such a history.119
Chronic Kidney Disease
(See Chapter 12 for more information.)
 ● The CHS (NHLBI) showed that people with creatinine ≥1.5 
mg/dL were at increased risk for stroke, with an adjusted 
HR of 1.77 (95% CI, 1.08–2.91).120
 ● Participants in REGARDS with a reduced eGFR were 
also shown to have increased risk of stroke symptoms,121 
and a meta-analysis of >280 000 patients showed a 43% 
increased incident stroke risk among patients with a GFR 
<60 mL·min−1·1.73 m−2.122
 ● In a study of 539 287 Swedish men and women followed up 
for 12 years,123 HRs for ICH were as follows: for GFR 60 to 
90 mL·min−1·1.73 m−2 (mild), 1.04 (95% CI, 0.93–1.15); for 
GFR 30 to 60 mL·min−1·1.73 m−2 (moderate), 1.26 (95% CI, 
0.96–1.64); and for GFR 15 to 30 mL·min−1·1.73 m−2 (severe 
impairment), 2.31 (95% CI, 1.10–4.87). Among 128 patients 
with ICH, the presence of GFR <45 mL·min−1·1.73 m−2 was 
associated with larger, lobar hematomas and poor outcome.124
 ● A urinary albumin to creatinine ratio >30 mg/g was associ-
ated with a 40% increased risk of stroke in black partici-
pants but not white participants in the REGARDS study.125
Risk Factor Issues Specific to Women
See the “Guidelines for the Prevention of Stroke in Women: 
A Statement for Healthcare Professionals From the American 
Heart Association/American Stroke Association”126 for more 
in-depth coverage of stroke risk factors unique to women.126
 ● On average, women are ≈4 years older at stroke onset than 
men (≈75 years compared with 71 years).14
 ● In the setting of AF, women have a significantly higher risk 
of stroke than men.127–131
 ● Analysis of data from the FHS found that women with nat-
ural menopause before 42 years of age had twice the isch-
emic stroke risk of women with natural menopause after 42 
years of age.132 However, no association was found between 
age at natural menopause and risk of ischemic or hemor-
rhagic stroke in the Nurse’s Health Study.133
 ● Overall, randomized clinical trial data indicate that 
the use of estrogen plus progestin, as well as estrogen 
alone, increases stroke risk in postmenopausal, generally 
healthy women and provides no protection for postmeno-
pausal women with established CHD134–137 and recent 
stroke or TIA.138
 ● In a nested case-control study of the United Kingdom’s 
General Practice Research Database, stroke risk was not 
increased for users of low-dose (≤50 µg) estrogen patches 
(RR, 0.81; 95% CI, 0.62–1.05) but was increased for users 
of high-dose (>50 µg) patches (RR, 1.89; 95% CI, 1.15–
3.11) compared with nonusers.139
 ● Low-estrogen-dose oral contraceptives are associated with 
a 93% increased risk of ischemic stroke, but the absolute 
increased risk is small (4.1 ischemic strokes per 100 000 
nonsmoking, normotensive women).140,141
 ● Migraine with aura is associated with ischemic stroke in 
younger women, particularly if they smoke or use oral con-
traceptives. The combination of all 3 factors increases the 
risk ≈9-fold compared with women without any of these 
factors.142,143
 ● In the Baltimore-Washington Cooperative Young Stroke 
Study, the risk of ischemic stroke or ICH during pregnancy 
and the first 6 weeks after giving birth was 2.4 times greater 
than for nonpregnant women of similar age and race. The 
excess risk of stroke (all types except SAH) attributable to 
the combined pregnancy/postpregnancy period was 8.1 per 
100 000 pregnancies.144
 ● Analyses of the US Nationwide Inpatient Sample from 
1994 to 1995 and from 2006 to 2007 show a temporal 
increase in the proportion of pregnancy hospitalizations 
that were associated with a stroke, with a 47% increase for 
antenatal hospitalizations and an 83% increase for postpar-
tum hospitalizations,. Increases in the prevalence of HD 
and hypertensive disorders accounted for almost all the 
increase in postpartum stroke hospitalizations but not the 
antenatal stroke hospitalizations.89
 ● Preeclampsia is a risk factor for ischemic stroke remote 
from pregnancy.145 The increase in stroke risk related to 
preeclampsia may be mediated by later risk of hyperten-
sion and DM.146
Sleep Apnea
 ● The prevalence of sleep-disordered breathing, defined as an 
AHI ≥5, has been estimated to be 34% for men and 17% for 
women aged 30 to 70 years.147
 ● Sleep apnea is common after stroke, with prevalence in 
excess of 50%.148
 ● In the Sleep Heart Health Study, obstructive sleep apnea 
measured by the obstructive AHI was associated with risk 
of incident ischemic stroke in men after adjustment for con-
founders (P=0.016 for linear trend associated with quartiles 
of AHI) but not in women. Compared with men in the low-
est quartile of AHI, men in the highest quartile (AHI >19) 
had an adjusted HR of 2.9 (95% CI, 1.1–7.4).149
 ● In a meta-analysis of 5 studies, obstructive sleep apnea was 
associated with incident stroke with an OR of 2.2 (95% 
CI, 1.6–3.2). Similar results were found in a second meta-
analysis that included additional studies (OR, 2.1; 95% CI, 
1.5–2.9).150,151
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 ● In a population-based stroke study, acute infarction involv-
ing the brainstem was associated with the presence of 
sleep-disordered breathing, defined as an AHI ≥10, with an 
OR of 3.76 (95% CI, 1.44–9.81) after adjustment for demo-
graphics, risk factors, and stroke severity.152
 ● Obstructive sleep apnea is associated with higher post-
stroke mortality153–155 and worse functional outcome.156
 ● No definitive study has been conducted to determine 
whether treatment with continuous positive airway pres-
sure prevents stroke or improves poststroke outcomes.
Psychosocial Risk Factors
 ● Among 6019 adults followed up for a mean of 16.3 years 
from the first NHANES, higher levels of anxiety symptoms 
were associated with increased risk of incident stroke after 
adjustment for demographic, cardiovascular, and behav-
ioral risk factors (HR, 1.14; 95% CI, 1.03–1.25). This asso-
ciation remained significant with further adjustment for 
depressive symptoms.157
 ● In the Chicago Health and Aging Project, higher psycho-
logical distress was associated with higher stroke mortality 
(HR, 1.29; 95% CI, 1.10–1.52) and incident hemorrhagic 
strokes (HR, 1.70; 95% CI, 1.28–2.25) among 4120 adults 
after risk adjustment for age, sex, race, and stroke risk 
factors.158
 ● Depression was associated with a nearly 2-fold increased 
odds of stroke after adjustment for age, socioeconomic sta-
tus, lifestyle, and physiological risk factors (OR, 1.94; 95% 
CI, 1.37–2.74) in a cohort of 10 547 women aged 47 to 52 
years who were followed up for 12 years as part of the Aus-
tralian Longitudinal Study on Women’s Health.159
 ● In a meta-analysis of 17 community-based or population-
based prospective studies published between 1994 and 
2010 involving 206 641 participants, people with a history 
of depression experienced a 34% higher risk for the devel-
opment of subsequent stroke after adjustment for potential 
confounding factors (pooled RR, 1.34; 95% CI, 1.17–1.54); 
however, substantial between-study heterogeneity was 
noted. Associations were similar for men and women.160
 ● A meta-analysis of 28 prospective cohort studies com-
prising 317 540 participants with a follow-up period that 
ranged from 2 to 29 years found that depression was pro-
spectively associated with an increased risk of total stroke 
(pooled HR, 1.45; 95% CI, 1.29–1.63), fatal stroke (pooled 
HR, 1.55; 95% CI, 1.25–1.93), and ischemic stroke (pooled 
HR, 1.25; 95 CI, 1.11–1.40).161
Awareness of Stroke Warning Signs and Risk 
Factors
 ● In the 2009 NHIS, 51.2% of subjects were aware of 5 
stroke warning symptoms and would first call 9-1-1 if they 
thought that someone was having a stroke. Awareness of all 
5 stroke warning symptoms and calling 9-1-1 was higher 
among whites than blacks and Hispanics (55.9%, 47.1%, 
and 36.5%, respectively), women than men (53.6% versus 
48.6%), and people with higher versus lower educational 
attainment (59.0% for people with a bachelor’s degree or 
more compared with 51.4% for people with a high school 
diploma or some college and 36.7% for those who had 
not received a high school diploma; unpublished NHLBI 
tabulation).
 ● In the BRFSS from 2005 (n=71 994), 43.6% of respondents 
were aware of the 5 principal stroke symptoms, but only 
18.6% responded correctly when they were also asked to 
identify that chest pain was not a stroke symptom. Respon-
dents who were white and college educated were more 
likely to identify stroke-related symptoms correctly, and 
there was significant geographic variability (highest pro-
portion of correct responses in Minnesota, Virginia, and 
Iowa; lowest in Louisiana, Oklahoma, and Tennessee).162
 ● A study was conducted of patients admitted to an ED with 
possible stroke to determine their knowledge of the signs, 
symptoms, and risk factors of stroke. Of the 163 patients 
able to respond, 39% did not know a single sign or symp-
tom. Patients ≥65 years of age were less likely than those 
<65 years old to know a sign or symptom of stroke (28% 
versus 47%), and 43% did not know a single risk factor. 
Overall, almost 40% of patients did not know the signs, 
symptoms, and risk factors for stroke.163
 ● A study of patients who had experienced a stroke found 
that only 60.5% were able to accurately identify 1 stroke 
risk factor and that 55.3% were able to identify 1 stroke 
symptom. Patients’ median delay time from onset of symp-
toms to admission in the ED was 16 hours, and only 31.6% 
accessed the ED in <2 hours. Analysis showed that the 
appearance of nonmotor symptoms as the primary symp-
tom and nonuse of the 9-1-1 system were significant pre-
dictors of delay >2 hours. Someone other than the patient 
made the decision to seek treatment in 66% of the cases.164
 ● Spanish-speaking Hispanics are less likely to know all 
stroke symptoms than English-speaking Hispanics, non-
Hispanic blacks, and non-Hispanic whites. Lack of Eng-
lish proficiency is strongly associated with lack of stroke 
knowledge among Hispanics.165
 ● A study of CVD awareness carried out by the AHA among 
women in the United States who were >75 years old 
(n=1205) showed that low proportions of women identified 
severe headache (23%), dizziness (20%), and vision loss/
changes (18%) as stroke warning symptoms.166
Aftermath
(See Charts 14-9 through 14-11.)
 ● Stroke is a leading cause of serious long-term disability in 
the United States (Survey of Income and Program Partici-
pation, a survey of the US Census Bureau).167
 ● Stroke was among the top 18 diseases contributing to years 
lived with disability in 2010; of these 18 causes, only the 
age-standardized rates for stroke increased significantly 
between 1990 and 2010 (P<0.05).168
 ● Among Medicare patients discharged from the hospital after 
stroke, ≈45% return directly home, 24% are discharged to 
inpatient rehabilitation facilities, and 31% are discharged 
to skilled nursing facilities. Of stroke patients returning 
directly home, 32% use home healthcare services.169
 ● The 30-day hospital readmission rate after discharge from 
postacute rehabilitation for stroke is 12.7% among fee-for-
service Medicare patients. The mean rehabilitation length 
of stay for stroke is 14.6 days.170
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 ● Visual impairments persist in 21% of stroke survivors 90 
days after stroke.171
 ● Initial severity of upper limb weakness is the best predictor 
of ultimate recovery of upper limb motor function.172
 ● Data from the BRFSS (CDC) 2005 survey on stroke sur-
vivors in 21 states and the District of Columbia found that 
30.7% of stroke survivors received outpatient rehabilitation. 
The findings indicated that the prevalence of stroke survi-
vors receiving outpatient stroke rehabilitation was lower 
than would be expected if clinical practice guideline rec-
ommendations for all stroke patients had been followed.173
 ● After stroke, women have greater disability than men. A 
cross-sectional analysis of 5888 community-living elderly 
people (>65 years of age) in the CHS who were ambula-
tory at baseline found that women were half as likely to be 
independent in activities of daily living after stroke, even 
after controlling for age, race, education, and marital sta-
tus.174 A prospective study from a Michigan-based stroke 
registry found that women had a 63% lower probability 
of achieving independence in activities of daily living 3 
months after discharge, even after controlling for age, race, 
subtype, prestroke ambulatory status, and other patient 
characteristics.175
 ● A national study of inpatient rehabilitation after first stroke 
found that blacks were younger, had a higher proportion of 
hemorrhagic stroke, and were more disabled on admission. 
Compared with non-Hispanic whites, blacks and Hispanics 
also had a poorer functional status at discharge but were 
more likely to be discharged to home rather than to another 
institution, even after adjustment for age and stroke sub-
type. After adjustment for the same covariates, compared 
with non-Hispanic whites, blacks also had less improve-
ment in functional status per inpatient day.176
 ● In a study of 90-day poststroke outcomes among ischemic 
stroke patients in the BASIC Project, Mexican Americans 
scored worse on neurological, functional, and cognitive 
outcomes than non-Hispanic whites after multivariable 
adjustment.177
Stroke in Children
 ● On the basis of pathogenic differences, pediatric strokes 
are typically classified as either perinatal (occurring at 
≤28 days of life and including in utero strokes) or (later) 
childhood.
 ● Estimates of the overall annual incidence of stroke in US 
children are 6.4 per 100 000 children (0 to 15 years) in 
1999 in the GCNKSS178 and 4.6 per 100 000 children (0 to 
19 years) in 1997 to 2003 in a northern California popula-
tion.179 Approximately half of all incident childhood strokes 
are hemorrhagic.178–180
 ● The prevalence of perinatal strokes is 29 per 100 000 live 
births, or 1 per 3500 live births in the 1997 to 2003 Kaiser 
Permanente of Northern California population.179
 ● A history of infertility, preeclampsia, prolonged rupture of 
membranes, and chorioamnionitis are independent maternal 
risk factors for perinatal arterial ischemic stroke.181 However, 
maternal health and pregnancies are normal in most cases.182
 ● Among children aged 1 month to 18 years presenting 
with a “brain attack,” defined as sudden onset focal brain 
dysfunction, 7% have a stroke, whereas more common 
diagnoses are migraine (28%), seizures (15%), and Bell’s 
palsy (10%).183
 ● The most common cause of arterial ischemic stroke in chil-
dren is a cerebral arteriopathy, found in more than half of 
all cases.184,185
 ● The annual incidence of new diagnoses of Moyamoya dis-
ease—a progressive cerebral arteriopathy that is more com-
mon in Asians, particularly Koreans and Japanese—is 0.15 
per 100 000 Taiwanese and 2.3 per 100 000 Koreans, with a 
peak incidence of 3.8 per 100 000 Korean children between 
5 and 10 years of age.186,187
 ● The age-adjusted incidence of stroke in childhood cancer 
survivors is 77 per 100 000 person-years compared with 9.3 
per 100 000 person-years in their siblings. Treatment with 
cranial radiation therapy increases stroke risk in a dose-
dependent fashion.188
 ● HD confers an 8- to 16-fold increased risk of arterial isch-
emic stroke but was present in only 8% of children with 
stroke in a population-based cohort.189 Congenital heart 
defects are 3-fold more common than acquired HD (eg, 
cardiomyopathy or endocarditis) in children with arterial 
ischemic stroke.190
 ● Exposure to minor infection in the prior month is an inde-
pendent risk factor for childhood arterial ischemic stroke, 
present in one third of cases (adjusted OR, 3.9; 95% CI, 
2.0–7.4). Head or neck trauma in the prior week is an even 
stronger risk factor (adjusted OR, 36; 95% CI, 5–281), 
present in 10% of cases.189
 ● Thrombophilias (genetic and acquired) are risk factors for 
childhood stroke, with summary ORs ranging from 1.6 to 
8.8 in a meta-analysis.191
 ● In a prospective Swiss registry,192 atherosclerotic risk fac-
tors were less common in children with arterial ischemic 
stroke than in young adults; the most common of these 
factors in children was hyperlipidemia (15%). However, 
an analysis of the Nationwide Inpatient Sample suggests a 
low but rising prevalence of these factors among US ado-
lescents and young adults hospitalized for ischemic stroke 
(1995 versus 2008).193
 ● Compared with girls, US boys have a 25% increased risk of 
ischemic stroke and a 34% increased risk of ICH, whereas 
a study in the United Kingdom found no sex difference in 
childhood ischemic stroke.194 Compared with white chil-
dren, black children in both the United States and United 
Kingdom have a >2-fold risk of stroke.195 The increased 
risk among blacks is not fully explained by the presence of 
sickle cell disease, nor is the excess risk among boys fully 
explained by trauma.195
 ● The excess ischemic stroke mortality in US black children 
compared with white children has diminished since 1998 
when the STOP trial was published, which established a 
method for primary stroke prevention in children with 
sickle cell disease.196
 ● Among young adult survivors of childhood stroke, 37% had 
a normal modified Rankin score, 42% had mild deficits, 8% 
had moderate deficits, and 15% had severe deficits.197 Con-
comitant involvement of the basal ganglia, cerebral cortex, 
and posterior limb of the internal capsule predicts a persis-
tent hemiparesis.198
 ● Survivors of childhood arterial ischemic stroke have, on 
average, low normal cognitive performance,199,200 with 
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poorest performance in visuoconstructive skills, short-term 
memory, and processing speed. Younger age at stroke and 
seizures, but not laterality of stroke (left versus right), pre-
dict worse cognitive outcome.200
 ● Despite current treatment, 1 of 10 children with ischemic 
or hemorrhagic stroke will have a recurrence within 5 
years.201,202 The 5-year recurrence risk is as high as 60% 
among children with cerebral arteriopathy. The recurrence 
risk after perinatal stroke, however, is negligible.203
 ● Among 59 long-term survivors of pediatric brain aneu-
rysms, 41% developed new or recurrent aneurysm during a 
median follow-up of 34 years; of those, one third developed 
multiple aneurysms.204
 ● More than 25% of survivors of perinatal ischemic strokes 
develop delayed seizures within 3 years; babies with larger 
strokes are at higher risk.205 The cumulative risk of delayed 
seizures after later childhood stroke is 13% at 5 years and 
30% at 10 years.206 Children with acute seizures (within 7 
days of their stroke) have the highest risk for delayed sei-
zures, >70% by 5 years after the stroke.207
Stroke in the Very Elderly
 ● Stroke patients >85 years of age make up 17% of all stroke 
patients.208
 ● Very elderly patients have a higher risk-adjusted mor-
tality,209 have higher disability,209 have longer hospital-
izations,210 receive less evidenced-based care,211,212 and 
are less likely to be discharged to their original place of 
residence.210,213
 ● According to analyses from the US Nationwide Inpatient 
Sample, over the past decade, in-hospital mortality rates 
after stroke have declined for every age/sex group except 
men aged >84 years.214
 ● Over the next 40 years (2010–2050), the number of incident 
strokes is expected to more than double, with the major-
ity of the increase among the elderly (aged ≥75 years) and 
minority groups.215
Organization of Stroke Care
 ● Among 30 947 patients hospitalized with acute ischemic 
stroke in the state of New York between 2005 and 2006, 
admission to a designated stroke center was associated 
with lower 30-day mortality (10.1% versus 12.5%; adjusted 
mortality difference, −2.5%; 95% CI, −3.6% to −1.4%) and 
greater use of thrombolytic therapy (4.8% versus 1.7%; 
adjusted difference, 2.2%; 95% CI, 1.6%–2.8%), but there 
was no difference in 30-day all-cause readmission or dis-
charge to a skilled nursing facility.216
 ● A study using Medicare data found that among 6197 SAH 
and 31 272 ICH stroke discharges in 2006, patients treated 
at Joint Commission–certified primary stroke centers had 
lower 30-day risk-adjusted mortality than patients treated at 
noncertified centers (SAH OR, 0.66 [95% CI, 0.58–0.76]; 
ICH OR, 0.86 [95% CI, 0.80–0.92]), but no difference was 
seen for 30-day all-cause readmission.217
 ● A Cochrane review of 28 trials involving 5855 participants 
concluded that stroke patients who receive organized inpa-
tient care in a stroke unit had better outcomes, including a 
decreased odds of mortality (median of 1 year; OR, 0.87; 
95% CI, 0.69–0.94), death or institutionalized care (0.78; 
95% CI, 0.68–0.89), and death or dependency (OR, 0.79; 
95% CI, 0.68–0.90) than patients treated in an alternative 
form of inpatient care. The findings were independent of 
patient age, sex, initial stroke severity, or stroke type.218
 ● Data have shown a steady increase in the proportion of isch-
emic stroke patients who are treated with tPA therapy. For 
example, administrative data in 2009 found that between 
3.4% and 5.2% of acute ischemic strokes were treated with 
tPA, which was approximately double the treatment rate 
observed in 2005.219 Similarly, analysis of data from the 
GWTG-Stroke program demonstrated substantial increases 
in tPA treatment rates over the period from 2003 to 2011.220
 ● Analysis of tPA-treated patients in the GWTG-Stroke pro-
gram between 2003 and 2009 found that the majority were 
not treated within the guideline-recommended interval 
of 60 minutes from hospital arrival and that this propor-
tion had increased only modestly during this period (from 
19% in 2003 to 29% in 2009).221 Paradoxically, door-to-
needle times were found to be inversely related to onset to 
arrival times; thus, tPA-treated patients who arrived earlier 
were less likely to receive treatment within 60 minutes of 
arrival.222
 ● Implementation of Target Stroke, a national quality 
improvement initiative to improve the timeliness of tPA 
administration, found that among 71 169 patients with 
acute ischemic stroke treated with tPA at 1030 GWTG-
Stroke participating hospitals, participation in the program 
was associated with a decreased door-to-needle time, lower 
in-hospital mortality (OR, 0.89; 95% CI, 0.83–0.94) and 
intracranial hemorrhage (OR, 0.83; 95% CI, 0.76–0.91), 
and an increase in the percentage of patients discharged 
home (OR, 1.14; 95% CI, 1.09–1.19).223
 ● Approximately 70% of Medicare beneficiaries discharged 
with acute stroke use Medicare-covered postacute care,224 
with most receiving care from more than 1 type of set-
ting.225,226 The majority of stroke patients receive rehabilita-
tion care in a skilled nursing facility after discharge (32%), 
followed by an inpatient rehabilitation facility (22%), and 
then home health care (15%).227
 ● The proportion of stroke patients not referred to any post-
acute care has increased in recent years,227 with an analysis 
of 2006 Medicare data finding that proportion to be as high 
as 42%.228
Hospital Discharges/Ambulatory Care Visits
(See Table 14-1.)
 ● From 2000 to 2010, the number of inpatient discharges 
from short-stay hospitals with stroke as the first-listed diag-
nosis remained about the same, with discharges of 981 000 
and 1 015 000, respectively (NHDS, NHLBI tabulation).229
 ● Data from 2010 from the NHDS of the NCHS showed 
that the average length of stay for discharges with stroke 
as the first-listed diagnosis was 6.1 days (median, 3 days) 
compared with 9.5 days (median, 6 days) in 1990 (NHDS, 
NHLBI tabulation).229
 ● In 2010, men and women accounted for roughly the same 
number of hospital stays for stroke in the 18- to 44-year-old 
age group. Among people 45 to 64 years of age, 57.1% of 
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stroke patients were men. After 65 years of age, women were 
the majority. Among people 65 to 84 years of age, 53.4% of 
stroke patients were women, whereas among those ≥85 years 
of age, women constituted 66.2% of all stroke patients.230
 ● A first-ever county-level Atlas of Stroke Hospitalizations 
Among Medicare Beneficiaries was released in 2008 by 
the CDC in collaboration with the Centers for Medicare & 
Medicaid Services. It found that the stroke hospitalization 
rate for blacks was 27% higher than for the US population 
in general, 30% higher than for whites, and 36% higher 
than for Hispanics. In contrast to whites and Hispanics, the 
highest percentage of strokes in blacks (42.3%) occurred in 
the youngest Medicare age group (65–74 years of age).56
 ● In 2010, there were 671 000 ED visits and 257 000 outpa-
tient department visits with stroke as the first-listed diagnosis 
(NHAMCS, unpublished NHLBI tabulation). In 2010, phy-
sician office visits for a first-listed diagnosis of stroke totaled 
2 207 000 (NAMCS, unpublished NHLBI tabulation).229
Operations and Procedures
(See Chart 14-12.)
 ● In 2010, an estimated 100 000 inpatient endarterectomy 
procedures were performed in the United States. Carotid 
endarterectomy is the most frequently performed surgical 
procedure to prevent stroke (NHDS, NHLBI tabulation).
 ● Although rates of carotid endarterectomy have decreased 
between 1997 and 2010, the use of carotid stenting has 
increased dramatically (Nationwide Inpatient Sample, 
HCUP, AHRQ).
 ● The practice of carotid stenting in the United States is 
expanding, from <3% of all carotid artery revascularization 
procedures in 1998 to 13% in 2008.231
 ● The randomized CREST study compared carotid endarter-
ectomy and stenting for symptomatic and asymptomatic 
carotid stenosis. There was no overall difference in the pri-
mary end point of stroke, MI, or death; however, carotid 
endarterectomy showed superiority with increasing age, 
with the crossover point at approximately age 70 years, 
and was associated with fewer strokes, which had a greater 
impact on quality of life than MI.232,233
 ● In-hospital mortality for carotid endarterectomy has 
decreased steadily from 1993 to 2010 (Nationwide Inpa-
tient Sample, HCUP, AHRQ).
 ● In the Medicare population, in-hospital stroke rate and 
mortality are similar for carotid endarterectomy and carotid 
stenting.234
 ● Carotid stenting is associated with significantly higher costs 
than carotid endarterectomy in asymptomatic patients235 
and may be less cost-effective in general.236
 ● The percentage of patients undergoing carotid endarterec-
tomy within 2 weeks of the onset of stroke increased from 
13% in 2007 to 47% in 2010.237
Cost
(See Table 14-1.)
 ● In 2011:
—The direct and indirect cost of stroke was $33.6 billion 
(MEPS, NHLBI tabulation).
—The estimated direct medical cost of stroke was $17.5 
billion. This includes hospital outpatient or office-based 
provider visits, hospital inpatient stays, ED visits, pre-
scribed medicines, and home health care.238
—The mean expense per patient for direct care for any type 
of service (including hospital inpatient stays, outpatient 
and office-based visits, ED visits, prescribed medicines, 
and home health care) in the United States was esti-
mated at $4692.238
 ● Between 2012 and 2030, total direct medical stroke-related 
costs are projected to triple, from $71.6 billion to $184.1 
billion, with the majority of the projected increase in costs 
arising from those 65 to 79 years of age.9
 ● The total cost of stroke from 2005 to 2050, in 2005 dollars, 
is projected to be $1.52 trillion for non-Hispanic whites, 
$313 billion for Hispanics, and $379 billion for blacks. 
The per capita cost of stroke estimate is highest in blacks 
($25 782), followed by Hispanics ($17 201) and non-His-
panic whites ($15 597). Loss of earnings is expected to be 
the highest cost contributor in each race/ethnic group.239
 ● During 2001 to 2005, the average cost for outpatient stroke 
rehabilitation services and medications the first year after 
inpatient rehabilitation discharge was $11 145. The cor-
responding average yearly cost of medication was $3376, 
whereas the average cost of yearly rehabilitation service 
utilization was $7318.240
 ● Recurrent stroke patients had 38% higher costs per patient 
1 year after discharge from index hospitalization than new 
stroke patients.241
 ● In adjusted models that controlled for relevant covariates, 
the attributable 1-year cost of poststroke aphasia was esti-
mated at $1703 in 2004 dollars.242
 ● Data from Sweden show that healthcare costs associated 
with stroke survivors with spasticity are 4-fold higher than 
for stroke survivors without spasticity.243
 ● The estimated cost of acute pediatric stroke in the United 
States was $42 million in 2003. The mean cost of short-
term hospital care was $20 927 per discharge.244
 ● After adjustment for routine healthcare costs, the average 
5-year cost of a neonatal stroke was $51 719 and that of a 
childhood stroke was $135 161. Costs among children with 
stroke continued to exceed those in age-matched control 
children even in the fifth year by an average of $2016.245
Global Burden of Stroke
Although global age-adjusted mortality rates for ischemic and 
hemorrhagic stroke decreased between 1990 and 2010, the 
absolute number of people who have strokes annually, as well 
as related deaths and DALYs lost, increased. The majority of 
global stroke burden is in low-income and middle-income 
countries.246
 ● Worldwide in 2010
—Prevalence of stroke was 33 million, with 16.9 million 
people having a first stroke.247
—5.2 million (31%) first strokes were in those <65 years 
of age.247
—There were an estimated 11.6 million events of inci-
dent ischemic stroke and 5.3 million events of incident 
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hemorrhagic stroke, 63% and 80%, respectively, in low- 
and middle-income countries.246
—Stroke was the second-leading global cause of death 
behind ischemic HD, accounting for 11.13% of total 
deaths worldwide.248
—2.8 million individuals died of ischemic stroke and 3.0 
million of hemorrhagic stroke (57% and 84%, respec-
tively, in low- and middle-income countries).246
—39.4 million DALYs were lost because of ischemic 
stroke and 62.8 million because of hemorrhagic stroke 
(64% and 85%, respectively, in low- and middle-income 
countries).246
 ● Between 1990 and 2010246
—Incidence of ischemic stroke was significantly reduced 
by 13% (95% CI, 6%–18%) in high-income countries. 
No significant change was seen in low- or middle-
income countries.
—Incidence of hemorrhagic stroke decreased by 19% (95% 
CI, 9%–15%) in high-income countries. Rates increased 
by 22% (95% CI, 5%–30%) in low- and middle-income 
countries, with a 19% (95% CI, 5%–30%) increase in 
those aged <75 years.
—Ischemic stroke mortality decreased 37% in high-income 
countries and by 14% in low- and middle-income 
countries.
—Hemorrhagic stroke mortality decreased 38% in high-
income countries and by 23% in low- and middle-
income countries.
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Table 14-1.  Stroke
Population Group
Prevalence, 2012: Age 
≥20 y
New and Recurrent 
Attacks, All Ages Mortality, 2011: All Ages*
Hospital Discharges, 2010: 
All Ages Cost, 2011
Both sexes 6 600 000 (2.6%) 795 000 128 932 1 015 000 $33.6 Billion
Males 3 000 000 (2.6%) 370 000 (46.5%)† 52 335 (40.6%)† 485 000 …
Females 3 600 000 (2.7%) 425 000 (53.5%)† 76 597 (59.4%)† 530 000 …
NH white males 2.2% 325 000‡ 43 264 … …
NH white females 2.5% 365 000‡ 65 278 … …
NH black males 4.2% 45 000‡ 7039 … …
NH black females 4.7% 60 000‡ 8814 … …
Hispanic males 2.8% … * … …
Hispanic females 2.0% … * … …
Asian … … 3937§ … …
American Indian or Alaska 
Native
2.7%║¶ … 600 … …
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths of people of Hispanic and non-Hispanic 
origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total stroke incidence or mortality that applies to males vs females.
‡Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
§ Includes Chinese, Filipino, Hawaiian, Japanese, and other Asian or Pacific Islander. 
║ National Health Interview Survey (2013), National Center for Health Statistics; data are weighted percentages for Americans ≥18 years of age.249
¶Estimate considered unreliable or does not meet standards of reliability or precision.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012, National Center for Health Statistics (NCHS) and National Heart, Lung, and 
Blood Institute (NHLBI). Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 
US population. Incidence: Greater Cincinnati/Northern Kentucky Stroke Study/National Institutes of Neurological Disorders and Stroke data for 1999 provided on August 
1, 2007. US estimates compiled by NHLBI. See also Kissela et al.250 Data include children. Mortality: Centers for Disease Control and Prevention/NCHS, 2011 Mortality 
Multiple Cause-of-Death–United States. These data represent underlying cause of death only. Mortality data for white and black males and females include Hispanics. 
Hospital discharges: National Hospital Discharge Survey, NCHS. Data include those inpatients discharged alive, dead, or status unknown. Cost: NHLBI. Data include 
estimated direct and indirect costs for 2011.
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Table 14-2. Modifiable Stroke Risk Factors
Factor Prevalence, % PAR, %* RR
Cigarette smoking
  Overall 19.8 12–14† 1.9
   Men 22.3
   Women 17.4
Hypertension ‡ 8
  Ages 20–34 y
   Men 13.4 99
   Women 6.2 98
  Ages 35–44 y
   Men 23.2 99
   Women 16.5 106
  Ages 45–54 y
   Men 36.2 100
   Women 35.9 103
  Ages 55–64 y
   Men 53.7 100
   Women 55.8 102
  Ages 65–74 y
   Men 64.7 100
   Women 69.6 101
  Ages ≥75 y
   Men 64.1 100
   Women 76.4 101
Diabetes mellitus 7.3 5–27 1.8–6.0
High total cholesterol Data calculated for highest 
quintile (20%) vs lowest 
quintile
9.1 (5.7–13.8) 1.5 (95% CI, 1.3–1.8)
Continuous risk for ischemic 
stroke
… 1.25 per 1-mmol/L (38.7 
mg/dL) increase
Low HDL cholesterol
  <40 mg/dL
   Men 35
   Women 15
Data calculated for highest 
quintile (20%) vs lowest 
quintile
23.7 0.4
  <35 mg/dL 26 20.6 (10.1–30.7) 2.00 (95% CI, 1.43–2.70)
Continuous risk for ischemic 
stroke
≈0.5–0.6 for each 
1-mmol/L increase
AF (nonvalvular)
  Overall age, y
   50–59 0.5 1.5 4.0
   60–69 1.8 2.8 2.6
   70–79 4.8 9.9 3.3
   80–89 8.8 23.5 4.5
Asymptomatic carotid stenosis 2–8 2–7§ 2.0
Sickle cell disease 0.25 (of blacks) … 200–400║
Postmenopausal hormone 
therapy
25 (Women 50–74 y of age) 9 1.4
Oral contraceptive use 13 (women 25–44 y) 9.4 2.3
(Continued)
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Chart 14-1. Prevalence of stroke by age and sex (National Health and Nutrition Examination Survey: 2009–2012). Source: National Cen-
ter for Health Statistics and National Heart, Lung, and Blood Institute.
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Age (Years)
Men Women
Dietary factors
  Na intake >2300 mg 75–90 Unknown Unknown
  K intake <4700 mg 90–99 Unknown Unknown
Physical inactivity 25 30 2.7
Obesity 1.39 Stroke death per 
increase of 5 kg/m2
  Men 33.3
  Women 35.3
CHD
  Men 8.4 5.8 1.73 (1.68–1.78)
  Women 5.6 3.9¶ 1.55 (1.17–2.07)
Heart failure
  Men 2.6 1.4
  Women 2.1 1.1¶
Peripheral arterial disease 4.9 3.0¶
AF indicates atrial fibrillation; CHD, coronary heart disease; CI, confidence interval; HDL, high-density lipoprotein; 
PAR, population attributable risk; and RR, relative risk.
*PAR is the proportion of ischemic stroke in the population that can be attributed to a particular risk factor (see 
Goldstein et al101 for formula).
†PAR is for stroke deaths, not ischemic stroke incidence.
‡PAR percent=100×{[prevalence (RR−1)/prevalence (RR−1)+1]}.
§Calculated on the basis of referenced data provided in the table or text.
║Relative to stroke risk in children without sickle cell disease.
¶Calculated on the basis of point estimates of referenced data provided in the table. For peripheral arterial 
disease, calculation was based on average RR for men and women.
Adapted from Goldstein et al101 with permission. Copyright © 2011, American Heart Association, Inc.
Table 14-2. Continued
Factor Prevalence, % PAR, %* RR
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Chart 14-3. Annual rate of first cerebral infarction by age, sex, and race (Greater Cincinnati/Northern Kentucky Stroke Study: 1999). 
Rates for black men and women 45 to 54 years of age and for black men ≥75 years of age are considered unreliable. Source: Unpub-
lished data from the Greater Cincinnati/Northern Kentucky Stroke Study.
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Chart 14-2. Annual age-adjusted incidence of first-ever stroke by race. Hospital plus out-of-hospital ascertainment, 1993 to 1994, 1999, 
and 2005. ICH indicates intracerebral hemorrhage; and SAH, subarachnoid hemorrhage. Data derived from Kleindorfer et al.13
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Chart 14-4. Annual rate of all first-ever strokes by age, sex, and race (Greater Cincinnati/Northern Kentucky Stroke Study: 1999). Rates 
for black men and women 45 to 54 years of age and for black men ≥75 years of age are considered unreliable.
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Chart 14-5. Age-adjusted incidence of stroke/transient ischemic attack by race and sex, ages 45 to 44 years, Atherosclerosis Risk 
in Communities study cohort, 1987 to 2001. Data derived from the National Heart, Lung, and Blood Institute’s 2006 Chart Book on 
 Cardiovascular and Lung Diseases.251
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Chart 14-7. Stroke death rates, 2008 through 2010. Adults ≥35 years of age, by county. Rates are spatially smoothed to enhance the 
stability of rates in counties with small populations. International Classification of Diseases, 10th Revision codes for stroke: I60 through 
I69. Data source: National Vital Statistics System and the US Census Bureau.
Chart 14-6. Age-adjusted death rates for stroke by sex and race/ethnicity, 2011. Death rates for the American Indian/Alaska Native and 
Asian or Pacific Islander populations are known to be underestimated. Stroke includes International Classification of Diseases,  
10th  Revision codes I60 through I69 (cerebrovascular disease). Source: National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
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Chart 14-8. Estimated 10-year stroke risk in adults 55 years of age according to levels of various risk factors (Framingham Heart Study). 
AF indicates atrial fibrillation; and CVD, cardiovascular disease. Data derived from Wolf et al252 with permission of the publisher. Copyright 
© 1991, American Heart Association.
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Chart 14-9. Proportion of patients dead 1 year after first stroke. Source: Pooled data from the Framingham Heart Study, Atherosclerosis 
Risk in Communities Study, and Cardiovascular Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-11. Proportion of patients with recurrent stroke in 5 years after first stroke. Source: Pooled data from the Framingham Heart 
Study, Atherosclerosis Risk in Communities Study, and Cardiovascular Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-10. Proportion of patients dead within 5 years after first stroke. Source: Pooled data from the Framingham Heart Study, Athero-
sclerosis Risk in Communities Study, and Cardiovascular Health Study of the National Heart, Lung, and Blood Institute.
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Chart 14-12. Trends in carotid endarterectomy and carotid stenting procedures (United States: 1980–2010). Source: Nationwide Inpa-
tient Sample, Healthcare Cost and Utilization Project, Agency for Healthcare Research and Quality.
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15 . Congenital Cardiovascular 
Defects and Kawasaki Disease
ICD-9 745 to 747, ICD-10 Q20 to Q28. See Tables 15-1 
through 15-4.
Congenital cardiovascular defects, also known as congenital 
heart defects, are structural problems that arise from abnormal 
formation of the heart or major blood vessels. ICD-9 lists 25 
congenital heart defect codes, of which 21 designate specific 
anatomic or hemodynamic lesions; however, there are many 
more lesions that are not well described by ICD-9 or ICD-10 
codes because of the wide diversity of congenital heart malfor-
mations. Defects range in severity from tiny pinholes between 
chambers that may resolve spontaneously to major malfor-
mations that can require multiple surgical procedures before 
school age and may result in death in utero, in infancy, or in 
childhood. As such, congenital heart defects are serious and 
common conditions that have a significant impact on morbidity, 
mortality, and healthcare costs in children and in adults.1 Some 
types of congenital heart defects are associated with depression2 
and diminished quality of life. Health outcomes are improving 
for congenital cardiovascular defects and survival is increasing, 
leading to a population shift toward adulthood, which means 
there are many more adults with both congenital heart disease 
and adult medical diagnoses,3 adding to the complexity of their 
management4,5 and emphasizing the need for coordinated care 
by an adult congenital heart defects specialist.6
Incidence
The incidence of congenital heart defects in the United States 
is commonly reported as being between 4 and 10 per 1000, 
clustering around 8 per 1000 live births.7 Incidence (birth 
prevalence) in Europe is reported as 6.9 per 1000 births; birth 
prevalence in Asia is reported as 9.3 per 1000.8 Variations in 
incidence rates may be related to the age at detection; major 
defects may be apparent in the prenatal or neonatal period, but 
minor defects may not be detected until adulthood, making it 
challenging to estimate incidence and prevalence. To distin-
guish more serious defects, some studies report the number of 
new cases of sufficient severity to result in death or an invasive 
procedure within the first year of life, in addition to overall 
birth prevalence. Incidence rates are likely to increase over 
time because of better detection by fetal cardiac ultrasound,9 
screening pulse oximetry,10 and echocardiography during 
infancy.
Overall Incidence
(See Table 15-2.)
 ● Population-based data from the MACDP in Atlanta, GA: 
Congenital heart defects occurred in 1 of every 111 to 125 
births (live, still, or >20 weeks’ gestation) from 1995 to 
1997 and from 1998 to 2005. Some defects showed varia-
tions by sex and racial distribution.11
 ● Population-based data from Alberta, Canada: Total preva-
lence of 12.42 per 1000 total births (live, still, or >20 
weeks’ gestation).12
 ● An estimated minimum of 40 000 infants are expected to be 
affected by congenital heart defects each year in the United 
States. Of these, ≈25%, or 2.4 per 1000 live births, require 
invasive treatment in the first year of life.13
Incidence of Specific Defects
 ● The National Birth Defects Prevention Network for 13 
states in the United States from 2004 to 2006 showed the 
average prevalence of 21 selected major birth defects. These 
data indicated that there are >6100 estimated annual cases 
of 5 cardiovascular defects: truncus arteriosus (0.07/1000 
births), TGA (0.3/1000 births), TOF (0.4/1000 births), AV 
septal defect (0.47/1000 births), and HLHS (0.23/1000 
births).14
 ● MACDP data for specific defects at birth: VSD, 4.2/1000 
births; ASD, 1.3/1000 births; valvar pulmonic stenosis, 
0.6/1000 births; TOF, 0.5/1000 births; aortic coarctation, 
0.4/1000 births; AV septal defect, 0.4/1000 births; and 
TGA (0.2/1000 births).11,15
 ● Bicuspid aortic valve occurs in 13.7 per 1000 people; these 
defects may not require treatment in infancy but can cause 
problems later in adulthood.16
Prevalence
(See Tables 15-1 through 15-3.)
The 32nd Bethesda Conference estimated that the total 
number of adults living with congenital HD in the United 
States in 2000 was 800 000.1,17 In the United States, 1 in 150 
adults are expected to have some form of congenital HD.5 In 
population data from Canada, the measured prevalence of 
congenital heart defects in the general population was 11.89 
Abbreviations Used in Chapter 15
AHA American Heart Association
ASD atrial septal defect
AV atrioventricular
BMI body mass index
CABG coronary artery bypass graft
CDC Centers for Disease Control and Prevention
CI confidence interval
DM diabetes mellitus
HCUP Healthcare Cost and Utilization Project
HD heart disease
HLHS hypoplastic left heart syndrome
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
KD Kawasaki disease
MACDP Metropolitan Atlanta Congenital Defects Program
NCHS National Center for Health Statistics
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
RR relative risk
STS Society of Thoracic Surgeons
TGA transposition of the great arteries
TOF tetralogy of Fallot
VSD ventricular septal defect
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per 1000 children and 4.09 per 1000 adults in the year 2000.18 
Extrapolated to the US population in the same year, this yields 
published estimates of 859 000 children and 850 000 adults for 
the year 2000.15 The expected growth rates of the congenital 
heart defects population vary from 1% to 5% per year depend-
ing on age and the distribution of lesions.16 Limited infor-
mation is available about the prevalence of congenital heart 
defects outside the United States. The overall birth prevalence 
of congenital heart defects at the Bhabha Atomic Research 
Centre Hospital in Mumbai from 2006 through 2011 was 
13.28 per 1000 live births.19
Estimates of the distribution of lesions in the congenital heart 
defects population using available data vary with assumptions 
made. If all those born with congenital heart defects between 
1940 and 2002 were treated, there would be 750 000 survi-
vors with simple lesions, 400 000 with moderate lesions, and 
180 000 with complex lesions; in addition, there would be 3.0 
million subjects alive with bicuspid aortic valves.20 Without 
treatment, the number of survivors in each group would be 
400 000, 220 000, and 30 000, respectively. The actual num-
bers surviving were projected to be between these 2 sets of 
estimates as of 1 decade ago.20 Using measurements from 
population data in Canada, the prevalence of severe forms 
of congenital heart defects increased 85% in adults and 22% 
in children from 1985 to 2000.18 The most common types of 
defects in children are VSD, 620 000 people; ASD, 235 000 
people; valvar pulmonary stenosis, 185 000 people; and patent 
ductus arteriosus, 173 000 people.20 The most common lesions 
seen in adults are ASD and TOF.17
Mortality
(See Tables 15-1 and 15-4.)
 ● Overall mortality attributable to congenital heart defects:
—In 2011:
 ◯ Mortality related to congenital cardiovascular defects 
was 3166 deaths. Any-mention mortality related to 
congenital cardiovascular defects was 4900 deaths.21
 ◯ In 2011, congenital cardiovascular defects (ICD-10 
Q20–Q28) were the most common cause of infant 
deaths resulting from birth defects (ICD-10 Q00–
Q99); 23.8% of infants who died of a birth defect had 
a heart defect.21
 ◯ The age-adjusted death rate (deaths per 100 000 peo-
ple) attributable to congenital cardiovascular defects 
was 1.0.22
—In population-based data from Canada, 8123 deaths 
occurred among 71 686 patients with congenital heart 
defects followed up for nearly 1 million patient-years.5
—In 2007, 189 000 life-years were lost before 55 years of 
age because of deaths attributable to congenital cardio-
vascular defects. This is almost as many life-years as 
were lost from leukemia and asthma combined (NHLBI 
tabulation of NCHS mortality data).
—Death rates attributed to congenital heart defects 
decrease as gestational age advances toward 40 weeks,23 
and similarly, in-hospital death of infants with major 
congenital HDs is independently associated with late-
preterm birth (OR, 2.70; 95% CI, 1.69–4.33) compared 
with delivery at later gestational ages.24 The presence of 
congenital heart defects substantially increases mortal-
ity of very low-birth-weight infants; in a study of very 
low-birth-weight infants, the mortality rate with serious 
congenital heart defects was 44% compared with 12.7% 
in very low-birth-weight infants without serious con-
genital HD.25
 ● Congenital heart defect–related mortality varies substan-
tially by age, with infants showing the highest mortality 
rates.
—Analysis of the STS Congenital Heart Surgery Database, 
a voluntary registry with self-reported data for a 4-year 
cycle (2007–2010) from 103 centers performing con-
genital heart defects surgery (98 from the United States, 
3 from Canada, and 1 from Japan),26 showed that of 
95 357 total operations, the aggregate hospital discharge 
mortality rate was 3.5%.27 The mortality rate was 10.1% 
for neonates (0–30 days of age),28 2.9% for infants (31 
days to 1 year of age),29 1.1% for children (>1 year to 18 
years of age),30 and 1.9% for adults (>18 years of age).31
 ● Congenital heart defect mortality varies by race/ethnicity 
and sex.
—The US 2011 age-adjusted death rate (deaths per 100 000 
people) attributable to congenital cardiovascular defects 
was 1.2 for white males, 1.3 for black males, 0.9 for 
white females, and 1.1 for black females. Infant (<1 year 
of age) death rates were 33.7 for white infants, 40.3 for 
black infants, 26.6 for Asian or Pacific Islander infants, 
and 31.1 for American Indian or Alaska Natives.22
—Mortality after congenital heart surgery also differs 
between races/ethnicity, even after adjustment for access 
to care. The risk of in-hospital mortality for minority 
patients compared with white patients is 1.22 (95% CI, 
1.05–1.41) for Hispanics, 1.27 (95% CI, 1.09–1.47) for 
non-Hispanic blacks, and 1.56 (95% CI, 1.37–1.78) for 
other non-Hispanics.32 Similarly, another study found 
that a higher risk of in-hospital mortality was associated 
with nonwhite race (OR, 1.36; 95% CI, 1.19–1.54), as 
well as Medicaid insurance (OR, 1.26; 95% CI, 1.09–
1.46).33 One center’s experience suggested race was 
independently associated with neonatal surgical out-
comes only in the patients with less complex congenital 
heart defects.34
—Data from HCUP’s Kids’ Inpatient Database from 2000, 
2003, and 2006, show male children had more congeni-
tal heart defects surgeries in infancy, more high-risk 
surgeries, and more procedures to correct multiple car-
diac defects. Female infants with high-risk congenital 
heart defects had a 39% higher adjusted mortality than 
males.35 According to CDC multiple-cause death data 
from 1999 to 2006, sex differences in mortality over 
time varied with age. Between the ages of 18 and 34 
years, mortality over time decreased significantly in 
females but not in males.36
 ● Congenital heart defect mortality is declining.
—In studies looking at trends since 1979, age-adjusted 
death rates declined 22%37 for critical congenital 
heart defects, 39%38 for all congenital heart defects, 
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and deaths tended to occur at progressively older 
ages.  CDC mortality data from 1979 to 2005 show 
all-age death rates have declined by 60% for VSD and 
40% for TOF.39 Population-based data from Canada 
show overall mortality has decreased by 31%, and the 
median age of death has increased from 2 to 23 years 
between 1987 and 2005.5
—Further analysis of the Kids’ Inpatient Database from 
2000 to 2009 showed a decrease in HLHS stage 3 
mortality by 14% and a decrease in stage 1 mortality 
by 6%.40 Surgical interventions are the primary treat-
ment for reducing mortality. A Pediatric Heart Network 
study of 15 North American centers revealed that even 
in lesions associated with the highest mortality, such as 
HLHS, aggressive palliation can lead to an increase in 
the 12-month survival rate, from 64% to 74%.41 Surgi-
cal interventions are common in adults with congeni-
tal heart defects. Mortality rates for 12 congenital heart 
defect procedures were examined using data from 1988 
to 2003 reported in the Nationwide Inpatient Sample. A 
total of 30 250 operations were identified, which yielded 
a national estimate of 152 277±7875 operations. Of 
these, 27% were performed in patients ≥18 years of age. 
The overall in-hospital mortality rate for adult patients 
with congenital heart defects was 4.71% (95% CI, 
4.19%–5.23%), with a significant reduction in mortal-
ity observed when surgery was performed on such adult 
patients by pediatric versus nonpediatric heart surgeons 
(1.87% versus 4.84%; P<0.0001).42
Risk Factors
 ● Numerous intrinsic and extrinsic nongenetic risk factors 
contribute to congenital heart defects.43
 ● Intrinsic risk factors for congenital heart defects include 
various genetic syndromes. Twins are at higher risk for con-
genital heart defects44; one report from Kaiser Permanente 
data showed monochorionic twins were at particular risk 
(RR, 11.6; CI, 9.2–14.5).45 Known risks generally focus on 
maternal exposures, but a study of paternal occupational 
exposure documented a higher incidence of congenital HD 
with paternal exposure to phthalates.46
 ● Other paternal exposures that increase risk for congenital 
heart defects include paternal anesthesia, which has been 
implicated in TOF (3.6%); sympathomimetic medication 
and coarctation of the aorta (5.8%); pesticides and VSDs 
(5.5%); and solvents and HLHS (4.6%).47
 ● Known maternal risks include maternal smoking48 during 
the first trimester of pregnancy, which has also been associ-
ated with a ≥30% increased risk of the following lesions 
in the fetus: ASD, pulmonary valvar stenosis, truncus arte-
riosus, TGA,49 and septal defects (particularly for heavy 
smokers [≥25 cigarettes daily]).50
 ● Exposure to secondhand smoke has also been implicated 
as a risk factor.51
 ● Maternal binge drinking52 is also associated with an 
increased risk of congenital cardiac defects, and the combi-
nation of binge drinking and smoking may be particularly 
dangerous: Mothers who smoke and report any binge drink-
ing in the 3 months before pregnancy are at an increased 
risk of giving birth to a child with congenital heart defects 
(adjusted OR, 12.65).52
 ● A greater risk of congenital heart defects is also seen in 
women who both have a high BMI.53,54
 ● Gestational DM has also been associated with cardiac 
defects, both isolated and multiple.55
 ● Folate deficiency is a well-accepted risk for congenital 
defects, including congenital heart defects, and folic acid 
supplementation is recommended during pregnancy.43
 ● A US population-based case-control study showed 
an inverse relationship between folic acid use and the 
risk of TGA (Baltimore-Washington Infant Study, 
1981–1989).57
 ● An observational study from Quebec, Canada, of 1.3 mil-
lion births from 1990 to 2005 found a 6% per year reduc-
tion in severe congenital heart defects using a time-trend 
analysis before and after public health measures were 
instituted that mandated folic acid fortification of grain and 
flour products in Canada.58
 ● High altitude has also been described as a risk factor for 
congenital heart defects; Tibetan children living at 4200 
to 4900 m had a higher prevalence of congenital heart 
defects, 12.09 per 1000 versus lower altitudes of 3500 to 
4100 m; patent ductus arteriosus and ASD contributed to 
the increased prevalence.59
Screening
Pulse oximetry screening for critical congenital heart dis-
ease, a group of defects that cause severe and life-threatening 
symptoms and require intervention within the first days or 
first year of life, was recommended by the US Department 
of Health and Human Services on October 15, 2010,60 was 
incorporated as part of the US recommended uniform screen-
ing panel for newborns in 2011, and has been endorsed by the 
AHA and the American Academy of Pediatrics.61 The recom-
mendation has been controversial, yet several studies demon-
strate benefit.62–64
 ● Several key factors contribute to effective screening, 
including probe placement (postductal), oximetry cutoff 
(<95%), timing (>24 hours of life), and altitude (<2643 
ft, 806 m).
 ● If fully implemented, screening would identify 1189 addi-
tional infants with critical congenital heart defects and 
would result in 1975 false-positive results.65
 ● The cost of identifying a newborn with critical congeni-
tal heart defects has been estimated at $20 862 per new-
born detected and $40 385 per life-year gained (2011 US 
dollars).
 ● A meta-analysis of 13 studies that included 229 421 new-
borns found pulse oximetry had a sensitivity of 76.5% 
(95% CI, 67.7%–83.5%) for detection of critical con-
genital heart defects and a specificity of 99.9% (95% CI, 
99.7%–99.9%) with a false-positive rate of 0.14% (95% CI, 
0.06%–0.33%).66
Hospitalizations
(See Table 15-1.)
 ● In 2004, birth defects accounted for >139 000 hospitaliza-
tions, representing 47.4 stays per 100 000 people. Cardiac 
and circulatory congenital anomalies accounted for 34% of 
all hospital stays for birth defects. Between 1997 and 2004, 
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hospitalization rates increased by 28.5% for cardiac and 
circulatory congenital anomalies.67
 ● Although the most common congenital heart defect lesions 
were shunts, including patent ductus arteriosus, VSDs, and 
ASDs, TOF accounted for a higher proportion of in-hospi-
tal death than any other birth defect.
Cost
 ● Hospital costs for congenital heart defects totaled $2.6 
 billion in 2004. The highest aggregate costs were for stays 
related to cardiac and circulatory congenital anomalies, 
which accounted for ≈$1.4 billion, more than half of all 
hospital costs for birth defects.67
 ● Data from the HCUP 2003 Kids’ Inpatient Database and 
2003 information on birth defects in the Congenital Mal-
formations Surveillance Report found the most expensive 
average neonatal hospital charges were for 2 congenital 
heart defect lesions: HLHS ($199 597) and truncus arterio-
sus ($192 781). Two other congenital heart defect diagno-
ses, coarctation of the aorta and TGA, were associated with 
average hospital charges in excess of $150 000. For the 
11 selected congenital heart defect diagnoses (of 35 birth 
defects considered), there were 11 578 hospitalizations in 
2003 and 1550 in-hospital deaths (13.4%). Estimated total 
hospital charges for these 11 conditions were $1.4 billion 
in 2003.68
 ● Other studies confirm the high cost of HLHS. An analy-
sis of 1941 neonates with HLHS showed a median cost 
of $99 070 for stage 1 palliation (Norwood or Sano pro-
cedure), $35 674 for stage 2 palliation (Glenn procedure), 
$36 928 for stage 3 palliation (Fontan procedure), and 
$289 292 for transplantation.69
 ● Other congenital heart defect lesions are less costly. In 2124 
patients undergoing congenital heart operations between 
2001 and 2007, total costs for the surgeries were $12 761 
(ASD repair), $18 834 (VSD repair), $28 223 (TOF repair), 
and $55 430 (arterial switch operation).70
Kawasaki Disease
ICD-9 446.1; ICD-1 0 M30.3.
Mortality—6. Any-mention mortality—12.
 ● KD is an acute inflammatory illness characterized by fever, 
rash, nonexudative limbal sparing conjunctivitis, extrem-
ity changes, red lips and strawberry tongue, and a swollen 
lymph node. The most feared consequence of this vascu-
litis is coronary artery aneurysms.71 The cause of KD is 
unknown, but it may be an immune response to an acute 
infectious illness based in part on genetic susceptibili-
ties.72,73 This is supported by variation in incidence related 
to geography, race/ethnicity, sex, age, and season.74
 ● The incidence of KD is highest in Japan, at 239.6 cases 
per 100 000 children aged <4 years,75 followed by Taiwan 
at 164.6/100 000 in children <5 years old76 and Korea, 
where the rate reached 113.1/100 000 children <5 years old 
in 2008.77 KD is much less common in the United States, 
with an incidence of 20.8/100 000 children aged <5 years in 
2006. The incidence of KD is rising worldwide, including 
in the United States. US hospitalizations for KD rose from 
17.5/100 000 children aged <5 years in 2000 to 19/100 000 
children <5 years of age in 2009.78,79 Japan experienced its 
highest-ever incidence rate in 2010.75 In addition to geo-
graphic variation in the incidence of KD, the age of chil-
dren affected may also differ. In northern Europe (Finland, 
Sweden, and Norway), 67.8% of patients with KD were 
<5 years of age, compared with 86.4% of patients in Japan 
(P<0.001).80
 ● Race-specific incidence rates indicate that KD is most com-
mon among Americans of Asian and Pacific Island descent 
(30.3/100 000 children <5 years of age), occurs with inter-
mediate frequency in non-Hispanic blacks (17.5/100 000 
children <5 years of age) and Hispanics (15.7/100 000 
children <5 years of age), and is least common in whites 
(12.0/100 000 children <5 years of age).81 US states with 
higher Asian American populations have higher rates of 
KD; for example, rates are 2.5-fold higher in Hawaii than 
in the continental United States.79
 ● Boys have a 1.5-fold higher incidence of KD than girls.79 
Although KD can be seen as late as adolescence, 76.8% 
of children with KD are <5 years of age.78,79,81 There are 
seasonal variations in KD: KD is more common during the 
winter and early spring months, except in Hawaii, where no 
clear seasonal trend is seen.82
 ● Treatment of KD rests on diminishing the inflamma-
tory response with intravenous immunoglobulin infusion, 
which reduces the incidence of coronary artery aneurysms 
from ≈25% to ≈2%. Addition of prednisolone to the stan-
dard regimen of intravenous immunoglobulin for patients 
with severe KD appears to result in further reductions in 
the incidence of coronary artery anomalies (RR, 0.20; 95% 
CI, 0.12–0.28),83 a result supported by a meta-analysis of 
steroid treatment in 9 trials that included 1011 patients 
with KD.84 Successful surgical treatment of late sequelae 
of symptomatic coronary artery stenoses (eg, CABG) has 
been described.85
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Table 15-1. Congenital Cardiovascular Defects
Population Group
Estimated 
Prevalence, 2002, 
All Ages
Mortality, 2011, 
All Ages*
Hospital 
Discharges, 2010, 
All Ages
Both sexes 650 000 to  
1.3 million20
3166 62 000
Males … 1725 (54.5%)† 38 000
Females … 1441 (45.5%)† 24 000
White males … 1342 …
White females … 1117 …
Black males … 291 …
Black females … 258 …
Asian or Pacific 
Islander
… 116 …
American Indian or 
Alaska Native
… 42 …
Ellipses (…) indicate data not available.
*Mortality data for the white, black, Asian or Pacific Islander, and American 
Indian or Alaska Native populations include deaths among people of Hispanic 
and non-Hispanic origin. Death rates for Hispanic, American Indian or Alaska 
Native, and Asian and Pacific Islander people should be interpreted with caution 
because of inconsistencies in reporting Hispanic origin or race on the death 
certificate compared with censuses, surveys, and birth certificates. Studies have 
shown underreporting on death certificates of American Indian or Alaska Native, 
Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of 
these groups in censuses.
†These percentages represent the portion of total congenital cardiovascular 
mortality that is for males vs females.
Sources: Mortality: Centers for Disease Control and Prevention/National 
Center for Health Statistics, 2011 Mortality Multiple Cause-of-Death —United 
States. These data represent underlying cause of death only; data include 
Hispanics. Hospital discharges: National Hospital Discharge Survey, National 
Center for Health Statistics; data include those inpatients discharged alive, 
dead, or status unknown.
Table 15-2. Annual Birth Prevalence of Congenital 
Cardiovascular Defects in the United States9,13,16,86–88
Type of Presentation
Rate per 1000  
Live Births
Estimated Number 
(Variable With Yearly  
Birth Rate)
Fetal loss Unknown Unknown
Invasive procedure during 
the first year
2.4 9200
Detected during first year* 8 36 000
Bicuspid aortic valve 13.7 54 800
*Includes stillbirths and pregnancy termination at <20 weeks gestation; 
includes some defects that resolve spontaneously or do not require treatment.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2015 Update: Chapter 15   e213
Table 15-3. Estimated Prevalence of Congenital Cardiovascular Defects and 
Percent Distribution by Type, United States, 2002* (in Thousands)
Prevalence, n Percent of Total
Type Total Children Adults Total Children Adults
Total 994 463 526 100 100 100
VSD† 199 93 106 20.1 20.1 20.1
ASD 187 78 109 18.8 16.8 20.6
Patent ductus arteriosus 144 58 86 14.2 12.4 16.3
Valvular pulmonic stenosis 134 58 76 13.5 12.6 14.4
Coarctation of aorta 76 31 44 7.6 6.8 8.4
Valvular aortic stenosis 54 25 28 5.4 5.5 5.2
TOF 61 32 28 6.1 7 5.4
AV septal defect 31 18 13 3.1 3.9 2.5
TGA 26 17 9 2.6 3.6 1.8
Hypoplastic right heart syndrome 22 12 10 2.2 2.5 1.9
Double-outlet right ventricle 9 9 0 0.9 1.9 0.1
Single ventricle 8 6 2 0.8 1.4 0.3
Anomalous pulmonary venous 
connection
9 5 3 0.9 1.2 0.6
Truncus arteriosus 9 6 2 0.7 1.3 0.5
HLHS 3 3 0 0.3 0.7 0
Other 22 12 10 2.1 2.6 1.9
Average of the low and high estimates, two thirds from low estimate.20
ASD indicates atrial septal defect; AV, atrioventricular; HLHS, hypoplastic left heart syndrome; TGA, 
transposition of the great arteries; TOF, tetralogy of Fallot; and VSD, ventricular septal defect.
*Excludes an estimated 3 million bicuspid aortic valve prevalence (2 million in adults and 1 million in 
children).
†Small VSD, 117 000 (65 000 adults and 52 000 children); large VSD, 82 000 (41 000 adults and 
41 000 children).
Source: Reprinted from Hoffman et al20 with permission from Elsevier. Copyright © 2004.
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Table 15-4. Surgery for Congenital Heart Disease
Sample Population, Weighted
Surgery for congenital heart 
disease, n
14 888 25 831
  Deaths, n 736 1253
  Mortality rate, % 4.9 4.8
By sex (81 missing in sample)
  Male, n 8127 14 109
   Deaths, n 420 714
   Mortality rate, % 5.2 5.1
  Female, n 6680 11 592
   Deaths, n 315 539
   Mortality rate, % 4.7 4.6
By type of surgery
  ASD secundum surgery, n 834 1448
   Deaths, n 3 6
   Mortality rate, % 0.4 0.4
  Norwood procedure for HLHS, n 161 286
   Deaths, n 42 72
   Mortality rate, % 26.1 25.2
In 2003, 25 000 cardiovascular operations for congenital cardiovascular 
defects were performed on children <20 years of age. Inpatient mortality rate 
after all types of cardiac surgery was 4.8%. Nevertheless, mortality risk varies 
substantially for different defect types, from 0.4% for ASD repair to 25.2% for 
first-stage palliation for HLHS. Fifty-five percent of operations were performed 
in males. In unadjusted analysis, mortality after cardiac surgery was somewhat 
higher for males than for females (5.1% vs 4.6%).
ASD indicates atrial septal defect; and HLHS, hypoplastic left heart syndrome.
Source: Data derived from Ma et al.89
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16 . Disorders of Heart Rhythm
See Table 16-1 and Charts 16-1 through 16-10.
Bradyarrhythmias
ICD-9 426.0, 426.1, 427.81; ICD-10 I44.0 to I44.3, I49.5.
Mortality—935. Any-mention mortality—5190. Hospital 
discharges—110 000.
AV Block
Prevalence and Incidence
(See Chart 16-1.)
 ● In a healthy sample of participants from the ARIC study 
(mean age 53 years), the prevalence of first-degree AV 
block was 7.8% in black men, 3.0% in black women, 
2.1% in white men, and 1.3% in white wome.1 Lower 
prevalence estimates were noted in the relatively younger 
population (mean age 45 years) of the CARDIA study at 
its year 20 follow-up examination: 2.6% in black men, 
1.9% in black women, 1.2% in white men, and 0.1% in 
white women.1
 ● The prevalence of PR interval prolongation was observed 
to be 2.1% in Finnish middle-aged people, but the authors 
noted that the PR interval normalized in follow-up in 30% 
of these people.2
 ● Mobitz II second-degree AV block is rare in healthy individu-
als (≈0.003%), whereas Mobitz I (Wenckebach) is observed in 
1% to 2% of healthy young people, especially during sleep.1
 ● The prevalence of third-degree AV block in the general 
adult population is ≈0.02% to 0.04%.3,4
 ● Third-degree AV block is very rare in apparently healthy 
individuals. Johnson et al5 found only 1 case among 
>67 000 symptom-free individuals; Rose et al,6 in their 
study of >18 000 civil servants, did not find any cases. 
On the other hand, among 293 124 patients with DM and 
552 624 with hypertension enrolled with Veterans Health 
Administration hospitals, third-degree AV block was 
present in 1.1% and 0.6% of those patients, respectively.7
 ● Congenital complete AV block is estimated to occur in 1 
of 15 000 to 20 000 live births.8 An English register study 
estimated the incidence of infant complete AV block as 2.1 
per 100 000 live births.9 Congenital complete heart block 
may be attributable to transplacental transfer of maternal 
anti-SSA/Ro-SSB/La antibodies.8
Abbreviations Used in Chapter 16
AF atrial fibrillation
AMI acute myocardial infarction
ARIC Atherosclerosis Risk in Communities study
ASSERT Asymptomatic Atrial Fibrillation and Stroke Evaluation in 
Pacemaker Patients and the Atrial Fibrillation Reduction 
Atrial Pacing Trial
AV atrioventricular
BMI body mass index
BP blood pressure
CABG coronary artery bypass graft
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHADS
2 clinical prediction rule for estimating the risk of stroke 
based on congestive heart failure, hypertension,  
age ≥75 y, diabetes mellitus (1 point each), and prior 
stroke/transient ischemic attack/thromboembolism  
(2 points)
CHA
2DS2-VASc clinical prediction rule for estimating the risk of stroke 
based on congestive heart failure, hypertension, diabetes 
mellitus, and sex (1 point each); age ≥75 y and stroke/
transient ischemic attack/thromboembolism (2 points each); 
plus history of vascular disease, age 65 to 74 y,  
and (female) sex category 
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EF ejection fraction
EMPHASIS-HF Eplerenone in Mild Patients Hospitalization and Survival 
Study in Heart Failure
ESRD end-stage renal disease
FHS Framingham Heart Study
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LV left ventricular
MI myocardial infarction
MESA Multi-Ethnic Study of Atherosclerosis
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
ORBIT-HF Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation 
PAR population attributable risk
PVT polymorphic ventricular tachycardia
REGARDS Reasons for Geographic and Racial Differences in Stroke study
RR relative risk
SBP systolic blood pressure
SVT supraventricular tachycardia
TdP torsade de pointes
VF ventricular fibrillation
VT ventricular tachycardia
Click here to go to the Table of Contents
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Risk Factors
 ● In healthy individuals without CVD or its risk factors from 
the MESA study, PR interval was longer with advancing 
age, in men compared with women, and in blacks com-
pared with whites.10
 ● Although first-degree AV block and Mobitz type I second-
degree AV block can occur in apparently healthy individu-
als, presence of Mobitz II second-degree or third-degree 
AV block usually indicates underlying HD, including CHD 
and HF.1
 ● Reversible causes of AV block include electrolyte abnor-
malities, drug-induced AV block, perioperative AV block 
attributable to hypothermia, or inflammation near the AV 
conduction system after surgery in this region. Some con-
ditions may warrant pacemaker implantation because of 
the possibility of disease progression even if the AV block 
reverses transiently (eg, sarcoidosis, amyloidosis, and neu-
romuscular diseases).11
 ● Long sinus pauses and AV block can occur during sleep 
apnea. In the absence of symptoms, these abnormalities are 
reversible and do not require pacing.12
Prevention
 ● Detection and correction of reversible causes of acquired 
AV block could be of potential importance in preventing 
symptomatic bradycardia and other complications of AV 
block.11
 ● In utero detection of congenital AV block is possible by 
echocardiography.13
Aftermath
 ● In the FHS, PR interval prolongation (>200 ms) was asso-
ciated with an increased risk of AF (HR, 2.06; 95% CI, 
1.36–3.12),14,15 pacemaker implantation (HR, 2.89; 95% 
CI, 1.83–4.57),15 and all-cause mortality (HR, 1.44; 95% 
CI, 1.09–1.91).15 Compared with individuals with a PR 
≤200 ms, individuals with a PR interval >200 ms had an 
absolute increased risk per year of 1.04% for AF, 0.55% for 
pacemaker implantation, and 2.05% for death.
 ● Patients with abnormalities of AV conduction may be 
asymptomatic or may experience serious symptoms related 
to bradycardia, ventricular arrhythmias, or both.
 ● Decisions about the need for a pacemaker are influenced 
by the presence or absence of symptoms directly attribut-
able to bradycardia. Permanent pacing improves survival in 
patients with third-degree AV block, especially if syncope 
has occurred.11 Nevertheless, the overall prognosis depends 
to a large extent on the underlying HD.
 ● Although there is little evidence to suggest that pacemak-
ers improve survival in patients with isolated first-degree 
AV block,16 it is now recognized that marked first-degree 
AV block (PR >300 ms) can lead to symptoms even in the 
absence of higher degrees of AV block.17
Prognosis
 ● Investigators at Northwestern University compared older 
adult (age >60 years) outpatients with (n=470) and with-
out (n=2090) asymptomatic bradycardia. Over a mean 
follow-up of 7.2 years, patients with asymptomatic bra-
dycardia had a higher adjusted incidence of pacemaker 
insertion (HR, 2.14; 95% CI, 1.30–3.51; P=0.003), which 
appeared after a lag time of 4 years. However, the absolute 
rate of pacemaker implantation was low (<1% per year), 
and asymptomatic bradycardia was not associated with a 
higher risk of death.18
Sinus Node Dysfunction
Prevalence and Incidence
 ● The prevalence of sinus node dysfunction has been esti-
mated to be between 403 and 666 per million, with an inci-
dence rate of 63 per million per year requiring pacemaker 
therapy.19
 ● Sinus node dysfunction occurs in 1 of every 600 cardiac 
patients >65 years of age and accounts for ≈50% of implan-
tations of pacemakers in the United States.20,21
 ● Sinus node dysfunction is commonly present with other 
causes of bradyarrhythmias (carotid sinus hypersensitivity 
in 33% of patients and advanced AV conduction abnormali-
ties in 17%).22,23
Risk Factors
 ● The causes of sinus node dysfunction can be classified as 
intrinsic (secondary to pathological conditions involving 
the sinus node) or extrinsic (caused by depression of sinus 
node function by external factors such as drugs or auto-
nomic influences).24
 ● Sinus node dysfunction may occur at any age but is pri-
marily a disease of the elderly, with the average being ≈68 
years of age.20
 ● Idiopathic degenerative disease is probably the most com-
mon cause of sinus node dysfunction.25
 ● Collected data from 28 different studies on atrial pacing 
for sinus node dysfunction showed a median annual inci-
dence of complete AV block of 0.6% (range, 0%–4.5%) 
with a total prevalence of 2.1% (range, 0%–11.9%). This 
suggests that the degenerative process also affects the spe-
cialized conduction system, although the rate of progres-
sion is slow and does not dominate the clinical course of 
disease.26
 ● Ischemic HD can be responsible for one third of cases of 
sinus node dysfunction. Transient sinus node dysfunction 
can complicate MI; it is common during inferior MI and 
is caused by autonomic influences. Cardiomyopathy, long-
standing hypertension, infiltrative disorders (eg, amyloido-
sis and sarcoidosis), collagen vascular disease, and surgical 
trauma can also result in sinus node dysfunction.27,28
Aftermath
(See Chart 16-2.)
 ● The course of sinus node dysfunction is typically progres-
sive, with 57% of patients experiencing symptoms over a 
4-year period if untreated, and a 23% prevalence of syn-
cope over the same time frame.29
 ● Approximately 50% of patients with sinus node dysfunc-
tion develop tachy-brady syndrome over a lifetime; such 
patients have a higher risk of stroke and death. The survival 
of patients with sinus node dysfunction appears to depend 
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primarily on the severity of underlying cardiac disease and 
is not significantly changed by pacemaker therapy.30–32
 ● In a retrospective study,33 patients with sinus node dys-
function who had pacemaker therapy were followed up 
for 12 years; at 8 years, mortality among those with ven-
tricular pacing was 59% compared with 29% among those 
with atrial pacing. This discrepancy may be attributed to 
selection bias. For instance, the physiological or anatomic 
disorder (eg, fibrosis of conductive tissue) that led to the 
requirement for the particular pacemaker may have influ-
enced prognosis, rather than the type of pacemaker used.
 ● In a multicenter study from the Netherlands of individu-
als with bradycardia treated with pacemaker implantation, 
the actuarial 1-, 3-, 5-, and 7-year survival rates were 93%, 
81%, 69%, and 61%, respectively. Individuals without 
CVD at baseline had similar survival rates as age- and sex-
matched control subjects.34
 ● The incidence of sudden death is extremely low, and sinus 
node dysfunction does not appear to affect survival whether 
untreated or treated with pacemaker therapy.11
 ● SVT including AF occurs in 47% to 53% of patients with 
sinus node dysfunction.32,35
 ● On the basis of records from the NHDS, age-adjusted pace-
maker implantation rates increased progressively from 370 
per million in 1990 to 612 per million in 2002. This escalat-
ing implantation rate is attributable to increasing implan-
tation for isolated sinus node dysfunction; implantation 
for sinus node dysfunction increased by 102%, whereas 
implantation for all other indications did not increase.36
 ● In patients paced for sick sinus syndrome, CHA2DS2-VASc 
score is associated with an increased risk of stroke and 
death, even in individuals without AF at baseline.37
SVT (Excluding AF and Atrial Flutter)
ICD-9 427.0; ICD-10 I47.1.
Mortality—130. Any-mention mortality—1245. Hospital 
discharges—23 000.
Prevalence and Incidence
(See Chart 16-3.)
 ● Data from the Marshfield Epidemiologic Study Area in 
Wisconsin suggested the incidence of documented parox-
ysmal SVT is 35 per 100 000 person-years. The mean age at 
SVT onset was 57 years, and both female sex and age >65 
years were significant risk factors.38
 ● A review of ED visits from 1993 to 2003 revealed that 
550 000 visits were for SVT (0.05% of all visits; 95% 
CI, 0.04%–0.06%), or ≈50 000 visits per year. Of these 
patients, 24% (95% CI, 15%–34%) were admitted to the 
hospital, and 44% (95% CI, 32%–56%) were discharged 
without specific follow-up.39
 ● The prevalence of SVT that is clinically undetected is likely 
much greater than the estimates from ED visits and elec-
trophysiology procedures would suggest. For example, 
among a random sample of 604 participants in Finland, 
7 (1.2%) fulfilled the diagnostic criteria for inappropriate 
sinus tachycardia.40
 ● Of 1383 participants in the Baltimore Longitudinal Study 
of Aging undergoing maximal exercise testing, 6% exhib-
ited SVT during the test; increasing age was a significant 
risk factor. Only 16% exhibited >10 beats of SVT, only 4% 
were symptomatic, and the SVT participants were more 
likely to develop spontaneous SVT or AF.41
 ● From the surface ECG, the prevalence of atrial tachycar-
dia is estimated to be 0.34% in asymptomatic patients and 
0.46% in symptomatic patients.42
Aftermath
 ● Rare cases of incessant SVT can lead to a tachycardia-
induced cardiomyopathy,43 and rare cases of sudden death 
attributed to SVT as a trigger have been described.44
 ● A California administrative database study suggested that 
after the exclusion of people with diagnosed AF, SVT was 
associated with an adjusted doubling of the risk of stroke 
in follow-up (HR, 2.10; 95% CI, 1.69–2.62). The absolute 
stroke rate was low, however. The cumulative stroke rate 
was 0.94% (95% CI, 0.76%–1.16%) in patients with SVT 
versus 0.21% (95% CI, 0.21%–0.22%; P<0.001, log-rank 
test) in those without SVT.45
Specific Types
 ● Among those presenting for invasive electrophysiologi-
cal study and ablation, AV nodal reentrant tachycardia 
(a circuit that requires 2 AV nodal pathways) is the most 
common mechanism of SVT46,47 and usually represents 
the majority of cases (56% of 1 series of 1754 cases from 
Loyola University Medical Center).47
 ● AV reentrant tachycardia (an arrhythmia that requires the 
presence of an extranodal connection between the atria and 
ventricles or specialized conduction tissue) is the second 
most common48,49 type of SVT (27% in the Loyola series),47 
and atrial tachycardia is the third most common (17% in the 
Loyola series).47
 ● In the pediatric population, AV reentrant tachycardia is 
the most common SVT mechanism, followed by AV nodal 
reentrant tachycardia and then atrial tachycardia.50
 ● AV reentrant tachycardia prevalence decreases with age, 
whereas AV nodal reentrant tachycardia and atrial tachy-
cardia prevalences increase with advancing age.47
 ● The majority of AV reentrant tachycardia patients in the 
Loyola series were men (55%), whereas the majority of 
patients with AV nodal reentrant tachycardia (70%) or atrial 
tachycardia (62%) were women.47
 ● Multifocal atrial tachycardia is an arrhythmia that is com-
monly confused with AF and is characterized by 3 distinct 
P-wave morphologies, irregular R-R intervals, and a rate 
>100 beats per minute. It is uncommon in both children48 
and adults,49 with a prevalence in hospitalized adults esti-
mated at 0.05% to 0.32%.51,52 The average age in adults is 70 
to 72 years. Adults with multifocal atrial tachycardia have a 
mortality rate that is high, with estimates around 45%, but 
this is generally ascribed to the underlying condition(s).49,53
Wolff-Parkinson-White Syndrome
 ● Wolff-Parkinson-White syndrome, a diagnosis reserved 
for those with both ventricular preexcitation (evidence 
of an anterograde conducting AV accessory pathway on 
a 12-lead ECG) and tachyarrhythmias,54 deserves special 
attention because of the associated risk of sudden death. 
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Sudden death is generally attributed to rapid heart rates in 
AF conducting down an accessory pathway and leading to 
VF.55,56 Of note, AF is common in Wolff-Parkinson-White 
patients, and surgical or catheter ablation of the accessory 
pathway often results in elimination of the AF.57
 ● Ventricular preexcitation with or without tachyarrhythmia 
was observed in 0.11% of 47 358 ECGs in adults partici-
pating in 4 large Belgian epidemiological studies51 and in 
0.17% of 32 837 Japanese high school students in ECGs 
obtained by law before the students entered school.52
 ● Asymptomatic adults with ventricular preexcitation appear 
to be at no increased risk of sudden death compared with 
the general population,55,56,58,59 although certain charac-
teristics found during invasive electrophysiological study 
(including inducibility of AV reentrant tachycardia or AF, 
accessory pathway refractory period, and the shortest R-R 
interval during AF) can help risk stratify these patients.56,60
 ● In a meta-analysis of 20 studies involving 1869 asymptom-
atic patients with a Wolff-Parkinson-White ECG pattern fol-
lowed up for a total of 11 722 person-years, the risk of sudden 
death in a random effects model that was used because of 
heterogeneity across studies was estimated to be 1.25 (95% 
CI, 0.57–2.19) per 1000 person-years. Risk factors for sud-
den death included male sex, inclusion in a study of children 
(<18 years of age), and inclusion in an Italian study.61
 ● Symptomatic adult patients with the Wolff-Parkinson-White 
syndrome are at a higher risk of sudden death. In a study of 
60 symptomatic patients in Olmsted County, MN, including 
some who underwent curative surgery, 2 (3.3%) experienced 
sudden death over a 13-year period. Of 690 Wolff-Parkin-
son-White syndrome patients referred to a single hospital in 
the Netherlands, 15 (2.2%) had aborted sudden death, and 
VF was the first manifestation of the disease in 8 patients.62
 ● Of 379 Wolff-Parkinson-White patients with induced AV 
reentrant tachycardia during electrophysiology study who 
did not undergo ablation, 29 (8%) exhibited a “malignant 
presentation” over a mean 3.6 years of follow-up: syncope/
presyncope in 25 patients, rapid preexcited AF causing 
hemodynamic collapse in 3 patients, and VF in 1 patient.63 
Those with such a presentation were more often male, had 
a shorter accessory pathway effective refractory period dur-
ing electrophysiology study, more often had AV reentrant 
tachycardia that triggered AF during electrophysiology 
study, and more often had >1 accessory pathway.
 ● Although some studies in asymptomatic children with ven-
tricular preexcitation suggest a benign prognosis,58,64 oth-
ers suggest that electrophysiological testing can identify a 
group of asymptomatic children with a risk of sudden death 
or VF as high as 11% over 19 months of follow-up.65 In a 
pediatric hospital retrospective review of 444 children with 
Wolff-Parkinson-White, 64% were symptomatic at presen-
tation, and 20% had onset of symptoms in follow-up. The 
incidence of sudden death was 1.1 per 1000 person years in 
patients without structural HD.66
Subclinical Atrial Tachyarrhythmias, Unrecognized 
AF, Screening for AF
Device-Detected AF
 ● Pacemakers and defibrillators have increased clinician 
awareness of the frequency of subclinical AF and atrial 
high-rate episodes in individuals without a documented 
history of AF. Several studies have suggested that device-
detected high-rate atrial tachyarrhythmias are surprisingly 
frequent and are associated with an increased risk of AF,60 
thromboembolism,60,67 and total mortality.60
 ● Investigators in the ASSERT study prospectively enrolled 
2580 patients with a recent pacemaker or defibrillator 
implantation who were ≥65 years of age, had a history of 
hypertension, and had no history of AF. They classified 
individuals by presence versus absence of subclinical atrial 
tachyarrhythmias (defined as atrial rate >190 beats per min-
ute for >6 minutes in the first 3 months) and conducted fol-
low-up for 2.5 years.68 Subclinical atrial tachyarrhythmias 
in the first 3 months occurred in 10.1% of the patients and 
were associated with the following:
—An almost 6-fold higher risk of clinical AF (HR, 5.56; 
95% CI, 3.78–8.17; P<0.001)
—A more than doubling in the adjusted risk of the primary 
end point, ischemic stroke or systemic embolism (HR, 
2.50; 95% CI, 1.28–4.89; P<0.008)
—An annual ischemic stroke or systemic embolism rate of 
1.69% (versus 0.69% in those without)
—A 13% PAR for ischemic stroke or systemic embolism
 ● Over the subsequent 2.5 years of follow-up, an additional 
34.7% of the patients had subclinical atrial tachyarrhyth-
mias, which were 8-fold more frequent than clinical AF 
episodes.
 ● A pooled analysis of 5 prospective studies in patients with-
out permanent AF revealed that over 2 years of follow-up, 
cardiac implanted electronic devices detected ≥5 minutes 
of AF in 43% of the patients (total n=10 016). Adjustment 
for CHADS2 score and anticoagulation revealed that AF 
burden was associated with an increased risk of stroke.69
Community Screening
 ● In a community-based study in Sweden, all inhabitants aged 
75 to 76 years were invited to a stepwise screening program 
for AF. Of 848 participants, 10 had clinically unrecognized 
AF diagnosed on a 12-lead ECG. Of 403 individuals with 
≥2 stroke risk factors who completed a 2-week, once-a-day 
handheld ECG event recorder, an additional 30 were diag-
nosed with paroxysmal AF. The study suggests that the bur-
den of unrecognized AF in the community is higher than 
appreciated.70
 ● There have been 2 recent systematic reviews regarding the 
effectiveness of screening to detect unknown AF.
—Lowres et al71 identified 30 separate studies that included 
outpatient clinics or community screening. In individu-
als without a prior diagnosis of AF, they observed that 
1.0% (95% CI, 0.89%–1.04%) of those screened had AF 
(14 studies, n=67 772), whereas among those individu-
als ≥65 years of age, 1.4% (95% CI, 1.2%–1.6%; 8 stud-
ies, n=18 189) had AF.
—Another systematic review by Moran et al72 observed that 
in individuals >65 years of age, systematic screening 
(OR, 1.57; 95% CI, 1.08–2.26) and opportunistic screen-
ing (OR, 1.58; 95% CI, 1.10–2.29) were associated with 
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enhanced detection of AF. The number needed to screen 
by either method was ≈170 individuals.
 ● There has been increasing interest in the use of smart phone 
technology to aid in community screening.73,74
AF and Atrial Flutter
ICD-9 427.3; ICD-10 I48.
Prevalence
(See Chart 16-4.)
 ● Estimates of the prevalence of AF in the United States 
ranged from ≈2.7 million to 6.1 million in 2010, and AF 
prevalence is expected to rise to between ≈5.6 and 12 mil-
lion in 2050.75,76
 ● In the European Union, the prevalence of AF in adults 
>55 years of age was estimated to be 8.8 million (95% CI, 
6.5–12.3 million) in 2010 and was projected to rise to 17.9 
million (95% CI, 13.6–23.7 million).77
 ● Data from a California health plan suggest that compared 
with whites, blacks (OR, 0.49; 95% CI, 0.47–0.52), Asians 
(OR, 0.68; 95% CI, 0.64–0.72), and Hispanics (OR, 0.58; 
95% CI, 0.55–0.61) have significantly lower adjusted preva-
lences of AF.78
 ● Data from the NHDS/NCHS (1996–2001) on cases that 
included AF as a primary discharge diagnosis found the 
following:
—Approximately 44.8% of patients were men.
—The mean age for men was 66.8 years versus 74.6 years 
for women.
—The racial breakdown for admissions was 71.2% white, 
5.6% black, and 2.0% other races (20.8% were not 
specified).
—Black patients were much younger than patients of other 
races.
 ● Among Medicare patients aged ≥65 years, diagnosed from 
1993 to 2007, the prevalence of AF increased ≈5% per 
year, from ≈41.1 per 1000 beneficiaries to 85.5 per 1000 
beneficiaries.79
Incidence
(See Table 16-1 and Chart 16-5.)
 ● Data from the NHDS/NCHS (1996–2001) on cases that 
included AF as a primary discharge diagnosis found the 
following:
—The incidence in men ranged from 20.6 per 100 000 peo-
ple per year for patients between 15 and 44 years of age 
to 1077.4 per 100 000 people per year for patients ≥85 
years of age.
—In women, the incidence ranged from 6.6 per 100 000 people 
per year for patients between 15 and 44 years of age to 1203.7 
per 100 000 people per year for those ≥85 years of age.
 ● Data from California administrative databases were ana-
lyzed regarding racial variation in incidence of AF. After 
adjustment for AF risk factors, compared with their white 
counterparts, lower incidence rates were found in blacks 
(HR, 0.84; 95% CI, 0.82–0.85; P<0.001), Hispanics (HR, 
0.78; 95% CI, 0.77–0.79; P<0.001), and Asians (HR, 0.78; 
95% CI, 0.77–0.79; P<0.001).80
 ● In a Medicare sample, the incidence of AF was ≈28 per 
1000 person-years and did not change substantively 
between 1993 and 2007. Of individuals with incident AF 
in 2007, ≈55% were women, 91% were white, 84% had 
hypertension, 36% had HF, and 30% had cerebrovascular 
disease.79
 ● Using data from a health insurance claims database cover-
ing 5% of the United States, the incidence of AF was esti-
mated at 1.6 million cases in 2010 and was projected to 
increase to 2.6 million cases in 2030.81
Mortality
 ● In 2011, AF was mentioned on 116 247 US death cer-
tificates and was the underlying cause in 17 729 of those 
deaths (NCHS, NHLBI).
 ● In adjusted analyses from the FHS, AF was associated 
with an increased risk of death in both men (OR, 1.5; 95% 
CI, 1.2–1.8) and women (OR, 1.9; 95% CI, 1.5–2.2).82 
Furthermore, there was an interaction with sex, such that 
AF appeared to diminish the survival advantage typically 
observed in women.
 ● In Medicare beneficiaries ≥65 years of age with new-
onset AF, mortality decreased modestly but significantly 
between 1993 and 2007. In 2007, the age- and sex-
adjusted mortality at 30 days was 11%, and at 1 year, it 
was 25%.79
 ● A study of >4600 patients diagnosed with first AF showed 
that risk of death within the first 4 months after the AF diag-
nosis was high. The most common causes of CVD death were 
CAD, HF, and ischemic stroke, which accounted for 22%, 
14%, and 10%, respectively, of the early deaths (within the 
first 4 months) and 15%, 16%, and 7%, respectively, of the 
late deaths.83
 ● Although stroke is the most feared complication of AF, 
a recent clinical trial reported that stroke accounted 
for only ≈7.0% of deaths in AF, with sudden cardiac 
death (22.25%), progressive HF (15.1%), and noncar-
diovascular death (35.8%) accounting for the majority 
of deaths.84
 ● AF is also associated with increased mortality in indi-
viduals with other cardiovascular conditions and proce-
dures, including HF,85,86 HF with preserved EF,87 MI,88,89 
CABG,90,91 and stroke,92 and with noncardiovascular condi-
tions such as sepsis93 and noncardiac surgery.94
Lifetime Risk and Cumulative Risk
(See Chart 16-6.)
 ● Largely European ancestry participants in the NHLBI-
sponsored FHS were followed up from 1968 to 1999. At 40 
years of age, remaining lifetime risks for AF were 26.0% 
for men and 23.0% for women. At 80 years of age, lifetime 
risks for AF were 22.7% for men and 21.6% for women. In 
further analysis, counting only those who had development 
of AF without prior or concurrent HF or MI, lifetime risk 
for AF was ≈16%.95 Estimates of lifetime risks of AF were 
similar in the Rotterdam Study.96
 ● Investigators from the NHLBI-sponsored ARIC study 
observed that the cumulative risk of AF was 21% in white 
men, 17% in white women, and 11% in African Americans 
of both sexes by 80 years of age.97
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Risk Factors
 ● Standard risk factors
—Both ARIC89 and FHS (http://www.framinghamheart-
study.org/risk-functions/atrial-fibrillation/10-year-
risk.php)14,98 have developed risk prediction models 
to predict new-onset AF. Predictors of increased risk 
of new-onset AF include advancing age, European 
ancestry, body size (greater height and BMI), elec-
trocardiography features (LV hypertrophy, left atrial 
enlargement), DM, BP (SBP and hypertension treat-
ment), and presence of CVD (CHD, HF, valvular HD).
—More recently, the ARIC, CHS, and FHS investigators 
developed and validated a risk prediction model.91
—Other consistently reported risk factors for AF include 
clinical and subclinical hyperthyroidism,99,100 CKD,101 
and heavy alcohol consumption.102
 ● Family history
—Although unusual, early-onset familial lone AF has long 
been recognized as a risk factor.103,104
—In the past decade, the heritability of AF in the commu-
nity has been appreciated. In studies from the FHS
 ◯ Adjusted for coexistent risk factors, having at least 
1 parent with AF was associated with a 1.85-fold 
increased risk of AF in the adult offspring (multivari-
able-adjusted 95% CI, 1.12–3.06; P=0.02).105
 ◯ A history of a first-degree relative with AF also was 
associated with an increased risk of AF (HR, 1.40; 
95% CI, 1.13–1.74).90 The risk was greater if the first-
degree relative’s age of onset was ≤65 years (HR, 
2.01; 95% CI, 1.49–2.71) and with each additional 
affected first-degree relative (HR, 1.24; 95% CI, 
1.05–1.46).106
—Similar findings were reported from Sweden.107
 ● Genetics
—Mutations in genes coding channels (sodium and potas-
sium), gap junction proteins, and signaling have been 
described, often in lone AF or familial AF series, but they 
are responsible for few cases of AF in the community.108
—Meta-analyses of genome-wide association studies 
have revealed single-nucleotide polymorphisms on 
chromosomes 4q25 (upstream of PITX2),109–111 16q22 
(ZFHX3),110,112 and 1q21 (KCNN3),111 as well as 6 other 
novel susceptibility loci (near PRRX1, CAV1, C9orf3, 
SYNPO2L, SYNE2, and HCN4),113 are associated with 
AF in individuals of European and Japanese ancestry.114 
Although an area of intensive inquiry, the causative single-
nucleotide polymorphisms and the functional basis of the 
associations have not been revealed.
—Some studies suggest that genetic markers of AF may 
improve risk prediction for AF over models that include 
clinical factors.115
Awareness
 ● In a US national biracial study of individuals with AF, com-
pared with whites, blacks had approximately one third the 
likelihood (OR, 0.32; 95% CI, 0.20–0.52) of being aware 
that they had AF.116
Prevention
(See Chart 16-7.)
 ● Data from the ARIC study indicated that having at least 1 
elevated risk factor explained 50% and having at least 1 bor-
derline risk factor explained 6.5% of incident AF cases. The 
estimated overall incidence rate per 1000 person-years at a 
mean age of 54.2 years was 2.19 for those with optimal risk, 
3.68 for those with borderline risk, and 6.59 for those with 
elevated risk factors.117
 ● Hypertension accounted for ≈14%118 to 22%117 of AF cases.
 ● Observational data from the CHS suggested that moderate-
intensity exercise (such as regular walking) was associated 
with a lower risk of AF (HR, 0.72).119 However, data from 
many studies suggested that vigorous-intensity exercise 5 
to 7 days a week was associated with a slightly increased 
risk of AF (HR, 1.20; P=0.04).120
 ● Meta-analyses have suggested that renin-angiotensin sys-
tem blockers may be useful in primary and secondary 
(recurrences) prevention of AF in trials of hypertension, 
after MI, in HF, and after cardioversion.92,121 However, the 
studies were primarily secondary or post hoc analyses, and 
the results were fairly heterogeneous. Recently, in an analy-
sis of the EMPHASIS-HF trial, in one of many secondary 
outcomes, eplerenone was nominally observed to reduce 
the incidence of new-onset AF.122
 ● Although heterogeneous in their findings, modest-sized 
short-term studies suggested that the use of statins might 
prevent AF; however, larger longer-term studies do not pro-
vide support for the concept that statins are effective in AF 
prevention.123
 ● Treatment of obstructive sleep apnea has been noted 
to decrease risk of recurrent AF, after cardioversion124 
and ablation,125 but its role in primary prevention is 
unproven.
 ● In a national outpatient registry of AF patients (ORBIT-
AF), 93.5% had indications for guideline-based primary 
or secondary prevention in addition to oral anticoagulants; 
however, only 46.6% received all guideline-indicated 
therapies, consistent with an underutilization of evidenced-
based preventive therapies for comorbid conditions in 
individuals with AF.125 Predictors of not receiving all guide-
line-indicated therapies included frailty, comorbid illness, 
geographic region, and antiarrhythmic drug therapy.
Aftermath
(See Chart 16-8.)
 ● Stroke
—Stroke rates per 1000 patient-years declined in AF 
patients taking anticoagulants, from 46.7 in 1992 to 19.5 
in 2002, for ischemic stroke but remained fairly steady 
for hemorrhagic stroke (1.6–2.9).126
—When standard stroke risk factors were accounted for, 
AF was associated with a 4- to 5-fold increased risk of 
ischemic stroke.127
—Although the RR of stroke associated with AF did not 
vary (≈3- to 5-fold increased risk) substantively with 
advancing age, the proportion of strokes attributable to 
AF increased significantly. In FHS, AF accounted for 
≈1.5% of strokes in individuals 50 to 59 years of age 
and ≈23.5% in those 80 to 89 years of age.127
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—Paroxysmal, persistent, and permanent AF all appeared 
to increase the risk of ischemic stroke to a similar 
degree.121
—AF was also an independent risk factor for ischemic stroke 
severity, recurrence, and mortality.92 In one study, individ-
uals who had AF and were not treated with anticoagulants 
had a 2.1-fold increase in risk for recurrent stroke and a 
2.4-fold increase in risk for recurrent severe stroke.128
—Studies have demonstrated an underutilization of war-
farin therapy. In a recent meta-analysis, men and indi-
viduals with prior stroke were more likely to receive 
warfarin, whereas factors associated with lower use 
included alcohol and drug abuse, noncompliance, war-
farin contraindications, dementia, falls, both gastroin-
testinal and intracranial hemorrhage, renal impairment, 
and advancing age.129 The underutilization of antico-
agulation in AF has been demonstrated to be a global 
problem.130
 ● Cognition
—Individuals with AF have an adjusted 2-fold increased 
risk of dementia.131
—A meta-analysis of 21 studies indicated that AF was 
associated with an increased risk of cognitive impair-
ment in patients after stroke (RR, 2.70; 95% CI, 1.82–
4.00) and in patients without a history of stroke (RR, 
1.37; 95% CI, 1.08–1.73). The risk of dementia was 
similarly increased (RR, 1.38; 95% CI, 1.22–1.56]).132
—In individuals with AF in Olmsted County, MN, the 
cumulative rate of dementia at 1 and 5 years was 2.7% 
and 10.5%, respectively.122
 ● Physical disability and subjective health
—AF has been associated with physical disability and 
poor subjective health.133,134 A recent systematic review 
suggested that among individuals with AF, moderate-
intensity activity improved exercise capacity and qual-
ity of life.120
 ● Heart failure
—AF and HF share many antecedent risk factors, and 
≈40% of individuals with either AF or HF will develop 
the other condition.85
—In the community, estimates of the incidence of HF in 
individuals with AF ranged from 3.385 to 4.4135 per 100 
person-years of follow-up.
—Among older adults with AF in Medicare, the 5-year 
event rate was high, with rates of death and HF exceed-
ing stroke. Higher event rates after new-onset AF were 
associated with older age and higher mean CHADS2 
score.136
 ● Myocardial infarction
—In the REGARDS study, in models that adjusted for 
standard risk factors, AF was associated with a 70% 
increased risk of incident MI (HR, 1.96; 95% CI, 
1.52–2.52); the risk was higher in women and blacks. 
In individuals with AF, the age-adjusted incidence rate 
per 1000 person-years was 12.0 (95% CI, 9.6–14.9) in 
those with compared with 6.0 (95% CI, 5.6–6.6) in those 
without AF.137
 ● Chronic kidney disease
—In a Japanese community-based study, individuals with 
AF had approximately a doubling in increased risk of 
developing kidney dysfunction or proteinuria, even in 
individuals without baseline DM or hypertension. Per 
1000 person-years of follow-up, the incidence of kidney 
dysfunction was 6.8 in individuals without and 18.2 in 
individuals with AF at baseline.138
—In a Kaiser Permanente Study of individuals with CKD, 
new-onset AF was associated with an adjusted 1.67-
fold increased risk of developing ESRD compared with 
those without AF (74 versus 64 per 1000 person-years 
of follow-up).139
 ● Sudden cardiac death
—In a study that examined data from 2 population-based 
studies, AF was associated with a doubling in the risk 
of sudden cardiac death after accounting for baseline 
and time-varying confounders. In ARIC, the unad-
justed incidence rate was 1.30 (95% CI, 1.14–1.47) 
in those without AF and 2.89 (95% CI, 2.00–4.05) in 
those with AF; corresponding rates in CHS were 3.82 
(95% CI, 3.35–4.35) and 12.00 (95% CI, 9.45–15.25), 
respectively.140
Global Burden of AF
(See Chart 16-9.)
 ● The vast majority of research on the epidemiology of AF 
has been conducted in Europe and North America. Inves-
tigators from the GBD project noted that the global preva-
lence, incidence, mortality, and DALYs increased from 
1990 to 2010.141
—The 2010 worldwide prevalence of AF was estimated 
at 33.5 million: 20.9 million men (95% uncertainty 
interval, 19.5–22.2 million) and 12.6 million women 
(95% uncertainty interval, 12.0–13.7). In 2010, the 
age-adjusted AF prevalence per 100 000 people was 
estimated to be 596.2 (95% uncertainty interval, 558.4–
636.7) in men and 373.1 (95% uncertainty interval, 
347.9–402.2) in women.
—The 2010 estimated annual AF incidence per 100 000 
person-years was estimated to be 77.5 (95% uncertainty 
interval, 65.2–95.4) in men and 59.5 (95% uncertainty 
interval, 49.9–74.9) in women.
—Although AF accounted for <1% of global deaths, the 
age-adjusted mortality rate was 1.6 (95% uncertainty 
interval, 1.0–2.4) in men and 1.7 (95% uncertainty inter-
val, 1.4–2.2) in women in 2010.
—The 2010 estimated DALYs per 100 000 population from 
AF were 64.5 (95% uncertainty interval, 46.8–84.2) and 
45.9 (95% uncertainty interval, 35.7–58.5) in 2010; 
DALYs were higher in developed than in developing 
countries.
Hospitalization
 ● Data from the NHDS/NCHS 2010 on cases that included 
AF as a primary discharge diagnosis found the following142:
—Hospital discharges—479 000.
—Approximately 50.8% of patients were males.
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—The mean age for males was 65.5 years versus 74.1 years 
for females.
—The rate of AF hospitalization in males ranged from 32.6 
per 100 000 people per year for patients between 15 and 
44 years of age to 1275.8 per 100 000 people per year for 
patients ≥85 years of age.
—The rate of AF hospitalization in females ranged from 
5.4 per 100 000 people per year for patients between 15 
and 44 years of age to 1323.4 per 100 000 people per 
year for those ≥85 years of age.
 ● From 1996 to 2001, hospitalizations with AF as the first-
listed diagnosis increased by 34%.143
 ● On the basis of Medicare and MarketScan databases, annu-
ally, individuals with AF (37.5%) are approximately twice 
as likely to be hospitalized as age- and sex-matched control 
subjects (17.5%).144
Cost
(See Chart 16-10.)
 ● Investigators examined Medicare and MarketScan data-
bases (2004–2006) to estimate costs attributed to AF in 
2008 US dollars144:
—Annual total direct costs for AF patients were ≈$20 670 
versus ≈$11 965 in the control group, for an incremental 
per-patient cost of $8705.
—Extrapolating to the US population, it is estimated that 
the incremental cost of AF was ≈$26 billion, of which 
$6 billion was attributed to AF, $9.9 billion to other car-
diovascular expenses, and $10.1 billion to noncardio-
vascular expenses.
Tachycardia
 ICD-9 427.0, 427.1, 427.2; ICD-10 I47.1, I47.2, I47.9.
Mortality—688. Any-mention mortality—6213. Hospital 
discharges—78 000.
Monomorphic VT
Prevalence and Incidence
 ● The true prevalence and incidence of monomorphic VT in 
the US general population are not known.
 ● Of 150 consecutive patients with wide-complex tachycar-
dia subsequently studied by invasive electrophysiological 
study, 122 (81%) had VT; the remainder had SVT.145
 ● Of patients with ventricular arrhythmias presenting for 
invasive electrophysiological studies, 11% to 21% had no 
structural HD, and the majority of those with structural HD 
had CAD.146,147
 ● In 634 patients with implantable cardioverter-defibrillators 
who had structural HD (including both primary and sec-
ondary prevention patients) followed up for a mean 11±3 
months, ≈80% of potentially clinically relevant ventricu-
lar tachyarrhythmias were attributable to VT amenable 
to antitachycardia pacing (implying a stable circuit and 
therefore monomorphic VT).148 Because therapy may have 
been delivered before spontaneous resolution occurred, the 
proportion of these VT episodes with definite clinical rel-
evance is not known.
 ● Of those with VT in the absence of structural HD, right 
ventricular outflow tract VT is the most common form.149
 ● Among 2099 subjects (mean age, 52; 52.2% male) without 
known CVD, exercise-induced nonsustained VT occurred 
in nearly 4% and was not independently associated with 
total mortality.150
Aftermath
 ● Although the prognosis of those with VT or frequent pre-
mature ventricular contractions in the absence of structural 
HD is good,146,149 a potentially reversible cardiomyopathy 
may develop in patients with very frequent premature ven-
tricular contractions,151,152 and some cases of sudden death 
attributable to short-coupled premature ventricular contrac-
tions have been described.153,154
Polymorphic VT
Prevalence and Incidence
 ● The true prevalence and incidence of PVT in the US gen-
eral population are not known.
 ● During ambulatory cardiac monitoring, PVT prevalence 
ranged from 0.01% to 0.15%155,156; however, among patients 
who developed sudden cardiac death during ambulatory 
cardiac monitoring, PVT was detected in 30% to 43%.156–158
 ● In the setting of AMI, the prevalence of PVT ranged from 
1.2% to 2%.159,160
 ● Out-of-hospital PVT is estimated to be present in ≈25% of 
all cardiac arrest cases involving VT.161,162
 ● A prevalence range of 15% to 19% was reported during 
electrophysiological study in patients resuscitated from 
cardiac arrest.158,163,164
Risk Factors
 ● PVT in the setting of a normal QT interval is most fre-
quently seen in the context of acute ischemia or MI.165,166
 ● Less frequently, PVT with a normal QT interval can occur 
in patients without apparent structural HD. Catecholamin-
ergic PVT, which is discussed under inherited arrhythmic 
syndromes, is one such disorder.
 ● A prolonged QT interval, whether acquired (drug 
induced) or congenital, is a common cause of PVT. Drug-
induced prolongation of the QT interval that causes PVT 
is discussed under TdP, whereas congenital prolonged 
QT interval is discussed under inherited arrhythmic 
syndromes.
Aftermath
 ● The presentation of PVT can range from a brief, asymp-
tomatic, self-terminating episode to recurrent syncope or 
sudden cardiac death.167
 ● The overall hospital discharge rate (survival) of PVT has 
been estimated to be ≈28%.168
Torsade de Pointes
Prevalence and Incidence
 ● The true incidence and prevalence of drug-induced TdP in 
the US general population are largely unknown.
 ● By extrapolating data from non-US registries,169 it has been 
estimated that 12 000 cases of drug-induced TdP occur 
annually in the United States.159
 ● The prevalence of drug-induced prolongation of QT inter-
val and TdP is 2 to 3 times higher in women than in men.160
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 ● With the majority of QT-interval–prolonging drugs, drug-
induced TdP may occur in 3% to 15% of patients.158
 ● Antiarrhythmic drugs with QT-interval–prolonging poten-
tial carry a 1% to 3% risk of TdP over 1 to 2 years of 
exposure.170
Risk Factors
 ● TdP is usually related to administration of QT-interval–pro-
longing drugs.171 An up-to-date list of drugs with the poten-
tial to cause TdP may be found at http://www.azcert.org/
medical-pros/drug-lists/drug-lists.cfm, a Web site main-
tained by the University of Arizona Center for Education 
and Research on Therapeutics.
 ● Specific risk factors for drug-induced TdP include pro-
longed QT interval, female sex, advanced age, bradycardia, 
hypokalemia, hypomagnesemia, LV systolic dysfunction, 
and conditions that lead to elevated plasma concentrations 
of causative drugs, such as kidney disease, liver disease, 
drug interactions, or some combination of these.159,172,173
 ● Predisposition was also noted in patients who had a history 
of ventricular arrhythmia and who experienced a recent 
symptomatic increase in the frequency and complexity of 
ectopy.174
 ● Drug-induced TdP rarely occurs in patients without con-
comitant risk factors. An analysis of 144 published articles 
describing TdP associated with noncardiac drugs revealed 
that 100% of the patients had at least 1 risk factor, and 71% 
had at least 2 risk factors.175
 ● Both common and rare genetic variants have been shown 
to increase the propensity to drug-induced QT interval 
prolongation.176,177
Aftermath
 ● Drug-induced TdP may result in morbidity that requires 
hospitalization and in mortality attributable to sudden car-
diac death in ≤31% of patients.159,178
 ● Patients with advanced HF with a history of drug-induced 
TdP had a significantly higher risk of sudden cardiac death 
during therapy with amiodarone than amiodarone-treated 
patients with no history of drug-induced TdP (55% versus 
15%).179
 ● Current use of antipsychotic drugs was associated with 
a significant increase in the risk of sudden cardiac death 
attributable to TdP (OR, 3.3; 95% CI, 1.8–6.2).180
 ● In a cohort of 459 614 Medicaid and Medicaid-Medicare 
enrollees 30 to 75 years of age who were taking antipsy-
chotic medications, the incidence of sudden death or ven-
tricular arrhythmia was 3.4 per 1000 person-years.181
 ● Hospitalization was required in 47% and death occurred 
in 8% of patients with QT interval prolongation and TdP 
caused by administration of methadone.182
Prevention
 ● Keys to reducing the incidence of drug-induced cardiac 
arrhythmias include increased awareness among the medi-
cal, pharmaceutical, and nursing professions of the poten-
tial problems associated with the use of certain agents.
 ● Appropriate monitoring when a QT-interval–prolonging 
drug is administered is essential. Also, prompt withdrawal 
of the offending agent should be initiated.183 
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Table 16-1. Cumulative Incidence Rate (%) Over 5 Years After AF Diagnosis by Age
Age Group, y Mortality Heart Failure Myocardial Infarction Stroke Gastrointestinal Bleeding
67–69 28.8 11.0 3.3 5.0 4.4
70–74 32.3 12.1 3.6 5.7 4.9
75–79 40.1 13.3 3.9 6.9 5.9
80–84 52.1 15.1 4.3 8.1 6.4
85–89 67.0 15.8 4.4 8.9 6.6
≥90 84.3 13.7 3.6 6.9 5.4
AF indicates atrial fibrillation.
Data derived from Puccini et al136 by permission of the European Society of Cardiology.
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Chart 16-1. Long-term outcomes in individuals with prolonged PR interval (>200 ms; first-degree atrioventricular block) compared with 
individuals with normal PR interval in the Framingham Heart Study. Data derived from Cheng et al.15
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Chart 16-2. Reason for pacemaker implantation. Primary indications (in thousands) for pacemaker placement between 1990 and 2002 
from National Hospital Discharge Survey. AV indicates atrioventricular. Data derived from Birnie et al.36
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Chart 16-3. Incidence rate of paroxysmal supraventricular tachycardia per 100 000 person-years by age and sex. Data derived from 
 Orejarena et al.38
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Chart 16-4. Current and future US prevalence projections for atrial fibrillation (AF). Projections assume no increase (red dashed line) 
or logarithmic growth (blue dashed line) in incidence of AF from 2007. Data derived from Go et al75 and modified from Colilla et al,81  
 copyright 2013, with permission from Elsevier.
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Chart 16-5. Atrial fibrillation (AF) incidence by race. Incidence of AF increases with age among different races and sexes in the United 
States. Data derived from Dewland et al.80
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Chart 16-6. Lifetime risk for atrial fibrillation (AF) at different ages by sex. Cumulative risk for AF through age 94 years at selected ages 
by sex. With increasing incidence of AF with aging, lifetime risk is unchanged. Reprinted with permission from Lloyd-Jones et al.95 
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Chart 16-7. Population attributable fraction of major risk factors for atrial fibrillation in the Atherosclerosis Risk in Communities study. 
BMI indicates body mass index; cardiac disease, patients with history of coronary artery disease or heart failure; and smoking, current 
smoker. Data derived from Huxley et al.117
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Chart 16-8. Cumulative incidence of events in the 5 years after diagnosis of incident atrial fibrillation in Medicare patients. Reprinted from 
Puccini et al136 by permission of the European Society of Cardiology.
Chart 16-9. Global age-adjusted atrial fibrillation prevalence rates (per 100 000 population) in the 2010 Global Burden of Disease Study. 
Reprinted with permission from Chugh et al.141 Copyright © 2014, American Heart Association, Inc.
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Chart 16-10. Atrial fibrillation (AF) cost estimates. Costs where AF is primary diagnosis in inpatient and outpatient encounters. Indirect 
costs are incremental costs of inpatient and outpatient visits. Data derived from Kim et al144 and Coyne et al.184
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17 . Sudden Cardiac Arrest
See Tables 17-1 and 17-2 and Charts 17-1 and 17-2.
Cardiac Arrest (Including VF and  
Ventricular Flutter)
ICD-9 427.4, 427.5; ICD-10 I46.0, I46.1, I46.9, I49.0
Mortality—16 265. Any-mention mortality—338 699.
Cardiac arrest is defined as the cessation of cardiac mechan-
ical activity, as confirmed by the absence of signs of circula-
tion.1 Cardiac arrest is traditionally categorized as being of 
cardiac or noncardiac origin. An arrest is presumed to be of 
cardiac origin unless it is known or likely to have been caused 
by trauma, submersion, drug overdose, asphyxia, exsangui-
nation, or any other noncardiac cause as best determined by 
rescuers.1 In practice, the accuracy of this classification is dif-
ficult, and some data sets do not attempt to make the distinc-
tion. Because of fundamental differences in underlying causes 
and the system of care, epidemiological data for out-of-hos-
pital and in-hospital cardiac arrest are typically collected and 
reported separately. For similar reasons, data for adults and 
children (age 1–18 years) are commonly reported separately.
There are a number of ongoing challenges to understanding 
the epidemiology of cardiac arrest in the United States. Despite 
being a leading cause of HD death, there are currently no 
nationwide standards for surveillance to monitor the incidence 
and outcomes of cardiac arrest. In addition, it is challenging to 
define what is “unexpected” or “sudden” death. Sudden cardiac 
death has been defined as unexpected death without an obvi-
ous noncardiac cause that occurs within 1 hour of symptom 
onset (witnessed) or within 24 hours of last being observed in 
normal health (unwitnessed).2 However, this definition is dif-
ficult to apply in the real-world setting. Out-of-hospital cardiac 
arrest registries and clinical trials typically include patients in 
cardiac arrest who were either assessed by EMS providers or 
treated by EMS providers. Regional and cultural differences in 
EMS system access and decision to treat are potential sources 
of variability in these data sets. Similar challenges exist related 
to the epidemiology of in-hospital cardiac arrest.
Out-of-Hospital Cardiac Arrest
For additional details on out-of-hospital cardiac arrest treat-
ment, please refer to Chapter 23, Quality of Care, Tables 23-8 
and 23-9.
There are wide variations in the reported incidence of and 
outcomes for out-of-hospital cardiac arrest. These differences 
are caused in part by differences in definition and ascertain-
ment of cardiac arrest data, as well as differences in treatment 
after the onset of cardiac arrest.
Children
(See Table 17-1.)
Incidence and Risk Factors
 ● The incidence of out-of-hospital cardiac arrest among 
individuals <18 years of age in the United States is best 
characterized by an ongoing registry. Extrapolation of the 
incidence of EMS-assessed out-of-hospital cardiac arrest 
reported by ROC (ROC Investigators, unpublished data, 
August 12, 2014) suggests that each year, 6328 (quasi-CI, 
5519–7064) children experience EMS-assessed out-of-hos-
pital cardiac arrest in the United States.
 ● Most sudden deaths in young athletes were attributable to 
CVD (56%). Of the cardiovascular deaths that occurred, 29% 
occurred in blacks, 54% in high school students, and 82% 
with physical exertion during competition/training; only 11% 
occurred in females, although this proportion has increased 
over time.3
 ● A longitudinal study of students 17 to 24 years of age par-
ticipating in National Collegiate Athletic Association sports 
showed that the incidence of nontraumatic out-of-hospital 
cardiac arrest was 1 per 22 903 athlete participant-years. The 
incidence of cardiac arrest tended to be higher among blacks 
than among whites and among men than among women.4
 ● In the state of Minnesota between 1993 and 2012, the 
incidence of sudden cardiac death in high school athletes 
screened every 3 years with standard preparticipation eval-
uations during Minnesota State High School League activi-
ties was 0.24 per 100 000 athlete-years.5
Aftermath
 ● In the ROC Epistry, survival to hospital discharge in 2011 
after EMS-treated nontraumatic cardiac arrest with any 
Abbreviations Used in Chapter 17
AF atrial fibrillation
AV atrioventricular
BMI body mass index
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CARES Cardiac Arrest Registry to Enhance Survival
CI confidence interval
CVD cardiovascular disease
ECG electrocardiogram
EMS emergency medical services
GWTG Get With The Guidelines
HCM hypertrophic cardiomyopathy
HD heart disease
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LQTS long-QT syndrome
LV left ventricular
MI myocardial infarction
OR odds ratio
PA physical activity
PAR population attributable risk
PVT polymorphic ventricular tachycardia
ROC Resuscitation Outcomes Consortium
RR relative risk
SD standard deviation
VF ventricular fibrillation
VT ventricular tachycardia
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first recorded rhythm was 7.3% (95% CI, 5.0%–9.6%) for 
children (ROC Investigators, unpublished data, August 12, 
2014). Survival after bystander-witnessed VF was 53.3% 
(95% CI, 28.1%–78.6%) for children (ROC Investigators, 
unpublished data, August 14, 2014).
Adults
Incidence
(See Table 17-1 and Charts 17-1 and 17-2.)
 ● The incidence of EMS-assessed, EMS-treated nontrau-
matic cardiac arrest and bystander-witnessed VF among 
individuals of any age during 2011 in the United States is 
best characterized by an ongoing registry from ROC.
 ● The total resident population of the United States is 
316 128 839 individuals.6 Extrapolation of the incidence 
of EMS-assessed out-of-hospital cardiac arrest reported 
by ROC (ROC Investigators, unpublished data, August 12, 
2014) to the total population of the United States suggests 
that each year, 326 200 (quasi-CI, 320 200–332 200) people 
(320 157 adults) experience EMS-assessed out-of-hospital 
cardiac arrests in the United States.
 ● Approximately 60% of out-of-hospital cardiac arrests are 
treated by EMS personnel.7
 ● Twenty-five percent of those with EMS-treated out-of-hos-
pital cardiac arrest have no symptoms before the onset of 
arrest.8
 ● Among EMS-treated out-of-hospital cardiac arrests, 23% 
have an initial rhythm of VF or VT or are shockable by an 
automated external defibrillator.9
 ● The incidence of cardiac arrest with an initial rhythm of VF 
is decreasing over time; however, the incidence of cardiac 
arrest with any initial rhythm is not decreasing.10
 ● On the basis of extrapolation of data from the Oregon Sud-
den Unexpected Death Study, the estimated risk-adjusted 
incidence of sudden cardiac arrest was 76/100 000 per 
year (234 085 per year in the United States) and the esti-
mated risk-adjusted incidence of sudden cardiac death 
was 69/100 000 per year (212 910 per year in the United 
States).11 This data set excluded cases that were judged to 
have a noncardiac cause of arrest. In the same study, the 
estimated societal burden of premature death was 2 million 
years of potential life lost for men and 1.3 million years of 
potential life lost for women.
 ● The median age for out-of-hospital cardiac arrest is 66 
years.12
 ● Cardiac arrest is witnessed by a bystander in 38.7% of 
cases and by an EMS provider in 10.9% of cases and is 
unwitnessed in 50.4% of cases.12
 ● According to the CARES registry, in 2013 the majority of 
out-of-hospital cardiac arrests occurred at a home or resi-
dence (69.5%).12
 ● Among 10.9 million registered participants in 40 mara-
thons and 19 half marathons, the overall incidence of 
cardiac arrest was 0.54 per 100 000 participants (95% CI, 
0.41–0.70).13 Those with cardiac arrest were more often 
male and were running a marathon versus a half marathon. 
Seventy-one percent of those with cardiac arrest died; 
those who died were younger (mean 39±9 years of age) 
than those who did not die (mean 49±10 years of age), 
were more often male, and were more often running a full 
marathon.
Risk Factors
 ● A study conducted in New York City found the age-adjusted 
incidence of out-of-hospital cardiac arrest per 10 000 adults 
was 10.1 among blacks, 6.5 among Hispanics, and 5.8 
among whites.14
 ● Prior HD is a major risk factor for cardiac arrest. A study 
of 1275 health maintenance organization enrollees 50 to 79 
years of age who had cardiac arrest showed that the inci-
dence of out-of-hospital cardiac arrest was 6.0 per 1000 
person-years in subjects with any clinically recognized 
HD compared with 0.8 per 1000 person-years in subjects 
without HD. In subgroups with HD, incidence was 13.6 per 
1000 person-years in subjects with prior MI and 21.9 per 
1000 person-years in subjects with HF.15
 ● A family history of cardiac arrest in a first-degree relative 
is associated with an ≈2-fold increase in risk of cardiac 
arrest.3,4
 ● In a study of 81 722 women in the Nurses’ Health Study, 
the PAR of sudden death associated with 4 lifestyle fac-
tors (smoking, PA, diet, and weight) was 81% (95% CI, 
52%–93%).16
 ● A study of 1275 health maintenance organization enrollees 
50 to 79 years of age who had cardiac arrest showed that 
the incidence of out-of-hospital cardiac arrest was 6.0/1000 
subject-years in subjects with any clinically recognized HD 
compared with 0.8/1000 subject-years in subjects without 
HD. Among enrollees with HD, incidence was 13.6 and 
21.9 per 1000 subject-years in those with prior MI and with 
HF, respectively.15
Aftermath
 ● In the ROC Epistry, survival to hospital discharge in 2011 
after nontraumatic EMS-treated cardiac arrest with any first 
recorded rhythm was 10.6% (95% CI, 10.1%–11.2%) for 
patients of any age (Table 17-2; ROC Investigators, unpub-
lished data, August 12, 2014). Survival after bystander-wit-
nessed VF was 31.4% (95% CI, 29.2%–33.7%) for patients 
of any age. Contemporary survival data will be available on 
completion of ongoing randomized trials.
 ● In CARES, 31 127 out-of-hospital cardiac arrests were 
treated in 2013. Survival to hospital discharge was 10.6%, 
and survival with good neurological function (Cerebral 
Performance Category 1 or 2) was 8.3%. For bystander-
witnessed arrest with a shockable rhythm, survival to hos-
pital discharge was 33.0%.12
 ● In a study using the US Nationwide Inpatient Sample data, 
in-hospital mortality for patients hospitalized after treat-
ment for cardiac arrest declined 11.8%, from 69.6% in 
2001 to 57.8% in 2009.17
 ● A study conducted in New York City found the age-adjusted 
survival to 30 days after discharge was more than twice as 
poor for blacks as for whites, and survival among Hispanics 
was also lower than among whites.14
 ● A study in Denmark of 1218 out-of-hospital cardiac arrest 
patients between 2002 and 2010 demonstrated that trans-
port to a non–tertiary care center versus a tertiary care 
center after return of spontaneous circulation or with 
ongoing resuscitation was independently associated with 
increased risk of death (HR, 1.32; 95% CI, 1.09–1.59; 
P=0.004).18
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In-Hospital Cardiac Arrest
For additional details on in-hospital arrest treatment out-
comes, please refer to Chapter 23, Quality of Care.
Children
Aftermath
●● Survival rates are not available for children with in-hospital 
cardiac arrest due to small sample size.
●● Among 1031 children at 12 hospitals in the GWTG-
Resuscitation Registry between 2001 and 2009, the initial 
cardiac arrest rhythm was asystole and pulseless electri-
cal activity in 874 children (84.8%) and VF and pulse-
less VT in 157 children (15.2%). Risk-adjusted rates of 
survival to discharge increased from 14.3% in 2000 to 
43.4% in 2009 (adjusted rate ratio per year, 1.08; 95% CI, 
1.01–1.16; P for trend=0.02) without an increased rate of 
neurological disability among survivors over time (unad-
justed P for trend=0.32).20
Adults
Incidence
●● Extrapolation of the incidence of in-hospital cardiac 
arrest reported by GWTG-Resuscitation to the total 
population of hospitalized patients in the United States 
suggests that each year, 209 000 (quasi-CI, 192 000–
211 000) people are treated for in-hospital cardiac 
arrest.19
●● Analysis of the UK National Cardiac Arrest Audit data-
base between 2011 and 2013 (144 acute hospitals and 
22 628 patients ≥16 years of age) revealed an incidence 
of in-hospital cardiac arrest of 1.6 per 1000 hospital 
admissions, with a median across hospitals of 1.5 (inter-
quartile range, 1.2–2.2). The overall unadjusted survival 
rate was 18.4%.21
Aftermath
●● According to the GWTG-Resuscitation Investigators 
(unpublished data, September 4, 2014), 25.5% (95% CI, 
24.9%–26.1%) of adults who experienced in-hospital car-
diac arrest with any first recorded rhythm in 2013 survived 
to discharge.
●● Chan et al22 demonstrated that rates of survival to discharge 
were lower for black patients (25.2%) than for white 
patients (37.4%) after in-hospital cardiac arrest. Lower 
rates of survival to discharge for blacks reflected lower 
rates of both successful resuscitation (55.8% versus 67.4% 
for blacks versus whites, respectively) and postresuscita-
tion survival (45.2% versus 55.5%, respectively). Adjust-
ment for the hospital site at which patients received care 
explained a substantial portion of the racial differences 
in successful resuscitation (adjusted RR, 0.92; 95% CI, 
0.88–0.96; P<0.001) and eliminated the racial differences 
in postresuscitation survival (adjusted RR, 0.99; 95% CI, 
0.92–1.06; P=0.68).
●● In the United Kingdom National Cardiac Arrest Audit data-
base between 2011 and 2013, the overall unadjusted sur-
vival rate was 18.4%. Survival was 49% when the initial 
rhythm was shockable and 10.5% when the initial rhythm 
was not shockable.21
●● Inherited Syndromes Associated With Sudden 
Cardiac Death
Long-QT Syndrome
●● The hereditary LQTS is a genetic channelopathy character-
ized by prolongation of the QT interval (typically >460 ms) 
and susceptibility to ventricular tachyarrhythmias that lead 
to syncope and sudden cardiac death. Investigators have 
identified mutations in 13 genes leading to this phenotype 
(LQT1 through LQT13). LQT1 (KCNQ1), LQT2 (KCNH2), 
and LQT3 (SCN5A) mutations account for the majority 
(≈80%) of the typed mutations.23,24
●● Prevalence of LQTS is estimated at 1 per 2000 live births 
from ECG-guided molecular screening of ≈44 000 infants 
(mostly white) born in Italy.25 A similar prevalence was 
found among nearly 8000 Japanese school children 
screened by use of an ECG-guided molecular screening 
approach.26
●● LQTS has been reported among those of African descent, 
but its prevalence is not well assessed.27
●● There is variable penetrance and a sex-time interaction for 
LQTS symptoms. Risk of cardiac events is higher among 
boys than girls (21% among boys and 14% among girls 
by 12 years of age). Risk of events during adolescence is 
equivalent between sexes (≈25% for both sexes from ages 
12–18 years). Conversely, risk of cardiac events in young 
adulthood is higher among women than men (39% among 
women from ages 18–40 years and 16% among men).24
●● In addition to age and sex, the clinical course is influenced 
by prior syncope or aborted cardiac arrest, family history, 
QT-interval duration, genotype, number of mutations, and 
congenital deafness.23,24,28
●● Risk of cardiac events is decreased during pregnancy but 
increased during the 9-month postpartum period.29
●● The mainstay of therapy and prevention is β-blockade 
treatment.28,30 Implantable defibrillators are considered for 
high-risk individuals.31
●● Individuals may be risk stratified for increased risk of sud-
den cardiac death32 according to their specific long-QT 
mutation and their response to β-blockers.30
●● Among 403 patients from the LQTS Registry from birth 
through age 40 years, multivariate analysis demonstrated that 
patients with multiple LQTS gene mutations had a 2.3-fold 
(P=0.015) increased risk for life-threatening cardiac events 
(comprising aborted cardiac arrest, implantable defibrillator 
shock, or sudden cardiac death) compared with patients with 
a single mutation.33
Short-QT Syndrome
●● Short-QT syndrome is a recently described inherited men-
delian condition characterized by shortening of the QT 
interval (typically QT <320 ms) and predisposition to AF, 
ventricular tachyarrhythmias, and sudden death. Mutations 
in 5 ion channel genes have been described (SQT1–SQT5).34
●● In a population of 41 767 young, predominantly male Swiss 
transcripts, 0.02% of the population had a QT interval 
shorter than 320 ms.35
●● Among 53 patients from the European Short QT Syndrome 
Registry (75% males, median age 26 years),36 a familial 
or personal history of cardiac arrest was present in 89%. 
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Twenty-four patients received an implantable cardioverter-
defibrillator, and 12 received long-term prophylaxis with 
hydroquinidine. During a median follow-up of 64 months, 
2 patients received an appropriate implantable cardioverter-
defibrillator shock, and 1 patient experienced syncope. 
Nonsustained PVT was recorded in 3 patients.36
 ● In a cohort of 25 patients with short-QT syndrome ≤21 years 
of age followed up for 5.9 years, 6 patients had aborted sud-
den death (24%).37 Sixteen patients (84%) had a familial or 
personal history of cardiac arrest. A gene mutation associ-
ated with short-QT syndrome was identified in 5 (24%) of 
21 probands.
Brugada Syndrome
 ● The Brugada syndrome is an inherited channelopathy char-
acterized by persistent ST-segment elevation in the precordial 
leads (V1–V3), right bundle-branch block, and susceptibility 
to ventricular arrhythmias and sudden cardiac death.38
 ● Mutations in several ion channel–related genes have been 
identified that lead to Brugada syndrome.38
 ● Prevalence is estimated at 1 to 5 per 10 000 individuals. 
Prevalence is higher in Southeast Asian countries, includ-
ing Thailand and the Philippines. There is a strong male 
predominance (80% male).38–43
 ● Cardiac event rates for Brugada syndrome patients fol-
lowed up prospectively in northern Europe (31.9 months) 
and Japan (48.7 months) were similar: 8% to 10% in 
patients with prior aborted sudden death, 1% to 2% in 
those with history of syncope, and 0.5% in asymptomatic 
patients.44,45 Predictors of poor outcome included family 
history of sudden death and early repolarization pattern 
on ECG.46,47
 ● Among patients with spontaneous or drug-induced Bru-
gada syndrome, first-degree AV block, syncope, and spon-
taneous type 1 ST-segment elevation were independently 
associated with risk of sudden death or implantable cardio-
verter-defibrillator–appropriate therapies.48
Catecholaminergic PVT
 ● Catecholaminergic PVT is a familial condition character-
ized by adrenergically induced ventricular arrhythmias 
associated with syncope and sudden death. It is associated 
with frequent ectopy, bidirectional VT, and PVT with exer-
cise or catecholaminergic stimulation (such as emotion, or 
medicines such as isoproterenol).
 ● Mutations in genes encoding RYR249,50 are found in the 
majority, and mutations in genes encoding CASQ251,52 are 
found in a small minority.44 However, a substantial propor-
tion of individuals with catecholaminergic PVT do not have 
an identified mutation.
 ● Statistics regarding catecholaminergic PVT are primarily 
from case series. Of 101 patients with catecholaminergic 
PVT, the majority had experienced symptoms before 21 
years of age.44
 ● In small series (n=27 to n=101 patients) of patients followed 
up over a mean of 6.8 to 7.9 years, 27% to 62% experienced 
cardiac symptoms, and fatal or near-fatal events occurred in 
13% to 31%.44,45,49
 ● Risk factors for cardiac events included younger age at 
diagnosis and absence of β-blocker therapy. A history of 
aborted cardiac arrest and absence of β-blocker therapy 
were risk factors for fatal or near-fatal events.44
Arrhythmogenic Right Ventricular Cardiomyopathy
 ● Arrhythmogenic right ventricular cardiomyopathy is a 
form of genetically inherited structural HD that presents 
with fibrofatty replacement of the myocardium, with 
clinical presentation of palpitations, syncope, and sudden 
death.50
 ● Twelve arrhythmogenic right ventricular cardiomyopathy 
loci have been described (ARVC1–ARVC12). Disease-
causing genes for 8 of these loci have been identified, the 
majority of which are in desmosomally related proteins.50
 ● Prevalence is estimated at 2 to 10 per 10 000 individu-
als.53,54 Of 100 patients reported on from the Johns Hopkins 
Arrhythmogenic Right Ventricular Dysplasia Registry, 51 
were men and 95 were white, with the rest being of black, 
Hispanic, or Middle Eastern origin. Twenty-two percent of 
index cases had evidence of the familial form of arrhythmo-
genic right ventricular cardiomyopathy.51
 ● The most common presenting symptoms were palpitations 
(27%), syncope (26%), and sudden cardiac death (23%).51
 ● During a median follow-up of 6 years, 47 patients received 
an implantable cardioverter-defibrillator, 29 of whom 
received appropriate implantable cardioverter-defibrillator 
shocks. At the end of follow-up, 66 patients were alive. 
Twenty-three patients died at study entry, and 11 died dur-
ing follow-up (91% of deaths were attributable to sudden 
cardiac arrest).51 Similarly, the annual mortality rate was 
2.3% for 130 patients with arrhythmogenic right ventricu-
lar cardiomyopathy from Paris, France, who were followed 
up for a mean of 8.1 years.52
Hypertrophic Cardiomyopathy
(Please refer to Chapter 20, Cardiomyopathy and Heart 
Failure, for statistics regarding the general epidemiology of 
HCM.)
 ● Over a mean follow-up of 8±7 years, 6% of HCM patients 
experienced sudden cardiac death.55
 ● Among 1866 sudden deaths in athletes between 1980 and 
2006, HCM was the most common cause of cardiovascular 
sudden death (in 251 cases, or 36% of the 690 deaths that 
could be reliably attributed to a cardiovascular cause).3
 ● The risk of sudden death increases with increasing maxi-
mum LV wall thickness,56,57 and the risk for those with wall 
thickness ≥30 mm is 18.2 per 1000 patient-years (95% 
CI, 7.3–37.6),56 or approximately twice that of those with 
maximal wall thickness <30 mm.56,57 Of note, an associa-
tion between maximum wall thickness and sudden death 
has not been found in every HCM population.56
 ● Nonsustained VT is a risk factor for sudden death,54,58 par-
ticularly in younger patients. Nonsustained VT in those 
≤30 years of age is associated with a 4.35-greater odds of 
sudden death (95% CI, 1.5–12.3).54
 ● A history of syncope is also a risk factor for sudden death 
in these patients,59 particularly if the syncope was recent 
before the initial evaluation and not attributable to a neu-
rally mediated event.60
 ● The presence of LV outflow tract obstruction ≥30 mm Hg 
appears to increase the risk of sudden death by ≈2-fold.61,62 
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The presence of LV outflow tract obstruction has a low 
positive predictive value (7%–8%) but a high negative pre-
dictive value (92%–95%) for predicting sudden death.61,63
 ● The rate of malignant ventricular arrhythmias detected by 
implantable cardioverter-defibrillators appears to be similar 
between those with a family history of sudden death in ≥1 
first-degree relatives and those with at least 1 of the risk 
factors described above.64
 ● The risk of sudden death increases with the number of risk 
factors.65
Early Repolarization Syndrome
(See Table 17-1.)
 ● Early repolarization, observed in ≈4% to 19% of the pop-
ulation66–69 (more commonly in young men66,68,70 and in 
athletes67), has conventionally been considered a benign 
finding.
 ● A clinically relevant syndrome was initially described in 
which ≥1-mm positive deflections (sometimes referred 
to as “J waves”) in the S wave of ≥2 consecutive infe-
rior or lateral leads were found in 31% of 206 patients 
with idiopathic VF compared with 5% of control subjects 
(P<0.001).66 These findings have been validated in a sec-
ond study demonstrating similar J-point elevation in 42% 
of 45 patients with idiopathic VF compared with 13% of 
age- and sex-matched control subjects (P=0.001).67 Given 
an estimated risk of idiopathic VF in the general population 
(among those aged 35–45 years) of 3.4 per 100 000, the 
positive predictive value of such J-wave findings in a per-
son 35 to 45 years of age increases the chances of having 
idiopathic VF to 11 of 100 000.67
 ● In an analysis of the Social Insurance Institution’s Coronary 
Disease Study in Finland, J-point elevation was identified 
in 5.8% of 10 864 people.68 Those with inferior-lead J-point 
elevation more often were male and more often were smok-
ers; had a lower resting heart rate, lower BMI, lower BP, 
shorter corrected QT interval, and longer QRS duration; 
and were more likely to have ECG evidence of CAD. Those 
with lateral J-point elevation were more likely to have LV 
hypertrophy. Before and after multivariable adjustment, 
subjects with J-point elevation ≥1 mm in the inferior leads 
(n=384) had a higher risk of cardiac death (adjusted RR, 
1.28; 95% CI, 1.04–1.59; P=0.03) and arrhythmic death 
(adjusted RR, 1.43; 95% CI, 1.06–1.94; P=0.03). However, 
these patients did not have a significantly higher rate of 
all-cause mortality. Before and after multivariable adjust-
ment, subjects with J-point elevation >2 mm (n=36) had 
an increased risk of cardiac death (adjusted RR, 2.98; 95% 
CI, 1.85–4.92; P=0.03), arrhythmic death (adjusted RR, 
3.94; 95% CI, 1.96–7.90; P=0.03), and death of any cause 
(adjusted RR, 1.54; 95% CI, 1.06–2.24; P=0.03). 
 ● In CARDIA, 18.6% of 5069 participants had early repolar-
ization restricted to the inferior and lateral leads at baseline; 
by year 20, only 4.8% exhibited an early repolarization pat-
tern.69 Younger age, black race, male sex, longer exercise 
duration and QRS duration, and lower BMI, heart rate, QT 
index, and Cornell voltage were associated cross-section-
ally with the presence of baseline early repolarization. Pre-
dictors of maintenance of the ECG pattern from baseline 
to year 20 were black race (OR, 2.62; 95% CI, 1.61–4.25), 
BMI (OR, 0.62 per 1 SD; 95% CI, 0.40–0.94), serum 
triglyceride levels (OR, 0.66 per 1 SD; 95% CI, 0.45–0.98), 
and QRS duration (OR, 1.68 per 1 SD; 95% CI, 1.37–2.06) 
at baseline.
 ● Evidence from families with a high penetrance of the early 
repolarization syndrome associated with a high risk of sud-
den death suggests that the syndrome can be inherited in an 
autosomal dominant fashion.71 A meta-analysis of genome-
wide association studies performed in population-based 
cohorts failed to identify any genetic variants that met cri-
teria for statistical significance.72 
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Table 17-1. Incidence of Out-of-Hospital Cardiac Arrest in US 
Sites of Resuscitation Outcomes Consortium
Incidence per 100 000 
(95% CI)
Annual No. of Cases 
(Quasi-CI)
EMS assessed
  Any age 103.2 (101.3, 105.1) 326 200 (320 200, 332 300)
  Adults 132.0 (129.5, 134.5) 320 200 (314 100, 326 200)
  Children 8.6 (7.5, 9.6) 6300 (5500, 7100)
EMS treated
  Any age 55.7 (54.3, 57.1) 176 100 (171 700, 180 500)
  Adults 71.5 (69.7, 73.3) 173 400 (169 100, 177 800)
  Children 6.4 (7.3, 5.4) 4700 (4000, 5400)
VF*
  Any age 11.0 (10.4, 11.7) 34 800 (32 900, 37 000)
  Adults 14.5 (13.7, 15.3) 35 200 (33 200, 37 100)
  Children 0.4 (0.1, 0.6) 300 (100, 400)
Bystander-witnessed VF
  Any age 6.1 (5.7, 6.6) 19 300 (18 000, 20 900)
  Adults 8.1 (7.4, 8.7) 19 600 (17 900, 21 100)
  Children 0.2 (0.1,0.4) 100 (100, 300)
Time frame: June 1, 2012 to May 31, 2013.
EMS indicates emergency medical services; and VF, ventricular fibrillation.
*The estimated number of annual VF cases of any age is less than the 
estimated number of cases in adults alone due to rounding as well as missing 
information about patient age. 
Source: Resuscitation Outcomes Consortium Investigators, unpublished data, 
July 23, 2014.
Table 17-2. Survival After Out-of-Hospital Cardiac Arrest in US 
Sites of Resuscitation Outcomes Consortium
Survival to Discharge (95% CI), %
EMS assessed
  Any age 5.6 (5.3–5.8)
  Adults 6.4 (6.1–6.7)
  Children 6.2 (4.2–8.1)
  Unknown age 0.1 (0–0.1)
EMS treated
  Any age 10.6 (10.1–11.2)
  Adults 10.8 (10.3–11.3)
  Children 7.3 (5.0–9.6)
  Unknown age 3.3 (0–7.9)
VF
  Any age 29.0 (27.3–30.7)
  Adults 29.0 (27.3–30.7)
  Children 36.0 (17.2–54.8)
Bystander-witnessed VF
  Any age 31.4 (29.2–33.7)
  Adults 31.2 (28.9–33.5)
  Children 53.3 (28.1–78.6)
CI indicates confidence interval; EMS, emergency medical services; and VF, 
ventricular fibrillation.
Source: Resuscitation Outcomes Consortium, unpublished data, time frame: 
January 1, 2011, to December 31, 2011. Exclusion: Episodes screened for trial.
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38.7%
10.9%
50.4%
Bystander
EMS Provider
Unwitnessed
Chart 17-2. Out-of-hospital cardiac arrest witness status, 2013. EMS indicates emergency medical services. Data derived from 2013 
Cardiac Arrest  Registry to Enhance Survival National Summary Report.12
4.8%
69.5%
0.6%
10.8%
0.7%
1.5%
7.2%
4.7% 0.3%
Healthcare Facility
Home/Residence
Industrial Place
Nursing Home
Other
Place of Recreation
Public/Commercial Building
Street/Highway
Transport Center
Chart 17-1. Location of out-of-hospital cardiac arrest, 2013. Data derived from 2013 Cardiac Arrest Registry to Enhance Survival 
National Summary Report.12
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18 . Subclinical Atherosclerosis
See Table 18-1 and Charts 18-1 through 18-6.
Atherosclerosis, a systemic disease process in which fatty depos-
its, inflammation, cells, and scar tissue build up within the walls 
of arteries, is the underlying cause of the majority of clinical 
cardiovascular events. Atherosclerosis can develop in large and 
small arteries supplying a variety of end-organs, including the 
heart, brain, kidneys, and extremities. There can be significant 
variability in which size arteries and locations are affected in 
individual patients, although atherosclerosis is often a systemic 
disease. In recent decades, advances in imaging technology 
have allowed for improved ability to detect and quantify ath-
erosclerosis at all stages and in multiple different vascular beds. 
Early identification of subclinical atherosclerosis could lead to 
more aggressive lifestyle modifications and medical treatment 
to prevent clinical manifestations of atherosclerosis such as MI, 
stroke, or renal failure. Two modalities, CT of the chest for eval-
uation of CAC and B-mode ultrasound of the neck for evalua-
tion of carotid artery IMT, have been used in large studies with 
outcomes data and may help define the burden of atherosclerosis 
in individuals before they develop clinical events such as heart 
attack or stroke. Another commonly used method for detecting 
and quantifying atherosclerosis in the peripheral arteries is the 
ABI. Data on cardiovascular outcomes are beginning to emerge 
for additional modalities that measure anatomic and functional 
measures of subclinical disease, including brachial artery reac-
tivity testing, aortic and carotid magnetic resonance imaging, 
and tonometric methods of measuring vascular compliance or 
microvascular reactivity. Further research may help to define 
the role of these techniques in cardiovascular risk assessment. 
Some guidelines have recommended screening for subclinical 
atherosclerosis, especially by CAC, or IMT may be appropriate 
in people at intermediate risk for HD (eg, 10-year estimated risk 
of 10%– 20%) but not for lower-risk general population screen-
ing or for people with preexisting HD or most other high-risk 
conditions.1,2 However, a recent guideline notes those with DM 
who are ≥40 years of age may be suitable for screening of risk 
by coronary calcium.1 There are still limited data demonstrat-
ing whether screening with these and other imaging modali-
ties can improve patient outcomes or whether it only increases 
downstream medical care costs. A recently published report in 
a large cohort randomly assigned to coronary calcium screen-
ing or not showed such screening to result in an improved risk 
factor profile without increasing downstream medical costs.3 In 
addition, a recent cost-effectiveness analysis based on data from 
MESA4 reported that CAC testing and statin treatment for those 
with CAC >0 was cost-effective (<$50 000 per quality-adjusted 
life year) in intermediate-risk scenarios (CHD risk 5%–10%) 
considering less favorable statin assumptions ($1.00 per pill).
Coronary Artery Calcification
Background
 ● CAC is a measure of the burden of atherosclerosis in the 
heart arteries and is measured by CT. Other components of 
the atherosclerotic plaque, including fatty (eg, cholesterol-
rich components) and fibrotic components, often accom-
pany CAC and may be present even in the absence of CAC.
 ● The presence of any CAC, which indicates that at least 
some atherosclerotic plaque is present, is defined by an 
Agatston score >0. Clinically significant plaque, frequently 
an indication for more aggressive risk factor management, 
is often defined by an Agatston score ≥100 or a score ≥75th 
percentile for one’s age and sex. However, although they 
predict short- to intermediate-term risk, absolute CAC 
cutoffs offer more prognostic information across all age 
groups in both men and women.5 An Agatston score ≥400 
has been noted to be an indication for further diagnostic 
evaluation (eg, exercise testing or myocardial perfusion 
imaging) for CAD.
Abbreviations Used in Chapter 18
ABI ankle-brachial index
AF atrial fibrillation
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
CAC coronary artery calcification
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CONFIRM Coronary CT Angiography Evaluation for Clinical Outcomes: An 
International Multicenter Registry
CRP C-reactive protein
CT computed tomography
CVD cardiovascular disease
DBP diastolic blood pressure
DM diabetes mellitus
FHS Framingham Heart Study
FMD flow-mediated dilation
FRS Framingham Risk Score
HDL high-density lipoprotein
HD heart disease
HR hazard ratio
IMT intima-media thickness
JUPITER Justification for the Use of Statins in Primary Prevention: An 
Intervention Trial Evaluating Rosuvastatin
LDL low-density lipoprotein
MASALA Mediators of Atherosclerosis in South Asians Living in America
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NHLBI National Heart, Lung, and Blood Institute
NNT
5 5-year number needed to treat
RR relative risk
SBP systolic blood pressure
SD standard deviation
TIPS The Indian Polycap Study
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Prevalence
(See Table 18-1 and Charts 18-1 and 18-2.)
 ● The NHLBI’s FHS reported CAC measured in 3238 white 
adults in age groups ranging from <45 years of age to ≥75 
years of age.6
—Overall, 32.0% of women and 52.9% of men had preva-
lent CAC.
—Among participants at intermediate risk according to 
FRS, 58% of women and 67% of men had prevalent 
CAC.
 ● The NHLBI’s CARDIA study measured CAC in 3043 
black and white adults 33 to 45 years of age (at the CAR-
DIA year 15 examination).7
—Overall, 15.0% of men and 5.1% of women, 5.5% of 
those 33 to 39 years of age and 13.3% of those 40 to 
45 years of age, had prevalent CAC. Overall, 1.6% of 
participants had an Agatston score that exceeded 100.
—Chart 18-1 shows the prevalence of CAC by ethnicity 
and sex. The prevalence of CAC was lower in black men 
than in white men but was similar in black and white 
women at these ages.
 ● The NHLBI’s MESA measured CAC in 6814 participants 
45 to 84 years of age, including white (n=2619), black 
(n=1898), Hispanic (n=1494), and Chinese (n=803) men 
and women.8
—Chart 18-2 shows the prevalence of CAC by sex and 
ethnicity.
—The prevalence and 75th percentile levels of CAC were 
highest in white men and lowest in black and Hispanic 
women. Significant ethnic differences persisted after 
adjustment for risk factors, with the RR of coronary cal-
cium being 22% less in blacks, 15% less in Hispanics, 
and 8% less in Chinese than in whites.
—Table 18-1 shows the 75th percentile levels of CAC by 
sex and race at selected ages. These might be considered 
cut points above which more aggressive efforts to con-
trol risk factors (eg, elevated cholesterol or BP) could 
be implemented and/or at which treatment goals might 
be more aggressive (eg, LDL cholesterol <100 mg/dL 
instead of <130 mg/dL).
 ● In a comparison of MESA with the MASALA study, which 
is a community-based cohort of South Asians in the United 
States (mean age 58 years), the age-adjusted prevalence of 
CAC was similar among white (68.8%) and South Asian 
(67.9%) men, with these groups having a greater preva-
lence of CAC than Chinese (57.8%), African-American 
(51.2%), and Hispanic (57.9%) men. In contrast, the age-
adjusted prevalence of CAC was lower in South Asian 
women (36.8%) than in white women (42.6%) and women 
of other races/ethnicities.9
 ● The prevalence of CAC varies widely according to base-
line risk profile, including global scores such as FRS. In a 
report from MESA,10 the prevalence of CAC among indi-
viduals with very low FRS (≤2.5%) was 22%, and it was 
39% among those with FRS 2.5% to 5% 10-year risk. In 
recent studies from MESA, the prevalence of CAC in those 
with no lipid abnormalities was 42%,11 and nearly one fifth 
(22%) of individuals in MESA with no known traditional 
CVD risk factors had presence of CAC.12
CAC and Incidence of Cardiovascular Events
(See Charts 18-3 and 18-4.)
 ● The NHLBI’s MESA recently reported on the association 
of CAC scores with first CHD events over a median follow-
up of 3.9 years among a population-based sample of 6722 
men and women (39% white, 27% black, 22% Hispanic, 
and 12% Chinese).13
—Chart 18-3 shows the HRs associated with CAC scores 
of 1 to 100, 101 to 300, and >300 compared with those 
without CAC (score=0), after adjustment for standard 
risk factors. People with CAC scores of 1 to 100 had ≈4 
times greater risk and those with CAC scores >100 were 
7 to 10 times more likely to experience a coronary event 
than those without CAC.
—CAC provided similar predictive value for coronary 
events in whites, Chinese, blacks, and Hispanics (HRs 
ranging from 1.15–1.39 for each doubling of coronary 
calcium).
 ● In another report of a community-based sample, not referred 
for clinical reasons, the South Bay Heart Watch examined 
CAC in 1461 adults (average age 66 years) with coronary 
risk factors, with a median of 7.0 years of follow-up.14
—Chart 18-4 shows the HRs associated with increasing 
CAC scores (relative to CAC=0 and <10% risk cate-
gory) in low-risk (<10%), intermediate-risk (10%–15% 
and 16%–20%), and high-risk (>20%) FRS categories 
of estimated risk for CHD in 10 years. Increasing CAC 
scores further predicted risk in intermediate- and high-
risk groups.
 ● In a study of healthy adults 60 to 72 years of age who were 
free of clinical CAD, predictors of the progression of CAC 
were assessed. Predictors tested included age, sex, race/
ethnicity, smoking status, BMI, family history of CAD, 
CRP, several measures of DM, insulin levels, BP, and lip-
ids. Insulin resistance, in addition to the traditional cardiac 
risk factors, independently predicts progression of CAC.15 
Clinically, however, it is not yet recommended to conduct 
serial scanning of CAC to measure effects of therapeutic 
interventions.
 ● A recent publication from MESA also used CAC, in par-
ticular, and carotid IMT to stratify CHD and CVD event 
risk in people with metabolic syndrome and DM; those 
with low levels of CAC or carotid IMT have CHD and 
CVD event rates as low as many people without metabolic 
syndrome and DM. Those with DM who have CAC scores 
<100 have annual CHD event rates of <1%.16
 ● It is noteworthy, as recently demonstrated in MESA in 
5878 participants with a median of 5.8 years of follow-up, 
that the addition of CAC to standard risk factors resulted in 
significant improvement of classification of risk for inci-
dent CHD events, placing 77% of people in the highest or 
lowest risk categories compared with 69% based on risk 
factors alone. An additional 23% of those who experienced 
events were reclassified as high risk, and 13% with events 
were reclassified as low risk.17 The contribution of CAC 
to risk prediction has also been observed in other cohorts, 
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including both the Heinz Nixdorf Recall Study18 and the 
Rotterdam Study.19
 ● An absence of CAC, observed in 40% to 50% of individu-
als, confers a very low risk for future cardiovascular events. 
In a meta-analysis of 13 studies assessing the relation-
ship of CAC with adverse cardiovascular outcomes that 
included 71 595 asymptomatic patients, 29 312 patients 
(41%) did not have any evidence of CAC.20 In a follow-up 
that averaged 3 to 5 years, 154 of 29 312 patients without 
CAC (0.47%) experienced a cardiovascular event com-
pared with 1749 of 42 283 patients with CAC (4.14%). The 
cumulative RR was 0.15 (95% CI, 0.11–0.21; P<0.001). 
These findings were confirmed in MESA, which reported a 
rate of 0.52% for CHD events during a median of 4 years of 
follow-up among people with no detectable CAC.21
 ● The value of CAC zero has been confirmed in various high-
risk groups. For example, in MESA, 38% of individuals 
with DM have CAC=0, and the annualized CHD and CVD 
event rates were 0.4% and 0.8%, respectively.16 A recent 
publication12 from MESA demonstrated a low hard CHD 
event rate per 1000 years during a median follow-up of 7.1 
years across the entire spectrum of baseline FRS (0%–6%: 
0.9; 6%–10%: 1.1; 10%–20%: 1.9; >20%: 2.5). Among 
high-risk individuals considered for various polypill crite-
ria in MESA,22 based on age and risk factors, the prevalence 
of CAC=0 ranged from 39% to 59%, and the respective 
rate of CHD events varied from 1.2 to 1.9 events per 1000 
person-years during a median follow-up of 7.6 years.
 ● A recent meta-analysis23 also highlighted the utility of CAC 
testing in the diabetic population. In this meta-analysis, 8 
studies were included (n=6521; 802 events; mean follow-
up, 5.18 years). The RR for all-cause mortality or cardio-
vascular events or both comparing a total CAC score ≥10 
with a score <10 was 5.47 (95% CI, 2.59–11.53; I2=82.4%, 
P<0.001). For people with a CAC score <10, the posttest 
probability of the composite outcome was ≈1.8%, which 
represents a 6.8-fold reduction from the pretest probabil-
ity, which suggests that those with low or absent CAC may 
facilitate risk stratification by enabling the identification of 
people at low risk within this high-risk population.23
 ● In the Heinz Nixdorf Recall Study,24 CAC independently 
predicted stroke during a mean follow-up of 7.9 years. Cox 
proportional hazards regressions were used to examine 
CAC as a predictor of stroke in addition to established vas-
cular risk factors (age, sex, SBP, LDL, HDL, DM, smoking, 
and AF). Study participants who had a stroke had signifi-
cantly higher CAC values at baseline than the remaining 
subjects (median 104.8 [quartile 1, 14.0; quartile 3, 482.2] 
versus 11.2 [quartile 1, 0; quartile 3, 106.2]; P<0.001). In a 
multivariable Cox regression, log10(CAC+1) was an inde-
pendent stroke predictor (HR, 1.52; 95% CI, 1.19–1.92; 
P=0.001). CAC discriminated stroke risk specifically in 
participants in the low (<10%) and intermediate (10%–
20%) FRS categories.24
 ● In the Rotterdam Study, CAC independently predicted 
incident HF during a median follow-up of 6.8 years. Those 
with severe CAC (>400) after adjustment for risk factors 
had a 4.1-fold higher risk (95% CI, 1.7–10.1) of HF than 
those with CAC scores of 0 to 10.25 In addition, CAC sub-
stantially improved the risk classification of subjects (net 
reclassification index, 34.0%).
CAC Progression and Risk
 ● A recent report in 4609 individuals who had baseline and 
repeat cardiac CT found that progression of CAC provided 
incremental information over baseline score, demograph-
ics, and cardiovascular risk factors in predicting future all-
cause mortality.26
 ● More recently, data from 6778 people in MESA showed 
annual CAC progression was an average of 25 Agatston 
units, and among those without CAC at baseline, a 5-U 
annual change in CAC was associated with HRs of 1.4 and 
1.5 for total and hard CHD events, respectively. Among 
those with CAC >0 at baseline, HRs per 100-U annual 
change in CAC were 1.2 and 1.3, respectively, and for 
those with annual progression ≥300 versus no progression, 
HRs were 3.8 and 6.3, respectively.27 Progression of CAC 
in MESA was also shown to be greater in those with meta-
bolic syndrome and DM than in those with neither condi-
tion, and progression of CAC in each of these conditions 
was associated with a greater future risk of CHD events.28
 ● In MESA, greater adherence to a healthy lifestyle based on 
a healthy lifestyle score was associated with slower pro-
gression of CAC and lower mortality rates relative to those 
with the most unhealthy lifestyle.29
Carotid IMT
Background
 ● Carotid IMT measures the thickness of 2 layers (the intima and 
media) of the wall of the carotid arteries, the largest conduits of 
blood going to the brain. Carotid IMT is thought to be an even 
earlier manifestation of atherosclerosis than CAC, because 
thickening precedes the development of frank atherosclerotic 
plaque. Carotid IMT methods are still being refined, so it is 
important to know which part of the artery was measured 
(common carotid, internal carotid, or bulb) and whether near 
and far walls were both measured. This information can affect 
the average-thickness measurement that is usually reported.
 ● Unlike CAC, everyone has some thickness to the layers of 
their arteries, but people who develop atherosclerosis have 
greater thickness. Ultrasound of the carotid arteries can 
also detect plaques and determine the degree of narrowing 
of the artery they may cause. Epidemiological data, includ-
ing the data discussed below, have indicated that high-risk 
levels of thickening might be considered as those in the 
highest quartile or quintile for one’s age and sex, or ≥1 mm.
 ● Although ultrasound is commonly used to diagnose plaque 
in the carotid arteries in people who have had strokes or 
who have bruits (sounds of turbulence in the artery), guide-
lines are limited as to screening of asymptomatic people 
with carotid IMT to quantify atherosclerosis or predict risk. 
However, some organizations have recognized that carotid 
IMT measurement by B-mode ultrasonography may pro-
vide an independent assessment of coronary risk.30
Prevalence and Association With Incident Cardiovascular 
Events
(See Charts 18-5 and 18-6.)
 ● The Bogalusa Heart Study measured carotid IMT in 518 
black and white men and women at a mean age of 32±3 
years. These men and women were healthy but overweight.31
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—The mean values of carotid IMT for the different seg-
ments are shown in Chart 18-5 by sex and race. Men 
had significantly higher carotid IMT in all segments 
than women, and blacks had higher common carotid and 
carotid bulb IMTs than whites.
—Even at this young age, after adjustment for age, race, 
and sex, carotid IMT was associated significantly and 
positively with waist circumference, SBP, DBP, and 
LDL cholesterol. Carotid IMT was inversely correlated 
with HDL cholesterol levels. Participants with greater 
numbers of adverse risk factors (0, 1, 2, 3, or more) had 
stepwise increases in mean carotid IMT levels.
 ● In a subsequent analysis, the Bogalusa investigators exam-
ined the association of risk factors measured since child-
hood with carotid IMT measured in these young adults.32 
Higher BMI and LDL cholesterol levels measured at 4 
to 7 years of age were associated with increased risk for 
being >75th percentile for carotid IMT in young adulthood. 
Higher SBP and LDL cholesterol and lower HDL choles-
terol in young adulthood were also associated with having 
high carotid IMT. These data highlight the importance of 
adverse risk factor levels in early childhood and young 
adulthood in the early development of atherosclerosis.
 ● Among both women and men in MESA, blacks had the 
highest common carotid IMT, but they were similar to 
whites and Hispanics in internal carotid IMT. Chinese par-
ticipants had the lowest carotid IMT, in particular in the 
internal carotid, of the 4 ethnic groups (Chart 18-6).
 ● The NHLBI’s CHS reported follow-up of 4476 men and 
women ≥65 years of age (mean age 72 years) who were 
free of CVD at baseline.33
—Mean maximal common carotid IMT was 1.03±0.20 
mm, and mean internal carotid IMT was 1.37±0.55 mm.
—After a mean follow-up of 6.2 years, those with maximal 
combined carotid IMT in the highest quintile had a 4- to 
5-fold greater risk for incident heart attack or stroke than 
those in the bottom quintile. After adjustment for other 
risk factors, there was still a 2- to 3-fold greater risk for 
the top versus the bottom quintile.
 ● In MESA, during a median follow-up of 3.3 years, IMT 
rate of change of 0.5 mm/year was associated with an HR 
of 1.23 (95% CI, 1.02–1.48) for incident stroke. The upper 
quartile of IMT rate of change had an HR of 2.18 (95% CI, 
1.07–4.46) compared with the lower 3 quartiles combined.34
 ● A study of 441 individuals ≤65 years of age without a his-
tory of CAD, DM, or hyperlipidemia who were examined 
for carotid IMT found 42% had high-risk carotid ultrasound 
findings (carotid IMT ≥75th percentile, adjusted for age, 
sex, and race or presence of plaque). Among those with an 
FRS ≤5%, 38% had high-risk carotid ultrasound findings.35
 ● Conflicting data have been reported on the contribution of 
carotid IMT to risk prediction. In 13 145 participants in the 
NHLBI’s ARIC study, the addition of carotid IMT com-
bined with identification of plaque presence or absence 
to traditional risk factors reclassified risk in 23% of indi-
viduals overall, with a net reclassification improvement 
of 9.9%. There was a modest but statistically significant 
improvement in the area under the receiver operating char-
acteristic curve, from 0.742 to 0.755.36 In contrast, data 
reported recently from the Carotid Atherosclerosis Progres-
sion Study observed a net reclassification improvement of 
−1.4% that was not statistically significant.37
 ● In the Rotterdam Study, 3580 nondiabetic individuals aged 
55 to 75 years were followed up for a median of 12.2 years. 
In older men, addition of carotid IMT to Framingham risk 
factors did not improve prediction of hard CHD or stroke. 
In older women, addition of carotid IMT to Framingham 
risk factors yielded a net reclassification improvement in 
women of 8.2% (P=0.03) for hard CHD and 8.0% (P=0.06) 
for stroke.38
 ● A recent study from a consortium of 14 population-based 
cohorts consisting of 45 828 individuals followed up for a 
median of 11 years demonstrated little additive value of 
common carotid IMT to FRS for purposes of discrimina-
tion and reclassification as far as incident MI and stroke 
were concerned. The C statistics of the model with FRS 
alone (0.757; 95% CI, 0.749–0.764) and with addition of 
common carotid IMT (0.759; 95% CI, 0.752–0.766) were 
similar. The net reclassification improvement with the addi-
tion of common carotid IMT was small (0.8%; 95% CI, 
0.1%–1.6%). In those at intermediate risk, the net reclas-
sification improvement was 3.6% among all individuals 
(95% CI, 2.7%–4.6%).39
CAC and Carotid IMT
 ● In the NHLBI’s MESA, a study of white, black, Chinese, 
and Hispanic adults 45 to 84 years of age, carotid IMT and 
CAC were found to be commonly associated, but patterns 
of association differed somewhat by sex and race.40
—Common and internal carotid IMT were greater in 
women and men who had CAC than in those who did 
not, regardless of ethnicity.
—Overall, CAC prevalence and scores were associated 
with carotid IMT, but associations were somewhat 
weaker in blacks than in other ethnic groups.
—In general, blacks had the thickest carotid IMT of all 4 
ethnic groups, regardless of the presence of CAC.
—Common carotid IMT differed little by race/ethnicity in 
women with any CAC, but among women with no CAC, 
IMT was higher among blacks (0.86 mm) than in the 
other 3 groups (0.76–0.80 mm).
 ● In a more recent analysis from the NHLBI’s MESA, the 
investigators reported on follow-up of 6698 men and 
women in 4 ethnic groups over 5.3 years and compared the 
predictive utility of carotid IMT and CAC.41
—CAC was associated more strongly than carotid IMT 
with the risk of incident CVD.
—After adjustment for each other (CAC score and IMT) 
and for traditional CVD risk factors, the HR for CVD 
increased 2.1-fold for each 1-SD increment of log-trans-
formed CAC score versus 1.3-fold for each 1-SD incre-
ment of the maximum carotid IMT.
—For CHD events, the HRs per 1-SD increment increased 
2.5-fold for CAC score and 1.2-fold for IMT.
—A receiver operating characteristic curve analysis also 
suggested that CAC score was a better predictor of inci-
dent CVD than was IMT, with areas under the curve of 
0.81 versus 0.78, respectively.
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—Investigators from the NHLBI’s CARDIA and MESA 
studies examined the burden and progression of sub-
clinical atherosclerosis among adults <50 years of age. 
Ten-year and lifetime risks for CVD were estimated for 
each participant, and the participants were stratified into 
3 groups: (1) those with low 10-year (<10%) and low 
lifetime (<39%) predicted risk for CVD; (2) those with 
low 10-year (<10%) but high lifetime (≥39%) predicted 
risk; and (3) those with high 10-year risk (>10%). The 
latter group had the highest burden and greatest pro-
gression of subclinical atherosclerosis. Given the young 
age of those studied, ≈90% of participants were at low 
10-year risk, but of these, half had high predicted life-
time risk. Compared with those with low short-term/low 
lifetime predicted risks, those with low short-term/high 
lifetime predicted risk had significantly greater burden 
and progression of CAC and significantly greater bur-
den of carotid IMT, even at these younger ages. These 
data confirm the importance of early exposure to risk 
factors for the onset and progression of subclinical 
atherosclerosis.42
CT Angiography
 ● CT angiography is widely used by cardiologists to aid in 
the diagnosis of CAD, particularly when other test results 
may be equivocal. It is also of interest because of its ability 
to detect and possibly quantitate overall plaque burden and 
certain characteristics of plaques that may make them prone 
to rupture, such as positive remodeling or low attenuation.
 ● Compared with the established value of CAC scanning 
for risk reclassification in asymptomatic patients, there 
are limited data regarding the utility of CT angiography 
in asymptomatic people. This was recently assessed by 
the investigators of the CONFIRM registry,43 from which 
>7500 asymptomatic subjects with CAC and CT angiog-
raphy were followed up for death and nonfatal MI for a 
median of 2 years. Overall, 2.2% either died or experienced 
nonfatal MI, and in multivariable models, compared with 
those without atherosclerosis, there was increasing risk 
across groups with increasing degrees of atherosclerosis 
measured by CT angiography. However, after the inclusion 
of CAC in the multivariable risk model, CT angiography 
did not provide incremental prognostic value over this short 
period of follow-up.43
 ● Because of the limited outcome data in asymptomatic 
people, as well as the associated expense and risk of CT 
angiography (including generally higher radiation levels 
than CT scanning to detect CAC), current guidelines do not 
recommend its use as a screening tool for assessment of 
cardiovascular risk in asymptomatic people.2
Measures of Vascular Function and Incident  
CVD Events
Background
 ● Measures of arterial tonometry (stiffness) are based on the 
concept that pulse pressure has been shown to be an impor-
tant risk factor for CVD. Arterial tonometry offers the 
ability to directly and noninvasively measure central pulse 
wave velocity in the thoracic and abdominal aorta.
 ● Brachial FMD is a marker for nitric oxide release from the 
endothelium that can be measured by ultrasound. Impaired 
FMD is an early marker of CVD.
 ● Recommendations have not been specific, however, as to 
which, if any, measures of vascular function may be use-
ful for CVD risk stratification in selected patient subgroups. 
Because of the absence of significant prospective data relat-
ing these measures to outcomes, latest guidelines do not cur-
rently recommend measuring either FMD or arterial stiffness 
for cardiovascular risk assessment in asymptomatic adults.2
Arterial Tonometry and CVD
 ● The Rotterdam Study measured arterial stiffness in 2835 
elderly participants (mean age 71 years).44 They found that 
as aortic pulse wave velocity increased, the risk of CHD 
was 1.72 (second versus first tertile) and 2.45 (third versus 
first tertile). Results remained robust even after accounting 
for carotid IMT, ABI, and pulse pressure.
 ● A study from Denmark of 1678 individuals aged 40 to 70 
years found that each 1-SD increment in aortic pulse wave 
velocity (3.4 m/s) increased CVD risk by 16% to 20%.45
 ● The FHS measured several indices of arterial stiffness, 
including pulse wave velocity, wave reflection, and cen-
tral pulse pressure.46 They found that not only was higher 
pulse wave velocity associated with a 48% increased risk of 
incident CVD events, but pulse wave velocity additionally 
improved CVD risk prediction (integrated discrimination 
improvement of 0.7%, P<0.05).
FMD and CVD
 ● MESA measured FMD in 3026 participants (mean age 
61 years) who were free of CVD. As FMD increased (ie, 
improved brachial function), the risk of CVD was 16% 
lower.47 FMD also improved CVD risk prediction com-
pared with the FRS by improving net reclassification by 
29%.
 ● A recent meta-analysis assessed relation of FMD with 
CVD events. Thirteen studies involving 11 516 individuals 
without established CVD, with a mean duration of 2 to 7.2 
years and adjusted for age, sex, and risk factors, reported 
a multivariate RR of 0.93 (95% CI, 0.90–0.96) per 1% 
increase in brachial FMD.48
Comparison of Measures
 ● In MESA, a comparison of 6 risk markers—CAC, ABI, 
high-sensitivity CRP, carotid IMT, brachial FMD, and fam-
ily history of CHD—and their clinical utility over FRS was 
evaluated in 1330 intermediate-risk individuals. After 7.6 
years of follow-up, CAC, ABI, high-sensitivity CRP, and 
family history were independently associated with incident 
CHD in multivariable analyses (HRs of 2.6, 0.79, 1.28, 
and 2.18, respectively), but carotid IMT and brachial FMD 
were not. CAC provided the highest incremental improve-
ment over the FRS (0.784 for both CAC and FRS versus 
0.623 for FRS alone), as well as the greatest net reclassifi-
cation improvement (0.659).49
 ● Similar findings were also noted in the Rotterdam Study, in 
which among 12 CHD risk markers, improvements in FRS 
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predictions were most statistically and clinically significant 
with the addition of CAC scores.50
Utility for Risk Stratification for Treatment
 ● CAC has been examined in multiple studies for its potential 
to identify those most likely and not likely to benefit from 
treatment.
 ● In a recent report, 950 participants from MESA who met 
JUPITER clinical trial entry criterion (risk factors plus 
LDL cholesterol <130 mg/dL and CRP ≥2 mg/L) were 
identified and stratified according to CAC scores of 0, 1 
to 100, or >100; CHD event rates were calculated, and the 
number needed to treat was calculated by applying the ben-
efit found in JUPITER to the event rates found in each of 
these groups. For CHD, the predicted NNT5 was 549 for 
those with CAC of 0, 94 for scores of 1 to 100, and 24 for 
scores >100.
 ● In a similar fashion, 2 studies extrapolated the NNT5 for 
LDL cholesterol lowering by statins, applying the 30% 
RR reduction associated with a 1 mmol/L (39 mg/dL) 
reduction in LDL cholesterol from a Cochrane meta-
analysis of statin therapy in primary prevention across 
the spectrum of lipid abnormalities (LDL cholesterol 
≥130 mg/dL, HDL cholesterol <40 mg/dL for men or 
<50 mg/dL for women, and triglycerides ≥150 mg/dL), 
as well as across 10-year FRS categories (0–6%, 6–10%, 
10–20%, and >20%). The estimated NNT5 for prevent-
ing 1 CVD event across dyslipidemia categories in this 
MESA cohort ranged from 23 to 30 in those with CAC 
≥100.11 The NNT5 was 30 in participants with no lipid 
abnormality and CAC >100, whereas the NNT5 was 154 
in those with 3 lipid abnormalities and CAC=0.11 A very 
high NNT5 of 186 and 222, respectively, was estimated to 
prevent 1 CHD event in the absence of CAC among those 
with 10-year FRS of 11% to 20% and >20%. The respec-
tive estimated NNT5 were as low as 36 and 50 with the 
presence of a very high CAC score (>300) among those 
with 10-year FRS of 0% to 6% and 6% to 10%, respec-
tively.22 These collective data show the utility of CAC in 
identifying those most likely to benefit from statin treat-
ment across the spectrum of risk profiles with an appro-
priate number needed to treat.
 ● Similarly, CAC testing also identified appropriate can-
didates who may derive the highest benefit with aspirin 
therapy. In MESA, individuals with CAC ≥100 had an esti-
mated net benefit with aspirin regardless of their traditional 
risk status; the estimated NNT5 was 173 for individuals 
classified as having <10% FRS and 92 for individuals with 
≥10% FRS, and the estimated 5-year number needed to 
harm was 442 for a major bleed.51 Conversely, individuals 
with zero CAC had unfavorable estimates (estimated NNT5 
of 2036 for individuals with <10% FRS and 808 for indi-
viduals with ≥10% FRS; estimated 5-year number needed 
to harm of 442 for a major bleed). Sex-specific and age-
stratified analyses showed similar results.
 ● A recent study from MESA also examined the role of CAC 
testing to define the target population to treat with a polyp-
ill.22 The 5-year NNT5 to prevent 1 event was estimated by 
applying the expected 62% CHD event reduction associ-
ated with the use of the polypill (based on TIPS). The esti-
mated NNT5 to prevent 1 CHD event ranged from 170 to 
269 for patients with CAC=0, from 58 to 79 for those with 
CAC scores from 1 to 100, and from 25 to 27 for those with 
CAC scores >100,22 which enabled significant reductions in 
the population considered for treatment with more selective 
use of the polypill and, as a result, avoidance of treatment 
of those who were unlikely to benefit.
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Table 18-1. CAC Scores for the 75th Percentile of Men and 
Women of Different Race/Ethnic Groups, at Specified Ages
75th Percentile CAC Scores*
Age, y Black Chinese Hispanic White
Women
45 0 0 0 0
55 0 2 0 1
65 26 45 19 54
75 138 103 116 237
Men
45 0 3 0 0
55 15 34 27 68
65 95 121 141 307
75 331 229 358 820
CAC indicates coronary artery calcification.
*The 75th percentile CAC score is the score at which 75% of people of the 
same age, sex, and race have a score at or below this level and 25% of people 
of the same age, sex, and race have a higher score. 
Source: MESA (Multi-Ethnic Study of Atherosclerosis) CAC Tools Web site.52
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Chart 18-1. Prevalence (%) of coronary calcium: US adults 33 to 45 years of age. P<0.0001 across race-sex groups. Data derived from 
Loria et al.7
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women. Data derived from Bild et al.8
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19 . Coronary Heart Disease, Acute Coronary 
Syndrome, and Angina Pectoris
See Tables 19-1 and 19-2 and Charts 19-1 through 19-11; see 
Glossary (Chapter 27) for details and definitions.
Coronary Heart Disease
ICD-9 410 to 414, 429.2; ICD-10 I20 to I25; including MI 
ICD-10 I21 to I22.
Prevalence
(See Table 19-1 and Charts 19-1 and 19-2.)
 ● On the basis of data from NHANES 2009 to 2012 (NHLBI 
tabulation), an estimated 15.5 million Americans ≥20 years 
of age have CHD.
—Total CHD prevalence is 6.2% in US adults ≥20 years 
of age. CHD prevalence is 7.6% for men and 5.0% for 
women.
—Among non-Hispanic whites, CHD prevalence is 7.8% 
for men and 4.6% for women.
—Among non-Hispanic blacks, CHD prevalence is 7.2% 
for men and 7.0% for women.
—Among Hispanics, CHD prevalence is 6.7% for men and 
5.9% for women.
 ● On the basis of data from the 2013 NHIS1
—Among Asians ≥18 years of age, the estimate is 3.7%.
—Among American Indian/Alaska Natives ≥18 years of 
age, the estimate is 4.5%; however, this is not reliable.
 ● According to data from NHANES 2009 to 2012 (NHLBI 
tabulation), the overall prevalence for MI is 2.8% in US adults 
≥20 years of age. MI prevalence is 4.0% for men and 1.8% for 
women.
—Among non-Hispanic whites, MI prevalence is 4.1% for 
men and 1.8% for women.
—Among non-Hispanic blacks, MI prevalence is 3.4% for 
men and 2.2% for women.
—Among Hispanics, MI prevalence is 3.5% for men and 
1.7% for women.
 ● Data from the BRFSS 2013 survey indicated that 4.0% of 
respondents had been told that they had had an MI. The highest 
prevalence was in West Virginia (6.5%) and the lowest in Min-
nesota (2.7%). In the same survey, 3.8% of respondents were 
told that they had angina or CHD. The highest prevalence was 
in West Virginia (6.2%), and the lowest was in Hawaii (2.3%).2
 ● Projections show that by 2030, prevalence of CHD will 
increase ≈18% from 2013 estimates (AHA computation, 
based on methodology described in Heidenreich et al3).
Abbreviations Used in Chapter 19
ACC American College of Cardiology
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes Network
AHA American Heart Association
AMI acute myocardial infarction
AP angina pectoris
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
BP blood pressure
BRFSS Behavioral Risk Factor Surveillance System
CABG coronary artery bypass graft
CAD coronary artery disease
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of the 
ACC/AHA Guidelines
CVD cardiovascular disease
DM diabetes mellitus
ECG electrocardiogram
ED emergency department
EHS-ACS-II second Euro Heart Survey on ACS
EMS emergency medical services
FHS Framingham Heart Study
GRACE Global Registry of Acute Coronary Events
GWTG Get With The Guidelines
HCUP Healthcare Cost and Utilization Project
HD heart disease
HDL-C high-density lipoprotein-cholesterol
HF heart failure
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MEPS Medical Expenditure Panel Survey
MI myocardial infarction
NAMCS National Ambulatory Medical Care Survey
NCDR National Cardiovascular Data Registry
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHIS National Health Interview Study
NHLBI National Heart, Lung, and Blood Institute
NRMI National Registry of Myocardial Infarction
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PCI percutaneous coronary intervention
SBP systolic blood pressure
STEMI ST-segment–elevation myocardial infarction
UA unstable angina
WISE Women’s Ischemia Syndrome Evaluation
YLL years of life lost
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Incidence
(See Table 19-1 and Charts 19-3 through 19-5.)
 ● Approximately every 43 seconds, an American will have an 
MI (AHA computation).
 ● On the basis of data from the ARIC study4 of the NHLBI:
—This year, ≈635 000 Americans will have a new coronary 
event (defined as first hospitalized MI or CHD death), 
and ≈300 000 will have a recurrent event. It is estimated 
that an additional 155 000 silent MIs occur each year. 
That assumes that ≈21% of the 735 000 first and recur-
rent MIs are silent.
—The estimated annual incidence of MI is 525 000 new 
attacks and 210 000 recurrent attacks.
—Average age at first MI is 65.0 years for men and 71.8 
years for women.
 ● On the basis of the NHLBI-sponsored FHS5
—CHD makes up more than half of all cardiovascular 
events in men and women <75 years of age.
—The incidence of CHD in women lags behind men by 10 
years for total CHD and by 20 years for more serious 
clinical events such as MI and sudden death.
 ● In the NHLBI-sponsored ARIC study, in participants 35 
to 84 years of age, the average age-adjusted first MI or fatal 
CHD rates per 1000 population were as follows: white men, 
3.7; black men, 5.9; white women, 2.1; and black women, 
4.0 (unpublished data from ARIC Surveillance 2005–2011, 
NHLBI).
 ● Incidence rates for MI in the NHLBI-sponsored ARIC study 
are displayed in Charts 19-3 and 19-4, stratified by age, race, 
and sex. The annual age-adjusted rates per 1000 population 
of first MI (2005–2011) were 4.9 in black men, 3.2 in white 
men, 3.5 in black women, and 1.9 in white women (unpub-
lished data from ARIC Surveillance 2005–2011, NHLBI).
Trends in Incidence
 ● Analysis of >40 years of physician-validated AMI data in 
the NHLBI’s FHS found that AMI rates diagnosed by elec-
trocardiographic criteria declined ≈50%, with a concomi-
tant 2-fold increase in rates of AMI diagnosed by blood 
markers.6
 ● Data from the Worcester Heart Attack Study showed that 
incidence rates for AMI were 277 per 100 000 person-years 
in 1975 and 209 per 100 000 person-years in 2005 (P=0.42 
for overall trend). The incidence rate rose from 1975 to 
1981, decreased from 1981 to 1988, increased from 1981 
to 2001, and decreased from 2001 to 2005.7
 ● In Olmsted County, MN, no significant change in the over-
all age- and sex-adjusted incidence rate for hospitalized 
MI was noted between 1987 and 2006 (186 per 100 000 
person-years in 1987 and 180 per 100 000 person-years in 
2006; P=0.171), but a significant decline in the age- and 
sex-adjusted incidence rate for hospitalized MI based on 
creatine kinase/creatine kinase-MB markers, to 141 per 
100 000 person-years (P=0.020), was observed in 2006, 
which represents a 20% decrease during the study period.8
 ● Data from Kaiser Permanente Northern California 
showed that the age- and sex-adjusted incidence rate of 
hospitalizations for MI changed from 274 per 100 000 
person-years in 1999 to 208 per 100 000 person-years in 
2008. Furthermore, the age- and sex-adjusted incidence 
rate of hospitalizations for STEMI changed from 133 per 
100 000 person-years in 1999 to 50 per 100 000 person-
years in 2008 (P linear trend <0.001). The trajectory of the 
age- and sex-adjusted incidence rate of hospitalizations 
for NSTEMI did not change significantly over the entire 
study period, although it did show a significant decline 
after troponin became widely used to diagnose MI.9
 ● From 1987 to 2011, the age- and biomarker-adjusted 
incidence rates of hospitalization for AMI or fatal CHD 
decreased by 5.0% per year (95% CI, −5.3% to −4.7%) 
among white men, 3.9% per year (95% CI, −4.4% to 
−3.5%) among white women, 2.2% per year (95% CI, 
−2.8% to −1.6%) among black men, and 3.4% per year 
(95% CI, −4.2% to −2.7%) among black women in the 
ARIC study (1987–2011).10
 ● From 2002 to 2007, the incidence of hospitalized MI 
decreased among Medicare beneficiaries; however, the 
degree of reduction was more significant in whites than in 
African Americans.11
 ● Declines in MI incidence among Medicare beneficiaries 
occurred in all US census divisions between 1999 and 2008 
in this population, although wide geographic disparities 
were observed throughout the study period.12 
 ● On the basis of data from the NHIS, the NHDS, and the 
National Vital Statistics System, rates of MI among people 
with DM declined by 67.8% between 1990 and 2010, falling 
from 141.1 events per 10 000 person-years in 1990 to 45.5 
per 10 000 person-years in 2010. By comparison, rates of MI 
in nondiabetics fell by 31.2%, from 37.5 per 10 000 to 25.8 
per 10 000.13
Predicted Risk
Ten-Year Predicted Risk
 ● Another analysis of NHANES data concluded that 10-year 
predicted risk for CHD among adults 30 to 74 years of age 
decreased from 10.0% during 1976 to 1980 to 7.9% during 
1988 to 1994 (P<0.001) and to 7.4% during 1999 to 2004 
(P<0.001).14
 ● More recently, it was reported that the mean predicted 
10-year risk for CHD among adults aged 30 to 74 years 
decreased from 7.2% during 1999 to 2000 to 6.5% dur-
ing 2009 to 2010 (P=0.005). Mean predicted risk declined 
among men, women, whites, and adults 40 to 59, 50 to 59, 
and 60 to 74 years of age. Risk increased nonsignificantly 
among African American adults.15
 ● Individuals with atherosclerotic stroke should be included 
among those deemed to be at high risk (20% over 10 years) 
of further atherosclerotic coronary events. For primary pre-
vention, ischemic stroke should be included among CVD 
outcomes in absolute risk assessment algorithms. The 
inclusion of atherosclerotic ischemic stroke as a high-risk 
condition has important implications, because the number 
of people considered to be at high risk will increase over 
time.16
 ● A survey of US family physicians, general internists, and 
cardiologists found that 41% of respondents reported using 
global CHD risk assessment at least occasionally.17
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Lifetime Risk
 ● Lifetime risk for CHD varies drastically as a function of 
risk factor profile. With an optimal risk factor profile, life-
time risk for CHD is 3.6% for men and <1% for women; 
with ≥2 major risk factors, it is 37.5% for men and 18.3% 
for women.18
Mortality
 ● Based on 2011 mortality data19
—CHD was an underlying cause of death in ≈1 of every 7 
deaths in the United States in 2011.
—CHD mortality was 375 295, and CHD any-mention 
mortality was 543 652.
—MI mortality was 119 905. MI any-mention mortality 
was 157 073 (NCHS, NHLBI tabulation).
—The overall CHD death rate per 100 000 was 109.2.
—From 2001 to 2011, the annual death rate attributable to 
CHD declined 39.0% and the actual number of deaths 
declined 25.3% (NHLBI computation).
—CHD death rates per 100 000 were 146.5 for white males 
and 161.5 for black males; for white females, the rate 
was 80.1, and for black females, it was 99.7.
—74% of CHD deaths occurred out of the hospital. Accord-
ing to NCHS mortality data, 278 000 CHD deaths occur 
out of the hospital or in hospital EDs annually (NCHS, 
AHA tabulation).
—The estimated average number of YLL because of an MI 
death is 17.1 (NHLBI tabulation).
 ● Approximately 34% of the people who experience a 
coronary event in a given year will die of it, and ≈15% 
who experience a heart attack (MI) will die of it (AHA 
computation).
 ● A study of 1275 health maintenance organization enrollees 
50 to 79 years of age who had cardiac arrest showed that 
the incidence of out-of-hospital cardiac arrest was 6.0/1000 
subject-years in subjects with any clinically recognized HD 
compared with 0.8/1000 subject-years in subjects without 
HD. Among enrollees with HD, incidence was 13.6 and 
21.9 per 1000 subject-years in those with prior MI and with 
HF, respectively.20
 ● Researchers investigating variation in hospital-specific 
30-day risk-stratified mortality rates for patients with 
AMI found teaching status, number of hospital beds, AMI 
volume, cardiac facilities available, urban/rural location, 
geographic region, hospital ownership type, and socioeco-
nomic status profile of the patients were all significantly 
associated with mortality rates. However, a substantial 
proportion of variation in outcomes for patients with AMI 
between hospitals remains unexplained by measures of 
hospital characteristics.21
Temporal Trends in CHD Mortality
 ● The decline in CHD mortality rates in part reflects the shift 
in the pattern of clinical presentations of AMI. In the past 
decade, there has been a marked decline in STEMI (from 
133 to 50 cases per 100 000 person-years).9
 ● According to data from the NRMI:
—From 1990 to 1999, in-hospital AMI mortality declined 
from 11.2% to 9.4%.22
—From 1990 to 2006, in-hospital AMI mortality declined 
from 10.4% to 6.3% (P<0.001; STEMI: 11.5% to 
8.0%, P<0.001; NSTEMI: 7.1% to 5.2%, P<0.001). 
Approximately 37% of the decline in annual mortality 
for patients with NSTEMI and 21% for patients with 
STEMI was judged to be attributable to improvements 
in acute treatments.23
 ● Other studies also reported declining case fatality rates 
after MI:
—In Olmsted County, MN, the age- and sex-adjusted 
30-day case fatality rate decreased by 56% from 1987 
to 2006.8
—In Worcester, MA, the hospital case fatality rates, 30-day 
postadmission case fatality rates, and 1-year post-
discharge case fatality rates for STEMI were 11.1%, 
13.2%, and 10.6%, respectively, in 1997 and 9.7%, 
11.4%, and 8.4%, respectively, in 2005. The hospital 
case fatality rates, 30-day postadmission case fatality 
rates, and 1-year postdischarge case fatality rates for 
NSTEMI were 12.9%, 16.0%, and 23.1%, respectively, 
in 1997 and 9.5%, 14.0%, and 18.7%, respectively, in 
2005.24
—Among enrollees of the Kaiser Permanente Northern 
California healthcare delivery system, the age- and sex-
adjusted 30-day mortality rate for MI dropped from 
10.5% in 1999 to 7.8% in 2008, and the 30-day mortal-
ity rate for NSTEMI dropped from 10.0% in 1999 to 
7.6% in 2008.9
—Among Medicare beneficiaries, between 1995 and 2006, 
the 30-day mortality rate attributable to MI decreased, 
as did hospital variation in mortality attributable to MI.25 
Declines in 30-day mortality after MI occurred in all US 
census divisions between 2000 and 2008.12
 ● CHD death rates have fallen from 1968 to the present. 
Analysis of NHANES (NCHS) data compared CHD death 
rates between 1980 and 2000 to determine how much of the 
decline in deaths attributable to CHD over that period could 
be explained by the use of medical and surgical treatments 
versus changes in CVD risk factors (resulting from life-
style/behavior). It was estimated that ≈47% of the decrease 
in CHD deaths was attributable to treatments, including the 
following26:
—Secondary preventive therapies after MI or revascular-
ization (11%)
—Initial treatments for AMI or UA (10%)
—Treatments for HF (9%)
—Revascularization for chronic angina (5%)
—Other therapies (12%), including antihypertensive and 
lipid-lowering primary prevention therapies
 ● It was also estimated that a similar amount of the reduction 
in CHD deaths, ≈44%, was attributable to changes in risk 
factors, including the following26:
—Lower total cholesterol (24%)
—Lower SBP (20%)
—Lower smoking prevalence (12%)
—Decreased physical inactivity (5%)
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—Nevertheless, these favorable improvements in risk fac-
tors were offset in part by increases in BMI and in DM 
prevalence, which accounted for an increased number of 
deaths (8% and 10%, respectively).
 ● Between 1980 and 2002, death rates attributable to CHD 
among men and women ≥35 years of age fell by 52% in men 
and 49% in women. Among men, the death rate declined 
on average by 2.9% per year in the 1980s, 2.6% per year 
during the 1990s, and 4.4% per year from 2000 to 2002. 
Among women, death rates fell by 2.6%, 2.4%, and 4.4%, 
respectively; however, when stratified by age, among men 
35 to 54 years of age, the average annual rate of death fell 
by 6.2%, 2.3%, and 0.5%, respectively. Among women 35 
to 54 years of age, the average annual rate of death fell by 
5.4% and 1.2% and then increased by 1.5%, respectively. 
This increase was not statistically significant; however, 
in even younger women (35–44 years of age), the rate of 
death has been increasing by an average of 1.3% annually 
between 1997 and 2002, which is statistically significant.27
 ● In an analysis of 28 studies published from 1977 to 2007, 
significantly improved survival was described in patients 
with nonacute CAD treated with revascularization by 
CABG or PCI in conjunction with medical therapy com-
pared with patients treated with medical therapy alone.28
Risk Factors
Risk factors for CHD act synergistically to increase CHD risk, 
as shown in the examples in Charts 19-6 and 19-7.
Awareness of Warning Signs and Risk Factors for HD
 ● Women’s awareness that CVD is their leading cause of 
death increased from 30% in 1997 to 56% in 2012.29
—Depending on age, 44% to 50% identified HD/heart 
attack as the leading cause of death for women, a sig-
nificant increase from 16% to 34% in the original 1997 
survey.
—The percentages of women identifying warning 
signs for a heart attack were as follows: pain in the 
chest, neck, shoulder, and arm—56%; shortness of 
breath—38%; chest tightness—17%; nausea—18%; 
and fatigue—10%.
—The 5 most commonly cited HD prevention strategies in 
2012 were maintaining a healthy BP (78%), seeing the 
doctor (78%), and increasing fiber intake, eating food 
with antioxidants, and maintaining healthy cholesterol 
levels (each 66%).
—Among online survey participants, 21% responded that 
their doctor had talked to them about HD risk. Rates 
were lower among Hispanic women (12%) than whites 
(22%) or blacks (22%) and increased with age from 6% 
(25–34 years) to 33% (≥65 years).
Time of Symptom Onset and Arrival at Hospital
 ● A meta-analysis of 48 studies enrolling >1.8 million 
patients showed that off-hours presentation for MI was 
associated with higher short-term mortality. In addition, 
those patients with STEMI who presented off hours had 
longer door-to-balloon times.30
 ● System improvements in Dallas County, TX, resulted 
in decreases in the median time from symptom onset to 
balloon (catheterization) from the fourth quarter of 2010 to 
the first quarter of 2012.31
 ● Data from CRUSADE and the NCDR ACTION Registry–
GWTG showed a longer median time to hospital presenta-
tion in men (3 hours) than in women (2.8 hours; P<0.001). 
From 2002 to 2007, presentation time did not change sig-
nificantly in men or women.32
 ● Individuals with documented CHD have 5 to 7 times the 
risk of having a heart attack or dying as the general popula-
tion. Survival rates improve after a heart attack if treatment 
begins within 1 hour; however, most patients are admitted 
to the hospital 2.5 to 3 hours after symptoms begin. More 
than 3500 patients with a history of CHD were asked to 
identify possible symptoms of heart attack. Despite their 
history of CHD, 44% had low knowledge levels. Among 
these high-risk participants, 43% underestimated their risk 
for a future AMI (men 47%, women 36%).33
 ● Data from Worcester, MA, indicate that the average time 
from symptom onset to hospital arrival has not improved 
and that delays in hospital arrival are associated with 
less receipt of guidelines-based care. Mean and median 
prehospital delay times from symptom onset to arrival at 
the hospital were 4.1 and 2.0 hours in 1986 and 4.6 and 
2.0 hours in 2005, respectively. Receipt of thrombolytic 
therapy and PCI within 90 minutes of hospital arrival was 
less likely among patients who arrived within ≥2 hours of 
symptom onset than among those who arrived <2 hours 
after onset.34
 ● In an analysis from ARIC, low neighborhood house-
hold income (OR, 1.46; 95% CI, 1.09–1.96) and being a 
Medicaid recipient (OR, 1.87; 95% CI, 1.10–3.19) were 
associated with increased odds of having prolonged pre-
hospital delays from symptom onset to hospital arrival for 
AMI compared with individuals with higher neighbor-
hood household income and other insurance providers, 
respectively.35
 ● An analysis of data from the NCDR ACTION Registry–
GWTG showed that 60% of 37 634 STEMI patients used 
EMS to get to the hospital. Older adults, women, adults 
with comorbidities, and sicker patients were more likely to 
use EMS than their counterparts. Hospital arrival time was 
shorter for those who used EMS (89 minutes) than self-
transport (120 minutes).36
Aftermath
 ● Depending on their sex and clinical outcome, people who 
survive the acute stage of an MI have a chance of illness and 
death 1.5 to 15 times higher than that of the general popula-
tion. Among these people, the risk of another MI, sudden 
death, AP, HF, and stroke—for both men and women—is 
substantial (FHS, NHLBI).5
 ● On the basis of pooled data from the FHS, ARIC, and CHS 
studies of the NHLBI (1986–2007), within 1 year after a 
first MI:
—At ≥45 years of age, 19% of men and 26% of women 
will die.
—At 45 to 64 years of age, 5% of white men, 8% of white 
women, 14% of black men, and 9% of black women 
will die.
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—At ≥65 years of age, 25% of white men, 30% of white 
women, 25% of black men, and 30% of black women 
will die.
—In part because women have MIs at older ages than men, 
they are more likely to die of MIs within a few weeks.
 ● Within 5 years after a first MI:
—At ≥45 years of age, 36% of men and 47% of women 
will die.
—At 45 to 64 years of age, 11% of white men, 18% of 
white women, 22% of black men, and 28% of black 
women will die.
—At ≥65 years of age, 46% of white men, 53% of white 
women, 54% of black men, and 58% of black women 
will die.
 ● Of those who have a first MI, the percentage with a recur-
rent MI or fatal CHD within 5 years is as follows:
—At 45 to 64 years of age, 15% of men and 22 of women
—At ≥65 years of age, 22% of men and women
—At 45 to 64 years of age, 14% of white men, 18% of 
white women, 22% of black men, and 28% of black 
women
—At ≥65 years of age, 21% of white men and women, 33% 
of black men, and 26% of black women
 ● The percentage of people with a first MI who will have HF 
in 5 years is as follows:
—At 45 to 64 years of age, 8% of men and 18% of women
—At ≥65 years of age, 20% of men and 23% of women
—At 45 to 64 years of age, 7% of white men, 15% of white 
women, 13% of black men, and 25% of black women
—At ≥65 years of age, 19% of white men, 23% of white 
women, 31% of black men, and 24% of black women
 ● The percentage of people with a first MI who will have a 
stroke within 5 years is as follows:
—At 45 to 64 years of age, 2% of men and 6% of women
—At ≥65 years of age, 5% of men and 8% of women
—At 45 to 64 years of age, 2% of white men, 4% of white 
women, 3% of black men, and 10% of black women
—At ≥65 years of age, 5% of white men, 8% of white 
women, 9% of black men, and 10% of black women
 ● The median survival time (in years) after a first MI is
—At 55 to 64 years of age, 17.0 for men and 13.3 for women
—At 65 to 74 years of age, 9.3 for men and 8.8 for women
—At ≥75 years of age, 3.2 for men and 3.2 for women
 ● An analysis of Medicare claims data revealed that only 
13.9% of Medicare beneficiaries enroll in cardiac reha-
bilitation after an AMI, and only 31% enroll after CABG. 
Older people, women, nonwhites, and individuals with 
comorbidities were less likely to enroll in cardiac rehabili-
tation programs.37
 ● In a community-based analysis of residents in Olmstead 
County, MN, discharged with first MI between 1987 and 
2010, 52.5% participated in cardiac rehabilitation. The 
overall rate of participation did not change during the study 
period. Cardiac rehabilitation was associated with reduc-
tions in all-cause mortality and readmission.38
Hospital Discharges and Ambulatory Care Visits
(See Table 19-1 and Chart 19-8.)
 ● From 2000 to 2010, the number of inpatient discharges 
from short-stay hospitals with CHD as the first-listed 
diagnosis decreased from 2 165 000 to 1 346 000 (NHDS, 
NHLBI tabulation).
 ● In 2010, there were 11 921 000 ambulatory care visits 
with CHD as the first-listed diagnosis (NCHS, NAMCS, 
NHAMCS). There were 10 570 000 physician office visits, 
587 000 ED visits, and 764 000 outpatient department vis-
its with a primary diagnosis of CHD (NHAMCS, NHLBI 
tabulation). The majority of these visits (77.7%) were for 
coronary atherosclerosis.39
 ● The age-adjusted hospitalization rate for MI per 100 000 
people was 215 in 1979 to 1981, increased to 342 in 
1985 to 1987, stabilized for the next decade, and then 
declined after 1996 to 242 during the period from 2003 
to 2005. The rate for men exceeded that for women by 
almost a factor of 2. Hospitalization rates increased 
strongly with age.40
 ● Total office visits for angina declined from 3.6 million per 
year in 1995 to 1998 to 2.3 million per year in 2007 to 
2010, based on data from the NAMCS and the NHAMCS.41
Operations and Procedures
 ● In 2010, an estimated 954 000 inpatient PCI procedures, 
397 000 inpatient bypass procedures, 1 029 000 inpa-
tient diagnostic cardiac catheterizations, 97 000 inpatient 
implantable defibrillator procedures, and 370 000 pace-
maker procedures were performed for inpatients in the 
United States (NHLBI tabulation).
 ● An analysis of data from HCUP showed that between 2001 
and 2008, there had been a 15% decrease in the annual 
rate of coronary revascularization, primarily attributable to 
declines in CABG (1742 procedures per million in 2001–
2002 versus 1081 procedures per million in 2007–2008). 
Rates of PCI did not change significantly over the same 
period.42
 ● However, in Massachusetts, age- and sex-adjusted rates of 
coronary revascularization (PCI or CABG) declined from 
423 to 258 per 100 000 residents (39% decline) between 
2003 and 2012. Rates of elective PCI declined by 50% 
over the period, whereas rates of PCI in the setting of MI 
declined by 16%.43
Cost
(See Table 19-1.)
 ● The estimated direct and indirect cost of heart disease in 
2010 was $204.4 billion (MEPS, NHLBI tabulation).
 ● MI ($11.5 billion) and CHD ($10.4 billion) were 2 of the 
10 most expensive hospital principal discharge diagnoses 
in 2011.44
 ● Between 2013 and 2030, medical costs of CHD (real 
2010$) are projected to increase by ≈100%
—Indirect costs for all CVD (real 2010$) are projected to 
increase 52% (from $202.5 billion to $308.2 billion) 
between 2013 and 2030. Of these indirect costs, CHD 
is projected to account for ≈43% and has the largest 
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indirect costs (AHA computation, based on methodol-
ogy described by Heidenreich et al3).
Acute Coronary Syndrome
ICD-9 410, 411; ICD-10 I20.0, I21, I22.
The term acute coronary syndrome includes the diagnoses 
of AMI (STEMI or NSTEMI) and UA. UA is chest pain or 
discomfort that is accelerating in frequency or severity and 
may occur while at rest but does not result in myocardial 
necrosis. The discomfort may be more severe and prolonged 
than typical stable AP, or it may be the first time a person 
has had AP. UA, NSTEMI, and STEMI share common patho-
physiological origins related to coronary plaque progression, 
instability, or rupture with or without luminal thrombosis and 
vasospasm.
 ● A conservative estimate for the number of discharges with 
ACS from hospitals in 2010 is 625 000. Of these, an esti-
mated 363 000 are males and 262 000 are females. This 
estimate is derived by adding the first-listed inpatient hos-
pital discharges for MI (595 000) to those for UA (30 000; 
NHDS, NHLBI).
 ● When secondary discharge diagnoses in 2010 were 
included, the corresponding number of inpatient hospi-
tal discharges was 1 141 000 unique hospitalizations for 
ACS; 653 000 were males, and 488 000 were females. Of 
the total, 813 000 were for MI alone, 322 000 were for UA 
alone, and 6000 hospitalizations received both diagnoses 
(NHDS, NHLBI).
 ● Among commercially insured adults 18 to 64 years of age, 
the 1-year medical costs for an ACS event during 2004 to 
2005 were $34 087 for those who were treated with medi-
cal management, $52 673 for those who were treated with 
percutaneous intervention, and $86 914 for those who had 
coronary artery bypass surgery. The 1-year short-term dis-
ability costs were $6048, $9221, and $17 335, respectively, 
and the 1-year absenteeism costs were $9826, $9460, and 
$14 960, respectively.45 Another study of the same data-
base using adults 18 to 64 years of age who had a principal 
inpatient diagnosis of ACS during 2003 to 2006 estimated 
that the incremental annual direct cost was $40 671 and the 
incremental short-term disability cost was $999.46
Decisions about medical and interventional treatments are 
based on specific findings noted when a patient presents with 
ACS. Such patients are classified clinically into 1 of 3 cat-
egories according to the presence or absence of ST-segment 
elevation on the presenting ECG and abnormal (“positive”) 
elevations of myocardial biomarkers, such as troponins, as 
follows:
 ● STEMI
 ● NSTEMI
 ● UA
The percentage of ACS or MI cases with ST-segment eleva-
tion varies in different registries/databases and depends heav-
ily on the age of patients included and the type of surveillance 
used. According to NRMI-4, ≈29% of patients with MI are 
patients with STEMI.47 The AHA GWTG project found that 
32% of the patients with MI in the CAD module were patients 
with STEMI (personal communication from AHA GWTG 
staff, October 1, 2007). The GRACE study, which includes 
US patient populations, found that 38% of ACS patients have 
STEMI, whereas the EHS-ACS-II reported that ≈47% of 
patients with ACS have STEMI.48
In addition, the percentage of ACS or MI cases with 
ST-segment elevation appears to be declining. In an analysis 
of 46 086 hospitalizations for ACS in the Kaiser Permanente 
Northern California study, the percentage of MI cases with 
ST-segment elevation decreased from 47.0% to 22.9% 
between 1999 and 2008.9
 ● Analysis of data from the GRACE multinational observa-
tional cohort study of patients with ACS found evidence of 
a change in practice for both pharmacological and inter-
ventional treatments in patients with either STEMI or 
non–ST-segment–elevation ACS. These changes have been 
accompanied by nonsignificant decreases in the rates of 
in-hospital death, cardiogenic shock, and new MI among 
patients with non–ST-segment–elevation ACS. The use of 
evidence-based therapies and PCI interventions increased 
in the STEMI population. This increase was matched by a 
statistically significant decrease in the rates of death, car-
diogenic shock, and HF or pulmonary edema.49
 ● A study of hospital process performance in 350 centers of 
nearly 65 000 patients enrolled in the CRUSADE National 
Quality Improvement Initiative found that ACC/AHA 
guideline–recommended treatments were adhered to in 
74% of eligible instances.50 A better composite guideline 
adherence rate was significantly associated with decreased 
in-hospital mortality among all patients with ACS and 
those with NSTEMI.
 ● After adjustment for clinical differences and the severity of 
CAD by angiogram, 30-day mortality after ACS is similar 
in men and women.51
Stable AP
ICD-9 413; ICD-10 I20.1 to I20.9.
Prevalence
(See Table 19-2 and Chart 19-9 to 19-10.)
 ● A study of 4 national cross-sectional health examina-
tion studies found that among Americans 40 to 74 years 
of age, the age-adjusted prevalence of AP was higher 
among women than men. Increases in the prevalence of AP 
occurred for Mexican American men and women and Afri-
can American women but were not statistically significant 
for the latter.52
 ● On the basis of data from NHANES from 1998 to 2004 and 
the six 2-year surveys from 2001 to 2012, in 2009 to 2012, 
there were an average of 3.4 million people ≥40 years of 
age in the United States with angina each year compared 
with 4 million in 1988 to 1994. Declines in angina symp-
toms have occurred for whites but not for blacks.53
Incidence
(See Table 19-2 and Chart 19-11.)
 ● Only 18% of coronary attacks are preceded by long-
standing AP (NHLBI computation of FHS follow-up since 
1986).
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 ● The annual rates per 1000 population of new episodes of 
AP for nonblack men are 28.3 for those 65 to 74 years of 
age, 36.3 for those 75 to 84 years of age, and 33.0 for those 
≥85 years of age. For nonblack women in the same age 
groups, the rates are 14.1, 20.0, and 22.9, respectively. For 
black men, the rates are 22.4, 33.8, and 39.5, and for black 
women, the rates are 15.3, 23.6, and 35.9, respectively 
(CHS, NHLBI).54
Cost
 ● For women with nonobstructive CHD enrolled in the WISE 
study of the NHLBI, the average lifetime cost estimate was 
≈$770 000 and ranged from $1.0 to $1.1 million for women 
with 1- to 3-vessel CHD.55 
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Table 19-1.  Coronary Heart Disease
Population Group
Prevalence, CHD, 
2012 Age ≥20 y
Prevalence, MI, 
2012 Age ≥20 y
New and Recurrent 
MI and Fatal CHD, 
Age ≥35 y
New and 
Recurrent MI, 
Age ≥35 y
Mortality,* CHD, 
2011 All Ages
Mortality,* MI, 
2011 All Ages
Hospital 
Discharges CHD, 
2010 All Ages
Both sexes 15 500 000 (6.2%) 7 600 000 (2.8%) 935 000 735 000 375 295 119 905 1 346 000
Males 8 900 000 (7.6%) 4 900 000 (4.0%) 545 000 430 000 206 908 (55.1%)† 66 765 (55.7%)† 828 000
Females 6 600 000 (5.0%) 2 700 000 (1.8%) 390 000 305 000 168 387 (44.9%)† 53 140 (44.3%)† 518 000
NH white males 7.8% 4.1% 475 000‡ … 180 658 58 447 …
NH white females 4.6% 1.8% 330 000‡ … 145 443 45 576 …
NH black males 7.2% 3.4% 70 000‡ … 20 693 6551 …
NH black females 7.0% 2.2% 60 000‡ … 18 760 6228 …
Hispanic males 6.7% 3.5% … … * * …
Hispanic females 5.9% 1.7% … … * * …
Asian … … … … 7828§ 2476§ …
American Indian/Alaska Native 4.5%  ¶ … … … 1913 627 …
CHD includes people who responded “yes” to at least 1 of the questions in “Has a doctor or other health professional ever told you that you had coronary heart 
disease, angina or angina pectoris, heart attack, or myocardial infarction?” Those who answered “no” but were diagnosed with Rose angina are also included (the Rose 
questionnaire is only administered to survey participants >40 years of age).
CHD indicates coronary heart disease; ellipses (…), data not available; MI, myocardial infarction; and NH, non-Hispanic.
*Mortality data for the white, black, Asian or Pacific Islander, and American Indian/Alaska Native populations include deaths of people of Hispanic and non-Hispanic 
origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†These percentages represent the portion of total CHD and MI mortality that is for males vs females.
‡Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races.
§Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific Islander. 
 National Health Interview Survey, National Center for Health Statistics 2013; data are weighted percentages for Americans ≥18 years of age.1
¶Estimate considered unreliable or does not meet standards of reliability or precision.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) and National Heart, Lung, and Blood 
Institute. Percentages for racial/ethnic groups are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 US population 
estimates. These data are based on self-reports. Incidence: Atherosclerosis Risk in Communities study (2005–2011), National Heart, Lung, and Blood Institute. Mortality: 
Centers for Disease Control and Prevention/National Center for Health Statistics, 2011 Mortality Multiple Cause-of-Death–United States. Hospital discharges: National 
Hospital Discharge Survey, National Center for Health Statistics (data include those inpatients discharged alive, dead, or status unknown).
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Chart 19-1. Prevalence of coronary heart disease by age and sex (National Health and Nutrition Examination Survey: 2009–2012). 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
Table 19-2.  Angina Pectoris
Population Group
Prevalence,  
2012, Age ≥20 y
Incidence of 
Stable AP,  
Age ≥45 y
Hospital 
Discharges,  
2010, All Ages*
Both sexes 8 200 000 (3.3%) 565 000 22 000
Males 4 000 000 (3.4%) 370 000 12 000
Females 4 200 000 (3.2%) 195 000 10 000
NH white males 3.4% … …
NH white females 2.9% … …
NH black males 3.3% … …
NH black females 5.0% … …
Hispanic males 3.2% … …
Hispanic females 3.8% … …
AP is chest pain or discomfort that results from insufficient blood flow to the 
heart muscle. Stable AP is predictable chest pain on exertion or under mental or 
emotional stress. The incidence estimate is for AP without myocardial infarction.
AP indicates angina pectoris; ellipses, data not available; and NH, non-
Hispanic.
*There were 56 000 days of care for discharges of patients with AP from 
short-stay hospitals in 2010.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 
to 2012 (National Center for Health Statistics) and National Heart, Lung, and 
Blood Institute; percentages for racial/ethnic groups are age adjusted for US 
adults ≥20 years of age. AP includes people who either answered “yes” to the 
question of ever having angina or AP or who were diagnosed with Rose angina 
(the Rose questionnaire is only administered to survey participants >40 years 
of age). Estimates from National Health and Nutrition Examination Survey 2009 
to 2012 (National Center for Health Statistics) were applied to 2010 population 
estimates (≥20 years of age). Incidence: AP uncomplicated by a myocardial 
infarction or with no myocardial infarction (Framingham Heart Study [the original 
cohort and the Offspring Cohort 1986–2009], National Heart, Lung, and Blood 
Institute). Hospital discharges: National Hospital Discharge Survey, National 
Center for Health Statistics; data include those inpatients discharged alive, 
dead, or status unknown.
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Chart 19-2. Prevalence of myocardial infarction by age and sex (National Health and Nutrition Examination Survey: 2009–2012). 
 Myocardial infarction includes people who answered “yes” to the question of ever having had a heart attack or myocardial infarction. 
Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 19-3. Annual number of adults per 1000 having diagnosed heart attack or fatal coronary heart disease (CHD) by age and sex 
 (Atherosclerosis Risk in Communities Surveillance: 2005–2011 and Cardiovascular Health Study). These data include myocardial 
 infarction (MI) and fatal CHD but not silent MI. Source: National Heart, Lung, and Blood Institute.
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Chart 19-4. Incidence of heart attack or fatal coronary heart disease by age, sex, and race (Atherosclerosis Risk in Communities Surveil-
lance: 2005–2011). Source: National Heart, Lung, and Blood Institute.
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Chart 19-5. Incidence of myocardial infarction by age, sex, and race (Atherosclerosis Risk in Communities Surveillance: 2005-2011). 
Source: Unpublished data from Atherosclerosis Risk in Communities study, National Heart, Lung, and Blood Institute.
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Chart 19-6. Estimated 10-year coronary heart disease risk in adults 55 years of age according to levels of various risk factors (Framing-
ham Heart Study). HDL-C indicates high-density lipoprotein cholesterol. Data derived from Wilson et al.56
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Chart 19-7. Prevalence of low coronary heart disease risk, overall and by sex (National Health and Nutrition Examination Survey:  
1971–2006). Low risk is defined as systolic blood pressure <120 mm Hg and diastolic blood pressure <80 mm Hg; cholesterol  
<200 mg/dL; body mass index <25 kg/m2; currently not smoking cigarettes and no prior myocardial infarction or diabetes mellitus. 
Source: Personal communication with the National Heart, Lung, and Blood Institute, June 28, 2007.
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Chart 19-8. Hospital discharges for coronary heart disease by sex (United States: 1970–2010). Hospital discharges include people dis-
charged alive, dead, and “status unknown.” Source: National Hospital Discharge Survey/National Center for Health Statistics and National 
Heart, Lung, and Blood Institute.
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Chart 19-9. Prevalence of angina pectoris by age and sex (National Health and Nutrition Examination Survey: 2009–2012). Angina pec-
toris includes people who either answered “yes” to the question of ever having angina or angina pectoris or were diagnosed with Rose 
angina. Source: National Center for Health Statistics and National Heart, Lung, and Blood Institute.
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Chart 19-10. Secular trends in age-and sex-standardized prevalence rates of angina for adults aged ≥40 years in the United States, by 
race, for angina symptoms defined using the Rose questionnaire. Reprinted with permission from Will et al.53 Copyright © 2014, American 
Heart Association, Inc.
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Chart 19-11. Incidence of angina pectoris* by age and sex (Framingham Heart Study 1986–2009). *Angina pectoris deemed uncompli-
cated on the basis of physician interview of patient. Data derived from National Heart, Lung, and Blood Institute.
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20 . Cardiomyopathy and Heart Failure
See Table 20-1 and Charts 20-1 through 20-4.
Cardiomyopathy
ICD-9 425; ICD-10 I42.
Mortality—23 117. Any-mention mortality—46 545. 
Hospital discharges—34 000.
Youth
(See Chart 20-1.)
 ● Since 1996, the NHLBI-sponsored Pediatric Cardiomy-
opathy Registry has collected data on all children with 
newly diagnosed cardiomyopathy in New  England and 
the Central Southwest (Texas, Oklahoma, and Arkansas).1
—The overall incidence of cardiomyopathy is 1.13 cases 
per 100 000 among children <18 years of age.
—Among children <1 year of age, the incidence is 8.34, 
and among children 1 to 18 years of age, it is 0.70 per 
100 000.
—The annual incidence is lower in white than in black 
children, higher in boys than in girls, and higher in 
New England (1.44 per 100 000) than in the Central 
 Southwest (0.98 per 100 000).
 ● Dilated cardiomyopathy is the most common form of 
cardiomyopathy among children. The Pediatric Cardio-
myopathy Registry recently reported an annual inci-
dence of dilated cardiomyopathy in children <18 years 
of age of 0.57 per 100 000 overall. The annual incidence 
was higher in boys than in girls (0.66 versus 0.47 cases 
per 100 000), in blacks than in whites (0.98 versus 0.46 
cases per 100 000), and in infants (<1 year of age) than 
in children (4.40 versus 0.34 cases per 100 000). The 
majority of children (66%) had idiopathic disease. The 
most common known causes of dilated cardiomyopa-
thy were myocarditis (46%) and neuromuscular dis-
ease (26%).2 Risk factors for death and transplantation 
in children varied according to cause of dilated car-
diomyopathy. For idiopathic dilated cardiomyopathy, 
increased LV end-diastolic dimension was associated 
with increased risk for transplantation but not mortality. 
Short stature was significantly related to death but not 
transplantation.3
 ● HCM is the most common inherited heart defect, 
occurring in 1 of 500 individuals. In the United States, 
≈500 000 people have HCM, yet most are unaware of it.4 
In a recent report of the Pediatric Cardiomyopathy Reg-
istry, the overall annual incidence of HCM in children 
was 4.7 per 1 million children. There was a higher inci-
dence in the New England than in the Central Southwest 
region, in boys than in girls, and in children diagnosed at 
<1 year of age than in older children.5 The 5-year inci-
dence rate of sudden cardiac death among children with 
dilated cardiomyopathy is 3%.6 See Chapter 16, Disor-
ders of Heart Rhythm, for statistics regarding sudden 
death in HCM.
 ● Data from Kaiser Permanente indicate that the incidence of 
PPCM is 4.84 per 10 000 live births (95% CI, 3.98–5.83), 
and PPCM is associated with higher maternal and neona-
tal death rates and worse neonatal outcomes.7 There was a 
trend toward an increase in the incidence of PPCM in the 
United States from 1990–1993 to 2000–2002, which might 
be related to a rise in maternal age.8
Global Burden of Cardiomyopathy
 ● Between 1990 and 2010, the global number of deaths attrib-
uted to cardiomyopathy and myocarditis increased 40.8% 
from 286 800 to 403 900, but the age-standardized death 
rate decreased 9.8%, from 6.7 to 6.1 per 100 000.9 How-
ever, between 1990 and 2010, the global years lived with 
disability for cardiomyopathy and myocarditis increased 
11.4%, from 5 to 6 years lived with disability per 100 000.10 
The reported incidence of PPCM in the United States var-
ies considerably, whereas the reported incidences in several 
African and Asian countries are similar.
Abbreviations Used in Chapter 20
ABC Health Aging, and Body Composition Study
ARIC Atherosclerosis Risk in Communities Study
BMI body mass index
BNP B-type natriuretic peptide
BP blood pressure
CAD coronary artery disease
CARDIA Coronary Artery Risk Development in Young Adults Study
CHS Cardiovascular Health Study
CI confidence interval
CRP C-reactive protein
CVD cardiovascular disease
DM diabetes mellitus
ED emergency department
EF ejection fraction
FHS Framingham Heart Study
HbA
1c hemoglobin A1c (glycosylated hemoglobin)
HBP high blood pressure
HCM hypertrophic cardiomyopathy
HF heart failure
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
LV left ventricular
MESA Multi-Ethnic Study of Atherosclerosis
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHAMCS National Hospital Ambulatory Medical Care Survey
NHANES National Health and Nutrition Examination Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PAR population attributable risk
PPCM peripartum cardiomyopathy
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Heart Failure
ICD-9 428; ICD-10 I50.
Prevalence
(See Table 20-1 and Chart 20-2.)
 ● On the basis of data from NHANES 2009 to 2012, an esti-
mated 5.7 million Americans ≥20 years of age have HF 
(NHLBI tabulation).
 ● Projections show that the prevalence of HF will increase 
46% from 2012 to 2030, resulting in >8 million people ≥18 
years of age with HF.11
Incidence
(See Table 20-1 and Chart 20-3.)
 ● On the basis of data from the community surveillance com-
ponent of the ARIC study of the NHLBI:
—There are 870 000 new HF cases annually (ARIC 2005 
through 2011; based on community trends in the occur-
rence of hospitalized HF and case fatality; unpublished 
report for NHLBI.)
—At ages <75 years, HF incidence is higher in blacks than 
whites.
 ● Data from the NHLBI-sponsored FHS12 indicate the 
following:
—HF incidence approaches 10 per 1000 population after 
65 years of age.
—Seventy-five percent of HF cases have antecedent 
hypertension.
—At 40 years of age, the lifetime risk of developing HF for 
both men and women is 1 in 5.
—At 80 years of age, remaining lifetime risk for develop-
ment of new HF remains at 20% for men and women, 
even in the face of a much shorter life expectancy.
—At 40 years of age, the lifetime risk of HF occurring 
without antecedent MI is 1 in 9 for men and 1 in 6 for 
women.
—The lifetime risk for people with BP >160/90 mm Hg is 
double that of those with BP <140/90 mm Hg.
 ● The annual rates per 1000 population of new HF events for 
white men are 15.2 for those 65 to 74 years of age, 31.7 for 
those 75 to 84 years of age, and 65.2 for those ≥85 years of 
age. For white women in the same age groups, the rates are 
8.2, 19.8, and 45.6, respectively.13
 ● In MESA, African Americans had the highest risk of develop-
ing HF, followed by Hispanic, white, and Chinese Americans 
(4.6, 3.5, 2.4, and 1.0 per 1000 person-years, respectively). 
This higher risk reflected differences in the prevalence of 
hypertension, DM, and low socioeconomic status.14
 ● African Americans had the highest proportion of incident 
HF not preceded by clinical MI (75%).14
 ● In the NHLBI’s ARIC study, the age-adjusted incidence 
rate per 1000 person-years was 3.4 for white women, less 
than for all other groups, that is, white men (6.0), black 
women (8.1), and black men (9.1). The 30-day, 1-year, and 
5-year case fatality rates after hospitalization for HF were 
10.4%, 22%, and 42.3%, respectively. Blacks had a greater 
5-year case fatality rate than whites (P<0.05). HF incidence 
rates in black women were more similar to those of men 
than of white women. The greater HF incidence in blacks 
than in whites is explained largely by blacks’ greater levels 
of atherosclerotic risk factors.15
 ● Data from Kaiser Permanente indicated an increase in the 
incidence of HF and improved survival among the elderly, 
with the effect being greater in men.16
 ● Data from hospitals in Worcester, MA, indicate that dur-
ing 2000, the incidence rates for HF were 219 per 100 000 
and 897 per 100 000, respectively. HF was more frequent in 
women and the elderly.16
 ● In the CARDIA study, HF before 50 years of age was more 
common among blacks than whites. Hypertension, obesity, 
and systolic dysfunction are important risk factors that may 
be targets for prevention.17
 ● The lifetime risks of HF were assessed in a large group 
of 39 578 participants from several cohorts (Chicago Heart 
Association Detection Project in Industry, ARIC, and 
CHS). At age 45 years, lifetime risks for HF through age 75 
or 95 years were 30% to 42% in white men, 20% to 29% in 
black men, 32% to 39% in white women, and 24% to 46% 
in black women. HBP and higher BMI at all ages in both 
blacks and whites led to higher lifetime risks.18
Mortality
(See Table 20-1.)
 ● One in 9 deaths has HF mentioned on the death certificate 
(NCHS, NHLBI).
 ● In 2011, HF any-mention mortality was 284 388 (129 635 
males and 154 753 females). HF was the underlying cause in 
58 309 of those deaths in 2011.19 Table 20-1 shows the num-
bers of these deaths that are coded for HF as the underlying 
cause.
 ● The 2011 overall any-mention death rate for HF was 83.0. 
Any-mention death rates in males were 98.5 for whites, 
98.0 for blacks, 44.1 for Asians or Pacific Islanders, and 
73.2 for American Indians or Alaska Natives. In females, 
the respective death rates were 73.6 for whites, 77.4 for 
blacks, 33.9 for Asians or Pacific Islanders, and 61.9 for 
American Indians or Alaska Natives.19
 ● The number of any-mention deaths attributable to HF was 
approximately as high in 1995 (287 000) as it was in 2011 
(284 000; NCHS, NHLBI).20
 ● Survival after HF diagnosis has improved over time, as 
shown by data from the FHS21 and the Olmsted County 
Study.22 However, the death rate remains high: ≈50% of 
people diagnosed with HF will die within 5 years.19,22
 ● In the elderly, data from Kaiser Permanente indicate that 
survival after the onset of HF has also improved.23
 ● In the CHS, both the presence of depression and elevated 
N-terminal pro-BNP levels were independent risk factors 
that identified HF patients with a high risk of all-cause 
mortality.24
 ● Among Medicare beneficiaries, the overall 1-year HF mor-
tality rate declined slightly from 1998 to 2008 but remained 
high at 29.6%.25 Rates of mortality decline were uneven 
across states.
Global Burden of HF
 ● HF is common throughout sub-Saharan Africa. Forty-four 
percent of patients with newly diagnosed CVD have HF, 
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whereas only 10% have CAD.26 Common causes include 
nonischemic cardiomyopathies, rheumatic heart disease, 
congenital heart disease, hypertensive heart disease, and 
endomyocardial fibrosis; ischemic HD remains relatively 
uncommon. HF strikes individuals in sub-Saharan Africa at 
a much younger age than in the United States and Europe.27 
The prevalence estimates for HF across Asia range from 
1.26% to 6.7%. Rheumatic heart disease is a major con-
tributor to HF in certain parts of South Asia, such as India, 
but recently, trends toward an ischemic cause for HF have 
been observed in Asia, such as in China and Japan.28
 ● For men, HF prevalence in 2010 was highest (>5 per 
1000) in high-income North America, Oceania, and East-
ern Europe. In women, HF prevalence in 2010 was highest 
(4.53 per 1000) in Oceania, followed by high-income North 
America and North Africa/Middle East. For both men and 
women, HF prevalence was lowest in west sub-Saharan 
Africa (0.74/1000 in men and 0.57/1000 in women).29 HF 
made the largest contribution to age-standardized years 
lived with disability among men in high-income North 
America, Oceania, Eastern and Western Europe, southern 
Latin America, and Central Asia.29 HF risk factors vary 
substantially across world regions, with hypertension being 
highly associated with HF in all regions but with cardiomy-
opathy being most common in Latin America, the Carib-
bean, and sub-Saharan Africa, and a minimal association 
with ischemic HD in sub-Saharan Africa.30
Risk Factors
 ● In the NHLBI-sponsored FHS, BNP, urinary albumin-to-
creatinine ratio, elevated serum γ-glutamyl transferase, and 
higher levels of hematocrit were identified as risk factors 
for incident HF.31–33
 ● In the Framingham Offspring Study, among 2739 partici-
pants, increased circulating concentrations of resistin were 
associated with incident HF independent of prevalent coro-
nary disease, obesity, insulin resistance, and inflammation.34
 ● Among 20 900 male physicians in the Physicians Health 
Study, the lifetime risk of HF was higher in men with 
hypertension; healthy lifestyle factors (normal weight, not 
smoking, regular exercise, moderate alcohol intake, con-
sumption of breakfast cereals, and consumption of fruits 
and vegetables) were related to lower risk of HF.35 Adi-
ponectin was also associated with risk of HF (J-shaped 
relationship).36
 ● Among 2934 participants in the ABC study, the incidence 
of HF was 13.6 per 1000 person-years. Men and black par-
ticipants were more likely to develop HF. Coronary dis-
ease (PAR 23.9% for white participants, 29.5% for black 
participants) and uncontrolled BP (PAR 21.3% for white 
participants, 30.1% for black participants) had the highest 
PARs in both races. There was a higher proportion of HF 
attributable to modifiable risk factors in black than in white 
participants (67.8% versus 48.9%).37 Inflammatory markers 
(interleukin-6 and tumor necrosis factor-α), serum albumin 
levels, and cigarette smoking exposure were also associ-
ated with HF risk.38–40
 ● In the CHS, baseline cardiac high-sensitivity troponin and 
changes in high-sensitivity troponin levels were signifi-
cantly associated with incident HF.41 Circulating individual 
and total omega-3 fatty acid concentrations were associated 
with lower incidence of HF.42
 ● In the ARIC study, white blood cell count, CRP, albumin-
uria, HbA1c among individuals without DM, cardiac tropo-
nin, ventricular premature complexes, and socioeconomic 
position over the life course were all identified as risk fac-
tors for HF.43–48
 ● In the MESA study, plasma N-terminal pro-BNP provided 
incremental prognostic information beyond the tradi-
tional risk factors and the magnetic resonance imaging–-
determined LV mass index for incident symptomatic HF.49
LV Function
 ● Data from Olmsted County, MN, indicate the following:
—Among all individuals (asymptomatic or with validated 
clinical HF), the prevalence of LV diastolic dysfunction 
was 21% for mild diastolic dysfunction and 7% for mod-
erate or severe diastolic dysfunction. The prevalence of 
systolic dysfunction was 6%. The presence of any LV 
dysfunction (systolic or diastolic) was associated with 
an increased risk of overt HF, and asymptomatic dia-
stolic dysfunction was predictive of all-cause death.50,51 
After 4 years of follow-up, the prevalence of diastolic 
dysfunction increased to 39.2%. Diastolic dysfunction 
was associated with development of clinical HF during 
6 years of subsequent follow-up after adjustment for 
age, hypertension, DM, and CAD (HR, 1.81; 95% CI, 
1.01–3.48).52
—Among individuals with symptomatic HF, 55% had 
HF with preserved EF. The prevalence of LV diastolic 
dysfunction was 6% for mild and 75% for moderate 
or severe diastolic dysfunction. HF with preserved EF 
is associated with a high mortality rate, comparable to 
that of HF with reduced EF.53 Over a 15-year follow 
up period, survival trends improved among individuals 
with HF with reduced EF but not among those with HF 
with preserved EF.54
 ● In the NHLBI-sponsored FHS, among asymptomatic indi-
viduals, the prevalence of systolic dysfunction was 5%; 
the prevalence of LV diastolic dysfunction was 36%. LV 
systolic dysfunction and LV diastolic dysfunction were 
associated with increased risk of incident HF. major organ 
system dysfunction (higher serum creatinine, lower ratios 
of FEV1 [forced expiratory volume in 1 second] to FVC 
[forced vital capacity], and lower hemoglobin concentra-
tions) were also independently associated with increased 
risk of new-onset HF.50
 ● In MESA, the overall prevalence of asymptomatic LV sys-
tolic dysfunction was higher in African Americans than in 
whites, Chinese, and Hispanics. After 9 years of follow-up, 
asymptomatic LV dysfunction was associated with incident 
clinical HF (8.69 HR; 95% CI [4.89–15.45]) after adjust-
ment for cardiac risk factors.51
Hospital Discharges/Ambulatory Care Visits
(See Table 20-1 and Chart 20-4.)
 ● Hospital discharges for HF were essentially unchanged 
from 2000 to 2010, with first-listed discharges of 1 008 000 
and 1 023 000, respectively (NHDS, NHLBI tabulation).55
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 ● In 2010, there were 1 801 000 physician office visits with 
a primary diagnosis of HF.55 In 2010, there were 676 000 
ED visits and 236 000 outpatient department visits for HF 
(NHAMCS, NHLBI tabulation).56
 ● Among 1077 patients with HF in Olmsted County, MN, 
hospitalizations were common after HF diagnosis, with 
83% patients hospitalized at least once and 43% hospital-
ized at least 4 times. More than one half of all hospitaliza-
tions were related to noncardiovascular causes.57
 ● Among Medicare beneficiaries, the overall HF hospitalization 
rate declined substantially from 1998 to 2008 but at a lower 
rate for black men.25 Changes were uneven across states.
Cost
 ● In 2012, total cost for HF was estimated to be $30.7 billion. 
Of this total, 68% was attributable to direct medical costs.11
 ● Projections show that by 2030, the total cost of HF will 
increase almost 127% to $69.7 billion from 2012. This 
equals ≈$244 for every US adult.11 
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Table 20-1. Heart Failure
Population Group
Prevalence, 2012, 
Age ≥20 y
Incidence (New Cases), 
Age ≥55 y
Mortality, 2011, 
All Ages*
Hospital Discharges, 
2010, All Ages
Cost, 
2012†
Both sexes 5 700 000 (2.2%) 870 000 58 309 1 023 000 30.7 billion
Males 2 700 000 (2.3%) 415 000 24 609 (42.2%)‡ 501 000 …
Females 3 000 000 (2.2%) 455 000 33 700 (57.8%)‡ 522 000 …
NH white males 2.2% 365 000§ 21 802 … …
NH white females 2.2% 395 000§ 30 036 … …
NH black males 2.8% 50 000§ 2371 … …
NH black females 3.2% 60 000§ 3143 … …
Hispanic males 2.1% … * … …
Hispanic females 2.1% … * … …
Asian or Pacific Islander … … 727  … …
American Indian or Alaska 
Native
… … 230 … …
Heart failure includes people who answered “yes” to the question of ever having congestive heart failure.
Ellipses (…) indicate data not available; and NH, non-Hispanic.
*Mortality data for the white, black, Asian or Pacific Islander, and American Indian or Alaska Native populations include deaths among people of Hispanic and 
non-Hispanic origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of 
inconsistencies in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting 
on death certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
†Cost data are from Heidenreich et al.11
‡These percentages represent the portion of total mortality attributable to heart failure that is for males vs females.
§Estimates include Hispanics and non-Hispanics. Estimates for whites include other nonblack races. 
 Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific Islander.
Sources: Prevalence: National Health and Nutrition Examination Survey 2009 to 2012 (National Center for Health Statistics) and National Heart, Lung, and Blood 
Institute. Percentages are age adjusted for Americans ≥20 years of age. Age-specific percentages are extrapolated to the 2012 US population estimates. These data 
are based on self-reports. Incidence: Atherosclerosis Risk in Communities Study Community Surveillance, 2005 to 2011 from National Heart, Lung, and Blood Institute. 
Mortality: Centers for Disease Control and Prevention/National Center for Health Statistics, 2011 Mortality Multiple Cause-of-Death–United States.
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Chart 20-2. Prevalence of heart failure by sex and age (National Health and Nutrition Examination Survey: 2009–2012). Source: National 
Center for Health Statistics and National Heart, Lung, and Blood Institute.
Chart 20-1. Incidence of peripartum cardiomyopathy (PPCM). Reproduced from Blauwet et al,58 copyright 2011, with permission from 
BMJ Publishing Group Ltd.
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Chart 20-3. First acute decompensated heart failure annual event rates per 1000 from Atherosclerosis Risk in Communities community 
surveillance (2005–2011). Source: National Heart, Lung, and Blood Institute.
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Chart 20-4. Hospital discharges for heart failure by sex (United States: 1980–2010). Hospital discharges include people discharged alive, 
dead, and status unknown. Source: National Hospital Discharge Survey/National Center for Health Statistics and National Heart, Lung, 
and Blood Institute.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
Heart Disease and Stroke Statistics—2015 Update: Chapter 21  e277
21 . Valvular, Venous, and Aortic Diseases
See Tables 21-1 and 21-2 and Chart 21-1.
Mortality and any-mention mortality in this section are for 
2010. “Mortality” is the number of deaths in 2010 for the given 
underlying cause based on ICD-10. Prevalence data are for 
2006. Hospital discharge data are from the NHDS/NCHS; data 
include inpatients discharged alive, dead, or status unknown. 
Hospital discharge data for 2010 are based on ICD-9 codes.
Valvular HD
(See Table 21-1.)
ICD-9 424; ICD-10 I34 to I38.
Mortality—23 141. Any-mention mortality—47 830. 
Hospital discharges—85 000.
 ● Two important factors have contributed to the changing 
epidemiology of valvular HD in the United States over the 
past few decades: aging of the population and the increased 
ability to diagnose valvular HD by echocardiography.
 ● A large population-based epidemiological study with sys-
tematic use of echocardiography on 16 501 participants 
from Olmsted County, MN, showed an overall age-adjusted 
prevalence of clinically diagnosed (moderate or greater) 
valvular HD of 1.8%.1
 ● Prevalence of any valve disease increased with age1:
—18 to 44 years: 0.3% (95% CI, 0.2%–0.3%)
—45 to 54 years: 0.7% (95% CI, 0.6%–0.9%)
—55 to 64 years: 1.6% (95% CI, 1.4%–1.9%)
—65 to 75 years: 4.4% (95% CI, 3.9%–4.9%)
—≥75 years: 11.7% (95% CI, 11.0%–12.5%)
 ● Pooled echocardiographic data from 11 911 participants from 
CARDIA (4351), ARIC (2435), and CHS (5125) demon-
strated a similar increase in prevalence with age (Table 21-1).1
—18 to 44 years: 0.7% (95% CI, 0.5%–1.0%)
—45 to 54 years: 0.4% (95% CI, 0.1%–1.3%)
—55 to 64 years: 1.9% (95% CI, 1.2%–2.8%)
—65 to 75 years: 8.5% (95% CI, 7.6%–9.4%)
—≥75 years: 13.3% (95% CI, 11.7%–15.0%)
 ● Adjusted to the entire US population, these data suggest that the 
prevalence of any valve disease is 2.5% (95% CI, 2.2%–2.7%), 
with no difference between men (2.4% [95% CI, 2.1%–2.8%]) 
and women (2.5% [95% CI, 2.1%–2.9%]). Within this sample, 
0.4% had aortic stenosis, 0.5% had aortic regurgitation, 0.1% 
had mitral stenosis, and 1.7% had mitral regurgitation.1
 ● In CARDIA, ARIC, and CHS, survival of participants with 
valve disease was 79% (SE 2%) at 5 years and 68% (1.9%) 
at 8 years compared with 93% (0.2%) and 86% (0.4%) in 
participants without valve disease.
Aortic Valve Disorders
ICD-9 424.1; ICD-10 I35.
Mortality—15 576. Any-mention mortality—31 746. 
Hospital discharges—55 000.
 ● The prevalence of moderate or severe aortic stenosis in 
patients ≥75 years old is 2.8% (95% CI, 2.1%–3.7%), and 
the prevalence of moderate or severe aortic regurgitation in 
patients ≥75 years is 2.0% (95% CI, 1.4%–2.7%).1
 ● In MESA participants aged 45 to 84 years (n=5880), aortic 
valve calcium was quantified with serial CT images. Dur-
ing a mean follow-up of 2.4 years, 210 (4.1%) of the 5142 
participants with no aortic valve calcium had a mean inci-
dence rate of progression of 1.7% per year, which increased 
with age. Incident aortic valve calcium was associated with 
several conventional cardiovascular risk factors, including 
age, male sex, BMI, and smoking.2
 ● Approximately 50% of patients with severe aortic stenosis 
are referred for cardiothoracic surgery, and ≈40% undergo 
Abbreviations Used in Chapter 21
AAA abdominal aortic aneurysm
AHA American Heart Association
AVR aortic valve replacement
ARIC Atherosclerosis Risk in Communities study
BMI body mass index
CARDIA Coronary Artery Risk Development in Young Adults
CHD coronary heart disease
CHS Cardiovascular Health Study
CI confidence interval
CT computed tomography
DM diabetes mellitus
DVT deep vein thrombosis
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HD heart disease
HR hazard ratio
ICD International Classification of Diseases
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
IE infective endocarditis
IRAD International Registry of Acute Aortic Dissection
LV left ventricular
MESA Multi-Ethnic Study of Atherosclerosis
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
OVER Open Versus Endovascular Repair
PAD peripheral artery disease
PARTNER Placement of Aortic Transcatheter Valves study
PE pulmonary embolism
RR relative risk
SD standard deviation
SE standard error
STS Society of Thoracic Surgeons
TAVR transcatheter aortic valve replacement
TIA transient ischemic attack
VTE venous thromboembolism
WHO World Health Organization
YLL years of life lost
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AVR according to data from 10 US centers of various sizes 
and geographic distribution. Reasons for not undergoing 
AVR included high perioperative risk, age, lack of symp-
toms, and patient/family refusal.3
 ● On the basis of data from the PARTNER B cohort that com-
pared TAVR with medical therapy in patients who were not 
surgical candidates for AVR, 2-year mortality rates were 
43.3% and 68% (P<0.001) and 2-year hospitalization rates 
were 35% and 72.5% (P<0.001), respectively.4
 ● One-year costs of TAVR were higher than with medical 
therapy ($106 076 versus $53 621), with an incremen-
tal cost-effectiveness of $50 200 per life-year gained and 
$61 889 per quality-adjusted life-year gained.5
 ● In a cohort of 416 community-based participants from Olm-
sted County, MN, with bicuspid aortic valves followed up 
for a mean (SD) of 16 (7) years, the incidence of aortic 
dissection in individuals ≥50 years of age at baseline was 
17.4 (95% CI, 2.9–53.6) cases per 10 000 patient years. For 
patients aged ≥50 years with a bicuspid valve and a baseline 
aortic aneurysm, the incidence of aortic dissection was 44.9 
(95% CI, 7.5–138.5) cases per 10 000 patient-years. In the 
remaining participants without baseline aortic aneurysm, the 
incidence of aneurysm was 84.9 (95% CI, 63.3–110.9) cases 
per 10 000 patient-years, for an age-adjusted RR of 86.2 
(95% CI, 65.1–114) compared with the general population.6
Aortic Valve Interventions
 ● Lipid-lowering therapy does not appear to reduce aortic 
stenosis progression on the basis of any echocardiographic 
measures of aortic stenosis, as reported by a meta-analysis 
of 4 randomized controlled trials by Teo and colleagues.7
 ● Immediate postoperative and 1-, 3-, 5-, and 10-year pooled 
survival rates from 48 studies of 13 216 octogenarians were 
93.7%, 87.6%, 78.7%, 65.4%, and 29.7%, respectively.8
 ● TAVR has emerged as an innovative technology for treat-
ment of aortic stenosis in patients at high risk for periopera-
tive complications.
—A systematic review9 of TAVR from 16 studies that 
included 3519 patients and reported at least 1 outcome 
using the Valve Academic Research Consortium’s defi-
nitions demonstrated the following:
 ◯ Device success 92.1% (88.7%–95.5%)
 ◯ 30-day all-cause mortality 7.8% (5.5%–11.1%)
 ◯ 1-year all-cause mortality 22.1% (17.9%–26.9%)
 ◯ Major vascular complications 11.9% (8.6%–16.4%)
 ◯ Major stroke 3.2% (2.1%–4.8%)
—More recent data from the PARTNER A cohort that com-
pared TAVR with surgical AVR showed that 2-year mor-
tality rates were 33.9% and 35% (P=0.78), respectively. 
Stroke or TIA rates were higher in the TAVR arm (11.2% 
versus 6.5%, P=0.05) than in the surgical AVR arm, as 
were major vascular complications (11.6% versus 3.8%, 
P<0.001).10
Mitral Valve Disorders
ICD-9 424.0; ICD-10 I34.
Mortality—2215. Any-mention mortality—5125. Hospital 
discharges—22 000.
Prevalence
(See Table 21-1.)
 ● In pooled data from CARDIA, ARIC, and CHS, mitral 
valve disease was the most common valvular lesion. At 
least moderate mitral regurgitation occurred at a frequency 
of 1.7% as adjusted to the US adult population of 2000, 
increasing from 0.5% in participants aged 18 to 44 years to 
9.3% in participants aged ≥75 years.1
 ● A systematic review by de Marchena and colleagues11 
found that in the US population, the prevalence of mitral 
regurgitation according to Carpentier’s functional classifi-
cation system was as follows:
—Type I (congenital mitral regurgitation and endocarditis): 
<20 per 1 million
—Type II (myxomatous mitral regurgitation): 15 000 per 
1 million
—Type IIIa (rheumatic HD, systemic lupus erythematosus, 
antiphospholipid syndrome): 10 520 per 1 million
—Type IIIb (ischemic mitral regurgitation, LV dysfunc-
tion, dilated cardiomyopathy): 23 250 per 1 million
 ● Data from the STS adult cardiac surgery database of 14 604 
isolated, nonemergent mitral valve repair operations dem-
onstrate an operative mortality rate of 2.59%. Over a mean 
(SD) follow-up of 5.9 (3.9) years and a mean (SD) age of 
73.3 (5.5) years, survival was 74.9%. The 10-year actuar-
ial survival rate of 57.4% was similar to the matched US 
population.12
 ● Data from the Centers for Medicare & Medicaid Services 
from 47 602 isolated mitral valve operations demon-
strate an operative mortality of 7.1%. Women had higher 
operative mortality rates than men (7.7% versus 6.1%, 
P<0.001). After multivariable adjustment, female sex 
was associated with higher risk of operative mortality for 
both mitral valve repair (OR, 1.18; 95% CI, 1.00–1.39) 
and mitral valve replacement (OR, 1.24; 95% CI, 1.14–
1.36), but these differences were no longer present after 
long-term follow-up (median, 5 years; interquartile range, 
2.7–7.7 years).13
Pulmonary Valve Disorders
ICD-9 424.3; ICD-10 I37.
Mortality—13. Any-mention mortality—37.
Tricuspid Valve Disorders
ICD-9 424.2; ICD-10 I36.
Mortality—11. Any-mention mortality—92.
Rheumatic Fever/Rheumatic HD
(See Table 21-2 and Chart 21-1.)
ICD-9 390 to 398; ICD-10 I00 to I09.
Mortality—3105. Any-mention mortality—5886. Hospital 
discharges—20 000.
 ● Rheumatic HD is uncommon in high-income countries 
such as the United States but remains endemic in Africa, 
Asia, and the Pacific, affecting >15 million individuals and 
causing 233 000 deaths annually.14
 ● The reported prevalence of rheumatic HD is increasing in 
all regions of the world except Europe.15
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 ● Recent echocardiography-based screening studies in 
schoolchildren have demonstrated rheumatic HD preva-
lence rates ranging from 14.8 (95% CI, 7.3–22.3) per 
1000 (Uganda)16 to 20.4 (95% CI, 16.9–23.9) per 1000 
in northern India17 to 21.5 (95% CI, 16.8–26.2) per 1000 
in Cambodia and 30.4 (95% CI, 23.2–37.6) per 1000 in 
Mozambique.18
—Echocardiography reveals a 3- to 10-fold higher preva-
lence of rheumatic HD than clinical examination.16,18
 ● Acute rheumatic fever incidence is decreasing in all 
WHO regions except for the Americas, where it appears 
to be increasing slightly, and the Western Pacific, where it 
appears to be increasing steadily.15
 ● In 1950, ≈15 000 Americans (adjusted for changes in ICD 
codes) died of rheumatic fever/rheumatic HD compared 
with ≈3100 annually in the present era (NCHS/NHLBI).
 ● The 2011 overall age-adjusted death rate for rheumatic 
fever/rheumatic HD was 0.9 per 100 000. Death rates 
varied across race/ethnic groups but were generally low: 
white, 0.9 per 100 000; black or African American, 0.7 per 
100 000; Asian or Pacific Islander, 0.6 per 100 000; Ameri-
can Indian or Alaska Native, 0.8 per 100 000; and Hispanic 
or Latino origin individuals, 0.6 per 100 000.19
Bacterial Endocarditis
ICD-9 421.0; ICD-10 I33.0.
Mortality—1140. Any-mention mortality—2325. Hospital 
discharges—34 000, primary plus secondary diagnoses.
 ● The 2007 AHA guidelines on prevention of IE20 state that IE 
is thought to result from the following sequence of events: 
(1) Formation of nonbacterial thrombotic endocarditis on 
the surface of a cardiac valve or elsewhere that endothe-
lial damage occurs; (2) bacteremia; and (3) adherence of 
the bacteria in the bloodstream to nonbacterial thrombotic 
endocarditis and proliferation of bacteria within a veg-
etation. Viridans group streptococci are part of the normal 
skin, oral, respiratory, and gastrointestinal tract flora, and 
they cause ≥50% of cases of community-acquired native 
valve IE not associated with intravenous drug use.21
 ● Although the absolute risk for acquiring IE from a dental 
procedure is impossible to measure precisely, the best avail-
able estimates are as follows: If dental treatment causes 1% 
of all cases of viridans group streptococcal IE annually in 
the United States, the overall risk in the general population 
is estimated to be as low as 1 case of IE per 14 million den-
tal procedures. The estimated absolute risk rates for acquir-
ing IE from a dental procedure in patients with underlying 
cardiac conditions are as follows20:
—Mitral valve prolapse: 1 per 1.1 million procedures
—CHD: 1 per 475 000
—Rheumatic HD: 1 per 142 000
—Presence of a prosthetic cardiac valve: 1 per 114 000
—Previous IE: 1 per 95 000 dental procedures
 ● Cessation of antibiotic prophylaxis for IE before dental pro-
cedures has not led to a change in pediatric cases of endo-
carditis. Using 2003 to 2010 data from 37 centers in the 
Pediatric Health Information Systems Database, Pasquali 
and colleagues22 did not demonstrate a significant differ-
ence in the number of IE hospitalizations after the guide-
lines were implemented in 2007 (1.6% difference after 
versus before guideline implementation; 95% CI, −6.4% to 
10.3%; P=0.7).
 ● A systematic review that included 161 studies and 
27 354 patients from 1960 to 2011 demonstrated that in 
hospital-based studies (143 studies; 23 877 patients), 
staphylococcal endocarditis has increased over time (coag-
ulase-negative Staphylococcus 2% to 10%, P<0.001), 
with recent increases in Staphylococcus aureus (21% to 
30%, P<0.05) over the past decade and a corresponding 
decrease in streptococcal endocarditis (32% to 17%) over 
the same time period.23
 ● Cardiac device IE appears to be present in 6.4% (95% CI, 
5.5%–7.4%) of patients with definite IE, according to data 
from the International Collaboration on Endocarditis–Pro-
spective Cohort Study (2000–2006). Nearly half (45.8%; 
95% CI, 38.3%–53.4%) of such cases are associated with 
healthcare-associated infection. In-hospital and 1-year 
mortality rates for these patients were 14.7% (26/177; 95% 
CI, 9.8%–20.8%) and 23.2% (41/177; 95% CI, 17.2%–
30.1%), respectively.24
Endocarditis, Valve Unspecified
ICD-9 424.9; ICD-10 I38.
Mortality—5326. Any-mention mortality—11 034.
VTE Epidemiology (Including DVT and PE)25
Pulmonary Embolism
ICD-9 415.1; ICD-10 I26.
Mortality—7518. Any-mention mortality—30 351. 
Hospital discharges—186 000.
Deep Vein Thrombosis
ICD-9 451.1; ICD-10 I80.2.
Mortality—2564. Any-mention mortality—13 228.
Incidence
 ● Based on 35 years of data from 1966 to 2000 in Olmsted 
County, MN, the average annual incidence of VTE among 
whites is 108 per 100 000 person-years, with 250 000 inci-
dent cases occurring annually among US whites.
 ● VTE incidence appears to be similar or higher among Afri-
can Americans and lower among Asian Americans and 
Native Americans than among whites.
 ● After adjustment for the different age and sex distribution 
of African Americans, VTE incidence is 78 per 100 000, 
which suggests that 27 000 incident VTE cases occur annu-
ally among US blacks.
 ● VTE incidence has not changed significantly over the past 
25 years according to data from Olmsted County, MN.
 ● Incidence rates increase exponentially with age for both 
men and women and for both DVT and PE.
 ● Incidence rates are higher in women during childbearing years, 
whereas incidence rates after age 45 years are higher in men.
 ● PE accounts for an increasing proportion of VTE with 
increasing age in both sexes.
 ● VTE event type (DVT versus PE) has a common familial 
background and shared genetic susceptibility.26
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Survival
 ● For almost one quarter of PE patients, the initial clinical 
presentation is sudden death.
 ● Data from 1999 show that 30-day VTE survival is 72.0% 
(DVT alone, 94.5% PE with or without DVT, 55.6%).27
 ● PE is an independent predictor of reduced survival for ≤3 
months.
 ● Because most PE deaths are sudden and usually attributed 
to underlying disease (eg, cancer; other chronic heart, lung, 
or renal disease), secular trends in VTE survival are con-
founded by autopsy rates.
Recurrence
 ● VTE is a chronic disease with episodic recurrence; ≈30% 
of patients develop recurrence within the next 10 years.
 ● Independent predictors of early (within 180 days) recur-
rence include active cancer, proportion of time spent taking 
heparin with a heparin level ≥0.2 anti-Xa U/mL, and pro-
portion of time spent taking warfarin with an international 
normalized ratio ≥2. Two-week case fatality for recurrent 
DVT alone and recurrent PE with or without DVT is 2% 
and 11%, respectively.28
Complications
 ● The 20-year cumulative incidence of venous stasis syn-
drome and venous ulcer after proximal DVT is 40% and 
3.7%, respectively.
 ● The incidence of chronic thromboembolic pulmonary 
hypertension is 6.5 per million person-years; ≈1400 inci-
dent cases occur annually among US whites.
Risk Factors
 ● Independent VTE risk factors include increasing patient 
age, surgery, trauma/fracture, hospital or nursing home 
confinement, active cancer, central vein catheterization or 
transvenous pacemaker, prior superficial vein thrombosis, 
infection, varicose veins, and neurological disease with 
leg paresis, and among women, use of oral contraceptives, 
pregnancy/postpartum period, and hormone therapy.29
 ● Compared with residents in the community, hospitalized 
residents have a >130-fold higher VTE incidence (71 ver-
sus 9605 per 100 000 person-years).30
 ● In Olmsted County, MN, between 1976 and 1990, hospi-
talization and nursing home residence together account 
for almost 60% of incident VTE events that occur in the 
community.
 ● Among patients hospitalized for acute medical illness, 
independent risk factors for VTE include prior VTE, 
thrombophilia, cancer, age >60 years, leg paralysis, immo-
bilization ≥7 days, and admission to an intensive care unit 
or coronary care unit.31
 ● Among cancer patients beginning chemotherapy, tumor 
site, BMI, hemoglobin, platelet and white blood cell count, 
and plasma D-dimer and soluble P-selectin levels are pre-
dictors of VTE in the next 6 months.32
 ● In a large cohort study of middle-aged women, including 
women undergoing surgery, current smoking increased the 
risk for hospitalization for or death attributable to VTE.33 
However, whether smoking represents an independent VTE 
risk factor remains uncertain.
 ● In a case-crossover study, novel predictors of hospitaliza-
tion for VTE included recent infection, erythropoiesis-
stimulating agents, and blood transfusion.34
 ● An association between systemic, intestinal, or inhaled 
glucocorticoids and VTE was reported recently36; how-
ever, this association may be spurious because of residual 
confounding.
 ● Among patients with immune thrombocytopenia, sple-
nectomy was associated with an increased incidence of 
abdominal vein thrombosis within 90 days after surgery 
and an increased incidence of leg DVT and PE.37 Whether 
these associations are independent of immune thrombocy-
topenia disease activity is uncertain.
 ● Pregnancy-associated VTE incidence is 200 per 100 000 
woman-years; compared with nonpregnant women of 
childbearing age, the RR for VTE is increased 4-fold. VTE 
risk appears to be higher for pregnancies after in vitro fer-
tilization compared with natural pregnancies.38
 ● VTE risk during the postpartum period is ≈5-fold higher 
than during pregnancy.
Arteries, Diseases of
ICD-9 440 to 448; ICD-10 I70 to I78. Includes PAD.
Penetrating Aortic Ulcers
 ● A single-center evaluation of 388 penetrating aortic ulcers 
found on CT angiography (2003–2009) demonstrated pen-
etrating aortic ulcers in the aortic arch (6.8%), descend-
ing thoracic aorta (61.2%), and abdominal aorta (29.7%). 
Nearly 2 of every 3 penetrating aortic ulcers (57.7%) did 
not have a saccular aneurysm or intramural hematoma, 
whereas ≈1 in 4 (27.8%) had associated saccular aneu-
rysms, and ≈1 in 7 (14.4%) had an associated intramural 
hematoma. Rupture was present in ≈1 in 25 penetrating 
aortic ulcers (4.1%).39
Aortic Aneurysm
ICD-9 441; ICD-10 I71.
Mortality—10 073. Any-mention mortality—16 417. 
Hospital discharges—64 000.
 ● According to the GBD, the age-standardized death rate 
attributable to aortic aneurysm in 2010 was 3.4 per 100 000 
(95% CI, 2.5–4.8), with a 27% median decrease since 1990. 
The YLL because of aortic aneurysms was 57.4 (95% CI, 
43.8–80.4), with a 29% median decrease since 1990.40
 ● The prevalence of AAAs that are 2.9 to 4.9 cm in diameter 
ranges from 1.3% in men 45 to 54 years of age to 12.5% 
in men 75 to 84 years of age. For women, the prevalence 
ranges from 0% in the youngest to 5.2% in the oldest age 
groups.41
 ● A meta-analysis of 15 475 individuals from 18 studies on 
small AAAs (3.0–5.4 cm) demonstrated that mean aneu-
rysm growth rate was 2.21 mm per year and was indepen-
dent of age and sex. Growth rates were higher in smokers 
(by 0.35 mm/y) and lower in patients with DM (by 0.51 
mm/y).42
 ● Rupture rates range from 0.71 to 11.03 per 1000 person-
years, with higher rupture rates in smokers (pooled HR, 
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2.02; 95% CI, 1.33–3.06) and women (pooled HR, 3.76; 
95% CI, 2.58–5.47).42
 ● Data from IRAD demonstrate that the rate of mesenteric 
malperfusion in 1809 patients with type A acute dissections 
is 3.7%, with a higher mortality rate than for patients with-
out malperfusion (63.2% versus 23.8%, P<0.001).43
 ● Data from IRAD demonstrated that patients with acute type 
B aortic dissection have heterogeneous in-hospital out-
comes. In-hospital mortality in patients with and without 
complications (such as mesenteric ischemia, renal failure, 
limb ischemia, or refractory pain) was 20.0% and 6.1%, 
respectively. In patients with complications, in-hospital 
mortality associated with surgical and endovascular repair 
was 28.6% and 10.1% (P=0.006), respectively.44
Thoracic Aortic Aneurysm Treatment
 ● A sample of 12 573 and 2732 Medicare patients who 
underwent open thoracic aortic aneurysm and endovascular 
repair demonstrated higher perioperative mortality for open 
repair in both intact (7.1% versus 6.1%, P=0.07) and rup-
tured (46% versus 28%, P<0.01) thoracic aortic aneurysms 
but higher 1-year (87% versus 82%, P=0.001) and 5-year 
(72% versus 62%, P=0.001) survival rates.44a
 ● Perioperative mortality rates for open thoracic aortic aneu-
rysms were higher for black Medicare patients than for 
white Medicare patients (18% versus 10%, P<0.001), but 
rates were similar for endovascular repair (8% versus 9%, 
P=0.56).45
AAA Treatment
 ● Data from 23 838 patients with ruptured AAAs collected 
through the Nationwide Inpatient Sample (2005–2010) 
demonstrate in-hospital mortality of 53.2% (95% CI, 
51.3%–54.9%), with 80.4% (95% CI, 79.0%–81.9%) 
undergoing intervention for repair. Of individuals who 
underwent repair, 20.9% (95% CI, 18.6%–23.2%) under-
went endovascular repair, with a 26.8% (95% CI, 23.7%–
30.0%) postintervention mortality, and 79.1% (95% CI, 
76.8%–81.4%) underwent open repair with a 45.6 (95% CI, 
43.6%–47.5%) postintervention mortality.46
 ● Long-term results from the OVER trial that compared open 
AAA repair to endovascular repair demonstrated no sur-
vival difference between open and endovascular repair at a 
median follow-up of 9 years (HR, 0.97; 95% CI, 0.77–1.22) 
despite reductions in mortality from endovascular repair at 
2 years (HR, 0.63; 95% CI, 0.40–0.98) and 3 years (HR, 
0.72; 95% CI, 0.51–1.00).47
 ● After multivariable adjustment, Medicare patients who 
underwent open AAA repair had a higher risk of all-cause 
mortality (HR, 1.24; 95% CI, 1.05–1.47) and AAA-related 
mortality (HR, 4.37; 95% CI, 2.51–7.66) at 1 year than 
patients who underwent endovascular repair.48 
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Table 21-1. Pooled Prevalence of Valvular Heart Disease From CARDIA, ARIC, and CHS Cohorts
Age, y
18–44 45–54 55–64 65–74 ≥75 P Value for Trend
Frequency Adjusted to 2000 US 
Adult Population
Participants, n 4351 696 1240 3879 1745 … 209 128 094
Male 1959 (45) 258 (37) 415 (33) 1586 (41) 826 (47) … 100 994 367 (48)
Mitral regurgitation (n=449) 23 (0.5) 1 (0.1) 12 (1.0) 250 (6.4) 163 (9.3) <0.0001 1.7% (95% CI, 1.5%–1.9%)
Mitral stenosis (n=15) 0 (0) 1 (0.1) 3 (0.2) 7 (0.2) 4 (0.2) 0.006 0.1% (95% CI, 0.02%–0.2%)
Aortic regurgitation (n=90) 10 (0.2) 1 (0.1) 8 (0.7) 37 (1.0) 34 (2.0) <0.0001 0.5% (95% CI, 0.3%–0.6%)
Aortic stenosis (n=102) 1 (0.02) 1 (0.1) 2 (0.2) 50 (1.3) 48 (2.8) <0.0001 0.4% (95% CI, 0.3%–0.5%)
Any valve disease
Overall (n=615) 31 (0.7) 3 (0.4) 23 (1.9) 328 (8.5) 230 (13.2) <0.0001 2.5% (95% CI, 2.2%–2.7%)
Women (n=356) 19 (0.8) 1 (0.2) 13 (1.6) 208 (9.1) 115 (12.6) <0.0001 2.4% (95% CI, 2.1%–2.8%)
Men (n=259) 12 (0.6) 2 (0.8) 10 (2.4) 120 (7.6) 115 (14.0) <0.0001 2.5% (95% CI, 2.1%–2.9%)
Values are n (%) unless otherwise indicated.
ARIC indicates Atherosclerosis Risk in Communities study; CARDIA, Coronary Artery Risk Development in Young Adults; CHS, Cardiovascular Health Study; CI, 
confidence interval; and ellipses (…), not applicable.
Reprinted from The Lancet, Nkomo et al1 with permission from Elsevier. Copyright © 2006, Elsevier Ltd.
Table 21-2. Rheumatic Fever/Rheumatic Heart Disease
Population Group
Mortality, 2011: 
All Ages*
Hospital Discharges, 
2010: All Ages
Both sexes 3105 20 000
Males 997 (32.1%)† 5000
Females 2108 (67.9%)† 15 000
White males 879 …
White females 1868 …
Black males 84 …
Black females 168 …
Asian or Pacific Islander 83‡ …
American Indian or Alaska Native 23 …
Ellipses (…) indicate data not available.
*Mortality data include Hispanics. Death rates for American Indian or Alaska 
Native, and Asian and Pacific Islander people should be interpreted with 
caution because of inconsistencies in reporting race on the death certificate 
compared with censuses, surveys, and birth certificates. Studies have shown 
underreporting on death certificates of American Indian or Alaska Native, Asian 
and Pacific Islander, and Hispanic decedents, as well as undercounts of these 
groups in censuses
†These percentages represent the portion of total mortality that is for males 
vs females.
‡Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific 
Islander.
Sources: Mortality: Centers for Disease Control and Prevention/National 
Center for Health Statistics, 2011 Mortality Multiple Cause-of-Death–United 
States; data represent underlying cause of death only. Hospital discharges: 
National Hospital Discharge Survey, National Center for Health Statistics, 
and National Heart, Lung, and Blood Institute; data include those inpatients 
discharged alive, dead, or of unknown status.
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Chart 21-1. Rheumatic heart disease prevalence trends per 1000 people for each World Health Organization region: A, The Americas; B, 
Europe; C, Africa; D, Eastern Mediterranean; E, Western Pacific; and F, Southeast Asia. Reprinted from Seckeler and Hoke.15 Copyright © 
2011, Seckeler and Hoke.
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22 . Peripheral Artery Disease
ICD-9: 440.20 to 440.24, 440.30 to 440.32, 440.4, 440.9, 
443.9, 445.02; ICD-10: I70.2, I70.9, I73.9, I74.3, I74.4. See 
Table 22-1 and Charts 22-1 through 22-3.
Prevalence and Incidence
(See Table 22-1 and Charts 22-1 and 22-2.)
 ● PAD affects ≈8.5 million Americans aged ≥40 years and is 
associated with significant morbidity and mortality.1
 ● The age-standardized prevalence rate of PAD per 100 000 
in 2010 was 185.6 (95% CI, 150.3–226.1), with minimal 
change (median percent change, 0.19% [95% CI, −24.1% 
to 31.6%]) since 1990. The age-standardized DALY rate of 
PAD per 100 000 in 2010 was 23.9 (95% CI, 15.7–38.3), 
with a median change of 24.9% since 1990.2
 ● The highest prevalence of PAD has been observed among 
elderly people, non-Hispanic blacks, and women. In a mul-
tivariable age-, sex-, and race/ethnicity-adjusted regression 
model, hypertension, DM, CKD, and smoking were associ-
ated with incident PAD (P≤0.05 for each).3,4
 ● A 2003 to 2008 sample of US national insurance claims of 
adults aged >40 years demonstrated that 263 270 eligible 
individuals had a PAD diagnosis, with an annual incidence 
and prevalence of 2.76% (95% CI, 2.75%–2.77%) and 
12.29% (95% CI, 12.8%–12.31%), respectively.5
 ● In the general population, only ≈10% of people with PAD 
have the classic symptom of intermittent claudication. 
Approximately 40% do not complain of leg pain, whereas 
the remaining 50% have a variety of leg symptoms differ-
ent from classic claudication.6,7 Data from NHANES 1999 
to 2002 suggest that up to two thirds of US adults with PAD 
who are ≥40 years old are asymptomatic, with one fourth 
having severe PAD (ABI <0.7).8 In an older, disabled popu-
lation of women, as many as two thirds of individuals with 
PAD had no exertional leg symptoms.9
Mortality
(See Table 22-1.)
 ● In 2011, PAD any-mention mortality was 62 183 (29 237 males 
and 32 946 females). PAD was the underlying cause in 13 484 
of those deaths in 2011.10 Table 22-1 shows the numbers of 
these deaths that were coded for PAD as the underlying cause.
 ● The 2011 overall any-mention age-adjusted death rate for 
PAD was 18.1 per 100 000. Any-mention death rates in 
males were 21.6 for whites, 24.7 for blacks, 8.8 for Asians 
or Pacific Islanders, and 16.7 for American Indians or 
Alaska Natives. In females, rates were 15.7 for whites, 18.3 
for blacks, 6.9 for Asians or Pacific Islanders, and 13.0 for 
American Indians or Alaska Natives.10
 ● The number of any-mention deaths attributable to PAD 
was higher in 2001 (93 444) than in 2011 (62 183; NCHS, 
AHA).10,11
 ● Data from the GBD project suggest that the age-standard-
ized death rate attributable to PAD was 1.7 (95% CI, 1.0–
2.9) per 100 000, with a 42% median increase since 1990. 
The YLL because of PAD was 21.2 (95% CI, 13.4–35.9), 
with a 29% median increase since 1990.2
 ● A 2008 meta-analysis of 24 955 men and 23 339 women 
demonstrated that the association of the ABI with mortal-
ity has a reverse J-shaped distribution in which participants 
with an ABI of 1.11 to 1.40 are at lowest risk for mortal-
ity. Low ABI (≤0.9) carried a 3-fold (RR, 3.33; 95% CI, 
2.74–4.06) risk of all-cause death compared with men with 
normal ABI (1.11–1.40) and a similar risk in women (RR, 
2.71; 95% CI, 2.03–3.62).12
 ● Among 508 patients (449 men) identified from 2 vascular 
laboratories in San Diego, CA, a decline in ABI of >0.15 
within a 10-year period was associated with a subsequent 
increased risk of all-cause mortality (RR, 2.4; 95% CI, 
1.2–4.8) and CVD mortality (RR, 2.8; 95% CI, 1.3–6.0) at 
3 years’ follow-up.13
 ● Among 440 patients with PAD, male sex and smoking 
were more associated with aortoiliac (proximal) disease 
than with infrailiac (distal) disease. In addition, aortoiliac 
disease was associated with an increased risk of mortality 
or cardiovascular events compared with infrailiac disease 
(adjusted HR, 3.28; 95% CI, 1.87–5.75).14
Risk Factors
 ● The risk factors for PAD are similar but not identical to 
those for CHD. DM and cigarette smoking are stronger risk 
factors for PAD than for CHD.15 ORs for associations of 
DM and smoking with symptomatic PAD are ≈3.0 to 4.0. 
Most studies suggest that the prevalence of PAD is similar 
in men and women.16
Abbreviations Used in Chapter 22
ABI ankle brachial index
AHA American Heart Association
Amer. American
CHD coronary heart disease
CI confidence interval
CKD chronic kidney disease
CVD cardiovascular disease
DALY disability-adjusted life-year
DM diabetes mellitus
ED emergency department
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
HR hazard ratio
ICD-9 International Classification of Diseases, 9th Revision
ICD-10 International Classification of Diseases, 10th Revision
MI myocardial infarction
NCHS National Center for Health Statistics
NH non-Hispanic
NHANES National Health and Nutrition Examination Survey
NHAMCS National Hospital Ambulatory Medical Care Survey
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
OR odds ratio
PA physical activity
PAD peripheral artery disease
REACH Reduction of Atherothrombosis for Continued Health
RR relative risk
YLL years of life lost
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 ● Pooled data from 11 studies in 6 countries found that PAD 
(defined by ABI <0.9) is a marker for systemic athero-
sclerotic disease. The pooled age-, sex-, risk factor–, and 
CVD-adjusted RR for all-cause death was 1.60 (95% CI, 
1.32–1.95), the RR for cardiovascular mortality was 1.96 
(95% CI, 1.46–2.64), the RR for CHD was 1.45 (95% 
CI, 1.08–1.93), and the RR for stroke was 1.35 (95% CI, 
1.10–1.65).17
 ● Cigarette smoking, DM, hypertension, and hypercholester-
olemia, in that order, were important risk factors in high-
income and low-income or middle-income countries.18
 ● A study of 3.3 million people in the United States 40 to 99 
years of age showed that risk factor burden is associated 
with increased prevalence of PAD, and there is a graded 
association between the number of risk factor and the prev-
alence of PAD.19
 ● When the ABI was used to identify PAD, hypertension in 
pregnancy was found to be an independent risk factor for 
PAD decades after pregnancy after adjustment for demo-
graphics and traditional CVD risk factors.20
Global Burden of PAD
(See Chart 22-3.)
 ● A systematic study of 34 studies reported that globally, 
202 million people were living with PAD, and during the 
preceding decade, the number of individuals with PAD 
increased by ≈29% in the low-income or middle-income 
countries and by 13% in high-income countries.18
Awareness and Aftermath
 ● A cross-sectional, population-based telephone survey of 
>2500 adults ≥50 years of age, with oversampling of blacks 
and Hispanics, found that 26% expressed familiarity with 
PAD. Of these, half were not aware that DM and smoking 
increase the risk of PAD. One in 4 knew that PAD is associ-
ated with increased risk of MI and stroke, and only 14% 
were aware that PAD could lead to amputation. All knowl-
edge domains were lower in individuals with lower income 
and education levels.21
 ● People with PAD have impaired function and quality of life. 
This is true even for people who do not report leg symp-
toms. Furthermore, patients with PAD, including those 
who are asymptomatic, experience a significant decline in 
lower-extremity functioning over time.22–24
 ● Among patients with established PAD, higher PA levels 
during daily life are associated with better overall survival 
rate, a lower risk of death because of CVD, and slower rates 
of functional decline.25,26 In addition, better 6-minute walk 
performance and faster walking speed are associated with 
lower rates of all-cause mortality, cardiovascular mortality, 
and mobility loss.27,28
 ● From 2000 to 2008, the overall use of lower-extremity 
amputation decreased significantly during the study period, 
from 7258 to 5790 per 100 000 Medicare beneficiaries with 
PAD. There was significant geographic variation in the 
rate of lower-extremity amputation, from 8400 amputa-
tions per 100 000 patients with PAD in the East South Cen-
tral region to 5500 amputations per 100 000 patients with 
PAD in the Mountain region. After adjustment for cluster-
ing at the US Census Bureau level, geographic variation in 
lower-extremity amputations remained. Lower-extremity 
amputation was performed more often in the East South 
Central region (adjusted OR, 1.152; 95% CI, 1.131–1.174; 
P< 0.001) and West South Central region (adjusted OR, 
1.115; 95% CI, 1.097–1.133; P<0.001) and less often in 
the Middle Atlantic region (OR, 0.833; 95% CI, 0.820–
0.847; P<0.001) than in the South Atlantic region.29
 ● A 2003 to 2008 sample of US national insurance claims of 
adults >40 years of age demonstrated that 44 431 patients 
had a diagnosis of critical limb ischemia over the study 
period, with an annual incidence and prevalence of 0.47% 
(95% CI, 0.46%–0.47%) and 1.90% (95% CI, 1.89%–
1.91%), respectively.5
Interventions
 ● Data from the REACH registry of 8273 PAD participants 
suggest that only 70% of PAD patients receive lipid-low-
ering therapy and only 82% receive antiplatelet therapy for 
secondary CVD prevention.30
 ● A 2011 systematic review evaluated lower-extremity aero-
bic exercise against usual care and demonstrated a range of 
benefits, including the following31:
—Increased claudication time by 71 seconds (79%) to 918 
seconds (422%)
—Increased claudication distance by 15 m (5.6%) to 232 
m (200%)
—Increased walking distance/time by 67% to 101% after 
40 minutes of walking 2 to 3 times per week
 ● In a study that randomized patients with PAD to 3 groups 
(optimal medical care, supervised exercise training, and 
iliac artery stent placement), supervised exercise resulted 
in superior treadmill walking distance compared with stent-
ing. Results in the exercise group and stent group were 
superior to optimal medical care alone.32
 ● In-hospital mortality was higher in women regardless of 
disease severity or procedure performed, even after adjust-
ment for age and baseline comorbidities: 0.5% versus 
0.2% after percutaneous transluminal angioplasty or stent-
ing for intermittent claudication; 1.0% versus 0.7% after 
open surgery for intermittent claudication; 2.3% versus 
1.6% after percutaneous transluminal angioplasty or stent-
ing for critical limb ischemia; and 2.7% versus 2.2% after 
open surgery for critical limb ischemia (P< 0.01 for all 
comparisons).33
 ● Among 186 338 older Medicare PAD patients undergoing 
major lower-extremity amputation, mortality was found to 
be 48.3% at 1 year.34
Hospital Discharges
(See Table 22-1.)
 ● Hospital discharges for PAD slightly increased from 
2000 to 2010, with first-listed discharges of 135 000 and 
146 000, respectively (unreliable estimate, NHDS, NHLBI 
tabulation).35
 ● In 2010, there were 1 539 000 physician office visits with 
a primary diagnosis of PAD.35 In 2010, there were 20 000 
ED visits and 109 000 outpatient department visits for PAD 
(NHAMCS, NHLBI tabulation).35 
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Table 22-1. Peripheral Artery Disease
Population 
Group
Prevalence,  
Age ≥40 y
Mortality, 2011,  
All Ages*
Hospital 
Discharges,  
2010, All Ages
Both sexes ≥6.8 Million 13 484 146 000
Males … 5634
(41.8%)†
84 000
Females … 7850 (58.2%)† 62 000
White males … 4933 …
White females … 6898 …
Black males … 591 …
Black females … 841 …
Asian or Pacific 
Islander
… 165‡ …
American 
Indian/ 
Alaska Native
… 56 …
Ellipses (…) indicate data not available.
*Mortality data for the white, black, Asian or Pacific Islander, and American 
Indian or Alaska Native populations include deaths among people of Hispanic 
and non-Hispanic origin. Death rates for Hispanic, American Indian or Alaska 
Native, and Asian and Pacific Islander people should be interpreted with caution 
because of inconsistencies in reporting Hispanic origin or race on the death 
certificate compared with censuses, surveys, and birth certificates. Studies have 
shown underreporting on death certificates of American Indian or Alaska Native, 
Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of 
these groups in censuses.
†These percentages represent the portion of total mortality attributable to 
heart failure that is for males vs females.
‡ Includes Chinese, Filipino, Hawaiian, Japanese, and Other Asian or Pacific 
Islander.
Sources: Prevalence: Data derived from Allison et al.1 Prevalence of 
peripheral artery disease is based on an ankle-brachial index <0.9 or a previous 
revascularization for peripheral artery disease. Mortality: Centers for Disease 
Control and Prevention/National Center for Health Statistics, 2011 Mortality 
Multiple Cause-of-Death–United States.
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Chart 22-1. Estimates of prevalence of peripheral artery disease in males by age and ethnicity. Amer. indicates American; and NH, 
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23 . Quality of Care
See Tables 23-1 through 23-13.
The Institute of Medicine defines quality of care as “the 
degree to which health services for individuals and popula-
tions increase the likelihood of desired health outcomes and 
are consistent with current professional knowledge.”1 The 
Institute of Medicine has defined 6 specific domains for 
improving health care, including care that is safe, effective, 
patient-centered, timely, efficient, and equitable.
In the following sections, data on quality of care will be 
presented based on the 6 domains of quality as defined by 
the Institute of Medicine. This is intended to highlight cur-
rent care and to stimulate efforts to improve the quality of 
cardiovascular care nationally. Where possible, data are 
reported from recently published literature or standardized 
quality indicators from quality-improvement registries (ie, 
those consistent with the methods for quality performance 
measures endorsed by the ACC and the AHA).2 Additional 
data related to quality of care, such as adherence to ACC/AHA 
clinical practice guidelines, are also included to provide a 
spectrum of quality-of-care data. The data selected are meant 
to provide examples of the current quality of care as reflected 
by the Institute of Medicine domains and are not meant to be 
comprehensive given the sheer number of publications yearly.
Safety
The safety domain has been defined as avoiding injuries to 
patients from the care that is intended to help them. The fol-
lowing are several recent publications that have focused on 
safety issues related to cardiac care:
Abbreviations Used in Chapter 23
ACC American College of Cardiology
ACEI angiotensin-converting enzyme inhibitor
ACS acute coronary syndrome
ACTION Acute Coronary Treatment and Intervention Outcomes 
Network
AED automated external defibrillator
AF atrial fibrillation
AHA American Heart Association
AMI acute myocardial infarction
ARB angiotensin receptor blocker
BMI body mass index
BP blood pressure
CABG coronary artery bypass grafting
CAD coronary artery disease
CHD coronary heart disease
CHF congestive heart failure
CI confidence interval
COURAGE Clinical Outcomes Utilizing Revascularization and Aggressive 
Drug Evaluation
CPR cardiopulmonary resuscitation
CRUSADE Can Rapid Risk Stratification of Unstable Angina Patients 
Suppress Adverse Outcomes With Early Implementation of the 
ACC/AHA Guidelines
CVD cardiovascular disease
DES drug-eluting stent
DM diabetes mellitus
DNR do not resuscitate
DVT deep vein thrombosis
ECG electrocardiogram
EF ejection fraction
EMS emergency medical services
ETco2 end-tidal carbon dioxide
GBD Global Burden of Diseases, Injuries, and Risk Factors Study
GWTG Get With The Guidelines
HbA1c hemoglobin A1c (glycosylated hemoglobin)
HD heart disease
HF heart failure
HIQR Hospital Inpatient Quality Reporting
HMO health maintenance organization
HR hazard ratio
IV intravenous
LDL low-density lipoprotein
LV left ventricular
LVEF left ventricular ejection fraction
LVSD left ventricular systolic dysfunction
MD medical doctor
MI myocardial infarction
N/A not available or not applicable
NCDR National Cardiovascular Data Registry
NM not measured
NSTEMI non–ST-segment–elevation myocardial infarction
OR odds ratio
PCI percutaneous coronary intervention
PINNACLE Practice Innovation and Clinical Excellence
PPO preferred provider organization
ROC Resuscitation Outcomes Consortium
RR relative risk
SBP systolic blood pressure
SCD-HeFT Sudden Cardiac Death in Heart Failure Trial
SD standard deviation
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
TAVR transcatheter aortic valve replacement
TIA transient ischemic stroke
tPA tissue-type plasminogen activator
TVR target-vessel revascularization
UFH unfractionated heparin
VHA Veterans Health Administration
VT/VF ventricular tachycardia/ventricular fibrillation
YLL years of life lost
Click here to go to the Table of Contents
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 ● In a small, single-center study conducted over a 2-month 
period in the cardiac care unit of a tertiary center, Rahim 
et al3 demonstrated that iatrogenic adverse events were com-
mon (99 of 194 patients), of which bleeding (27%) was the 
most common preventable iatrogenic adverse event.
 ● Using the NCDR CathPCI Registry, Tsai et al4 found that almost 
one fourth of dialysis patients undergoing PCI (n=22 778) 
received a contraindicated antithrombotic agent, specifically 
enoxaparin, eptifibatide, or both. Patients who received a con-
traindicated antithrombotic agent had an increased risk of in-
hospital bleeding (OR, 1.63; 95% CI, 1.35–1.98) and a trend 
toward increased mortality (OR, 1.15; 95% CI, 0.97–1.36).4
 ● Using data from the NCDR PINNACLE registry, Hira and 
colleagues5 showed that among 27 533 patients receiving 
prasugrel, 13.9% (3824) did so for an inappropriate indica-
tion (history of TIA or strokes) and a further 4.4% (1210) 
did so for a nonrecommended indication (age >75 years 
without history of DM or MI). Both inappropriate and 
nonrecommended prasugrel use showed wide facility-level 
variation (median rate ratio of 2.89 [95% CI, 2.75–3.03] 
and 2.29 [95% CI, 2.05–2.51], respectively).
 ● In a random sample of medical and surgical long-term 
care adult patients in Massachusetts hospitals, López et al6 
assessed the association between disclosure of an adverse 
event and patients’ perception of quality of care. Overall, 
only 40% of adverse events were disclosed. Higher quality 
ratings were associated with disclosure of an adverse event. 
Conversely, lower patient perception of quality of care was 
associated with events that were preventable and with events 
that caused discomfort.6
 ● Using Medicare Patient Safety Monitoring System data 
abstracted from medical records on 21 adverse events in 
61 523 patients hospitalized between 2005 and 2011 for 
AMI, CHF, pneumonia, or conditions requiring surgery, 
Wang et al7 reported that among patients with AMI, the rate 
of occurrence of adverse events declined from 5.0% to 3.7% 
(difference, 1.3%; 95% CI, 0.7%–1.9%). Among patients 
with CHF, the rate of occurrence of adverse events declined 
from 3.7% to 2.7% (difference, 1.0%; 95% CI, 0.5%–1.4%), 
Patients with pneumonia and those with conditions requiring 
surgery had no significant declines in adverse event rates.7
Effectiveness
(See Tables 23-1 through 23-10.)
Effective care has been defined as providing services based 
on scientific knowledge to all who could benefit and refrain-
ing from providing services to those not likely to benefit. It 
also encompasses monitoring results of the care provided and 
using them to improve care for all patients.1
 ● Weintraub et al8 reported results from a comparative effec-
tiveness study of PCI versus CABG using observational 
data among patients ≥65 years of age with 2- or 3-vessel 
CAD without AMI. Their results showed that at 1 year, 
there was no significant difference in adjusted mortality 
between groups (6.24% in the CABG group versus 6.55% 
in the PCI group). At 4 years, there was lower mortality 
in the CABG group than in the PCI group (16.4% versus 
20.8%; RR, 0.79; 95% CI, 0.76–0.82).8
 ● Choudhry et al9 reported results of a cluster randomized 
trial that evaluated the impact of eliminating out-of-pocket 
costs (ie, full prescription coverage) on medication adher-
ence and cardiovascular outcomes in patients discharged 
after MI. Compared with the usual prescription coverage, 
rates of adherence to statins, β-blockers, ACEIs, and ARBs 
were on average 4% to 6% higher in the full-coverage 
group. There was no significant difference in the primary 
outcome (first major vascular event or revascularization) 
between the 2 groups (17.6 per 100 person-years in the full-
coverage group versus 18.8 in the usual-coverage group; 
HR, 0.93; 95% CI, 0.82–1.04). The rates of secondary 
outcomes of total major vascular events or revasculariza-
tion were significantly reduced in the full-coverage group 
(21.5 versus 23.3; HR, 0.89; 95% CI, 0.90–0.99), as was 
the rate of first major vascular event (11 versus 12.8; HR, 
0.86; 95% CI, 0.74–0.99). The elimination of copayments 
did not increase total spending, although patient costs were 
reduced for drugs and other services.
 ● Using data from the ACTION Registry among 202 213 
patients discharged after AMI from 526 US participating 
sites between January 2007 and March 2011, Rao and col-
leagues showed that only 14.5% of the eligible patients 
without documented contraindication received aldosterone 
antagonists. Fewer than 2% of the participating sites used 
aldosterone antagonists in ≥50% of eligible patients.10
 ● Data from the ACC PINNACLE outpatient registry11 of 
patients with CAD (n=38 775) showed that 77.8% of the 
patients (30 160) were prescribed statins, 5.3% (2042) were 
treated only with nonstatin lipid-lowering medications, and 
17% (6573) were not taking any lipid-lowering medication. 
Lack of medical insurance (RR, 0.94; 95% CI, 0.89–1.00) 
was associated with a lower likelihood of statin treatment, 
whereas male sex (RR, 1.10; 95% CI, 1.07–1.13), coex-
isting hypertension (RR, 1.07; 95% CI, 1.02–1.12), prior 
CABG (RR, 1.09; 95% CI, 1.05–1.14), and prior PCI (RR, 
1.11; 95% CI, 1.06–1.16) were associated with a higher 
likelihood of statin treatment.
 ● Another publication from the same registry showed that 
among 156 145 CAD patients in 58 practices, just over two 
thirds (n=103 830, 66.5%) of patients were prescribed the 
optimal combination of medications (β-blockers, ACEIs/
ARBs, statins) for which they were eligible. After adjust-
ment for patient factors, the practice median rate ratio for 
prescription was 1.25 (95% CI, 1.20–1.32), which indicates 
a 25% likelihood that any 2 practices would differ in treat-
ing identical CAD patients.12
 ● Heisler et al13 reported results of a prospective, multisite, 
cluster randomized trial that evaluated the effectiveness 
of a pharmacist-led intervention that targeted medica-
tion management and adherence counseling to improve 
BP control in patients with DM in 2 high-performing 
integrated healthcare systems. Although the mean SBP 
of patients in the intervention arm was 2.4 mm Hg lower 
(95% CI, –3.4 to –1.5 mm Hg; P<0.001) immediately 
after the intervention than that of patients in the control 
arm, the mean SBP decrease from 6 months before to 6 
months after the intervention (primary outcome) was sim-
ilar in magnitude (≈9 mm Hg) in both arms.13
 ● In 2013, investigators from the GBD 2010 study described 
their findings of a systematic analysis of disease burden, 
injuries, and leading risk factors in the United States 
and compared them with those of 34 countries in the 
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Organisation for Economic Co-operation and Develop-
ment.14 They reported that the US life expectancy for both 
sexes combined increased from 75.2 years in 1990 to 78.2 
years in 2010. During the same time period, healthy life 
expectancy (ie, the number of years that a person at a given 
age can expect to live in good health, taking into account 
mortality and disability) increased from 65.8 to 68.1 years 
in the United States. Despite declines in the YLLs because 
of premature mortality secondary to ischemic HD and 
stroke, 15.9% of YLLs were related to ischemic HD and 
4.3% of YLLs were related to stroke in the United States 
in 2010, which highlights the continued dominance of 
CVD in causing premature death. Despite these absolute 
improvements, the US rank among 34 countries in the 
Organisation for Economic Co-operation and Development 
changed from 18th to 27th for the age-standardized death 
rate, from 20th to 27th for life expectancy at birth, from 
14th to 26th for healthy life expectancy, and from 23rd to 
28th for the age-standardized YLL. These results indicate 
that improvements in population health in the United States 
have not kept pace with advances in population health in 
other wealthy nations.
 ● Outcome measures of 30-day mortality and 30-day read-
mission after hospitalization for AMI or HF have been 
developed that adjust for patient mix (eg, comorbidi-
ties) so that comparisons can be made across hospitals.15 
According to national Medicare data from July 2009 
through June 2012
—The median (10th, 90th percentile) hospital risk-stan-
dardized mortality rate was 15.1% (13.3%, 16.9%) for 
AMI and 11.7% (9.9%, 13.8%) for HF.
—The median risk-standardized readmission rate was 
18.3% (16.9%, 19.8%) for AMI and 23.0% (21.0%, 
25.4%) for HF.
—Distinct regional patterns were seen for both measures 
and both conditions.
—The median risk-standardized mortality rate for AMI 
admissions declined by 0.7% from 15.3% in 2009 to 
2010 and 2010 to 2011 to 14.6% in 2011 to 2012.
—The median risk-standardized mortality rate for HF 
admissions increased from 11.4% in 2009 to 2010 to 
11.9% in 2010 to 2011 and decreased to 11.7% in 2011 
to 2012.
—The median risk-standardized readmission rate for AMI 
declined from 18.6% in 2009 to 2010 to 18.5% in 2010 
to 2011 and 17.7% in 2011 to 2012.
—The median risk-standardized readmission rate for HF 
declined from 23.3% in 2009 to 2010 to 23.2% in 2010 
to 2011 and 22.5% in 2011 to 2012.
 ● A study of 30 947 patients admitted with ischemic strokes 
showed that admission to a designated stroke center com-
pared with admission to a nondesignated hospital was 
associated with more frequent use of thrombolytic therapy 
(4.8% versus 1.7%, P<0.001) and lower 30-day all-cause 
mortality (10.1% versus 12.5%, P<0.001).16
 ● A study of 458 hospitals participating in the STS National 
Cardiac Database showed that an intervention of receiv-
ing quality-improvement educational material designed 
to influence the prescription rates of 4 medication classes 
(aspirin, β-blockers, lipid-lowering therapy, and ACEIs) 
after CABG discharge in addition to site-specific feedback 
reports led to a significant improvement in adherence for 
all 4 secondary prevention medications at the intervention 
sites compared with the control sites.17
 ● A study from the PINNACLE registry showed that unin-
sured patients with CAD were 9%, 12%, and 6% less likely 
to receive treatment with a β-blocker, an ACEI/ARB, and 
lipid-lowering therapy, respectively, than privately insured 
CAD patients, and CAD patients with public insurance 
were 9% less likely to be prescribed ACEI/ARB therapy. 
Most of the differences were attenuated after adjustment 
for the site providing care.18
 ● In 2013, a transcatheter valve therapy registry was created 
through a partnership between the STS and the ACC.19 The 
objective of this registry is to provide an “objective, com-
prehensive, and scientifically based resource to improve 
the quality of patient care, to monitor the safety and effec-
tiveness of TVT [transcatheter valve therapy] devices, to 
serve as an analytic resource for TVT [transcatheter valve 
therapy] research, and to enhance communication among 
key stakeholders.”
 ● Inpatient ACS, HF, and stroke quality-of-care measures 
data, including trends in care data, where available from 
national registries, are given in Tables 22-1 through 22-6.
 ● Selected outpatient quality-of-care measures from the 
National Committee for Quality Assurance for 2012 appear 
in Table 23-7.
 ● Quality-of-care measures for patients who had out-of-hos-
pital cardiac arrest and were enrolled in the ROC cardiac 
arrest registry in 2013 (ROC Investigators, unpublished 
data, September 1, 2014) are given in Table 23-8.
 ● Quality-of-care measures for patients who had in-hospital 
cardiac arrest and were enrolled in the AHA’s GWTG-
Resuscitation quality-improvement project in 2013 
(GWTG-Resuscitation Investigators, unpublished data, 
September 1, 2014) are given in Table 23-9.
Patient-Centered Care
Patient-centered care has been defined as the provision of 
care that is respectful of and responsive to individual patient 
preferences, needs, and values and that ensures that patient 
values guide all clinical decisions. Dimensions of patient-
centered care include the following: (1) Respect for patients’ 
values, preferences, and expressed needs; (2) coordination 
and integration of care; (3) information, communication, and 
education; (4) physical comfort; (5) emotional support; and 
(6) involvement of family and friends. Studies that focused on 
some of these aspects of patient-centered care are highlighted 
below.
 ● The COURAGE trial,20 which investigated a strategy of 
PCI plus optimal medical therapy versus optimal medical 
therapy alone, demonstrated that both groups had signifi-
cant improvement in health status during follow-up. By 3 
months, health status scores had increased in the PCI group 
compared with the medical therapy group, to 76±24 ver-
sus 72±23 for physical limitation (P=0.004), 77±28 versus 
73±27 for angina stability (P=0.002), 85±22 versus 80±23 
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for angina frequency (P<0.001), 92±12 versus 90±14 for 
treatment satisfaction (P<0.001), and 73±22 versus 68±23 
for quality of life (P<0.001). The PCI plus optimal medical 
therapy group had a small but significant incremental ben-
efit compared with the optimal medical therapy group early 
on, but this benefit disappeared by 36 months.
 ● In SCD-HeFT,21 a study of a single-lead implantable car-
dioverter-defibrillator versus amiodarone for moderately 
symptomatic HF, patients with implantable cardioverter-
defibrillators had improvement in quality of life compared 
with patients who received medical therapy at 3 and 12 
months but not at 30 months. Implantable cardioverter-defi-
brillator shocks in the month preceding a scheduled assess-
ment were associated with a decrease in quality of life in 
multiple domains. The authors concluded that the presence 
of a single-lead implantable cardioverter-defibrillator was 
not associated with any detectably adverse quality of life 
during 30 months of follow-up.
 ● Peikes et al22 reported on 15 care-coordination programs as 
part of a Medicare demonstration project for patients with 
CHF, CAD, DM, and other conditions. Thirteen of the 15 
programs did not show a difference in hospitalization rates, 
and none of the programs demonstrated net savings. The 
interventions tested varied significantly, but the majority 
of the interventions included patient education to improve 
adherence to medication, diet, exercise, and self-care regi-
mens and improving care coordination through various 
approaches. These programs had favorable effects on none 
of the adherence measures and only a few of the many qual-
ity-of-care indicators examined. The authors concluded 
that programs with substantial in-person contact that target 
moderately to severely ill patients can be cost-neutral and 
improve some aspects of care.
 ● Hernandez et al23 showed that patients with outpatient 
follow-up within 7 days of discharge for an HF hospital-
ization were less likely to be readmitted within 30 days in 
the GWTG-HF registry of patients who were ≥65 years of 
age. The median length of stay was 4 days (interquartile 
range, 2–6 days), and 21.3% of patients were readmitted 
within 30 days. At the hospital level, the median percentage 
of patients who had early follow-up after discharge from 
the index hospitalization was 38.3% (interquartile range, 
32.4%–44.5%).
 ● Smolderen et al24 assessed whether health insurance sta-
tus affects decisions to seek care for AMI. Uninsured and 
insured patients with financial concerns were more likely 
to delay seeking care during AMI and had prehospital 
delays of >6 hours (48.6% of uninsured patients and 44.6% 
of insured patients with financial concerns compared with 
39.3% of insured patients without financial concerns). Lack 
of health insurance and financial concerns about accessing 
care among those with health insurance were each associ-
ated with delays in seeking emergency care for AMI.
 ● A randomized trial tested a multifaceted intervention to 
improve adherence to 4 cardioprotective medications 
(clopidogrel, statins, ACEIs/ARBs, and β-blockers) after 
ACS. A total of 253 patients were randomized to either 
a multifaceted intervention (including pharmacist-led 
medication reconciliation and tailoring; patient education; 
collaborative care between a pharmacist and a patient’s 
primary care provider and/or cardiologist; and 2 types of 
voice messaging for patient education and medication refill 
reminder) or to usual care. After a 1-year period, 89.3% of 
the patients in the intervention group were adherent to the 
4 cardioprotective medications (mean proportion of days 
covered >0.8) compared with 73.9% in the usual care group 
(P=0.003). A greater proportion of patients in the interven-
tion arm than in the usual care group were adherent to 
clopidogrel (86.8% versus 70.7%, P=0.03), statins (93.2% 
versus 71.3%, P<0.001), and ACEIs/ARBs (93.1% versus 
81.7%, P=0.03) but not β-blockers (88.1% versus 84.8%, 
P=0.59). There were no statistically significant differences 
in the proportion of patients who achieved BP or LDL cho-
lesterol level goals.25
 ● Reynolds et al26reported results on health-related quality 
of life after TAVR in inoperable patients with severe aortic 
stenosis compared with those receiving standard therapy. 
Health-related quality of life was assessed at baseline and 
at 1, 6, and 12 months with the Kansas City Cardiomyopa-
thy Questionnaire and the 12-item Short Form-12 General 
Health Survey. Although the Kansas City Cardiomyopathy 
Questionnaire summary scores improved in both groups, 
the extent of improvement was greater in the TAVR group 
than in the standard-care group at 1 month (mean between-
group difference, 13 points; 95% CI, 8–19), with larger 
benefits at 6 months (mean difference, 21 points; 95% CI, 
15–27 points) and 12 months (mean difference, 26 points; 
95% CI, 19–33). At 12 months, TAVR patients also reported 
higher physical and mental health scores on the 12-item 
Short Form-12 General Health Survey, with a mean differ-
ence of 5.7 and 6.4 points, respectively (P<0.001 for both 
comparisons) compared with standard care.26
Timely Care
(See Table 23-10.)
The timely care domain relates to reducing waits and some-
times harmful delays for both those who receive and those 
who give care. Timeliness is an important characteristic of any 
service and is a legitimate and valued focus of improvement in 
health care and other industries.
 ● Data from the CRUSADE national quality-improvement 
initiative showed that median delay from onset of symp-
toms to hospital presentation for patients presenting with 
NSTEMI was 2.6 hours and was significantly associated 
with in-hospital mortality but did not change over time 
from 2001 to 2006.27
 ● Among patients who underwent primary PCI for STEMI 
and were enrolled in the CathPCI Registry (n=96 738) in a 
period that coincided with national efforts to reduce door-
to-balloon times, median door-to-balloon times declined 
from 83 minutes in 12 months from July 2005 to June 2006 
to 67  minutes in 12 months from July 2008 to June 2009. 
This improvement in processes of care was not associated 
with improved outcome (risk-adjusted in-hospital mortality 
5.0% in 2005–2006 versus 4.7% in 2008–2009, P=0.34).28
 ● Using data between 2005 and 2007 from the NCDR Cath-
PCI Registry, Wang et al29 demonstrated that among STEMI 
patients, only 10% of the transfer patients received PCI 
within 90 minutes (versus 63% for direct-arrival patients; 
P<0.0001).
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 ● Glickman et al30 showed that a year-long implementation of 
standardized protocols as part of a statewide regionalization 
program was associated with a significant improvement in 
median door-in–door-out times among 436 STEMI patients 
who presented at non-PCI hospitals who required transfer 
(before intervention: 97 minutes [interquartile range, 56–
160 minutes]; after intervention: 58 minutes [interquartile 
range, 35–90 minutes]; P<0.0001).
 ● A study31 of 204 591 patients with ischemic and hemor-
rhagic strokes admitted to 1563 GTWG-Stroke participat-
ing hospitals between April 1, 2003, and June 30, 2010, 
showed that 63.7% of the patients arrived by EMS in the 
hospital. Older patients, those with Medicaid and Medicare, 
and those with severe strokes were more likely to activate 
EMS. Conversely, minority race/ethnicity (black, Hispanic, 
Asian) and living in rural communities were associated with 
a lower likelihood of EMS use. EMS transport was inde-
pendently associated with an onset-to-door time ≤3 hours, 
a higher proportion of patients meeting door-to-imaging 
time of ≤25 minutes, more patients meeting a door-to-nee-
dle time of ≤60 minutes, and more eligible patients being 
treated with tPA if onset of symptoms was ≤2 hours. The 
authors concluded that although EMS use was associated 
with rapid evaluation and treatment of stroke, more than 
one third of stroke patients fail to use EMS.
 ● Data on time to reperfusion for STEMI or ischemic stroke 
are provided from national registries in Table 23-11.
Efficiency
Efficiency has been defined as avoiding waste, in particular 
waste of equipment, supplies, ideas, and energy. In an efficient 
healthcare system, resources are used to get the best value for 
the money spent.
 ● Using data from the NCDR CathPCI registry from 2004 
through 2010, Amin et al32 examined the association 
between risk of TVR and use of DES and the cost-effec-
tiveness of lower use of DES in patients at low risk of TVR 
(<10% TVR risk). The authors showed a marked variation 
in physicians’ use of DES (range, 2%–100%). Even in 
groups with low TVR risk, 73.9% of the patients received 
DES. The authors projected that by reducing the use of 
DES by 50% in patients at low risk of TVR, US healthcare 
costs could be lowered by $205 million, whereas the over-
all TVR event rate would be increased by 0.5%.
 ● A study of 35 191 CHD patients from the US Department of 
Veterans Affairs healthcare system showed that among 27 947 
patients with LDL cholesterol levels <100 mg/dL, 9200 
(32.9% of those with LDL cholesterol <100 mg/dL) received 
additional lipid assessments without any treatment intensi-
fication during 11 months from the index lipid panel. Even 
among 13 114 patients with LDL cholesterol <70 mg/dL, 
repeat lipid testing was performed in 8177 patients (62.4% of 
those with LDL cholesterol <70 mg/dL) during 11 months of 
follow-up. These results show that redundant lipid testing is 
common in patients with CHD.33
 ● Himmelstein et al34 analyzed whether more-computerized 
hospitals had lower costs of care or administration or better 
quality, to address a common belief that computerization 
improves healthcare quality, reduces costs, and increases 
administrative efficiency. They found that hospitals that 
increased computerization faster had more rapid admin-
istrative cost increases (P=0.0001); however, higher over-
all computerization scores correlated weakly with better 
quality scores for AMI (r=0.07, P=0.003) but not for HF, 
pneumonia, or the 3 conditions combined. In multivariate 
analyses, more-computerized hospitals had slightly better 
quality. The authors concluded that hospital computing 
might modestly improve process measures of quality but 
does not reduce administrative or overall costs.
 ● In a retrospective cohort study of cases (111 707) submitted 
to the NCDR ICD (implantable cardioverter-defibrillator) 
Registry between January 1, 2006, and June 30, 2009, 
25 145 (22.5%) received non–evidence-based implantable 
cardioverter-defibrillator therapy. Patients who received 
non–evidence-based implantable cardioverter-defibrillator 
therapy had a significantly higher risk of in-hospital death 
(0.57% versus 0.18%, P<0.001) and any postprocedure 
complication (3.23% versus 2.41%, P<0.001) than those 
who received evidence-based implantable cardioverter-
defibrillator therapy.35
 ● In a multicenter study of patients within the NCDR under-
going PCI, Chan et al36 reported results of the appropriate-
ness of PCI for both acute and nonacute indications. Among 
patients undergoing PCI for acute indications (71.1% of 
the cohort), 98.5% of the procedures were classified as 
appropriate, 0.3% as uncertain, and 1.1% as inappropri-
ate. Among patients undergoing PCI for nonacute indica-
tions (28.9% of the cohort), 50.4% of the procedures were 
classified as appropriate, 38% as uncertain, and 11.6% as 
inappropriate. There was also substantial variation for inap-
propriate nonacute PCI across hospitals (median hospital 
rate 10.8%; interquartile range, 6.0%–16.7%).
Equitable Care
(See Tables 23-11 through 23-13.)
Equitable care means the provision of care that does not 
vary in quality because of personal characteristics such as sex, 
ethnicity, geographic location, and socioeconomic status. The 
aim of equity is to secure the benefits of quality health care for 
all the people of the United States. With regard to equity in 
caregiving, all individuals rightly expect to be treated fairly by 
local institutions, including healthcare organizations.
 ● Chan et al37 demonstrated that rates of survival to discharge 
were lower for black patients (25.2%) than for white 
patients (37.4%) after in-hospital cardiac arrest. Lower 
rates of survival to discharge for blacks reflected lower 
rates of both successful resuscitation (55.8% versus 67.4%) 
and postresuscitation survival (45.2% versus 55.5%). 
Adjustment for the hospital site at which patients received 
care explained a substantial portion of the racial differences 
in successful resuscitation (adjusted RR, 0.92; 95% CI, 
0.88–0.96; P<0.001) and eliminated the racial differences 
in postresuscitation survival (adjusted RR, 0.99; 95% CI, 
0.92–1.06; P=0.68). The authors concluded that much of 
the racial difference was associated with the hospital center 
in which black patients received care.
 ● Kapoor et al38 evaluated 99 058 HF admissions from 244 
sites between January 2005 and September 2009. Patients 
were grouped on the basis of payer status (private/health 
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maintenance organization, no insurance, Medicare, or 
Medicaid). Compared with private/health maintenance 
organization group, the other 3 groups were less likely to 
receive evidence-based therapies (β-blockers, implantable 
cardioverter-defibrillators, anticoagulation for AF, ACEIs, 
or ARBs) and had longer hospital stays. Higher adjusted 
rates of in-hospital mortality were also seen in patients with 
Medicaid (OR, 1.22; 95% CI, 1.06–1.41) and in patients 
with reduced EF and no insurance (OR, 1.61; 95% CI, 
1.15–2.25).
 ● Cohen et al39 demonstrated that among hospitals engaged 
in a national quality monitoring and improvement pro-
gram, evidence-based care for AMI appeared to improve 
over time for patients irrespective of race/ethnicity, and 
differences in care by race/ethnicity care were reduced 
or eliminated. They analyzed 142 593 patients with AMI 
(121 528 whites, 10 882 blacks, and 10 183 Hispanics) at 
443 hospitals participating in the GWTG-CAD program. 
Overall, defect-free care was 80.9% for whites, 79.5% for 
Hispanics (adjusted OR versus whites, 1.00; 95% CI, 0.94–
1.06; P=0.94), and 77.7% for blacks (adjusted OR versus 
whites, 0.93; 95% CI, 0.87–0.98; P=0.01). A significant 
gap in defect-free care was observed for blacks during the 
first half of the study but was no longer present during the 
remainder of the study. Overall, progressive improvements 
in defect-free care were observed regardless of race/ethnic 
groups.
 ● Thomas et al40 analyzed data among hospitals that volun-
tarily participated in the AHA’s GWTG-HF program from 
January 2005 through December 2008. Relative to white 
patients, Hispanic and black patients hospitalized with HF 
were significantly younger (median age 78, 63, and 64 
years, respectively) but had lower EFs (mean EF 41.1%, 
38.8%, and 35.7%, respectively) with a higher prevalence 
of DM (40.2%, 55.7%, and 43.8%, respectively) and hyper-
tension (70.6%, 78.4%, and 82.8%, respectively). The pro-
vision of guideline-based care was comparable for white, 
black, and Hispanic patients. Black (1.7%) and Hispanic 
(2.4%) patients had lower in-hospital mortality than white 
patients (3.5%). Improvement in adherence to all-or-none 
HF measures increased annually from year 1 to year 3 for 
all 3 racial/ethnic groups.40
 ● Al-Khatib et al41 analyzed implantable cardioverter-
defibrillator use for primary prevention among 11 880 
patients with a history of HF, LVEF <35%, and age >65 
years enrolled in the GWTG-HF registry from January 
2005 through December 2009. From 2005 to 2007, over-
all implantable cardioverter-defibrillator use increased 
from 30.2% to 42.4% and then remained unchanged in 
2008 to 2009. After adjustment for confounders, implant-
able cardioverter-defibrillator use increased significantly 
in the overall study population during 2005 to 2007 (OR, 
1.28; 95% CI, 1.11–1.48 per year; P=0.0008) and in black 
women (OR, 1.82; 95% CI, 1.28–2.58 per year; P=0.0008), 
white women (OR, 1.30; 95% CI, 1.06–1.59 per year; 
P=0.010), black men (OR, 1.54; 95% CI, 1.19–1.99 per 
year; P=0.0009), and white men (OR, 1.25; 95% CI, 1.06–
1.48 per year; P=0.0072). The increase in implantable car-
dioverter-defibrillator use was greatest among blacks. They 
concluded that although previously described racial dis-
parities in the use of implantable cardioverter-defibrillators 
were no longer present in their study by the end of the study 
period, a sex difference in their use persisted.41
 ● In 2013, the AHA published an advisory that provided a 
recommendation on improving bystander CPR in commu-
nities with low bystander CPR rates (in the United States, 
rates ranged from 10%–65%) and the metrics to evaluate 
the impact of community-based CPR training programs.42
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Table 23-2. HF Quality-of-Care Measures, 2013
Quality-of-Care Measure National Data From HIQR Program* AHA GWTG- HF VHA
LVEF assessment 98.9 99.3 100
ARB/ACEI at discharge for patients with LVSD 96.8 96.0 96
Complete discharge instructions 94.1 94.5 96
Adult smoking cessation advice/counseling NM† 96.0 Retired
β-Blockers at discharge for patients with LVSD, no contraindications NM 97.9 NM
Anticoagulation for AF or atrial flutter, no contraindications NM 80.7 Retired
Values are percentages. 
In the GWTG registry, mechanical ventilation was required in 0.9% of patients. In-hospital mortality was 2.5%, and mean length of hospital 
stay was 5.0 days (median 4.0 days).
AF indicates atrial fibrillation; AHA GWTG-HF, American Heart Association’s Get With The Guidelines–Heart Failure; ARB/ACEI, angiotensin 
receptor blocker/angiotensin-converting enzyme inhibitor; HF, heart failure; HIQR, Hospital Inpatient Quality Reporting; LVEF, left ventricular 
ejection fraction; LVSD, left ventricular systolic dysfunction; NM, not measured; and VHA, Veterans Health Administration.
*HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from the third quarter of 2011 
to the second quarter of 2012.
†Measure was retired in January 2012.
Table 23-1. ACS Quality-of-Care Measures, 2013
Quality-of-Care Measure VHA* National Data From HIQR Program† ACTION-GWTG STEMI‡ ACTION-GWTG NSTEMI‡
Aspirin within 24 h of admission 99 99.3 96.6 94.6
Aspirin at discharge 99 99.2 98.9 98.0
β-Blockers at discharge 99 99.0 97.7 96.7
Lipid-lowering medication at discharge§ 99 98.2 99.1 98.5
ARB/ACEI at discharge for patients with LVEF <40% 95 97.8 91.8 88.6
ACEI at discharge for AMI patients NM NM 71.5 59.6
ARB at discharge for AMI patients NM NM 9.3 13.3
Adult smoking cessation advice/counseling Retired NM║ 98.6 98.2
Cardiac rehabilitation referral for AMI patients NM NM 82.3 73.7
Values are percentages.
ACEI indicates angiotensin-converting enzyme inhibitor; ACS, acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention Outcomes 
Network Registry–Get With The Guidelines; AMI, acute myocardial infarction; ARB, angiotensin receptor blocker; HIQR, Hospital Inpatient Quality Reporting; LVEF, left 
ventricular ejection fraction; NM, not measured; NSTEMI, non–ST-segment–elevation myocardial infarction; STEMI, ST-segment–elevation myocardial infarction; and 
VHA, Veterans Health Administration.
*VHA: AMI patients. Data reported include data from October 1, 2011, to September 30, 2012.
†HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from the third quarter of 2012 to the second quarter 
of 2013.
‡ACTION Registry: STEMI and NSTEMI patients are reported separately. Patients must be admitted with acute ischemic symptoms within the previous 24 hours, 
typically reflected by a primary diagnosis of STEMI or NSTEMI. Patients who are admitted for any other clinical condition are not eligible. Data reported include data from 
the second quarter of 2012 to the first quarter of 2013.
§Denotes statin use at discharge. Use of nonstatin lipid-lowering agent was 7.2% for STEMI patients and 10.5% for NSTEMI patients in the ACTION registry.
║Measure was retired in January 2012.
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Table 23-3. Time Trends in GWTG-ACS Quality-of-Care Measures, 2006 to 2013
Quality-of-Care Measure 2006 2007 2008 2009 2010* 2011* 2012* 2013*
Aspirin within 24 h of admission 94.7 92.8 91.2 90.9 97 97.6 97.8 95.4
Aspirin at discharge 94.4 95.8 94.9 95.5 98 98.3 98.4 98.4
β-Blockers at discharge 92.8 94.6 94.5 94.9 96 96.7 97.1 97.1
Lipid-lowering medication at discharge 84.5 85.6 81.6 86.8 92† 98.4† 98.8† 98.8
Lipid therapy at discharge if LDL 
cholesterol >100 mg/dL
89.1 90.7 91.9 92.5 NM NM NM NM
ARB/ACEI at discharge for patients with 
LVEF <40%
87.3 91.1 91.9 91.9 86 87.8 89.7 90.0
Adult smoking cessation advice/counseling 94.3 97.4 98.4 98.4 98 98.4 98.4 98.4
Cardiac rehabilitation referral for AMI 
patients
71.1 63.6 52.0 49.1 75 76.5 77.3 77.2
Values are percentages. 
In the ACTION (Acute Coronary Treatment and Intervention Outcomes Network) registry, the unadjusted in-hospital mortality rate for 2013 was 4.6% (95% confidence 
interval, 4.5%–4.7%; excludes transfer-out patients). The American Heart Association’s Get With The Guidelines–Coronary Artery Disease (GWTG-CAD) program has 
merged into the ACTION registry.
AMI indicates acute myocardial infarction; ARB/ACEI, angiotensin receptor blocker/angiotensin-converting enzyme inhibitor; GWTG-ACS, Get With The Guidelines–
Acute Coronary Syndrome; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; and NM, not measured.
*Measures from 2006 to 2009 are from the American Heart Association’s GWTG-CAD registry. The 2010 to 2012 measures are from the American Heart Association’s 
ACTION registry. The 2013 data reported include data from the second quarter of 2012 to the first quarter of 2013.
†Represents statin use.
Table 23-4. Time Trends in GWTG-HF Quality-of-Care Measures, 2006 to 2013
Quality-of-Care Measure 2006 2007 2008 2009 2010 2011 2012 2013
LVEF assessment* 93.5 95.5 96.4 98.0 98.0 96.6 96.5 99.3
ARB/ACEI at discharge for patients with LVSD* 85.4 89.1 91.5 92.9 94.2 95.2 95.4 96.0
Postdischarge appointment (new for 2011)* … … … … … 16.3 47.4 62.2
Complete discharge instructions 91.0 94.9 97.2 97.7 99.3 93.8 93.4 94.5
Adult smoking cessation advice/counseling 90.8 94.7 97.1 97.6 99.3 99.2 97.3 96.0
Evidence-based specific β-blockers* 67.7 58.9 54.1 45.2 48.4 57.1 82.6 90.0
β-Blockers at discharge for patients with 
LVSD, no contraindications
90.0 90.4 92.6 92.5 94.8 96.0 97.2 97.9
Anticoagulation for AF or atrial flutter, no 
contraindications
62.3 61.2 60.5 68.8 70.2 75.9 78.7 80.6
Values are percentages.
In the GWTG registry, mechanical ventilation was required in 0.9% of patients. In-hospital mortality was 2.9%, and mean length of hospital stay was 5.0 days (median 
4.0 days).
AF indicates atrial fibrillation; ARB/ACEI, angiotensin receptor blocker/angiotensin-converting enzyme inhibitor; GWTG-HF, Get With The Guidelines–Heart Failure; 
LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.
*Indicates the 4 key achievement measures targeted in GWTG-HF. The composite quality-of-care measure for 2013 was 96.3%. The composite quality-of-care 
measure indicates performance on the provision of several elements of care. It is computed by summing the numerators for each key achievement measure across the 
population of interest to create a composite numerator (all the care that was given), summing the denominators for each measure to form a composite denominator (all 
the care that should have been given), and reporting the ratio (the percentage of all the needed care that was given). The composite performance measure includes β-
blocker at discharge instead of evidence-based specific β-blockers and complete discharge instructions instead of postdischarge appointment until the data collection 
for the new achievement measures stabilizes.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e300  Circulation  January 27, 2015
Table 23-5. Time Trends in GWTG-Stroke Quality-of-Care Measures, 2006 to 2013
Quality-of-Care Measure 2006 2007 2008 2009 2010 2011 2012 2013
IV tPA in patients who arrived ≤2 h after 
symptom onset, treated ≤3 h*
56.0 60.5 64.4 73.9 76.2 78.3 82.0 86.3
IV tPA in patients who arrived <3.5 h after 
symptom onset, treated ≤4.5 h
… … … … 42.5 57.9 60.4 65.4
IV tPA door-to-needle time ≤60 min 22.5 24.9 25.9 28.0 29.5 33.8 39.9 59.7
Thrombolytic complications: IV tPA 
and life-threatening, serious systemic 
hemorrhage
20.8 17.3 16.1 15.1 13.1 15.7 16.5 16.5
Antithrombotic agents <48 h after 
admission*
94.9 95.8 96.0 96.1 96.3 96.7 96.9 97.3
DVT prophylaxis by second hospital day* 85.4 88.9 92.2 92.7 92.2 93.5 98.4 98.4
Antithrombotic agents at discharge* 94.1 95.1 97.0 97.8 97.7 98.1 97.8 98.1
Anticoagulation for atrial fibrillation at 
discharge*
88.2 89.5 93.1 93.5 93.5 93.1 93.4 94.3
Therapy at discharge if LDL >100 mg/dL 
or LDL not measured or on therapy at time 
of admission*
61.6 67.5 73.4 88.1 89.0 89.8 94.5 96.1
Counseling for smoking cessation* 86.1 92.1 94.3 96.3 96.7 97.0 96.8 96.6
Lifestyle changes recommended for BMI 
>25 kg/m2
42.5 45.7 51.7 57.3 57.8 57.8 57.2 54.9
Composite quality-of-care measure 83.1 86.1 89.7 94.7 94.2 94.4 96.3 96.8
Values are percentages.
In-hospital mortality for the 2013 patient population was 6.6% percent, and mean length of hospital stay was 5.3 days (median 3.0 days).
BMI indicates body mass index; DVT, deep vein thrombosis; GWTG-Stroke, Get With the Guidelines–Stroke; IV, intravenous; LDL, low-density lipoprotein; and tPA, 
tissue-type plasminogen activator.
*Indicates the 7 key achievement measures targeted in GWTG-Stroke.
Table 23-6.  Additional ACTION-GWTG Quality-of-Care Metrics for ACS Care, 2013*
Quality Metrics Overall STEMI NSTEMI
ECG within 10 min of arrival 63.5 73.8 58.8
Aspirin within 24 h of arrival 95.4 96.6 94.6
Any anticoagulant use† 93.7 97.3 91.3
Dosing error
  UFH dose 49.3 46.2 49.4
  Enoxaparin dose 10.9 10.9 10.9
  Glycoprotein IIb/IIIa inhibitor dose 6.9 7.0 6.8
Aspirin at discharge 98.4 98.9 98.0
Prescribed statins on discharge 98.8 99.1 98.5
Adult smoking cessation advice/counseling 98.4 98.6 98.2
Cardiac rehabilitation referral 77.2 82.3 73.7
In-hospital mortality‡ (95% CI) 4.6 (4.5–4.7) 6.2 (6.0–6.4) 3.5 (3.4–3.6)
Values are percentages.
ACS indicates acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention Outcomes 
Network Registry–Get With The Guidelines; CI, confidence interval; NSTEMI, non–ST-segment–elevation myocardial 
infarction; STEMI, ST-segment–elevation myocardial infarction; and UFH, unfractionated heparin.
*2012 data reported include data from second quarter of 2012 to first quarter of 2013.
†Includes UFH, low-molecular-weight heparin, or direct thrombin inhibitor use.
‡Excludes transfer-out patients.
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Table 23-7. National Committee for Quality Assurance Health Plan Employer Data and Information Set Measures of Care, 2012
Commercial Medicare
HMO PPO HMO PPO Medicaid (HMO)
AMI
  β-Blocker persistence* 83.9 79.5 88.9 88.5 82
Cholesterol management for patients with CVD
  Cholesterol screening 88.3 83.7 89.3 87.6 81.5
  LDL cholesterol control (<100 mg/dL) 59.9 49.7 56.6 53.2 41.3
Hypertension
  BP <140/90 mm Hg  63 57.4 63.6 58.6 56.3
DM
  HbA
1c testing 90.1 87.2 91.4 91.0 83
  HbA
1c >9.0% 28.5 35.2 27.1 29.3 44.7
  Eye examination performed 56.8 48.8 66.8 64.6 53.2
  LDL cholesterol screening 85.4 81.7 88.0 86.6 75.5
  LDL cholesterol <100 mg/dL 48.4 41.7 51.5 49.6 33.9
  Monitoring nephropathy 84.3 78.6 90.0 88.3 78.4
  BP <140/90 mm Hg 66.5 58.3 63.3 61.2 58.9
Advising smokers and tobacco users to quit 77.8 70.8 81.2 80.4 75.6
BMI percentile assessment in children and adolescents 51.6 31.2 N/A N/A 51.8
Nutrition counseling (children and adolescents) 54.3 35.4 N/A N/A 55
Counseling for physical activity (children and adolescents) 50.4 32.6 N/A N/A 44.2
BMI assessment for adults 66.1 35.2 80.8 75.3 67.5
Physical activity discussion in older adults (≥65 y of age) N/A 54.5 55.5 N/A
Physical activity advice in older adults (≥65 y of age) N/A 50.1 48.9 N/A
Values are percentages.
AMI indicates acute myocardial infarction; BMI, body mass index; BP, blood pressure; CVD, cardiovascular disease; DM, diabetes mellitus; HbA
1c, hemoglobin A1c; 
HMO, health maintenance organization; LDL, low-density lipoprotein; N/A, not available or not applicable; and PPO, preferred provider organization.
*β-Blocker persistence: Received persistent β-blocker treatment for 6 months after AMI hospital discharge.
Table 23-8. Quality of Care for Patients With Out-of-Hospital Cardiac Arrest at US ROC Sites
Overall Adults Children
Bystander and EMS care*
  Bystander CPR, % 45.9 (44.7–47.0) 45.3 (44.1–46.5) 63.5 (56.8–70.2)
  Shocked by AED before EMS, % 2.2 (1.9–2.6) 2.2 (1.9–2.6) 2.0 (0.1–3.9)
  Chest compression fraction during first 5 min of CPR (%), mean (SD) 0.84 (0.13) 0.84 (0.13) 0.83 (0.13)
  Compression depth (mm), mean (SD) 45.9 (11.7) 45.9 (11.7) 44.9 (11.8)
  Preshock pause duration (sec), mean (SD) 11.3 (10.5) 11.3 (10.5) 11.7 (9.2)
  Time to first EMS defibrillator applied (min), mean (SD) 8.8 (4.4) 8.8 (4.3) 9.0 (5.9)
Hospital care†
  Hypothermia induced after initial VT/VF, %‡ 67.9 (63.5–72.4) 68.1 (63.6–72.5) N/A (N/A)
  No order for withdrawal/DNR during first 72 h, %§ 43.1 (40.0–46.1) 43.0 (39.9–46.0) 66.7 (13.3–100)
  Implantable cardioverter-defibrillator assessment, initial VT/VF, 
no AMI per MD notes or final ECG interpretation, %║
22.9 (17.3–28.5) 23.0 (17.4–28.7) N/A (N/A)
Values are mean (95% confidence interval) or mean (SD). 
Because age is missing for some cases, these cases are not included in either adults or children, thus explaining why overall rates equal the adult rates when rates 
for children are not available.
AED indicates automated external defibrillator; AMI, acute myocardial infarction; CPR, cardiopulmonary resuscitation; DNR, do not resuscitate; EMS, emergency 
medical services; MD, medical doctor; N/A, not available; ROC, Resuscitation Outcomes Consortium; and VT/VF, ventricular tachycardia/ventricular fibrillation. 
*Data are from EMS-treated cases.
†During 2013, there were 0 pediatric cases with initial rhythm VT/VF that were admitted to the hospital.
‡Denominator is all cases with initial rhythm VT/VF and admitted to the hospital.
§Denominator is all cases admitted to the hospital.
║Denominator is all cases with initial rhythm VT/VF, no indication of AMI, no percutaneous coronary intervention, no bypass, and admitted to the hospital.
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Table 23-9. Quality of Care of Patients With In-Hospital Cardiac Arrest Among GWTG-
Resuscitation Hospitals, 2013
Adults Children
Monitored before arrest 85.7 (85.2–86.2) 86.9 (84.9–88.9)
ETco2 used during arrest 5.3 (5.0–5.6) 12.4 (10.4–14.4)
Induced hypothermia after resuscitation from shockable rhythm 7.5 (6.5–8.5) 9.8 (0.7–18.8)
Values are mean percentages (95% confidence interval).
ETco2 indicates end-tidal CO2; and GWTG, Get With the Guidelines.
Source: GWTG-Resuscitation Investigators, September 4, 2014.
Table 23-10. Timely Reperfusion for ACS and Stroke, 2013
Quality-of-Care Measure
VHA (for STEMI) or 
GWTG-Stroke (for Stroke)
National Data From 
HIQR Program*
ACTION-GWTG 
STEMI†
STEMI
  tPA within 30 min 33‡ 58.2 45.3‡
  PCI within 90 min 67 95.6 78.9
Stroke
  IV tPA in patients who arrived <2 h after symptom onset, treated ≤3 h 82.0 N/A N/A
  IV tPA in patients who arrived <3.5 h after symptom onset, treated ≤4.5 h 60.4 N/A N/A
  IV tPA door-to-needle time ≤60 min 39.9 N/A N/A
Values are percentages.
ACS indicates acute coronary syndrome; ACTION-GWTG, Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With 
The Guidelines; GWTG-Stroke, Get With The Guidelines–Stroke; HIQR, Hospital Inpatient Quality Reporting; IV, intravenous; N/A, not applicable; 
PCI, percutaneous coronary intervention; STEMI, ST-segment–elevation myocardial infarction; tPA, tissue-type plasminogen activator; and VHA, 
Veterans Health Administration.
*HIQR Program includes data from all payers, including Medicare and Medicaid. Data reported include data from third quarter of 2011 to second 
quarter of 2012.
†ACTION Registry: Data reported include data from second quarter of 2012 to first quarter of 2013.
‡Indicates low number.
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Table 23-12. Quality-of-Care by Race/Ethnicity and Sex in the GWTG-HF Program, 2013
Quality-of-Care Measure White Black Hispanic Men Women
Postdischarge appointment (new for 2011)* 62.6 64.8 62.7 63.8 62.5
Complete set of discharge instructions† 94.3 95.2 95.2 94.8 94.1
Measure of LV function* 99.4 99.3 99.3 99.4 99.2
ACEI or ARB at discharge for patients with LVSD, no contraindications* 95.6 96.6 96.1 96.0 96.0
Smoking cessation counseling, current smokers† 96.3 95.7 96.0 96.1 95.6
Evidence-based specific β-blockers* 89.2 92.0 89.2 90.6 89.3
β-Blockers at discharge for patients with LVSD, no contraindications† 97.8 98.2 98.3 98.0 97.9
Hydralazine/nitrates at discharge for patients with LVSD, no contraindications‡ … 19.9 … 21.4 17.5
Anticoagulation for AF or atrial flutter, no contraindications 81.3 79.0 76.3 81.7 79.3
Composite quality-of-care measure (using discharge instructions and β-blocker at discharge) 96.8 97.0 97.1 96.8 96.6
Values are percentages.
ACEI indicates angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; AF, atrial fibrillation; GWTG-HF, Get With the Guidelines−Heart 
Failure; LV, left ventricular; and LVSD, left ventricular systolic dysfunction. 
*Indicates the 4 key achievement measures targeted in GWTG-HF.
†Indicates historical key achievement measures in GWTG-HF.
‡For black patients only.
Table 23-11. Quality of Care by Race/Ethnicity and Sex in the ACTION Registry, 2012
Quality-of-Care Measure White Black Other Men Women
Aspirin at admission 97.9 97.8 97.6 98.1 97.3
Aspirin at discharge 98.5 97.8 98.5 98.7 98.0
β-Blockers at discharge 97.2 96.8 97.6 97.4 96.5
Time to PCI ≤90 min for STEMI patients 95.5 94.1 93.9 95.7 94.1
ARB/ACEI at discharge for patients with LVEF <40% 89.6 90.4 89.1 89.9 89.3
Statins at discharge 98.8 98.5 98.9 99.0 98.3
Values are percentages.
Data reported include data from second quarter of 2012 to first quarter of 2013.
ACTION indicates Acute Coronary Treatment and Intervention Outcomes Network; ARB/ACEI angiotensin receptor 
blocker/angiotensin-converting enzyme inhibitor; LVEF, left ventricular ejection fraction; PCI, percutaneous coronary 
intervention; and STEMI, ST-segment–elevation myocardial infarction.
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Table 23-13. Quality-of-Care by Race/Ethnicity and Sex in the GWTG-Stroke Program, 2013
Quality-of-Care Measure White Black Hispanic Male Female
IV tPA in patients who arrived ≤2 h after symptom onset, treated ≤3 h* 86.2 85.4 88.1 87.1 85.6
IV tPA in patients who arrived <3.5 h after symptom onset, treated ≤4.5 h 64.7 65.6 69.9 66.6 64.1
IV tPA door-to-needle time ≤60 min 59.1 59.5 62.7 60.8 58.6
Thrombolytic complications: IV tPA and life-threatening, serious systemic hemorrhage 16.3 20.0 8.3 14.7 18.1
Antithrombotic agents <48 h after admission* 97.4 97.1 97.3 97.5 97.1
DVT prophylaxis by second hospital day* 98.4 98.2 98.2 98.3 98.4
Antithrombotic agents at discharge* 98.3 97.8 97.7 98.3 97.9
Anticoagulation for atrial fibrillation at discharge* 94.3 94.3 94.8 94.6 94.0
Therapy at discharge if LDL >100 mg/dL or LDL not measured or on therapy at admission* 96.0 96.4 96.0 96.7 95.5
Counseling for smoking cessation* 96.8 96.5 95.9 96.8 96.4
Lifestyle changes recommended for BMI >25 kg/m2 55.5 52.6 57.5 55.2 54.6
Composite quality-of-care measure 96.9 96.8 96.7 97.1 96.6
Values are percentages.
BMI indicates body mass index; DVT, deep vein thrombosis; GWTG-Stroke, Get With The Guidelines–Stroke; IV, intravenous; LDL, low-density lipoprotein; and tPA, 
tissue-type plasminogen activator.
*Indicates the 7 key achievement measures targeted in GWTG-Stroke.
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24 . Medical Procedures
See Tables 24-1 and 24-2 and Charts 24-1 through 24-4.
Trends in Operations and Procedures
(See Tables 24-1 and 24-2 and Charts 24-1 and 24-2.)
 ● The total number of inpatient cardiovascular operations 
and procedures increased 28%, from 5 939 000 in 2000 to 
7 588 000 in 2010 (NHLBI computation based on NCHS 
annual data). Data from the NHDS were examined for trends 
from 1990 to 2004 for use of PCI and CABG and in-hospital 
mortality rate attributable to PCI and CABG by sex1:
—Discharge rates (per 10 000 population) for PCI increased 
58%, from 37.2 in 1990 to 1992 to 59.2 in 2002 to 2004.
—Discharge rates for CABG increased from 34.1 in 1990 
to 1992 to 38.6 in 1996 to 1998, then declined to 25.2 
in 2002 to 2004.
—In 1990 to 1992, discharge rates for CABG were 53.5 
for males and 18.1 for females; these rates increased 
through 1996 to 1998, then declined to 38.8 and 13.6, 
respectively, in 2002 to 2004. The magnitude of these 
declines decreased by age decile and were essentially 
flat for both men and women ≥75 years of age.
—PCI discharge rates increased from 54.5 for males and 
23.0 for females to 83.0 and 38.7, respectively, over the 
15-year time interval. In 2002 to 2004, discharge rates 
for men and women 65 to 74 years of age were 135.1 
and 64.0, respectively. For those ≥75 years of age, the 
rates were 128.7 and 69.0, respectively.
—In-hospital mortality rate (deaths per 100 CABG dis-
charges) declined from 4.3 to 3.5 between 1990 to 
1992 and 2002 to 2004 despite an increase in Charlson 
comorbidity index. The mortality rate declined in all age 
and sex subsets, but especially in women.
 ● Data from the Acute Care Tracker database were used to 
estimate the population-based rates per 100 000 population 
for PCI and CABG procedures from 2002 to 2005, stan-
dardized to the 2005 US population2:
—Adjusted for age and sex, the overall rate for coronary 
revascularization declined from 382 to 358 per 100 000. 
PCI rates during hospitalization increased from 264 to 267 
per 100 000, whereas CABG rates declined from 121 to 94.
 ● Data from men and women enrolled in Medicare from 1992 
to 2001 suggest that efforts to eliminate racial disparities 
in the use of high-cost cardiovascular procedures (PCI, 
CABG, and carotid endarterectomy) were unsuccessful.3
—In 1992, among women, the age-standardized rates of 
carotid endarterectomy were 1.59 per 1000 enrollees 
for whites and 0.64 per 1000 enrollees for blacks. By 
2002, the rates were 2.42 per 1000 enrollees among 
white women and 1.15 per 1000 enrollees among black 
women. For men, the difference in rates between whites 
and blacks remained the same. In 1992, the rates were 
3.13 per 1000 enrollees among white men and 0.82 per 
1000 enrollees among black men; in 2001, the rates 
were 4.42 and 1.44, respectively.
Cardiac Catheterization and PCI
(See Tables 24-1 and 24-2.)
 ● From 2000 to 2010, the number of cardiac catheterizations 
decreased slightly, from 1 221 000 to 1 029 000 annually 
(NHDS, NHLBI tabulation).
 ● In 2010, an estimated 492 000 patients underwent PCI (pre-
viously referred to as percutaneous transluminal coronary 
angioplasty, or PTCA) procedures in the United States 
(NHDS, NHLBI tabulation).
 ● In 2010, ≈67% of PCI procedures were performed on men, 
and ≈51% were performed on people ≥65 years of age 
(NHDS, NHLBI tabulation).
 ● In-hospital death rates for PCI have remained stable, 
although comorbidities increased for patients who received 
the procedure.1
 ● In 2010, ≈75% of stents implanted during PCI were DES 
compared with 25% that were bare-metal stents (NHDS, 
NHLBI computation).
 ● In a study of nontransferred patients with STEMI treated 
with primary PCI from July 2006 to March 2008, there 
was significant improvement over time in the percentage of 
patients receiving PCI within 90 minutes, from 54.1% from 
July to September 2006 to 74.1% from January to March 
2008, among hospitals participating in the GWTG-CAD 
program. This improvement was seen whether or not hospi-
tals joined the Door-to-Balloon Alliance during that period.4
 ● The rate of any cardiac stent procedure rose by 61% from 
1999 to 2006, then declined by 27% between 2006 and 
2009.5
Cardiac Open Heart Surgery
 ● The NHDS (NCHS) estimates that in 2010, in the United 
States, 219 000 patients underwent a total of 397 000 
coronary artery bypass procedures (defined by procedure 
Abbreviations Used in Chapter 24
CABG coronary artery bypass graft
CHF congestive heart failure
DES drug-eluting stent
GWTG-CAD Get With the Guidelines–Coronary Artery Disease
HCUP Healthcare Cost and Utilization Project
HD heart disease
HLHS hypoplastic left heart syndrome
ICD-9-CM International Classification of Diseases, 9th Revision, Clinical 
Modification
NCHS National Center for Health Statistics
NHDS National Hospital Discharge Survey
NHLBI National Heart, Lung, and Blood Institute
PCI percutaneous coronary intervention
PTCA percutaneous transluminal coronary angioplasty
STEMI ST-segment–elevation myocardial infarction
STS Society of Thoracic Surgeons
TOF tetralogy of Fallot
VSD ventricular septal defect
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codes). CABG volumes have declined nationally since 
1998. Risk-adjusted mortality for CABG has declined sig-
nificantly over the past decade.
 ● Data from the STS Adult Cardiac Surgery Database, which 
voluntarily collects data from ≈80% of all hospitals that 
perform CABG in the United States, indicate that a total of 
158 008 procedures involved CABG in 2010.6
Congenital Heart Surgery, 1998 to 2002 (From STS)
 ● There were 103 664 procedures performed from July 2006 
to June 2010. The in-hospital mortality rate was 3.2% in 
2010. The 5 most common diagnoses were the following: 
patent ductus arteriosus (7.4%); HLHS (6.9%); VSD, type 
2 (6.3%); cardiac, other (5.3%); and TOF (4.9%).7
 ● There were 16 920 procedures performed from 1998 to 
2002 at 18 centers. In 2002, there were 4208 procedures 
performed. The in-hospital mortality rate ranged from 
5.7% in 1998 to 4.3% in 2002. Of these procedures, ≈46% 
were performed in children >1 year old, ≈32% in infants 
between 29 days and 1 year of age, and ≈22% in neonates 
(<29 days old). The conditions for which these procedures 
were most commonly performed were the following: patent 
ductus arteriosus (6.5%), VSD (6.4%), and TOF (6.0%).7
Heart Transplantations (Organ Procurement and 
Transplantation Network, August 15, 2014)
(See Charts 24-3 and 24-4.)
 ● In 2013, 2531 heart transplantations were performed in the 
United States (Chart 24-3). There are 249 transplant hos-
pitals in the United States, 129 of which performed heart 
transplantations (based on Organ Procurement and Trans-
plantation Network data as of August 1, 2014).
 ● Of the recipients in 2013, 69.6% were male, and 64.4% 
were white; 22.0% were black, whereas 8.6% were His-
panic. Heart transplantations by recipient age are shown in 
Chart 24-4.
 ● For transplants that occurred between 2009 and 2010, 
the 1-year survival rate was 90.8% for males and 90.6% 
for females; the 5-year rates between 2005 and 2010 
were 77.5% for males and 75.6% for females. The 1- and 
5-year survival rates for white cardiac transplant patients 
were 91.2% and 79.1%, respectively. For black patients, 
they were 88.3% and 68.6%, respectively. For Hispanic 
patients, they were 91.9% and 76.3%, respectively. For 
Asian patients, they were 89.9% and 81.2%, respectively.
 ● As of August 6, 2014, 4002 patients were on the transplant 
waiting list for a heart transplant, and 51 patients were on 
the list for a heart/lung transplant.
Cardiovascular Healthcare Expenditures
 ● An analysis of claims and enrollment data from the Contin-
uous Medicare History Sample and from physician claims 
from 1995 to 2004 was used to evaluate the conditions 
that contributed to the most expensive 5% of Medicare 
beneficiaries.7
 ● Ischemic HD, CHF, and cerebrovascular disease, respec-
tively, constituted 13.8%, 5.9%, and 5.7% of the conditions 
of all beneficiaries in 2004. In patients in the top 5% over-
all for all expenditures, the respective figures were 39.1%, 
32.7%, and 22.3% for these cardiovascular conditions.
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Table 24-1. 2012 National HCUP Statistics: Mean Hospital Charges, In-Hospital Death Rates, and Mean Length of Stay for Various 
Cardiovascular Procedures
Procedure
Mean Hospital 
Charges, $
In-Hospital  
Death Rate, %
Mean Length of 
Stay, d ICD-9-CM Procedure Codes
Total vascular and cardiac surgery and procedures 78 897 2.93 6.1 35–39, 00.50–00.51,  
00.53–00.55, 00.61–00.66
Cardiac revascularization (bypass) 149 480 1.44 9.2 36.1–36.3
PCI 70 027 1.31 3.2 00.66
Cardiac catheterization 47 862 1.04 3.9 37.21–37.23
Pacemakers 74 515 1.24 5.1 37.7–37.8, 00.50, 00.53
Implantable defibrillators 152 384 0.43 5.4 37.94–37.99, 00.51, 00.54
Endarterectomy 38 847 0.32 2.6 38.12
Valves 190 194 3.40 11.0 35.1–35.2, 35.99
Heart transplantations 676 328 6.54 39.8 37.51
HCUP indicates Healthcare Cost and Utilization Project; ICD-9-CM, International Classification of Diseases, Clinical Modification, 9th Revision; and PCI, percutaneous 
coronary intervention.
Data derived from the Agency for Healthcare Research and Quality, HCUP Nationwide Inpatient Sample, 2012.
Table 24-2. Estimated* Inpatient Cardiovascular Operations, Procedures, and Patient Data by Sex and Age: United States, 2010 (in 
Thousands)
Sex Age, y
Operation/Procedure/ 
Patients
ICD-9-CM Procedure  
Codes All Male Female <15 15–44 45–64 ≥65
Valves 35.1, 35.2, 35.99 106 64 42 4† 5† 32 65
Angioplasty 36.0, 0.66 955 642 313 … 44 421 489
PCI (patients) 36.06, 36.07, 0.66 492 330 162 … 23 216 253
PCI 0.66 500 334 166 … 23 220 257
PCI with stents 36.06, 36.07 454 308 146 … 21 201 233
Cardiac revascularization‡ 36.1–36.3 397 298 99 … 9† 157 231
Cardiac revascularization 
(patients)
36.1–36.3 219 164 55 … 5† 86 128
Cardiac catheterization 37.21–37.23 1029 638 391 7† 64 456 502
Pacemakers 37.7, 37.8, 00.50, 00.53 370 196 174 3† 6† 57 305
  Pacemaker devices 37.8, 00.53 159 81 78 1† 3† 20 135
  Pacemaker leads 37.7, 00.50 212 115 96 1† 3† 36 171
Implantable defibrillators 37.94–37.99, 00.51, 00.54 97 71 26 … 8† 31 58
Endarterectomy 38.12 100 55 45 … … 29 71
Total vascular and cardiac 
surgery and procedures§║
35–39, 00.50–00.51, 
00.53– 00.55, 00.61–00.66
7588 4397 3191 310 681 2706 3891
These data do not reflect any procedures performed on an outpatient basis. Many more procedures are being performed on an outpatient basis. Some of the lower 
numbers in this table compared with 2006 probably reflect this trend. Data include procedures performed on newborn infants.
Ellipses (…) indicate data not available; ICD-9-CM, International Classification of Diseases, Clinical Modification, 9th Revision; and PCI, percutaneous coronary 
intervention.
*Breakdowns are not available for some procedures, so entries for some categories do not add to totals. These data include codes for which the estimated number 
of procedures is <5000. Categories with such small numbers are considered unreliable by the National Center for Health Statistics and in some cases may have been 
omitted.
†Estimate should be used with caution because it may be unreliable or does not meet standards of reliability or precision.
‡Because ≥1 procedure codes are required to describe the specific bypass procedure performed, it is impossible from these (mixed) data to determine the average 
number of grafts per patient.
§Totals include procedures not shown here.
║This estimate includes angioplasty and stent insertions for noncoronary arteries.
Data derived from the National Hospital Discharge Survey/National Center for Health Statistics, 2010. Estimates are based on a sample of inpatient records from 
short-stay hospitals in the United States.
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Chart 24-1. Trends in cardiovascular procedures, United States: 1979 to 2010. PCI indicates percutaneous coronary intervention. Note: 
Inpatient procedures only. Source: National Hospital Discharge Survey, National Center for Health Statistics, and National Heart, Lung, 
and Blood Institute.
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Chart 24-3. Trends in heart transplantations, 1975 to 2013. Source: Organ Procurement and Transplantation Network data as of August 
1, 2014.
22 57
719
2,107
2,363
2,199
2,125
2,332
2,531
0
500
1000
1500
2000
2500
3000
1975 1980 1985 1990 1995 2000 2005 2010 2013
N
um
be
r o
f T
ra
ns
pl
an
ts
Year
Chart 24-4. Heart transplantations in the United States by recipient age, 2013. Source: Organ Procurement and Transplantation Network 
data as of August 1, 2014.
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25 . Economic Cost of Cardiovascular Disease
See Tables 25-1 and 25-2 and Charts 25-1 through 25-5.
The annual direct and indirect cost of CVD and stroke in the 
United States is an estimated $320.1 billion (Table 25-1; Chart 
25-1). This figure includes $195.6 billion in expenditures 
(direct costs, which include the cost of physicians and other 
professionals, hospital services, prescribed medication, and 
home health care, but not the cost of nursing home care) and 
$124.5 billion in lost future productivity attributed to prema-
ture CVD and stroke mortality in 2011 (indirect costs).
The direct costs for CVD and stroke are the healthcare expen-
ditures for 2011 available on the Web site of the nationally rep-
resentative MEPS of the AHRQ.1 Details on the advantages or 
disadvantages of using MEPS data are provided in the “Heart 
Disease and Stroke Statistics–2011 Update.”2 Indirect mortality 
costs are estimated for 2011 by multiplying the number of deaths 
that year attributable to CVD and strokes, in age and sex groups, 
by estimates of the present value of lifetime earnings for those age 
and sex groups as of 2011. Mortality data are from the National 
Vital Statistics System of the NCHS.3 The present values of life-
time earnings are unpublished estimates furnished by the Institute 
for Health and Aging, University of California, San Francisco, by 
Wendy Max, PhD, on April 25, 2012. Those estimates have a 3% 
discount rate, the recommended percentage.4 The discount rate 
removes the effect of inflation in income over the lifetime of earn-
ings. The estimates are for 2009, inflated to 2011 by 3% to account 
for the 2009 to 2011 change in hourly worker compensation in the 
business sector reported by the US Bureau of Labor Statistics.5
The indirect costs exclude lost productivity costs attrib-
utable to CVD and stroke illness during 2011 among work-
ers, people keeping house, people in institutions, and people 
unable to work. Those morbidity costs were substantial in 
very old studies, but an adequate update could not be made.
Most Costly Diseases
(See Table 25-2 and Chart 25-2.)
 ● CVD and stroke accounted for 15% of total health expendi-
tures in 2011, more than any major diagnostic group.1,6 That 
is also the case for indirect mortality costs. By way of com-
parison, CVD total direct and indirect costs shown in Table 
25-1 are higher than the official National Cancer Institute 
estimates for cancer and benign neoplasms in 2009, which 
were cited as $216.6 billion total ($86.6 billion in direct 
costs and $130 billion in indirect mortality costs).7
 ● Table 25-2 shows direct and indirect costs for CVD by sex 
and by 2 broad age groups. Chart 25-2 shows total direct 
costs for the 23 leading chronic diseases in the MEPS list. 
HD is the most costly condition.6
Projections
(See Charts 25-3 through 25-5.)
The AHA developed methodology to project future costs of 
care for HBP, CHD, HF, stroke, and all other CVD.8
 ● By 2030, 43.9% of the US population is projected to have 
some form of CVD.
 ● Between 2012 and 2030, total direct medical costs of CVD 
are projected to increase from $396 billion to $918 billion 
(2012 $ in billions). Of this total, 60.5% is attributable to 
hospital costs, 15.6% to medications, 10.8% to physicians, 
6.8 % to nursing home care, 5.3% to home health care, and 
1.1% to other costs.
 ● Indirect costs (attributable to lost productivity) for all 
CVDs are estimated to increase from $183 billion in 
2012 to $290 billion in 2030 (2012 $ in billions), an 
increase of 58%.
These data indicate that CVD prevalence and costs are pro-
jected to increase substantially.
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AHRQ Agency for Healthcare Research and Quality
CHD coronary heart disease
CHF congestive heart failure
COPD chronic obstructive pulmonary disease
CVD cardiovascular disease
GI gastrointestinal (tract)
HBP high blood pressure
HD heart disease
HF heart failure
MEPS Medical Expenditure Panel Survey
NCHS National Center for Health Statistics
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Table 25-1. Estimated Direct and Indirect Costs (in Billions of Dollars) of CVD and Stroke: 
United States, 2011
Heart 
Disease* Stroke
Hypertensive 
Disease†
Other 
Circulatory 
Conditions Total CVD
Direct costs‡
  Hospital inpatient stays 70.5 7.6 4.9 8.7 91.7
  Hospital emergency department visits 4.8 1.2 1.5 0.6 8.1
  Hospital outpatient or office-based provider visits 23.1 2.0 13.5 5.9 44.5
  Home health care 6.6 5.1 3.9 2.3 17.9
  Prescribed medicines 11.3 1.7 19.0 1.5 33.5
  Total expenditures 116.3 17.5 42.8 19.0 195.6
Indirect costs§
  Lost productivity/mortality║ 99.3 16.0 3.6 5.6 124.5
Grand totals 215.6 33.6 46.4 24.6 320.1
Numbers do not add to total because of rounding.
CVD indicates cardiovascular disease.
*This category includes coronary heart disease, heart failure, part of hypertensive disease, cardiac dysrhythmias, 
rheumatic heart disease, cardiomyopathy, pulmonary heart disease, and other or ill-defined heart diseases.
†Costs attributable to hypertensive disease are limited to hypertension without heart disease.
‡Medical Expenditure Panel Survey healthcare expenditures are estimates of direct payments for care of a patient with 
the given disease provided during the year, including out-of-pocket payments and payments by private insurance, Medicaid, 
Medicare, and other sources. Payments for over-the-counter drugs are not included. These estimates of direct costs do 
not include payments attributed to comorbidities. Total CVD costs are the sum of costs for the 4 diseases but with some 
duplication. 
§The American Heart Association Statistics Committee agreed to suspend the presentation of estimates of lost productivity 
attributable to morbidity until a better estimating method can be developed.
║Lost future earnings of people who died in 2011, discounted at 3%.
Sources: Estimates from the Household Component of the Medical Expenditure Panel Survey of the Agency for Healthcare 
Research and Quality for direct costs (2011).1 Indirect mortality costs are based on 2011 counts of deaths by the National 
Center for Health Statistics and an estimated present value of lifetime earnings furnished for 2009 by Wendy Max (Institute 
for Health and Aging, University of California, San Francisco, April 25, 2012) and inflated to 2011 from change in worker 
compensation reported by the US Bureau of Labor Statistics.
All estimates prepared by Michael Mussolino, National Heart, Lung, and Blood Institute.
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Table 25-2. Costs of Total CVD in Billions of Dollars by Age 
and Sex: United States, 2011
Total Male Female Age <65 y Age >65 y
Direct 195.6 99.0 96.6 96.2 99.4
Indirect mortality 124.5 91.4 33.1 107.1 17.4
Total 320.1 190.4 129.7 203.3 116.8
Numbers may not add to total because of rounding.
CVD indicates cardiovascular diseases and stroke.
Source: Medical Expenditure Panel Survey, 2011 (direct costs) and mortality 
data from the National Center for Health Statistics and present value of lifetime 
earnings from the Institute for Health and Aging, University of California, San 
Francisco (indirect costs).
All estimates prepared by Michael Mussolino, National Heart, Lung, and Blood 
Institute.
Chart 25-1. Direct and indirect costs of cardiovascular disease (CVD) and stroke (in billions of dollars), United States, 2011. Source: 
 Prepared by the National Heart, Lung, and Blood Institute.1–4
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Chart 25-3. Projected total costs of cardiovascular disease (CVD), 2015 to 2030 (2012 $ in billions) in the United States. CHD indicates 
coronary heart disease; CHF, congestive heart failure; and HBP, high blood pressure. Unpublished data tabulated by the American Heart 
Association using methods described in Heidenreich et al.8
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Chart 25-2. The 23 leading diagnoses for direct health expenditures, United States, 2011 (in billions of dollars). COPD indicates chronic 
obstructive pulmonary disease; and GI, gastrointestinal (tract). Source: National Heart, Lung, and Blood Institute; estimates are from the 
Medical Expenditure Panel Survey, Agency for Healthcare Research and Quality, and exclude nursing home costs. 
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Chart 25-4. Projected total (direct and indirect) costs of total cardiovascular disease by age (2012 $ in billions). Unpublished data tabu-
lated by the American Heart Association using methods described in Heidenreich et al.8
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Chart 25-5. Projected direct costs of total cardiovascular disease by type of cost (2010 $ in billions). Unpublished data tabulated by the 
American Heart Association using methods described in Heidenreich et al.8
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26 . At-a-Glance Summary Tables
See Tables 26-1 through 26-4.
Sources: See the following summary tables and charts for 
complete details:
 ● Smoking—Table 3-1
 ● Physical activity —Table 4-1
 ● Overweight/obesity—Table 6-1; Chart 6-1
 ● Blood cholesterol—Table 8-1
 ● High blood pressure—Table 9-1
 ● Diabetes mellitus—Table 10-1
 ● Total cardiovascular diseases—Table 13-1
 ● Stroke—Table 14-1
 ● Congenital heart defects—Table 15-1
 ● Coronary heart disease—Table 19-1
 ● Heart failure—Table 20-1
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Table 26-1. Males and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Males White Males Black Males Hispanic Males
Smoking
 Prevalence, 2013* 43.4 M (17.9%) 24.1 M (20.4%) 21.7% 21.1% 16.6%
PA†
 Prevalence, 2013, %* 20.9 24.9 22.7‡ 17.7‡ 16.6‡
Overweight and obesity
  Prevalence, 2012
   Overweight and obesity, BMI 
>25.0 kg/m2§
159.2 M (68.5%) 81.5 M (72.5%) 72.7% 69.4% 80.1%
   Obesity, BMI >30.0 kg/m2§ 81.8 M (35.2%) 38.6 M (34.4%) 34.2% 37.9% 38.4%
Blood cholesterol
  Prevalence, 2012
   Total cholesterol >200 mg/dL§ 100.1 M (42.8%) 45.3 M (40.4%) 39.9% 37.4% 46.2%
   Total cholesterol >240 mg/dL§ 30.9 M (13.1%) 13.0 M (11.6%) 11.5% 8.8% 14.8%
   LDL cholesterol >130 mg/dL§ 73.5 M (31.7%) 34.9 M (31.0%) 29.4% 30.7% 38.8%
   HDL cholesterol <40 mg/dL§ 44.6 M (19.9%) 32.4 M (28.9%) 28.7% 20.0% 33.8%
HBP
  Prevalence, 2012§ 80.0 M (32.6%) 38.3 M (33.5%) 32.9% 44.9% 29.6%
  Mortality, 2011║ 65 123 29 363 21 830 6610 ║
DM
  Prevalence, 2012
   Physician-diagnosed DM§ 21.1 M (8.5%) 10.5 M (9.0%) 7.6% 13.8% 12.5%
   Undiagnosed DM§ 8.1 M (3.3%) 5.1 M (4.4%) 4.0% 4.8% 6.8%
   Prediabetes§ 80.8 M (35.3%) 46.4 M (42.4%) 43.0% 36.3% 43.0%
   Incidence, diagnosed DM§ 1.7 M N/A N/A N/A N/A
  Mortality, 2011║ 73 831 38 324 30 783 6048 ║
Total CVD
  Prevalence, 2012§ 85.6 M (35.0%) 41.8 M (36.4%) 36.1% 46.0% 32.4%
  Mortality, 2011║# 786 641 388 606 331 751 46 081 ║
Stroke
  Prevalence, 2012§ 6.6 M (2.6%) 3.0 M (2.6%) 2.2% 4.2% 2.8%
  New and recurrent strokes║ 795.0 K 370.0 K 325.0 K 45.0 K N/A
  Mortality, 2011║ 128 932 52 335 43 264 7039 ║
CHD
  Prevalence, CHD, 2012§ 15.5 M (6.2%) 8.9 M (7.6%) 7.8% 7.2% 6.7%
  Prevalence, MI, 2012§ 7.6 M (2.8%) 4.9 M (4.0%) 4.1% 3.4% 3.5%
  Prevalence, AP, 2012§ 8.2 M (3.3%) 4.0 M (3.4%) 3.4% 3.3% 3.2%
  New and recurrent CHD**†† 935.0 K 545.0 K 475.0 K 70.0 K N/A
  New and recurrent MI†† 735.0 K 430.0 K N/A N/A N/A
  Incidence, AP (stable angina), 2010‡‡ 565.0 K 370.0 K N/A N/A N/A
  Mortality, 2011, CHD║ 375 295 206 908 180 658 20 693 ║
  Mortality, 2011, MI║ 119 905 66 765 58 447 6551 ║
HF
  Prevalence, 2012§ 5.7 M (2.2%) 2.7 M (2.3%) 2.2% 2.8% 2.1%
  Incidence, 2010§§ 870.0 K 415.0 K 365.0 K 50.0 K N/A
  Mortality, 2011║ 58 309 24 609 21 802 2371 ¶
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, AP chest pain, or both); CVD, cardiovascular 
disease; DM, diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, millions; MI, 
myocardial infarction (heart attack); N/A, data not available; and PA, physical activity.
*Age ≥18 years (National Health Interview Survey, 2013).
†Met 2008 full federal PA guidelines for adults.
‡Both sexes (National Health Interview Survey).
§Age ≥20 years.
║All ages.
¶Mortality data for the white and black populations include deaths of people of Hispanic and non-Hispanic origin.
#Total CVD mortality includes deaths of congenital heart disease.
**New and recurrent MI and fatal CHD.
††Age ≥35 years.
‡‡Age ≥45 years.
§§Age ≥55 years.
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Table 26-2. Females and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Females White Females Black Females Hispanic Females
Smoking
  Prevalence, 2013* 43.4 M (17.9%) 19.3 M (15.5%) 18.7% 15.0% 6.7%
PA†
  Prevalence, 2013, %* 20.9 17.0 22.7‡ 17.7‡ 16.6‡
Overweight and obesity
  Prevalence, 2012
   Overweight and obesity, BMI >25.0 kg/m2§ 159.2 M (68.5%) 77.7 M (64.7%) 61.2% 81.9% 76.3%
   Obesity, BMI >30.0 kg/m2§ 81.8 M (35.2%) 43.2 M (36.0%) 32.5% 57.5% 42.9%
Blood cholesterol
  Prevalence, 2012
   Total cholesterol >200 mg/dL§ 100.1 M (42.8%) 54.8 M (44.9%) 45.9% 40.7% 43.4%
   Total cholesterol >240 mg/dL§ 30.9 M (13.1%) 17.9 M (14.4%) 15.3% 10.9% 13.7%
   LDL cholesterol >130 mg/dL§ 73.5 M (31.7%) 38.6 M (32.0%) 32.0% 33.6% 31.8%
   HDL cholesterol <40 mg/dL§ 44.6 M (19.9%) 12.2 M (10.4%) 10.2% 10.3% 12.8%
HBP
  Prevalence, 2012§ 80.0 M (32.6%) 41.7 M (31.7%) 30.1% 46.1% 29.9%
  Mortality, 2011║ 65 123 35 760 27 907 6783 ¶
DM
  Prevalence, 2012
   Physician-diagnosed DM§ 21.1 M (8.5%) 10.6 M (8.0%) 6.1% 14.6% 11.8%
   Undiagnosed DM§ 8.1 M (3.3%) 3.0 M (2.4%) 1.7% 2.3% 5.0%
   Prediabetes§ 80.8 M (35.3%) 34.4 M (28.4%) 28.9% 27.8% 26.0%
   Incidence, diagnosed DM§ 1.7 M N/A N/A N/A N/A
  Mortality, 2011║ 73 831 35 507 27 191 6847 ¶
Total CVD
  Prevalence, 2012§ 85.6 M (35.0%) 43.8 M (33.7%) 31.9% 48.3% 32.5%
  Mortality, 2011║# 786 641 398 035 340 803 47 130 ¶
Stroke
  Prevalence, 2012§ 6.6 M (2.6%) 3.6 M (2.7%) 2.5% 4.7% 2.0%
  New and recurrent strokes║ 795.0 K 425.0 K 365.0 K 60.0 K N/A
  Mortality, 2011║ 128 932 76 597 65 278 8814 ¶
CHD
  Prevalence, CHD, 2012§ 15.5 M (6.2%) 6.6 M (5.0%) 4.6% 7.0% 5.9%
  Prevalence, MI, 2012§ 7.6 M (2.8%) 2.7 M (1.8%) 1.8% 2.2% 1.7%
  Prevalence, AP, 2012§ 8.2 M (3.3%) 4.2 M (3.2%) 2.9% 5.0% 3.8%
  New and recurrent CHD**†† 935.0 K 390.0 K 330.0 K 60.0 K N/A
  New and recurrent MI†† 735.0 K 305.0 K N/A N/A N/A
  Incidence, AP (stable angina), 2010‡‡ 565.0 K 195.0 K N/A N/A N/A
  Mortality, 2011, CHD║ 375 295 168 387 145 443 18 760 ¶
  Mortality, 2011, MI║ 119 905 53 140 45 576 6228 ¶
HF
  Prevalence, 2012§ 5.7 M (2.2%) 3.0 M (2.2%) 2.2% 3.2% 2.1%
  Incidence, 2010§§ 870.0 K 455.0 K 395.0 K 60.0 K N/A
  Mortality, 2011║ 58 309 33 700 30 036 3143 ¶
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, AP chest pain, or both); CVD, cardiovascular 
disease; DM, diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, millions; MI, 
myocardial infarction (heart attack); N/A, data not available; and PA, physical activity.
*Age ≥18 years (National Health Interview Survey, 2013).
†Met 2008 full federal PA guidelines for adults.
‡Both sexes (National Health Interview Survey).
§Age ≥20 years.
║All ages.
¶ Mortality data for the white and black populations include deaths of people of Hispanic and non-Hispanic origin.
#Total CVD mortality includes deaths of congenital heart disease.
**New and recurrent MI and fatal CHD.
††Age ≥35 years.
‡‡Age ≥45 years.
§§Age ≥55 years.
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Table 26-3. Race/Ethnicity and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes
Whites Blacks Hispanics/Latinos
Asians:  
Both Sexes
American Indian/ 
Alaska Native:  
Both SexesMales Females Males Females Males Females
Smoking
  Prevalence, 2013* 43.4 M (17.9%) 21.7% 18.7% 21.1% 15.0% 16.6% 6.7% 9.5% 21.0%
PA†
  Prevalence, 2013, %* 20.9 22.7 17.7 16.6 18.2 16.6
Overweight and obesity
  Prevalence, 2012
   Overweight and obesity,  
BMI >25.0 kg/m2‡
159.2 M (68.5%) 72.7% 61.2% 69.4% 81.9% 80.1% 76.3% N/A N/A
   Obesity, BMI >30.0 kg/m2‡ 81.8 M (35.2%) 34.2% 32.5% 37.9% 57.5% 38.4% 42.9% 10.8%* 46.5%*
Blood cholesterol
  Prevalence, 2012
   Total cholesterol >200 mg/dL‡ 100.1 M (42.8%) 39.9% 45.9% 37.4% 40.7% 46.2% 43.4% N/A N/A
   Total cholesterol >240 mg/dL‡ 30.9 M (13.1%) 11.5% 15.3% 8.8% 10.9% 14.8% 13.7% N/A N/A
   LDL cholesterol >130 mg/dL‡ 73.5 M (31.7%) 29.4% 32.0% 30.7% 33.6% 38.8% 31.8% N/A N/A
   HDL cholesterol <40 mg/dL‡ 44.6 M (19.9%) 28.7% 10.2% 20.0% 10.3% 33.8% 12.8% N/A N/A
HBP
  Prevalence, 2012‡ 80.0 M (32.6%) 32.9% 30.1% 44.9% 46.1% 29.6% 29.9% N/A 26.2%*
  Mortality, 2011§ 65 123 21 830 27 907 6610 6783 ║ ║ 1667║ 326║
DM
  Prevalence, 2012  
   Physician-diagnosed DM‡ 21.1 M (8.5%) 7.6% 6.1% 13.8% 14.6% 12.5% 11.8% N/A N/A
   Undiagnosed DM‡ 8.1 M (3.3%) 4.0% 1.7% 4.8% 2.3% 6.8% 5.0% N/A N/A
   Prediabetes‡ 80.8 M (35.3%) 43.0% 28.9% 36.3% 27.8% 43.0% 26.0% N/A N/A
   Incidence, diagnosed DM‡ 1.7 M N/A N/A N/A N/A N/A N/A N/A N/A
  Mortality, 2011§ 73 831 30 783 27 191 6048 6847 ║ ║ 2035║ 927║
Total CVD
  Prevalence, 2012‡ 85.6 M (35.0%) 36.1% 31.9% 46.0% 48.3% 32.4% 32.5% N/A N/A
  Mortality, 2011§¶ 786 641 331 751 340 803 46 081 47 130 ║ ║ 17 050║ 3826║
Stroke
  Prevalence, 2012‡ 6.6 M (2.6%) 2.2% 2.5% 4.2% 4.7% 2.8% 2.0% N/A 2.7%*#
  New and recurrent strokes§ 795.0 K 325.0 K 365.0 K 45.0 K 60.0 K N/A N/A N/A N/A
  Mortality, 2011§ 128 932 43 264 65 278 7039 8814 ║ ║ 3937║ 600║
CHD
  Prevalence, CHD, 2012‡ 15.5 M (6.2%) 7.8% 4.6% 7.2% 7.0% 6.7% 5.9% N/A 4.5%*#
  Prevalence, MI, 2012‡ 7.6 M (2.8%) 4.1% 1.8% 3.4% 2.2% 3.5% 1.7% N/A N/A
  Prevalence, AP, 2012‡ 8.2 M (3.3%) 3.4% 2.9% 3.3% 5.0% 3.2% 3.8% N/A N/A
  New and recurrent CHD**†† 935.0 K 475.0 K 330.0 K 70.0 K 60.0 K N/A N/A N/A N/A
  Mortality, 2011, CHD§ 375 295 180 658 145 443 20 693 18 760 ║ ║ 7828║ 1913║
  Mortality, 2011, MI§ 119 905 58 447 45 576 6551 6228 ║ ║ 2476║ 627║
HF
  Prevalence, 2012‡ 5.7 M (2.2%) 2.2% 2.2% 2.8% 3.2% 2.1% 2.1% N/A N/A
  Incidence, 2010§§ 870.0 K 365.0 K 395.0 K 50.0 K 60.0 K N/A N/A N/A N/A
  Mortality, 2011§ 58 309 21 802 30 036 2371 3143 ║ ║ 727║ 230║
AP indicates angina pectoris (chest pain); BMI, body mass index; CHD, coronary heart disease (includes heart attack, angina pectoris chest pain, or both); CVD, 
cardiovascular disease; DM, diabetes mellitus; HBP, high blood pressure; HDL, high-density lipoprotein; HF, heart failure; K, thousands; LDL, low-density lipoprotein; M, 
millions; MI, myocardial infarction (heart attack); N/A, data not available; and PA, physical activity;.
*Age ≥18 years (National Health Interview Survey, 2013).
†Met 2008 full federal PA guidelines for adults.
‡Age ≥20 years.
§All ages.
║Mortality data for the white, black, Asian or Pacific Islander, and American Indian/Alaska Native populations include deaths of people of Hispanic and non-Hispanic 
origin. Death rates for Hispanic, American Indian or Alaska Native, and Asian and Pacific Islander people should be interpreted with caution because of inconsistencies 
in reporting Hispanic origin or race on the death certificate compared with censuses, surveys, and birth certificates. Studies have shown underreporting on death 
certificates of American Indian or Alaska Native, Asian and Pacific Islander, and Hispanic decedents, as well as undercounts of these groups in censuses.
¶Total CVD mortality includes deaths from congenital heart disease.
#Figure not considered reliable.
**New and recurrent MI and fatal CHD.
††Age ≥35 years.
‡‡Age ≥45 years.
§§Age ≥55 years.
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Table 26-4. Children, Youth, and CVD: At-a-Glance Table
Diseases and Risk Factors Both Sexes Total Males Total Females
NH Whites NH Blacks Hispanic
Males Females Males Females Males Females
Smoking, %
  Prevalence, grades 9–12, 2013*
   Current cigarette smoking, 2013 15.7 16.4 15.0 19.1 18.1 10.5 6.2 15.0 13.1
   Current cigar smoking, 2013 12.6 16.5 8.7 18.1 8.0 14.0 9.4 14.7 9.2
   Current smokeless tobacco 
use, 2013
8.8 14.7 2.9 20.6 3.1 4.4 1.0 7.7 3.5
PA, %†
  Prevalence, grades 9–12, 2013*
   Met currently recommended 
levels of PA
27.1 36.6 17.7 37.5 18.7 37.2 16.0 33.9 17.4
Overweight and obesity
  Prevalence, 2012‡
   Children and adolescents, ages 
2–19 y, overweight or obese
23.7 M (31.8%) 12.2 M (32.0%) 11.5 M (31.6%) 27.8% 29.2% 34.4% 36.1% 40.7% 37.0%
   Children and adolescents,  
age 2–19 y, obese
12.6 M (16.9%) 6.3 M (16.7%) 6.3 M (17.2%) 12.6% 15.6% 19.9% 20.5% 24.1% 20.6%
Blood cholesterol, mg/dL, 2012
  Mean total cholesterol
   Ages 6–11 y 160.2 160.5 159.8 158.6 158.2 163.7 159.8 160.5 161.2
   Ages 12–19 y 158.3 155.2 161.6 155.2 163.2 153.9 158.6 157.0 160.4
  Mean HDL cholesterol
   Ages 6–11 y 53.9 55.4 52.4 55.1 52.5 58.5 54.5 53.5 51.4
   Ages 12–19 y 51.4 49.4 53.4 48.9 52.4 52.6 55.1 48.1 53.6
  Mean LDL cholesterol
   Ages 12–19 y 89.3 88.3 90.3 89.5 91.1 86.7 90.9 87.4 88.9
Congenital cardiovascular defects
  Mortality, 2011§ 3166 1725 1441 1342 1117 291 258 ║ ║
Overweight indicates a body mass index in the 95th percentile of the Centers for Disease Control and Prevention 2000 growth chart.
CVD indicates cardiovascular disease; HDL, high-density lipoprotein; LDL, low-density lipoprotein; M, millions; NH, non-Hispanic; and PA, physical activity.
*Kann L, Kinchen S, Shanklin S, Flint KH, Hawkins J, Harris WA, Lowry R, Olsen EO, McManus T, Chyen D, Whittle L, Taylor E, Demissie Z, Brener ND, Thornton J, 
Moore J, Zaza S. Youth risk behavior surveillance: United States, 2013 [published correction appears in MMWR Surveill Summ. 2014;63:576]. MMWR Surveill Summ. 
2014;63:1–168.
†Physically active at least 60 min/d on all 7 days.
‡Ogden CL, Carroll MD, Kit BK, Flegal KM. Prevalence of childhood and adult obesity in the United States, 2011–2012. JAMA. 2014;311:806–814.
§All ages.
║Mortality data for the white and black populations include deaths of people of Hispanic and non-Hispanic origin.
D
ow
nloaded from
 http://ahajournals.org by on November 19, 2019
e320  Circulation  January 27, 2015
Click here to go to the Table of Contents
27 . Glossary
 ● Age-adjusted rates—Used mainly to compare the rates of 
≥2 communities or population groups or the nation as a 
whole over time. The American Heart Association (AHA) 
uses a standard population (2000), so these rates are not 
affected by changes or differences in the age composition 
of the population. Unless otherwise noted, all death rates 
in this publication are age adjusted per 100 000 population 
and are based on underlying cause of death.
 ● Agency for Healthcare Research and Quality (AHRQ)—A 
part of the US Department of Health and Human Services, 
this is the lead agency charged with supporting research 
designed to improve the quality of health care, reduce the cost 
of health care, improve patient safety, decrease the number 
of medical errors, and broaden access to essential services. 
The AHRQ sponsors and conducts research that provides 
evidence-based information on healthcare outcomes, quality, 
cost, use, and access. The information helps healthcare deci-
sion makers (patients, clinicians, health system leaders, and 
policy makers) make more informed decisions and improve 
the quality of healthcare services. The AHRQ conducts the 
Medical Expenditure Panel Survey (MEPS; ongoing).
 ● Bacterial endocarditis—An infection of the heart’s inner 
lining (endocardium) or of the heart valves. The bacteria 
that most often cause endocarditis are streptococci, staphy-
lococci, and enterococci.
 ● Body mass index (BMI)—A mathematical formula to 
assess body weight relative to height. The measure corre-
lates highly with body fat. It is calculated as weight in kilo-
grams divided by the square of the height in meters (kg/m2).
 ● Centers for Disease Control and Prevention/National 
Center for Health Statistics (CDC/NCHS)—CDC is an 
agency within the US Department of Health and Human 
Services. The CDC conducts the Behavioral Risk Factor 
Surveillance System (BRFSS), an ongoing survey. The 
CDC/NCHS conducts or has conducted these surveys 
(among others):
—National Health Examination Survey (NHES I, 1960–
1962; NHES II, 1963–1965; NHES III, 1966–1970)
—National Health and Nutrition Examination Survey I 
(NHANES I; 1971–1975)
—National Health and Nutrition Examination Survey II 
(NHANES II; 1976–1980)
—National Health and Nutrition Examination Survey III 
(NHANES III; 1988–1994)
—National Health and Nutrition Examination Survey 
(NHANES; 1999 to …) (ongoing)
—National Health Interview Survey (NHIS) (ongoing)
—National Hospital Discharge Survey (NHDS) 
(1965–2010)
—National Ambulatory Medical Care Survey (NAMCS) 
(ongoing)
—National Hospital Ambulatory Medical Care Survey 
(NHAMCS) (ongoing)
—National Nursing Home Survey (periodic)
—National Home and Hospice Care Survey (periodic)
—National Vital Statistics System (ongoing)
 ● Centers for Medicare & Medicaid Services, formerly 
Health Care Financing Administration—The federal 
agency that administers the Medicare, Medicaid, and Child 
Health Insurance programs.
 ● Comparability ratio—Provided by the NCHS to allow 
time-trend analysis from one International Classification 
of Diseases (ICD) revision to another. It compensates for 
the “shifting” of deaths from one causal code number to 
another. Its application to mortality based on one ICD revi-
sion means that mortality is “comparability modified” to 
be more comparable to mortality coded to the other ICD 
revision.
 ● Coronary heart disease (CHD) (ICD-10 codes I20–I25)—
This category includes acute myocardial infarction 
(I21–I22), other acute ischemic (coronary) heart disease 
(I24), angina pectoris (I20), atherosclerotic cardiovascu-
lar disease (I25.0), and all other forms of chronic ischemic 
 (coronary) heart disease (I25.1–I25.9).
 ● Death rate—The relative frequency with which death 
occurs within some specified interval of time in a popula-
tion. National death rates are computed per 100 000 pop-
ulation. Dividing the total number of deaths by the total 
population gives a crude death rate for the total population. 
Rates calculated within specific subgroups, such as age-
specific or sex-specific rates, are often more meaningful 
and informative. They allow well-defined subgroups of the 
total population to be examined. Unless otherwise stated, 
all death rates in this publication are age adjusted and are 
per 100 000 population.
 ● Diseases of the circulatory system (ICD codes I00–
I99)—Included as part of what the AHA calls “cardio-
vascular disease” (“Total cardiovascular disease” in this 
Glossary).
 ● Diseases of the heart—Classification the NCHS uses in 
compiling the leading causes of death. Includes acute rheu-
matic fever/chronic rheumatic heart diseases (I00–I09), 
hypertensive heart disease (I11), hypertensive heart and 
renal disease (I13), CHD (I20–I25), pulmonary heart dis-
ease and diseases of pulmonary circulation (I26–I28), heart 
failure (I50), and other forms of heart disease (I29–I49, 
I50.1–I51). “Diseases of the heart” are not equivalent to 
“total cardiovascular disease,” which the AHA prefers to 
use to describe the leading causes of death.
 ● Health Care Financing Administration—See Centers for 
Medicare & Medicaid Services.
 ● Hispanic origin—In US government statistics, “Hispanic” 
includes people who trace their ancestry to Mexico, Puerto 
Rico, Cuba, Spain, the Spanish-speaking countries of Cen-
tral or South America, the Dominican Republic, or other 
Spanish cultures, regardless of race. It does not include 
people from Brazil, Guyana, Suriname, Trinidad, Belize, or 
Portugal, because Spanish is not the first language in those 
countries. Most of the data in this update are for Mexican 
Americans or Mexicans, as reported by government agen-
cies or specific studies. In many cases, data for all Hispan-
ics are more difficult to obtain.
 ● Hospital discharges—The number of inpatients (including 
newborn infants) discharged from short-stay hospitals for 
whom some type of disease was the first-listed diagnosis. 
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Discharges include those discharged alive, dead, or “status 
unknown.”
 ● International Classification of Diseases (ICD) codes—A 
classification system in standard use in the United States. 
The International Classification of Diseases is published 
by the World Health Organization. This system is reviewed 
and revised approximately every 10 to 20 years to ensure 
its continued flexibility and feasibility. The 10th revision 
(ICD-10) began with the release of 1999 final mortality 
data. The ICD revisions can cause considerable change 
in the number of deaths reported for a given disease. The 
NCHS provides “comparability ratios” to compensate for 
the “shifting” of deaths from one ICD code to another. To 
compare the number or rate of deaths with that of an earlier 
year, the “comparability-modified” number or rate is used.
 ● Incidence—An estimate of the number of new cases of a 
disease that develop in a population, usually in a 1-year 
period. For some statistics, new and recurrent attacks, or 
cases, are combined. The incidence of a specific disease 
is estimated by multiplying the incidence rates reported in 
community- or hospital-based studies by the US popula-
tion. The rates in this report change only when new data are 
available; they are not computed annually.
 ● Major cardiovascular diseases—Disease classification 
commonly reported by the NCHS; represents ICD codes 
I00 to I78. The AHA does not use “major cardiovascular 
diseases” for any calculations. See “Total cardiovascular 
disease” in this Glossary.
 ● Metabolic syndrome—Metabolic syndrome is defined* as 
the presence of any 3 of the following 5 diagnostic mea-
sures: Elevated waist circumference (≥102 cm in men or 
≥88 cm in women), elevated triglycerides (≥150 mg/dL 
[1.7 mmol/L] or drug treatment for elevated triglycerides), 
reduced high-density lipoprotein cholesterol (<40 mg/dL 
[0.9 mmol/L] in men, <50 mg/dL [1.1 mmol/L] in women, 
or drug treatment for reduced high-density lipoprotein cho-
lesterol), elevated blood pressure (≥130 mm Hg systolic 
blood pressure, ≥85 mm Hg diastolic blood pressure, or 
drug treatment for hypertension), and elevated fasting glu-
cose (≥100 mg/dL or drug treatment for elevated glucose).
 ● Morbidity—Incidence and prevalence rates are both mea-
sures of morbidity (ie, measures of various effects of dis-
ease on a population).
 ● Mortality—Mortality data for states can be obtained from 
the NCHS Web site (http://cdc.gov/nchs/), by direct com-
munication with the CDC/NCHS, or from the AHA on 
request. The total number of deaths attributable to a given 
disease in a population during a specific interval of time, 
usually 1 year, are reported. These data are compiled from 
death certificates and sent by state health agencies to the 
NCHS. The process of verifying and tabulating the data 
takes ≈2 years.
 ● National Heart, Lung, and Blood Institute (NHLBI)—
An institute in the National Institutes of Health in the US 
Department of Health and Human Services. The NHLBI 
conducts such studies as the following:
—Framingham Heart Study (FHS; 1948 to …) (ongoing)
—Honolulu Heart Program (HHP) (1965–1997)
—Cardiovascular Health Study (CHS; 1988 to …) 
(ongoing)
—Atherosclerosis Risk in Communities (ARIC) study 
(1985 to …) (ongoing)
—Strong Heart Study (SHS) (1989–1992, 1991–1998)
—The NHLBI also published reports of the Joint National 
Committee on Prevention, Detection, Evaluation, and 
Treatment of High Blood Pressure and the Third Report 
of the Expert Panel on Detection, Evaluation, and Treat-
ment of High Blood Cholesterol in Adults (Adult Treat-
ment Panel III).
 ● National Institute of Neurological Disorders and Stroke 
(NINDS)—An institute in the National Institutes of Health 
of the US Department of Health and Human Services. The 
NINDS sponsors and conducts research studies such as 
these:
—Greater Cincinnati/Northern Kentucky Stroke Study 
(GCNKSS)
—Rochester (Minnesota) Stroke Epidemiology Project
—Northern Manhattan Study (NOMAS)
—Brain Attack Surveillance in Corpus Christi (BASIC) 
Project
 ● Physical activity—Any bodily movement produced by the 
contraction of skeletal muscle that increases energy expen-
diture above a basal level.
 ● Physical fitness—The ability to perform daily tasks with 
vigor and alertness, without undue fatigue, and with ample 
energy to enjoy leisure-time pursuits and respond to emer-
gencies. Physical fitness includes a number of components 
consisting of cardiorespiratory endurance (aerobic power), 
skeletal muscle endurance, skeletal muscle strength, skel-
etal muscle power, flexibility, balance, speed of movement, 
reaction time, and body composition.
 ● Prevalence—An estimate of the total number of cases of a 
disease existing in a population during a specified period. 
Prevalence is sometimes expressed as a percentage of 
population. Rates for specific diseases are calculated from 
periodic health examination surveys that government agen-
cies conduct. Annual changes in prevalence as reported in 
this statistical update reflect changes in the population size. 
Changes in rates can be evaluated only by comparing prev-
alence rates estimated from surveys conducted in different 
years. Note: In the data tables, which are located in the dif-
ferent disease and risk factor categories, if the percentages 
shown are age adjusted, they will not add to the total.
 ● Race and Hispanic origin—Race and Hispanic origin are 
reported separately on death certificates. In this publica-
tion, unless otherwise specified, deaths of people of His-
panic origin are included in the totals for whites, blacks, 
American Indians or Alaska Natives, and Asian or Pacific 
Islanders according to the race listed on the decedent’s 
death certificate. Data for Hispanic people include all peo-
ple of Hispanic origin of any race. See “Hispanic origin” in 
this Glossary.
 ● Stroke (ICD-10 codes I60–I69)—This category includes 
subarachnoid hemorrhage (I60); intracerebral hemorrhage 
(I61); other nontraumatic intracranial hemorrhage (I62); 
cerebral infarction (I63); stroke, not specified as hemor-
rhage or infarction (I64); occlusion and stenosis of pre-
cerebral arteries not resulting in cerebral infarction (I65); 
*According to criteria established by the AHA/NHLBI and published 
in Circulation (Circulation. 2005;112:2735–2752).
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occlusion and stenosis of cerebral arteries not resulting in 
cerebral infarction (I66); other cerebrovascular diseases 
(I67); cerebrovascular disorders in diseases classified else-
where (I68); and sequelae of cerebrovascular disease (I69).
 ● Total cardiovascular disease (ICD-10 codes I00–I99, Q20–
Q28)—This category includes rheumatic fever/rheumatic 
heart disease (I00–I09); hypertensive diseases (I10–I15); 
ischemic (coronary) heart disease (I20–I25); pulmonary 
heart disease and diseases of pulmonary circulation (I26–
I28); other forms of heart disease (I30–I52); cerebrovascu-
lar disease (stroke) (I60–I69); atherosclerosis (I70); other 
diseases of arteries, arterioles, and capillaries (I71–I79); 
diseases of veins, lymphatics, and lymph nodes not clas-
sified elsewhere (I80–I89); and other and unspecified 
disorders of the circulatory system (I95–I99). When data 
are available, we include congenital cardiovascular defects 
(Q20–Q28).
 ● Underlying cause of death or any-mention cause of 
death—These terms are used by the NCHS when defin-
ing mortality. Underlying cause of death is defined by 
the World Health Organization as “the disease or injury 
which initiated the chain of events leading directly to 
death, or the circumstances of the accident or violence 
which produced the fatal injury.” Contributing cause of 
death would be any other disease or condition that the 
decedent may also have had and that was reported on the 
death certificate but was not part of the chain of events 
leading directly to death.
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